From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Durvalumab (MEDI 4736) is an human anti-PD-L1monoclonalantibody . Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively .
Zanidatamab (ZW25) is a humanised, bispecific monoclonalantibody targeting 2 distinct HER2 epitopes (ECD2 and ECD4). Zanidatamab has anti-tumour activity .
Avelumab (Anti-Human PD-L1) a fully human IgG1 anti-PD-L1monoclonalantibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab can be used for the study of chordoma .
Camoteskimab is a fully human monoclonalantibody with high affinity targeting IL-18. Camoteskimab is applicable to the research of autoinflammatory diseases .
Pivekimab is a human IgG1 monoclonalantibody that targets interleukin-3 (IL-3) and CD123. Pivekimab is used to synthesize pivekimab sunirine, a CD123-directed antibody-active molecule conjugate (ADC). Pivekimab is used in the study of blastic plasmacytoid dendritic cell neoplasm (BPDCN) .
Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonalantibody targets fibroblast activation protein (FAP). Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC) .
Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonalantibody that binds CD56 (NCAM1). Lorvotuzumab can be used to synthesize an ADC compound, Lorvotuzumab mertansine .
Durvalumab (anti-PD-L1)(MEDI 4736) is a human anti-PD-L1 protein monoclonalantibody. Durvalumab (anti-PD-L1) completely blocks PD-L1 binding to PD-1 and CD80, IC 50 are 0.1 and 0.04 nM respectively, has anti-tumor activity .
Prasinezumab (PRX 002) is a humanized IgG1 monoclonalantibody directed against aggregated α-synuclein. Prasinezumab has the potential for Parkinson's disease research .
Polatuzumab is a monoclonalantibody that targets CD79b on the surface of B cells. Polatuzumab can be used to synthesize the ADC Polatuzumab Vedotin (HY-132253), which has anti-tumor activity .
Disitamab (RC48-0) is a humanized monoclonalantibody targeting HER2. Disitamab can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (HY-P9985) .
Vadastuximab (Anti-Human CD33 Recombinant Antibody) is a humanized monoclonalantibody targeting CD33. Vadastuximab can be used to synthesize an ADC compound, Vadastuximab talirine .
Olaratumab (IMC-3G3; LY3012207) is an anti-platelet-derived growth factor receptor alpha (PDGFRα) human monoclonal IgG1 antibody with antitumor activity .
Bermekimab (MABp1) is a human monoclonalantibody targeting interleukin-1α(IL-1α) . Bermekimab can prevent tumor-related inflammation. Bermekimab can be used in the research of atopic dermatitis .
Siplizumab (MEDI-507) is a humanized IgG1 monoclonalantibody against CD2. Siplizumab depletes T cells, decreases T cell activation, inhibites T cell proliferation and enriches naïve and bona fide regulatory T cells .
Indusatumab (5F9 Monoclonalantibody) is a monoclonalantibody against human GUCY2C (Guanylate cyclase 2C). Indusatumab fails to bind to granulocytes or erythrocytes. Indusatumab can be used to synthesize ADCs, such as Indusatumab vedotin (HY-P99662). Indusatumab can be used in cancer research .
Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonalantibody and ADC antibody. Tisotumab targets tissue factor (TF). Tisotumab can be used to synthesize antibody-drug conjugates (ADCs) targeting tissue factor (TF), Tisotumab vedotin (HY-152963). Tisotumab can be used for the research of solid tumors .
Elgemtumab(LJM716) is a fully human IgG monoclonalantibody. Elgemtumab can specifically bind to HER3, block ligand-dependent and independent HER3 signal transduction and cell proliferation, and has good anti-tumor potential .
Azintuxizumab is an anti-SLAMF7 human IgG4κ monoclonalantibody. Azintuxizumab can be used in the synthesis of antibody-drug conjugate (ADC), Azintuxizumab vedotin .
Tixagevimab (AZD8895) is a human monoclonalantibody that targets the SARS-CoV-2 receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor .
Naratuximab (Anti-TSPAN26/CD37 Reference Antibody (naratuximab)) is a humanized monoclonalantibody that binds CD37 (TSPAN26). Naratuximab can be used to synthesize an ADC compound, Naratuximab emtansine .
Matuzumab (EMD 72000) is a humanized anti-EGFRmonoclonalantibody that blocks EGFR activation and downstream signaling, inhibits tumor growth. Deglycosylation and the possible elimination of ADCC activity can reduce the in vivo anti-tumor activity of Mattuzumab .
Olokizumab (CDP 6038) is a humanized monoclonalantibody that targets interleukin-6 (IL-6). Olokizumab inhibits IL-6-induced STAT-3 phosphorylation. Olokizumab is used in the study of arthritis .
NN-8828 (NNC-114-0005) is a humanized monoclonalantibody inhibitor targeting interleukin-21 (IL-21). NN-8828 is promising for research of immune system diseases .
Imgatuzumab (RG 7160) is a humanized monoclonalantibody against the EGFR. Imgatuzumab acts as an immunomodulator. Imgatuzumab can be used in research of cancer .
IRAB-B is a human monoclonalantibody targeting INSR. IRAB-B is an insulin receptor (IR) antagonist and can be used in the study of insulin resistance and diabetes .
Ublituximab (LFB-R603; TG-1101; TGTX-1101) is a next-generation, type 1 chimeric monoclonalantibody targeting a unique epitope on the CD20 antigen. Ublituximab has anticancer effects .
Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonalantibody targeting CTLA-4 (CTLA-4). Zalifrelimab antagonizes the inhibitory checkpoints of immune cell activation regulated by CTLA-4 signaling .
Sipavibart (AZD3152) is a human IgG1 λ2 monoclonalantibody against SARS-CoV-2. Sipavibart is applicable to research related to COVID-19. The isotype control product for Sipavibart is Human IgG1 lambda2, Isotype Control (HY-P990096) .
Belantamab (FUT8-KO) is an anti-BCMA (TNFRSF17) monoclonalantibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Belantamab (FUT8-KO) can be used to synthesize antibody-active molecule conjugate (ADC), Belantamab mafodotin .
Oregovomab (Alt-2 monoclonalantibody) is a murine mAb targeting CA125. Oregovomab induces cytotoxic immune response against CA125 expressing tumor cells .
Disitamab (RC48-0) (powder) is a humanized monoclonalantibody targeting HER2. Disitamab (powder) can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (HY-P9985) .
Perakizumab (RG4934) is a humanized IgG1κ monoclonalantibody against IL-17A (Interleukin Related). Perakizumab can be uesd for the research of autoimmune diseases, such as psoriatic arthritis .
Levilimab (BCD-089) is a fully humanized anti-interleukin-6 receptor (IL-6R) monoclonalantibody. Levilimab is an inflammation-alleviating antibody. Levilimab can be used for the research of rheumatoid .
Nurulimab (BCD-145) is an anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA-4) human monoclonalantibody. Nurulimab can be can be used in research of melanoma .
BI-1206 is a recombinant and antagonistic human monoclonalantibody targeting FcγRIIB (CD32B). BI-1206 can block CD20 internalization induced by Rituximab (HY-P9913) itself or combined with others including Ibrutinib (HY-10997), Venetoclax (HY-15531), and CHOP. BI-1206 can enhance or recover the activity of Rituximab or other anti-CD20 monoclonalantibodies. BI-1206 has cytolytic activity against malignant B cells. BI-1206 can be studied for cancer research such as mantle cell lymphoma (MCL) .
Lerdelimumab (CAT-152) is an IgG4 human anti-TGF-β2 recombinant monoclonalantibody. Lerdelimumab can be used as an anti-scarring agent for glaucoma research .
Renvistobart is an immunoglobulin G1-κ, anti-[Homo sapiens TIGIT (T cell immunoreceptor with Ig domain and ITIM, VSIG9, VSTM3)] Homo sapiensmonoclonalantibody .
Ranevetmab (NV-01) is a caninised anti-NGFmonoclonalantibody (mAb). Ranevetmab can alleviate pain, and is used for the research of degenerative joint disease (DJD) pain .
Emzotamig is a monoclonalantibody inhibitor targeting tumor necrosis factor (TNF). Emzotamig is promising for research of autoimmune diseases associated with TNF overexpression, such as rheumatoid arthritis and ankylosing spondylitis .
Ticalicibart is a humanized IgG4κ monoclonalantibody inhibitor targeting PCSK9. Ticalicibart has anti-hyperlipidaemic activity. Ticalicibart can be used for cardiovascular disease like hypercholesterolaemia research .
Befovacimab (BAY 1093884) is a fully human monoclonal IgG2 antibody able to bind to tissue factor pathway inhibitor (TFPI). Befovacimab can be used for haemophilia A/B research .
Beludavimab (BMS 4182137; VIR 7832) is a monoclonalantibody targeting the spike glycoprotein of SARS-CoV-2. Beludavimab binds to recombinant spike protein receptor-binding domain (S-RBD) with an EC50 value of 14.9 ng/mL and a Kd of 0.21 nM .
Tisotumab (Anti-Human F3 Recombinant Antibody) (powder) is a human IgG1 monoclonalantibody and ADC antibody. Tisotumab (powder) targets tissue factor (TF). Tisotumab (powder) can be used to synthesize antibody-drug conjugates (ADCs) targeting tissue factor (TF), Tisotumab vedotin (HY-152963). Tisotumab (powder) can be used for the research of solid tumors .
Rozibafusp alfa (AMG-570) is a humanized IgG2-κ monoclonalantibody targets ICOSL and BAFF. Rozibafusp alfa can be used for the research of systemic lupus erythematosus and other autoimmune diseases .
Tomuzotuximab (Anti-Human EGFR Recombinant Antibody) is a fully human glycoengineered IgG1 monoclonalantibody against EGFR. Tomuzotuximab has anticancer effects .
Imbotolimod, immunoglobulin G1-kappa, is a humanized monoclonalantibody with anti-ERBB2 and antineoplastic activity. Imbotolimod is a derivative of telratolimod .
Ledostomig is an immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonalantibody targeting human netrin-5 (NTS5) and programmed death-1 (PD-1). Ledostomig is promising for research of various cancers .
Ongericimab (JS002) is a humanized anti-PCSK9monoclonalantibody. Ongericimab has lipid-lowering efficacy. Ongericimab can be used in research of hypercholesteremia and hyperlipidemia .
Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonalantibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) .
Fenhexamid-butyric acid (Compound FHo) is a hapten designed based on fenhexamid, which can produce monoclonalantibodies with an IC50 value of 0.66-0.93 nM .
HLX26 is a humanised anti-LAG-3monoclonalantibody. HLX26 has antitumor activity especially advanced solid tumours. HLX26 can be used for lymphoma research .
Anti-α-Tubulin Antibody, AF555 conjugate is a conjugate of mouse anti-α-tubulin monoclonalantibody and the red fluorescent dye Alexa Fluor 555. Anti-α-Tubulin Antibody, AF555 conjugate can be used for the detection of tubulin (Ex/Em: 554/567 nm) .
Humanized anti-tac (HAT) binding peptide is a peptide that can specifically bind to the Fc region of HAT. HAT is a humanized monoclonalantibody against the low affinity p55 subunit of the interleukin IL-2 receptor. Humanized anti-tac (HAT) binding peptide can be used to develop affinity chromatography media to purify specific monoclonalantibodies .
Minokitug is a humanized monoclonalantibody targeting the CCR2 protein. Minokitug can be used for the research of refractory/relapsed ulcerative colitis .
Elfetabart (DB-1311 Antibody; BNT324 Antibody) is a humanized monoclonalantibody targeting CD276 with antitumor activity. The antibody isotype of Elfetabart is human IgG1κ, and the recommended isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
Olevaprubart is a humanized IgG1-κ monoclonalantibody targeting TNFSF4, which can be used for the research of autoimmune diseases such as atopic dermatitis and alopecia areata .
Anti-Big-ET-1 Antibody is a humanized monoclonalantibody targeting Big-ET-1. Recommended Isotype Control: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
Daxdilimab (FUT8-KO) is an anti-ILT7monoclonalantibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody.
Ombetoxabart is a humanized IgG1-κ monoclonalantibody targeting TcdB (Clostridioides difficile toxin B), which exerts its function by neutralizing the toxicity of TcdB. Ombetoxabart can be used for the study of Clostridioides difficile infection .
Vonaprument is an intravitreally injected C1qantibody fragment, which is a human monoclonalantibody. Vonaprument is applicable to research related to age-related macular degeneration .
Solaprubart is a humanized IgG1-κ monoclonalantibody targeting TNFSF4/OX40L. Solaprubart regulates immune homeostasis by blocking the OX40L-OX40 signaling pathway and can be used for the research of autoimmune diseases such as atopic dermatitis .
Vedastotug is a human monoclonalantibody targeting TNFRSF4/OX40/CD134, with its corresponding isotype control being Human IgG1 kappa, Isotype Control (HY-P99001) .
INA01 is an unlabeled human monoclonalantibody targeting CD71/TFRC, which can be used in ELISA, FACS and functional assays. INA01 is promising for leukemia-related research .
Anti-IL-6 Antibody (Chugai SK2) is a murine monoclonalantibody, targeting IL-6. Anti-IL-6 Antibody (Chugai SK2) can be used for inflammatory diseases and cancers research, such as rheumatoid arthritis (RA), crohn's disease (CD) and pancreatic, lung and colon cancer .
Pemtumomab Antibody (R-1549) is an anti-MUC1monoclonalantibody. Pemtumomab Antibody is applicable to research related to breast cancer and other cancers. For isotype control, refer to Mouse IgG1 kappa, Isotype Control (HY-P99977).
Ulviprubart (FUT8-KO) is a humanized anti-KLRG1monoclonalantibody lacking fucosyltransferase 8 (FUT8). Ulviprubart (FUT8-KO) can be used for the research of diseases such as inclusion body myositis (IBM) .
Anti-Nucleocapsid Antibody (N-P10) is a highly specific SARS-CoV-2 Nucleocapsid (N) protein-targeted recombinant monoclonalantibody. Anti-Nucleocapsid Antibody (N-P10) can be used for research on SARS-CoV-2 infection .
Anti-Nucleocapsid Antibody (N-P11) is a highly specific SARS-CoV-2 Nucleocapsid (N) protein-targeted recombinant monoclonalantibody. Anti-Nucleocapsid Antibody (N-P11) can be used for research on SARS-CoV-2 infection .
p-SCN-Bn-DOTA is a bifunctional chelating agent. p-SCN-Bn-DOTA can simultaneously chelate radionuclides and link monoclonalantibody for radioimmunoresearch of tumor .
Uliledlimab is a potent against CD73 humanizedized monoclonalantibody. Uliledlimab inhibits the conversion of extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab can be used in research of cancer .
Bertilimumab (CAT 213; iCo-008) is a human monoclonalantibody targeting eotaxin-1 (CCL11). Bertilimumab has the potential for allergic disorders research .
Garadacimab (CSL312) is a first-in-class, fully human IgG4 monoclonalantibody targeting activated factor XII (FXIIa). Garadacimab has the potential for hereditary angioedema research .
ALMB-0168 is a Cx43 hemichannel agonist monoclonalantibody. ALMB-0168 activates Cx43 hemichannels to inhibit the growth and migration of osteosarcoma. ALMB-0168 is applicable to relevant research on osteosarcoma .
Afivastobart (AB598) is a human ENTPD1 (CD39)-targeting monoclonalantibody with antineoplastic activity.Afivastobart binds as a monoclonalantibody to modulate Homo sapiensENTPD1 activity.Afivastobart constitutes a glycoform alfa immunoglobulin G1-kappa monoclonalantibody .
Elotuzumab (HuLuc 63) is an IgG1 monoclonalantibody targeting the SLAMF7 receptor. Elotuzumab exerts antitumor activity by activating natural killer cells and inducing antibody-dependent cell-mediated cytotoxicity. Elotuzumab can be combined with Lenalidomide (HY-A0003), Dexamethasone (HY-14648), etc., for the research of tumors such as multiple myeloma .
OSE-703 is a humanized monoclonalantibody inhibitor targeting interleukin-7 receptor α subunit (IL-7Rα). OSE-703 is promising for research of tumors and respiratory diseases .
Cenvacibart is a monoclonalantibody with anticoagulant activity, targeting human coagulation factor XI (F11). Cenvacibart blocks the role of coagulation factor XI in the coagulation cascade, reducing thrombus formation. Cenvacibart is promising for research of thrombotic diseases .
Pamvatamig (FUT8-KO) is an anti-EGFR/METmonoclonalantibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody.
Apitegromab (SRK-015) is an anti-promyostatin monoclonalantibody. Apitegromab can be used for the research of neuromuscular disease including spinal muscular atrophy .
Alsevalimab is a humanized, afucosylated IgG1 monoclonalantibody against B7-H4. Alsevalimab blocks the binding of the B7-H4 protein to the receptors on the surface of T cells, reversing the immunosuppressive state in the tumor microenvironment, thereby activating the killing effect of T cells on cancer cells. Alsevalimab can be used in combination with Pembrolizumab (HY-P9902), and shows good safety profiles .
Rovelizumab is a humanized monoclonal leukointegrin antibody. Rovelizumab is a monoclonalantibody directed against the CD11/CD18 cell adhesion proteins. Rovelizumab can be used for research of multiple sclerosis (MS), hemorrhagic shock, myocardial infarction (MI) and stroke .
Glarivibart is a humanized IgG1κ monoclonalantibody inhibitor targeting Respiratory syncytial virus (RSV) fusion F protein (RSV-F). Glarivibart has significant antiviral activity. Glarivibart can be used for RSV infections research .
Sotevtamab (16B5) is a humanized IgG2 anti-clusterinmonoclonalantibody (mAb). Sotevtamab is an inhibitor of the epithelial to mesenchymal transition. Sotevtamab can be used for cancer research .
Donanemab (LY3002813) is a humanized IgG1 monoclonalantibody directed at an N-terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research .
Emicizumab is a bispecific monoclonalantibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research .
Vemzatatug is a humanized IgG1κ monoclonalantibody inhibitor targeting GPRC5D. Vemzatatug has an antitumor activity. Vemzatatug can be used for cancers like multiple myeloma (MM) research .
BLX-301 is a humanized monoclonalantibody targeting CD20. BLX-301 exhibits anti-tumor activity and can be used in the research of diseases such as non-Hodgkin lymphoma and rheumatoid arthritis .
Clenoliximab (IDEC-151) is a macaque-human chimeric monoclonalantibody (immunoglobulin G4) specific for the CD4 molecule on the surface of T lymphocytes. Clenoliximab can be used for the research of rheumatoid arthritis .
MC-AAA-NHCH2OCH2COO-7-aminomethyl-10-methyl-11-fluoro camptothecin (compound 21a), a camptothecin payload, can be conjugated to a monoclonalantibody (mAb) for the synthesis of camptothecin antibody-drug conjugate (ADC) .
Gantenerumab is a fully humanized anti-Aβ IgG1 monoclonalantibody. Gantenerumab can specifically bind to Aβ fibrils and plaques and can be used in Alzheimer's disease research .
Bepranemab is a humanized IgG4 monoclonalantibody that binds to the central region of tau protein. Bepranemab inhibits the seeding, aggregation of pathological tau protein and the spread of tau pathology to distal brain regions. Bepranemab is applicable to research related to Alzheimer's disease .
MINT1526A (RG-7594) is a humanized IgG1 monoclonalantibody inhibitor targeting α5β1 integrin. MINT1526A has significant anti-angiogenic activity. MINT1526A can be used for cancers research .
Galcanezumab (LY 2951742) is a humanized IgG4 monoclonalantibody against the CGRP ligand. Galcanezumab can be used for migraine or cluster headaches research .
Quilizumab (Anti-Human IGHE Recombinant Antibody) is a humanized IgG1κ monoclonalantibody targeting immunoglobulin epsilon (also konwn as: IGHE, IgE). Quilizumab targets the M1-prime fragment of membrane-expressed IGHE/IgE, leading to IGHE/IgE switching and memory B cell depletion. Quilizumab has potential in asthma research .
Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonalantibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation .
SFN68 is a humanized IgG1 neutralizing monoclonalantibody targeting HGF. SFN68 significantly inhibits HGF/c-Met interaction, c-Met activation, and, cell scattering and proliferation mediated by HGF. SFN68 can be used for cancers research .
Tucotuzumab (Anti-EPCAM Recombinant Antibody) is an antigen-specific IgG1 monoclonalantibody that targets human epithelial cell adhesion molecule (EpCAM). Tucotuzumab links two IL-2 molecules and is an immunosuppressant and anti-tumor active molecule .
Inetetamab is a monoclonalantibody binding to domain IV of HER2 receptor. Inetetamab alone or together with tyrosine kinase inhibitors has antitumor activities .
Pozelimab (REGN3918) is a fully human IgG4 anti-C5monoclonalantibody. Pozelimab binds to C5 and C5 variants with high affinity and blocks complement-mediated hemolysis. Pozelimab can be used for the research of complement-mediated diseases .
Rovalpituzumab is a humanized monoclonalantibody against delta-like protein 3 (DLL3). Rovalpituzumab can be used in the synthesis of antibody-drug conjugate (ADC), Rovalpituzumab Tesirine. Rovalpituzumab has activity against small cell lung cancer (SCLC) .
Emaretamig is a humanized IgG1κ monoclonalantibody inhibitor targeting CLDN18 and CD3E. Abdakibart can be used for cancers like gastric and pancreatic cancer research .
Lesabelimab (LDP) is an immunoglobulin G1-kappa anti-CD274monoclonalantibody. CD274 is an immune checkpoint ligand, represses antitumour immunity through the interaction with PDCD1 receptor .
Glembatumumab is a fully human IgG2 monoclonalantibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. Glembatumumab can be coupled to the microtubule inhibitor monomethyl auristatin E to form glembatumumab vedotin. Glembatumumab vedotin is an antibody-agent coupling (ADC) with antitumor activity .
Garetosmab (REGN 2477) is a fully human IgG4 monoclonalantibody that specifically inhibits activin A. Garetosmab can be used for fibrodysplasia ossificans progressiva (FOP) research .
Abdakibart is a humanized IgG4 monoclonalantibody inhibitor targeting IL-1β. Abdakibart can be used for inflammatory disease like type 2 diabetes research .
Tibulizumab (LY 3090106) is a tetravalent bispecific monoclonalantibody targeting B-cell activating factor (BAFF) and IL-17A with Kd values of 60 pM and 14 pM, respectively. Tibulizumab can be used for autoimmune disease research .
Blinatumomab (Anatumomab) is a bispecific monoclonalantibody with two binding sites, one for CD3E on T cells and one for CD19 on B cells. Blinatumomab can be used in research for acute lymphoblastic leukemia .
Vulinacimab (HLX-06) is a human monoclonalantibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2). Vulinacimab specifically binds to and inhibits VEGFR-2, which may inhibit tumor angiogenesis and tumor cell proliferation. Vulinacimab can be used for the research of solid tumors and non-small cell lung cancer .
Ponezumab (PF-04360365; RN 1219) is a humanized anti-amyloid-β (Amyloid-β) IgG2 monoclonalantibody. Ponezumab reduces Aβ levels in the central nervous system and improves the performance of mice in various learning and memory models. Ponezumab is applicable to the research of Alzheimer's disease .
Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research .
Pinatuzumab is a humanized monoclonalantibody targeting cell-surface antigen CD22. Pinatuzumab can be used to synthesize antibody-drug conjugate (ADC) such as Pinatuzumab vedotin (HY-141602). Pinatuzumab can be studied in research on cancer such as non-Hodgkin lymphoma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
IT1208 is a humanized anti-CD4monoclonal IgG1 antibody. IT1208 depletes CD4 + T cells with a manageable safety profile in vivo. IT1208 can be used for colon cancer research .
Tigatuzumab (CS-1008) is a humanized IgG1 monoclonalantibody targets death receptor 5 (DR5). Tigatuzumab induces cell apoptosis of cancer cells and inhibits tumor growth in vivo. Tigatuzumab can be used for the research of cancer .
Depatuxizumab MMAE is an antibody-drug conjugate (ADC) comprising an antiEGFRmonoclonalantibody (Depatuxizumab) (HY-P99849) and the cytotoxic agent Monomethyl auristatin E (MMAE) (HY-15162). Depatuxizumab MMAE can be used for the study of EGFR-expressing advanced solid tumors.
Girentuximab (G250) is a chimeric monoclonalantibody that binds carbonic anhydrase IX (CAIX), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC) .
Ensituximab (NEO-102; NPC-1C) is a chimeric monoclonal IgG1 antibody targeting a variant of MUC5AC. Ensituximab shows specificity to colorectal and pancreatic cancer .
Lenzilumab (KB 003) is a human monoclonalantibody targeting CSF2/GM-CSF for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies .
Barzolvolimab is a humanized anti-KIT IgG1 monoclonalantibody. Barzolvolimab specificity and potently inhibits KIT activation by SCF. Barzolvolimab can reduce skin mast cells and disease activity in chronic inducible urticaria .
Onvatilimab (JNJ-61610588) is a human IgG1κ anti-VISTA (V-domain Ig Suppressor of T-cell Activation) monoclonalantibody. Onvatilimab can be used in colorectal cancer research .
Isatuximab is a monoclonalantibody targeting the transmembrane receptor and ectoenzyme CD38, a protein highly expressed on hematological malignant cells, including those in multiple myeloma (MM). Isatuximab has antitumor activity via multiple biological mechanisms, including antibody-dependent cellular-mediated cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and direct induction of apoptosis without crosslinking. Isatuximab also directly inhibits CD38 ectoenzyme activity, which is implicated in many cellular functions .
Emapalumab (NI-0501) is a human monoclonal IgG1 antibody that noncompetitively inhibits IFN-γ. Emapalumab binds with high affinity (Kd= 1.4 pM) to both free IFN-γ as well as IFN-γ bound to its receptor. Emapalumab can be used in research of hemophagocytic lymphohistiocytosis (HLH) .
REGN-1400 is a humanized monoclonalantibody inhibitor targeting ErbB3. REGN-1400 reduces tumor cell proliferation by inhibiting ErbB3 and blocking related signaling pathways. REGN-1400 is promising for research of solid tumors such as non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and squamous cell carcinoma of the head and neck (SCCHN) .
VRC01LS is a humanized monoclonalantibody inhibitor targeting the CD4-binding site of HIV-1 envelope glycoprotein (Env). VRC01LS blocks the binding of HIV-1 to host cell CD4 receptor, inhibiting viral entry. VRC01LS is promising for research of HIV-1 infection .
Ganitumab (AMG 479) is a recombinant human monoclonalantibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (KD=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer .
Nemolizumab (CIM331) is a humanized monoclonalantibody that targets the human interleukin-31 receptor a, preventing interleukin-31 (IL-31) from binding to its receptor and the subsequent signaling. Nemolizumab can help reduce itching and sleep disturbances, and it is being studied for atopic dermatitis (AD) .
Apolizumab (Hu1D10) is a humanized monoclonalanti-Human leukocyte antigen-DR beta-chain antibody. Apolizumab can mediate apoptosis of chronic lymphocytic leukemia (CLL) cells in vitro .
MLN2201 is a humanized monoclonalantibody inhibitor, targeting Integrin β2. MLN2201 inhibits the reperfusion injury after stroke and can be used for inflammatory diseases like ischemic stroke research .
Abelacimab (MAA868) is a fully human IgG1 monoclonalantibody that binds with high affinity to the catalytic structural domain of FXI and locks it in the zymogen conformation, thereby preventing its activation by FXIIa or thrombin. Abelacimab can be used in thromboembolic disease studies .
CDX-3379 is a humanized monoclonalantibody inhibitor targeting ErbB3. CDX-3379 binds to ErbB3, blocking the dimerization of ErbB3 with other receptors, thereby inhibiting the phosphorylation of ErbB3. CDX-3379 can inhibit the growth and proliferation of tumor cells. CDX-3379 is promising for research of tumors expressing ErbB3 and NRG1, such as HNSCC .
Geptanolimab (CBT-501) is a humanized IgG4k monoclonalantibody against programmed death-1 (PD-1). Siplizumab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. Siplizumab can be used in research of cancer .
Varlilumab (CDX-1127) is an agonist anti-CD27monoclonalantibody. Varlilumab can promote T cell expansion and activate the immune response. Varlilumab has anti-tumor activity and can be used in the research of hematological malignancies and solid tumors .
Vanucizumab is a first-in-class, bispecific IgG1-like monoclonalantibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects .
Aducanumab (BIIB037) is a human monoclonalantibody that selectively targets aggregated amyloid-beta (Aβ). Aducanumab shows blood-brain-barrier penetration, and can be used for Alzheimer's disease (AD) research .
NC762 is a humanized IgG1κ monoclonalantibody that targets human B7-H4 (B7 homolog 4). NC762 has enhanced binding to CD16a (FcγRIIIa) after being Fc engineered with three point mutations (S239D/A330L/I332E; DLE) and demonstrate increased antibody-dependent cellular cytotoxicity (ADCC) activity. NC762 inhibits tumor growth in vivo through binding to tumor-expressing B7-H4. NC762 can be studies in research on cancer such as advanced or metastatic solid tumors .
Tremelimumab (Ticilimumab) is a fully human monoclonalantibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research .
Tusamitamab is an IgG1 monoclonalantibody that targets CEACAM5. Tusamitamab can be used to synthesize ADC Tusamitamab ravtansine (SAR408701) (HY-P99542) .
Nesvacumab is a fully human immunoglobulin G1 (IgG1) monoclonalantibody that specifically binds and inactivates the Tie2 receptor ligand Angiopoietin-2 (Ang2) with high affinity, but shows no binding to Ang1. Nesvacumab can be used in vascular researches .
Frovocimab (LY 3015014) is a humanized IgG4 monoclonalantibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9 .
Bapineuzumab is an anti-β-amyloid protein (APP)monoclonalantibody. Bapineuzumab is a humanized IgG1 that recognizes the N terminus of Aβ cleared plaques from the brains. Bapineuzumab can be used for the research of Alzheimer’s disease (AD) .
Onvontatug (BAT8006 Antibody) is a humanized monoclonalantibody targeting folate receptor α (FRα). Onvontatug can be used to construct antibody-drug conjugates (ADCs), such as BAT8006. It is applicable to research related to platinum-resistant ovarian cancer .
Rocatinlimab (AMG 451) (KHK4083) is a fully human immunoglobulin G1 (IgG1) anti-OX40 monoclonalantibody. Rocatinlimab can be used for the research of atopic dermatitis (AD) .
Tralokinumab (CAT354) is a humanized IgG4 monoclonalantibody that specifically binds to and neutralizes IL-13. Tralokinumab can be used in the research of diseases such as asthma, atopic dermatitis, and pulmonary fibrosis .
Enlimomab (BI-RR 0001), a murine IgG2a monoclonalantibody to the human ICAM-1, inhibits leukocyte adhesion to the vascular endothelium, thereby decreasing leukocyte extravasation and inflammatory tissue injury. Enlimomab has anti-inflammatory effects, and can be used for stroke research .
GBR-401 is a humanized anti-CD19monoclonalantibody with high affinity for FcγRIIIa. GBR-401 exerts a potent in vitro and in vivo cytotoxic activity against various B-cell malignancies. GBR-401 induces cell death by antibody dependent cellular cytotoxicity (ADCC) and direct killing effect. GBR-401 demonstrates potent activity of depleting malignant B cells and prolongs mice survival in multiple xenograft severe combined immunodeficiency (SCID) mice models .
PF-07329640 is a humanized monoclonalantibody inhibitor targeting TNFRSF3. PF-07329640 can be used for advanced/metastatic solid tumors like non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) research .
Rosnilimab (Mouse IgG2a) is a mouse-derived IgG2a, Rosnilimab. Rosnilimab is a PD-1 agonistic monoclonalantibody. Rosnilimab (Mouse IgG2a) can be used in research related to ulcerative colitis .
Aprutumab (BAY 1179470) is a fully human fibroblast growth factor receptor 2 (FGFR2)-specific monoclonalantibody. Aprutumab induces FGFR2 endocytosis and degradation in cancer cells expressing FGFR2. Aprutumab serves as the targeted monoclonalantibody component of the antibody-drug conjugate BAY 1187982 (HY-141600) and mediates the endocytosis of the antibody-drug conjugate into FGFR2-positive cells. Aprutumab can be used for the research of FGFR2-positive solid tumors, including studies on gastric cancer and triple-negative breast cancer .
Oleclumab (MEDI9447) is a human IgG1λ monoclonalantibody targeting CD73 and inhibits the exonuclease activity of the extracellular enzyme CD73. Oleclumab can adjust the composition of bone marrow and lymphoid infiltrating leukocyte populations in the tumor microenvironment and has anti-tumor activity .
Emicizumab (Anti-F9 & Factor IX) is a bispecific monoclonalantibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab (Anti-F9 & Factor IX) can be used for hemophilia A research .
Afasevikumab (RG 7624; RO 5553110; NI-1401) is a fully human monoclonal IgG1κ antibody neutralizing both IL-17A and IL-17F. Afasevikumab has anti-inflammatory activities .
p-SCN-Bn-DOTA (Standard) is the analytical standard of p-SCN-Bn-DOTA. This product is intended for research and analytical applications. p-SCN-Bn-DOTA is a bifunctional chelating agent. p-SCN-Bn-DOTA can simultaneously chelate radionuclides and link monoclonalantibody for radioimmunoresearch of tumor .
Erenumab (AMG-334) is a fully human monoclonalantibody. Erenumab inhibits the calcitonin gene-related peptide (CGRP) receptor. Erenumab prevents the increase in dermal blood flow in cynomolgus monkeys. Erenumab can be used in the research of episodic migraine .
Ibalizumab (TMB-355) is a humanized anti-CD4 IgG4 monoclonalantibody. Ibalizumab prevents HIV cell entry by binding to CD4 receptor. Ibalizumab can be used for the research of infection, such as HIV-1 infection .
Botensilimab (AGEN 1181), a human anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonalantibody, is an innate and adaptive immune activator. Botensilimab can be used for the research of cancer .
IgdE protease is a cysteine protease, which is initially isolated from Streptococcus agalactiae. IgdE protease digests monoclonalantibodies (mAbs) of the IgG1 type specifically at their upper hinge region, produces Fc/2, hinge peptide dimers, and Fab fragment. IgdE protease can be used in disulfide bonds and free thiol analysis, as it requires no reducing agents for cleavage .
Xeligekimab (GR 1501) is an anti-human interleukin 17A (IL-17A) humanized monoclonalantibody. Xeligekimab inhibits the pro-inflammatory cascade. Xeligekimab can be used for the research of inflammatory disease, such as radiographic axial spondyloarthritis .
CAP-100 is a monoclonalantibody that targets CCR7. CAP-100 neutralizes the ligand-binding site and signaling of CCR7. CAP-100 strongly inhibits CCR7-induced migration, extravasation, homing, and survival in chronic lymphocytic leukemia (CLL) samples. CAP-100 triggers potent tumor cell killing, mediated by host immune mechanism. CAP-100 shows a favorable toxicity profile on relevant hematopoietic subsets. CAP-100 is involved in research on anti-tumor and disease such as CLL .
Camidanlumab (HuMax-TAC) is a humanized IgG1 monoclonalantibody against CD25. Camidanlumab can be used to synthesize the ADC molecule Camidanlumab tesirine (HY-141599). Camidanlumab can be used in the research of tumors such as lymphoma and leukemia. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
XmAb-2513 is a humanized monoclonalantibody inhibitor targeting CD30. XmAb-2513 has significant anti-proliferative activity and superior antibody-dependent cell-mediated cytotoxicity (ADCC) as well as antibody-dependent cell-mediated phagocytosis (ADCP). XmAb-2513 can be used for hematologic malignancies like Hodgkin Lymphoma (HL) and Anaplastic Large Cell Lymphoma (ALCL) research .
IBI356 is a humanized monoclonalantibody inhibitor targeting OX40L/CD134L/CD252. IBI356 can be used to study chronic inflammatory skin diseases, such as atopic dermatitis .
Sibeprenlimab (VIS649) is a humanized IgG2monoclonalantibody which inhibits a proliferation-inducing ligand (APRIL). Sibeprenlimab suppresses pathogenic immunoglobulins (IgA and IgM), while preserving antibody responses to mRNA-based vaccines against SARS-COV-2. Sibeprenlimab reduces urinary protein-to-creatinine ratio (UPCR) and glomerular filtration rate (GFR). Sibeprenlimab is promising for the research of IgA nephropathy (IgAN) .
Fasinumab (Anti-Human NGF) is a human IgG4 monoclonalantibody to nerve growth factor (NGF). Fasinumab can be used in acute sciatica and knee osteoarthritis (OA) studies .
Paridiprubart (NI-0101) is a humanised anti-TLR4monoclonalantibody. Paridiprubar inhibits the production of pro-inflammatory cytokines by monocytes from rheumatoid arthritis specimen induced by rheumatoid arthritis synovial fluid (RASF). Paridiprubart can be used for the study of rheumatoid arthritis .
Girancitug is a humanized IgG1κ monoclonalantibody inhibitor targeting VEGFR2/KDR/CD309. Girancitug effectively inhibits angiogenesis. Girancitug can be used for anti-angiogenic therapy in cancers like colorectal and ovarian cancer research .
Galiximab (IDEC-114) is a primatized monoclonal IgG1 antibody targeting CD80. Galiximab variable regions are primatized, and the constant regions are humanized. Galiximab induces antibody-dependent cellular cytotoxicity by blocking CD80-CD28 binding. Galiximab has antitumor activity and can induce apoptosis in tumor cells. Galiximab can be used in the research of relapsed Hodgkin lymphoma and solid tumors .
Betifisolimab (MSB-2311) is a humanized monoclonalantibody directed against the immunosuppressive ligand PD-L1. Betifisolimab has the potential for advanced solid tumors and hematological malignancies research .
S095024 is a humanized IgG1 monoclonalantibody inhibitor targeting CD73. S095024 can be used to study acute respiratory distress syndrome (ARDS), non-small cell lung cancer (NSCLC) and advanced solid tumor malignancies .
Povovetug is a humanized IgG1κ chimeric monoclonalantibody inhibitor targeting NGF/bNGF. Povovetug has a significant analgesic activity. Povovetug can be used for central neuroinflammation like chronic radicular pain research .
Sotigalimab, a CD40 agonistic monoclonalantibody. Sotigalimab binds CD40 with high affinity and activates antigen-presenting cells, thereby stimulating cancer-specific T cell responses. Sotigalimab is mainly used in the study of metastatic pancreatic cancer and metastatic melanoma .
Lanadelumab (SHP643) is a human IgG1 monoclonalantibody against plasma kallikrein (pKal) with an Ki value of 0.12 nM. Lanadelumab inhibits both free and HMWK (high molecular weight kininogen)-bound pKal. Lanadelumab has the potential for the research of hereditary angioedema .
Ixekizumab (LY2439821) is a humanized IgG4 monoclonalantibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab directly blocks IL-17A binding to IL-17RA (IL-17A receptor) but does not bind to other IL-17 family members. Ixekizumab is used for the research of moderate-to-severe plaque psoriasis .
Varlilumab (CDX-1127) (anti-CD27) is an agonist anti-CD27monoclonalantibody. Varlilumab (anti-CD27) can promote T cell expansion and activate the immune response. Varlilumab (anti-CD27) has anti-tumor activity and can be used in the research of hematological malignancies and solid tumors .
HGS004 is a humanized IgG4 monoclonalantibody inhibitor targeting CCR5. HGS004 has potent antivival activity against a diverse panel of CCR5-tropic HIV-1 and durg (such as Maraviroc (HY-13004))-resistant strains. HGS004 can be used for HIV-1 infections research .
JMT203 is a monoclonalantibody against GFRAL and a body weight gain inducer. JMT203 induces early-onset, sustained and progressive body weight gain in cancer cachexia. JMT203 can be used for research related to cancer cachexia .
GSK-1070806 (Aletekitug) is a humanized IgG1/κ monoclonalantibody targeting IL-18. GSK-1070806 neutralizes IL-18 activity.GSK-1070806 can be used for the research of inflammation. The isotype control for GSK-1070806 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
Sirukumab (CNTO-136) is a humanized monoclonalanti-IL6 (Interleukin Related) IgG1κ antibody. Sirukumab binds to IL6, preventing IL6-mediated signal transduction and activation of transcriptional activators, thereby blocking the downstream biological effects of IL6. Sirukumab can be used in the study of active lupus nephritis and rheumatoid arthritis .
TQB2916 is a humanized IgG2 monoclonalantibody agonist targeting CD40. TQB2916 has a significant antitumor activity with CD40 occupancy and immune activation. TQB2916 can be used for advanced solid tumors and lymphomas research .
MDX1201 is a humanized monoclonalantibody targeting PSMA1/7. MDX1201 conjugated with a fluorescent dye AlexaTM488 can be used as a probe for near-infrared fluorescence imaging (NIRF) imaging of prostate cancer .
ANB004 is a humanized monoclonalantibody inhibitor, targeting IL-17. ANB004 can be used for autoimmune and inflammatory diseases like multiple sclerosis and rheumatoid arthritis (RA) research .
Mirzotamab is an IgG1κmonoclonalantibody targeting to CD276/B7-H3 with anti-tumor activity. Mirzotamab conjugates with Clezutoclax (HY-137774), a BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC) .
Anti-ITGB1 Antibody (AIIB2) is a monoclonalantibody targeting integrin-β1 (integrin-β1). Anti-ITGB1 Antibody blocks the binding of the ITGB1 subunit to type I collagen ligands, and abrogates the adhesion of cancer cells to type I collagen-coated surfaces. Anti-ITGB1 Antibody inhibits the proliferation and induces apoptosis of human osteosarcoma cells by activating caspase-3 and regulating apoptosis-related proteins. Anti-ITGB1 Antibody is applicable to research related to osteosarcoma and medulloblastoma .
PSB102 is a humanized Fc-enhanced IgG1 monoclonalantibody directed against the human B-cell-specific cell surface antigen and tumor-associated antigen CD20 .
CS5001 Antibody is an IgG1 human monoclonalantibody targeting ROR1. CS5001 Antibody can be used for the synthesis of the ADC CS5001. It is applicable to research related to advanced solid tumors and lymphomas. The recommended isotype control is human IgG1 kappa (HY-P99001) .
BMS-986156 is a fully humanized IgG1 agonist monoclonalantibody agonist corticosteroid-induced tumor necrosis factor receptor-related protein (GITR). BMS-986156 binds to GITR and promotes activation of T effector cells and inactivates T regulatory cells. BMS-986156 is indicated for use in advanced solid tumor studies .
PF-04840082 is a humanized IgG2 monoclonalantibody inhibitor targeting Dkk-1. PF-04840082 binds the physiological antagonist (Dkk-1) of the Wnt/LRP5 signal pathway and increases bone mass and bone mass density by activating osteoblasts. PF-04840082 can be used for osteoporosis research .
Farletuzumab (MORAb-003) is a potent folate receptor-alpha (FRα) inhibitor. Farletuzumab is a humanized monoclonalantibody with high affinity for FRα. Farletuzumab possesses growth-inhibitory functions on cells overexpressing FRα. Farletuzumab can be used in research of cancer .
Lampalizumab (RG 7417) is a humanised monoclonalantibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research .
Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonalantibody targeted against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in mice. Eculizumab can be used in hemolysis studies .
Iladatuzumab (MCDS0593A) is a humanized IgG1 anti-human CD79Bmonoclonalantibody. Iladatuzumab can be used to synthesize antibody-drug conjugates (ADC) Iladatuzumab vedotin (DCDS0780A; HY-P99657), which has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research .
Panitumumab (ABX-EGF) is a fully human IgG2 anti-EGFRmonoclonalantibody with anti-tumor activity. Panitumumab inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab can be used in the research of cancers, such as colon cancer .
FFP-104 is a humanized IgG4 monoclonalantibody inhibitor targeting TNFRSF5/CD40. VX70 can be used for chronic autoimmune liver diseases research, such as primary biliary cholangitis (PBC) .
CTM01 is a murine IgG1 (or humanized IgG4) monoclonalantibody inhibitor targeting MUC1. CTM01 has a broad spectrum anticancer activity against solid tumors of epithelial origin, such as breast, lung and ovarian cancer .
ELDKWA is the highly conserved amino acids on the ecto-domain of gp41. ELDKWA acts as the epitope of a neutralizing monoclonalantibody 2F5 (mAb 2F5) directed against human immunodeficiency virus type 1 .
Veltuzumab (IMMU-106) is a humanized anti-CD20 monoclonalantibody. Veltuzumab has low EC50 value of 0.08-0.09 μg/mL in the Daudi cell line. Veltuzumab can be used for the research of cancer including non-Hodgkin lymphoma (NHL) .
Calpurbatug is an immunoglobulin G1 antibody. Calpurbatug has activity with anti-bacterial DNA-binding protein DNABII family and anti-human monoclonal TRL1068 γ1-chain .
Foralumab (NI-0401) is a potent, orally active human monoclonalantibody targeting the CD3. Foralumab modulates immune responses by human cells in NSG mice that were reconstituted with human hematopoietic stem cells .
Zalutumumab is a high affinity, completely human IgG1 monoclonalantibody targeting EGFR. Zalutumumab binds to domain III of the EGF receptor and acts by blocking the binding of EGF and by sterically interfering with the active conformation of the receptor. Zalutumumab binds with IgG and its Fab fragment with EC50s of 7 and 19 nM, respectively. Zalutumumab can be used for the research of cancer .
Panitumumab (ABX-EGF) (powder) is a fully human IgG2 anti-EGFRmonoclonalantibody with anti-tumor activity. Panitumumab (powder) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (powder) can be used in the research of cancers, such as colon cancer .
Enokizumab (MEDI-528) is a monoclonalantibody targeting to interleukin (IL)-9. IL-9 regulates the development of airway inflammation, mucus production, airway hyperresponsiveness, and airway fibrosis largely by increasing mast cell numbers and activity in the airways .
SCH708980 is a humanized monoclonalantibody inhibitor targeting IL-10. SCH708980 has anti-immunosuppressive activity. SCH708980 can be used for visceral leishmaniasis, sepsis-associated kidney injury (SAKI) and osteoporosis research .
Serplulimab (HLX 10) is a humanized anti-PD-1monoclonalantibody. Serplulimab can inhibit tumor growth, regulate the tumor microenvironment, and has anti-tumor activity. Serplulimab can be used in the research of cancer such as lung cancer and colon cancer .
Somantadine, an adamantane derivative, is an antiviral agent with high cross-reactivity with anti-amantadine monoclonalantibodies. Somantadine can be used for research of coronavirus-related diseases .
XKH001 is a recombinant humanized IgG1 monoclonalantibody targeting IL-25. XKH001 has low immunogenicity. XKH001 can be used for the research of type 2 inflammatory diseases .
Relatlimab (BMS-986016) is a human monoclonalantibodyanti-LAG-3antibody generated by immunization of transgenic mice bearing human immunoglobulin miniloci with recombinant LAG-3 protein. Relatlimab blocks LAG-3/MHC II interaction with an IC50 value of 0.67 nM and LAG-3/FGL1 interaction with an IC50 value of 0.019 nM. Relatlimab can be used in research of cancer .
Vantictumab (OMP-18R5) is a fully human IgG2 monoclonalantibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab can be studied against cancers through direct actions on tumor cells, including CSCs, and effects on the stroma, such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma .
Fresolimumab (GC1008) is a human monoclonalantibody against TGF-β that neutralizes all mammalian active subtypes of TGF-β. The binding affinity of Fresolimumab to TGF-β2 is 1.8 nM. Fresolimumab improves Bleomycin (HY-108345)-induced acute lung injury. Fresolimumab radiolabeled with 89Zr can be used for PET analysis of TGF-β expression, antibody uptake and organ distribution. Fresolimumab can be used in the study of cancer, osteogenesis imperfecta, fibrosis and kidney disease .
S-095029 is a humanized IgG1 monoclonalantibody inhibitor targeting NKG2A. S-095029 significantly attenuates Fc-effector functions, inhibits the interaction with its ligand HLA-E, and increases the antibody-dependent cellular cytotoxicity mediated by other Fc-competent mAbs. S-095029 has a potent antitumor activity with enhancement of killing activity and cytokine secretion (IFNγ, TNF-α and CXCL9) of NK and γδ T-cells in co-culture with cancer cells .
Abrilumab is a fully human monoclonalantibody directed against α4β7. Abrilumab selectively binds the α4β7 integrin heterodimer. Abrilumab can be used for the research of inflammatory bowel disease (IBD) .
Zalutumumab (powder) is a high affinity, completely human IgG1 monoclonalantibody targeting EGFR. Zalutumumab (powder) binds to domain III of the EGF receptor and acts by blocking the binding of EGF and by sterically interfering with the active conformation of the receptor. Zalutumumab (powder) binds with IgG and its Fab fragment with EC50s of 7 and 19 nM, respectively. Zalutumumab (powder) can be used for the research of cancer .
Canakinumab (ACZ885) is a recombinant human anti-IL-1βmonoclonalantibody. Canakinumab shows IC50 values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin .
Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonalantibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules. Ieramilimab restores T-cell and NK-cell-mediated antileukemic immunity by reducing exhaustion and augmenting cytokine output and cytotoxicity. Ieramilimab increases the infiltration of cytotoxic T lymphocytes and reduces baseline densities of regulatory T cells (Tregs) and ADAM10-expressing tumor cells. Ieramilimab can be used for the study of various malignancies including melanoma, RCC, and advanced solid tumors .
HuL001 is a specific monoclonalantibody targeting ENO1. HuL001 remodels the tumor microenvironment by inhibiting cancer-associated fibroblasts, thereby suppressing the progression of multiple myeloma. HuL001 can be used for research on cancers such as colorectal cancer, pancreatic ductal adenocarcinoma, and myeloma .
Panitumumab (anti-EGFR) is a fully human IgG2 anti-EGFRmonoclonalantibody with anti-tumor activity. Panitumumab (anti-EGFR) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (anti-EGFR) can be used in the research of cancers, such as colon cancer .
BI-1607 is a humanized monoclonalantibody targeting CD32b/FcγRIIB. BI-1607 has an antagonistic function capable of blocking the inhibitory function of FcγRIIB on immune effector cells. BI-1607 has a significant cytolytic activity against malignant B cells and antitumor activity against HER2-positive solid tumors including advanced gastric cancer (GC) with combination with Trastuzumab (HY-P9907) .
REGN7999 is a monoclonalantibody that inhibits TMPRSS6. REGN7999 inhibits TMPRSS6 activity, preventing Hemojuvelin (HJV) lysis, thereby enhancing BMP6-HJV signaling and increasing serum hepcidin. REGN7999 ameliorates iron overload and impaired erythropoiesis in a β-thalassemia mouse model by inhibiting TMPRSS6 activity. REGN7999 is indicated for research in β-thalassemia .
Tinurilimab (Bay 1834942) is an anti-CEACAM6 (carcinoembryonic antigen-related cell adhesion molecule 6) humanized IgG2 monoclonalantibody. CEACAM6 is an immune checkpoint regulator suppressing the activity of effector T-cells against tumors. Tinurilimab shows an increased tumor cell killing effect in the tumor-cell/T-cell co-culture system .
Pucotenlimab (HX008) is a humanized immunoglobulin G4 (IgG4) anti programmed cell death protein 1 (anti-PD-1)monoclonalantibody. Pucotenlimab can be used for the research of tumor .
HY-0102 is a humanized IgG anti-NKG2Amonoclonalantibody and immune checkpoint inhibitor targeting the NKG2A/HLA-E axis. HY-0102 is applicable for the research of advanced solid tumors .
Sunakiment is a humanized IgG1λ monoclonalantibody inhibitor targeting Thymic stromal lymphopoietin (TSLP). Sunakiment can be used for inflammatory and immune system disorders like ulcerative colitis, rheumatoid arthritis and allergy and cancers research .
ABT-147 is a humanized IgG1 monoclonalantibody inhibitor targeting IL-12. ABT-147 can be used to study autoimmune diseases like rheumatoid arthritis (RA), inflammatory diseases like inflammatory bowel disease (IBD) and other diseases like Asthma .
Inclacumab (Anti-Human selectin P Recombinant Antibody) is a human monoclonal IgG4 antibody selectively targets P-selectin with a Kd value of 9.9 nM. Inclacumab inhibits P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide bind with P-selectin with an IC50 value of 1.9 μg/mL and strongly inhibits cell adhesion .
Olsutamig is a bivalent humanized IgG4κ monoclonalantibody inhibitor targeting FOLH1/PSMA and CD3E. Olsutamig simultaneously binds to PSMA on the tumor cell surface and CD3E on the T cell surface, markedly activating T cells and thereby specifically killing prostate cancer cells .
PUR001 is a monoclonalantibody targeting NTPDase 1 (CD39). PUR001 blocks the hydrolysis of extracellular ATP and ADP into AMP by inhibiting CD39, reduces the production of immunosuppressive adenosine, and increases extracellular ATP concentration to activate anti-tumor immune responses. PUR001 can be used in studies related to solid tumors .
Mavrilimumab (CAM 3001) is a monoclonalantibody that binds to the α subunit of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor and blocks intracellular signalling downstream of GM-CSF. GM-CSF might be a mediator of the hyperactive inflammatory response associated with respiratory failure and death .
Narsoplimab (OMS 721) is a high-affinity fully human immunoglobulin gamma 4 (IgG4) monoclonalantibody that binds MASP-2 and blocks lectin pathway activation. Narsoplimab can be used in research of hematopoietic stem-cell transplantation and SARS-CoV-2 .
Beruzatatug (BNT326/YL202 Antibody) is an IgG1 monoclonalantibody against HER3. Beruzatatug can be used for the synthesis of ADCs, such as BNT326/YL202 .
Raxibacumab (ABthrax) is a human IgG1 monoclonalantibody against Bacillus anthracis protective antigen (PA). Raxibacumab blocks the toxin’s deleterious effects by preventing binding of the protective antigen component of the anthrax toxin to its receptors in host cells, thereby blocking the toxin’s deleterious effects. Raxibacumab can be used for anti-anthrax research .
AFM15 is a humanized monoclonalantibody inhibitor targeting CD3E. AFM15 can be used to study metabolic and immune system diseases, such as type 1 diabetes and inflammatory bowel disease (IBD) .
Elsilimomab (B-E8) is a IgG1 monoclonalantibody against interleukin-6 (IL-6), with a KD of 22 pM and an IC50 of 1.4 nM. Elsilimomab can be used for the research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA) .
Surzebiclimab (BGB-A425) is a humanized IgG1-variant monoclonalantibody against T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). Surzebiclimab binds to the extracellular domain of human Tim-3 with high affinity (KD=0.36 nM) and specificity. Surzebiclimab can be used in research of cancer .
Toralizumab (IDEC-131) is a humanized monoclonalantibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab is an immunosuppressive agent. Toralizumab can lead to increased thrombosis. Toralizumab can be studied in research for diseases such as multiple sclerosis, systemic lupus erythematosus (SLE), and Crohn’s disease .
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonalantibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .
Retifanlimab is an anti-programmed cell death protein 1 (anti-PD-1) monoclonalantibody (mAb). Retifanlimab can be used for the research of gastroesophageal adenocarcinoma (GEA) .
Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6monoclonalantibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19 .
CC-90002 is a humanized anti-CD47 monoclonalantibody (mAb). CC-90002 has a high affinity for binding to CD47 with a subnanomolar Kd value. CC-90002 can be used for the research of hematologic malignancies and solid tumors .
Lirentelimab (AK002) is a humanized IgG1 monoclonalantibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab induces cell apoptosis of IL-5-activated eosinophils and inhibits IgE-mediated mast cell activation. Lirentelimab can be used for the research of eosinophilic gastritis and duodenitis .
ZM-008 is an anti-LLT1monoclonalantibody. ZM-008 blocks the interaction between LLT1 and CD161 on the surface of NK cells and T cells. ZM-008 restores anti-tumor immune activity, shifts the tumor microenvironment to an immune-responsive state, and recovers NK cell-mediated cytotoxicity against tumor cells, thereby reversing immunosuppression in immune-resistant "cold" tumors. ZM-008 is applicable to the research of immune-resistant solid tumors .
SAIT-301 is a Met-targeting monoclonalantibody. SAIT-301 inhibits Met activation, induces downregulated expression of phosphorylated Met(p-Met) and phosphorylated ERK(p-ERK), and reduces EGR-1 expression. SAIT-301 inhibits the migration and invasion of nasopharyngeal carcinoma cells. SAIT-301 is applicable to relevant research on nasopharyngeal carcinoma. For the isotype control of SAIT-301, refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
Belimumab (LymphoStat B) is a humanized IgG1λmonoclonalantibody against B-lymphocyte stimulator (BLyS) protein. Belimumab antagonizes BLyS activity in autoimmune diseases and B-lymphocyte malignancies. Belimumab can be used for systemic lupus erythematosus (SLE) research . The component ratio of this product is Active ingredient: Excipients = 1:1.0-1:1.2.
MEDI-5884 is a humanized IgG4Pκ neutralizing monoclonalantibody targeting Endothelial lipase (EL). MEDI-5884 inhibits EL and increases quantity (particularly phosphatidylinositols and cholesteryl esters) and function of high-density lipoproteins (HDL). MEDI-5884 can be used for cardiovascular disease like coronary artery disease (CAD) research .
FTL004 is an anti-CD38monoclonalantibody. FTL004 exhibits enhanced Proapoptotic activity and displays stronger ADCC against CD38 + malignant cells. FTL004 can be used for the research of multiple myeloma and non-Hodgkin lymphoma[1].
Ofatumumab is a fully human anti-CD20monoclonalantibody that induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in CD20-expressing B lymphocytes. Ofatumumab has strong lytic activity against CD20-positive B lymphocytes and eliminates CD20-positive tumor cells through ADCC and CDC. Ofatumumab is particularly effective against drug-resistant cells with low CD20 expression and can be applied to the research of chronic lymphocytic leukemia (CLL) .
RSM-01 is a monoclonalantibody targeting site Ø of the pre-fusion F glycoprotein (Fusion glycoprotein F0) of respiratory syncytial virus (RSV). RSM-01 can be used in studies related to RSV infection .
Prezalumab (AMG 557) is a humanized IgG2 monoclonalantibody targeting ICOSL. Prezalumab inhibits T cell activation and related immune responses by binding to ICOSL and blocking the interaction between ICOS and ICOSL. Prezalumab can be used in the research of autoimmune diseases and inflammatory diseases such as systemic lupus erythematosus. Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002) .
ALX-0651 is a biparatopic humanized monoclonalantibody inhibitor targeting CXCR4. ALX-0651 inhibits hematopoietic stem cell trafficking, tumor progression and metastasis. ALX-0651 can be used for non-Hodgkin’s lymphoma and multiple myeloma research .
CTX-471 is a fully human monoclonalantibody of CD137. CTX-471 has bind affinity for recombinant human, cynomolgus macaque CD137 and mouse CD137 with Kd values of 50 nM, 61 nM and 748 nM, respectively. CTX-471 can be used for the research of immunomodulation and cancer .
TQC2938 is a humanized IgG2 monoclonalantibody inhibitor targeting Stimulation-2 (ST2). TQC2938 inhibits the ST2/IL-33 signaling pathway, reduces the level of downstream Th2 cytokines (such as IL-4, IL-5, and IL-13) and eosinophils as well as other inflammatory cells. TQC2938 can be used for inflammatory diseases like asthma research .
AB011 is a recombinant humanized anti-CLDN18.2 IgG1 monoclonalantibody. AB011 exhibits synergistic effects with cytotoxic compounds in preclinical studies. AB011 can be used for research on advanced gastric/gastroesophageal junction adenocarcinoma and advanced pancreatic cancer .
Sudubrilimab (HS636) is an Ig G1-kappa monoclonalantibody against PDL1. Sudubrilimab is fused at the C terminus of the heavy chain to a TGF-β1 receptor Ⅱ ectodomain (TGFBR2-ECD), and which can sequester the PD-1/PD-L1 pathway and TGF-β bioactivity in the immunosuppressive tumor microenvironment .
Efalizumab is a targeted T cell modulator, and is a humanized monoclonalantibody of CD11a, the α subunit of LFA-1. Efalizumab inhibits T cell activation, cutaneous T cell trafficking, and T cell adhesion to keratinocytes, can be used for plaque psoriasis research .
Mepolizumab (SB 240563) is a humanized monoclonalantibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .
Satralizumab is a humanized monoclonalantibody that targets IL-6R. Satralizumab prevents dTAA formation and progression in rattus norvegicus. Satralizumab can be used for neuromyelitis optica spectrum disorder (NMOSD) and descending thoracic aorta aneurysm (dTAA) research .
Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research .
Mepolizumab (anti-IL5) is a humanized monoclonalantibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .
SCN-PYTA is a bifunctional chelator for trivalent radiometals. After conjugation with monoclonalantibodies, SCN-PYTA forms a stable complex with 225Ac to achieve efficient radiolabeling. SCN-PYTA can be used in cancer research .
SAR-446523 is a humanized IgG1 monoclonalantibody inhibitor targeting GPRC5D. SAR-446523 significantly induces antibody-dependent cell-mediated cytotoxicity (ADCC). SAR-446523 has potent antitumor activity with improvement of mouse survival in NK humanized NOG huIL15 transgenic mice model bearing MM cells. SAR-446523 can be used for multiple myeloma (MM) research .
Aducanumab (Mouse IGG2a) is a monoclonalantibody that selectively targets aggregated amyloid-beta (Aβ). The variable region of Aducanumab (Mouse IGG2a) is consistent with that of Aducanumab (HY-P9967), while the constant region is of Mouse IGG2a sequence. Aducanumab (Mouse IGG2a) has strong selectivity for Aβ fibrils with EC50s of >1 μM and 0.2 nM for monomeric Aβ1-40 and fibrillar Aβ1-42, respectively. Aducanumab (Mouse IGG2a) can be used for Alzheimer's disease (AD) research .
AGS-009 is a humanized monoclonal neutralising antibody targeting IFN-α. AGS-009 significantly reduces activated lymphocytes, such as CD4 + and CD8 + T cells as well as B cells in SIV infection rhesus macaque models. AGS-009 can be used for autoimmune diseases like systemic lupus erythematosus (SLE) and HIV infections research .
Modakafusp alfa (TAK-573) is a humanized, anti-CD38IgG4monoclonalantibody fused to 2 attenuated IFNα2b molecules, which delivers interferon-alpha to CD38-expressing cells. Modakafusp alfa has direct anti-proliferative activity on multiple myeloma (MM) cancer cells in vitro and induces robust and durable antitumor responses in MM xenograft tumor models. Modakafusp alfa in combination with anti-PD-1 antibodies induces immunomodulation and antitumor responses with good tolerance in mice .
AK006 is a humanized IgG1 monoclonalantibody agonist targeting Sialic acid-binding immunoglobulin-like lectin6 (Siglec-6). AK006 potently inhibits IgE-mediated human mast cell activation. AK006 can be used for inflammatory diseases like chronic urticaria (CU) and asthma research .
ART5803 is a humanized IgG1 monoclonalantibody inhibitor targeting NMDAR. ART5803 binds to the N-terminal domain (NTD) of the NMDAR GluN1 subunit (GluN1-NTD) with a high affinity. ART5803 blocks NMDAR internalization induced by pathogenic autoantibodies and restores cell-surface NMDAR expression and functions. ART5803 reverses behavioral abnormalities and NMDAR expression in marmoset disease models. ABT-147 can be used to study anti-NMDAR encephalitis .
Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonalantibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with Ki values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD) .
TRX585 is a humanised anti-immunoglobulin-like transcript 5 (ILT5) monoclonalantibody. TRX585 has a potent immunoregulatory activity. TRX585 significantly activates human T cells and upregulates NKG2D and Fas ligand, followed by enhancing antitumor activity with potent cytotoxicity. TRX585 can be used for viral infections and malignancies research .
ABX-MA1 is a humanized IgG2 monoclonalantibody inhibitor targeting MCAM/MUC18. ABX-MA1 significantly decreases homotypic aggregation and heterotypic adhesion to HUVECs, and the formation of experimental lung metastasis. ABX-MA1 potently inhibits tumor growth, angiogenesis, and MMP-2 expression in A375SM/WM2664 xenograft mice model, promising for melanoma research .
CQY684 (PCA062 antibody) is a monoclonalantibody targeting CDH3/P-cadherin, which locks P-cadherin in an X-dimer conformation and enhances the stability of this adhesion structure. CQY684 induces P-cadherin phosphorylation and promotes its dissociation from the cytoplasmic region of P-cadherin. As an endocytosis inducer and lysosome-targeting agent, CQY684 facilitates the internalization of the P-cadherin-CQY684 complex and improves the turnover efficiency of P-cadherin. CQY684 serves as a platform for the delivery of intracellular anticancer compounds, which is achieved through the targeted lysosomal transport of the antibody-P-cadherin complex. CQY684 is applicable to the research of breast cancer, esophageal cancer, and head and neck cancer .
VX5 (VX5/5261) is a humanized IgG1κ monoclonalantibody inhibitor targeting BCA-1/CXCL13. VX5 significantly inhibits human CXCL13-mediated internalization of CXCR5, blocks both human and mouse CXCL13-dependent B-cells chemotaxis and migration. VX5 can be used to study autoimmune diseases like multiple sclerosis and arthritis, and cancers like gastric lymphomas and colon cancer .
RO-7303509 (MTBT1466A; RG-6315) is a human monoclonalantibody and TGFβ3 neutralizer. RO-7303509 targets the profibrotic mediator TGFβ3 to alleviate fibrosis. RO-7303509 can be administered via subcutaneous or intravenous routes and is used in research on systemic sclerosis . Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
Spartalizumab is a humanized PD-1 IgG4 monoclonalantibody, with a Kd of 0.83 nM for human PD-1 and a Kd of 0.93 nM for cynomolgus monkey PD-1. Spartalizumab binds to PD-1 and blocks its interaction with the ligands PD-L1 and PD-L2. Spartalizumab induces increased IFNγ release. Spartalizumab can be used in the research of anaplastic thyroid carcinoma (ATC) and neuroendocrine neoplasms (NENs) .
Nidanilimab (CAN04) is a fully humanized monoclonalanti-IL1RAPantibody with a Kd value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) .
Briquilimab (JSP-191 or AMG-191) is a humanized IgG1 monoclonalantibody that binds human CD117 (c-Kit). Briquilimab blocks the interaction between CD117 receptor and stem cell factor on various CD117 expressing tissues. Briquilimab can lead to inhibition of SCF/c-Kit signaling and MC apoptosis. Briquilimab is a non-toxic approach to target and deplete HSC, enabling blood and immune reconstitution with minimal toxicity with the other agents being used for transient immune suppression to prevent immunologic rejection. Briquilimab can be used in various disease research such as severe combined immunodeficiency (SCID), myelodyplastic syndromes (MDS), acute myeloid leukemia (AML), chronic spontaneous urticarial (CSU), chronic inducible urticarial (CIndU) and asthema .
JS006 is a humanized IgG4κ monoclonalantibody inhibitor targeting TIGIT/CD155. JS006 can be used to study advanced and/or metastatic cancers with resistance to PD-1/PD-L1 inhibitor such as non-small cell lung cancer (NSCLC), advanced lymphoma and advanced/metastatic triple negative breast cancer (TNBC) .
Astegolimab (MSTT 1041A; RG 6149) is a human IgG2 monoclonalantibody. Astegolimab blocks IL-33 signaling by targeting the IL-33 receptor ST2. Astegolimab reduces p53 expression, mitigates IL33-upregulated SASP factors such as IL1α, IL6 and MCP1. Astegolimab mitigates IL33-increased p-p65/p65 ratio. Astegolimab blocks CM-induced neutrophil extracellular trap (NET) formation. Astegolimab is used in chronic obstructive pulmonary disease (COPD) and myocardial research .
MEDI4212 is a humanized IgG1λ monoclonalantibody inhibitor targeting IgE. MEDI4212 potently inhibits human IgE-mediated functional responses through its receptor FcεRI, such as calcium signaling, β-hexosaminidase release and phagocytosis. MEDI4212 prevents the binding of IgE to CD23 with an IC50 of 8 nM. MEDI4212 can be used severe asthma research .
Eptinezumab (ALD-403) is a human monoclonalantibody targeting the α and β subtypes of human calcitonin gene-related peptide (CGRP). Eptinezumab binds to the CGRP ligand and blocks its binding to endogenous CGRP receptors, thereby inhibiting receptor activation. Eptinezumab can be used in research related to migraine .
Ruplizumab (BG 9588) is a humanized anti-CD40L IgG1κ monoclonalantibody. By binding to CD40L, Ruplizumab blocks its interaction with the CD40 receptor, inhibits T-B cell costimulatory signals, and mediates the depletion of activated T cells via the Fc segment. Ruplizumab has immunosuppressive effects. Ruplizumab can be used in the study of systemic lupus erythematosus, organ transplant rejection, and autoimmune diseases. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
SHR-1702 is a monoclonalantibody targeting TIM-3, which specifically binds to and blocks the TIM-3 signaling pathway. SHR-1702 restores the function of immune cells and inhibits the proliferation process of malignant cells. SHR-1702 is mainly used in relevant research on acute myeloid leukemia and myelodysplastic syndromes .
Anafiltamig is a trivalent monoclonalantibody inhibitor targeting CD79B, CD3E and MS4A1. Anafiltamig consists of a humanized IgG1κ anti-CD79B arm and a bispecific scFv-based arm targeting CD3E and MS4A1. Anafiltamig simultaneously bridges T and B cells, activating T cells and specifically killing B cell tumors. Anafiltamig can be used for B cell malignancies such as non-Hodgkin lymphoma research .
Elfritatug (UCB4594) is a humanized monoclonalantibody targeting human leukocyte antigen-G (HLA-G). By binding to HLA-G on the surface of tumor cells, Elfritatug blocks its immunosuppressive effect, thereby enhancing the body's immune response against tumors .
Theralizumab (TGN1412) is a humanized lgG4 superagonistic anti-CD28monoclonalantibody that directly stimulates T cells. Theralizumab can cause cytokine release syndrome (CRS). Theralizumab can be used for the research of rheumatoid arthritis .
Sarilumab is a monoclonalantibody targeting IL6 that binds to IL6R and blocks the binding of IL6, thereby inhibiting the activation of the downstream STAT3 phosphorylation signaling pathway. In tumor cells with active IL6/STAT3 signaling pathways, Sarilumab induces Apoptosis and inhibits cell growth. Sarilumab is applicable to research related to prostate cancer, lung cancer and rheumatoid arthritis .
MM-151 is a humanized IgG1 monoclonalantibody targeting EGFR. MM-151 binds multiple regions of the EGFR extracellular domain (ECD) and reduces its mutations in circulating cell-free tumor DNA with EGFR resistance. MM-151 significantly inhibits EGFR signaling and cell growth. MM-151 can be used for drug-resistant cancers research, such as colorectal, non-small cell lung and triple negative breast cancer .
LY-2624587 is a humanized IgG4 monoclonalantibody antagonist targeting CXCR4. LY-2624587 blocks SDF-1/CXCR4 interaction and SDF-1-induced GTP binding. LY-2624587 significantly inhibits cell migration and induces apoptosis in human lymphoma and leukemia cells. LY-2624587 also inhibits CXCR4 and SDF-1 mediated cell signaling including activation of MAPK and AKT. LY-2624587 can be used for human hematological malignancies like acute myeloid leukemia (AML) research .
SHR-1906 is a selective fully humanized monoclonal IgG1 inhibitory antibody targeting CTGF. SHR-1906 specifically binds to CTGF, thereby blocking the interaction between CTGF and TGF-B1 with an inhibition rate of 55%. SHR-1906increases the survival rate in a pulmonary fibrosis model by reducing TGF-β1 levels and inhibiting fibrotic lesions in lung tissue in Bleomycin (HY-108345)-induced pulmonary fibrosis.SHR-1906 can be used for pulmonary fibrosis (IPF) research. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonalantibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab (HY-P9913). Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL) .
AB-004 is a humanized monoclonalantibody and ADC targeting uPARAP. AB-004 can be conjugated with the topoisomerase-1 inhibitor P1021 via a protease-cleavable tetrapeptide linker to form the ADC ADCE-D01. AB-004 binds to tumor cells expressing uPARAP, triggering the endocytosis of the ADC. AB-004 is applicable for cancer research .
Tislelizumab is a monoclonalantibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small cell lung cancer and hepatocellular carcinoma .
NSP-DMAE-NHS is an acridinium ester-based signal amplifier that can act as a luminescent probe to effectively improve the detection performance of biosensors. NSP-DMAE-NHS preserves the biochemical activity of biomolecules during the conjugation process. NSP-DMAE-NHS has been successfully applied to label mouse anti-human PI3monoclonalantibodies for chemiluminescent immunoassays, as well as for pre-competitive chemiluminescent immunochromatographic detection of TP53 fusion proteins. NSP-DMAE-NHS can be used in detection studies of cancer and related biomarkers .
HB-0017 is a humanized IgG1κ monoclonalantibody inhibitor, targeting IL-17A. HB-0017 inhibits the IL-6 secretion induced by IL-17A with an IC50 of 2.09 nM. HB-0017 significantly decreases ear thickness in Imiquimod (HY-B0180)-induced psoriasis-like mice model and alleviates inflammations in IL-17A-induced arthritis and air pouch mice model. The isotype control for the HB-0017 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
Frexalimab (SAR441344) is a second-generation monoclonalantibody targeting the CD40 ligand (CD40L) with a good safety profile. Frexalimab inhibits the binding between CD40 and CD40L to modulate immune response. Frexalimab is likely to help prevent the process of β-cell destruction. Frexalimab is proming for multiple sclerosis, lupus erythematosus, Sj gren’s syndrome and type I diabetes research .
KD6001 is a humanized IgG1κ monoclonalantibody, targeting CTLA4. KD6001 significantly disrupts CTLA-4 interactions with CD80 (IC50: 16 ng/mL) and CD86. KD6001 enhances IL-2 and IFNγ expression in PHA-activated human lymphocytes and exhibits potent antitumor effects. KD6001 effectively inhibits tumor growth in MC38, B16, and Hepa1-6 tumor mice model. KD6001 can be used for cancers research, such as advanced melanoma, hepatocellular carcinoma and liver cancer .
BXY-14 is a TLR2 agonist and vaccine adjuvant. BXY-14 significantly downregulates the expression of intratumoral PD-L1 in mouse models. BXY-14 acts as a vaccine adjuvant to induce antibody responses. BXY-14 exhibits synergistic efficacy when combined with the anti-PD-L1monoclonalantibody Atezolizumab (HY-P9904) in mouse models of melanoma, and prolongs overall survival. BXY-14 is applicable to research related to melanoma .
Elfetabart drozuntecan (DB-1311; BNT324) is an antibody-drug conjugate (ADC) targeting B7H3. Elfetabart drozuntecan conjugates a humanized anti-B7H3 IgG1 monoclonalantibody with a topoisomerase I inhibitor via a cleavable linker. Elfetabart drozuntecan exerts antitumor activity in solid tumors. Elfetabart drozuntecan can be used for the research of advanced/metastatic solid tumors .
IBI-325 is a humanized monoclonalantibody inhibitor targeting CD73. IBI-325 completely inhibits CD73 enzymatic activity without hook effect. IBI-325 reverses Adenosine monophosphate (HY-A0181)-mediated immune suppression and significantly inhibits T cell proliferation and cytokines (IL-2, IFN-γ and TNF-α) release. IBI-325 has potent antitumor activities in hPBMC-reconstituted mice model and hCD73 knock-in mice model. IBI-325 can be used for cancer immunotherapy research .
AMG-172 is an antibody-drug conjugate (ADC) composed of a fully human IgG1 monoclonalanti-CD27Lantibody conjugated to DM1 (HY-19792) via the non-cleavable linker MCC. AMG-172 releases the intracellular active component Lysine-MCC-DM through catabolism. Lysine-MCC-DM inhibits the assembly and disassembly dynamics of Microtubule and induces cell arrest at metaphase. AMG-172 can be used for research on relapsed/refractory clear cell renal cell carcinoma .
Muromonab (Muromonab-CD3; OKT3) is a mouse monoclonalantibody targeting the CD3 antigen. Muromonab specifically binds to the CD3 antigen on the surface of human and higher primate T cells. Muromonab blocks the function of T cell receptors to recognize foreign antigens and inhibits T cell-mediated immune responses, including cell-mediated lymphocyte lysis and T cell proliferation responses. Muromonab can be used to study acute kidney, liver, heart and combined kidney-pancreas transplant rejection, and can also be used to study graft-versus-host disease in bone marrow transplant patients .
OM-RCA-01 is an anti-FGFR1monoclonalantibody with a Kd of 1.59 nM for human FGFR1. OM-RCA-01 inhibits the phosphorylation of FGFR1, blocks FGF-mediated signaling pathways, and suppresses the proliferation of downstream tumor cells. OM-RCA-01 delays tumor growth in lung cancer and renal cancer xenograft models expressing FGFR1. When combined with Nivolumab, OM-RCA-01 enhances the release of IFN-γ and IL-2. OM-RCA-01 is applicable for the research of lung cancer and renal cell carcinoma .
Navivumab (CT-P23) is a monoclonalantibody targeting the hemagglutinin (HA) of influenza A virus. Navivumab binds to the HA2 stem fusion domain and the low-variability HA2 region of influenza viruses. Navivumab neutralizes influenza A viruses of subtypes H1, H2, H5, and H9. Navivumab is applicable to research related to influenza and influenza A .
ING-1 (heMab) is a high-affinity humanized monoclonalantibody against epithelial cell adhesion molecule (Ep-CAM). ING-1 is a transmembrane glycoprotein mediating Ca 2+. ING-1 binds to Ep-CAM on tumor cells and exhibits potent in vitro activity, targeting and inhibiting tumor growth and metastasis in mouse cancer models. ING-1 is useful in the research of breast, colorectal, and lung cancers, among other cancers .
Sintilimab (IBI308) is a safe and effectivel humanized IgG4monoclonalantibody that binds to PD-1 with a KD value of 74 pM. Sintilimab blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .
IOR-T3 is a monoclonalantibody targeting CD3, with biological activities related to T cell activation regulation . IOR-T3 uses its variable region to competitively engage surface CD3 on lymphocytes and trigger robust T cell proliferation and activation. IOR-T3 and its derivatives can be used in studies related to acute transplant rejection .
Zaltenibart (OMS906) is an IgG4 humanized monoclonalantibody and MASP-3 inhibitor. By inhibiting MASP-3, Zaltenibart achieves upstream inhibition of the alternative complement pathway. MASP-3 is an upstream activator of Factor D (Factor D), a key enzyme in the alternative complement pathway. Zaltenibart prevents both intravascular hemolysis and extravascular hemolysis. Zaltenibart is applicable to research related to paroxysmal nocturnal hemoglobinuria .
Vasigrobart is a CHO-expressed human antibody that targets PDGFB. Vasigrobart has huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Vasigrobart can refer to Human IgG4 kappa, Isotype Control (HY-P99003) .
Lunaxafusp is an anti-ERBB2 scFv-heavy-κ monoclonalantibody composed of a single chain variable fragment, an antibody heavy chain, and a kappa antibody light chain .
Sulfonylurea Receptor HRP-Streptavidin is a biotin-binding signal amplifier designed to bind tightly with biotinylated anti-TSH monoclonalantibodies, thereby constituting a key component of the signal amplification system in immunoassays. HRP-Streptavidin is formed by the covalent coupling of Horseradish Peroxidase (HRP) with Streptavidin; it combines the highly efficient catalytic activity of the enzyme with the high affinity of Streptavidin for biotin, making it a potent and sensitive tool for signal amplification. HRP-Streptavidin is suitable for use in Western Blotting, ELISA, and other detection techniques .
Natalizumab (Anti-CD49d) (AN100226; BG00002) Solution is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d), blocking the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab solution inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 + T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thereby exerting anti-inflammatory and immunomodulatory activity. Natalizumab (Anti-CD49d) solution is used in the study of relapsing-remitting multiple sclerosis (RRMS) and is also applied in the research of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab (Anti-CD49d) can also prevent lymphocytes from entering the central nervous system, thus preventing acute demyelinating relapses .
DNA-PK-IN-16 is an orally active DNA-dependent protein kinase (DNA-PK) inhibitor with an IC50 of 10.2 nM. DNA-PK-IN-16 induces the upregulation of γH2A.X, a biomarker of DNA double-strand breaks. DNA-PK-IN-16 exhibits antiproliferative activity in various cancer cell lines. DNA-PK-IN-16 enhances the infiltration of CD8 + T cells in tumor tissues through synergistic action with anti-PD-L1monoclonalantibody. DNA-PK-IN-16 is applicable for cancer research .
Clivatuzumab-MMAE is an antibody-drug conjugate (ADC) (Clivatuzumab antibody (HY-P99968), Linker: VC linker, Payload: MMAE (HY-15162)). Anetumab is a humanized anti-mucinmonoclonalantibody.
Verekitug (ASP-7266; TRAB-1; UPB-101) is a human monoclonalantibody targeting the thymic stromal lymphopoietin receptor (TSLPR), with a mean half-life of approximately 20 days. At doses of Verekitug ≥100 mg, complete and sustained TSLPR-specific occupancy is achieved, and the antibody does not bind to IL-7Rα. By inhibiting TSLP-driven inflammatory responses, Verekitug blocks TSLP-induced cell proliferation and TARC expression, while reducing fractional exhaled NO levels, blood eosinophil counts, and levels of IL-5 and IgE. Verekitug significantly improves scores for nasal polyps, nasal congestion and olfactory dysfunction, with favorable safety and good tolerability; potential adverse reactions include headache, upper respiratory tract infection, sinusitis and nasopharyngitis. Verekitug is used in relevant studies on asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease .
DUBA is a toxin compound that acts on DNA, exhibiting alkylating activity. DUBA is an ADC payload that can be coupled with monoclonalantibodies to synthesize antibody-drug conjugates (ADCs) .
Anti-CD160 Antibody (MAT 303) is a human monoclonalantibody targeting CD160. Anti-CD160 Antibody (MAT 303) can be used in research related to cancer and autoimmune diseases.
Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1 is a cleavable linker-payload conjugate and cereblon-binding BTK bifunctional degrader. Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1 induces BTK degradation and exerts cytotoxic effects when delivered via CD79bmonoclonalantibody. Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1, when formulated as a CD79bantibody-drug conjugate, achieves sustained in vivoBTK degradation in tumor-bearing mice with reduced systemic payload exposure. Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1 can be used for the research of activated b-cell-like diffuse large b-cell lymphoma (ADC linker: (HY-130944); PROTAC: (HY-163295)) .
AMT-151 Antibody is a monoclonalantibody inhibitor targeting folate receptor α. AMT-151 Antibody can be used to synthesize the antibody-drug conjugate (ADC) AMT-151. AMT-151 Antibody can be used to research related to cancer .
MRG004A Antibody (HuSC1-39) is a monoclonalantibody inhibitor targeting tissue factor (TF). MRG004A Antibody can be used to synthesize the antibody-drug conjugate (ADC) MRG004A. MRG004A Antibody can be used to research related to cancer .
Cilgavimab (AZD-1061; COV2-2130) is a human SARS-CoV-2-neutralizing monoclonalantibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of SARS-CoV-2 infection .
Anti-PSMA Antibody (ARX517 antibody) is a humanized IgG1 monoclonalantibody that targets PSMA. Anti-PSMA Antibody is the antibody part of the ADC molecule ARX517. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
CSC012 Antibody is a monoclonalantibody inhibitor targeting IL-1RAP. CSC012 Antibody can be used to synthesize the antibody-drug conjugate (ADC) CSC012. ADV-101 Antibody can be used to research related to acute myeloid leukemia .
SOT102 Antibody is an IgG1 monoclonalantibody targeting CLDN18.2, and the antibody of ADC SOT102. SOT102 Antibody binds selectively to CLDN18.2, and promotes internalization. SOT102 Antibody can be used for the research of cancer [2].
Modotuximab (DS 1024) is an IgG1κ-type chimeric antibody targeting human EGFR protein. Modotuximab binds non-overlapping epitopes on domain III of EGFR, a domain that is intact in EGFRvIII. Modotuximab has antitumor activity in vivo .
Anti-PILRA Antibody is a monoclonalantibody that targets PILRA. Anti-PILRA Antibody can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-PILRA Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-PCI Antibody is a monoclonalantibody that targets PCI. Anti-PCI Antibody can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-PCI Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
ZV0201 Antibody (ZV02) is a monoclonalantibody inhibitor targeting Her2. ZV0201 Antibody can be used to synthesize the antibody-drug conjugate (ADC) ZV0201. ZV0201 Antibody can be used to research related to HER2-positive tumors .
IKS012 (IKS01) Antibody is a monoclonalantibody inhibitor targeting folate receptor α (FRA). IKS012 Antibody can be used to synthesize the antibody-drug conjugate (ADC) IKS012. IKS012 Antibody can be used to research related to platinum-resistant ovarian cancer .
ADV-101 Antibody is a monoclonalantibody inhibitor targeting IL-1RAP. ADV-101 Antibody can be used to synthesize the antibody-drug conjugate (ADC) ADV-101. ADV-101 Antibody can be used to research related to cancer .
Anti-Claudin 6 Antibody (IM-302) is a human monoclonalantibody targeting Claudin-6/CLDN6. Anti-Claudin 6 Antibody (IM-302) can be used in cancer research.
Anti-HER3 Antibody (Ab562) is an anti-HER3monoclonalantibody. Anti-HER3 Antibody (Ab562) can be used to synthesize the antibody-drug conjugate (ADC) AMT-562 (HY-171747) .
Anti-Galanin Antibody is a monoclonalantibody that targets galanin. It can be used in ELISA, FACS, and functional assays. For isotype controls of anti-Galanin Antibody, please refer to Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-NGAL Antibody is a monoclonalantibody targeting NGAL. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-NGAL Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-PTHrP Antibody is a monoclonalantibody that targets PTHrP. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-PTHrP Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CA6 Antibody (huDS6) is a Mucin 1-associated sialoglycotope (CA6) targeting humanized monoclonalantibody. Anti-CA6 Antibody (huDS6) can be used for synthesis of ADCs .
Anti-PRNP Antibody is a monoclonalantibody that targets PRNP. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-PRNP Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-OSCAR Antibody is a monoclonalantibody that targets OSCAR. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-OSCAR Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-LCAT Antibody is a monoclonalantibody targeting LCAT. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-LCAT Antibody, please refer to Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-Neublastin Antibody is a monoclonalantibody targeting neublastin. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Neublastin Antibody, please refer to Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-Apelin Antibody is a monoclonalantibody that targets apelin. It can be used in ELISA, FACS, and functional assays. For isotype controls of anti-Apelin Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Heparanase Antibody is a monoclonalantibody that targets heparanase. It can be used in ELISA, FACS, and functional assays. For isotype controls of anti-heparanase antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Tenascin C Antibody (Neuradiab antibody) is a human monoclonalantibody (mAb) targeting Tenascin C. Anti-Tenascin C Antibody can be used in Glioblastoma research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonalantibody with a linker to create an antibody-drug conjugate (ADC) .
MAS82590 (Arumakimig) is a bispecific IL-1β and IL-18monoclonalantibody that reduces inflammasome-mediated inflammation. MAS825 combines the anti-IL-1β and anti-IL-18 monoclonalantibodies (mAbs) inhibition domains in a single bispecific high-affinity cytokine capture molecule .
AVID100 (MAB100) Antibody is a monoclonalantibody inhibitor targeting EGFR, which can be used to synthesize a novel antibody-drug conjugate (ADC) molecule AVID100. AVID100 Antibody is applicable to relevant research on breast cancer, head and neck cancer, and lung cancer .
Anti-FOLH1/PSMA Antibody (J591) (MEDI3726 antibody) is a human monoclonalantibody (mAb) targeting FOLH1/PSMA. Anti-FOLH1/PSMA Antibody (J591) can be used in Prostate cancer research .
Opucolimab (HLX20) is an engineered anti-PD-L1 humanised IgG1 antibody. Opucolimab, when conjugated with camptothecin toxoid, yields the PD-L1-targeting ADC, HLX43 (HY-177439). HLX43 can be used for non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), esophageal squamous cell carcinoma (ESCC), melanoma (MEL), ovarian cancer (Ovc) research .
Anti-c-Met/HGFR Antibody is a humanized IgG1 monoclonalantibody that targets c-Met. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
Inebilizumab is an anti-CD19monoclonalantibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research .
ATG-022 Antibody is a humanized monoclonalantibody targeting Claudin 18.2 (CLDN 18.2). ATG-022 Antibody binds with VcMMAE (HY-15575) to form an Antibody-Drug Conjugate (ADC). ATG-022 Antibody can be used for the research of advanced/metastatic solid tumors and gastric cancer .
Anti-BCAM Antibody is a monoclonalantibody that targets BCAM. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-BCAM Antibody, please refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
Anti-Endothelial Lipase Antibody is a monoclonalantibody targeting endothelial lipase. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Endothelial Lipase Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Fibronectin III Antibody is a monoclonalantibody targeting Fibronectin III. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Fibronectin III Antibody, please refer to Mouse IgG2a kappa, Isotype Control (HY-P99978).
Anti-PRAME Antibody is a monoclonalantibody that targets the melanoma antigen preferentially/PRAME. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-PRAME Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TrkC Antibody is a monoclonalantibody targeting TrkC/NTRK3. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-TrkC Antibody, please refer to Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-Artemin Antibody is a monoclonalantibody that targets artemin. It can be used in ELISA, FACS, and functional assays. For isotype controls of anti-artemin antibody, please refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
Anti-Mouse CD20 Antibody (AISB12) is an anti-mouse CD20 IgG2a monoclonalantibody. Anti-Mouse CD20 Antibody (AISB12) can deplete B cells. Anti-Mouse CD20 Antibody (AISB12) can be used for research on immunology .
Ocrelizumab (Ocrevus) is a humanized anti-CD20monoclonalantibody. Ocrelizumab can induce B cell depletion and inhibit multiple sclerosis lesions in mice through antibody dependent cytotoxicity (ADCC) .
PF-06478924 (PF-06664178 antibody; RN926) is a human monoclonalantibody (mAb) targeting TROP2. PF-06478924 can be used in the study of advanced and metastatic solid tumors .
Anti-CXCR3 Antibody (5H7) is a mouse monoclonalantibody produced using CXCR3 as the antigen. The recommended isotype control is human IgG1 kappa (HY-P99001).
Pinatuzumab vedotin, an antibody-drug conjugate (ADC), is a CD22 humanized monoclonalantibody Pinatuzumab (HY-P99230) conjugated to VcMMAE (HY-15575). Pinatuzumab vedotin has antitumor activities .
Anti-CD79 Antibody is a monoclonalantibody that targets CD79. Anti-CD79 Antibody can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CD79 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-NGLY1 Antibody is a monoclonalantibody that targets NGLY1. Anti-NGLY1 Antibody can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-NGLY1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Mouse FAP Antibody (73.3) is an anti-mouse FAP IgG1 monoclonalantibody. Anti-Mouse FAP Antibody (73.3) can be used to accurately detect the expression and localization of FAP protein in mice. Anti-Mouse FAP Antibody (73.3) can be used for research on cancer .
Anti-MCT1 Antibody is a monoclonalantibody that targets MCT1. Anti-MCT1 Antibody can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-MCT1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD180 Antibody is a monoclonalantibody that targets CD180. Anti-CD180 Antibody can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CD180 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-MP1 Antibody is a monoclonalantibody that targets MP1. Anti-MP1 Antibody can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-MP1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Proteins separation resin is a hydrophobic interaction chromatography resin that can be used in the monoclonalantibody purification (Particle size: 65 μm) .
Anti-NKp46 Antibody is a monoclonalantibody targeting NKp46. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-NKp46 Antibody, please refer to Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-KLK7 Antibody is a monoclonalantibody targeting KLK7. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-KLK7 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CDH19 Antibody is a monoclonalantibody that targets CDH19. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CDH19 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-ADAM17 Antibody is a monoclonalantibody targeting ADAM17. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-ADAM17 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-RNF43 Antibody is a monoclonalantibody targeting RNF43. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-RNF43 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Notch4 Antibody is a monoclonalantibody targeting Notch4. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Notch4 Antibody, please refer to Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-ADMAST4 Antibody is a monoclonalantibody targeting ADMAST4. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-ADMAST4 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-RSPO2 Antibody is a monoclonalantibody that targets RSPO2. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-RSPO2 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD99 Antibody is a monoclonalantibody that targets CD99. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CD99 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-AGR2 Antibody is a monoclonalantibody that targets AGR2. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-AGR2 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TIMP-1 Antibody is a monoclonalantibody that targets TIMP1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-TIMP-1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD84 Antibody is a monoclonalantibody that targets CD84. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CD84 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-KLRB1 Antibody is a monoclonalantibody targeting KLRB1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-KLRB1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CCL21 Antibody is a monoclonalantibody targeting CCL21. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CCL21 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-APCDD1 Antibody is a monoclonalantibody that targets APCDD1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-APCDD1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-LAIR1 Antibody is a monoclonalantibody that targets LAIR1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-LAIR1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-STAT3 Antibody is a monoclonalantibody that targets STAT3. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-STAT3 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Robo4 Antibody is a monoclonalantibody targeting Robo4. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Robo4 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CCR9 Antibody is a monoclonalantibody targeting CCR9. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CCR9 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TSPAN33 Antibody is a monoclonalantibody targeting TSPAN33. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-TSPAN33 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-FZD5 Antibody is a monoclonalantibody targeting FZD5. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-FZD5 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-EMR2 Antibody is a monoclonalantibody targeting ADGRE2. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-EMR2 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-ApoL1 Antibody is a monoclonalantibody that targets ApoL1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-ApoL1 Antibody, please refer to Rabbit IgG1 kappa, Isotype Control (HY-P99980).
Anti-MSR1 Antibody is a monoclonalantibody that targets MSR1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-MSR1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CXCL13 Antibody is a monoclonalantibody targeting CXCL13. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CXCL13 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-LRP5 Antibody is a monoclonalantibody that targets LRP5. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-LRP5 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-PAD4 Antibody is a monoclonalantibody that targets PAD4. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-PAD4 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Notch2 Antibody is a monoclonalantibody targeting Notch2. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Notch2 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Feladilimab (Anti-ICOS/CD278 Reference Antibody (feladilimab); GSK3359609) is humanized IgG4 anti-ICOS/CD278 agonist monoclonalantibody. Feladilimab can be used for the research of cancer .
Cetuximab MMAE is an antibody-drug conjugate (ADC) consisting of the EGFR-targeting humanized monoclonalantibody Cetuximab (HY-P9905) conjugated to VcMMAE (HY-15575). Cetuximab MMAE exhibits antitumor activity .
Anti-GPRC5D Antibody (LM-305 antibody) is a humanized IgG1 monoclonalantibody that targets GPRC5D. Anti-GPRC5D Antibody is the antibody part of the ADC molecule LM-305. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Protein S Antibody is a monoclonalantibody targeting Protein S. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Protein S Antibody, please refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
Anti-Plexin A1 Antibody is a monoclonalantibody targeting Plexin A1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Plexin A1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Lipocalin-2 Antibody is a monoclonalantibody targeting Lipocalin-2. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Lipocalin-2 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-IL-32 Antibody is a monoclonalantibody that targets IL-32. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-32 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-IL-19 Antibody is a monoclonalantibody that targets IL-19. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-19 Antibody, please refer to Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-IL-26 Antibody is a monoclonalantibody that targets IL-26. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-26 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CHRDL-1 Antibody is a monoclonalantibody that targets CHRDL-1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CHRDL-1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-IL-24 Antibody is a monoclonalantibody that targets IL-24. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-24 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-MMP-16 Antibody is a monoclonalantibody targeting MMP-16. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-MMP-16 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
EU101 (NOV1801) is a humanized agonistic monoclonalantibody targeting the costimulatory receptor CD137, with potential immunostimulatory and antineoplastic activities .
Anti-DR3 Antibody is a monoclonalantibody that targets DR3. Anti-DR3 Antibody can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-DR3 Antibody, please refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
Anti-DKK2 Antibody is a monoclonalantibody that targets DKK2. Anti-DKK2 Antibody can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-DKK2 Antibody, please refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
Praluzatamab is a monoclonalantibody targeting the activated leukocyte cell adhesion molecule (ALCAM/CD116). Praluzatamab can be used to synthesize Praluzatamab ravtansine (antibody-drug conjugates). Praluzatamab can be used for research of cancers .
Ocaratuzumab (AME 133v) is an Fc-engineered humanized IgG1 anti-CD20monoclonalantibody, with a Kd of ~100 pM. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC) .
U-031 is an anti-tumor agent. U-031 can be connected to monoclonalantibodies via linkers to form antibody-drug conjugate (ADC) molecules. U-031 is commonly used in cancer research .
AGEN1307 is a human monoclonalantibody (mAb) targeting TIGIT. AGEN1307 has an active FcγR binding region and enhances antibody-dependent cellular cytotoxicity (ADCC). AGEN1307 can be used in cancer research .
Anti-Canine CD28 Antibody (1C6) is a mouse-derived monoclonalantibody that targets canine CD28, which isotype control is Mouse IgG1 kappa, Isotype Control (HY-P99977).
Gatipotuzumab (PankoMab) is a humanized monoclonalantibody which recognizes the tumor-specific epitope of mucin-1 (TA-MUC1). Gatipotuzumab reveals a potent tumor-specific antibody-dependent cell cytotoxicity (ADCC) .
Izeltabart (MGA021) is a humanized IgG1 monoclonalantibody targeting ADAM9, which can be used as an ADC Antibody to synthesize the ADC molecule IMGC936 (Izeltabart Tapatansine). Izeltabart can be used in the study of cancer .
Enfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .
Anti-CD326/EPCAM Antibody (3622W94) is a humanized antibody expressed in CHO cells, targeting EpCAM/TROP1/CD326. Anti-CD326/EPCAM Antibody (3622W94) can be used for epithelial cancers research, such as pancreatic, prostate and breast cancer.
Anti-Kremen2 Antibody is a monoclonalantibody that targets Kremen2. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Kremen2 Antibody, please refer to Human IgG1 (N297A) kappa, Isotype Control (HY-P99994).
Anti-CD300A Antibody is a monoclonalantibody targeting CD300A. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CD300A Antibody, please refer to Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-CD326 Antibody (17-1A) is a human monoclonalantibody targeting CD326. Anti-CD326 Antibody (17-1A) can be used in cancer research. The recommended isotype control is Mouse IgG1 kappa (HY-P99977).
SHR-A1403 Antibody is an anti-c-Metmonoclonalantibody. SHR-A1403 Antibody down-regulates phosphorylated c-Met, Akt, ERK, weakens intracellular signal cascades, and mediates antibody-c-Met complex endocytosis. SHR-A1403 Antibody can be used for the research of c-met-overexpressing cancers and pancreatic ductal adenocarcinoma .
AC Antibody purification resin 2 is based on spherical, highly cross-linked agarose beads with a narrow size distribution and high mechanical stability. Used for the separation and purification of complex antibodies such as monoclonalantibody, double antibody, multi-antibody and Fc fusion protein .
Substrate: highly crosslinked agarose microspheres; Particle size: 65μm; Ligand: alkali-resistant recombinant Protein A; ADC purified resin.
Anti-5T4 scFv-Fc Antibody (ASN004 Antibody) is a human IgG1 monoclonalantibody targeting TPBG. Anti-5T4 scFv-Fc Antibody (ASN004 Antibody) can be used in cancer research. The recommended isotype control is human IgG1 kappa (HY-P99001).
MDX-1411 is a fully human monoclonalantibody targeting CD70. MDX-1411 is capable of inducing antibody-dependent cellular cytotoxicity (ADCC). MDX-1411 can be used in the research of B-cell malignancies .
Anti-Dectin-1 Antibody (2M24) is a humanized IgG1 monoclonalantibody that targets Dectin-1. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
Tositumomab (Anti-Human CD20 Recombinant Antibody) is a mouse-derived IgG2a monoclonalantibody, targeting to human CD20. Tositumomab can deplete B cells. Tositumomab can be used for the research of cancer, such as lymphoma .
Onartuzumab (MetMAb) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonalantibody against the MET receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity .
Cusatuzumab (FUT8-KO) is an anti-CD70monoclonalantibody that prepared by knocking out the fucosyltransferase 8 gene (FUT8) to remove fucose and thereby enhance the ADCC activity of the antibody .
Marstacimab (PF-06741086) is an anti-tissue factor pathway inhibitor (TFPI) monoclonalantibody. Marstacimab can be used for the research of hemophilia .
Tavolixizumab (MEDI 0562; Tavolimab) is a human monoclonalantibody to TNFRSF4 (TNF receptor superfamily member 4) for use in cancer immunology research .
Fontolizumab (HuZAF) is a humanized monoclonalanti-IFN-gammaantibody. Fontolizumab is an immunosuppressive agent. Fontolizumab can be used in research of Crohn’s disease .
Birtamimab (NEOD001) is an investigational monoclonalantibody that specifically and selectively target and clear the amyloid. Birtamimab can be used for the research of light chain amyloidosis .
Anti-CCL28 Antibody is a monoclonalantibody targeting CCL28. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CCL28 Antibody, please refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
Maridebart (AMG133 antibody) is a human immunoglobulin G1-kappa, anti-GIPR (gastric inhibitory polypeptide receptor)monoclonalantibody. Maridebart is the antibody portion of Maridebart cafraglutide (HY-164535) and can be used for the synthesis of antibody-drug conjugates (ADC). Maridebart can be used for the reserrch of obesity and type 2 diabetes .
Lexucitug (DCSZ-11) is a humanized monoclonalantibody targeting CD93. The antibody isotype of Lexucitug is human IgG1κ; the recommended isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
Vorsetuzumab mafodotin (SGN-75) is an Auristatin-based anti-CD70antibody-drug conjugate (ADC). Vorsetuzumab mafodotin consists of a humanized monoclonalantibody, Vorsetuzumab and an ADC cytotoxin MMAF. Vorsetuzumab mafodotin has antineoplastic activity .
Anti-MST1R Antibody (MOR07692) is a humanized IgG1 monoclonalantibody that targets MST1R. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
Lanerkitug (BAY3375968) is a fully human monoclonal IgG1 anti-human CCR8 antibody. Lanerkitug selectively depletes human CCR8 + Tregs via antibody dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP). Lanerkitug can be used in the research of solid tumors .
Anti-IL-34 Antibody is a monoclonalantibody that targets IL-34. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-34 Antibody, please refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
DB-1310 Antibody is a monoclonalantibody inhibitor targeting HER3. DB-1310 Antibody can be used to synthesize the antibody-drug conjugate (ADC) DB-1310. DB-1310 Antibody is applicable to research related to HER3-positive solid tumors, non-small cell lung cancer, breast cancer, colon cancer and prostate cancer .
Labetuzumab is a humanised anti-carcinoembryonic antigen (CEA) monoclonalantibody that inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy .
Atoltivimab (REGN3470), or maftivimab/odesivimab (Inmazeb) is the first Food and agent Administration (FDA)-approved monoclonalantibody to target Zaire ebolavirus (EBOVs) infection .
Boserolimab (MK-5890) is a humanized agonist monoclonalantibody that binds to CD27 to provide a costimulatory signal that enhances T-cell–mediated responses .
CM369 is a humanized monoclonalantibody against CCR8 that possesses potential immunomodulatory and anti-tumor activities. CM369 can be used in cancer research.
Placulumab (ART621) is an anti-TNF α monoclonalantibody. Placulumab has anti-inflammatory activity and has potential applications in inflammatory diseases such as arthritis .
Sovipostobart is an immunoglobulin G1-kappa, anti-CTLA-4 human monoclonalantibody with cleavable prodomain. Sovipostobart is an immunostimulant and antineoplastic .
Dicamba 1-azidopropane (DCn) is an immunizing and heterologous hapten. Dicamba 1-azidopropane can be used to generate monoclonalantibodies specific of Dicamba .
Methotrexate-alpha-alanine is a prodrug for activation by enzyme-monoclonalantibody conjugates of Methotrexate (HY-14519). Methotrexate-alpha-alanine shows cytotoxicity .
Anti-UNC5B Antibody (YW88) is a monoclonalantibody against UNC5B. Anti-UNC5B Antibody (YW88) can inhibit the binding of Netrin-1 to Unc5B. Anti-UNC5B Antibody (YW88) can be used in research on angiogenesis .
Anti-Mouse TSLP Antibody (28F12) is an anti-mouse TSLP IgG2a monoclonalantibody. Anti-Mouse TSLP Antibody (28F12) weakens skin inflammation and allergic reactions by reducing Treg cells and lymph node cells. Anti-Mouse TSLP Antibody (28F12) can be used for research on allergic conditions .
Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonalantibody. Denintuzumab binds to CD19 on the surface of B cells. Denintuzumab can be used as the antibody moiety (ADC antibody) of antibody-drug conjugates to synthesize ADC, Denintuzumab Mafodotin (SGN-CD19A). Denintuzumab Mafodotin can be used in the research of acute lymphoblastic leukemia .
Anti-Human/Rat/Fish AChR Antibody (Mab35) is an anti-human/rat/fish AChR IgG1 monoclonalantibody. Anti-Human/Rat/Fish AChR Antibody (Mab35) can attack the AChR of neuromuscular junctions. Anti-Human/Rat/Fish AChR Antibody (Mab35) can be used for the construction of myasthenia gravis models .
Anti-LGR7 Antibody is a monoclonalantibody targeting LGR7/RXFP1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-LGR7 Antibody, please refer to Mouse IgG2a kappa, Isotype Control (HY-P99978).
Anti-UPK-1B Antibody is a monoclonalantibody targeting UPK1B. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-UPK-1B Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD300C Antibody is a monoclonalantibody targeting CD300C. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CD300C Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
CLT030 Antibody is a human monoclonalantibody targeting CLL1/CLEC12A/CD371, with a Kd value of 7.32 nM against human targets. CLT030 Antibody can be used to synthesize the ADC CLT030. It is applicable to research related to acute myeloid leukemia .
Anti-LGALS3BP Antibody is a monoclonalantibody targeting LGALS3BP. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-LGALS3BP Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TEM8 Antibody is a monoclonalantibody targeting TEM8/ANTXR1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-TEM8 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Mouse CD25 Antibody (7D4) is a mouse IgG2 monoclonalantibody targeting CD25. Anti-Mouse CD25 Antibody (7D4) enables the isolation of naive CD4 + T cells by depleting CD25-expressing cells .
Anti-NKG2C Antibody is a monoclonalantibody targeting NKG2C. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-NKG2C Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-SEMA3A Antibody is a monoclonalantibody targeting SEMA3A. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-SEMA3A Antibody, please refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
Anti-NGF2 Antibody is a monoclonalantibody targeting NGF2/NT-3. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-NGF2 Antibody, please refer to Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-Beta Klotho Antibody is a monoclonalantibody targeting *Beta Klotho*. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Beta Klotho Antibody, please refer to Human IgG1 (L234A/L235A) kappa, Isotype Control (HY-P991207).
Cantuzumab is a monoclonalantibody that can binds the CanAg antigen. Cantuzumab is typically linked to one of several cytotoxic agents, yielding antibody-drug conjugates (ADC), such as Cantuzumab mertansine (HY-P99492) and Cantuzumab ravtansine (HY-P99493) .
Anti-LAMP1/CD107a Antibody (SAR-428926 antibody) is an anti-LAMP1 humanized monoclonalantibody. Anti-LAMP1/CD107a Antibody can be used for the antibody part of SAR-428926. AntibodyAnti-LAMP1/CD107a Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
Exatecan analog 38 is a camptothecin derivative with potent topoisomerase I inhibitory activity. Exatecan analog 38 can be connected to monoclonalantibodies via linkers to form antibody-drug conjugate (ADC) molecules. Exatecan analog 38 can be used for cancer research .
MEDI-7836 is a humanized monoclonalantibody inhibitor that targets the interleukin-13 receptor. MEDI-7836 is promising for research of inflammation-related diseases .
NI-301 is a human monoclonalantibody (mAb) targeting Transthyretin/TTR. NI-301 can be used in Cardiomyopathies and Familial amyloid neuropathy research .
MC-DOXHZN ((E/Z)-Aldoxorubicin; Doxorubicin(6-maleimidocaproyl)hydrazone) is an albumin-binding proagent of Doxorubicin (HY-15142A) (DNA topoisomerase II inhibitor), with acid-sensitive properties. MC-DOXHZN can be used to synthesize ADC .
Anti-CLDN9 Antibody is a monoclonalantibody targeting CLDN9. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CLDN9 Antibody, please refer to Human IgG1 (L234A/L235A) kappa, Isotype Control (HY-P991207).
Anti-ALK7 Antibody is a monoclonalantibody that targets ALK7. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-ALK7 Antibody, please refer to Human IgG1 (L234A/L235A) kappa, Isotype Control (HY-P991207).
Anti-PD-L2 Antibody is a monoclonalantibody targeting PD-L2/CD273. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-PD-L2 Antibody, please refer to Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-IL-27RA Antibody is a monoclonalantibody that targets IL-27RA. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-27RA Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-LRP6 Antibody is a monoclonalantibody that targets LRP6. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-LRP6 Antibody, please refer to Human IgG1 (L234A/L235A) kappa, Isotype Control (HY-P991207).
Anti-IL-17F Antibody is a monoclonalantibody that targets IL-17F. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-17F Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-L1-CAM Antibody is a monoclonalantibody that targets L1-CAM. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-L1-CAM Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Varsetatug (CX-2051 antibody) is a humanized IgG1κ monoclonalantibody inhibitor targeting EpCAM/TROP1/CD326. Varsetatug serves as the antibody component of the ADC compound CX-2051. It can be used in research on cancers including breast cancer, prostate cancer and ovarian cancer .
Sigvotatug (SGN-B6A antibody) is a human IgG1 κ monoclonalantibody against ITGB6.
Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
Sigvotatug can be used as an ADC antibody to synthesize ADC Sigvotatug vedotin (HY-164957) .
Anti-IL-23R Antibody is a monoclonalantibody that targets IL-23R. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-23R Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-ROBO2 Antibody is a monoclonalantibody targeting ROBO2. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-ROBO2 Antibody, please refer to Human IgG1 (L234A/L235A) kappa, Isotype Control (HY-P991207).
Anti-B7-H7 Antibody is a monoclonalantibody targeting HHLA2. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-B7-H7 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-IL-17RB Antibody is a monoclonalantibody targeting IL-17RB. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-17RB Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD226 Antibody is a monoclonalantibody targeting CD226. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CD226 Antibody, please refer to Human IgG1 (L234A/L235A) kappa, Isotype Control (HY-P991207).
Anti-EGFR Antibody (D2C7) is a monoclonalantibody against EGFR. The recombinant immunotoxin D2C7-(scdsFv)-PE38KDEL constructed based on Anti-EGFR Antibody (D2C7) has antineoplastic activity in glioblastoma models .
IMC-D11 (LY-3076226 antibody) is an IgG1 monoclonalantibody against FGFR3. IMC-D11 can be used for the antibody part of LY3076226. IMC-D11 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
Furtisetabart is a humanized monoclonalantibody targeting CD147 with anti-tumor activity. Furtisetabart is of the human IgG4κ antibody subtype, and the recommended isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
Anti-CD172a Antibody (3F9) is a humanized IgG1 monoclonalantibody targeting SIRPα/CD172a. The recommended isotype control is Mouse IgG1 kappa, Isotype Control (HY-P99977).
Ladarutatug is a humanized monoclonalantibody targeting Tyrosine-protein kinase receptor UFO. The Ladarutatug antibody isotype is human IgG4κ; the recommended isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
thioxo-Dxd is a Camptothecin (HY-16560) derivative. thioxo-Dxd can be connected to monoclonalantibodies via linkers to form antibody-drug conjugate (ADC) molecules. thioxo-Dxd can be used for research on tumors with high HER2 or TROP2 expression .
Lifonebart is a humanized monoclonalantibody targeting TREM2 (triggering receptor expressed on myeloid cells 2). The antibody isotype of Lifonebart is human IgG1κ, and the recommended isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
LEESGGGLVQPGGSMK acetate, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK acetate can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α .
Gimsilumab (MORAb-022) is a human anti-GM-CSFmonoclonalantibody. Gimsilumab has the potential for the research of COVID-19 and rheumatoid arthritis (RA) .
BAT5906 is a human monoclonalantibody (mAb) targeting VEGFA. BAT5906 can be used in Wet age-related macular degeneration and Diabetic macular oedema research .
Mitumomab is an anti-idiotypic mouse IgG2b monoclonalantibody that mimics the ganglioside GD3. Mitumomab can be used for the research of small-cell lung carcinoma .
Gerilimzumab (GB224) is a humanized monoclonalantibody inhibitor targeting interleukin-6 (IL-6). Gerilimzumab is promising for research of autoimmune diseases such as rheumatoid arthritis .
LEESGGGLVQPGGSMK, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α .
Tirnovetmab (KIND-016) is a fully caninized, high-affinity monoclonalantibody that targets IL-31. Tirnovetmab can be used in research related to atopic dermatitis in dogs.
Galegenimab (FHTR 2163) is a humanized monoclonalantibody Fab fragment targeting the HtrA1 trimer. Galegenimab is used in research on age-related macular degeneration (AMD) .
TBL-100 is a human monoclonalantibody (mAb) targeting Tau. TBL-100 can be used in Alzheimer's disease (AD) and Progressive supranuclear palsy research .
Amesotatug is a humanized monoclonalantibody and ANXA1 binder. Amesotatug binds to Homo sapiensANXA1 and exhibits antineoplastic activity. Amesotatug can be used for the research of cancer .
Minretumomab (CC-49) is a murine monoclonalantibody against TAG-72 (tumor-associated glycoprotein 72). Minretumomab is used in cancer and immunity research .
DSTYSLSSTLTLSK is a generic human peptide and can be used for infliximab quantitative detection . Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α.
LYN00101 is a human monoclonalantibody (mAb) targeting VEGFA. LYN00101 can be used in Cervical cancer, Colorectal cancer, Gastric cancer and Ovarian cancer research .
CNTO4088 is a monoclonalantibody inhibitor targeting interleukin-23 (IL-23). CNTO4088 is promising for research of autoimmune diseases such as psoriasis and rheumatoid arthritis .
Anti-IL-13 Antibody (C836) is a neutralizing monoclonalantibody targeting human IL-13. The Fab fragment of Anti-IL-13 Antibody (C836) is a heterodimer composed of heavy chains and light chains, each folded into variable and constant domains. Anti-IL-13 Antibody (C836) can be used for chronic inflammatory diseases, such as asthma .
Turmetabart (Anti-SEZ6 Antibody (SC17)) is a humanized anti-SEZ6 IgG1 monoclonalantibody. Anti-SEZ6 Antibody (SC17) can be used to synthesize antibody-drug conjugates (ADC) product, ABBV-011. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Anti-Mouse CD8 beta Antibody (53-5.8) is an anti-mouse CD8 beta IgG2a monoclonalantibody. Anti-Mouse CD8 beta Antibody (53-5.8) can deplete CD8 + T cells and enhance cytotoxicity. Anti-Mouse CD8 beta Antibody (53-5.8) can be used for research on immunology .
Anti-Mouse TCRβ Antibody (HB218) is an anti-mouse TCRβ IgG2b monoclonalantibody. Anti-Mouse TCRβ Antibody (HB218) can deplete TCRβ + T cells. Anti-Mouse TCRβ Antibody (HB218) can be used for research on inflammation conditions and cancer such as spontaneous dermatitis and squamous cell carcinoma (SCC) .
Anti-Mouse/Rat/Human v-H-Ras Antibody (Y13-238) is an anti-mouse/rat/human v-H-Ras IgG2a monoclonalantibody. Anti-Mouse/Rat/Human v-H-Ras Antibody (Y13-238) can be used as a control antibody. Anti-Mouse/Rat/Human v-H-Ras Antibody (Y13-238) is often used for immunofluorescence and immunoprecipitation .
Anti-IL6 Antibody (MH166) is a murine anti-hIL-6monoclonalantibody. Anti-IL6 Antibody (MH166) can completely neutralize the activity of hIL-6 in vitro, but when used in combination with hIL-6 in vivo, Anti-IL6 Antibody (MH166) can enhance the activity and prolong the half-life of hIL-6, and increase the production of antigen-specific antibodies .
Anti-TSHR Antibody (K1-70) is an anti-TSHRmonoclonalantibody. Anti-TSHR Antibody (K1-70) incorporates a single-chain variable fragment into a chimeric antigen receptor to redirect T cells to TSHR-expressing cells. Anti-TSHR Antibody (K1-70) shows antitumor activity with no apparent toxicity. Anti-TSHR Antibody (K1-70) can be used for the research of differentiated thyroid cancer (DTC) .
Anti-CD28 Antibody (9.3) is an anti-human CD28 IgG2a monoclonalantibody. Anti-CD28 Antibody (9.3) can activate T cells. Anti-CD28 Antibody (9.3) can be used for research on immunology. The recommend isotype control of Anti-CD28 Antibody (9.3): Mouse IgG2a kappa, Isotype Control (HY-P99978) .
Anti-CD103 Antibody (hCD103.01A) is a monoclonalantibody targeting human CD103 and can be used in cancer immunotherapy and immunological research. Recommend Isotype Controls: human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Claudin 1 Antibody is a monoclonalantibody targeting CLDN1/CLD1/SEMP1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Claudin 1 Antibody, please refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
Anti-IL-18Rα Antibody is a monoclonalantibody targeting IL-18Ra. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-18Rα Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD133/PROM1 Antibody (CMab-43) is a human IgG2a monoclonalantibody (mAb) targeting PROM1/CD133. Anti-CD133/PROM1 Antibody (CMab-43) can be used in colon cancer research .
Anti-CD32b/FCGR2B Antibody (2B6) is a human monoclonalantibody targeting CD32B. Anti-CD32b/FCGR2B Antibody (2B6) can be used for research on B-cell lymphoma .
Anti-LILRB3 Antibody is a monoclonalantibody targeting LILRB3/ILT5/CD85a. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-LILRB3 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-LILRB1 Antibody is a monoclonalantibody targeting LILRB1/CD85j/ILT2. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-LILRB1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-P2XR4 Antibody is a monoclonalantibody targeting P2XR4. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-P2XR4 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Siglec-10/CD24 Antibody is a monoclonalantibody targeting Siglec-10. It can be used in ELISA, FACS, and functional assays. Isotype controls for Anti-Siglec-10/CD24 Antibody can be found in Human IgG1 kappa, Isotype Control (HY-P99001).
TLR7 agonist 28 (compound 3) is a potent TLR7 agonist. TLR7 agonist 28 can conjugat to antitumor monoclonalantibodies (mAbs) for cancer immunotherapy .
Sonepcizumab (LT 1009) is a fully human anti-S1Pmonoclonalantibody. Sonepcizumab has the potential for the research of metastatic renal cell carcinoma (mRCC) .
Crotedumab (REGN1193) is a fully human IgG4 monoclonalantibody that binds and inhibits glucagon receptor (GCGR), with a KD of 0.1 nM. Crotedumab can be used for the research of diabetes .
Carotuximab (TRC105) is a IgG1 monoclonalantibody that blocks endoglin (CD105) and its downstream Smad signaling pathway. Carotuximab has immunomodulatory and antineoplastic actions .
DSTYSLSSTLTLSK TFA is a generic human peptide and can be used for infliximab quantitative detection . Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α.
Remigromig (EYE-103; MK-3000) is a humanized bispecific monoclonalantibody targeting LRP5 and FZD4, suitable for use in research related to macular degeneration .
Suptavumab (REGN2222) is a human monoclonalantibody. Suptavumab can bind and block a conserved epitope on RSV A and B subtypes. Suptavumab can be used for the research of RSV infection .
MK-4166 is a humanized IgG1 agonist monoclonalantibody targeting GITR. MK-4166 enhances the proliferation of both naïve and tumor-infiltrating T lymphocytes .
NGM-707 is a humanized monoclonalantibody that blocks ILT2 and ILT4 receptors. NGM-707 has the potential for the study of advanced and metastatic solid tumors .
trans-Stilbene-NHCO-(CH2)3-acid, a trans-stilbene hapten, can be used to elicit a panel of monoclonalantibodies that display a range of fluorescent spectral behavior .
N-Boc-trans-4-fluoro-L-proline is a non-natural amino acid substitute used to construct monoclonalantibodies that specifically target the seed conformation of tau protein .
Lirilumab (IPH2102) is an anti-KIRmonoclonalantibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research .
Drozitumab (PRO 95780) is a human agonistic monoclonalantibody which binds the death receptor DR5. Drozitumab has potent antitumor activity against rhabdomyosarcoma .
Libivirumab (17.1.41) is a human anti-HBV monoclonalantibody. Libivirumab shows neutralization activity with IC50s of 35, 130 ng/mL for HBsAg, HBeAg, respectively .
Basiliximab (CHI 621) is a recombinant chimeric murine/human IgG1 monoclonalanti-interleukin-2 receptor antibody. Basiliximab can be used for the research of renal transplantation .
Crenezumab (MABT 5102A; RG 7412) is a fully humanized anti-Aβ monoclonalantibody that binds multiple forms of Aβ, such as soluble, oligomeric and fibrillar, for use in Alzheimer's disease research .
Anti-IL11RA Antibody (Hu16E12) is a humanized anti-IL-11αmonoclonalantibody, and its isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
Anti-TM4SF1 Antibody (AGX-A07) is a humanized IgG1 monoclonalantibody that targets TM4SF1. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
Xentuzumab (Anti-Human IGF1 and IGF2 Recombinant Antibody; BI836845) is a recombinant a human monoclonalantibody that targets IGF ligands IGF1 and IGF2. Xentuzumab inhibits both of IGF1 and IGF2 growth-promoting signalling and suppresses AKT activation .
Anti-Human/Mouse EGFR Antibody (7A7) ia an anti-mouse EGFRmonoclonalantibody proposed to be the mouse equivalent of cetuximab. Anti-Human/Mouse EGFR Antibody (7A7) fails to induce tumor regression in the HPV38 tumor model where EGFR is not expressed in mice. Anti-Human/Mouse EGFR Antibody (7A7) can be used in EGFR-expressing HPV38 tumor-related studies .
PE-Cy5 is a tandem fluorescent dye commonly used in flow cytometry, immunofluorescence, and cell biology research. It is formed by the covalent linkage of two fluorescent molecules, namely phycoerythrin and CY5. PE-Cy5 binds to human FcγRI (CD64), and this binding can be blocked by human pooled serum, anti-CD64 monoclonalantibodies targeting the ligand-binding region, or aggregated IgG. PE-Cy5 supports three-color flow cytometry analysis, and whole blood staining can partially reduce its non-specific binding (Ex/Em = 450-500 nm/665 nm) .
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen. Gemtuzumab affects cell necrosis by specifically targeting CD33 expressed on the surface of leukaemic cell blasts in acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonalantibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
Anti-Mouse VEGFR-2 Antibody (DC101-Mouse IgG2a) is an anti-mouse VEGFR-2 IgG2a monoclonalantibody. Anti-Mouse VEGFR-2 Antibody (DC101-Mouse IgG2a) is a chimeric antibody of the original DC101 antibody (HY-P990106). Anti-Mouse VEGFR-2 Antibody (DC101-Mouse IgG2a) can react with mouse VEGFR-2 .
Anti-IL-18RAP Antibody is a monoclonalantibody targeting IL-18RAP/IL-18RB. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-18RAP Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-IGFBP2 Antibody (M14) is an human anti-IGFBP2 monoclonal inhibitory antibody, which binds IGFBP2 with high affinity and blocks its binding with IGF1. Anti-IGFBP2 Antibody (M14) inhibits human endothelial cell recruitment, thus blocks the tumor progression of human metastatic cancer .
Anti-NRP2 Antibody is a monoclonalantibody targeting NRP2/VEGF165R2. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-NRP2 Antibody, please refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
Sutantatug (SYS6002 Antibody) is a monoclonalantibody targeting Nectin-4, and serves as the antibody moiety of the ADC CRB-701. Sutantatug is applicable to the research of Nectin-4-positive solid tumors, urothelial carcinoma and cervical cancer. The corresponding isotype control for Sutantatug is Human IgG1 kappa, Isotype Control (HY-P99001) .
Zanolimumab (Anti-Human CD4 Recombinant Antibody) is a fully human monoclonalantibody targets CD4. Zanolimumab effectively inhibits T-cell receptor (TCR) signal transduction. Zanolimumab can be used for the research of heumatoid arthritis, psoriasis, melanoma, cutaneous and peripheral T-cell lymphoma .
Tenatumomab (ST2146) is a murine monoclonalantibody against tenascin-C. And tenascin-C, the large extracellular glycoprotein, is overexpressed in cancer. Tenatumomab has been used for Pretargeted Antibody Guided Radioimmunoresearch (PAGRIT), and delivering radionuclides to tumors via PAGRIT and direct 131Iodine labeling approach .
(R)-thioxo-Dxd is a Camptothecin (HY-16560) derivative. (R)-thioxo-Dxd can be connected to monoclonalantibodies via linkers to form antibody-drug conjugate (ADC) molecules. (R)-thioxo-Dxd can be used for research on tumors with high HER2 or TROP2 expression .
Motavizumab (MEDI-524) is an anti-human RSV (respiratory syncytial virus) monoclonalantibody. Motavizumab can be used in respiratory syncytial virus infection in high-risk infants research .
Timolumab (BTT1023 ), a recombinant fully human monoclonalantibody that specifically binds VAP-1. Timolumab (BTT1023 ) could be used in the study of chronic inflammatory diseases .
Panobacumab (KBPA101) is a fully human IgM/κ monoclonalantibody generated by immortalizing human B lymphocytes against the LPS O polysaccharide of serotype O11 of P. aeruginosa .
Cetuximab (C225) is a human IgG1 monoclonalantibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity .
Ginisortamab (Mouse IgG1) is the anti-Gremlin-1 monoclonalantibody with mouse IgG1. Ginisortamab (Mouse IgG1) can be used in research of gastrointestinal (GI) tumors .
LEESGGGLVQPGGSMK TFA, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK TFA can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α .
XOMA 129 is a human monoclonalantibody targeting INSR. XOMA 129 is an insulin receptor (IR) antagonist that inhibits the drop in blood glucose. XOMA 129 can be used in the study of hypoglycemia .
Bersanlimab (BI-505) is a fully human monoclonalantibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab has anticancer effects .
Tarcocimab (OG1953) is a humanized anti-VEGFAmonoclonalantibody (IgG1 type). Tarcocimab is available for research in retinal vein occlusion (RVO) and wet age-related macular degeneration (AMD).
Frunevetmab (NV-02) is a felinized anti-nerve growth factor (NGF) monoclonalantibody with a Kd of 20 pM. Frunevetmab can effectively decrease osteoarthritis (OA) pain in cats .
Coprelotamab (GB-221) is an IgG-κ monoclonalantibody targeting EGFR2. The commonly used expression system for Coprelotamab is CHO DG44 (Chinese Hamster Ovary) cells .
hPV19 is a humanized inhibitory monoclonalantibody targeting vascular endothelial growth factor (VEGF) with a unique binding site. hPV19 can be used for the research of advanced solid tumors .
ASN-500 is a human monoclonalantibody (mAb) targeting F/Fusion glycoprotein F0. ASN-500 can be used in respiratory syncytial virus infection research .
Zansecimab (LY-3127804) is a monoclonalantibody against angiopoietin 2 (Ang‑2). Zansecimab can be used in research on angiogenesis, immunomodulation and anti-tumor activity .
UBX2050 is a human monoclonalantibody (mAb) targeting TIE2. UBX2050 can be used in Age-related macular degeneration, Diabetic macular oedema and Diabetic retinopathy research .
IN-002 is a human monoclonalantibody (mAb) targeting F, Fusion glycoprotein F0. IN-002 can be used in respiratory syncytial virus (RSV) infections research.
Anti-Mouse CD28 Antibody (PV-1) is an anti-mouse CD28 IgG monoclonalantibody. Anti-Mouse CD28 Antibody (PV-1) can activate T cells. Anti-Mouse CD28 Antibody (PV-1) can be used for researches on cancer and immunology such as leukemia. The recommend isotype control of Anti-Mouse CD28 Antibody (PV-1): Armenian hamster IgG, Isotype Control (HY-P990305) .
Anti-Mouse VISTA Antibody (13F3) is an anti-mouse VISTA IgG monoclonalantibody. Anti-Mouse VISTA Antibody (13F3) can reverse the immunosuppressive effect of VISTA by blocking its binding to ligands such as VSIG3. Anti-Mouse VISTA Antibody (13F3) exacerbates pulmonary fibrosis (PF) by promoting Th17 cell differentiation. Anti-Mouse VISTA Antibody (13F3) can be used for research on cancer such as breast cancer and PF .
HTI-1511 Antibody (Halozyme patent anti-EGFR) is a monoclonalantibody inhibitor targeting EGFR. HTI-1511 Antibody can be used to synthesize a novel anti-EGFR-ADC, HTI-1511. HTI-1511 Antibody can be used in the research of head and neck squamous cell carcinoma, non-small cell lung cancer, pancreatic cancer, colorectal cancer, renal cell carcinoma, and epidermoid carcinoma .
Amivantamab (FUT8-KO) is an anti-EGFR-METmonoclonalantibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Amivantamab (FUT8-KO) inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells .
Anti-CD68 Antibody (KP1) is a anti-CD68 monoclonalantibody (mAb). CD68 is present in various cell types, including monocytes/macrophages and fibroblasts. Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977) .
BI-836826 is a IgG1 chimerized and Fc-engineered anti-CD37monoclonalantibody. BI 836826 displays both antibody-dependent cell-mediated cytotoxicity (ADCC) and direct pro-apoptotic activities. BI-836826 can be used for the study of chronic lymphocytic leukemia .
Bimagrumab (Anti-ACVR2B Reference Antibody) is a human monoclonalantibody that blocks activin type II receptor (ActRII), with KDs of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab can be used for the research of pathological muscle loss and weakness .
Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate comprising the humanized monoclonalantibody zilovertamab and and the anti-microtubule cytotoxin monomethyl vedotin. Zilovertamab vedotin binding to tumor cell ROR1 results in rapid internalization, trafficking to lysosomes, antibody–agent conjugate cleavage, and monomethyl vedotin release. Zilovertamab vedotin induces apoptosis. Zilovertamab vedotin can be used in research of cancer .
ZL-1218 (FUT8-KO) is an anti-CCR8monoclonalantibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody. ZL-1218 (FUT8-KO) can be used for the research of solid tumour .
S-531011 (FUT8-KO) is an anti-CCR8monoclonalantibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody. S-531011 (FUT8-KO) can be used for the research of cancer immunity .
Mertansine-d3 (DM1-d3) is the deuterium labeled Mertansine (HY-19792). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonalantibody with a linker to create an antibody-drug conjugate (ADC) .
Namilumab (AMG203) is a human IgG1 monoclonalantibody that binds with high affinity to the GM-CSF ligand, potently neutralizing GM-CSF. Namilumab can be used for the research of rheumatoid arthritis .
Raludotatug is a humanized anti-CDH6 IgG1 monoclonalantibody. Raludotatug has antitumor activity and can be used to synthesize the ADC molecule Raludotatug deruxtecan (HY-164734) .
BIIB023 is a human monoclonalantibody (mAb) targeting TNFRSF12A/TWEAKR/CD266. BIIB023 can be used in lupus nephritis and rheumatoid arthritis research .
EVO-46120 is a human monoclonalantibody (mAb) targeting F, Fusion glycoprotein F0. EVO-46120 can be used in respiratory syncytial virus (RSV) and metapneumovirus infections research.
Sirexatamab (DKN-01) is a humanized IgG4 monoclonalantibody that can bind to and neutralize circulating DKK1. Sirexatamab exhibits antitumor activity in tumor models expressing DKK1 .
Landogrozumab (LY2495655) is an humanized anti-myostatinmonoclonalantibody. Landogrozumab effectively improves muscle volume, hand grip strength and function. Landogrozumab can be used for the research of muscle wasting disease .
Prolgolimab (BCD-100) is a human IgG1 anti-PD-1monoclonalantibody containing the Fc-silencing 'LALA' mutation. Prolgolimab can be used for the research of advanced melanoma .
Imalumab (BAX69) is a recombinant, human IgG1 monoclonalantibody that targets macrophage inhibitory factor (MIF). Imalumab can be used for the research of ovarian carcinoma, recurrent malignant ascites and cancer .
Nofazinlimab (CS1003) is a humanised IgG4 anti-PD-1monoclonalantibody. Nofazinlimab shows antitumor activity and can be used for the research of unresectable or metastatic hepatocellular carcinoma .
FM-303 is a monoclonalantibody inhibitor targeting interleukin-23 (IL-23). FM-303 is promising for research of immune system diseases and diseases of digestive system .
Ligufalimab (AK 117) is a humanized IgG4 anti-CD47 monoclonalantibody. Ligufalimab does not induce RBC hemagglutination, and induces phagocytosis. Ligufalimab shows anti-tumor activity .
Amrecibart is an anti-coagulation factor 11 human IgG4 κ monoclonalantibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
Garetatug is a humanized monoclonalantibody targeting human CLDN18 (claudin-18). Garetatug specifically binds to CLDN18, interfering with relevant cell signaling pathways and exerting antitumor activity .
Ersodetug is an anti-INSR (insulin receptor) human IgG2 κ monoclonalantibody . Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002).
Vibostolimab is an anti-TIGIT (T cell immunoglobulin and ITIM domain) monoclonalantibody. Vibostolimab shows antitumor activity, and can be used in non-small cell lung cancer (NSCLC) and melanoma research .
Brodalumab (AMG 827) is a human anti-interleukin-17-receptor IgG2 monoclonalantibody that can be used for the research of moderate-to-severe plaque psoriasis and rheumatoid arthritis .
Dazukibart (PF-06823859) is a potent, selective humanized IgG1 neutralizing monoclonalantibody that targets interferon β (IFNβ). Dazukibart can be used in the study of moderate to severe dermatomyositis .
EVO-46135 is a human monoclonalantibody (mAb) targeting F/Fusion glycoprotein F0. EVO-46135 can be used in Respiratory syncytial virus infections and Metapneumovirus infections research.
AT008 is an anti-GPCRmonoclonalantibody that blocks the binding of chemokine ligands to its cell surface receptor CCR4. AT008 can be studied in research for certain haematological and solid cancers.
Anti-EphA2 Antibody (1C1) (MEDI-547 antibody) is an anti-EphA2monoclonalantibody. Anti-EphA2 Antibody (1C1) can induce degradation of EphA2 protein. Anti-EphA2 Antibody (1C1) conjugated with McMMAF (HY-15578) can form an antibody-conjugated drugs, which has potent antitumor activity. Anti-EphA2 Antibody (1C1) can be used for the research of cancer, such as prostate cancer and glioma .
Anti-Mouse NKG2AB6 Antibody (16A11) is an anti-mouse NKG2AB6 IgG2b monoclonalantibody. Anti-Mouse NKG2AB6 Antibody (16A11) reduces depletion of antigen-specific CD8 T cells. Anti-Mouse NKG2AB6 Antibody (16A11) can be used for research on cancer such as lung cancer and colon cancer .
Anti-Rat FcRn heavy chain heterodimers Antibody (2G3) is an anti-rat FcRn heavy chain heterodimers IgG1 monoclonalantibody. Anti-Rat FcRn heavy chain heterodimers Antibody (2G3) effectively inhibits the binding of FcRn to IgG. Anti-Rat FcRn heavy chain heterodimers Antibody (2G3) is used in studies of the MHC class I heavy chain FcRn heterodimers and their interaction with IgG .
Anti-Mouse myeloperoxidase/MPO Antibody (6G4) is an anti-mouse myeloperoxidase/MPO IgG2c monoclonalantibody. Anti-Mouse myeloperoxidase/MPO Antibody (6G4) can activate the cGAS/STING pathway. Anti-Mouse myeloperoxidase/MPO Antibody (6G4) induces acute and chronic kidney injury in mice. Anti-Mouse myeloperoxidase/MPO Antibody (6G4) is often used in the construction of inflammation conditions models such as anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) .
Anti-TROP2 Antibody (RN927C antibody) is a human monoclonalantibody targeting Trop-2. Anti-TROP2 Antibody exerts in vitro inhibitory effects on a variety of tumor cell lines. Anti-TROP2 Antibody exhibits anti-tumor activity in mouse pancreatic PDX, ovarian PDX, lung PDX and triple-negative breast cancer (TNB) PDX models. Anti-TROP2 Antibody can be used for research on pancreatic cancer, ovarian cancer, lung cancer and triple-negative breast cancer .
Belantamab mafodotin (GSK2857916) is composed of humanized and focused monoclonalantibody against B cell maturation antigen (BCMA) and McMMAF. The antibody portion is Belantamab (HY-P9980), and the drug-linker conjugate for ADC is McMMAF (HY-15578). Belantamab mafodotin has anti-myeloma activity .
Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonalantibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases .
Clazakizumab is a monoclonalantibody with high affinity and specificity for the IL-6 (interleukin-6) cytokine. Clazakizumab may be helpful in inhibiting the cytokine response to SARS-CoV-2 in COVID-19. Clazakizumab can be used for the research of psoriatic arthritis (PsA) and renal antibody-mediated rejection .
ACT017 is a Fab fragment of humanized anti-GPVImonoclonalantibody. ACT017 inhibits collagen-induced platelet aggregation. ACT017 has the potential for the research of acute ischemic stroke .
Zemocimig is an anti-coagulation factor F9 human IgG4 κ monoclonalantibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
Rinumafusp alfa is a human monoclonalantibody targeting ERBB3/HER3. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001).
Ansuvimab (Ansuvimab-zyk) is a recombinant human monoclonal IgG1 antibody that exhibits antiviral activity against Zaire ebolavirus. Ansuvimab binds to the glycoprotein on Zaire ebolavirus to block its entry into host cells .
Izalontamab (SI-B001) is a bispecific anti-EGFR/HER3monoclonalantibody with high selectivity for EGFR/HER3 heterodimer. Izalontamab can be used for the research of cancer .
Iscalimab (CFZ-533) is a non-depleting IGg1 monoclonalantibody targeting CD40 (KD: 0.3 nM). Iscalimab can be used for research of Graves' hyperthyroidism and autoimmune diseases .
Domagrozumab is an anti-myostatin humanized monoclonalantibody with a KD value of 2.6 pM for human myostatin. Domagrozumab induces muscle anabolic activity. Domagrozumab can be used in research of duchenne muscular dystrophy (DMD) .
Adintrevimab (ADG 20) is a human IgG1 monoclonalSARS-CoV (SARS-CoV) antibody. Adintrevimab inhibits SARS-CoV-2 variants and other SARS-like coronaviruses with pandemic potential .
Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonalantibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research .
BAT-6004 is a monoclonalantibody that targets CD47 and is a CD47 inhibitor. BAT-6004 can be used in research on acute myeloid leukemia and diffuse large B-cell lymphoma .
Lorvotuzumab mertansine is an ADC consisting of a humanized N901 monoclonalantibody against CD56 bound to maytansinoid DM1 via a stable disulfide linker. Lorvotuzumab mertansine has antitumor activity .
Narnatumab (IMC-RON8) is a neutralizing human monoclonalantibody that blocks RON binding to its ligand, macrophage-stimulating protein (MSP), with a Kd of 32 pM. Narnatumab can be used for the research of cancer .
Idarucizumab is a humanized monoclonalantibody fragment. Idarucizumab is first reversal agent for a direct oral anticoagulant (DOAC). Idarucizumab can specifically neutralize the effects of the oral direct thrombin inhibitor in order to restore hemostasis .
Pidilizumab (CT-011) is a humanized IgG1k anti-PD-1monoclonalantibody. Pidilizumab acts as a DLL1 antagonist. Pidilizumab has the potential for hematologic malignancies research .
Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonalantibody (IgG4P), is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases .
BMS-986090 is a humanized monoclonalantibody antagonist targeting CD40. BMS-986090 is promising for research of autoimmune diseases such as systemic lupus erythematosus (SLE) and focal segmental glomerulosclerosis (FSGS) .
MAIPGG is a bifunctional chelator and an intermediate in the synthesis of radionuclide drug conjugates (RDCs). MAIPGG can be for the radiolabeling of a variety of monoclonalantibodies with 99mTc or 186Re, which then can be used for radioimmunodetection and radioimmunotherapy of cancer .
Depatuxizumab is a brain-penetrant and humanized tumor-specific antiEGFRmonoclonalantibody. Depatuxizumab inhibits the growth of xenograft models of mutant EGFRvIII and wild-type EGFR. Depatuxizumab can be used for research on cancer .
Cetuximab (PBS) is a human IgG1 monoclonalantibody that can inhibit EGFR. The SPR method measured the Kd value of Cetuximab for EGFR to be 0.201 nM; Cetuximab has a highly effective anti-tumor effect .
DX-2240 is a human monoclonalantibody (mAb) targeting TIE1. DX-2240 inhibits tumor growth and sensitizes tumor vasculature to anti-angiogenic agents (VEGF pathway inhibitors) .
Tezepelumab (anti-TSLP) is human monoclonalantibody (IgG2λ) that binds specifically to TSLP, blocking it from interacting with its heterodimeric receptor. Tezepelumab can be used for the research of severe, uncontrolled asthma .
Ulviprubart (ABC-008) is a monoclonalantibody targeting the KLRG1 receptor that selectively depletes highly differentiated cytotoxic T cells. Ulviprubart can be used in the study of inclusion body myositis (IBM) .
Anti-LGR5/GPR49 Antibody (18G7H6A3) is a human monoclonalantibody (mAb) targeting LGR5/GPR49. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD371/CLEC12A Antibody (H6e7) is a human monoclonalantibody (mAb) targeting CD371/CLEC12A. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Dacetuzumab (SGN-40) is a humanized IgG1, anti-CD40monoclonalantibody with anti-lymphoma activity. Dacetuzumab kills tumor cells via immune effector functions (antibody-dependent cellular cytotoxicity and phagocytosis [ADCC/ADCP]). Dacetuzumab ((SGN-40) can be used for multiple myeloma research .
Mogamulizumab (KW-0761) is a recombinant anti-CCR4monoclonalantibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL) .
Mezagitamab (TAK-079) is a IgG1λ anti-CD38monoclonalantibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP) .
7-MAD-MDCPT-AC-(s-cyclopropane) is a derivative of camptothecin. 7-MAD-MDCPT-AC-(s-cyclopropane) can be connected to monoclonalantibodies via linkers to form antibody-drug conjugate (ADC) molecules. 7-MAD-MDCPT-AC-(s-cyclopropane) can be used for cancer research .
Mirvetuximab (M9346A) is an anti-FOLR1 (folate receptor 1) monoclonalantibody. Mirvetuximab is the antibody moiety of folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research .
Benralizumab (MEDI-563) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonalantibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma .
MB-66 (MAPP-66) is a fully human IgG1 antibody that targets HSV and HIV. MB-66 is a monoclonalantibody film for vaginal application. The isotype control for MB-66 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
Codrituzumab (GC33) is a humanized monoclonalantibody targeting human GPC3 (glypican-3), with high affinity (Kd of 0.673 nM). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth .
Anti-TREM2 Antibody (AL2p-58) is a humanized IgG1 monoclonalantibody targeting TREM2. Anti-TREM2 Antibody (AL2p-58) can be used for the research of neuroinflammation. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Anti-IL-21R Antibody is a monoclonalantibody targeting IL-21R. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-21R Antibody, please refer to Human IgG1 (L234A/L235A) kappa, Isotype Control (HY-P991207).
Bemarituzumab (FUT8-KO) is an anti-FGFR2bmonoclonalantibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Bemarituzumab (FUT8-KO) lacks a core fucose in the polysaccharide portion of the Fc domain of the antibody, and results in a high affinity to human FcγRIIIa .
Puxitatug (INT-016; AZD8205 Antibody) is a monoclonalantibody targeting VTCN1/B7-H4. Puxitatug can be used to synthesize antibody-drug conjugates (ADCs), such as Puxitatug samrotecan (HY-171689), which can be applied to various solid tumors. Puxitatug can also be used for researching adjuvant therapies for gastric cancer .
Anti-Human/Mouse GRP78 Antibody (N88) is an anti-human/mouse GRP78 IgG1 monoclonalantibody. Anti-Human/Mouse GRP78 Antibody (N88) can activate the Akt signaling pathway. Anti-Human/Mouse GRP78 Antibody (N88) can inhibit the expression of inflammatory factors and plasminogen activator inhibitors induced by TLR agonists. Anti-Human/Mouse GRP78 Antibody (N88) can be used for research on inflammation conditions. Anti-Human/Mouse GRP78 Antibody (N88) can be used for immunoprecipitation .
Sevirumab (MSL-109) is a human IgG1 neutralizing monoclonalantibody against cytomegalovirus (CMV). Sevirumab recognizes CMV gH complexes and inhibits CMV replication with an EC50 of 0.3 μg/mL .
Ontuxizumab (MORAb-004) is a humanized IgG1/κ anti-endosialin (TEM-1 or CD248) monoclonalantibody with antitumor effects. Ontuxizumab can be used for the research of cancer .
Ontamalimab (SHP647) is a fully-human IgG2 monoclonalantibody targeting mucosal addressin cell adhesion molecule-1 (MAdCAM-1). Ontamalimab can be used for the research of Crohn's disease .
ASP5094 is a humanized monoclonalantibody against integrin alpha-9. ASP5094 has good safety and tolerability. ASP5094 can be used in the research of diseases such as rheumatoid arthritis .
Ciltistotug is a monoclonalantibody targeting human CD40 (TNFRSF5). Ciltistotug activates immune cells after binding to CD40, exerting immunostimulatory and antitumor activities. Ciltistotug is promising for research of cancer immunotherapy .
Futermestotug is a humanized immunoglobulin G1-κ monoclonalantibody targeting human cytotoxic T-lymphocyte associated protein 4 (CTLA4). Futermestotug is promising for research of various malignant tumors .
Vatelizumab (GBR500) is a monoclonalantibody that targets the α2 subunit (CD49b) of very late antigen 2 (VLA-2). Vatelizumab can be used for research on multiple sclerosis .
MAI1738 is a human monoclonalantibody targeting PODXL. MAI1738 can be used for cancer-related research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
Rosmantuzumab (OMP-131R10) is an anti-R-spondin 3 (RSPO3) humanized monoclonalantibody. Rosmantuzumab can be used for the research of advanced telapsed and refractory solid tumors .
Stromab (DS9231) is a human IgG1 monoclonalantibody (mAb) targeting Serpin F2. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
CNTO-6785 is a humanized monoclonalantibody inhibitor targeting interleukin-17A (IL-17A). CNTO-6785 is promising for research of chronic obstructive pulmonary disease (COPD) .
Siltuximab is an anti-IL-6 (interleukin-6) monoclonalantibody, and shows antitumor activity. Siltuximab can be used in Multicentric Castleman's Disease (MCD) and COVID-19 research .
SCH-900117 is a humanized monoclonalantibody inhibitor targeting interleukin-17A (IL-17A). SCH-900117 is promising for research of autoimmune diseases such as psoriasis and rheumatoid arthritis .
Oturkibart is a humanized immunoglobulin G4-κ monoclonalantibody targeting the human interleukin 4 receptor (IL4R). Oturkibart is promising for research of inflammatory diseases, such as asthma and atopic dermatitis .
Demcizumab (OMP 21M18) is an anti-DLL4monoclonalantibody. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models .
Rafivirumab (CR57) is an anti-rabies virus monoclonalantibody for the prophylaxis of rabies. Rafivirumab has neutralizing potency against a broad spectrum of RABV variants. Rafivirumab can be used for research of cocktails .
Anti-CD27 Antibody (M2177) is a human monoclonalantibody (mAb) targeting TNFRSF7/CD27. Anti-CD27 Antibody (M2177) inhibits the binding of sCD70 to human CD27 ECD-Fc. Anti-CD27 Antibody (M2177) can be used in the study of anti-tumor immunity. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Anti-CD27 Antibody (M2191) is a human monoclonalantibody (mAb) targeting TNFRSF7/CD27. Anti-CD27 Antibody (M2191) inhibits the binding of sCD70 to human CD27 ECD-Fc. Anti-CD27 Antibody (M2191) can be used in the study of anti-tumor immunity. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Anti-Mouse/Human Integrin β7 Antibody (FIB504) is an anti-mouse/human Integrin β7 IgG2a monoclonalantibody. Anti-Mouse/Human Integrin β7 Antibody (FIB504) can reduce the residence of type 2 innate lymphoid cells (ILC2s). Anti-Mouse/Human Integrin β7 Antibody (FIB504) can be used for researches on inflammation conditions and cancer such as lupus nephritis and glioma .
Enzelkitug (RO-7502175; RG-6411) (FUT8-KO) is an anti-CCR8monoclonalantibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody. Enzelkitug (FUT8-KO) can be used for the research of various solid tumors and hematological malignancies .
Inebilizumab (FUT8-KO) is an anti-CD19monoclonalantibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody.Inebilizumab (FUT8-KO) exhibits enhanced ADCC against B cells and can be used for research on multiple sclerosis and neuromyelitis optica .
SCT200 is a fully humanized IgG1 anti-EGFRmonoclonalantibody with a Kd of 0.08 nM. SCT200 can kill tumor cells by complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) through the Fc. SCT200 can be used for the study of refractory RAS and BRAF wild-type metastatic colorectal cancer .
Nimotuzumab is a humanized IgG1 monoclonalantibody targeting EGFR with a KD of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab, a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) .
Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonalantibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity .
MIL62 is an anti-CD20monoclonalantibody. MIL62 shows enhanced affinity for the FcγRⅢa receptors and direct B-cell killing effects. MIL62 has antibody-dependent cell-mediated cytotoxicity (ADCC) activity. MIL62 can be used for the study of non-Hodgkin lymphoma (NHL) .
TG20 is an anti-CD20monoclonalantibody that binds to a specific discontinuous epitope on CD20 with a Kd of 10–20 nM. TG20 exhibits enhanced antibody-dependent cellular cytotoxicity (ADCC). TG20 also enhances complement-dependent cytotoxicity (CDC) activity. TG20 can be used in research on B-cell lymphomas .
Mirvetuximab (M9346A) (powder) is an anti-FOLR1 (folate receptor 1) monoclonalantibody. Mirvetuximab (powder) is the antibody moiety of folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research .
Anti-Mouse GITR (D265A) Antibody (DTA-1) is an anti-mouse GITR IgG1 monoclonalantibody. Anti-Mouse GITR (D265A) Antibody (DTA-1) is a chimeric antibody of the original DTA-1 antibody (HY-P990124). Anti-Mouse GITR (D265A) Antibody (DTA-1) contains the D265A mutation region. Anti-Mouse GITR (D265A) Antibody (DTA-1) can be used for research on cancer and allergic conditions. The recommed isotype control of Anti-Mouse GITR (D265A) Antibody (DTA-1) is Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-Mouse CD28 (LALA-PG) Antibody (D665) is an anti-mouse CD28 IgG2a monoclonalantibody. Anti-Mouse CD28 (LALA-PG) Antibody (D665) is a chimeric antibody of the original D665 antibody (HY-P990793). Anti-Mouse CD28 (LALA-PG) Antibody (D665) contains the LALA-PG mutation region. Anti-Mouse CD28 Antibody (D665) induces the activation of T cells. Anti-Mouse CD28 Antibody (D665) can be used for research on neurological conditions, inflammation, immunology and cancer, such as Parkinson disease (PD), arthritis and graft-versus-host disease (GVHD).
Anti-Mouse GITR (LALA-PG) Antibody (DTA-1) is an anti-mouse GITR IgG2a monoclonalantibody. Anti-Mouse GITR (LALA-PG) Antibody (DTA-1) is a chimeric antibody of the original DTA-1 antibody (HY-P990124). Anti-Mouse GITR (LALA-PG) Antibody (DTA-1) contains the LALA-PG mutation region. Anti-Mouse GITR (LALA-PG) Antibody (DTA-1) can be used for research on cancer and allergic conditions. The recommed isotype control of Anti-Mouse GITR (LALA-PG) Antibody (DTA-1) is Mouse IgG2a kappa, Isotype Control (HY-P99978).
Anti-Mouse NK1.1 Antibody (PK136) is an anti-mouse NK1.1 IgG2a monoclonalantibody. Anti-Mouse NK1.1 Antibody (PK136) can deplete natural killer (NK) cells. Anti-Mouse NK1.1 Antibody (PK136) inhibits the JAK-STAT and NF-κB signaling pathways. Anti-Mouse NK1.1 Antibody (PK136) can be used for research on inflammation conditions such as non-alcoholic steatohepatitis (NASH) .
Anti-Rat CD8α Antibody (OX-8) is an anti-rat CD8α IgG1 monoclonalantibody. Anti-Rat CD8α Antibody (OX-8) can deplete CD8 + T cells. Anti-Rat CD8α Antibody (OX-8) can enhance airway remodeling. Anti-Rat CD8α Antibody (OX-8) can be used for researches on allergic conditions and infections such as RHV-rn1 virus infection and asthma .
Anti-Mouse FGL-1 Antibody (177R4) is an anti-mouse FGL-1 IgG2a monoclonalantibody. Anti-Mouse FGL-1 Antibody (177R4) can increase CD8 + T cell infiltration. Anti-Mouse FGL-1 Antibody (177R4) enhances the anti-tumor immune effect by blocking FGL1. Anti-Mouse FGL-1 Antibody (177R4) can be used for research on cancer such as lung cancer and breast cancer .
Anti-Flu A (H7N9) HA/Hemagglutinin Antibody (m826) is a humanized monoclonalantibody targeting H7N9. Anti-Flu A (H7N9) HA/Hemagglutinin Antibody (m826) induces antibody-dependent cellular cytotoxicity (ADCC) against cells expressing H7N9 HA. Anti-Flu A (H7N9) HA/Hemagglutinin Antibody (m826) is applicable to studies related to H7N9 avian influenza virus infection .
Armanezumab is a monoclonalantibody that targets and inhibits tau protein, and it specifically binds to the exposed N-terminal domain of pathological tau protein. Armanezumab can be used in relevant studies on Alzheimer's disease, frontotemporal dementia, and Pick's disease .
ALT-100 (Human IgG1) is a humanized IgG1 monoclonalantibody that targets NAMPT. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Diridavumab is a monoclonalanti-HA stalk antibody. Diridavumab stabilizes the prefusion HA structure and prevents pH-dependent fusion of cellular and viral membranes in endosomes. Diridavumab can be used in research of H2 influenza virus .
Arcitumomab is a murine anti-carcinoembryonic antigen (CEA) monoclonalantibody Fab’ fragment. Arcitumomab can be labeled with technetium-99m and can be used for single-photon emission computed tomography (SPECT) imaging .
Secukinumab (Anti-Human IL-17A) is a fully human anti-interleukin-17Amonoclonalantibody. Anti-Human IL-17A can be used for research in psoriasis pathogenesis .
Sontuzumab (AS1402) is a humanizedised IgG1κ MUC1 specific monoclonalantibody. Sontuzumab binds the extracellular MUC1 peptide sequence PDTR with a Kd of ~1 nM. Sontuzumab can be used for the research of breast cancer .
Ompekimig is a humanized immunoglobulin monoclonalantibody targeting human interleukin 4 (IL-4) and interleukin 13 (IL-13). Ompekimig is promising for research of immune-mediated inflammatory diseases, such as asthma and atopic dermatitis .
Gremubamab (MEDI3902) is a humanized IgG1 kappa anti-PcrV/Pslmonoclonalantibody. Gremubamab binds to the PA PcrV protein and Psl exopolysaccharide. Gremubamab has the potential for the research of pseudomonas aeruginosa infections .
Imgatuzumab (FUT8-KO) is a humanized monoclonalantibody against EGFR expressed in CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Imgatuzumab is an immunomodulator. Imgatuzumab may be used in cancer research.
Tozorakimab (MEDI-3506) is a human immunoglobulin G1 monoclonalantibody targeting interleukin-33. Tozorakimab reduces inflammation and epithelial dysfunction. Tozorakimab can be used to research chronic obstructive pulmonary disease .
Cetuximab sarotalocan (RM-1929) is an IRdye700DX (near-infrared photosensitizing dye) conjugate of Cetuximab (anti-EGFRmonoclonalantibody). Cetuximab sarotalocan can be used for head and neck cancers research .
Zolimomab is an anti-human monoclonalantibody targeting-CD5. Zolimomab binds to the CD5 antigen found on mature T-cells. Zolimomab can be used for the research of graft-versus-host disease (GVHD) .
PD-360324 is a human monoclonalantibody (mAb) targeting CSF1/M-CSF. PD-360324 can be used in cutaneous lupus erythematosus, pulmonary sarcoidosis and rheumatoid arthritis research .
Tovetumab (MEDI-575) is an anti-PDGFRα monoclonalantibody that selectively blocks the PDGFRα signal transduction. Tovetumab can be used in the research of glioblastoma and non-small cell lung cancer (NSCLC) .
XmAb-7195 (AIMab-7195) is a human monoclonalantibody (mAb) targeting IGHE. XmAb-7195 can be used in Food hypersensitivity, Allergic asthma, Allergic rhinitis, Atopic dermatitis and Conjunctivitis research .
BIIB036 is a human IgG1 monoclonalantibody (mAb) targeting TNFRSF12A/Fn14. BIIB036 inhibits the growth of patient-derived primary colorectal tumors in SCID mice .
Ormutivimab (rhRIG) is a recombinant human monoclonalantibody, targeting rabies virus. Ormutivimab neutralizes a variety of rabies virus strains. Ormutivimab exhibits potent potency against rabies post-exposure prophylaxis (PEP) model .
Anselamimab (CAEL-101) is a chimeric monoclonalantibody for systemic light chain (AL) amyloidosis. Anselamimab can promote phagocytic destruction and subsequent clearance of amyloid deposits. Anselamimab can be used in the research of amyloidosis .
Rulonilimab is a human IgG1 monoclonalantibody against PD-1 that targets, binds and inhibits PD-1 and its downstream signalling pathways with potential immune checkpoint inhibition and anti-tumour activity .
Iparomlimab is an anti-human PD-1/CD279/PDCD1 IgG4κ antibody. Iparomlimab also targets to human monoclonal PSB103 γ4-chain, disulfided with human monoclonal PSB103 κ-chain to form a dimer. Iparomlimab can be used for Oncology research .
MT204 is a humanized IgG1 antibody inhibitor targeting IL-2 of human and rhesus monkey origin. MT204 prevents soluble IL-2 from binding to intermediate-affinity IL-2 receptors and blocks CD25-bound IL-2 on high-affinity IL-2 receptors. MT204 has potently anti-proliferative activity with NKL cells and primary NK cells. MT204 has good tolerability and potent immunosuppressive activity in allogeneic skin graft model of rhesus monkey, promising for immunosuppressive and anti-proliferative therapy .
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonalantibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL) .
Mertansine- 13C,d3 (DM1- 13C,d3) is the 13C- and deuterium labeled Mertansine (HY-19792). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonalantibody with a linker to create an antibody-drug conjugate (ADC) .
Anti-CD19 Antibody (4G7) is an anti-human CD19 IgG1 monoclonalantibody. Anti-CD19 Antibody (4G7) reduces the killing effect of CAR T cells on Raji cells. Anti-CD19 Antibody (4G7) can be used for research on immunology. Anti-CD19 Antibody (4G7) is often used in flow cytometry. The recommend isotype control of Anti-CD19 Antibody (4G7): Mouse IgG1 kappa, Isotype Control (HY-P99977) .
Exatecan-3-amine is an effective exatecan derivative. Exatecan-3-amine can be connected to monoclonalantibodies via linkers to form antibody-drug conjugate (ADC) molecules. Exatecan-3-amine is often combined with CLDN6 mAb to form ADC drugs for the study of tumors with high expression of CLDN6 .
Evinacumab (REGN1500) is a human anti-ANGPTL3 (angiopoietin-like protein 3) monoclonalantibody (IgG4 class antibody). Evinacumab reduces plasma lipids in dyslipidemic mice by blocking ANGPTL3. Evinacumab can be used in studies of homozygous familial hypercholesterolaemia (HoFH), refractory hypercholesterolaemia (both familial and non-familial) and severe hypertriglyceridaemia .
Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonalantibody and an Interleukin-17A (IL-17A) inhibitor. Vunakizumab binds to IL-17A to inhibit downstream cytokines and block inflammatory signaling. Vunakizumab can be used for the research of chronic plaque psoriasis and ankylosing spondylitis .
GB-223 is a human monoclonalantibody (mAb) targeting TNFSF11/RANKL/CD254. GB-223 can be used in Giant cell tumour of bone and Postmenopausal osteoporosis research .
Goat Serum Albumin is a plasma protein derived from goats. Goat Serum Albumin is a versatile protein commonly used in various life sciences research applications, including immunoassays and the production and purification of monoclonalantibodies .
Izenivetmab (ZTS-00075623) is an anti-NGFB IgG2κ monoclonalantibody. Izenivetmab shows anti-inflammatory and analgesic effects by targeting anti-nerve growth factor (NGF). Izenivetmab can be used for the research of osteoarthritis .
Enzelkitug is a humanized immunoglobulin G1-κ monoclonalantibody targeting the human C-C motif chemokine receptor 8 (CCR8). Enzelkitug is promising for research of various solid tumors and hematological malignancies .
Ravulizumab (ALXN1210) is a humanized monoclonalantibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis .
Odesivimab is a human monoclonalantibody, targeting Ebola virus glycoprotein with a KD value of 7.74 nM for recombinant histidine-tagged Makona strain Ebola virus glycoprotein ectodomain protein. Odesivimab can be used in research of Ebola virus infection .
Brazikumab (AMG 139) is a human IgG2 monoclonalantibody, selectively binds the p19 subunit of IL-23, with a KD of 0.138 nM for human IL-23. Brazikumab can be used for the research of Crohn's disease .
Ipilimumab is a fully human monoclonalantibody IgG1κ that blocks the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells. Ipilimumab can be used in unresectable or metastatic melanoma (MM) studies .
MEDI-1912 is a human monoclonalantibody (mAb) targeting NGF/bNGF. MEDI-1912 inhibits signaling through TrkA and p75 receptors. MEDI-1912 can be used in chronic pain research .
Tadocizumab (C4G1; YM-337) is a humanized monoclonalantibody tageting integrin αIIbβ3. Tadocizumab has antiplatelet and antithrombotic effects, and can be used for cardiovascular disease research .
Otilimab (GSK 3196165) is an anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) human monoclonalantibody. Otilimab neutralises the biological function of GM-CSF by blocking the interaction of GM-CSF with its cell surface receptor .
Ficlatuzumab is a monoclonalantibody (McAb) targeting human hepatocyte growth factor (HGF). Ficlatuzumab blocks the activation of the HGF/c-Met signaling pathway, and inhibits c-Met receptor-mediated cancer cell proliferation, migration, and invasion .
Ixotatug is a monoclonalantibody targeting human CLDN6 (claudin-6). Ixotatug specifically binds to CLDN6, interfering with relevant signaling pathways in tumor cells and exerting antitumor activity. Ixotatug is promising for research of cancers .
SIM-0235 is humanized immunoglobulin G1 (IgG1) monoclonalantibody that targets and inhibits TNFR2, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) [1].
PMN310 is a monoclonalantibody targeting amyloid-β oligomers (AβO). PMN310 prevents AβO-induced memory loss and reduces synaptic loss and inflammation in vivo. PMN310 is potentially useful in Alzheimer's disease research .
Anti-Rat β-2-Microglobulin Antibody (4C9) is an anti-rat β-2-Microglobulin IgG1 monoclonalantibody. Anti-Rat β-2-Microglobulin Antibody (4C9) reduces pJNK nuclear translocation and restore SMAD nuclear localization. Anti-Rat β-2-Microglobulin Antibody (4C9) is often used in immunoprecipitation experiments .
Anti-Mouse IL-23 p19 Antibody (G23-8) is a rat-derived anti-mouse IL-23 p19 IgG1 monoclonalantibody. Anti-Mouse IL-23 p19 Antibody (G23-8) alleviates inflammation by restoring CLDN8 expression. Anti-Mouse IL-23 p19 Antibody (G23-8) can be used for research on inflammation conditions such as colitis and asthma .
Anti-DAG1/Dystroglycan Antibody (DAG-6F4) is a human monoclonalantibody against DAG1/Dystroglycan. Anti-DAG1/Dystroglycan Antibody (DAG-6F4) can bind specifically to the α and β subunits of the dystroglycan protein complex. Anti-DAG1/Dystroglycan Antibody (DAG-6F4) is applicable to research related to muscular dystrophy .
Lanerkitug (FUT8-KO) (BAY3375968 (FUT8-KO)) is an anti-CCR8 monoclonalantibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Lanerkitug (HY-P991942) selectively depletes human CCR8+Tregs via antibody dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP). Lanerkitug can be used in the research of solid tumors .
Anti-Mouse TNFR2 Antibody (TR75-54.7) is an anti-mouse TNFR2 IgG monoclonalantibody. Anti-Mouse TNFR2 Antibody (TR75-54.7) can reduce white blood cell count (WBC) and decrease the expression of some pro-inflammatory cytokines such as CCL2 and CXCL5. Anti-Mouse TNFR2 Antibody (TR75-54.7) can be used for researches on inflammation conditions and cancer such as breast cancer .
Anti-Mouse LAG-3 (D265A) Antibody (C9B7W) is an anti-mouse LAG-3 IgG1 monoclonalantibody. Anti-Mouse LAG-3 (D265A) Antibody (C9B7W) is a chimeric antibody of the original C9B7W antibody (HY-P99141). Anti-Mouse LAG-3 (D265A) Antibody (C9B7W) contains the D265A mutation region. Anti-Mouse LAG-3 (D265A) Antibody (C9B7W) can be used for research on cancer .
Anti-CD11a Antibody (AL-57) is a monoclonalantibody targeting human CD11a. Anti-CD11a Antibody (AL-57) binds to HA cells in a dose-dependent manner but did not bind to LA cells. Anti-CD11a Antibody (AL-57) preferentially binds to the active conformation of LFA-1 and blocks LFA-1-mediated adhesion and lymphocyte proliferation. Anti-CD11a Antibody (AL-57) can be used for the research of inflammatory and autoimmune diseases .
Anti-Human/Rat HER2 (neu) Antibody (7.16.4) is an anti-human and anti-rat HER2 IgG2a monoclonalantibody. Anti-Human/Rat HER2 (neu) Antibody (7.16.4) reduces tumor cell proliferation by inhibiting the HER2 signaling pathway. Anti-Human/Rat HER2 (neu) Antibody (7.16.4) can activate CD8 + T cells. Anti-Human/Rat HER2 (neu) Antibody (7.16.4) can be used for research on cancer such as breast cancer .
Anti-Mouse Notch4 Antibody (HMN4-14) is an anti-mouse Notch4 IgG monoclonalantibody. Anti-Mouse Notch4 Antibody (HMN4-14) reduces inflammation by restoring the expression of bispecific proteins. Anti-Mouse Notch4 Antibody (HMN4-14) can inhibit Th2/Th17 cell differentiation and improve Treg cell function. Anti-Mouse Notch4 Antibody (HMN4-14) can be used for research on inflammation conditions such as viral pneumonia and airway inflammation .
Anti-Mouse VEGFR-2 Antibody (DC101) is a rat anti-mouse VEGFR2monoclonalantibody. Anti-Mouse VEGFR-2 Antibody (DC101) inhibits tumor angiogenesis by blocking the binding of VEGF and VEGFR2. Anti-Mouse VEGFR-2 Antibody (DC101) promotes immune cell infiltration and induces tumor cell apoptosis. Anti-Mouse VEGFR-2 Antibody (DC101) can be used for researches on various types of cancer such as melanoma, lung cancer and breast cancer .
Anti-Mouse CD8α Antibody (YTS 105.18) is a non-depleting rat IgG2a monoclonalantibody. Anti-Mouse CD8α Antibody (YTS 105.18) binds to CD8α (epitope c) on mouse CD8 + T cells; when used in combination with a non-depleting anti-CD4 antibody, it does not deplete CD8 + T cells but instead promotes the induction of peripheral tolerance in this cell subset. Anti-Mouse CD8α Antibody (YTS 105.18) can be used in studies of graft rejection .
Anti-CD2 Antibody (CB.219) is an anti-human CD2 IgG2b monoclonalantibody. Anti-CD2 Antibody (CB.219) can reduce the infiltration of T cells, macrophages, and the number of Tregs in the colon. Anti-CD2 Antibody (CB.219) can be used for research on infection and inflammation such as toxoplasma infection and colitis. The recommend isotype control of Anti-CD2 Antibody (CB.219): Mouse IgG2b kappa, Isotype Control (HY-P99982) .
Anti-CD85a/LILRB3 Antibody (7C5) is a human monoclonalantibody targeting LILRB3/ILT5/CD85a. Anti-CD85a/LILRB3 Antibody (7C5) can be used for research on inflammatory and immune diseases. The recommended isotype control is human IgG1 kappa, isotype control (HY-P99001).
Anti-Human/Mouse/Bovine LAG-3 Antibody (ADI-31853) is a monoclonalantibody that specifically binds to human, mouse and bovine LAG-3. Anti-Human/Mouse/Bovine LAG-3 Antibody (ADI-31853) can be used in the research of colon cancer, colorectal cancer and rectal cancer. The recommended isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
M3554 is an anti-GD2 antibody-drug conjugate (ADC) based on the humanized anti-GD2 antibody. M3554 consists of the humanized monoclonalantibody hu14.18 (K322A) (HY-P991040) linked to a topoisomerase 1 inhibitor Exatecan (HY-13631) via a cleavable β-glucuronide linker. M3554 can be used for the study of neuroblastoma, osteosarcoma or glioma .
Polatuzumab vedotin solution is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonalantibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin solution has the potential for the research of Large B-cell lymphomas (LBCL) .
XmAb5485 is an Fc-engineered humanized anti-CD40 monoclonalantibody with high affinity to Fc-γ receptors. XmAb5485 induces potent antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) against tumor cells. XmAb5485 inhibits proliferation and induces apoptosis of tumor cells. XmAb5485 shows highly cytotoxic against lymphoma, leukemia and multiple myeloma cell lines as well as primary cancer cells .
Erlizumab (rhuMAb) is a monoclonalantibody against the Integrin b2/ITGB2/CD18 subunit of the Mac-1 receptor. Erlizumab can reduce reperfusion injury in myocardial infarction .
Laventatug is a humanized monoclonalantibody targeting human SLC39A6. Laventatug specifically binds to SLC39A6, interfering with the intracellular zinc ion transport process and thus exerting antitumor activity. Laventatug is promising for research of cancers .
Exerenibart is an immunoglobulin G4-κ monoclonalantibody targeting human transmembrane serine protease 6 (TMPRSS6). Exerenibart is promising for research of diseases associated with iron metabolism disorders, such as iron overload or iron deficiency .
Palivizumab (MEDI 493) is a humanized monoclonalantibody against respiratory syncytial virus (RSV). Palivizumab can bind to RSV F protein with a Kd value of 1.4 nM. Palivizumab can prevent respiratory syncytial virus infection in cotton mice .
Ascrinvacumab (PF-03446962) is a human IgG2 monoclonalantibody targets ALK-1. Ascrinvacumab shows binding efficiency with human ALK1 with a Kd value of 7 nM. Ascrinvacumab can be used for the research of hepatocellular carcinoma (HCC) .
Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3monoclonalantibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes .
GB-0895 is a human monoclonalantibody (mAb) targeting TSLP. GB-0895 can be used in Asthma research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Gimvekibart is a humanized IgG4κ monoclonalantibody inhibitor targeting IL-4Ra/CD124. Gimvekibart can be used for inflammatory diseases like idiopathic pulmonary fibrosis (IPF) research .
Abituzumab (DI17E6) is a humanised anti-integrin αV monoclonalantibody (IgG2 type). Abituzumab effectively reduces the phosphorylation of FAK, Akt and ERK. Abituzumab can be used in cancer research, particularly in prostate cancer .
BMS-986184 is a fully human monoclonalantibody targeting interferon gamma-induced protein 10 (IP-10)/CXCL10. BMS-986184 can be used for the research of lupus nephritis .
Capromab is an anti-human PSMA-targeting monoclonalantibody. Capromab binds specifically to the intracellular domain of PSMA, does not undergo internalization after binding, and targets necrotic cells with disrupted membranes. Capromab can be used for the research of prostate cancer .
Dicamba-propionic acid (DCa3) is a heterologous hapten that can be used to develop high-affinity monoclonalantibodies (mAb) against Dicamba. The Dicamba-propionic acid- developed mAb can be used to determine the residual amount of Dicamba in environmental water samples .
Inolimomab is an anti-interleukin-2 receptor (IL-2R) α chain monoclonalantibody. Inolimomab improves the survival rate in the early research of treating acute graft-versus-host disease (aGVHD) .
SM-17 is a humanized monoclonalantibody inhibitor targeting interleukin 25 (IL-25) and interleukin-17 receptor B (IL17RB). SM-17 is promising for research of immune system diseases .
FF-21101 is a human IgG1 monoclonalantibody (mAb) targeting CDH3/P-cadherin. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Isecarosmab (M-6495) is an anti-ADAMTSmonoclonalantibody (mAb) with a KD value of 3.65 pM. Isecarosmab has chondroprotective and anti-inflammatory activities. Isecarosmab can bind albumin to extend plasma half-life .
huCC49 is a human monoclonalantibody targeting TAG-72. huCC49 can be used in cancer-related research. The recommended isotype control is human IgG1 kappa, with the isotype control (HY-P99001) .
ANB032 is a human IgG4 kappa BTLA agonist monoclonalantibody. ANB032 inhibits activated T cell proliferation and reduces secretion of inflammatory cytokines.ANB032 can be used for the research of atopic dermatitis[1].
Zampilimab (UCB-7858) is a monoclonalantibody against transglutaminase 2 (TG2). Zampilimab inhibits TG2 crosslinking transamidation activity with an IC50 of 0.25 nM and a Kd of <50 pM. Zampilimab improves renal fibrosis .
SGM-101 Antibody is a chimeric monoclonalantibody targeting carcinoembryonic antigen (CEA). SGM-101 Antibody can serve as a tumor-specific fluorescent imaging probe after being covalently conjugated with the near-infrared fluorescent dye BM104 . SGM-101 Antibody accumulates in CEA-positive tumor tissues via antigen-antibody specific binding, and emits near-infrared fluorescence to enable imaging of tumor lesions. SGM-101 Antibody can be used in research related to gastric cancer, colorectal cancer, pancreatic cancer, non-small cell lung cancer, breast cancer, peritoneal carcinomatosis, and liver metastases .
MB-314 is a human IgG1 monoclonalantibody (mAb) targeting Lewis Y. MB-314 induces enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. MB-314 increases the release of IFN-γ, TNF-α, MCP-1, and IL-6. MB-314 can be used in cancer research .
Nimotuzumab (powder) is a humanized IgG1 monoclonalantibody targeting EGFR with a KD value of 0.21 nM. Nimotuzumab (powder) is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab (powder), a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) .
Becotatug vedotin (MRG003) is an Antibody-Drug Conjugate (ADC) that consists of an anti-EGFR humanized IgG1 monoclonalantibody Becotatug (HY-P990049) and MMAE (HY-15162). These two parts are connected through a valine-citrulline (valine-citrulline) linker, where the linker and MMAE constitute the ADC's Drug-Linker conjugate VcMMAE (HY-15575) .
Lucatumumab (HCD122) is a fully human anti-CD40 antagonist monoclonalantibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research .
ADC Control Human IgG1-vcMMAE (solution) is a humanized monoclonalantibody that is an isotype control of ADC human IgG1-vcMMAE and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is vcMMAE (HY-15575) .
MIL93 is a humanized defucosylated IgG1 monoclonalantibody targeting Claudin18.2 (CLDN18.2) with enhanced antibody-dependent cellular cytotoxicity (ADCC) activity. MIL93 can be used for research on advanced solid tumors and gastric cancer. The recommended isotype control is human IgG1 kappa (HY-P99001) .
Flanvotumab (IMC-20D7S) is a human monoclonalantibody targeting to tyrosinase-related protein (TYRP1), specifically expressed in melanocytes and melanoma cells. Flanvotumab acts function via natural killing-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Flanvotumab has potent anti-tumor activity and good tolerance .
H2Mab-139 (H2Mab-141;H2Mab-19) is an anti-HER2monoclonalantibody. H2Mab-139 specifically binds to HER2 on various cancer cells. H2Mab-139 can detect HER2 overexpression in colorectal cancer via flow cytometry and immunohistochemical analysis. H2Mab-139 exhibits anti-tumor activity in mouse oral cancer and breast cancer xenografts. H2Mab-139 is applicable to research related to multiple cancers including colon cancer, oral cancer, and breast cancer .
Anti-Mouse OX40/CD134 (LALA-PG) Antibody (OX86) is an anti-mouse OX40/CD134 (LALA-PG) IgG2a monoclonalantibody. Anti-Mouse OX40/CD134 (LALA-PG) Antibody (OX86) is a chimeric antibody of the original OX86 antibody (HY-P990115). Anti-Mouse OX40/CD134 (LALA-PG) Antibody (OX86) can significantly enhance the generation of antigen-specific effector T cells. Anti-Mouse OX40/CD134 (LALA-PG) Antibody (OX86) can be used for research on cancer .
8-Bromo-2'-deoxyguanosine is an inflammation-related DNA halogenated adduct and an early biomarker of inflammation-induced oxidative tissue damage. The formation of 8-Bromo-2'-deoxyguanosine precedes that of oxidative and nitrative products, and it can be generated via the MPO-H2O2-Cl --Br - system. 8-Bromo-2'-deoxyguanosine serves as the immunogen for preparing the monoclonalantibody mAb8B3, which can be used to detect early DNA modifications in preclinical models; its urinary level also increases significantly in inflammatory disease models. 8-Bromo-2'-deoxyguanosine can also be produced in the dermis of UV-B irradiated mice, and the extract of Coprinus comatus significantly reduces its level. 8-Bromo-2'-deoxyguanosine finds applications in studies related to inflammatory diseases, diabetes, hepatocellular carcinoma, and UV-B induced skin inflammation .
Zigakibart (BION-1301) is an IgG4-kappa, humanized monoclonalantibody against TNFSF13 (tumor necrosis factor (TNF) superfamily member 13, APRIL, CD256). Zigakibart exhibits anti-inflammatory activity .
XMT-1519 conjugate-1 (compound 31) is part of the drug-linker conjugate for ADC and can be conjugated with the HER-2 monoclonalantibody Calotatug (XMT-1519) (HY-P990909) for the synthesis of ADC .
Revdofilimab (ABBV-368) is a human IgG1 agonist monoclonalantibody against OX40. Among them, OX40 is a member of the TNF receptor superfamily expressed on activated and memory T cell subsets and T regulatory cells .
Bavunalimab (Anti-Human CTLA4xLAG3) is a bispecific human anti-CTLA-4/LAG-3monoclonalantibody. Bavunalimab activates T cells in NSG mice. Bavunalimab can be used for the research of cancer .
Danburstotug (IMC-001) is an IgG1-lambda anti-CD274 (PDL1, B7 homologue 1, B7H1) human monoclonalantibody. Danburstotug also is immunostimulant and antineoplastic .
Sifalimumab (MEDI-545) is an anti-IFNαmonoclonalantibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. Sifalimumab can be used in systemic lupus erythematosus (SLE) research .
Margetuximab (MGAH22) is a chimeric anti-HER2monoclonalantibody optimized Fc domain, with an EC50 value of 39.33 ng/mL. Margetuximab can be used for researching metastatic HER2-positive breast cancer .
Vecantoxatug is a humanized monoclonalantibody targeting Clostridium tetani toxin (TeNT, neurotoxin). Vecantoxatug specifically binds to Clostridium tetani toxin, preventing the toxin from binding to cell receptors and thus exerting antitoxin activity. Vecantoxatug is promising for research of tetanus .
Anrukinzumab (IMA-638) is a humanized anti-IL-13 monoclonalantibody. Anrukinzumab effectively reduces lung inflammation in a cynomolgus monkey model. Anrukinzumab can be used in studies of ulcerative colitis (UC) as well as asthma .
Vedolizumab (anti-α4β7-integrin) is a humanized IgG1 monoclonalantibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease .
CNTO-5825 is a humanized monoclonalantibody inhibitor targeting interleukin-13 (IL-13). CNTO-5825 is promising for research of Th2-type inflammatory related diseases such as asthma and atopic dermatitis .
Gumokimab (AK 111) is a monoclonalantibody targeting IL-17A, which can be used in the study of psoriasis, ankylosing spondylitis. Gumokimab competitively blocks the binding of human IL-17A to IL-17R.
SEA-TGT is a human monoclonalantibody (mAb) targeting TIGIT. SEA-TGT enhances binding to the activating FcγRIIIA while reducing binding to the inhibitory FcγRIIb. SEA-TGT can be used in advanced solid tumors and Lymphoma research .
Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of Spike protein and ACE2. Anti-Spike-RBD mAb is a potential therapeutic approach for SARS-CoV-2 treatment .
Anti-VSIR/VISTA Antibody (SG7) is a human monoclonalantibody (mAb) targeting VISTA/B7-H5. Anti-VSIR/VISTA Antibody (SG7) inhibits VISTA function and prevents PSGL-1 and VSIG3 from binding to VISTA. Anti-VSIR/VISTA Antibody (SG7) has anti-tumor activity in the mouse B16F10 melanoma model. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Anti-RSV F Antibody (R4.C6) is a monoclonalantibody against RSV F, with a Kd of 0.34 nM for the post-fusion RSV F trimer. Anti-RSV F Antibody (R4.C6) recognizes a unique neutralizing epitope spanning epitopes II and IV on both pre-fusion and post-fusion RSV F. Anti-RSV F Antibody (R4.C6) can be used in studies related to respiratory syncytial virus infection .
Anti-Mouse E-selectin/CD62E Antibody (9A9) is an anti-mouse E-selectin/CD62E IgG2b monoclonalantibody. Anti-Mouse E-selectin/CD62E Antibody (9A9) has an inhibitory effect on cancer cell colonization. Anti-Mouse E-selectin/CD62E Antibody (9A9) can be used for researches on inflammation conditions and cancer such as acute microvascular inflammation and breast cancer .
Anti-Mouse MAdCAM-1 Antibody (MECA-367) is an anti-mouse MAdCAM-1 IgG2a monoclonalantibody. Anti-Mouse MAdCAM-1 Antibody (MECA-367) significantly inhibits the migration of pig peripheral blood lymphocytes (PBL) by blocking the function of MAdCAM-1. Anti-Mouse MAdCAM-1 Antibody (MECA-367) selectively inhibits B cell migration to exacerbate inflammation. Anti-Mouse MAdCAM-1 Antibody (MECA-367) can be used for researches on inflammation, metabolic conditions and xenotransplantation such as colitis and diabetes .
Anti-Mouse Jagged 2 Antibody (HMJ2-1) is an anti-mouse Jagged 2 IgG monoclonalantibody. Anti-Mouse Jagged 2 Antibody (HMJ2-1) regulates Treg/Th17 balance through IL-9. Anti-Mouse Jagged 2 Antibody (HMJ2-1) increases Jagged2-Notch signaling through activation of RBP-Jk. Anti-Mouse Jagged 2 Antibody (HMJ2-1) can be used for researches on inflammation conditions and xenotransplantation such as experimental autoimmune encephalomyelitis (EAE) .
Anti-HCMV gB Antibody (SM5-1) is an efficient neutralizing human monoclonalantibody that targets the human cytomegalovirus (HCMV) glycoprotein B (gB). Anti-HCMV gB Antibody (SM5-1) neutralizes HCMV by blocking the conformational changes of gB and interfering with its binding to the gH/gL complex. Anti-HCMV gB Antibody (SM5-1) can broadly neutralize different virus strains and inhibit the infection of various cell types (such as fibroblasts, epithelial cells, and dendritic cells). Anti-HCMV gB Antibody (SM5-1) can be used in HCMV vaccine research .
Anti-Mouse F4/80 Antibody (CI:A3-1) is an anti-mouse F4/80 IgG2b monoclonalantibody. Anti-Mouse F4/80 Antibody (CI:A3-1) can clear macrophages. Anti-Mouse F4/80 Antibody (CI:A3-1) can be used for research on inflammation conditions such as endometriosis. Anti-Mouse F4/80 Antibody (CI:A3-1) often used for flow cytometry analysis and immunohistochemical analysis .
Anti-Mouse CTLA-4 Antibody (9D9) is an anti-mouse CTLA-4 IgG2b monoclonalantibody. Anti-Mouse CTLA-4 Antibody (9D9) can bind to CTLA-4 and block its binding to B7. Anti-Mouse CTLA-4 Antibody (9D9) enhances T cell function by increasing the ratio of CD8 + T cells to regulatory T cells (Tregs). Anti-Mouse CTLA-4 Antibody (9D9) can be used for research on cancer such as colon cancer and melanoma .
Anti-Mouse IL-4 Antibody (11B11) is an anti-mouse IL-4 IgG1 monoclonalantibody. Anti-Mouse IL-4 Antibody (11B11) can inhibit Th2 cell differentiation by blocking the IL-4 signaling pathway. Anti-Mouse IL-4 Antibody (11B11) can significantly reduce fibrosis combined with anti-IL13 mAb. Anti-Mouse IL-4 Antibody (11B11) can be used for researches on cancer and inflammation conditions such as colorectal cancer and prostatitis .
Anti-Mouse/Human IL-7 Antibody (M25) is an anti-mouse IL-7 IgG2b monoclonalantibody. Anti-Mouse/Human IL-7 Antibody (M25) alleviates inflammation by blocking IL-7 signaling and inhibiting innate lymphoid cells (ILC2s) activation. Anti-Mouse/Human IL-7 Antibody (M25) can reduce the number of B cell precursors. Anti-Mouse/Human IL-7 Antibody (M25) can be used for researches on inflammation conditions such as airway inflammation .
Anti-Mouse Vβ4 TCR Antibody (KT4) is an anti-mouse Vβ4 TCR IgG2b monoclonalantibody. Anti-Mouse Vβ4 TCR Antibody (KT4) can reduce the proportion of Vβ4 + T cells without affecting their function. Anti-Mouse Vβ4 TCR Antibody (KT4) can be used for research on immunology and infection conditions such as virus infection. Anti-Mouse Vβ4 TCR Antibody (KT4) is often used in flow cytometry .
Anti-IL-12 p70 Antibody (20C2) is an anti-human IL-12 p70 IgG1 monoclonalantibody. Anti-IL-12 p70 Antibody (20C2) can inhibit the production of IFN-γ. Anti-IL-12 p70 Antibody (20C2) can be used for research on inflammation conditions. The recommend isotype control of Anti-IL-12 p70 Antibody (20C2): Rat IgG1 kappa, Isotype Control (HY-P99979) .
Anti-Mouse CD38 Antibody (NIMR5) is an anti-mouse CD38 IgG2a monoclonalantibody. Anti-Mouse CD38 Antibody (NIMR5) can activate the ERK signaling pathway and promote cell apoptosis. Anti-Mouse CD38 Antibody (NIMR5) can restore T cell function. Anti-Mouse CD38 Antibody (NIMR5) upregulates the expression of CD1d protein and enhances spleen cell proliferation, dendritic cell (DC) and natural killer T cell (NKT) expansion. Anti-Mouse CD38 Antibody (NIMR5) can be used for researches on cancer and immunology such as melanoma and colon cancer .
Anti-CD1a Antibody (OKT-6) is an anti-human CD1a IgG1 monoclonalantibody. Anti-CD1a Antibody (OKT-6) blocks T cell activation by blocking CD1a function. Anti-CD1a Antibody (OKT-6) can reduce the production of IFN-γ. Anti-CD1a Antibody (OKT-6) can be used for researches on cancer and inflammation such as leukemia. The recommend isotype control of Anti-CD1a Antibody (OKT-6): Mouse IgG1 kappa, Isotype Control (HY-P99977) .
Anti-Mouse CD8α Antibody (2.43) is an anti-mouse CD8α IgG2b monoclonalantibody. Anti-Mouse CD8α Antibody (2.43) can significantly deplete CD8 + T cells. Anti-Mouse CD8α Antibody (2.43) can prolong the survival time of liver cell transplantation. Anti-Mouse CD8α Antibody (2.43) can be used for research on immunology. The recommend isotype control of Anti-Mouse CD8α Antibody (2.43): Rat IgG2b kappa, Isotype Control (HY-P990682) .
Zumilokibart (APG-777) is an anti-IL-13 IgG1κ type humanized antibody. The recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).Zumilokibart can be used for the research of atopic dermatitis (AD) .
Etalanetug (Mouse IgG2a) (7G6 Antibody) is a mouse monoclonalantibody targeting the HVPGG motif in the microtubule-binding domain of tau protein. Etalanetug (Mouse IgG2a) reduces the levels of insoluble tau protein in multiple brain regions and inhibits the seeding and spread of pathological tau protein. Etalanetug (Mouse IgG2a) is applicable to research related to Alzheimer's disease .
Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonalantibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 (HY-12454), via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.8 .
Vobramitamab is a humanized B7-H3monoclonalantibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. MGC018 displays potent antitumor activity in preclinical tumor models of breast, ovarian, and lung cancer, as well as melanoma .
Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonalantibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE) (HY-15162), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Disitamab vedotin enhances antitumor immunity .
Delpacibart is a humanized IgG1κ monoclonalantibody targeting the transferrin receptor TFRC. Delpacibart can be conjugated with the phosphorodiamidate morpholino oligonucleotide (PMO) Zotadirsen (HY-177972), which targets exon 44 of the dystrophin gene, to synthesize the antibody-oligonucleotide conjugate (AOC) Delpacibart zotadirsen (HY-177564). Delpacibart is suitable for use in Duchenne muscular dystrophy (DMD44) research .
Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) is a humanised monoclonalantibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab blocks the inflammation-driven osteogenic differentiation .
Osemitamab (FUT8-KO) is an anti-claudin-18.2monoclonalantibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study .
Empasiprubar (ARGX-117) is a humanized inhibitory monoclonalantibody targeting complement C2. Empasiprubar binds to the Sushi-2 domain of C2, preventing the formation of C3 pre convertase and inhibiting the activation of classical and lectin pathways upstream of C3 activation. Empasiprubar can prevent complement mediated autoimmune hemolytic anemia and antibody mediated organ transplant rejection. Empasiprubar can prevent neuroglial lymphoconjunctival injury in GM1 antibody mediated mouse models .
2,5-Dioxopyrrolidin-1-yl 6-hydrazinylnicotinate hydrochloride is an intermediate of a radionuclide molecular probe targeting the CD4 receptor. 2,5-Dioxopyrrolidin-1-yl 6-hydrazinylnicotinate hydrochloride serves as an imaging agent for heart transplant rejection. This CD4 probe is prepared by mixing leukocyte differentiation antigen 4 monoclonalantibody with a solution of 6-hydrazinylnicotinoyl succinimide ester hydrochloride, followed by extraction and reaction to obtain 6-hydrazinylnicotinate-leukocyte differentiation antigen 4 monoclonalantibody; this antibody is then mixed with N-tris (hydroxymethyl) glycine, stannous chloride and technetium for an oscillatory reaction. This CD4 probe exhibits high affinity for CD4 + T lymphocytes, along with the characteristics of high sensitivity and high specificity, enabling early diagnosis of acute rejection .
W0180 is a human IgG1 monoclonalantibody (mAb) targeting VISTA/B7-H5. W0180 has the potential to activate T cells. W0180 can be used in solid tumors research .
Dalidnetug is a humanized monoclonalantibody targeting human amyloid-beta precursor protein (APP). Dalidnetug specifically binds to APP to reduce the production of amyloid-beta (Aβ), thus exerting the activity of clearing amyloid-beta. Dalidnetug is promising for research of Alzheimer's disease .
Vomitoxin-BSA (DON-BSA) is an artificial antigen containing Deoxynivalenol (Vomitoxin) (HY-N6684) and BSA. Deoxynivalenol is one of the most important mycotoxins related to food chains. Vomitoxin-BSA can be used to generate anti-Deoxynivalenol monoclonalantibodies .
Zamerovimab (CTB011) is an anti-rabies humanized IgG1κ monoclonalantibody that binds to the non-overlapping epitopes on the rabies virus (RABV) glycoprotein. Zamerovimab targets residues at and near antigenic site III. Zamerovimab can be used in rabies studies .
GSK-315234 is a human IgG1 monoclonalantibody (mAb) targeting OSM . GSK-315234 can be used in the study of atherosclerosis Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Figitumumab (CP-751871) is a potent and fully human monoclonalanti–insulin-like growth factor 1 receptor (IGF1R) antibody. Figitumumab prevents IGF1 from binding to IGF1R with an IC50 of 1.8 nM .
Regdanvimab (CT-P59) is a human monoclonalantibody that targets the receptor-binding domain of SARS-CoV-2 spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19 .
Cosibelimab (CK-301) is a high-affinity, fully human PD-L1-blocking monoclonalantibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab exhibits antitumor efficacy .
Cenzestotug is a monoclonalantibody targeting human tumor necrosis factor receptor superfamily member 4 (TNFRSF4). Cenzestotug activates relevant immune cells by binding to TNFRSF4, exerting immunostimulatory and antitumor activities. Cenzestotug is promising for research of cancer immunotherapy .
Certolizumab pegol (Certolizumab) is a recombinant, polyethylene glycosylated, antigen-binding fragment of a humanized monoclonalantibody that selectively targets and neutralizes tumour necrosis factor-α (TNF-α). Certolizumab pegol can be used for rheumatoid arthritis and Crohn disease research .
RTX-003 is a monoclonalantibody targeting CD25. RTX-003 induces the death of regulatory T cells (Tregs) by targeting the IL-2 receptor α chain (CD25), and can enhance anti-tumor immune responses.
XMT-1519 conjugate-1 TFA (compound 31) is part of the drug-linker conjugate for ADC and can be conjugated with the HER-2 monoclonalantibody Calotatug (XMT-1519) (HY-P990909) for the synthesis of ADC .
Daxdilimab is an anti-ILT7monoclonalantibody, ILT7 is a cell surface molecule specific to the pDC type of dendritic cells. Daxdilimab can be used in acute lung injury (ALI) in patients with COVID-19 infection research .
BI-1808 is a human IgG1 monoclonalantibody that targets TNFR2by blocking interaction of TNFR2 with ligand TNF-α, confers FcγR-dependent depletion of Treg and mediates expansion of intratumoral CD8 + T cells .
Abciximab (C7E3), a chimeric mouse/human monoclonalantibody fragment, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors .
hCBE-11 is a human monoclonalantibody (mAb) targeting TNFRSF3. hCBE-11 can be used in solid tumors research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Rapaprutug is a monoclonalantibody targeting human KARS1 (lysyl-tRNA synthetase 1). Rapaprutug blocks the relevant inflammatory signaling pathways in which KARS1 is involved, reducing the production and release of inflammatory factors. Rapaprutug is promising for research of inflammatory diseases .
LiLo is a new bifunctional chelator that has the activity of forming kinetically stable chelates with metal ions (such as indium). After using LiLo to bind indium-111 to monoclonalantibodies, the in vitro stability and in vivo biodistribution of the conjugates are superior to those using other chelators.
SAR442257 is a humanized IgG4-S228P, kappa monoclonalantibody targeting CD38 and CD28 on multiple myeloma cells and co-stimulates CD3 and CD28 on T cells .
Anti-SARS-CoV-2 Spike mAb (CR3022) is a a CHO cell derived human monoclonal IgG1 antibody. It binds to both S1 domain of SARS-CoV/SARS-CoV-2 Spike protein .
CNTO-860 is a humanized anti-tissue factormonoclonalantibody. CNTO-860 can improve tumor control when combined with Paclitaxel (HY-B0015) in colon cancer model and significantly increase tumor-free survival .
JAB-BX102 is a human monoclonalantibody (mAb) targeting NT5E/CD73. JAB-BX102 can be used in the study of cancers such as breast cancer, pancreatic cancer, and prostate cancer .
Anti-Mouse IL-2 Antibody (JES6-1A12) is an anti-mouse IL-2 IgG1 monoclonalantibody. Anti-Mouse IL-2 Antibody (JES6-1A12) can inhibit Treg amplification and enhance Th1 response. Anti-Mouse IL-2 Antibody (JES6-1A12) can form a complex with IL-2 for experimentation. Anti-Mouse IL-2 Antibody (JES6-1A12) can be used for research on infection conditions such as malaria .
Anti-Mouse Vβ8 TCR Antibody (F23.1) is an anti-mouse Vβ8 TCR IgG2a monoclonalantibody. Anti-Mouse Vβ8 TCR Antibody (F23.1) can clear Vβ8 + T cells to alleviate immune conditions. Anti-Mouse Vβ8 TCR Antibody (F23.1) can be used for research on autoimmune conditions. Anti-Mouse Vβ8 TCR Antibody (F23.1) is often used in flow cytometry .
Anti-Mouse L-Selectin/CD62L Antibody (Mel-14) is an anti-mouse L-Selectin/CD62L IgG2a monoclonalantibody. Anti-Mouse L-Selectin/CD62L Antibody (Mel-14) can significantly inhibit the migration of T cells and B cells. Anti-Mouse L-Selectin/CD62L Antibody (Mel-14) can block initial lymphocyte homing. Anti-Mouse L-Selectin/CD62L Antibody (Mel-14) can be used for researches on inflammation, metabolic and infection conditions such as diabetes and parasitic infections .
Anti-Mouse IL-1a Antibody (ALF-161) is an anti-mouse IL-1a IgG1 monoclonalantibody. Anti-Mouse IL-1a Antibody (ALF-161) can inhibit CD8 + T cell response by blocking IL-1a signaling. Anti-Mouse IL-1a Antibody (ALF-161) can reversibly transform myeloid cell expansion and improve T cell function. Anti-Mouse IL-1a Antibody (ALF-161) can be used for researches on immune response and cancer such as breast cancer .
Anti-Mouse IFN gamma Antibody (R4-6A2) is an anti-mouse IFN gamma IgG1 monoclonalantibody. Anti-Mouse IFN gamma Antibody (R4-6A2) can increase the total serum IgG level. Anti-Mouse IFN gamma Antibody (R4-6A2) can be used for researches on immunology and infection conditions such as nymphs infection. The recommend isotype control of Anti-Mouse IFN gamma Antibody (R4-6A2): Rat IgG1 kappa, Isotype Control (HY-P99979) .
Anti-Mouse DKK3 Antibody (DKK3-4.22) is an anti-mouse DKK3 IgG1 monoclonalantibody. Anti-Mouse DKK3 Antibody (DKK3-4.22) can improve kidney function and increases T cell infiltration. Anti-Mouse DKK3 Antibody (DKK3-4.22) can reduce skin inflammation by blocking the immunosuppressive function of DKK3. Anti-Mouse DKK3 Antibody (DKK3-4.22) can be used for researches on inflammation conditions such as unilateral ureteral obstruction (UUO) and experimental autoimmune encephalomyelitis (EAE) .
RTX-002 is a human monoclonalantibody (mAb) targeting PDCD1/PD-1/CD279. RTX-002 can be used to study autoimmune diseases such as systemic lupus erythematosus and multiple sclerosis .
BTH1704 is a human monoclonalantibody (mAb) targeting MUC1. BTH1704 enables PGG-primed leukocytes to kill iC3b-opsonized tumor cells. BTH1704 can be used in pancreatic and breast cancer research .
Olinvacimab (TTAC-0001) is a fully human anti-VEGFR2monoclonalantibody. Olinvacimab inhibits VEGF binds to KDR with a Kd value of 0.23 nM. Olinvacimab has antiangiogenic activity. Olinvacimab can be used for the research of recurrent glioblastoma and breast cancer .
VPI-2690B is a human monoclonalantibody (mAb) targeting Integrin aVb3. VPI-2690B inhibits TGF-β signaling. VPI-2690B can be used in Diabetic nephropathies research .
HuMax-IL15 is a human IgG1 monoclonalantibody against IL-15. HuMax-IL15 is applicable to the research of rheumatoid arthritis. The recommended isotype control is human IgG1 kappa (HY-P99001) .
Polyphemusin II-Derived Peptide (T140), a CXCR4 inhibitor, shows high inhibitory activity against HIV-1 entry and the inhibitory effect on the binding of an anti-CXCR4 monoclonalantibody (12G5) to CXCR4 .
Secukinumab (AIN457) is a high affinity, human monoclonalantibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis .
Trimethoprim fumaric acid (Compound CDI) is a universal hapten for ASGs (Antibacterial synergists) and can be used to design broadly specific monoclonalantibodies (mAbs) against ASGs. The mAb developed by Trimethoprim fumaric acid can be applied in ELISA to detect the residues of ASGs in foods of animal origin .
Bemarituzumab is a humanized IgG1 monoclonalantibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has antitumor activity against gastric and breast cancer .
Vilamakitug (XB-2001) is an anti-IL-1α human IgG4 κ monoclonalantibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
Litifilimab (BIIB059) is a humanized anti-BDCA2 IgG1 monoclonalantibody administered subcutaneously. Litifilimab can inhibit the production of type I interferons, cytokines and chemokines. Litifilimab can be used in the research of diseases such as systemic lupus erythematosus .
ASKG-712 (AM712) is a recombinant anti-VEGF humanized monoclonalantibody and Ang-2 antagonist peptide fusion protein. ASKG-712 can be used in Wet age-related macular degeneration and Diabetic macular oedema research .
APNmAb005 is a human monoclonalantibody (mAb) targeting MAPT/Tau/PHF-tau. APNmAb005 blocks tau seeding in vitro and rescues neuronal loss in rTG4510 mice. APNmAb005 can be used in Alzheimer’s disease (AD) research .
Tuvonralimab (PSB-205) is a humanized IgG1 monoclonalantibody against CTLA-4. Tuvonralimab can be used in the research of tumors. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Omodenbamab is an anti-SpA (Staphylococcal protein A) human monoclonalantibody with a KD value of 0.0467 nM. Omodenbamab circumvents a key S. aureus evasion mechanism by targeting the cell wall moiety Protein A (SpA). Omodenbamab can be used in research of S. aureus bloodstream infection .
Elranatamab (PF-06863135) is an anti-CD3E/TNFRSF17 human IgG2κ monoclonalantibody . Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002).
Potravitug is a humanized immunoglobulin G1-κ monoclonalantibody targeting the major capsid protein VP1 of BK polyomavirus (BKV). Potravitug is promising for research of BKV-infection-related diseases, such as BKV-induced nephropathy after organ transplantation .
Letolizumab (BMS-986004) is a monoclonalantibody targeting CD40L, which is produced to express mutant IgG1 lacking effector function, including Fc binding and complement fixation. Letolizumab reduces rejection, thromboembolism and prolongs the survival time .
Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonalantibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research .
Domvanalimab (AB154) is an anti-TIGIT humanized monoclonalantibody. Domvanalimab binds human TIGIT9 and blocks the TIGIT-CD155 interaction. Domvanalimab can be used for studies of non-small cell lung cancer and esophageal cancer .
AMG-529 is a humanized monoclonalantibody against ASGR1 that binds to ASGR1, blocks ligand binding, and causes a dose-dependent increase in ALP (a biomarker of ASGR1 inhibition). AMG-529 can be used for the research of cardiovascular diseases .
Ciduvectamig is an anti-CD3E/TMEFF2 human IgG4 κ monoclonalantibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
Fanolesomab is an anti-human CD15-targeting monoclonalantibody. Fanolesomab binds to the CD15 epitope on white blood cells to enable imaging of white blood cell distribution, migration, and infection sites. Fanolesomab can be used for the research of infection .
Concizumab is an anti-TFPI monoclonalantibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. Concizumab can be used in the study of haemophilia .
Lomtegovimab (BI 767551) is a human anti-SARS-COV-2 spike glycoprotein monoclonalantibody. Lomtegovimab binds and neutralizes SARS-CoV-2. Lomtegovimab shows antiviral efficacy. Lomtegovimab has the potential for the research of COVID-19 .
Bocunebart is a humanized monoclonalantibody targeting human adenylate cyclase-activating polypeptide (ADCYAP1). Bocunebart exerts anti-inflammatory activity by specifically binding to ADCYAP1 and inhibiting related inflammatory signaling pathways. Bocunebart is promising for research of inflammation-related diseases .
Anti-Mouse CD8α Antibody (YTS169.4) is an IgG2 monoclonalantibody targeting mouse CD8α. Anti-Mouse CD8α Antibody (YTS169.4) rapidly depletes or downregulates CD8 + T cells in the spleens of Biozzi AB/H mice. Anti-Mouse CD8α Antibody (YTS169.4) is applicable to research related to hepatitis B virus infection . Recommended isotype control: Rat IgG2b kappa, Isotype Control (HY-P990682).
Anti-Mouse 4-1BB/CD137 Antibody (3H3) is an anti-mouse 4-1BB/CD137 IgG2a monoclonalantibody. Anti-Mouse 4-1BB/CD137 Antibody (3H3) can effectively activate memory T cells and inhibit tumors by increasing Bcl-xL and granzyme B levels. Anti-Mouse 4-1BB/CD137 Antibody (3H3) can be used for research on cancer such as lymphoma and colon cancer .
Anti-Human/Monkey CD16a Antibody (3G8) is a monoclonalantibody targeting CD16a. Anti-Human/Monkey CD16a Antibody (3G8) blocks FcγRIII/CD16a, upregulates the metabolic activity of CD16+ cells, downregulates CD87, a poor prognostic marker, and inhibits the engraftment and growth of leukemia cells in acute myeloid leukemia, and rapidly increases platelet counts in immune thrombocytopenia. Anti-Human/Monkey CD16a Antibody (3G8) is applicable to research related to tumor immunology .
Anti-Mouse LAG-3 Antibody (C9B7W) is an anti-mouse LAG-3 IgG1 monoclonalantibody. Anti-Mouse LAG-3 Antibody (C9B7W) can enhance CD4 + T cell function and exert anti-tumor effects without blocking the interaction between LAG-3 and MHCII. Anti-Mouse LAG-3 Antibody (C9B7W) can be used for research on cancer such as head and neck squamous cell carcinoma (HNSCC) .
Anti-Mouse CD4 Antibody (GK1.5) is an anti-mouse CD4 IgG2b monoclonalantibody. Anti-Mouse CD4 Antibody (GK1.5) can significantly deplete CD4 + T cells. Anti-Mouse CD4 Antibody (GK1.5) can extend the survival rate of xenograft models. Anti-Mouse CD4 Antibody (GK1.5) can be used for research on immunology. The recommend isotype control of Anti-Mouse CD4 Antibody (GK1.5): Rat IgG2b kappa, Isotype Control (HY-P990682) .
Fmoc-Val-Lys-PAB-Exatecan is a derivative of Exatecan (DX-8951) (HY-13631). Fmoc-Val-Lys-PAB-Exatecan can be connected to monoclonalantibodies via linkers to form antibody-drug conjugate (ADC) molecules. Fmoc-Val-Lys-PAB-Exatecan is often combined with CD70 mAb to form ADC drugs for the study of tumors with high CD70 expression .
ADC Control Human IgG1-Deruxtecan (DAR 4) is a humanized monoclonalantibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
Dargistotug (M-6223) is a fully human IgG1 monoclonalantibody targeting TIGIT (T cell immune receptor with Ig domain and ITIM). TIGIT is an inhibitory immune checkpoint that promotes NK cell depletion and reduces the secretion of cytokines by binding to CD155 and other antibodies. It can also directly or indirectly inhibit effector T cells and upregulate Tregs cells, thereby exerting immunosuppression. Function .
VIS832 is an anti-CD138monoclonalantibody. VIS832 induces antibody-dependent cellular cytotoxicity. VIS832 inhibits the growth of disseminated multiple myeloma tumors in vivo. VIS832 exerts anti-tumor effects on multiple myeloma in combination with Lenalidomide (HY-A0003) or Bortezomib (HY-10227). VIS832 can be used in research related to multiple myeloma .
ADC Control Human IgG1-Deruxtecan (DAR 8) is a humanized monoclonalantibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
ADC Control Human IgG1-vcMMAF is a humanized monoclonalantibody that is an isotype control of ADC human IgG1-vcMMAF and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is MC-Val-Cit-PAB-MMAF (vcMMAF; HY-112786) .
Osemitamab is an IgG1 antibody targeting to human claudin-18.2. Osemitamab consists of human-Mus musculus monoclonal TST001 γ1-chain, disulfide with human-Mus musculus monoclonal TST001 κ-chain, dimer (ACI). Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study .
Anti-Mouse GITR Antibody (DTA-1) is a rat derived IgG2b monoclonal agonist antibody targeting mouse GITR. Anti-Mouse GITR Antibody (DTA-1) can activate T cells and B cells to enhance immune response. Anti-Mouse GITR Antibody (DTA-1) selectively enhances Th2 cell effector function through GITR signaling. Anti-Mouse GITR Antibody (DTA-1) may exacerbate allergic reactions. Anti-Mouse GITR Antibody (DTA-1) can be used for researches on cancer and allergic conditions such as colon cancer and allergic asthma. The recommed isotype control of Anti-Mouse GITR Antibody (DTA-1) is Rat IgG2b kappa, Isotype Control (HY-P990682) .
Firsekibart is an immunoglobulin G4-λ2 monoclonalantibody targeting human interleukin 1β (IL-1β). Firsekibart is promising for research of inflammation-related diseases, such as rheumatoid arthritis and inflammatory bowel disease .
Priliximab (CEN 000029) is an anti-CD4 humanized monoclonalantibody. Priliximab binds to CD4 on the surface of T cells, resulting in a significant and sustained reduction in circulating CD4 + T cells. Priliximab can be used in research of rheumatoid arthritis (RA) .
Utomilumab (PF 05082566) is a fully human IgG2 agonist monoclonalantibody that selectively binds to 4-1BB/CD137. Utomilumab can be used in the research of tumors such as follicular and other CD20 + non-Hodgkin lymphomas .
Dectrekumab (QAX576) is a human monoclonalantibody that targets IL-13. Dectrekumab significantly improves intraepithelial esophageal eosinophil counts and dysregulated esophageal disease-related transcripts with Eosinophilic esophagitis (EoE) in a sustained manner and can be used for inflammation and immunology related research .
Pexelizumab (h5G1. 1-SC) is a humanized scFv monoclonalantibody directed against the C5 complement component. Pexelizumab inhibits apoptosis and leukocyte infiltration. Pexelizumab can be used for the research of cerebral IR injury and myocardial infarction .
Valanafusp alfa (AGT-181) is a chimeric monoclonalantibody that fuses human α-L-iduronidase (IDUA) and targets the human insulin receptor (HIR). Valanafusp alfa has brain penetrating properties, making it useful for research on mucopolysaccharidosis type I (MPS I) .
Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) receptor β subunitmonoclonalantibody. Vixarelimab inhibits IL-31 and OSM signalling. Vixarelimab can be used in studies of inflammatory skin diseases such as atopic dermatitis and itchy nodular rash .
AGEN-1571 is a human IgG1 monoclonalantibody (mAb) targeting ILT2. AGEN-1571 promotes adaptive and innate immune responses. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001)
HBM1020 is a fully human monoclonalantibody targeting B7H7. HBM1020 binds to B7H7 and enhances the anti-tumor response of T cells. HBM1020 can be used in research related to advanced solid tumors .
MEDI-8490 is a fully human monoclonalantibody targeting APP/Aβ. MEDI-8490 can be used in research related to neurodegenerative diseases. Recommended isotype control: Human IgG1 lambda1, Isotype Control (HY-P99992).
NMC-001 is a human IgG1 monoclonalantibody (mAb) targeting MDM2. NMC-001 can be used in pancreatic cancer research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Brontictuzumab (OMP 52M51) is a monoclonalantibody (MAb) that inhibits Notch1 signal. Brontictuzumab selectively binds the negative regulatory region of the Notch1. Brontictuzumab inhibits tumor cell proliferation. Brontictuzumab can be used in the research of leukemia and lymphoma .
Trevogrumab (REGN-1033) is a monoclonalantibody targeting GDF8 (growth differentiation factor 8, also known as myostatin). Trevogrumab is used in research on muscle wasting conditions, including disuse atrophy, chronic diseases, and changes in food and nutrient intake .
ES004 is a human monoclonalantibody (mAb) targeting SIRPα/CD172a. ES004 enhances macrophage phagocytosis and induces potent T cell responses to promote tumor killing. ES004 can be used in Solid tumours research .
SHR-2010 is a fully humanized monoclonalantibody targeting MASP-2. SHR-2010 selectively inhibits lectin pathway activation without affecting classical or alternative complement pathways. SHR-2010 can be used for the research of IgA nephropathy .
Cobolimab (TSR-022) is an anti-TIM-3monoclonalantibody. Cobolimab mediates the internalization of TIM3 with an IC50 value of 0.4464 nM. Cobolimab has potential application in solid tumors and non-small cell lung cancer (NSCLC) .
Semorinemab (RG 6100) is an anti-Tau humanized IgG4 monoclonalantibody, targets the N-terminal portion of the Tau protein (amino acid residues 6-23). Semorinemab binds with human Tau with a Kd value of 3.8 nM. Semorinemab can be used for the research of Alzheimer's Disease .
Tesidolumab (LFG316) is a fully-human IgG1/λ anti-C5 monoclonalantibody of 143 kDa (without glycosylation). Tesidolumab (LFG316) blocks cleavage of C5 and prevents subsequent formation of the membrane attack complex .
CJM-112 is a humanized monoclonalantibody inhibitor targeting interleukin-17A (IL-17A). CJM-112 is promising for research of inflammatory diseases, such as hidradenitis suppurativa associated with abnormal IL-17A-related pathways .
Inlecitug is a chimeric monoclonalantibody targeting human KDR (kinase insert domain receptor). Inlecitug specifically binds to KDR, blocking the binding of vascular endothelial growth factor (VEGF) to KDR and inhibiting angiogenesis, thus exerting antitumor activity. Inlecitug is promising for research of cancers .
FZ-A038 is a delta-like ligand 3 (DLL3) targeted, humanized monoclonalantibody. FZ-A038 can be used for synthesis of DLL3 targeting ADC FZ-AD005 (HY-164729) .
Anti-Mouse NKG2A/C/E Antibody (20D5) is an anti-mouse NKG2A/C/E IgG2a monoclonalantibody. Anti-Mouse NKG2A/C/E Antibody (20D5) can activate natural killer (NK) and CD8 + T cells. Anti-Mouse NKG2A/C/E Antibody (20D5) can exacerbate liver pathological damage by enhancing the activation of iNKT cells. Anti-Mouse NKG2A/C/E Antibody (20D5) can be used for researches on cancer and immunology such as lymphoma .
Anti-Mouse IL-9 Antibody (9C1) is an anti-mouse IL-9 IgG2a monoclonalantibody. Anti-Mouse IL-9 Antibody (9C1) can reduce the activation of NF-κB signaling pathway and decrease the infiltration of inflammatory cells. Anti-Mouse IL-9 Antibody (9C1) effectively reduces Th9 cell-mediated allergic reactions and anti-tumor effects. Anti-Mouse IL-9 Antibody (9C1) can be used for researches on inflammation, infection conditions and cancer such as parasitic infections, allergic reactions, breast cancer and osteosarcoma .
Anti-Monkey/Human MDR-1/CD243 Antibody (UIC2) is an anti-monkey/human MDR-1/CD243 IgG2a monoclonalantibody. Anti-Monkey/Human MDR-1/CD243 Antibody (UIC2) can efficiently inhibit P-glycoprotein. Anti-Monkey/Human MDR-1/CD243 Antibody (UIC2) enhances the inhibitory effect on multidrug resistance (MDR) by suppressing drug efflux. Anti-Monkey/Human MDR-1/CD243 Antibody (UIC2) can be used for research on cancer .
Anti-Mouse RANKL/CD254 Antibody (IK22/5) is an anti-mouse RANKL/CD254 IgG2a monoclonalantibody. Anti-Mouse RANKL/CD254 Antibody (IK22/5) inhibits osteoclast formation and activity by specifically blocking the binding of RANKL and RANK. Anti-Mouse RANKL/CD254 Antibody (IK22/5) can inhibit the expression of MuRF1/Trogin-1 and activation of NF-κB. Anti-Mouse RANKL/CD254 Antibody (IK22/5) can be used for research on cancer such as melanoma or colon cancer and osteoporosis .
Anti-Mouse ICOSL/CD275 Antibody (HK5.3) is an anti-mouse ICOSL/CD275 IgG2a monoclonalantibody. Anti-Mouse ICOSL/CD275 Antibody (HK5.3) can inhibit the adhesion between T cells and endothelial cells. Anti-Mouse ICOSL/CD275 Antibody (HK5.3) can reduce the expansion of tissue resident (TR) Treg cells. Anti-Mouse ICOSL/CD275 Antibody (HK5.3) can be used for researches on inflammation and infection conditions such as influenza virus infection and arthritis .
Anti-Mouse/Rat/Bovine VLDL-R Antibody (IgG-6A6) is an anti-mouse/rat/bovine VLDL-R IgG1 monoclonalantibody. Anti-Mouse/Rat/Bovine VLDL-R Antibody (IgG-6A6) can specifically recognize VLDLR type-I and type-II expressed in CHO cells. Anti-Mouse/Rat/Bovine VLDL-R Antibody (IgG-6A6) can be used to detect the expression of VLDLR in different cells and tissues. Anti-Mouse/Rat/Bovine VLDL-R Antibody (IgG-6A6) often used in western blot experiments .
Iluzanebart is a human monoclonal IgG1 antibody and is the agonist antibody for human TREM2 (hTREM2). Iluzanebart improves the survival and function of microglia by activating the TREM2 signaling pathway to compensate for the loss of CSF1R function. Iluzanebart can be used for research of adult-onset leukoencephalopathy associated with CSF1R (colony stimulating factor 1 receptor) (CSF1R-ALSP) .
Dinutuximab (APN-311) is a chimeric human-mouse anti-GD2monoclonalantibody. Dinutuximab can bind to GD2 on the cell surface, triggering antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, and promoting tumor regression. Dinutuximab can inhibit the growth, invasion, and migration and induce apoptosis of tumor cells. Dinutuximab can be used in the research of tumors such as neuroblastoma and breast cancer .
Avelumab (anti-PD-L1) a fully human IgG1 anti-PD-L1monoclonalantibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab (anti-PD-L1) enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab (anti-PD-L1) can be used for the study of chordoma .
MSH-TP15e is a humanized monoclonalantibody inhibitor targeting intercellular adhesion molecule-1 (ICAM-1). MSH-TP15e recruits natural killer cells and significantly triggers antibody-dependent cell-mediated cytotoxicity (ADCC) to inhibit tumor cell growth. MSH-TP15e is promising for research of multiple myeloma (MM) .
MDX-1401 is a fully human IgG1 (κ isotype) monoclonalantibody against CD30, with a Kd value of 0.83 nmol/L. MDX-1401 induces antibody-dependent cellular cytotoxicity in CD30-expressing cells and inhibits tumor growth in CD30+ lymphoma xenograft models. MDX-1401 can be used in research related to malignant lymphoma and Hodgkin lymphoma .
Praluzatamab ravtansine (CX-2009) is an anti-CD166antibody drug conjugate (ADC) with an Kd value of 25.15 nM. Praluzatamab ravtansine contains an anti-CD166 monoclonalantibody Praluzatamab (HY-P99788) conjugated to the microtubule inhibitor DM4 (HY-12454). Praluzatamab ravtansine shows tumor targeting and can be used for the study of lung cancer and breast cancer .
Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonalantibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research .
Sigvotatug (Biotinylated) is a biotinylated derivative of Sigvotatug (HY-P990764). Sigvotatug (Biotinylated) is a humanized IgG1 κ monoclonalantibody inhibitor against ITGB6. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
TB-402, a human IgG4 anticoagulant monoclonalantibody, is a partial Factor VIII inhibitor. TB-402 has a prolonged antithrombotic effect. TB-402 can be used for the prevention of venous thromboembolism (VTE) after total knee replacement (TKR) .
Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38monoclonalantibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .
QX-004N (HS-20137) is a monoclonalantibody inhibitor targeting the p19 subunit of interleukin-23 (IL-23). QX-004N is promising for research of immune system diseases and diseases of digestive system .
QX006N is a humanized monoclonalantibody inhibitor targeting human interferon α/β receptor 1 (IFNAR1). QX006N is promising for research of systemic lupus erythematosus (SLE) and other IFNAR1-related autoimmune diseases .
Radanstobart (HFB-200603) is a humanized monoclonalantibody targeting CD272 with antitumor activity. Radanstobart is of the human IgG4κ isotype, and the recommended isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
Sym029 is a human IgG monoclonalantibody (mAb) targeting TNFRSF5/CD40. Sym029 can be used in cancer research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Andecaliximab is a recombinant chimeric IgG4 monoclonalantibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF) .
MORAb-066 is a human monoclonalantibody (mAb) targeting CD142/F3/TF. MORAb-066 can be used in Breast cancer, Colorectal cancer, Non-small cell lung cancer and Pancreatic cancer research .
Elegrobart is an immunoglobulin G1-κ monoclonalantibody targeting the human insulin-like growth factor 1 receptor (IGF1R). Elegrobart is promising for research of diseases associated with abnormal IGF1R signaling, especially thyroid eye disease .
Avdoralimab (IPH 5401) is a fully human IgGκ monoclonalantibody that targets the complement C5a receptor 1 (C5aR1) that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research .
Anti-Mouse/Rat/Monkey/Human ICOS/CD278 Antibody (C398.4A) is an anti-mouse/rat/monkey/human ICOS/CD278 IgG monoclonalantibody. Anti-Mouse/Rat/Monkey/Human ICOS/CD278 Antibody (C398.4A) has limited effectiveness in improving T cell function and immune activation. Anti-Mouse/Rat/Monkey/Human ICOS/CD278 Antibody (C398.4A) can be used for researches on cancer and infection conditions such as gliomas and hepatitis B virus infection .
Anti-Mouse Thy1/CD90 Antibody (M5/49.4.1) is an anti-mouse Thy1/CD90 IgG2a monoclonalantibody. Anti-Mouse Thy1/CD90 Antibody (M5/49.4.1) can clear T cells from the spleen and bone marrow. Anti-Mouse Thy1/CD90 Antibody (M5/49.4.1) can be used for researches on immunology and inflammation conditions such as colitis .
Anti-Mouse/Human CD44 Antibody (IM7) is an anti-huamn and mouse CD44 IgG2b monoclonalantibody that recognizes a conserved epitope outside the HA-binding domain of the CD44 molecule. Anti-Mouse/Human CD44 Antibody (IM7) exerts a potent anti-inflammatory effect by inducing the shedding of cell surface CD44, significantly improving symptoms in mice with rheumatoid arthritis without affecting relevant immune responses. Anti-Mouse/Human CD44 Antibody (IM7) can be used for researches on inflammation conditions and cancer such as arthritis and osteosarcoma .
Anti-Mouse DR5/CD262 Antibody (MD5-1) is an anti-mouse DR5/CD262 IgG monoclonalantibody. Anti-Mouse DR5/CD262 Antibody (MD5-1) can eliminate myeloid derived suppressor cells (MDSCs) and enhance T cell anti-tumor immunity. Anti-Mouse DR5/CD262 Antibody (MD5-1) can be used for research on cancer such as gastric and colon cancer .
Anti-Mouse CD40 Antibody (FGK4.5/FGK45) is an agonistic rat-derived IgG2a monoclonalantibody targeting mouse CD40. Anti-Mouse CD40 Antibody (FGK4.5/FGK45) enhances T cells responses, dendritic cells maturation and NK cells activation. Anti-Mouse CD40 Antibody (FGK4.5/FGK45) can be used for the researches of cancer, infection, inflammation and immunology, such as CT26 tumor, vesicular stomatitis virus (VSV) infection and transplantation .
Garivulimab (BGB-A333) is a humanized IgG1-variant monoclonalantibody that specifically targets and binds to PD-L1. Garivulimab selectively blocks the interaction of PD-L1 and PD-1. Garivulimab has antitumor activity .
Fmoc-1,6-diaminohexane hydrochloride is the hydrochloride form of Fmoc-1,6-diaminohexane (HY-103664). Fmoc-1,6-diaminohexane hydrochloride conjugates with monoclonalantibody, and exhibits anticancer activity against p21-deficient cancer .
Lacnotuzumab (MCS110) is a neutralizing humanized IgG1/κ monoclonalantibody targeting CSF-1 that prevents CSF-1 from activating the CSF-1R. Lacnotuzumab can be used for the research of pigmented villonodular synovitis .
MEDI-6469 is a human monoclonalantibody (mAb) targeting TNFRSF4/OX40/CD134. MEDI-6469 targets the OX40 receptor on activated T cells to enhance the immune response against cancer cells. .
ADI-65534 is a human IgG1 monoclonalantibody (mAb) targeting Envelopment polyprotein, M polyprotein. ADI-65534 can be used in Hantavirus infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Tulisokibart (PRA023) is a humanized IgG1-κ monoclonalantibody. Tulisokibart targets to TNFSF15/TL1A. Tulisokibart can be used to study a variety of inflammatory/fibrotic diseases, such as Crohn's Disease (CD) and ulcerative colitis .
ADI-15878 is a human IgG monoclonalantibody (mAb) targeting Envelope glycoprotein, GP2. ADI-15878 can be used in Ebola virus infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonalantibody, acts as an immunomodulator and binds to EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition .
ENx-108A is a human IgG4 monoclonalantibody (mAb) targeting IL-11. BI-765423 can be used in fibrotic diseases research. Recommended isotype control: Human IgG4 kappa, Isotype Control (HY-P99003) .
Burfiralimab (hzVSF-v13) is a monoclonal IgG4 antibody against vimentin expressed on the surface of virus-infected cells, with broad-spectrum antiviral activity and anti-inflammatory effects against virus-induced inflammation. Burfiralimab can be used in severe COVID-19 studies .
Tabalumab (LY2127399) is a human anti-BAFF (B-cell activating factor) monoclonalantibody (IgG4 type) with neutralising activity against membrane bound and soluble BAFF. Tabalumab can be used in studies of autoimmune diseases such as rheumatoid arthritis, renal failure and systemic lupus erythematosus .
Trastuzumab (anti-HER2) is a humanized IgG1 monoclonalantibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab (anti-HER2) has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.
Solanezumab (LY-2062430) is a humanized monoclonal IgG1 antibody directed against the mid-domain of the amyloid-β (Aβ) peptide. Solanezumab binds to the mid-domain of monomeric amyloid-beta to slow brain amyloid accumulation. Solanezumab can be used for the research of Alzheimer’s disease .
ADI-65533 is a human IgG1 monoclonalantibody (mAb) targeting Envelopment polyprotein, M polyprotein. ADI-65533 can be used in Hantavirus infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Imsidolimab (ANB 019) is a high-affinity, humanized monoclonalantibody of anti-IL-36R. Imsidolimab antagonizes IL-36 cytokine signal transduction. Imsidolimab has potential application in generalized pustular psoriasis (GPP) and other inflammatory skin diseases .
Obertamig is an engineered, humanized, anti-CD3E/HLA-G monoclonalantibody with humanized CH2-CH3 modifications and consists of half immunoglobulin IgG1 λ2 and a single-chain variable fragment (scFv) .
Tilrekimig (PF-07275315) is a monoclonalantibody targeting human interleukin-4 (IL-4), interleukin-13 (IL-13) and thymic stromal lymphopoietin (TSLP). Tilrekimig can be used in the research of allergic and inflammatory diseases, such as asthma and atopic dermatitis .
AB054 is a humanized monoclonalantibody targeting factor XII (FXII). AB054 inhibits FXII activation and FXIIa activity through specific binding to the catalytic domain of FXII, and exerts antithrombotic effects in a concentration-dependent manner. AB054 can be used in studies related to thrombosis .
Teneliximab (BMS-224819) is a chimeric monoclonalantibody, blocks the CD40-CD40L interaction. Teneliximab (BMS-224819) has partial agonist activity resulting in some signaling through CD40 and peripheral B cell depletion .
Crizanlizumab is an anti-P-selectinmonoclonalantibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs) and can be used for research of sickle cell disease .
KHK-2866 is a recombinant humanized monoclonalantibody targeting heparin-binding epidermal growth factor-like growth factor (HB-EGF). The predicted molecular weight (MW) of KHK-2866 is 147.68 kDa. KHK-2866 can be used for tumor research .
IDB-002 is a human monoclonalantibody (mAb) targeting F/Fusion glycoprotein F0. IDB-002 can be used in respiratory syncytial virus infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
REGN5093-M114 is a bispecific antibody-drug conjugate (ADC) that targets two epitopes of the MET receptor tyrosine kinase inhibits the proliferation of NSCLC cells, exhibits antitumor efficacy in mouse models. REGN5093-M114 is composed of the human monoclonalanti-MET antibody Davutamig (HY-P990073) and the tubulin-inhibiting linker-payload (HY-148528) .
REGN4659 is a fully human anti-CTLA-4monoclonalantibody and IgG1 antibody. REGN4659 binds to the extracellular domain of human and monkey CTLA-4 with high affinity and specificity. REGN4659 blocks CTLA-4 interaction with CD80 and CD86 ligands. REGN4659 significantly suppresses MC38.Ova tumor growth in CTLA-4 knock-in mice .
AZD0516 is a first-in-class antibody-drug conjugate (ADC) targeting six-transmembrane epithelial antigen of the prostate-2 (STEAP2). The anti-STEAP2 monoclonalantibody (mAb) is conjugated via interchain cysteines to a maleimide-reactive, β-glucuronidase-cleavable linker (HY-173635) bearing the topoisomerase 1 inhibitor, Exatecan (HY-13631). AZD0516 can be used for the study of prostate cancer .
huXBR1-402 (NBE-002 Antibody) is a high-affinity (Kd=5.8 nM) humanized chimeric rabbit/human monoclonalantibody that targets ROR1. huXBR1-402 specifically binds to the Ig/Fz domain epitope of human ROR1, directly inhibits the proliferation of ROR1-positive tumor cells and induces apoptosis of leukemia cells (apoptosis) .
Ladiratuzumab vedotin (SGN-LIV1A) is a LIV-1 targeting antibody drug conjugate (ADC) (IC50: 5.6 nM for LIV-1). Ladiratuzumab vedotin consists of humanized IgG1 monoclonalantibody, MMAE and a protease-cleavable linker. Ladiratuzumab vedotin can drive immunogenic cell death (ICD) to elicit an immune response. Ladiratuzumab vedotin can be used for research of breast cancer .
Anti-CD220/Insulin Receptor Antibody (IR 83-22) is an anti-human CD220/Insulin Receptor IgG1 monoclonalantibody. Anti-CD220/Insulin Receptor Antibody (IR 83-22) can block Akt overactivation caused by Trip13 deficiency. Anti-CD220/Insulin Receptor Antibody (IR 83-22) can be used for research on cancer such as hepatocellular carcinoma (HCC). Anti-CD220/Insulin Receptor Antibody (IR 83-22) often used in western blotting. The recommend isotype control of Anti-CD220/Insulin Receptor Antibody (IR 83-22): Mouse IgG1 kappa, Isotype Control (HY-P99977) .
Anti-CD8α Antibody (OKT-8) is an anti-human CD8α IgG2a monoclonalantibody. Anti-CD8α Antibody (OKT-8) can reduce the secretion of IFNγ. Anti-CD8α Antibody (OKT-8) can deplete CD8 + T cells. Anti-CD8α Antibody (OKT-8) can be used for researches on inflammation conditions and cancer such as B non-Hodgkin lymphomas (B-NHLs). The recommend isotype control of Anti-CD8α Antibody (OKT-8): Mouse IgG2a kappa, Isotype Control (HY-P99978) .
Anti-Nicastrin Antibody (A5226A) is a monoclonalantibody against Nicastrin and an inhibitor of γ-secretase. Anti-Nicastrin Antibody (A5226A) recognizes the fully glycosylated mature presenilin enhancer in the active γ-secretase complex and inhibits its activity via competition for substrate binding. Anti-Nicastrin Antibody (A5226A) abrogates the growth of cancer cells dependent on γ-secretase activity. Anti-Nicastrin Antibody (A5226A) serves as an imaging tool to visualize the endocytic trafficking of active γ-secretase, and also acts as a detection reagent to evaluate the endocytic efficiency of γ-secretase. Anti-Nicastrin Antibody (A5226A) can be used in studies related to non-small cell lung cancer, T-cell acute lymphoblastic leukemia and Alzheimer's disease .
Anti-Rat TCR alpha/beta Antibody (R73) is an anti-mouse TCR alpha/beta IgG1 monoclonalantibody. Anti-Rat TCR alpha/beta Antibody (R73) suppresses immune response by depleting α/β + T cells. Anti-Rat TCR alpha/beta Antibody (R73) can inhibit the expression of pro-inflammatory cytokines. Anti-Rat TCR alpha/beta Antibody (R73) can extend graft survival time by reducing infiltration of T cells and neutrophils. Anti-Rat TCR alpha/beta Antibody (R73) can be used for researches on inflammation, metabolic conditions and xenotransplantation such as arthritis, acute inflammatory peripheral neuropathy and diabetes .
Anti-Rat FcRn heavy chain heterodimers Antibody (1G3) is an anti-rat FcRn heavy chain heterodimers IgG1 monoclonalantibody. Anti-Rat FcRn heavy chain heterodimers Antibody (1G3) can effectively bind to FcRn and competitively inhibit the binding of IgG to FcRn. Anti-Rat FcRn heavy chain heterodimers Antibody (1G3) can reduce the total serum IgG level. Anti-Rat FcRn heavy chain heterodimers Antibody (1G3) can be used for researches on autoimmune conditions such as experimental autoimmune myasthenia gravis (EAMG). The recommend isotype control of Anti-Rat FcRn heavy chain heterodimers Antibody (1G3): Mouse IgG1 kappa, Isotype Control (HY-P99977) .
Anti-Mouse IL-6 Antibody (MP5-20F3) is an anti-mouse IL-6 IgG1 monoclonalantibody. Anti-Mouse IL-6 Antibody (MP5-20F3) reshapes the tumor microenvironment by blocking IL-6. Anti-Mouse IL-6 Antibody (MP5-20F3) can inhibit the STAT3 pathway and enhance T cell infiltration. Anti-Mouse IL-6 Antibody (MP5-20F3) can be used for researches on inflammation and infection conditions such as malignant pleural effusion (MPE) .
Anti-Mouse IL-4 Antibody (BVD6-24G2) is an anti-mouse IL-4 IgG1 monoclonalantibody. Anti-Mouse IL-4 Antibody (BVD6-24G2) can inhibit IL-4 signaling and promote Treg differentiation. Anti-Mouse IL-4 Antibody (BVD6-24G2) can be used for research on immunology. The recommend isotype control of Anti-Mouse IL-4 Antibody (BVD6-24G2): Rat IgG1 kappa, Isotype Control (HY-P99979) .
Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1) is an anti-mouse E-Cadherin/CD324 IgG1 monoclonalantibody. Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1) can downregulate the HER signaling axis and PI3K/Akt/mTOR signaling pathway. Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1) can inhibit the proliferation of tumor cells and induce their apoptosis. Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1) can be used for researches on cancer and inflammation conditions such as breast cancer, chronic compression injury (CCI) and asthma .
Anti-Mouse CD40L/CD154 Antibody (MR-1) is an anti-mouse CD40L/CD154 IgG monoclonalantibody. Anti-Mouse CD40L/CD154 Antibody (MR-1) reduces the expression of IFN signaling pathway and lowers the level of IFN-β. Anti-Mouse CD40L/CD154 Antibody (MR-1) can prolong the survival time of transplants. Anti-Mouse CD40L/CD154 Antibody (MR-1) can be used for researches on cancer, inflammation conditions and xenotransplantation such as pancreatic cancer and autoimmune cholangitis .
Anti-Mouse IL-3 Antibody (MP2-8F8) is an anti-mouse IL-3 IgG1 monoclonalantibody. Anti-Mouse IL-3 Antibody (MP2-8F8) relieves joint inflammation by reducing synovial leukocyte infiltration and cytokine levels. Anti-Mouse IL-3 Antibody (MP2-8F8) can reduce the accumulation of basophils. Anti-Mouse IL-3 Antibody (MP2-8F8) can be used for researches on inflammation or infection conditions such as arthritis and parasitic infections .
Anti-Mouse IL-10 Antibody (JES5-2A5) is an anti-mouse IL-10 IgG1 monoclonalantibody. Anti-Mouse IL-10 Antibody (JES5-2A5) restores the anti-tumor activity of IL-6 by blocking the IL-10/SOCS3 axis. Anti-Mouse IL-10 Antibody (JES5-2A5) can reverse microcirculation and cognitive deficits. Anti-Mouse IL-10 Antibody (JES5-2A5) can be used for researches on cancer and metabolic disease such as osteosarcoma and type 1 diabetes mellitus (T1DM) .
Anti-Mouse OX40/CD134 Antibody (OX-86) is an anti-mouse OX40/CD134 IgG1 monoclonalantibody. Anti-Mouse OX40/CD134 Antibody (OX-86) can enhance the anti-tumor function of CD8 + T cells. Anti-Mouse OX40/CD134 Antibody (OX-86) can reverse immune suppression, enhance antigen presentation and T cell activation. Anti-Mouse OX40/CD134 Antibody (OX-86) can be used for research on cancer such as papilloma and leukemia .
Lumretuzumab (Anti-Human ERBB3 Recombinant Antibody) is a humanized anti-HER3 (ERBB3) monoclonalantibody. Lumretuzumab effectively inhibits the activity of key oncogenic signaling pathways such as PI3K/AKT and MAPK. Lumretuzumab has been optimized through glycosyl engineering to enhance antibody-dependent cell-mediated cytotoxicity (ADCC). Lumretuzumab can be used to study HER3-positive, HER2-low-expressing solid tumors, especially breast cancer .
Anti-Mouse/Human Mac-2/Galectin-3 Antibody (TIB-166) is a rat-derived anti-mouse/human Mac-2/Galectin-3 IgG2a monoclonalantibody. Anti-Mouse/Human Mac-2/Galectin-3 Antibody (TIB-166) significantly inhibits IL-6 expression (inhibition rates 34.7% and 55.3%). Anti-Mouse/Human Mac-2/Galectin-3 Antibody (TIB-166) is often used for immunoprecipitation, western blot, immunofluorescence, and flow cytometry .
VRDN-002 is a human monoclonalantibody (mAb) targeting IGF1R/CD221. VRDN-002 reduces inflammation and proptosis in thyroid eye disease (TED). VPI-2690B can be used in Graves ophthalmopathy research .
NG004 is a fully human monoclonalantibody targeting Nogo-A. NG004 reduces retinal Nogo-A levels, blocks the binding of the Nogo-A-receptor complex, and neutralizes the Nogo-A protein. NG004 can be used in studies related to diabetic retinopathy, stroke and acute spinal cord injury .
GSK2831781 is a human IgG1 monoclonalantibody (mAb) targeting CD223/LAG3. GSK2831781 can be used in the study of ulcerative colitis Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
KHK2823 is a humanized monoclonalanti-human CD123/IL3RA antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001). KHK2823 can be used in research related to leukemia .
Iratumumab (MDX-060) a human anti-CD30 IgG1κ monoclonalantibody. Iratumumab inhibits the growth of CD30-expressing tumor cells. Iratumumab can be used for research of Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) .
ALLO-647 is a human monoclonalantibody targeting CD52. ALLO-647 transiently and selectively depletes host lymphocytes to promote the proliferation of allogeneic CAR T-cell following infusion. ALLO-647 can be used for the research of B-cell lymphoma and follicular lymphoma .
Gilvetmab is a potent caninized anti-PD-1monoclonalantibody. Gilvetmab blocks the interaction between PD-1 and its ligand PD-L1/L2. Gilvetmab can be used in malignant melanoma and mast cell tumor research .
AMB8LK is a human monoclonalantibody targeting H-ferritin, with specificity for tumor-associated heterologous ferritin. AMB8LK specifically recognizes and binds to H-ferritin overexpressed on the surface of tumor cells. AMB8LK can be used in research related to cancer and immune diseases .
Abazistobart is an immunostimulant and antineoplastic agent targeting the programmed cell death protein 1 (PDCD1). Abazistobart is a chimeric and humanized monoclonalantibody that specifically binds to PDCD1 to block the relevant signaling pathway, thereby activating the immune system and exerting antineoplastic activity. Abazistobart is promising for research of cancers .
2,5-Dioxopyrrolidin-1-yl acrylate (N-Succinimidyl acrylate) is a protein crosslinker. 2,5-Dioxopyrrolidin-1-yl acrylate can react with a monoclonalanti-horseradish peroxidase IgG antibody (anti-HRP) to modify lysine residues .
COM902 is a human IgG4 monoclonalantibody (mAb) targeting TIGIT. COM902 enhances anti-tumor immune responses. COM902 can be used in Multiple myeloma, Solid tumours and Colorectal cancer research. Recommended isotype control: IgG4-lambda .
Mazorelvimab (CTB012) is an anti-rabies humanized IgG1κ monoclonalantibody that binds to the non-overlapping epitopes on the rabies virus (RABV) glycoprotein. Mazorelvimab binds to highly discontinuous conserved residues that are not in or near antigenic site III. Mezagitamab has potential application in the prevention of rabies .
Cliramitug (NI-006; ALXN2220) is a monoclonalantibody that targets human transthyretin (TTR). Cliramitug binds to TTR and inhibits its amyloidogenic process, exerting amyloid formation-inhibiting activity. Cliramitug can be used in the research of transthyretin amyloidosis-related diseases, such as certain neurological and cardiovascular diseases .
Tuvirumab (OST 577; SDZ-OST 577) is a human IgG1 subclass monoclonalantibody directed against HBV surface antigen (HBsAg). Tuvirumab binds specifically and with high affinity (K=3.6 nM) to HBsAg. Tuvirumab has the potential for chronic hepatitis B research .
Istiratumab (M-6495) is bispecific monoclonalantibody targeting IGF-1R and ErbB3. Istiratumab induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway Istiratumab can be used for research of cancers .
PF-06293620 (RN909) is a monoclonalantibody antagonist of the glucagon receptor.PF-06293620 produces dose-dependent, durable lowering of fasting plasma glucose and reduces HbA1c levels. PF-06293620 can be used for the research of type 2 diabetes mellitus .
MEDI-0680 (AMP-514) is a human IgG4 monoclonalantibody (mAb) targeting PDCD1/PD-1/CD279. MEDI-0680 can be used in Diffuse Large B-Cell Lymphoma (DLBCL) research .
Prafnosbart (DS-6016A) is an IgG1-kappa, anti-ACVR1 (activin A receptor type 1, ACVRLK2, ALK2, ACVR1A, SKR1) humanized monoclonalantibody. Prafnosbart can be used for bone metabolism disorders research .
Alemtuzumab (Campath-IH) is a humanized monoclonalantibody against CD52. Alemtuzumab does not cross-react with murine CD52. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. Alemtuzumab is capable of complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC), as well as induction of apoptosis. Alemtuzumab has the potential for B-cell chronic lymphocytic leukaemia research .
OMTX005 (OMTX705 antibody) is a humanized anti-FAP IgG1 monoclonalantibody that specifically binds to human (EC50: 0.33 nM)/mouse (EC50: 0.14 nM) FAP proteins and FAP-positive cells. OMTX005 exhibits no cytotoxicity when used alone and fails to induce an increase in caspase 3/7 activity in relevant cells. OMTX005 can be used to synthesize the ADC molecule OMTX705 for tumor research .
Tisotumab vedotin is an antibody drug conjugate (ADC) targeting tissue factor (TF), formed by covalently linking a fully human monoclonalantibody (TF-011) against TF with the microtubule disruptor Monomethyll Auristatin E (MMAE) (HY-15162), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Tisotumab vedotin has immunomodulatory and anti-tumor activities, and can be used in the study of advanced or metastatic solid tumors such as cervical cancer .
Duligotuzumab (MEHD-7945A; RG 7597) is a humanized IgG-κ monoclonalantibody targeting EGFR. Duligotuzumab blocks the binding of ligands to these two receptors, inhibits downstream HER/ErbB, AKT and MAPK signaling pathways, induces antibody-dependent cellular cytotoxicity, reduces the proliferation and migration abilities of cancer cells, promotes apoptosis, exerts radiosensitizing effects, and reverses EGFR resistance in cancer cells. Duligotuzumab can be used in tumor-related research .
Vobramitamab duocarmazine (AEX4089DC1; MGC018), a humanized antibody-drug conjugate (ADC) targeted against B7-H3 (CD276). Vobramitamab duocarmazine is comprised of the cleavable linker-Duocarmycin payload, Vc-seco-DUBA (HY-128957), conjugated to an anti-B7-H3 humanized IgG1κ monoclonalantibody. Vobramitamab duocarmazine has antineoplastic activity .
Lintuzumab (HUM-195) is an anti-CD33 humanized monoclonalantibody. Lintuzumab reduces the production of TNFα-induced pro-inflammatory cytokines and chemokines by AML cells. Lintuzumab promotes tumor cell killing through antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) activities against MDR and MDR+ AML cell lines and primary AML patient samples. Lintuzumab enhances survival and reduces tumor burden in mice .
Lifastuzumab vedotin (RG-7599; DNIB0600A) is an antibody-drug conjugate (ADC) that comprises a humanized IgG1 anti-NaPi2b monoclonalantibody (MNIB2126A) and a potent antimitotic agent, monomethyl auristatin E (MMAE), which inhibits cell division by blocking the polymerization of tubulin. Lifastuzumab vedotin has the potential for non-small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (PROC) research .
Denikitug (GS-1811; JTX-1811) is a humanized monoclonalantibody against CCR8 receptor with a KD of 16.8 pM. Denikitug specifically binds to human CCR8, inhibits CCL1-induced downstreamCCR8signaling. Denikitug selectively depletes cells expressing CCR8 via antibody-dependent cellular cytotoxicity (ADCC). Denikitug promotes anti-tumor immunity and can be used for the research of cancer and immunology .
Lokivetmab (Anti-Canine IL31 Recombinant Antibody) is an anti-canine IL-31monoclonalantibody. Lokivetmab inhibits IL-31-mediated activation of pruritogenic signals in peripheral sensory neurons and reduces TH2-weighted inflammation. Lokivetmab demonstrates long-term efficacy in controlling pruritus and improving skin lesions in dogs with canine atopic dermatitis (CAD). Lokivetmab can be used for the research of atopic dermatitis (AD) in dogs .
Telisotuzumab vedotin (ABBV-399) (Teliso-V) is an anti-c-Metantibody-drug conjugate. Telisotuzumab vedotin consists of an anti-c-Met monoclonalantibody Telisotuzumab (ABT-700) (HY-P99391) and Monomethyl Auristatin E (HY-15162). Telisotuzumab vedotin exerts antitumor activity with acceptable toxicity in vivo. Telisotuzumab vedotin can be used for non-small cell lung cancer (NSCLC) research .
PNT001 is a human IgG1 monoclonalantibody (mAb) targeting cis-pT231 Tau. PNT001 can be used in Neurodegenerative disorders and Traumatic brain injuries research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Daratumumab (PBS) (Anti-Human CD38) is the first-in-class human-specific anti-CD38monoclonalantibody (IgG1). Daratumumab (PBS) has anti-multiple myeloma (MM) effect. Daratumumab (PBS) impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .
HFB-100204 is a human monoclonalantibody (mAb) targeting CXCR5. HFB-100204 reduces CXCR5+ immune cells, including B cells and Tfh cells, in the blood and spleen of hCXCR5 knockout mice. HFB-100204 can be used in autoimmune diseases research .
Nirsevimab (MEDI8897) is a recombinant monoclonalantibody against human respiratory syncytial virus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC50 values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections .
Nezutatug (HMBD-001) is a humanized IgG1 monoclonalantibody inhibitor targeting HER3. Nezutatug inhibits the dimerization of HER3 and inhibits the growth, proliferation and other activities of tumor cells. Nezutatug is promising for research of cancers, such as pancreatic cancer and non-small cell lung cancer .
Bedinvetmab (ZTS-00508841) is a canine monoclonalantibody (mAb) targeting nerve growth factor (NGF). Bedinvetmab inhibits NGF interaction with tropomyosin receptor kinase A (trkA) and p75 neurotrophin receptor (p75NTR) receptors. Bedinvetmab can be used for the research of osteoarthritis pain in dogs .
Adebrelimab (SHR-1316) is a humanized IgG4 monoclonalPD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC) .
DNL-919 (TAK-920) is a human IgG1 monoclonalantibody (mAb) targeting TREM-2. DNL-919 can be used in Alzheimer's disease research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
RFB4 is an anti-CD22monoclonalantibody. RFB4 can be fused with Pseudomonas aeruginosa exotoxin (PE38) via disulfide bonds to construct recombinant immunotoxins, such as RFB4 (dsFv)-PE38. RFB4 is applicable to the research of cancers including lymphoma .
Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5monoclonalantibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer .
LAE-102 is the selective anti-ActRIIA (activin receptor type IIA or ACVR2) monoclonalantibody. LAE-102 increases muscle mass and reduces fat mass. LAE102 can increase serum activin A levels in vivo. LAE-102 is promising for research of obesity .
Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonalantibody. Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research .
ASP-1948 is a human monoclonalantibody (mAb) targeting NRP1/VEGF165R/CD34. ASP-1948 reverses the suppressive effects of regulatory T cells. ASP-1948 can be used in solid tumors research .
Bleselumab (ASKP 1240) is a human anti-CD40monoclonalantibody (mAb). Bleselumab binds to human CD40 with high affinity (Kd: 0.24 nM). Bleselumab inhibits immune responses by blocking the interaction of CD40 with its ligand CD40L. Bleselumab prevents organ transplant rejection .
Briakinumab (ABT-874) is a fully human anti-IL-12/23p40monoclonalantibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis .
GSK2862277 is a human monoclonalantibody (mAb) targeting TNFRSF1A. GSK2862277 increases neutrophil extracellular trap formation and alveolar macrophage phagocytosis. GSK2862277 can be used in Acute lung injury and Acute Respiratory Distress Syndrome (ARDS) research. Recommended isotype control: VHH-hFc .
Glembatumumab vedotin (CDX-011) is an ADC comprising a fully human IgG2 monoclonalantibody (CR011) directed against glycoprotein NMB (GPNMB) and conjugated to the potent tubulinbinding cytotoxic agent MMAE via a protease-sensitive vc linker. Glembatumumab vedotin has potent anticancer effects .
Keliximab (SB-210396) is a chimeric human/macaque IgG1 anti-CD4monoclonalantibody with a Ki value of 1.0 nM for soluble CD4. Keliximab blocks T cell proliferation and inhibits IL-2 production. Keliximab can be used for cancer research .
BC011 is a human monoclonalantibody (mAb) targeting TNFRSF1B. BC011 promotes CD8+T cell proliferation and depletes Treg cells, thereby increasing the proportion of effector T cells in the tumor microenvironment. BC011 can be used in tumor Immunity research.
BMS-986179 is a human monoclonalantibody (mAb) targeting NT5E/CD73. BMS-986179 inhibits CD73 enzymatic activity in tumor vasculature and tumor cells. BMS-986179 can be used in advanced solid tumors research .
Ragifilimab (INCAGN-1876) is an agonist monoclonalantibody targeting the glucocorticoid-induced TNFR-related protein (GITR). Ragifilimab binds to and activates GITR on T cells, which stimulates the immune system to enhance its anti-tumor activity. Ragifilimab can be used for advanced or metastatic solid tumors research .
REGN9533 is a human-derived monoclonalantibody against FXII/FXIIa with high affinity for FXII, FXIIa and β-FXIIa. REGN9533 selectively inhibits the intrinsic coagulation pathway and FXIIa-driven plasma kallikrein activity. REGN9533 is applicable to FXIIa-related diseases such as thrombosis and hereditary angioedema .
PF-07868489 is a recombinant monoclonalantibody targeting GDF2/BMP-9. PF-07868489 can be used for the research of pulmonary arterial hypertension (PAH). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Ecleralimab (CSJ-117; NVP-CSJ117) is a Fab-IgG1-λ2 antibody targeting the thymic stromal lymphopoietin (TSLP). Ecleralimab significantly attenuates allergen-induced airway responses and inflammation. Ecleralimab can be used for the study of inhaled asthma .
GNE-987 GSH linker-1, a PROTAC-linker Conjugate for PAC, comprises the chimeric BET degrader GNE-987 (HY-129937A) and disulfide-containing linker. GNE-987 GSH linker-1 remains inactive as a degrader until intracellular release of GNE-987 via disulfide reduction and linker self-immolation. GNE-987 GSH linker-1 can be used for the research of acute myeloid leukemia .
Lixarkitug (AZD9829 antibody; INT-020) is a humanized IgG1κ antibody targeting IL-3Ra/CD123. Lixarkitug can be conjugated with Samrotecan to form the intact ADC molecule lixarkitug samrotecan (AZD9829), which is used in studies of acute myeloid leukemia (AML) . The isotype control corresponding to Lixarkitug is Human IgG1 kappa, Isotype Control (HY-P99001).
Isatuximab (anti-CD38) is a monoclonalantibody that targets the transmembrane receptor and extracellular enzyme CD38, a protein highly expressed in hematological malignancies, including multiple myeloma. Isatuximab (anti-CD38) exhibits anti-tumor activity through multiple biological mechanisms, including antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cell phagocytosis, and non-crosslinking direct induction of apoptosis. Isatuximab (anti-CD38) also directly inhibits the extracellular enzyme activity of CD38, which is related to many cellular functions .
REGN6569 is a fully human IgG1 monoclonalantibody targeting glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR) with high specificity for GITR. REGN6569 exerts stronger in vitro antibody-dependent cell-mediated cytotoxicity (ADCC) against regulatory T cells expressing GITR. REGN6569 selectively depletes regulatory T cells via antibody-dependent cell-mediated cytotoxicity and increases the proportion of proliferative natural killer (NK) cells in peripheral blood. REGN6569 is applicable for advanced solid malignancies. Isotype control: HY-P99001 .
IASO-782 (RD126) is a fully human monoclonalantibody targeting human CD19. The Fc segment of IASO-782 is mutated to enhance antibody-dependent cell-mediated cytotoxicity (ADCC) while maintaining the integrity of other Fc segment functions, such as ADCP. IASO-782 effectively eliminates CD19+ B cells, plasmablasts, and some plasma cells, thereby reducing or completely eliminating autoreactive antibodies produced by these cells. IASO-782 can be used for the study of immune thrombocytopenic purpura (ITP), warm autoimmune hemolytic anemia (wAIHA) and systemic lupus erythematosus (SLE).
ZV05 (ZV0501 Antibody) is an anti-5T4monoclonalantibody with an EC50 of 4.3 ng/mL against h5T4. ZV05 does not induce apoptosis or interfere with cell cycle progression. ZV05 accumulates specifically in 5T4-positive tumor xenografts. ZV05 can serve as the antibody component of antibody-active molecule conjugates (ADCs) to bind the 5T4 glycoprotein, thereby enabling targeted delivery of toxins. ZV05 is used in studies of 5T4-positive cancers, including triple-negative breast cancer .
Anti-Mouse TL1A/TNFSF15 Antibody (5G4.6) is an anti-mouse TL1A/TNFSF15 IgG monoclonalantibody. Anti-Mouse TL1A/TNFSF15 Antibody (5G4.6) can reduce TL1A levels and block TL1A-DR3 interactions. Anti-Mouse TL1A/TNFSF15 Antibody (5G4.6) can be used for research on inflammation conditions such as colitis and collagen-induced arthritis (CIA) .
Anti-CD24 Antibody (SWA11) is a human IgG1 monoclonalantibody targeting CD24, with high affinity and specificity for CD24-expressing tumor cells. Anti-CD24 Antibody (SWA11) triggers endocytosis, alters STAT3-dependent gene expression, regulates Src phosphorylation, and blocks CD24-mediated signaling pathways. Anti-CD24 Antibody (SWA11) is applicable to cancer-related research such as lung cancer and ovarian cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Lasrekibart is a humanized monoclonalantibody targeting human interleukin 5 (IL-5). Lasrekibart specifically binds to IL-5, blocking the interaction between IL-5 and its receptor, thus exerting immunosuppressive and anti-inflammatory activities. Lasrekibart is promising for research of allergic and inflammatory diseases, such as asthma .
DCBY02 is a monoclonalantibody targeting CD93 expressed in CHO cells. DCBY02 has a heavy chain of the mlgG type and a light chain of the mkappa type, with a predicted molecular weight (MW) of 150 kDa. The isotype control for DCBY02 can be referenced as Mouse IgG1 kappa, Isotype Control.
Velaprumig is a monoclonalantibody targeting human CD99, CCL25, and anti-human Aβ (Aβ-47F). Velaprumig regulates immune cell migration and reduces β-amyloid-related pathological processes, exerting immunomodulatory and potential anti - Alzheimer's disease activities .
Lusvertikimab (OSE-127) is a humanized IL7Rmonoclonalantibody. Lusvertikimab is not internalized by target cells and prevents IL7R heterodimerization and subsequent downstream signaling. Lusvertikimab has anti-leukemic efficacy and has the potential for B cell precursor acute lymphoblastic leukemia (BCP-ALL) research .
Crusekitug is a humanized monoclonalantibody targeting human interleukin 17A (IL-17A). Crusekitug specifically binds to IL-17A, blocking its signal transduction, thus exerting immunosuppressive and anti-inflammatory activities. Crusekitug is promising for research of autoimmune and inflammatory diseases, such as psoriasis and rheumatoid arthritis .
ST2485 is a monoclonalantitenascinantibody. ST2485 shows additivity in tenascin C binding in vitro as well as in a xenograft model. ST2485 binds human tenascin at an epitope partially shared with BC2. ST2485 cross-reacts with murine tenascin. ST2485 can be studied in antitumor research .
Sym023 is a human monoclonalantibody (mAb) targeting TIM-3/HAVCR2/CD366. Sym023 enhances immunostimulatory and anti-tumor activities. Sym023 can be used in Non-small cell lung cancer, Solid tumors and Lymphoma research .
Gosuranemab (BMS-986168; IPN007; BIIB092) is a humanised IgG4 anti-taumonoclonalantibody. Gosuranemab neutralizes the extracellular tau protein, inhibiting the spread and aggregation of pathological tau protein. Gosuranemab can be used for the research of progressive supranuclear palsy and early Alzheimer’s disease .
Crizanlizumab (anti-P-selectin) is an anti-P-selectin monoclonalantibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs) and can be used for research of sickle cell disease .
Itepekimab (REGN-3500) is an IgG4 monoclonalantibody against IL-33. Itepekimab reduced airway inflammation and related tissue damage in preliminary clinical studies. Itepekimab has potential effects in asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis (AD) .
Sutimlimab is a humanized monoclonal IgG4 antibody. Sutimlimab inhibits complement protein component 1, s subcomponent (C1s). Sutimlimab blocks C3 and C4 activation. Sutimlimab can be used for the research of cold agglutinin disease and complement-mediated hemolytic uremic syndrome .
Latozinemab (AL001) is a recombinant human anti-Sortilinmonoclonalantibody. Latozinemab effectively binds Sortilin with a high affinity and blocks the interaction between progranulin protein (PGRN) and Sortilin receptor. Latozinemab has the potential for progranulin gene (GRN) mutations causative of Frontotemporal dementia (FTD) (FTD-GRN) research .
Anti-Mouse CD47/IAP Antibody (MIAP301) is an anti-mouse CD47/IAP IgG2a monoclonalantibody. Anti-Mouse CD47/IAP Antibody (MIAP301) can effectively block CD47 signaling and enhance macrophage phagocytic function. Anti-Mouse CD47/IAP Antibody (MIAP301) can increase the infiltration of immune cells. Anti-Mouse CD47/IAP Antibody (MIAP301) restores the phagocytic function of myeloid cells and alleviate B cell inhibition. Anti-Mouse CD47/IAP Antibody (MIAP301) may interfere with wound healing. Anti-Mouse CD47/IAP Antibody (MIAP301) can be used for researches on cancer, inflammation and infection conditions such as melanoma, intestinal mucosal repair and sepsis .
Anti-Mouse osteopontin/SPP1 Antibody (100D3) is an anti-mouse osteopontin/SPP1 IgG2c monoclonalantibody. Anti-Mouse osteopontin/SPP1 Antibody (100D3) can reverse the inhibition of osteopontin (OPN) on T cells and enhance cytotoxic T lymphocyte (CTL) killing ability. Anti-Mouse osteopontin/SPP1 Antibody (100D3) can improve dentin density. Anti-Mouse osteopontin/SPP1 Antibody (100D3) can be used for researches on cancer and dental related conditions such as colon cancer. The recommend isotype control of Anti-Mouse osteopontin/SPP1 Antibody (100D3): Mouse IgG2c kappa, Isotype Control (HY-P99981) .
Anti-Mouse Galectin-9 Antibody (RG9-1) is an anti-mouse Galectin-9 IgG2b monoclonalantibody. Anti-Mouse Galectin-9 Antibody (RG9-1) promotes inflammatory response by enhancing the secretion of IFN-γ, TNF-α, and IL-6. Anti-Mouse Galectin-9 Antibody (RG9-1) can increase CD8 T cell and Treg frequency. Anti-Mouse Galectin-9 Antibody (RG9-1) reduces graft survival time by increasing CD4 + and CD8 + T cell infiltration. Anti-Mouse Galectin-9 Antibody (RG9-1) can be used for researches on inflammation conditions, cancer and xenotransplantation such as ischemia-reperfusion, colon cancer, breast cancer and leukemia .
Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) is an anti-mouse/rat/human CD47/IAP IgG1 monoclonalantibody. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can effectively block CD47 signaling and enhance macrophage phagocytic function. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can increase the infiltration of immune cells. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) may interfere with wound healing. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can be used for researches on cancer and inflammation conditions such as breast cancer and intestinal mucosal repair .
Anti-Mouse ICOS Antibody (7E.17G9) is a mouse ICOS agonist IgG2b monoclonalantibody. Anti-Mouse ICOS Antibody (7E.17G9) can upregulate ICOS expression and enhance T cell function. Anti-Mouse ICOS Antibody (7E.17G9) can significantly inhibit the immune regulatory function of dendritic cells (DCs). Anti-Mouse ICOS Antibody (7E.17G9) can eliminate transplant tolerance. Anti-Mouse ICOS Antibody (7E.17G9) can be used for researches on inflammation conditions, cancer and xenotransplantation such as nephritis and pancreatic cancer .
Anti-Mouse/Human CD11b Antibody (M1/70) is an anti-mouse CD11b IgG2b monoclonalantibody. Anti-Mouse/Human CD11b Antibody (M1/70) can significantly inhibit the adhesion between dendritic cells (DCs) and platelets. Anti-Mouse/Human CD11b Antibody (M1/70) can kill ovarian cancer cells and inhibit their migration. Anti-Mouse/Human CD11b Antibody (M1/70) can alleviate renal fibrosis and inflammation. Anti-Mouse/Human CD11b Antibody (M1/70) can be used for researches on inflammation conditions and cancer such as ischemia-reperfusion injury (IRI), thrombotic inflammatory conditions and ovarian cancer .
Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) is an anti-mouse CXCL9/MIG IgG monoclonalantibody. Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) can reduce tumor infiltration of CD8 + cytotoxic T cells (CTLs). Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) can prolong the survival of transplanted hearts. Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) can be used for researches on immunology and cancer such as prostate cancer .
Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) is an anti-mouse CXCR3/CD183 IgG monoclonalantibody. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) weakens the immune response by reducing the infiltration of CD4 + and CD8 + T cells. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) significantly prolongs the survival time of heart or islet transplants in mice. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) can be used for researches on immunology and cancer such as pancreatic cancer .
Anti-Mouse Thy1.1/CD90.1 Antibody (19E12) is an anti-mouse Thy1.1/CD90.1 IgG2a monoclonalantibody. Anti-Mouse Thy1.1/CD90.1 Antibody (19E12) can deplete CD90.1 + cells. Anti-Mouse Thy1.1/CD90.1 Antibody (19E12) can clear Tregs. Anti-Mouse Thy1.1/CD90.1 Antibody (19E12) can be used for researches on inflammation conditions and immune response such as airway inflammation and experimental autoimmune encephalomyelitis (EAE) .
Anti-Mouse CD80/B7-1 Antibody (RM80) is an anti-mouse CD80/B7-1 IgG2a monoclonalantibody. Anti-Mouse CD80/B7-1 Antibody (RM80) can inhibit the number of tissue-resident memory (TRM) cells. Anti-Mouse CD80/B7-1 Antibody (RM80) can prolong the survival time of transplants combined with CD86 mAb. Anti-Mouse CD80/B7-1 Antibody (RM80) can be used for researches on inflammation conditions and immunology such as viral myocarditis and corneal transplant .
Anti-Mouse IL-1b Antibody (B122) is an anti-mouse IL-1b IgG monoclonalantibody. Anti-Mouse IL-1b Antibody (B122) enhances ferroptosis and increases levels of reactive oxygen species (ROS) combined with Sulfasalazine (SAS) (HY-14655). Anti-Mouse IL-1b Antibody (B122) can reduce monocyte infiltration and alleviate T cell exhaustion by blocking IL-1β signaling. Anti-Mouse IL-1b Antibody (B122) can be used for researches on cancer and cardiovascular conditions such as oral squamous cell carcinoma (OSCC), glioblastoma (GBM) and heart failure .
Clesrovimab (MK1654) is a humanized IgG1 monoclonalantibody targeting the respiratory syncytial virus (RSV) protein F. Clesrovimab binds to pre-fusion and post-fusion forms of RSV-A fusion protein with high affinity, with corresponding KD values of 71 pM and 480 pM, respectively. Clesrovimab is applicable for the research of RSV infection .
MEDI7814 is a humanized monoclonalantibody inhibitor targeting C5a and C5adesArg. MEDI7814 binds to recombinant human C5a and serum purified human C5a with affinities of 14 pM and 8 pM, respectively. MEDI7814 is acute inflammatory diseases such as sepsis and renal ischemia-reperfusion injury .
PAS-003 is a humanized monoclonalantibody targerting α5β1 integrin. PAS-003 modulates immune cell migration, immune cell adhesion, improves behavior, and improves survival in ALS mouse models. PAS-003 can be used for the research of amyotrophic lateral sclerosis .
Vofatamab (B-701) is an anti-FGFR3monoclonalantibody (mAb). Vofatamab blocks activation of both the wildtype and genetically activated receptor. Vofatamab can be used in the research of metastatic urothelial carcinoma (mUC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Ranibizumab (RG-6321) (anti-VEGF) is a humanized anti-VEGF monoclonalantibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165) . Ranibizumab (anti-VEGF) slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research .
Anti-SARS-80R mAb (SARS-80R) is a human monoclonal IgG1 antibody produced in CHO cells. Anti-SARS-80R mAb can specifically bind to Spike (S1) protein to prevent SARS virus infection of susceptible cells .
TQB2618 is a human IgG4 monoclonalantibody (mAb) targeting TIM-3/HAVCR2/CD366. TQB2618 activates immune cell function and induces significant anti-tumor activity when used in combination with anti-PD-1 agents .
Gedivumab (MHAA4549A; RG7745) is a human monoclonalantibody that targets influenza A virus (IAV) with high specificity and binds to the highly conserved stem region of the IAV haemagglutinin protein, thereby preventing haemagglutinin maturation and blocking haemagglutinin-mediated membrane fusion in the intranucleosome. Gedivumab can be used in IAV infection disease studies .
HAIL-12 (16G2) is anan anti-human Interleukin-12 (IL-12p70)monoclonalantibody. HAIL-12 inhibits IL-12-mediated proliferation of T cells from human peripheral blood mononuclear cells .
VIR-8190 is a human IgG1 monoclonalantibody (mAb) targeting F, Fusion glycoprotein F0. VIR-8190 can be used in respiratory syncytial virus (RSV) and metapneumovirus infections research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-MERS-3A1 mAb (MERS-3A1) is a human monoclonal IgG1 antibody with the high binding affinity produced in CHO cells.
Anti-MERS-3A1 mAb bocks the binding of MERS-CoV spike protein to DPP4 receptor .
IMP-761 is a human IgG4 monoclonalantibody (mAb) targeting CD223/LAG3. IMP-761 binds to D1 of human LAG32. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
SAR-439459 is a human monoclonalantibody (mAb) targeting TGFB1/TGFβ-1. SAR-439459 blocks TGFβ-mediated pSMAD signaling, and suppression of T cells and NK cells. SAR-439459 has anti-tumor activity .
CC-90006 is a human monoclonalantibody (mAb) targeting PDCD1/PD-1/CD279. CC-90006 can be used in psoriasis research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Conatumumab (AMG 655) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) (Kd: 1 nM for the long form of DR5, 0.8 nM for the short form of DR5). Conatumumab induces apoptosis via caspase activation. Conatumumab can be used in the research of cancers.
.
BVX20 is a human monoclonalantibody that binds to CD20. BVX20 can kill B-cells through recruiting the immune system. BVX20 can be studied in research for relapsed or chemotherapy-resistant follicular B-cell NHL and CD20-positive diffuse large B-cell NHL .
VY7523 is a monoclonalantibody and a selective inhibitor of pathological Tau. VY7523 reduces the propagation of pathogenic Tau in transgenic mouse models. VY7523 can be used in the research of Alzheimer's disease. The isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
Livmoniplimab (ABBV-151) is a monoclonalantibody against GARP/TGF-β1 that can inhibit the release of active TGF-β1. Livmoniplimab has anti-tumor activity in colon cancer mice. Livmoniplimab can be used for the study of locally advanced or metastatic solid tumors .
CBT004 (KB312) is a human IgG1κ type monoclonalantibody against CD83. CD83 is a type I transmembrane glycoprotein and is a highly expressed marker on the surface of mature DCs. It can also be induced to be expressed on activated B cells, some activated T cells, and activated monocytes.
Sacituzumab is a humanized IgG1monoclonalantibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .
BAT1006 is a monoclonalantibody targeting HER2 extracellular domain II with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) for the study of HER2-positive locally advanced/metastatic solid tumors. BAT1006 has an approximately 5-fold enhanced ADCC effect compared to pertuzumab (HY-P9912) and exhibits potent anti-tumor activity in the HER2-positive Calu-3 xenograft mouse model .
DS-1103a is a humanized IgG4 monoclonalantibody targeting SIRPa/CD172a. DS-1103a inhibits the interaction between SIRPα and CD47. DS-1103a enhances antibody-dependent cellular phagocytosis of cancer cells. DS-1103a can be used for the research of solid tumors. The recommended isotype control is: Human IgG4 (S228P) kappa, (HY-P99003) .
ADU-1805 is a humanized monoclonal IgG2 antibody, a selective, pan-allelic anti-SIRPα antibody, with a Kd value of 11.0 × 10 -9 M for hSIRPαV1. ADU-1805 binds to all known hSIRPα alleles. ADU-1805 blocks the SIRPα-CD47 interaction, promotes phagocytosis of cells, and enhances trogocytosis of cells. ADU-1805 can be used in research related to Burkitt lymphoma .
hu3S193 is a human IgG monoclonalantibody (mAb) targeting Lewis Y. hu3S193 has excellent immune effector function (complement-dependent cytotoxicity) (IC50: 1.0 μg/ml) and antibody-dependent cellular cytotoxicity (IC50: 5.0 μg/ml). hu3S193 can be used in small cell lung cancer (SCLC) research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Delpacibart zotadirsen (Del-zota), an antibody oligonucleotide conjugate (AOC), consists of a monoclonalantibody (Delpacibart) (HY-P990051) that binds to the transferrin receptor 1 (TfR1) conjugated to a phosphorodiamidate morpholino conjugate (PMO), Delpacibart zotadirsen is designed to deliver phosphorodiamidate morpholino oligomers (PMOs) to skeletal muscle and heart tissue to specifically skip exon 44 of the dystrophin gene and enable production of near-full length dystrophin. Delpacibart zotadirsen is used for the study of myotonic dystrophy type 1 (DM1) .
BI-836858 is a fully human anti-CD33monoclonalantibody. BI-836858 reduces CD33+ cells via antibody-dependent cellular cytotoxicity (ADCC), blocks downstream signaling of S100A9/CD33, decreases the secretion of immunosuppressive cytokines and reactive oxygen species-induced genomic instability, and restores bone marrow hematopoietic function. BI-836858 is applicable to the research of myelodysplastic syndrome (MDS) and AML .
Mirvetuximab soravtansine (IMGN853) solution is an anti-folate receptor α (FRα) antibody drug-conjugate (ADC) consisting of the cytotoxic maytansinoid, DM4, covalently linked to the humanized monoclonalantibody M9346A, and the drug-linker conjugate for ADC is sulfo-SPDB-DM4 (HY-101141). Mirvetuximab soravtansine selectively binds to folate receptor 1 (FOLR1). Mirvetuximab soravtansine has an anti-proliferative effect via growth arrest and augmented DNA damage .
Anti-Mouse MHC Class I (H-2Kd, H-2Dd) Antibody (34-1-2S) is an anti-mouse MHC Class I (H-2Kd, H-2Dd) IgG2a monoclonalantibody. Anti-Mouse MHC Class I (H-2Kd, H-2Dd) Antibody (34-1-2S) can block the interaction between Ly49 and MHC-I. Anti-Mouse MHC Class I (H-2Kd, H-2Dd) Antibody (34-1-2S) can be used for the construction of acute lung injury models .
Anti-Mouse TCR Vγ1.1/Cr4 Antibody (2.11) is an anti-mouse TCR Vγ1.1/Cr4 IgG monoclonalantibody. Anti-Mouse TCR Vγ1.1/Cr4 Antibody (2.11) can deplete Vγ1 γδ T cells. Anti-Mouse TCR Vγ1.1/Cr4 Antibody (2.11) can be used for research on cancer and inflammation conditions such as mastitis and colon cancer .
HLX43 is an antibody-drug conjugate (ADC) targeting PD-L1. HLX43 consists of a human monoclonalantibodyanti-PD-L1 antibody Opucolimab (HY-P99785) with the drug-linker conjugate being DL-01 (HY-155870A). HLX43 exerts superior anticancer efficacy with safety profile in vivo. HLX43 can be used for non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), esophageal squamous cell carcinoma (ESCC), melanoma (MEL), ovarian cancer (Ovc) research .
Anti-CD200R1/OX2R Antibody (I-4P) is a human monoclonalantibody (mAb) targeting CD200R1/OX2R. Anti-CD200R1/OX2R Antibody (I-4P) can be used in solid tumors research. Recommended isotype control: Human IgG4 kappa, Isotype Control (HY-P99003) .
Anti-CD11a Antibody (MHM24) is a monoclonalantibody targeting murine CD11a. Anti-CD11a Antibody (MHM24) binds to high-affinity (open) and low-affinity (closed) conformations of the αL subunit of LFA-1, and functionally blocks LFA-1-mediated interactions. Anti-CD11a Antibody (MHM24) blocks ICAM-1 binding to LFA-1-expressing cells. Anti-CD11a Antibody (MHM24) inhibits adhesion of high-affinity LFA-1-expressing cells to keratinocytes. Anti-CD11a Antibody (MHM24) inhibits PHA-induced lymphocyte proliferation. Anti-CD11a Antibody (MHM24) can be used for the research of inflammatory and autoimmune diseases. Recommend Isotype Controls: mouse IgG1 kappa, Isotype Control (HY-P99977) .
BOT1711 is a human IgG1κ monoclonalantibody targeting PDGFRB/CD140b. PDGFRB/CD140b belongs to type I receptor tyrosine kinases (RTKs), and is mainly expressed in vascular smooth muscle cells, pericytes, fibroblasts, certain mesenchymal stem cells, and tumor stromal cells.
Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research . The component ratio of this product is Active ingredient : Excipients = 9 : 47.
Omalizumab is a recombinant, humanized, monoclonalantibody against human immunoglobulin E (IgE) with a KD of 0.393 nM. Omalizumab binds to the human FcγRIIb receptors with a KD of 6.37 uM. Omalizumab has the potential for persistent allergic asthma research . The component ratio of this product is Active ingredient : Excipients = 1:1.3-1:1.5.
Arevirumab (Arevirumab-3) is a pan-lineage neutralizing human monoclonalantibody cocktail (8.9F, 12.1F, 37.D). Arevirumab protects cynomolgus monkeys from severe Lassa fever caused by lineage II and III LASV isolates. Arevirumab is applicable to research related to Lassa fever .
GSK-3174998 is a humanized IgG1 OX40/TNFRSF4 agonistic monoclonalantibody. GSK-3174998 has the potential for the study of advanced solid tumors. The isotype control for GSK-3174998 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
Pacibekitug (PF-04236921; TOUR-006) is a fully humanized IgG2 monoclonalantibody targeting IL-6. Pacibekitug binds to and neutralizes IL-6 signaling, thereby inhibiting the pathophysiological role of this pro-inflammatory cytokine in autoimmune diseases (such as rheumatoid arthritis, Crohn's disease, and systemic lupus erythematosus) [1][2].
Nipocalimab (M281) is a fully humanized, recombinant, and non-glycosylated IgG1 monoclonalantibody. Nipocalimab can bind to the IgG-binding site of FcRn with high affinity and inhibit the transplacental transfer of IgG. Nipocalimab can be used in the research of fetal and neonatal hemolytic disease, myasthenia gravis, and various IgG-mediated autoimmune diseases .
Anti-MSLN/Mesothelin (h7D9.v3) is a human monoclonalantibody (mAb) targeting MSLN. Anti-MSLN/Mesothelin (h7D9.v3) can be used in ovarian cancer, mesothelioma, and pancreatic cancer research .
Remternetug (LY3372993) is a monoclonalantibody that targets pyroglutamylated amyloid β fibrils (N3pG-Aβ). Remternetug specifically binds to N3pG-Aβ, thereby clearing amyloid plaques in the brain and reducing amyloid burden. Remternetug can be used in research related to Alzheimer's disease .
ADI-42898 is a human IgG1 monoclonalantibody (mAb) targeting Envelopment polyprotein, M polyprotein. ADI-42898 binds to the Gn/Gc complex and blocks the cell entry of seven HCPS- and HFRS-associated hantaviruses. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
MK-1248 is a human IgG4 monoclonalantibody (mAb) targeting TNFSF18. MK-1248 enhances the proliferative response of tumor-infiltrating lymphocytes to anti-CD3 stimulation and promotes the production of anti-tumor-associated regulatory cytokines. MK-1248 can be used in solid tumors research .
Lu AF87908 is an IgG1 monoclonalantibody targeting the p-Ser396/404 epitope of tau protein, which mainly binds to the pSer396 region. Lu AF87908 can be used in the research of Alzheimer's disease. The recommended isotype control is human IgG1 kappa (HY-P99001) .
Rosnilimab (ANB030) is a PD-1 agonist IgG1 monoclonalantibody. Rosnilimab can inhibit T cell proliferation, the secretion of inflammatory cytokines, and reduce CD4 and CD8 T cells with high PD-1 expression. Rosnilimab can be used in the research of inflammatory diseases such as colitis and rheumatoid arthritis .
Bamlanivimab (Anti-Human SARS-CoV-2) is the first COVID-19 monoclonalantibody (mAb) to be granted Emergency Use Authorization (EUA) in November 2020 by the U.S. Food and agent Administration (FDA). However, Bamlanivimab is withdrawn in April 2021 following the rise of SARS-CoV-2 virus variants resistant to Bamlanivimab .
Seribantumab (MM 121) is a fully human IgG2 monoclonalantibody that targets HER3. Seribantumab blocks the activation of epidermal growth factor receptor (ErbB) family members and its downstream signal. Seribantumab inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models .
AMG 317 is a humanized monoclonalanti-CD124/IL4R/IL-4Rα antibody. Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002). AMG 317 can be used in research related to asthma .
FB-825 is a human monoclonalantibody (mAb) targeting IGHE. FB-825 targets the CεmX domain of membrane IgE (mIgE), resulting in the downregulation of mIgE-positive B cells and the production of IgE. FB-825 can be used in Allergic asthma, Atopic dermatitis, Job syndrome and Allergic rhinitis research .
Carlumab (CNTO 888) is a human anti-CCL2 (chemokine ligand 2) monoclonalantibody. Carlumab binds and neutralises profibrotic activities of human CCL2. Carlumab inhibits tumor growth by reducing macrophage infiltration and decreasing tumor microvascular density. Carlumab can be used for the research of cancer, suah as prostate cancer .
ARGX-119 is a first-in-class humanized agonist monoclonalantibody specific for muscle-specific kinase (MuSK). ARGX-119 can be used for the study of neuromuscular diseases. The isotype control for ARGX-119 can refer to Human IgG1 lambda1, Isotype Control (HY-P99992) .
MEN1112 (OBT357NF) is a selective humanized monoclonalantibody targeting the Bst1/CD157 antigen (EC50=1 nM). MEN1112 exerts potent antitumor activity against acute myeloid leukemia (AML) cells. MEN1112 is promising for research of hematological malignancies such as AML .
SPX-101 (SX001) is a humanized monoclonalantibody targeting CLDN18.2. CLDN18.2 is only transiently expressed in the differentiated epithelial cells of the gastric mucosa and is hardly found in healthy tissues, thus having an extremely wide therapeutic window. SPX-101 can be used for the study of solid tumors.
Tecnemab K1 is an anti-Melanomamonoclonalantibody. Tecnemab K1 accumulates in metastatic lesions of malignant melanoma and some benign lesions. When radiolabeled, Tecnemab K1 can serve as a radiotracer for malignant melanoma research. The isotype control is Mouse IgG1 kappa, Isotype Control (HY-P99977) .
Dostarlimab (TSR-042) is a humanized anti-PD-1monoclonalantibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC50s of 1.8 and 1.5 nM, respectively .
Socazolimab (ZKAB001) is an anti-PD-L1monoclonalantibody. Socazolimab has lasting safety and efficacy in the treatment of recurrent or metastatic cervical cancer. Socazolimab also has potential applications in small cell lung cancer, esophageal squamous cell carcinoma (ESCC), advanced urothelial carcinoma and osteosarcoma .
RG-7258 is a human monoclonalantibody (mAb) targeting CRLF2. RG-7258 blocks dendritic cell activation and mast cell cytokine release. RG-7258 reduces Th2 inflammation in a non-human primate model of allergic lung inflammation. RG-7258 can be used in asthma research .
FPA154 is a human monoclonalantibody against TNFRSF18/GITR/CD357. FPA154 activates NF-κB via the GITR pathway. FPA154 can be used in solid tumor research. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
CSL-360 is a chimeric unconjugated IgG1 monoclonalantibody targeting CD123. CSL-360 efficiently prevents the binding of IL-3 to CD123, abolishing IL-3 induced cell proliferation. CSL-360 can be used for acute myeloid leukemia (AML) research .
Gosuranemab (BMS-986168; IPN007; BIIB092) (powder) is a humanised IgG4 anti-taumonoclonalantibody. Gosuranemab (powder) neutralizes the extracellular tau protein, inhibiting the spread and aggregation of pathological tau protein. Gosuranemab (powder) can be used for the research of progressive supranuclear palsy and early Alzheimer’s disease .
HLX-22 is a humanized monoclonalantibody targeting HER2. HLX-22 induces apoptosis in HER2-overexpressing breast and gastric cancer cells combined with Trastuzumab (HY-P9907). HLX-22 has potent antitumor activity against advanced solid tumors .
Tifcemalimab (JS004; Icatolimab) is a humanized IgG4 monoclonalantibody against BTLA (B and T lymphocyte attenuator). By binding to BTLA, tifcemalimab blocks the interaction of HVEM-BTLA, thereby inhibiting the BTLA-mediated inhibitory signaling pathway. Tifcemalimab can be used in research related to squamous cell non-small cell lung cancer .
Cantuzumab ravtansine (IMGN242; huC242-DM4), an ADC, is a humanized monoclonalantibody, huC242, covalently linked via a disulfide bond to DM4 (HY-12454). Cantuzumab ravtansine has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts .
Dafsolimab (SPV-T3a) is a Mouse IgG2b monoclonalantibody(anti-CD3). Dafsolimab can induce cell death through modulation and activation of the CD3/T cell receptor complex. Dafsolimab can be used for the research of graft-versus-host disease (GVHD) .
Obiltoxaximab (ETI 204) is the second and potent anti-protective antigen (PA) monoclonalantibody with immunogenicity. Obiltoxaximab plays a central role in anthrax toxin assembly and target cell intoxication, promoting survival, and inhibiting bacterial spread to the periphery in animal models. Obiltoxaximab can be used in the research of inhalational anthrax, bacteremia and toxemia .
Anti-Mouse CD3ε Antibody (145-2C11) is an orally active anti-mouse CD3ε IgG1 monoclonalantibody. Anti-Mouse CD3ε Antibody (145-2C11) can inhibit the proliferation of effector T cells and improve the function of regulatory T cells (Tregs). Anti-Mouse CD3ε Antibody (145-2C11) relieves inflammatory response by inhibiting the production of pro-inflammatory cytokines and increasing the secretion of anti-inflammatory factors. Anti-Mouse CD3ε Antibody (145-2C11) can be used for researches on metabolic and immune system conditions such as diabetes and lupus. The recommend isotype control of Anti-Mouse CD3ε Antibody (145-2C11): Armenian hamster IgG, Isotype Control (HY-P990305) .
Anti-Mouse IL-2 Antibody (S4B6-1) is an anti-mouse IL-2 IgG2a monoclonalantibody. Anti-Mouse IL-2 Antibody (S4B6-1) can reduce CD4 + T cells and increase Tregs. Anti-Mouse IL-2 Antibody (S4B6-1) can induce Th17 cell differentiation. Anti-Mouse IL-2 Antibody (S4B6-1) can be used for research on cancer such as melanoma. The recommend isotype control of Anti-Mouse IL-2 Antibody (S4B6-1): Rat IgG2a kappa, Isotype Control (HY-P990679) .
Anti-Mouse TCR gamma/delta Antibody (UC7-13D5) is an anti-mouse TCR gamma/delta IgG monoclonalantibody. Anti-Mouse TCR gamma/delta Antibody (UC7-13D5) can enter the blood-brain barrier. Anti-Mouse TCR gamma/delta Antibody (UC7-13D5) effectively depletes γδ T cells and reduces macrophage and neutrophil infiltration. Anti-Mouse TCR gamma/delta Antibody (UC7-13D5) can reduce the immune response of transplants. Anti-Mouse TCR gamma/delta Antibody (UC7-13D5) can be used for researches on inflammation conditions, virus infection and cancer such as arthritis, JHM virus and breast cancer .
Anti-CD62L Antibody (DREG-200) is a human monoclonalantibody targeting CD62L/L-selectin. Anti-CD62L Antibody (DREG-200) binds to residues 45, 46 and 47 of L-selectin, and blocks L-selectin-mediated interactions, neutrophil rolling, adhesion, aggregation, secondary anchoring, as well as leukocyte rolling on ligands. Anti-CD62L Antibody (DREG-200) reduces myocardial necrosis, coronary endothelial dysfunction, and neutrophil migration driven by neutrophil microparticles. Anti-CD62L Antibody (DREG-200) exerts cardioprotective effects in feline models. Anti-CD62L Antibody (DREG-200) can be used in studies related to myocardial ischemia-reperfusion injury. The recommended isotype control is Mouse IgG1 kappa (HY-P99977) .
Anti-ZnT8 Antibody (mAb43) is a monoclonalantibody targeting the zinc transporter ZnT8, with islet-specific biodistribution characteristics. Anti-ZnT8 Antibody (mAb43) binds to extracellular ZnT8 on the surface of pancreatic β-cells and masks its insulin-co-localizing sites to block autoimmune recognition. Anti-ZnT8 Antibody (mAb43) also promotes an increase in the proportion of regulatory T cells and inhibits B cell antigen presentation, thereby effectively blocking the T cell-mediated cascade of β-cell destruction. Anti-ZnT8 Antibody (mAb43) eliminates insulitis, preserves β-cell mass and induces seroconversion of autoantibodies, without directly altering the insulin secretion function or content of β-cells. Anti-ZnT8 Antibody (mAb43) can be used for research related to type 1 diabetes .
Anti-Mouse TIM-3 Antibody (B8.2C12) is an anti-mouse TIM-3 IgG1 monoclonalantibody. Anti-Mouse TIM-3 Antibody (B8.2C12) can block the binding of Tim-3 with Phosphatidylserine (PtdSer) and CEACAM1 without interfering with the binding to Galectin-9. Anti-Mouse TIM-3 Antibody (B8.2C12) can inhibit tumor growth and activate tumor infiltrating CD8 + T cells. Anti-Mouse TIM-3 Antibody (B8.2C12) can be used for studying cancer such as breast cancer and colon cancer and constructing experimental autoimmune encephalomyelitis (EAE) models .
Anti-CD25/IL-2Rα Antibody (7G7B6) is an anti-human CD25/IL-2Rα IgG2a monoclonalantibody. Anti-CD25/IL-2Rα Antibody (7G7B6) can inhibit the growth of tumors. Anti-CD25/IL-2Rα Antibody (7G7B6) can be used for research on leukemia. The recommend isotype control of Anti-CD25/IL-2Rα Antibody (7G7B6): Mouse IgG2a kappa, Isotype Control (HY-P99978) .
Anti-Mouse CD16/CD32 Antibody (2.4G2) is an anti-mouse CD16/CD32 IgG2b monoclonalantibody. Anti-Mouse CD16/CD32 Antibody (2.4G2) can block Fcγ receptor-mediated immune responses. Anti-Mouse CD16/CD32 Antibody (2.4G2) can block the combination of CD16 and FcγRs to reduce the production of foam cells. Anti-Mouse CD16/CD32 Antibody (2.4G2) can be used for researches on atherosclerosis and autoimmune hematological disorders .
ADC-VI (Compound 6) is a conjugate of a toxic molecule and a linker, in which the cytotoxin carried by CPD6 is Deruxtecan (HY-13631E). Tricyclene is used to form an antibody-drug conjugate (ADC) by a chemical conjugation reaction through linking with an anti-FGFR2b antibody .
AT-1413 is a human monoclonalantibody (mAb) targeting CD43. AT-1413 induces antibody-dependent cell-mediated cytotoxicity (ADCC) in melanoma cell lines and acute myeloid leukemia (AML) cells. AT-1413 has antitumor activity in AML mouse models. AT-1413 can be used in Acute myeloid leukaemia, Breast cancer, Malignant melanoma and Myelodysplastic syndromes research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Sacituzumab (powder) is a humanized IgG1monoclonalantibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab (powder) demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab (powder) can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .
Benralizumab (anti-IL5RA ) (MEDI-563 (anti-IL5RA ); BIW-8405 (anti-IL5RA)) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonalantibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma study .
MEDI-3622 is a human monoclonalantibody against ADAM17. MEDI-3622 blocks the ADAM17-mediated shedding of CD16A and CD62L on NK cells, and binds with high specificity to a surface loop unique to the metalloprotease catalytic domain of ADAM17. MEDI-3622 enhances IFNγ production by NK cells when they bind to antibody-coated tumor cells. MEDI-3622 can be used in the research of ovarian cancer, Burkitt lymphoma, head and neck cancer, and colorectal cancer .
AGS-1C4D4 is a fully human IgG1κ monoclonalantibody targeting PSCA, with a Ka value of 0.2 nM. AGS-1C4D4 mediates antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against PSCA-expressing cells. AGS-1C4D4 can be used for the research of pancreatic cancer .
Lifastuzumab is a humanized anti-NaPi2b IgG1monoclonalantibody. Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) (HY-15162) through ADC Linker to form an antibody-drug conjugate (ADC) Lifastuzumab vedotin (HY-P99705) with anticancer activity. Lifastuzumab vedotin can be studied in research for non-small cell lung cancer and ovarian cancer. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001) .
IT1208 (FUT8-KO) is a humanized anti-CD4monoclonal IgG1 antibody that has knocked out the fucosyltransferase 8 gene (FUT8). It exhibits enhanced antibody-mediated cytotoxicity (ADCC) effect. IT1208 (FUT8-KO) can effectively eliminate CD4+ T cells in vivo and shows controllable safety. IT1208 (FUT8-KO) can be used in related research on colon cancer .
Aprutumab ixadotin (BAY 1187982) is the first antibody-drug conjugate (ADC) to target FGFR2 and the first to use Auristatin-based payload. Aprutumab ixadotin contains a fully human anti-FGFR2 monoclonalantibody (Aprutumab) (HY-P99007) conjugated by lysine side chains to a non-cleavable linker and via this an innovative Auristatin W derivative. Aprutumab ixadotin can be used for the study of advanced solid tumors, such as FGFR2-positive gastric cancer and triple-negative breast cancer .
ZL-1211 is an anti-CLDN18.2monoclonalantibody. ZL-1211 exhibits enhanced binding affinity to CD16A. ZL-1211 induces ADCC-mediated cell lysis and triggers the production of IFNγ, TNFα and IL6. ZL-1211 promotes antibody-dependent cellular cytotoxicity. ZL-1211 exerts anti-tumor activity in a mouse xenograft model of gastric cancer. ZL-1211 can be used for the research of gastric cancer .
IPH4301 is a monoclonalantibody targeting MICA/B, with dual activities of cytotoxicity and immunoregulation . IPH4301 blocks the interaction between MICA/B and NKG2D, inhibits their hydrolysis into soluble sMICA/B, and mediates antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis against tumor cells expressing MICA/MICB. IPH4301 restores the expression and function of NKG2D on primary NK cells and T cells, reverses the immunosuppression induced by M2 macrophages, and enhances NK cell-mediated tumor cell apoptosis. IPH4301 can be used in research related to cancer and triple-negative breast cancer .
Ladiratuzumab (hLIV22) is a humanized monoclonalantibody against zinc transporter LIV-1/ZIP6. Ladiratuzumab is conjugated to MMAE (HY-15162) via a cleavable dipeptide linker to synthesize an antibody-drug conjugate (ADC) Ladiratuzumab vedotin (HY-P99683). Ladiratuzumab vedotin selectively targets LIV-1 protein overexpressed on the surface of tumor cells, enters cells through antibody-mediated receptor endocytosis, releases MMAE to inhibit microtubule polymerization, and kills adjacent tumor cells with a bystander effect. Ladiratuzumab can be used in the study of solid tumors such as metastatic triple-negative breast cancer (mTNBC) .
AX-202 is a humanized IgG4 monoclonalantibody targeting S100A4. AX-202 neutralizes the activity of S100A4. AX-202 effectively reverses established fibrosis and reduces inflammation and fibrosis-related biomarkers in a mouse model of skin fibrosis. AX-202 is applicable for the research of fibrotic and inflammatory diseases .
AB-3A4 is a human IgG1 monoclonalantibody (mAb) targeting KAAG1. AB-3A4 can be used in the study of ovarian cancer, triple-negative breast cancer, and prostate cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Ziltivekimab (COR-001) is a fully human monoclonalantibody and also an IL-6 inhibitor. Ziltivekimab significantly reduces inflammatory biomarkers and Lipoprotein (a) in chronic kidney disease patients with systemic inflammation. Ziltivekimab does not increase pro-atherosclerotic lipid levels. Ziltivekimab is used in studies related to atherosclerotic thrombotic diseases and chronic kidney disease .
Tildrakizumab (SCH 900222) is a humanized anti-IL-23 (p19 subunit) monoclonalantibody. IL-23 is a critical cytokine to maintain the Th17 cell phenotype. Tildrakizumab has high-affinity for single-chain IL-23 (Kd: 136 pM). Tildrakizumab is effective against moderate to severe plaque psoriasis .
Opamtistomig is a humanized immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonalantibody targeting human programmed death ligand 1 (PD-L1), CD274 and tumor necrosis factor receptor superfamily member 9 (TNFRSF9). Opamtistomig is promising for research of various solid tumors and hematological malignancies .
VERT-002 is a MET degrader and monoclonalantibody. VERT-002 induces nearly complete and profound degradation of the MET protein by enhancing the intrinsic shedding of the MET extracellular domain (ECD). VERT-002 demonstrates significant anti-tumor activity. VERT-002 can be used in non-small cell lung cancer research. .
Losatuxizumab is an anti-EGFRmonoclonalantibody. Losatuxizumab binds to EGFR with EC50s of 0.96 nM for EGFR wild-type, 0.09 nM for EGFR C271A,C283A, 0.12 nM for EGFRvIII, 0.66 nM for EGFR1-501. Losatuxizumab can be used for research of EGFR-expressing cancers .
Rosopatamab (HuJ591) is a humanized antiPSMA IgG1 monoclonalantibody that can be used in cancer research, especially prostate cancer. Rosopatamab can be linked to the low-energy beta-emitting radioisotope lutetium-177 ( 177Lu) through the bifunctional chelator DOTA-NHS ester to obtain a radioimmunoconjugate that targets malignant prostate cells with high efficiency .
Fepixnebart (LY3016859) is a humanized monoclonal hIgG4 antibody, which binds and neutralizes only TGFα and epiregulin with high affinity. Fepixnebart can be used for the study of diabetic nephropathy and broad-spectrum chronic pain, including diabetic peripheral neuropathic pain (DPNP), signs and symptoms of osteoarthritis (OA), and chronic low back pain (CLBP) .
AMG-119 is a humanized IgG1 monoclonalantibody that targets delta-like ligand 3 (DLL3). AMG-119 can be used for the study of relapsed/refractory (R/R) small cell lung cancer (SCLC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Exbivirumab is a monoclonalantibody directed against highly conserved HBsAg epitopes. Exbivirumab enhances the antiviral activity of hepatitis B immunoglobulin (HBIG). Exbivirumab combined with Libivirumab (HY-P99703) decreases circulating HBsAg and hepatitis B virus (HBV) DNA levels in a chronically infected chimpanzee. Exbivirumab can be used for HBV re-infection in liver transplant .
TXB4 is a brain-permeable human monoclonalantibody (mAb) targeting CD71. TXB4 prevents 6-OHDA-induced death of TH-positive neurons in the SNc in a 6-OHDA mouse model of Parkinson's disease (PD). TXB4 can be used in neurodegenerative diseases, acute brain and spinal cord injury, and depression research .
MDX-1414 is a human IgG1 monoclonalantibody (mAb) targeting GPC3. MDX-1414 has antitumor activity in the HepG2 xenograft model. MDX-1414 can be used in liver cancer research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Tafolecimab (IBI-306) is a human lgG2 monoclonalantibody that specifically binds PCSK-9 and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in LDL-C levels. Tafolecimab may be used in studies of hypercholesterolaemia .
Anti-MERS-D12 mAb (MERS-D12; MERS Antibody-D12) is a human monoclonal IgG1. Anti-MERS-D12 mAb binds directly to the DPP4 interacting region of the MERS-CoV Spike receptor binding domain (RBD) and effect neutralization by directly blocking receptor binding .
Petosemtamab (MCLA 158) is an anti- EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonalantibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC) .
AT002 (CBAS-173, EJ212/007-Cl2-5) is a recombinant human IgG1 monoclonalantibody. AT002 targets the cell surface protein activated leukocyte adhesion molecule (ALCAM)/CD166. AT002 can be used in the research of cancer, autoimmune diseases and inflammatory diseases.
Loncastuximab (RB4v1.2) is an anti-CD19monoclonalantibody. Loncastuximab has antitumor activity and can be used in the research of Non-Hodgkin Lymphoma (NHL) and Diffuse Large B-cell Lymphoma (DLBCL). Loncastuximab is capable of synthesizing the ADC molecule Loncastuximab tesirine (HY-P99349) .
Ramucirumab (anti-VEGFR) is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab (anti-VEGFR) is a recombinant human immunoglobulin G1 monoclonalantibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab (anti-VEGFR) is also an angiogenesis inhibitor .
IBI37G5 is a human monoclonalantibody (mAb) targeting TNFRSF18/GITR/CD357. IBI37G5 has anti-tumor activity in MC38 and B16F10 mouse tumor models. IBI37G5 can be used in the study of cancer immunity .
Toripalimab is a selective, recombinant, humanized monoclonalantibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma .
ELB041 (AFS98) is a rat monoclonalanti-murine c-fmsantibody (IgG2a). AFS98 inhibits M-CSF–dependent colony formation and cell growth by blocking the binding of M-CSF to its receptor. AFS98 prevents development of fatty streaks in ApoE-deficient mice. ELB041 can be used for the research of atherosclerosis .
Tilavonemab (ABBV-8E12) is a humanized anti-taumonoclonalantibody that binds to amino acids 25-30 near the N-terminus of the tau protein. Tilavonemab can block the ability of human and mouse neurons to uptake tau aggregates. Tilavonemab can be used for research on Alzheimer’s disease and other tauopathies .
Anti-Mouse OX40L/CD134L Antibody (RM134L) is an anti-mouse OX40L/CD134L IgG2b monoclonalantibody. Anti-Mouse OX40L/CD134L Antibody (RM134L) reduces immune response by inhibiting the OX40/OX40L signaling pathway. Anti-Mouse OX40L/CD134L Antibody (RM134L) can inhibit plasma cell differentiation and antibody secretion. Anti-Mouse OX40L/CD134L Antibody (RM134L) can prolong the survival time of cell transplantation by inhibiting CD4 + T cells. Anti-Mouse OX40L/CD134L Antibody (RM134L) can be used for researches on inflammation and cancer such as graft versus host disease (GVHD), allergic reaction, lupus nephritis and hepatocellular carcinoma (HCC) .
Anti-Mouse Delta-like protein 1/DLL1 Antibody (HMD1-5) is an anti-mouse Delta-like protein 1/DLL1 IgG monoclonalantibody. Anti-Mouse Delta-like protein 1/DLL1 Antibody (HMD1-5) can reverse the inhibition of Treg cells. Anti-Mouse Delta-like protein 1/DLL1 Antibody (HMD1-5) can inhibit the upregulation of GLT-1 expression induced by endothelial cells. Anti-Mouse Delta-like protein 1/DLL1 Antibody (HMD1-5) reduces autoimmune response by reducing B cell activation. Anti-Mouse Delta-like protein 1/DLL1 Antibody (HMD1-5) can be used for research on inflammation conditions such as lupus nephritis .
DS-5573a is a human monoclonalantibody targeting B7-H3, with a Kd of 1.8 nM for the 4Ig isoform and 11 nM for the 2Ig isoform. DS-5573a induces antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis against B7-H3-expressing cancer cells. DS-5573a exerts dose-dependent anti-tumor activity via effector cells. DS-5573a can be used in the research of cancers including breast adenocarcinoma, non-small cell lung cancer, renal cell adenocarcinoma, gastric cancer and prostate cancer .
Ginisortamab (UCB6114) is a fully human IgG4P antiGremlin-1monoclonalantibody, with mean IC50 values of 8.2 nM and 9 nM against human and mouse gremlin-1, respectivly. Ginisortamab inhibits gremlin-1 antagonism of BMP signaling pathways. Ginisortamab has the potential for the research of gastrointestinal (GI) tumors .
Duvakitug (TEV-48574) is a humanized IgG1-λ2 monoclonalantibody targeting to TNFSF15/TL1A. Duvakitug' main expression system is CHOK1SV cells endogenously expressing glutamine synthetase (GS). Duvakitug can be used in the study of Crohn's Disease (CD) .
RO-5429083 (RG-7356) is a humanized monoclonalantibody targeting CD44. RO-5429083 binds to the extracellular domain of CD44 and inhibits constitutive EGFR phosphorylation. RO-5429083 suppresses tumor growth in xenograft models and can be used in research related to head and neck squamous cell carcinoma and acute myeloid leukemia .
Lixudebart (ALE.F02) is a humanized immunoglobulin G1-kappa, anti-CLDN1monoclonalantibody. Lixudebart disrupts CLDN1 interactions with CD44 and MMP14, reduces renal macrophage infiltration, epithelial activation, and urinary albumin-to-creatinine ratio, and attenuates glomerulosclerosis. Lixudebart can be used for the research of focal segmental glomerulosclerosis .
JNJ-55920839 (CNTO-6358) is a fully human immunoglobulin G1κ monoclonalantibody and a selective Interferonα/ω neutralizer, with a Kd value of 0.9-10.7 pM against hIFNα and a Kd of 1.44 pM against IFNω. JNJ-55920839 can be used in research related to systemic lupus erythematosus .
GSK3178022 is a human IgG1 monoclonalantibody (mAb) targeting LRP6. GSK3178022 inhibits the expression of WNT target genes SP5 and AXIN2. GSK3178022 has antitumor activity in the RSPO fusion model of colorectal cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
ZEB85 is a human monoclonalantibody (mAb) targeting TrkB. ZEB85 activates TrkB and its downstream cascades, including the ERK, PLCγ, AKT, MAPK signaling pathways and cFOS expression, and enhances neuronal activity. ZEB85 prevents β-amyloid toxicity in cultured hippocampal neurons. ZEB85 is applicable to the research of Alzheimer's disease (AD) .
Tesnatilimab (JNJ-64304500) is a human IgG4 monoclonalantibody targeting NKG2D, with a KD value of 9.2 pM . Tesnatilimab blocks the binding of ligands to the NKG2D receptor, thereby inhibiting downstream proinflammatory cytokine, cytotoxic mediator signaling pathways and proinflammatory immune responses. Tesnatilimab is applicable to research related to Crohn's disease .
PRN100 is a fully humanized monoclonalantibody against cellular prion protein (PrPᶜ), belonging to the IgG4κ isotype. By binding to and stabilizing cellular prion protein, PRN100 is designed to prevent cellular prion protein from being recruited and converted into pathogenic, self-propagating prion (PrPˢᶜ) aggregates. PRN100 can be used for the study of Creutzfeldt-Jakob disease.
Infliximab (Anti-TNF-α) (Avakine (Anti-TNF-α)) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab (Anti-TNF-α) prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab (Anti-TNF-α) has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research .
Anti-HLA-A2 (Hu8F4) is a human monoclonalantibody (mAb) targeting HLA-A2. Anti-HLA-A2 (Hu8F4) can be used in Acute myeloid leukaemia research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Vonlerolizumab (Pogalizumab; MOXR 0916) is a humanized IgG1 monoclonalantibody targeting OX40 (CD134). Pogalizumab partially blocks the interaction between OX40 and its natural ligand OX40L upon binding, thereby activating the NF-κB signaling pathway. Pogalizumab enhances T cell activation and proliferation and has shown antitumor activity in mouse models .
Varisacumab (R 84; GNR-011) is a fully humanized IgG1 monoclonalantibody targeting VEGF. Varisacumab specifically blocks the interaction between VEGF and VEGFR2, but does not interfere with the interaction between VEGF and VEGFR1. Varisacumab achieves effective anti-tumor and anti-angiogenic effects and can be used in the research of non-small cell lung cancer and pancreatic cancer.
ABI793 is a human IgG1 anti-human CD154 (CD40 ligand) monoclonalantibody. ABI793 inhibits immune response by blocking the CD154-CD40 (IC50 = 75 nM) signaling pathway. ABI793 effectively prevents kidney transplant rejection. ABI793 can be used for research on immunological rejection .
Grisnilimab (WT1) is an IgG2a monoclonalantibody targeting CD7. Grisnilimab only binds to lymphoid tissues and T lymphocytes, with no off-target binding to normal tissues. Grisnilimab can be used to synthesize the immunotoxin WT1-SMPT-dgRTA, which exerts cytotoxic effects on T-lymphoblastic leukemia cells. Grisnilimab is applicable to relevant research on leukemia .
Pertuzumab-LD3 is a humanized antibody-drug conjugate (ADC) targeting HER2. Pertuzumab-LD3 consists of the anti-HER2 humanized IgG1 monoclonalantibody Pertuzumab (HY-P9912), the cleavable linker Gly-Gly-Phe-Gly (HY-P3669), and the PI3K/mTOR-IN-21 (HY-185456) payload. Pertuzumab-LD3 can be used in research on metastatic HER2-positive breast cancer.
QX008N is a humanized IgG1 monoclonalantibody and also a TSLP inhibitor with a KD value of 0.0175 nM. QX008N blocks TSLP-induced signaling pathways by inhibiting the interaction of TSLP-TSLPR-IL-7Rα. QX008N reduces eosinophil and IgE levels, improves pulmonary function, blocks TSLP-induced inflammation, and enhances the inhibitory effect on inflammatory mediators when administered in combination with anti-IL-4R antibodies. QX008N is applicable to relevant research on asthma .
SAR442085 is an Fc-engineered anti-CD38monoclonalantibody with a Kd of 0.2 nM for human CD38. SAR442085 inhibits CD38, induces apoptosis, and triggers antibody-dependent cellular cytotoxicity and phagocytosis in CD38-expressing tumor cells. SAR442085 binds allelic variants of FcγRIIa and FcγRIIIa, enhances NK cell activation, degranulation and cytokine secretion, and exerts anti-tumor activity in human Fc receptor transgenic mice. SAR442085 can be used in the research of multiple myeloma .
MGTA-117 is a humanized monoclonalantibody targeting CD117. MGTA-117 can be used for synthesis of antibody-drug conjugate (ADC), utilizing an amanitin payload. MGTA-117 has potent anti-tumor activity and increases survival in three acute myeloid leukemia (AML) xenograft hNSG mice models (Kasumi-1, AML PDX 1 and AML PDX 2). MGTA-117 enables hematopoietic stem cell transplantation (HSCT) preprocessing in AML, myelodysplasia with excess blasts (MDS-EB) and gene therapy .
Petosemtamab (FUT8-KO) is an anti-EGFR and anti-LGR5monoclonalantibody expressed in CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucosyl loss enhances the ADCC effect of the antibody. Petosemtamab (FUT8-KO) leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab (FUT8-KO) can be used for research on solid tumors such as head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (CRC) .
AO-176 is a humanized anti-CD47 IgG2 monoclonalantibody. AO-176 induces tumor phagocytosis through blocking the CD47-SIRPα interaction. AO-176 preferentially binds to tumor versus normal cells and directly kills tumor by a cell autonomous mechanism not ADCC (antibody-dependent cell-mediated cytotoxicity). AO-176 demonstrates dose-dependent antitumor activity in tumor xenograft models. AO-176 can be used for the researches of cancer, such as lymphoma .
Anti-Canine PD-L1/B7-H1 Antibody (JC071) is an anti-canine PD-L1/B7-H1 IgG1 monoclonalantibody. Anti-Canine PD-L1/B7-H1 Antibody (JC071) can specifically bind to CHO-PDL1 cells and K562-cCD20-cPD-L1 cells. Anti-Canine PD-L1/B7-H1 Antibody (JC071) can enhance the level of IFN-γ. Anti-Canine PD-L1/B7-H1 Antibody (JC071) is often used in western blot experiments .
Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) is an anti-mouse CD106/VCAM-1 IgG1 monoclonalantibody. Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) reduces inflammatory response and oxidative stress by lowering p-STAT3 and reactive oxygen species (ROS) levels. Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) can alleviate cardiac inflammation and fibrosis by reducing the expression of collagen I and collagen III. Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) can be used for research on cardiovascular conditions such as hypertensive heart condition and subretinal fibrosis .
Anti-CD160 Antibody (MAT 302) (CL1-R2) is a human monoclonalantibody targeting CD160. Anti-CD160 Antibody (MAT 302) blocks the CD160-HVEM protein interaction, inhibits FGF2-mediated renal tubular vascular growth, and induces endothelial cell apoptosis. Anti-CD160 Antibody (MAT 302) targets CD160 on neovascularization to exert anti-angiogenic and vascular normalization effects, trigger the production of IFN-γ, TNF and IL-6 by NK cells, and enhance glucose metabolism of NK cells through the AKT/mTOR/s6k signaling pathway. Anti-CD160 Antibody (MAT 302) reduces vascular density, normalizes remaining tumor blood vessels, and inhibits tumor growth in melanoma-bearing mice. Anti-CD160 Antibody (MAT 302) can be used in research related to neovascularization, proliferative diabetic retinopathy, and melanoma .
Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) is an anti-mouse/rat/human CCL2/MCP-1 IgG monoclonalantibody. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can reverse the immunosuppressive microenvironment by blocking the CCL2 signaling pathway. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can reduce the secretion of IFN-γ and the infiltration of macrophages. CCL2/MCP-1 Antibody (2H5) can reduce the amount of HIV virus by increasing the proportion of T cells. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can be used for researches on inflammation conditions, virus infection and cancer such as inflammatory bowel disease (IBD), hepatocellular carcinoma (HCC) and HIV .
Cabotamig is a humanized bispecific T-cell engager antibody targeting CDH17/CD3. Cabotamig is generated from anti-CDH17 monoclonal ARB102 by linking a CD3-binding scFv in the format of IgG4-scFv. Cabotamig can be used for the research of cancer, such as gastric cancer and colon cancers .
Upifitamab is a humanized monoclonalantibody targeting NaPi2b. Upifitamab can be used to synthesize ADC such as Upfitamab rilsodotin. Upfitamab rilsodotin can be used in research for solid tumors including high-grade serious epithelial ovarian, fallopian tube and primary peritoneal cancer (OC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
BI-1910 is a human monoclonalantibody (mAb) targeting TNFRSF1B. BI-1910 enhances T cell activation and induces CD8 T cell-dependent anti-tumor effects. BI-1910 can be used in solid tumors research. Recommended isotype control: Human IgG2 lambda, Isotype Control (HY-P991206) .
ASP8374 is a human IgG4 monoclonalantibody (mAb) targeting TIGIT. ASP8374 increases IL-2 production in Jurkat cells and IFN-γ and TNF-α production in human PBMCs. ASP8374 can be used in advanced solid tumors research. Recommended isotype control: Human IgG4 kappa, Isotype Control (HY-P99003) .
Guselkumab is a recombinant human IgG1 monoclonalantibody against the IL-23p19 subunit. Guselkumab binds to human and cynomolgus monkey IL-23 with Kd values of 3.3 and 1.9 pmol/L, respectively. Guselkumab inhibits production of cytokines lying downstream of the IL-23 signaling pathway and can be used for psoriatic arthritis research .
REGN3051 is a human IgG1 monoclonalantibody (mAb) targeting MERS CoV. REGN3051 reduces viral titers in the lungs of mice expressing human DPP4. REGN3051 decreases lung disease severity and viral replication in marmosets inoculated with MERS-CoV. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
CRB0017 is a recombinant monoclonalantibody targeting ADAMTS5, with high affinity for the spacer domain of ADAMTS5 and strong antigen specificity. CRB0017 binds to the spacer domain of ADAMTS5 and reduces the proteolytic activity of this enzyme. CRB0017 delays articular cartilage degradation, alleviates the pathological severity of osteoarthritis, and decreases the osteoarthritis histopathological score. CRB0017 is applicable to the research of osteoarthritis .
SGN-B6A is an ADC, which targets integrin beta-6 (ITGB6) through human IgG1 monoclonalantibody Sigvotatug (HY-P990764), and exhibits cytotoxicity against multiple integrin beta-6-positive cancer cell through mitotic inhibitor MMAE (HY-15162) .
Tucotuzumab celmoleukin (EMD 273066) is an immunocytokine. Tucotuzumab celmoleukin consists of the following components: an IgG1 monoclonalantibody targeting human EpCAM antigen, and two molecules of IL2. Tucotuzumab celmoleukin binds to EpCAM. Tucotuzumab celmoleukin exerts anti-tumor effects on colon adenocarcinoma in synergy with radiofrequency ablation. Tucotuzumab celmoleukin can be used in research related to colon adenocarcinoma and colon cancer .
Eldelumab (BMS-936557) is a human anti-CXCL10 (IP-10) monoclonalantibody (IgG1 type). Eldelumab selectively binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab can be used in studies of autoimmune and auto-inflammatory diseases such as rheumatoid arthritis, ulcerative colitis and crohn's disease .
HBM1007 is a fully human monoclonalantibody targeting CD73. HBM1007 is an extracellular enzyme expressed on the surface of stromal cells and tumor cells, capable of converting extracellular adenosine monophosphate (AMP) into adenosine, and recognizing CD73 via a unique antigenic epitope. HBM1007 inhibits both CD73-dependent and CD73-independent enzyme activities.
Trastuzumab is a humanized IgG1 monoclonalantibody that selectively binds to HER2 with high affinity. Trastuzumab can be used for the research of HER2-positive metastatic breast cancer and gastric cancer . (Note: The product specifications below only indicate the effective content of Trastuzumab. The component ratio of this product is Trastuzumab : excipients = 1:0.6-1:0.9.)
Telisotuzumab (ABT-700) is a bivalent humanized IgG1 anti-c-Metmonoclonalantibody. Telisotuzumab binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab induces apoptosis. Telisotuzumab can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .
Vobarilizumab (ALX-0061) is a humanized bispecific anti-IL-6R and anti-human serum albumin (ALB) monoclonalantibody (mAb) (Kd: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis .
Adezkibart is a human monoclonalantibody immunosuppressant targeting the human FMS-like tyrosine kinase 3 ligand (FLT3LG). Adezkibart is found in the Chinese hamster ovary cell line CHO-K1, which binds to FLT3LG to block the relevant signaling pathway, inhibits the immune response, and exerts immunosuppressive activity. Adezkibart is promising for research of immune-related diseases .
ATR-107 (PF-05230900) is a humanized monoclonalantibody inhibitor that targets the interleukin-21 receptor (IL-21R). The Ka value of ATR-107 is 2-4 nM in cynomolgus monkeys, 16 nM in mice, and 71 nM in rats. ATR-107 can be used in research related to systemic lupus erythematosus and air pouch inflammation .
AR-201 is a human IgG1 monoclonalantibody (mAb) targeting F, Fusion glycoprotein F0. AR-201 has anti-respiratory syncytial virus (RSV) activity. AR-201 can be used in lower respiratory tract illness (LRTI) research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
Reslizumab (Sch 55700) is humanized monoclonalantibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab has high binding affinity for human IL-5, with KD values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively .
Mik-Beta-1 is a human IgG1-kappa anti-IL2RB monoclonalantibody. The isotype control of Mik-Beta-1 can be referenced to Human IgG1 kappa, Isotype Control (HY-P99001). Mik-Beta-1 can be used in research related to the prevention of allograft rejection .
(R)-IDO/TDO-IN-1 (compound 25) is an indoleamine-2,3-dioxygenase (IDO) inhibitor, with good pharmacokinetic properties. (R)-IDO/TDO-IN-1 exhibits anti-tumor activity in MC38 xenograft model. (R)-IDO/TDO-IN-1 shows synergistic effect with anti-PD-1 monoclonalantibody (SHR-1210) .
SM201 is a monoclonalantibody that targets FcγRIIB. SM201 specifically binds to FcγRIIB, enhances ITIM phosphorylation of FcγRIIB in an immune complex-dependent manner, and acts synergistically with immune complexes to amplify inhibitory signals. SM201 does not induce apoptosis, activate NK cells, or deplete B cells. SM201 can be used for the research of autoimmune diseases .
Quisovalimab (AVTX-002) is a human-derived monoclonalantibody against LIGHT (TNFSF14). Quisovalimab binds to LIGHT, blocks the signal transduction activity of LIGHT, reduces circulating LIGHT levels and attenuates pro-inflammatory effects. Quisovalimab can be used in research related to Crohn's disease, COVID-19-associated pneumonia and acute respiratory distress syndrome comorbidity .
Asedebart is a CHO-expressed human antibody that targets Adrenocorticotropic hormone (ACTH). Asedebart blocks the binding of ACTH to its receptor through antagonism. Asedebart has huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Asedebart can refer to Human IgG1 kappa, Isotype Control (HY-P99001). Asedebart can be used for inflammatory diseases such as psoriasis and ulcerative colitis research .
Nebaprubart (JJP-1212) is a humanized IgG4κ antibody against FCAR/CD89, and its corresponding isotype control is Human IgG4 kappa, Isotype Control (HY-P99003) .
Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonalantibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo .
Anti-Mouse CD276/B7-H3 Antibody (MJ18) is a rat-derived anti-mouse CD276/B7-H3 IgG1 monoclonalantibody. Anti-Mouse CD276/B7-H3 Antibody (MJ18) can inhibit CD276/B7-H3 and induce tumor cell apoptosis. Anti-Mouse CD276/B7-H3 Antibody (MJ18) enhances anti-tumor immune response by reducing immunosuppressive cells and promoting T cell activation. Anti-Mouse CD276/B7-H3 Antibody (MJ18) can be used for research on cancer such as breast cancer and prostate cancer .
CotH3 peptide is a functional peptide unique to Mucorales that binds to the host GRP78 receptor and allows them to invade endothelial cells. CotH3 peptide–targeted monoclonalantibodies protect immunosuppressed mice from mucormycosis caused by R. delemar and other Mucorales. CotH3 peptide also synergizes with antifungal drugs to protect mice with diabetic ketoacidosis (DKA) from R. delemar infection .
Bezlotoxumab (BLA761046; MBL-CDB1; MDX-1388) is a fully humanized IgG1/kappa monoclonalantibody directed against Clostridium difficile toxin B. Bezlotoxumab mediates the early reconstitution of gut microbiota to reduce the risk of recurrent Clostridium difficile infection (CDI). Bezlotoxumab can be used for the study of recurrent Clostridium difficile infection prevention .
SBT-100 (His Tag) is a human monoclonalantibody (mAb) targeting STAT3. SBT-100 (His Tag) inhibits IL-6-mediated P-STAT3 nuclear translocation in HEp-2 and PANC-1 cells. SBT-100 (His Tag) has tumor growth inhibitory effects on MDA-MB-231 .
BMS-981164 is a human anti-IL31 IgG1-κ monoclonalantibody. BMS-981164 effectively inhibits the IL-31 signaling pathway. The isotype control of BMS-981164 can be referenced to Human IgG1 kappa, Isotype Control (HY-P99001). BMS-981164 is applicable to research related to atopic dermatitis .
PE0116 is a fully human CD137 agonistic monoclonalantibody generated from immunized harbor H2L2 human transgenic mice. PE0116 is a ligand block. PE0116 activates NF-κB signaling which significantly promotes T-cell proliferation and increases cytokine secretion in vitro. PE0116 exhibits robust antitumor activity in MC38 tumor model .
Emactuzumab(RG 7155) is a specific monoclonalantibody that inhibits colonystimulating factor 1 receptor (CSF1R) activation. Emactuzumab has high affinity for CSF-1R with Ki value of 0.2 nM to blocks CSF-1R dimerization. Emactuzumab can be used for the research of several diseases, such as diffuse-type tenosynovial giant cell tumour (dt-GCT) .
KD014 (DX-2400) is a human monoclonalantibody that selectively targets MMP‑14. KD014 inhibits collagen degradation and regulates the polarization of macrophages toward an anti-inflammatory/anti-tumor phenotype. KD014 alleviates joint damage in rheumatoid arthritis and suppresses tumor growth and invasion. KD014 can be used in studies related to breast cancer and rheumatoid arthritis .
Risankizumab (BI 655066) is a humanised IgG monoclonalantibody, targeting IL-23 p19 subunit (Kd <10 pM) and inhibiting IL-17 production induced by human IL-23 in mouse splenocytes (IC50 = 2 pM). Risankizumab can be used to research immunological and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis and erythrodermic psoriasis .
Amlitelimab (FUT8-KO) is Amlitelimab (HY-P99434) expressed in cells with the fucosyltransferase 8 gene (FUT8) knocked out. Amlitelimab (KY1005) is a monoclonalantibody (mAb) against OX40 ligand (OX40L). Amlitelimab inhibits the OX40-OX40L interaction and can be used for research on atopic dermatitis .
LBL-019 is a humanized IgG1 monoclonalantibody targeting TNFR2. LBL-019 costimulates TNFR2 and activates the NF-κB signaling pathway in an Fc crosslinking-dependent manner. LBL-019 can be used for the research of advanced malignant tumors, including hepatocellular carcinoma and melanoma. The recommended isotype control is human IgG1 kappa (HY-P99001) .
Cabiralizumab (FPA 008) is an anti-CSF1Rmonoclonalantibody (MAb). Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis (RA). Cabiralizumab can combine with Nivolumab (HY-P9903) for lung cancer research .
Omoprubart is an anti-C5 complement recombinant humanized monoclonalantibody. Omolubat can prevent C5 from cleaving into C5a and C5b, thereby inhibiting the formation and activation of the C5b-dependent membrane attack complex (MAC) on the surface of susceptible cells, leading to cell lysis (destruction). Omoprubart can be used for the study of paroxysmal nocturnal hemoglobinuria (PNH).
Milatuzumab (hLL1; MEDI-115) is a humanized anti-CD74monoclonalantibody. CD74, a integral membrane protein, is associated with the promotion of B-cell growth and survival. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death .
Vilobelimab (CaCP-29, IFX-1) is a monoclonalanti-C5aantibody to the allergen C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. Vilobelimab acts as a C5a inhibitor, inhibiting neutrophil activation, chemotaxis, and reducing inflammatory signalling, and may be used in studies related to sepsis, COVID-19, etc .
NAMPT inhibitor-linker 2 is a agent-linker conjugates for ADC, composed of an NAMPT inhibitor as a payload, and a linker. ADC-4 consists of an NAMPT inhibitor-linker 2 and an anti-c-Kit monoclonalantibody, exihibits potent activity against c-Kit expressing cell lines such as GIST-T1 and NCI-H526, with IC50s of <7 pM and 40 pM, respectively.
Lecankitug is a humanized monoclonalantibody targeting human interleukin 17A (IL-17A) and interleukin 17F (IL-17F). Lecankitug specifically binds to IL-17A and IL-17F, blocking their signal transduction, thus exerting immunosuppressive and anti-inflammatory activities. Lecankitug is promising for research of autoimmune and inflammatory diseases, such as psoriasis and rheumatoid arthritis .
Cantuzumab mertansine (SB-408075; huC242-DM1), an ADC, is an immunoconjugate of the potent maytansine derivative (DM1 (HY-19792)) and the humanized monoclonalantibody (huC242) directed to CanAg. Cantuzumab mertansine has cytotoxic toward colon cancer cells and has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts .
PF-04382923 is a humanized IgG2Δa monoclonalantibody. PF-04382923 binds with high affinity to the free C-terminal regions of the amyloid-β peptides Aβ1-40 and Aβ1-42. PF-04382923 is indicated for the study of geographic atrophy (GA) associated with dry age-related macular degeneration (ARMD) .
Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) is an anti-mouse/human VLA-4/CD49d IgG2b monoclonalantibody. Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) can reduce VLA-4 positive cells. Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) can inhibit the migration of Tc1 cells to tumors. Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) inhibits the retention of leukemia cells in the spleen and bone marrow by blocking VLA-4. Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) can be used for research on inflammation conditions and cancer such as experimental autoimmune encephalomyelitis (EAE), melanoma and leukemia .
Anti-Mouse CD11a/LFA-1α Antibody (M17/4) is an anti-mouse CD11a/LFA-1α IgG2a monoclonalantibody. Anti-Mouse CD11a/LFA-1α Antibody (M17/4) can reduce the recruitment of effector memory CD8 T cells. Anti-Mouse CD11a/LFA-1α Antibody (M17/4) promotes the formation of xenograft tumors by reducing immune rejection reactions. Anti-Mouse CD11a/LFA-1α Antibody (M17/4) can be used for researches on cancer, infection conditions and immunology such as glioblastoma, parasitic and bacterial infections. The recommend isotype control of Anti-Mouse CD11a/LFA-1α Antibody (M17/4): Rat IgG2a kappa, Isotype Control (HY-P990679) .
DNP002 is a humanized IgG1 monoclonalantibody targeting tumor-associated CEACAM6. DNP002 binds to CEACAM1, CEACAM5 and CEACAM6, and exhibits antibody-dependent cellular cytotoxicity against tumor cells overexpressing these targets. DNP002 binds to CEACAM6 on the surface of tumor-associated neutrophils (including MDSCs) to reverse the immunosuppressive effect in the tumor microenvironment. DNP002 shows anti-tumor activity in advanced solid tumors. DNP002 can be used for the research of advanced solid tumors. The recommended isotype control is human IgG1 kappa (HY-P99001) .
Lonigutamab (hz208F2-4) is a humanized anti-IGF-1Rmonoclonalantibody, serveing as a targeting vector for antibody-drug conjugates (ADCs). Lonigutamab causes G2-M phase cell cycle arrest and increases apoptosis in IGF-1R-overexpressing tumor cells. Lonigutamab demonstrates potent antitumor efficacy in IGF-1R-overexpressing xenograft models. Lonigutamab can be used for the study of Solid tumors with overexpression of IGF-1R and thyroid eye
diseases .
GT103 is a human-derived monoclonalantibody targeting complement factor H (CFH). GT103 binds to a conformationally distinct epitope of CFH on tumor cells. GT103 activates the classical complement pathway, induces complement-dependent cytotoxicity, and triggers antibody-dependent cellular phagocytosis (ADCP) of tumor cells. GT103 increases calreticulin translocation to tumor cell plasma membranes. GT103 mediates B-cell activation via Syk kinase phosphorylation. GT103 inhibits tumor growth and metastasis in animal models. GT103 can be used for the research of non-small cell lung cancer .
PE-CF594 is a labeled monoclonalantibody conjugate that specifically binds to HLA-DR on the surface of monocytes and B cells, while acting as a signal attenuator. Through steric hindrance and a possible fluorescence resonance energy transfer mechanism, PE-CF594 specifically reduces the fluorescence intensity of PE-CD124 staining, but does not interfere with the staining of other PE-labeled antibodies such as CD40, CD4 or CD14. PE-CF594 can also be used to detect the emission signal of mt-Keima after excitation with a 561-nm laser, thereby effectively evaluating mitophagy activity .
Tobevibart (VIR-3434) is a human IgG1 lambda monoclonalantibody against hepatitis B virus (HBV) surface antigen (HBsAg). Tobevibart shows potent neutralization against HBsAg from all HBV genotypes in vitro and inhibits viral entry of HBV and hepatitis delta virus (HDV). Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096) .
γ-Amanitin an ADC cytotoxin and isolated from the mushroom. γ-Amanitin inhibits RNA polymerase II and disrupts synthesis of mRNA. γ-Amanitin shows similar effects to α-Amanitin and β-Amanitin. γ-Amanitin competitively binds to monoclonalantibody (mAb), with an IC50 of 163.1 ng/mL. γ-Amanitin is toxic to a variety of cells .
NAMPT inhibitor-linker 1 is a agent-linker conjugates for ADC, composed of an NAMPT inhibitor as a payload, and a linker. ADC-3 consists of an NAMPT inhibitor-linker 1 and an anti-c-Kit monoclonalantibody, exihibits potent activity against c-Kit expressing cell lines such as GIST-T1 and NCI-H526 cells, with IC50s of <3 pM and 9 pM, respectively.
[Lys3]-Bombesin is a biological active peptide. (PET (Positron Emission Tomography) imaging of [Lys3]-bombesin is able to detect gastrin-releasing peptide receptor (GRPR) positive prostate cancer. An immunoconjugate of [Lys3]-bombesin and corresponding monoclonalantibody can specifically induce (CD64)-dependent monocyte and neutrophil-mediated lysis of small cell carcinoma.)
BMS-986010 is a monoclonalantibody inhibitor targeting the p19 subunit of interleukin-23 (IL-23). BMS-986010 reduces IL-23-induced STAT3 phosphorylation and inhibits Th17 cell differentiation and the release of proinflammatory cytokines (such as IL-17 and TNF-α). BMS-986010 is promising for research of autoimmune diseases such as psoriasis and Crohn's disease .
Tabituximab barzuxetan (exclude Y90) (OTSA101-DTPA; OTSA101-DTPA-90Y; OTSA101-SS01) is a immunoconjugate composed of a humanized monoclonalantibody targeting FZD-10 (OTSA-101). Tabituximab barzuxetan exhibits anti-tumor activity. Tabituximab barzuxetan can be used for the research of synovial sarcoma .
Ogalvibart (C-135-LS) is a human anti-SARS-CoV-2 monoclonalantibody (IgG1 type). Ogalvibart binds to the spike (S) glycoprotein receptor-binding domain (RBD) of SARS-CoV-2. Ogalvibart in combination with C144LS (1:1 ratio) shows good preventive activity and can effectively block the development of COVID19 in a rhesus monkey disease model .
Cixutumumab (IMC-A12) is a human anti-IGF-1Rmonoclonalantibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer .
Afimkibart (PF-06480605; RVT-3101) is a fully human monoclonalantibody that selectively inhibits trimeric tumor necrosis factor-like ligand 1A (TL1A). Afimkibart neutralizes active trimeric TL1A, blocks TL1A-induced signaling pathways. Afimkibart inhibits NF-κB activation and IFN-γ production. Afimkibart can be used for the research of inflammatory bowel disease .
CAN10 is is a humanized monoclonalantibody inhibitor targeting interleukin 1RAP (IL1RAP). CAN10 blocks IL-1, IL-33, and IL-36 signalling by targeting IL1RAP, preventing downstream proinflammatory and profibrotic responses. CAN10 reduces dermal and pulmonary fibrosis. CAN10 can be used for the research of immune system diseases, such as systemic sclerosis .
Batoclimab (RVT-1401) is a fully humanized IgG1 monoclonalantibody targeting FcRn. Batoclimab has high affinity for the IgG-binding site on FcRn. By competitively binding to the IgG binding site on FcRn, Batoclimab blocks FcRn-mediated recycling of IgG, resulting in enhanced degradation and subsequent reductions in IgG levels. Batoclimab can be used in the research of autoimmune diseases such as myasthenia gravis and thyroid eye disease .
Denosumab is a human monoclonalantibody that targets the protein RANKL. Denosumab binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) and prevents its binding to the RANK receptor (KD of 0.003 nM for human RANKL). Denosumab promotes proliferation and spermatogenesis. Denosumab prevents bone resorption through inhibition of the NF-κB pathway. Denosumab can be used in bone-related studies .
SHR-1802 is a humanized anti-LAG-3monoclonalantibody.SHR-1802 specifically binds to LAG-3 and inhibits its binding to major histocompatibility complex class II (MHC-II), fibrinogen-like protein 1 (FGL1), galectin-3, and liver sinusoidal endothelial cell lectin.SHR-1802 can be used for the research of advanced solid tumors .
Telisotuzumab (ABT-700) (powder) is a bivalent humanized IgG1 anti-c-Metmonoclonalantibody. Telisotuzumab (powder) binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab (powder) induces apoptosis. Telisotuzumab (powder) can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .
Polzastobart (JTX-8064) is a humanized IgG4 monoclonal antagonist antibody that selectively binds LILRB2 and prevents it from binding its ligands, classical and non-classical MHC I molecules. Polzastobart enhances pro-inflammatory cytokine production in macrophages by blocking the ability of LILRB2 to bind HLA-A/B and/or HLA-G, a marker of immunotolerance on cancer cells. Polzastobart is a macrophage immune checkpoint inhibitor .
Suciraslimab (SM03) is an anti-human CD22monoclonalantibody. Suciraslimab inhibits NLRP3 and ASC signaling. Suciraslimab suppresses cytokine (IL-1β, IL-12, IL-23) secretion and α4 integrin expression. Suciraslimab improves working memory and neuroinflammation . Suciraslimab isotype control product: Human IgG1 kappa, Isotype Control (HY-P99001).
OX118 is a fully human, ADCC-enhanced monoclonalantibody targeting OX40L, the recommended isotype control is HY-P99001. OX118 blocks OX40L, suppresses effector T-cell proliferation, expands regulatory T-cell populations, and reduces bystander activation across natural killer cells, B cells, and CD14+ monocytes. OX118 can be used for the research of graft-versus-host disease .
Budigalimab (ABBV 181; PR 1648817) is a humanized, recombinant IgG1 monoclonalantibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab has an Fc mutation that reduces the inhibition of Fc receptor interactions and effector factors. Budigalimab can block the binding of PD-1 and PD-L1, which has anti-tumor activity. Budigalimab can be used in the study of solid tumors .
Mirikizumab (LY3074828) is a humanized IgG4 monoclonalantibody that targets the p19 subunit of interleukin 23 (IL-23). Mirikizumab binds to human and monkey IL-23 with high affinity, with Kd values of 21 pM and 55 pM, respectively. By inhibiting the binding of IL-23 to IL-23R, Mirikizumab modulates the immune response and holds potential for research in ulcerative colitis and Crohn's disease .
Suvratoxumab (MEDI4893) is a long-acting, high-affinity human anti-α-toxin monoclonalantibody (IgG1κ type). Suvratoxumab potently neutralizes α-toxin, a key S. aureus virulence factor. Suvratoxumab improves survival and reduces lung injury in an immunocompromised mice model of pneumonia. Suvratoxumab also enhances the antibacterial activity of Vancomycin (HY-B0671) or Linezolid (HY-10394) .
GR-1405 is a human monoclonalantibody (mAb) targeting B7-H1/PD-L1/CD274. GR-1405 enhances cytotoxic T lymphocyte (CTL)-mediated antitumor immune responses against PD-L1-expressing tumor cells. GR-1405 can be used in Lymphoma and Solid tumours research .
STX-100 (BG00011) is a humanized monoclonalantibody targeting αVβ6 integrin. STX-100 specifically binds αVβ6 integrin, blocks latent TGF-β activation via latency-associated peptide (LAP) interaction prevention, and reduces profibrotic responses. STX-100 can be used for the research of idiopathic pulmonary fibrosis, and cancer .
Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonalantibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease .
ALD1613 is a potent neutralizing monoclonalantibody against adrenocorticotropic hormone (ACTH). ALD1613 neutralizes ACTH-induced signaling and inhibits ACTH-induced cyclic AMP accumulation in a mouse adrenal cell line (Y1) via all five melanocortin receptors. ALD1613 significantly reduces plasma corticosterone levels in wild-type rats. ALD1613 can be used in the study of diseases associated with elevated ACTH levels .
Sym-021 is a human monoclonalantibody (mAb) targeting PDCD1/PD-1/CD279. Sym-021 blocks the binding of PD-L1 and PD-L2 ligands, inducing the secretion of interferon IFN-γ and IL-2 and the proliferation of T cells. Sym-021 has anti-tumor activity in PDX mouse models .
INCA033989 is a fully human IgG1 monoclonalantibody targeting mutCALR (KD = 1.75 nM for mutCALR del52; KD = 6.78 nM for mutCALR ins5). INCA033989 antagonizes mutCALR-driven signaling and proliferation. INCA033989 selectively inhibits pSTAT3/pSTAT5. INCA033989 prevents thrombocytosis and reduces the expansion of mutCALR-positive cells. INCA033989 is useful for research on myeloproliferative neoplasms .
Serrumab is a human monoclonalantibody that counteracts the biochemical and immunological effects of Tityus serrulatus venom. Serrumab inhibits the TsV-induced increase in the production of IL-6, TNFα and IL-10. Serrumab also prevents TsV-induced elevations in plasma urea, creatinine, aspartate transaminase and glucose levels, as well as the TsV-induced increase in neutrophil recruitment. Serrumab can be used in research related to envenoming by the Brazilian yellow scorpion .
BI-765423 is a selective monoclonalantibody inhibitor targeting IL-11. BI-765423 blocks IL-11-mediated signaling, inhibits fibroblast activation, and can extend the healthy lifespan of mammals, counteract cellular senescence in human cells, and alleviate inflammatory aging-related pathological processes. BI-765423 is primarily used in research on fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) .
Tinostamustine hydrochloride (EDO-S101 hydrochloride) is a compound with anti-multiple myeloma activity and the ability to promote CD38 expression. Tinostamustine hydrochloride enhances the sensitivity of tumor cells to the anti-CD38 monoclonalantibody daratumumab by increasing the acetylation level of histone H3. Tinostamustine hydrochloride can increase the expression of MICA and MICB, thereby activating NK cells. Tinostamustine hydrochloride can significantly delay tumor growth and improve the survival rate of mice .
NI-1201 is a monoclonalantibody that targets, in the human IL-6R sequence, the epitope recognized by 25F10 for mice. NI-1201 inhibits both IL-6 cis- and trans-signaling. NI-1201 targets site IIb of hIL-6R. NI-1201 inhibits gp130 binding to IL-6R .
IBI-397 is a human monoclonalantibody (mAb) targeting SIRPα/CD172a . IBI-397 promotes human monocyte-derived dendritic cell-mediated T cell proliferation and increases the expression of CD86 and HLA-DR. IBI-397 has antitumor activity in the mouse MDA-MB-231 tumor model. IBI-397 can be used in Myeloma research .
VHB937 is a potent and selective TREM2 agonist, a human monoclonalantibody, with sub-nanomolar affinity. VHB937 enhances TREM2 surface expression and downstream signaling, such as Syk phosphorylation and calcium mobilization. VHB937 exhibits robust neuroprotective effects in vivo, significantly reducing pathology and pro-inflammatory markers across a broad range of animal models of neuroinflammation and neurodegeneration. VHB937 can be used for neurodegenerative diseases research .
MEDI-8852 is a human IgG1 monoclonalantibody against influenza A virus hemagglutinin (HA). MEDI-8852 binds to the conserved HA stalk epitope and neutralizes viral infectivity. MEDI-8852 reduces viral titers in mouse lung tissues. MEDI-8852 is applicable to research related to pandemic influenza . Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
SAR228810 is a humanized IgG4 monoclonalantibody inhibitor targeting amyloid β (Aβ) with a KD? of ?0.43 ?nM for protofibrillar Aβ over monomeric Aβ. SAR228810 significantly inhibits the brain amyloid plaque formation and oligomer-induced synaptic dysfunction and neurite loss. SAR228810 has significant protection against Aβ-mediated neuritotoxicity. MINT1526A can be used for Alzheimer’s disease imaging and immunotherapy research .
V5 Epitope Tag Peptide TFA is a tag peptide derived from a small epitope present on the P and V proteins of the paramyxovirus of simian virus 5. V5 Epitope Tag Peptide TFA can be used for protein separation and purification, and competitive elution with target proteins .
hIMB1636 is a humanized monoclonalantibody targeting Trop2. By binding to the conformational Trop2 epitope, hIMB1636 regulates related signaling pathways, triggers lysosomal endocytosis, and further induces apoptosis, cell cycle arrest, and antibody-dependent cellular cytotoxicity. hIMB1636 effectively inhibits tumor cell proliferation, migration and in vivo tumor growth, and also exerts bystander killing effect and mediates long-term retention. hIMB1636 can be conjugated with NOTA/DOTA for radiolabeling to enable immuno-PET imaging, or prepared as hIMB1636-LDP-AE to significantly inhibit the growth of breast cancer and lung cancer xenografts .
Belantamab (GSK2857916) is a humanized IgG1 anti-BCMA/TNFRSF17 monoclonalantibody. Belantamab is linked to MMAF (HY-15579) through a non-cleavable ADC linker to synthesize the antibody-active molecule conjugate (ADC) Belantamab mafodotin (HY-P3239). After binding to BCMA on the surface of tumor cells, Belantamab mafodotin enters the cell through receptor-mediated endocytosis. After entering the cell, Belantamab mafodotin releases MMAF, blocks cell division by inhibiting tubulin polymerization, arrests the cell cycle and induces cell apoptosis. Belantamab can be used for the study of multiple myeloma, especially relapsed/refractory multiple myeloma .
TPP-9476 (BAY-943 antibody) is an anti-human IL3RA (CD123)monoclonalantibody with human IL3RAKd of 11 nM and cynomolgus monkey IL3RAKd of 16 nM. TPP-9476 binds specifically to human and cynomolgus monkey IL3RA, undergoes target-dependent internalization into lysosomes of IL3RA-positive cells.TPP-9476 exerts antiproliferative effects in IL3RA-expressing acute myeloid leukemia and classical Hodgkin lymphoma cells, reduces tumor burden, improves survival, and induces complete tumor remission in relevant xenograft mouse models .
BIIB022 is a human IgG4 monoclonalantibody (mAb) targeting IGF1R/CD221. BIIB022 blocks IGF-1 and IGF-2-induced phosphorylation of IGF-1R and downstream substrates. BIIB022 can be used in lung, pancreatic, and colon cancer research. Recommended isotype control: Human IgG4 kappa, Isotype Control (HY-P99003) .
MG-1131 is a human monoclonalantibody (mAb) targeting TIGIT. MG-1131 activates NF-κB signaling in T cells and enhances NK-mediated tumor killing activity in a PVR-dependent manner. MG-1131 blocks TIGIT to increase IFN-γ secretion. MG-1131 can be used in anti-tumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
LASN01 is a human IgG1 monoclonalantibody (mAb) targeting IL-11RA. LASN01 inhibits IGF-1 and IL-11-induced hyaluronic acid (HA) release and TGFβ-stimulated procollagen in orbital fibroblasts. LASN01 can be used in thyroid eye disease (TED) research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Metuzumab (Licartin) is a human-mouse chimeric IgG1 monoclonalantibody targeting CD147. Metuzumab induces Apoptosis, reduces levels of Cyclin D1, full-length Caspase-3, and Bcl-2, and increases Bax expression. Metuzumab enhances the sensitivity of non-small cell lung cancer (NSCLC) cells to Gemcitabine (HY-17026). Metuzumab is applicable for research on hepatocellular carcinoma and non-small cell lung cancer [1][2].
DS-8895(DS-8895A) is an anti-EphA2monoclonalantibody with specific binding to EphA2 receptors and EphA2-expressing cells. DS-8895, when conjugated with 89Zr, 111In, or 125I, supports molecular imaging of EphA2 expression in xenograft models. DS-8895 allows noninvasive measurement of EphA2 expresssion in tumors in vivo. .
RO5323441 (TB-403) is a human IgG1 monoclonalantibody (mAb) targeting PlGF. RO5323441 inhibits the binding of human PlGF-1 or PlGF-2 to VEGFR-1 (IC50 values are 0.1 and 0.2 nM, respectively). RO5323441 blocks PlGF-induced VEGFR-1 phosphorylation in Flt-1-transfected HEK293 cells. RO5323441 has antitumor activity .
Vamikibart (RG6179) is a monoclonalantibody targeting IL-6 that can be used to inhibit uveal macular edema (UME) and reduce retinal leakage. Vamikibart can reduce anterior chamber (AC) cell density, indicating a reduction in intraocular inflammation. Vamikibart can also be used to assess the leakage dynamics of ultra-wide-angle fluorescein angiography (UWFA) in the UME model to quantify changes in retinal leakage reflecting the effect of UME inhibition .
Anti-ERBB3/HER3 (SGP1) is a human monoclonalantibody (mAb) targeting ERBB3/HER3. Anti-ERBB3/HER3 (SGP1) inhibits Neuregulin stimulated growth of cultured breast cancer cells. Anti-ERBB3/HER3 (SGP1) can be used in breast cancer research .
IPH5301 is a human IgG1 monoclonalantibody (mAb) targeting NT5E/CD73. IPH5301 has a functionally silent Fc domain, specifically inhibits soluble and membrane CD73 enzyme activity, and restores the proliferation of immune T cells. IPH5301 can be used in anti-tumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
VRC-01 is a broadly neutralizing IgG1monoclonalantibody that targets HIV-1 envelope glycoprotein gp120 Protein. VRC-01 blocks HIV-1 viral entry by mimicking CD4 receptor interaction with HIV-1 gp120 and neutralizes broad HIV-1 clades. VRC-01 can be used for the research of HIV-1 infection .
Fmoc-1,6-diaminohexane hydrochloride (Standard) is the analytical standard of Fmoc-1,6-diaminohexane hydrochloride (HY-103664A). This product is intended for research and analytical applications. Fmoc-1,6-diaminohexane hydrochloride is the hydrochloride form of Fmoc-1,6-diaminohexane (HY-103664). Fmoc-1,6-diaminohexane hydrochloride conjugates with monoclonalantibody, and exhibits anticancer activity against p21-deficient cancer .
HGS101 is a fully human CCR5 monoclonalantibody with high affinity to CCR5. HGS101 binds to the 2nd extracellular loop (ECL-2) and acts as a signal antagonist. HGS101 restores Maraviroc (HY-13004) inhibition of Maraviroc-resistant HIV-1 infection of PBMCs. HGS101 shows anti-HIV activity by inhibiting CCR5 signaling in simian immunodeficiency virus-uninfected RMs models .
Ordesekimab (AMG 714; PRV-015) is a fully human IgG1κ anti-IL-15 (Interleukin Related) monoclonalantibody. The binding of Ordesekimab to IL-15 inhibits the interaction of IL-15 with the IL-2Rβ and common γ chain of the IL-15 receptor complex, but not with the IL-15Rα chain. Ordesekimab has the potential for study of nonresponsive celiac disease (NRCD) .
AL002 is a humanized monoclonal IgG1 antibody and a blood-brain barrier-permeable TREM2 modulator. AL002 binds to TREM2 on the surface of microglia, promotes TREM2 clustering and the formation of the TREM2-DAP12 complex, activates the TREM2 signaling pathway and PI3K cascade, and induces TREM2 internalization and degradation. AL002 is applicable to research related to Alzheimer's disease .
VIR-7229 is a human IgG1 monoclonalantibody (mAb) targeting Receptor-Binding Domain, RBD, Spike glycoprotein. VIR-7229 exerts antiviral activity by competing with ACE2 for binding and inducing S1 protein shedding. VIR-7229 can be used in SARS-CoV-2 infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
PTX-35 is a human IgG monoclonalantibody (mAb) targeting TNFRSF25. PTX-35 reduces the suppressive activity of regulatory T cells and enhances CD4+ T cell effector responses in a mouse melanoma model. PTX-35 can be used in Islet cell transplant rejection and Solid tumours research. Recommended isotype control: Human IgG1 lambda2, Isotype Control (HY-P990096) .
HeFi-1 is a mouse anti-CD30 IgG1 monoclonalantibody. HeFi-1 recognizes the ligand-binding site on CD30. HeFi-1 can inhibit the growth of tumor cells with high expression of CD30. HeFi-1 can induce eosinophil apoptosis. HeFi-1 can be used for researches on cancer or inflammation conditions such as anaplastic large-cell lymphoma (ALCL) and asthma .
Fezakinumab (ILV 094) is an anti-IL-22monoclonalantibody. Fezakinumab inhibits IL-22 signal transduction, and regulates the JAK1/STAT3 pathway as well as apoptotic proteins. Fezakinumab alleviates airway remodeling, alveolar enlargement and inflammatory cell infiltration in lung tissues. Fezakinumab reduces the levels of neutrophils, lymphocytes, eosinophils and macrophages in lung tissues. Fezakinumab can be used in the research of chronic obstructive pulmonary disease and skin diseases .
STT-5058 (ARGX-116; NN5058) is a human monoclonalantibody targeting ApoC3 and belongs to the class of ApoC3 inhibitors. STT-5058 exhibits pH-dependent circulation properties and binds to a unique epitope on ApoC3. STT-5058 reduces triglyceride levels and accelerates the clearance of atherogenic remnant lipoproteins containing ApoC3. STT-5058 can be used in research related to hypertriglyceridemia, dyslipidemia and cardiovascular diseases .
S-531011 is a human IgG1 monoclonalantibody (mAb) targeting CCR8. S-531011 reduces tumor-infiltrating CCR8+ Tregs and has anti-tumor activity in CT26.WT and EMT6 tumor-bearing mouse tumor models. S-531011 can be used in the study of cancer immunity. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Teprotumumab is an IGF-1 receptor (IGF-1R) blocking human monoclonalantibody. Teprotumumab binds to the ligand binding extracellular α-subunit domain of IGF-1R. Teprotumumab inhibits TSH and IGF-1 action in fibrocytes. Teprotumumab attenuates TSH-dependent IL-6 and IL-8 expression and Akt phosphorylation. Teprotumumab can be used for thyroid-associated ophthalmopathy research .
Opicinumab (BIIB033) is a human IgG1 monoclonalantibody targeting LINGO-1. Opicinumab binds LINGO-1 to block its negative regulatory signaling, suppress axonal degeneration, enhance axonal regeneration, promote remyelination, and exert neuroprotective effects.Opicinumab maintains axonal protective effects during co-administration with methylprednisolone. Opicinumab can be used for the research of multiple sclerosis, acute optic neuritis, and optic neuritis. .
Golimumab (CNTO-148) is a potent human IgG1 TNFα antagonist monoclonalantibody. Golimumab has anti-inflammation activitity and inhibits IL-6 and IL-1β production. Golimumab acts via targeting and neutralizing TNF to prevent inflammation and destruction of cartilage and bone. Golimumab has the anticancer activity and induces cell apoptosis. Golimumab can be used for rheumatoid arthritis, Crohn's disease and cancer research .
LR004 is an EGFRmonoclonalantibody, with a Kd of 2.80×10 -9 M against human EGFR. LR004 shows extremely weak inhibitory effect on the viability of EGFR-positive tumor cells in vitro, but inhibits the growth of EGFR-positive tumor xenografts as a single agent. LR004 is applicable to research related to advanced colorectal cancer, solid tumors, esophageal squamous cell carcinoma, epidermoid carcinoma, colon cancer and breast cancer .
SHR-1707 is a humanized anti-Aβ IgG1 monoclonalantibody. SHR-1707 binds Aβ fibrils and monomers, blocking plaque formation and promoting the microglial phagocytosis of Aβ. SHR-1707 reduces brain Aβ deposition in 5xFAD transgenic mice. SHR-1707 can be used for Alzheimer’s disease research. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
REGN-7257 is a humanized monoclonalantibody targeting IL2RG. REGN-7257 blocks the signal transduction induced by common gamma chain (γc) cytokines via the IL2RG chain of the γc cytokine receptor complex. REGN-7257 is applicable for research on immune-mediated diseases and T cell-mediated diseases . Its corresponding isotype control is Human IgG4 kappa, Isotype Control (HY-P99003).
Denosumab (anti-TNFSF11) is a human monoclonalantibody that targets the protein RANKL. Denosumab binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) and prevents its binding to the RANK receptor (KD of 0.003 nM for human RANKL). Denosumab promotes proliferation and spermatogenesis. Denosumab prevents bone resorption through inhibition of the NF-κB pathway. Denosumab can be used in bone-related studies .
Tepilukimig is a bivalent humanized IgG1κ monoclonalantibody inhibitor targeting TSLP-IL7Rα and TSLP-CRLF2. Tepilukimig inhibits the binding of TSLP to its receptors (IL7Rα and CRLF2) on the cell surface, thereby completely interrupting the inflammatory signaling pathway driven by TSLP. Tepilukimig can be used for allergic and inflammatory diseases like atopic dermatitis and asthma research .
Casirivimab (REGN10933) is a human monoclonalantibody that targets the SARS-CoV-2 virus, which causes COVID-19. Casirivimab is ineffective against COVID-19 variants. Casirivimab can be used in combination with Imdevimab (HY-P99342), which alters the lung response of K18-hACE2 mice to the SARS-CoV-2 δ variant, effectively reducing viral load and improving symptoms .
AR20.5 is a human monoclonalantibody (mAb) targeting MUC1. AR20.5 increases the number of activated CD8 T cells, CD3+CD4−CD8−(DN) T cells, and mature dendritic cells in pancreatic tumor-bearing mice. AR20.5 can be used in anti-pancreatic cancer immunity research .
ADG-106 is a fully human agonistic monoclonal IgG4 antibody against CD137 (4-1BB). ADG-106 has the mechanism to activate CD137 via strong FcγRIIB-mediated crosslinking while antagonizing CD137 ligands. The isotype control for ADG-106 can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
DS-1501 is a human monoclonalantibody (mAb) targeting Siglec-15/CD33L3. DS-1501 inhibits osteoclastogenesis. DS-1501 suppresses the decrease of lumbar spine bone mineral density (BMD) in ovariectomized (OVX) rats. DS-1501 can be used in Osteoporosis research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Vensobafusp alfa (KP-104) is a fusion protein composed of an IgG4 monoclonalantibody directed against terminal complement protein C5 fused to the complement factor H 1-5 domain (FH1-5). Vensobafusp alfa shows anti-inflammatory and immunomodulatory activities. The isotype control for Vensobafusp alfa can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) . .
NIAID RSVF2-5 is a human monoclonalantibody fragment. NIAID RSVF2-5 binds to conserved, distinct conformational epitopes on RSV fusion glycoprotein, and shows activity against RSVsubgroup A and B strains. NIAID RSVF2-5 reduces pulmonary and lung viral titers in RSV-infected rodents. NIAID RSVF2-5 can be used for the research of respiratory syncytial virus infection .
Imdevimab (REGN10987) is a human monoclonalantibody that targets SARS-CoV-2 virus. Imdevimab can be used in combination with Casirivimab (HY-P99341) to reduce viral load and transiently increases anti-receptor-binding domain IgG titers. Imdevimab maintains most of its neutralization activity against viruses with B.1.1.7, B.1.351 and mink cluster 5 spike proteins .
Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) is an anti-mouse Delta-like protein 4/DLL4 IgG monoclonalantibody. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can reduce angiogenesis and density by blocking the DLL4-Notch signaling pathway. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) reduces inflammatory response by decreasing NF-κB activity and pro-inflammatory factors (IL-1β, iNOS, IL-6) levels. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can inhibit Th17 cell differentiation and IL-17A production. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can reduce macrophage infiltration and alleviate insulin resistance. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can be used for researches on inflammation, metabolic conditions and cancer such as atherosclerosis, pancreatic cancer and asthma .
Necitumumab (11F8; IMC-11F8; LY3012211) is a human IgG monoclonalantibody directed against EGFR. Necitumumab binds to the EGF binding site of EGFR, blocks ligand binding, neutralizes ligand-induced EGFR phosphorylation and downstream signaling, induces EGFR internalization and degradation, and mediates antibody-dependent cellular cytotoxicity (ADCC) in EGFR-expressing cells. Necitumumab enhances antitumour activity in combination with Gemcitabine (HY-17026) and Cisplatin (HY-17394) in murine non-small-cell lung cancer xenograft models. Necitumumab can be used in research on cancers such as non-small cell lung cancer and colorectal cancer .
Neihulizumab (ALTB-168) is an immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), leading to downregulation of activated T-cells. Neihulizumab can be uesd for steroid-refractory acute graft-versus-host-disease (SR-aGVHD), psoriasis, psoriatic arthritis and ulcerative colitis research .
JS007 is a humanized IgG1 monoclonalantibody and also a CTLA-4 binder, with a Kd of 0.21 nM for CTLA-4. JS007 blocks the interaction between CTLA-4 and B7-1. JS007 activates T cells, promotes increased IL-2 secretion, and inhibits tumor growth in CTLA-4 knock-in mouse syngeneic tumor models. JS007 is applicable to research related to cancer and advanced solid tumors.
TQB-2858 is a bifunctional fusion protein composed of a monoclonalantibody against PD-L1 fused with the extracellular domain of TGF-β receptor. TQB-2858 has a high affinity for PD-L1, TGF-β1, and TGF-β3 and exhibited high PD-L1 target occupancy. TQB-2858 can be used for the study of osteosarcoma and alveolar soft part sarcoma (ASPS) .
Aquaporumab (AQmabAM) is an engineered human monoclonal IgG antibody. Aquaporumab is a selective inhibitor of aquaporin 4 (AQP4), binding tightly to AQP4 and competitively displacing AQP4-IgG from serum [1][2]. Aquaporumab significantly reduces neuromyelitis optica lesions in spinal cord slice cultures and in mice receiving intracerebral injection of AQP4-IgG and complement [1][2]. Aquaporumab can be used for research on neuromyelitis optica spectrum disorders [1][2]."}
Cofetuzumab (PF-06523435) is a humanized IgG1-κ monoclonalantibody targeting PTK7. The expression system of Cofetuzumab is typically CHO (Chinese hamster ovary) cells. Cofetuzumab downregulates PTK7 expression, modulates its downstream signaling pathways, and inhibits tumor sphere formation of ovarian cancer cells. Cofetuzumab can be used to synthesize the ADC molecule Cofetuzumab pelidotin (HY-P99829). Cofetuzumab is applicable to the research of tumors such as ovarian cancer .
JM1-24-3 is an anti-MUC18 mouse monoclonalantibody with a Kd value of 1.60e-9 M. JM1-24-3 reduces the phosphorylation levels of p-AKT (Ser473) and p-mTOR (Ser2448) in a time-dependent manner. JM1-24-3 exhibits anticancer activity against melanoma. JM1-24-3 can be used in studies related to metastatic melanoma .
WM-A1-3389 is an anti-human IGSF1monoclonal antibody and tumor growth inhibitor. WM-A1-3389 specifically binds to the C-terminus of IGSF1, increases secretion of Granzyme B, IFN?γ, and TNF?α, and inhibits growth of colon cancer or biliary tract cancer in xenogeneic or allogeneic mouse implantation models. WM-A1-3389 can be used for the research of colon cancer, biliary tract cancer, and head and neck cancer .
Temtokibart (ARGX-112) is a monoclonalantibody and also an IL-22RA1 inhibitor. Temtokibart inhibits the signal transduction of IL-22, IL-20 and IL-24. Temtokibart reduces the expression levels of inflammatory proteins, chemokines, immune cell migration and markers of activated immune pathways. Temtokibart improves the expression of genes related to immunity and epidermal barrier function. Temtokibart is applicable to research on moderate-to-severe atopic dermatitis .
Dalotuzumab (MK-0646) is a recombinant humanized monoclonalantibody (IgG1 type) targeting IGF-1R. Dalotuzumab acts by inhibiting IGF-1- and IGF-2-mediated tumor cell proliferation, IGF-1R autophosphorylation, and Akt phosphorylation. Dalotuzumab also induces apoptosis and cycle arrest. Dalotuzumab in combination with other anticancer agents such as statins can enhance the antitumor activity of Dalotuzumab in vitro and in vivo .
Netakimab (BCD-085) is a humanized IgG1κ monoclonalanti-IL-17antibody that binds to and blocks IL-17 and IL-17A activity, including reduction of downstream IL-6 production. Netakimab can be used for the research of moderate-to-severe plaque psoriasis, ankylosing spondylitis, and COVID-19 with cytokine release syndrome . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
Annexuzlimab is a humanised IgG1 monoclonalantibody which specifically binds to ANXA1 disrupting its interaction with formyl peptide receptors 1 and 2 (FPR1/2). Annexuzlimab arrests cell cycle progression with cancer cells accumulating in the G1 phase. Annexuzlimab targets secreted ANXA1, preventing FPR1/2 activation and reducing cancer progression. Annexuzlimab can be used for the research of triple negative breast cancer, pancreatic cancer and osteosarcoma .
Lecanemab (Mouse IGG2a) (Mab158) is a monoclonalantibody that targets soluble β-amyloid and has the potential to reduce cognitive decline. The variable region of Lecanemab (Mouse IGG2a) is consistent with that of Lecanemab, while the constant region is of Mouse IGG2a sequence. Lecanemab (Mouse IGG2a) almost abolishes Aβ accumulation in astrocytes and rescues neurons from Aβ-induced cell death. Lecanemab (Mouse IGG2a) holds promise for research in the field of Alzheimer's disease .
Plozalizumab (MLN-1202) is a humanized anti-CCR2 IgG1 monoclonalantibody. Plozalizumab blocks the recruitment of myeloid cells to the tumor microenvironment by inhibiting the CCL2/CCR2 axis. In addition, Plozalizumab also ameliorates synovial inflammation in rheumatoid arthritis. Plozalizumab can be used in the research of malignant melanoma and bone metastasis-related cancers. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
DLX-105 is a human monoclonalantibody (mAb) targeting TNFSF2/TNFa. DLX-105 reduces skin epidermal thickness and the expression of K16 and Ki67. DLX-105 down-regulates the mRNA levels of IL-17, TNF-α, IL-23p19, IL-12p40, and IFN-γ. DLX-105 can be used in psoriasis research .
VTX-0811 is a human IgG4 monoclonalantibody (mAb) targeting PSGL1/CD162. VTX-0811 up-regulates TNF-α/NF-κB and chemokine-mediated signaling and down-regulates oxidative phosphorylation, fatty acid metabolism, and Myc signaling pathways. VTX-0811 increases the proportion of CD8+ T cells among infiltrating T cells. VTX-0811 has antitumor activity in a humanized mouse PDX model of melanoma .
Favezelimab (MK-4280) is a humanized monoclonalantibody targeting LAG-3. Favezelimab blocks the interaction between LAG-3 and its ligand, MHC class II molecules. Favezelimab is applicable to research on relapsed/refractory classical Hodgkin lymphoma, relapsed/refractory diffuse large B-cell lymphoma, and relapsed/refractory indolent B-cell lymphoma . For the isotype control of Favezelimab, refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
Zaptuzumab (AD5-10) is a DR5-specific humanized monoclonalantibody that selectively binds to DR5 with high affinity. Zaptuzumab specifically induces cancer cell death by both caspase-apoptosis and autophagic cell death (ACD). Zaptuzumab activates both ADCC and CDC. Zaptuzumab induces ROS generation and GSH level reduction. Zaptuzumab shows a significant suppression of the tumor growth and good safety in various xenografts mice tumor models .
REGN2878 (PRLR ADC antibody) is a monoclonalantibody targeting the prolactin receptor (PRLR) and can block prolactin‑mediated activation of PRLR. REGN2878 exhibits an equilibrium dissociation constant (KD) of 1.05 nM and an IC50 of 0.344 nM for human PRLR. REGN2878 can be rapidly internalized and degraded in lysosomes by PRLR‑positive tumor cells, showing antigen‑specific binding and targeted enrichment properties. REGN2878 derivatives can be used as an immunoPET agent for antigen‑specific imaging of PRLR‑related tumors, and can also serve as a component of ADCs to exert anti‑tumor activity in breast cancer xenograft models. REGN2878 can be used in the research of breast cancer and prostate cancer. Isotype Comparison HY-P99001 .
WT1 126-134 peptide is a Wilms' tumor oncogene protein (WT1) peptide (RMFPNAPYL). WT1 126-134 peptide is presented by HLA-A0201 and induces cytotoxic CD8 T cells capable of killing WT1+ positive tumor cells. WT1 126-134 can form stable complexes with the H-2Db (mouse) or HLA-A0201 (human) molecules. WT1 126-134 peptide/HLA-A0201 complex has an extremely high affinity (Kd = 0.2 nM) with the humanized monoclonalantibody (IgG1). WT1 126-134 peptide can be used as a vaccine for T cells or as a target for antibodies .
Ifinatamab deruxtecan (DS-7300a) is a B7-H3-targeting Antibody-drug conjugate (ADC), which is composed of a humanized anti-B7-H3 monoclonalantibody, an enzymatically cleavable peptide-based linker, and Exatecan derivative (DXd) (HY-13631D). Ifinatamab deruxtecan is a DNA Topoisomerase I inhibitor. Ifinatamab deruxtecan induces Apoptosis. DS-7300a exerts potent antitumor activities against B7-H3-expressing tumors. against rhabdomyosarcoma, endometrial adenocarcinoma and lung adenocarcinoma. Ifinatamab deruxtecan does not exert direct immunomodulatory effects
Emiltatug ledadotin (Emi-Le; XMT-1660) is a B7-H4-targeted antibody-drug conjugate (ADC). Emiltatug ledadotin consists of the tumor-specific anti-B7-H4 monoclonalantibody Emiltatug (HY-P990918) and the linker-payload system Ledadotin (HY-177541), with site-specific conjugation achieved via GlycoConnect click chemistry. Emiltatug ledadotin inhibits the growth of B7-H4-positive cancer cells. Emiltatug ledadotin can be used to study advanced solid tumors with B7-H4 overexpression, particularly breast cancer, ovarian cancer, and endometrial cancer .
WT1 126-134 peptide acetate is a Wilms' tumor oncogene protein (WT1) peptide (RMFPNAPYL). WT1 126-134 peptide acetate is presented by HLA-A0201 and induces cytotoxic CD8 T cells capable of killing WT1+ positive tumor cells. WT1 126-134 can form stable complexes with the H-2Db (mouse) or HLA-A0201 (human) molecules. WT1 126-134 peptide acetate/HLA-A0201 complex has an extremely high affinity (Kd = 0.2 nM) with the humanized monoclonalantibody (IgG1). WT1 126-134 peptide acetate can be used as a vaccine for T cells or as a target for antibodies .
Unasnemab (MT-3921) is a humanised IgG1 monoclonalantibody that binds to repulsive guidance molecule A (RGMa). Unasnemab improves locomotor function and promotes neuroregeneration. Unasnemab exerts ameliorative effects on hippocampal neurogenesis impairment and cognitive decline in db/db mice, Streptozotocin (STZ) (HY-13753)-induced type 1 diabetic and bilateral common carotid artery stenosis (BCAS)-induced mice. Unasnemab can be used for the research of spinal cord injury, diabetes-induced neurological impairments .
MAb604.107 is a human monoclonalantibody (mAb) targeting NOTCH1. MAb604.107 inhibits the proliferation and CD34/CD44 expression of primary T-ALL cells. MAb604.107 has anti-tumor activity in four tumor xenograft mouse models: MDA-MB-231, HCC-1806, BT-474, and HCT-116. MAb604.107 can be used in T acute lymphoblastic leukemia research .
MEDI0639 (21H3RK) is a human monoclonalantibody (mAb) targeting DLL4. MEDI0639 inhibits Notch1 binding to Dll4. MEDI0639 reverses Notch1-mediated growth inhibition of human umbilical vein endothelial cells in vitro. MEDI0639 promotes human angiogenesis and reduces the number of vessels covered by smooth muscle actin-positive mural cells. MEDI0639 can be used in Small cell lung cancer and solid tumors research .
Ripertamab (SCT400) is a recombinant human-mouse chimeric anti-CD20 IgG1κ monoclonalantibody. As an immunomodulator, ripertamab reduces the levels of pathogenic autoantibodies, alleviates immune complex deposition, and blocks the antigen-presenting function of cells. Ripertamab depletes CD20-positive cells. Ripertamab can induce infusion-related reactions, pulmonary toxicity, neutropenia and thrombocytopenia. Ripertamab is applicable to research related to non-Hodgkin's lymphoma, primary membranous nephropathy and idiopathic membranous nephropathy .
ONC-841 is a blood-brain barrier-permeable, humanized monoclonalantibody targeting SIGLEC10. As an immune checkpoint inhibitor, ONC-841 restores the functions of immune effector cells such as T cells and enhances anti-tumor immune responses by blocking inhibitory signals mediated by SIGLEC10. ONC-841 restores the phagocytic and migratory activities of microglia, and promotes the phagocytosis of Amyloid-β and Tau protein aggregates by microglia. ONC-841 is applicable to research related to solid tumors and Alzheimer's disease .
Masavibart (ZRC3308-A7) is an anti-SARS-CoV-2 monoclonalantibody (IgG1 type). Masavibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2 spike protein. Masavibart can be used in combination with ZRC3308-B10 (HY-145643) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease .
Rendomab B4 (Rendomab-B49) is a monoclonalantibody targeting ETB. Rendomab B4 preferentially binds to ETB in the active conformational state and exhibits selectivity for ETB on melanoma cells. Rendomab B4 inhibits the G protein-dependent phospholipase C (PLC) pathway, blocks ET-3-induced Gαi/o-mediated inhibition of adenylate cyclase, and does not affect the activation of the ERK1/2 pathway. Rendomab B4 is applicable to melanoma-related research .
AG01 is a monoclonalantibody against progranulin (GP88). AG01 inhibits triple-negative breast cancer (TNBC) cell proliferation and migration, reduces the expression of phosphorylated protein kinases p-Src, p-AKT, and p-ERK, and reduces the expression of oncogenic proteins such as Axl, c-MET, HIF-1α, and VEGF. AG01 inhibits tumor growth and Ki67 expression in a TNBC xenograft mouse model. AG01 can be used in the research of TNBC and other cancers .
Brelovitug (BJT-778) is a humanized IgG1 neutralizing monoclonalantibody targeting hepatitis B surface antigen (HBsAg). Brelovitug binds with high affinity to HBsAg purified from HBV serotypes ad and ay, with Kd values of 0.22 nM and 0.39 nM, respectively. Brelovitug binds with high affinity to HBsAg of HBV genotypes A, B, C and D, with IC50 values of 0.07, 0.02, 0.02 and 0.07 nM, respectively. Brelovitug can be used in research related to chronic hepatitis B and chronic hepatitis D .
RLYB331 (KY1066) is a is a monoclonalantibody targeting Matriptase-2 (TMPRSS6) . RLYB331 binds to the serine protease active site of matriptase-2, blocking protease activity to increase hepcidin expression. RLYB331 reduces iron overload, inhibits α-aggregates, reduces ROS, inhibits apoptosis, and enhances erythroid differentiation. RLYB331 ameliorates ineffective erythropoiesis in β-thalassemic mouse models. RLYB331 can be used for the research of β-thalassemia .
GIGA-564 is a fully human anti-CTLA4 IgG1 monoclonalantibody with a Kd of 9.8 nM. GIGA-564 binds to a unique epitope of CTLA-4, mediates FcR-dependent signaling pathways, depletes CTLA-4-highly-expressing regulatory T cells within tumors, and inhibits the proliferation of peripheral regulatory T cells. GIGA-564 exhibits anti-tumor activity in mouse models. GIGA-564 can be used for tumor research .
Deferoxamine-DBCO is a bifunctional chelating agent. Deferoxamine-DBCO efficiently chelates with radioactive metals (such as 89Zr) through the DFO structure to achieve radiolabeling. Deferoxamine-DBCO undergoes a metal-free Huisgen cycloaddition reaction with azide-containing biomolecules (such as siRNA, monoclonalantibodies) under bioorthogonal conditions through the DBCO structure to achieve targeted coupling. Deferoxamine-DBCO has efficient metal chelating ability and specific bioorthogonal reaction activity. Deferoxamine-DBCO can be used for targeted radioactive imaging studies of tumors .
Gocdacimab (MEDI6570) is a fully human IgG1 monoclonalantibody inhibitor targeting the lectin-like oxidized low-density lipoprotein receptor LOX-1. By binding to LOX-1 and blocking its function, gocdacimab effectively reduces the level of free soluble LOX-1, thereby inhibiting key pathological processes such as lipid accumulation, foam cell formation, and vascular wall inflammation. Gocdacimab can interfere with atherosclerosis-related mechanisms, and it is used for research on atherosclerosis, and type 2 diabetes mellitus .
Mal-VC-PAB-seco-CBI-PBD dimer is a highly active drug-linker conjugate. Mal-VC-PAB-seco-CBI-PBD dimer integrates the DNA-damaging effects of two distinct types of compounds: seco-cyclopropabenzindoline (seco-CBI) and pyrrolobenzodiazepine (PBD). Mal-VC-PAB-seco-CBI-PBD dimer is linked via a valine-alanine (VC) linker cleavable by cathepsin B and achieves targeted delivery relying on monoclonalantibodies. Mal-VC-PAB-seco-CBI-PBD dimer is applicable for cancer research .
BND-35 is a human monoclonalantibody (mAb) targeting LILRB4/ILT3/CD85k. BND-35 blocks the interaction of ILT3 with APOE and fibronectin, enhances the pro-inflammatory activity of various myeloid cells, and reverses ILT3-mediated immunosuppression of T cells by various suppressive myeloid cells. BND-35 has anti-tumor activity in the hILT3 transgenic mouse tumor model .
Bovine Serum Albumin, Acetylated (Ac-BSA) is a polypeptide of known structure with strong antigenicity. Bovine Serum Albumin, Acetylated produced a significant immune response, validating the accuracy and reliability of the experimental method. Bovine Serum Albumin, Acetylated can be used as a positive control substance in ELISA or WB experiments, and can be used in experiments with acetylated lysine monoclonal or polyclonal antibodies. Bovine Serum Albumin, Acetylated also improves encapsulation efficiency at low concentrations of PLGA, a polymer for biopharmaceutical delivery with biocompatibility, degradability, and controlled release properties .
TRS-005 is an anti-CD20ADC, formed by conjugating an anti-CD20 monoclonalantibody to MMAE (HY-15162) via a Val-Cit (HY-140014) linker. TRS-005 targets CD20-positive tumor cells and delivers MMAE into cells through receptor-mediated endocytosis. TRS-005 can be used for research on relapsed/refractory B-cell non-Hodgkin lymphoma (specifically diffuse large B-cell lymphoma) .
Aldastotug (PYX-106; BSI-060T) is a human monoclonalantibody (mAb) targeting Siglec-15/CD33L3. Aldastotug reverses Siglec-15-mediated immunosuppression and enhances T-cell proliferation. Aldastotug induces significantly increased levels of IFNγ and TNFα in T cells. Aldastotug can be used in cancer immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Quavonlimab (MK-1308) is a humanized IgG1 monoclonalantibody targeting CTLA-4. As a competitive inhibitor of CTLA-4, Quavonlimab blocks the binding of CTLA-4 to its ligands CD80 and CD86. Quavonlimab increases interferon production, expands and activates T cells, reduces tumor regulatory T cells, inhibits tumor growth, and induces the proliferation of Ki67-positive CD4 and CD8 cells. Quavonlimab can be used in studies related to solid tumors .
Nepuvibart (ZRC3308-B10) is an anti-SARS-CoV-2 monoclonalantibody (IgG1 type). Nepuvibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2 spike protein. Nepuvibart can be used in combination with ZRC3308-A7 (HY-145642) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease .
Evolocumab (AMG 145) is a human monoclonalantibody that inhibits PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9 protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H2O2-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation .
Sphingomab (LT1002) is a mouse-derived IgG1 κ monoclonalantibody and also an inhibitor targeting S1P, with high affinity for S1P and a Kd value of 0.03 ± 0.002 nM. Sphingomab blocks S1P-mediated IL-8 release in ovarian cancer cells. Sphingomab exhibits anti-angiogenic activity in a mouse model of choroidal neovascularization. Sphingomab reduces peripheral blood lymphocyte counts. Sphingomab can be used in the research of ovarian cancer and age-related macular degeneration .
Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonalantibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent. Recommend Isotope Control: Human IgG1 lambda1, Isotype Control (HY-P99992) .
APX002 is an anti-IL-1β humanized monoclonalantibody that binds to IL-1β with an affinity of 1.99×10 ?10M. APX002 blocks IL-1β receptor binding, inhibits IL-1β-induced downstream cell signaling and biological effects.APX002 can be used for the research of rheumatoid arthritis, diabetes, gout, cryopyrin-associated periodic syndrome, chronic obstructive pulmonary disorder, atherosclerosis, vasculitis .
Firivumab (CT-P22; CT120) is a human IgG1 monoclonalinfluenza A virus hemagglutinin (Anti-IAV HA)antibody. Firivumab is capable of neutralizing H1N1, H5N1, H6N1, H6N2, H8N4, H8N8, H9N2 and H12N7. Firivumab shows protection against H1N1 virus in mice .
TQH-2722 is a humanized IgG4 anti-IL-4Rα monoclonalantibody. TQH-2722 targets the IL-4Rα receptor in humans, effectively disrupting the interaction between IL-4Rα and the downstream cytokines IL-4 and IL-13, thereby inhibiting inflammatory response. TQH-2722 can be used for the study of atopic dermatitis (AD) and chronic rhinosinusitis with nasal polyps (CRSwNP) .
VIR-2482 is a monoclonalantibody targeting influenza A hemagglutinin (HA). VIR-2482 is generated by introducing LS mutations (M428L/N434S) into the Fc region of MEDI8852 (HY-P991446). VIR-2482 binds to the conserved HA stem epitope across all 18 influenza A HA subtypes, neutralizes a broad spectrum of H1N1 and H3N2 strains, binds to FcγRIIIa, FcγRIIa and C1q, and induces antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. VIR-2482 reduces morbidity and mortality caused by seasonal influenza A strains and provides prophylactic protection in mice. VIR-2482 can be used in research related to influenza A disease .
Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1monoclonalantibody with an EC50 of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC50 values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma .
Erfonrilimab (KN-046) is a monoclonalantibody targeting PD-L1/CTLA-4. Erfonrilimab blocks the PD-L1 and CTLA-4 pathways, thereby regulating T cell function. Erfonrilimab enhances the secretion of IL-2 in superantigen-stimulated peripheral blood mononuclear cells. Erfonrilimab inhibits tumor growth in xenograft and double gene knock-in mouse models. Erfonrilimab can be used in research related to a variety of advanced solid tumors, including non-small cell lung cancer and nasopharyngeal carcinoma.
EU-103 is a humanized monoclonalantibody targeting V-Set And Immunoglobulin Domain Containing 4 (VSIG4) with a KD value ranging from 10 −7 and 10 −9. EU-103 blocks the interaction between VSIG4 and CD8+ T cells, promotes the conversion of M2 macrophages into M1 macrophages, induces the proliferation of CD8+ T cells and the secretion of pro-inflammatory cytokines, thereby inhibiting tumor growth. EU-103 is promising for research of cancers, such as bladder cancer, breast cancer, and colon cancer .
ABB071 is a humanized anti-CD180monoclonalantibody. ABB071 can down-regulate the highly expressed TLR7 and IRF5 genes in systemic lupus erythematosus and induce the expression of PNPT1 and DNASE1L3 genes. ABB071 can inhibit the expression of genes related to the type I interferon pathway as well as interferon-stimulated genes (ISGs). ABB071 has anti-inflammatory activity and can reduce the levels of inflammatory cytokines. ABB071 can be used for research on systemic lupus erythematosus and psoriasis .
CE-355621 is a humanized anti-c-Met IgG1 monoclonalantibody. CE-355621 can effectively bind with human c-Met (KD = 200 pM, IC50 = 466 pM) in A549 cells and cyno c-Met (KD = 610 pM) in cynomolgus kidney cells. CE-355621 inhibits the c-Met signaling pathway by blocking HGF binding. CE-355621 significantly inhibits the growth of tumors dependent on the c-Met/HGF pathway. CE-355621 can be used for research on cancer such as glioblastoma and gastric cancer .
Fremanezumab (TEV-48125) is a humanized lgG2 monoclonalantibody that selectively and potently binds to calcitonin gene related peptide (CGRp) (IC50 values = 7.943 nM). Fremanezumab binds to mouse CGRP with an IC50 value of 19.6 nM. Fremanezumab counteracts anti-inflammatory effects of CGRP in vitro, including CGRP-mediated inhibition of LPS (HY-D1056)-induced microglial activation. Fremanezumab selectively inhibits the activation of Aδ meningeal nociceptors by cortical spreading depression (CSD) in rats. Fremanezumab can be used for the study of inflammation and chronic migraine .
AMOZ is a carcinogenic metabolite of Furaltadone (HY-B1148A), which forms stable tissue residues by covalently binding to proteins as a hapten. AMOZ can be coupled with carrier proteins (such as BSA/OVA) to induce immune response and is released after acid hydrolysis. AMOZ residues can be detected by competitive ELISA method, and the detection limit in the monoclonalantibody 2E5.1 test is as low as 0.16 μg/kg (shrimp sample). AMOZ can be used as a typical marker to monitor drug residues in animal-derived foods in the field of food safety[1][2].
Alirocumab is an anti-PCSK9 human monoclonalantibody. Alirocumab inhibits PCSK9. Alirocumab reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab improves atherosclerosis and inflammation .
OI-3 is a monoclonalantibody targeting CD146 (MCAM). OI-3 specifically binds to CD146 on the surface of human mesothelioma cells and undergoes endocytosis; both chimeric (chOI-3) and murine (mOI-3) variants possess this activity. When conjugated with 212Pb to form 212Pb-TCMC-OI-3, OI-3 acts as a cytotoxic agent that delivers α-emitting radionuclides to induce targeted cytotoxicity. OI-3 can be used in research related to malignant peritoneal mesothelioma .
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonalantibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC50 of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al .
YS110 is a humanized anti-CD26 (DPP4) IgG1 monoclonalantibody. YS110 induces CD26 nuclear translocation through the caveolin pathway. YS110 inhibits the proliferation of tumor cell by delaying G2/M cell cycle transition. YS110 inhibits the infection of Middle East respiratory syndrome coronavirus (MERS CoV) by blocking the binding of MERS CoV S1 to CD26. YS110 can be used for researches on cancer or infection such as Malignant Mesothelioma and MERS .
Atibuclimab (IC14), is a chimeric monoclonalantibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab attenuates Lipopolysaccharides (HY-D1056) (LPS)-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist. Atibuclimab can be used for the research of amyotrophic lateral sclerosis, sepsis, community-acquired pneumonia, or acute lung injury .
Quetmolimab (E6011) is a humanized anti-Fractalkine (CX3CL1) monoclonalantibody. Quetmolimab binds to membrane-bound and soluble Fractalkine, neutralizes Fractalkine-induced migration of CX3CR1-expressing cells, mediates target-bound complex elimination from serum. Quetmolimab suppresses free soluble Fractalkine levels in cynomolgus monkeys, with target engagement linked to increased serum total Fractalkine concentration. Quetmolimab can be used for the research of Crohn’s disease, rheumatoid arthritis, and primary biliary cholangitis .
GSK2618960 is a human monoclonalantibody (mAb) targeting IL-7Ra/CD127. GSK2618960 inhibits IL-7-induced STAT5 phosphorylation. GSK2618960 enhances CD4 T cell proliferation response and increases CD83, CD86, and CD209 expression in PBMCs. GSK2618960 can be used for the research of autoimmune and allergic inflammatory diseases. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonalantibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC50 around 97 pM. Elezanumab promotes neuroregeneration and neuroprotection in neuronal injury and demyelination models binds N-terminal RGMa, blocks BMP signaling and lacks RGMc cross-reactivity. elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism .
SHR-1703 is a long-acting humanized anti-IL-5 IgG1 monoclonalantibody. SHR-1703 can selectively recognize and bind to IL-5, blocking the binding of IL-5 to the α chain of the receptor on the surface of eosinophils, thereby inhibiting the proliferation, activation, and migration of eosinophils, and ultimately reducing eosinophil-mediated inflammation and damage. SHR-1703 can be used in the research of eosinophil-related diseases, such as eosinophilic asthma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
FAZ-053 is a human monoclonalantibody (mAb) targeting B7-H1/PD-L1/CD274. FAZ-053 inhibits the interaction of PD-L1 with PD-1 and B7-1 on monocytes, dendritic cells, and B cells. FAZ-053 enhances interleukin 2 production. FAZ-053 can be used in advanced alveolar soft tissue sarcoma (ASPS), chordoma, and triple-negative breast cancer research .
FB102 is an anti-human CD122 (IL-2Rβ)monoclonalantibody with selective activity. FB102 blocks the proliferation and activation of pathogenic NK cells and specific T cell subsets induced by IL-2 and IL-15, without affecting the proliferation of regulatory T cells. FB102 inhibits IL-2/IL-15-induced activation of CD4+ and CD8+ T cells in in vitro disease models. FB102 is applicable to research related to celiac disease .
Mipletamig (APVO-436) is a bispecific CD123 x CD3monoclonalantibody. Mipletamig simultaneously binds to both CD3-expressing T cells and CD123-expressing cancer cells, thereby crosslinking CD123-expressing tumor cells and cytotoxic T lymphocytes (CTLs). This results in the activation and proliferation of T-cells and causes CTL-mediated cell lysis of CD123-expressing tumor cells. Mipletamig can be used for the study of acute myeloid leukemia (AML) .
MOR-106 (MOR12743) is a humanized anti-IL-17C IgG1 monoclonalantibody. MOR-106 inhibits the NF-κB signaling pathway by specifically binding to IL-17C (IC50 = 59 pM for human IL-17C, IC50 = 55 pM for mouse IL-17C). MOR-106 can effectively inhibit skin inflammation and reduce related inflammatory factors in animal models of psoriasis and atopic dermatitis .
Cusatuzumab (ARGX-110) is a selective competitive blocker targeting CD70 (with an equilibrium dissociation constant of 17 pM for binding to human CD70). Cusatuzumab also possesses enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. It is a humanized IgG1 monoclonalantibody, artificially synthesized through humanization and genetic engineering modifications (CH2 region mutation to enhance effector function). Cusatuzumab has a dual mechanism of action: firstly, it competitively blocks the interaction between CD70 and CD27, inhibiting the CD27-NF-κB signaling pathway, reducing regulatory T cell (Treg) activation and tumor cell proliferation; secondly, by enhancing binding to FcγRIIIa, it mediates ADCC and antibody-dependent cellular phagocytosis (ADCP), directly lysing CD70-positive tumor cells. Cusatuzumab can efficiently eliminate leukemia stem cells (LSCs), induce tumor cell differentiation and apoptosis, restore immune surveillance, and target CD70-positive tumors. Cusatuzumab is used in the study of acute myeloid leukemia (AML) .
NN3201 is a c-Kit-targeting antibody-drug conjugate (ADC) with high affinity (KD = 0.19 pM). NN3201 is composed of 4-(3-Tosyl-2-(tosylmethyl)propanoyl)benzoic acid-glu(PEG24-Me)-val-cit-NH-benzyloxyformic acid-MMAE (HY-178219) and an anti-c-Kit human monoclonalantibody NN2101 (HY-P991293). NN3201 rapidly internalizes and inhibits stem cell factor (SCF)-driven signaling, thereby delivering its payload to induce cell cycle arrest and apoptosis. NN3201 exhibits no Fc-mediated effector functions antibody-dependent cell-mediated cytotoxicity (ADCC)/complement-dependent cytotoxicity (CDC) due to reduced FcγR binding. NN3201 exhibits significant c-Kit-dependent anti-tumor efficacies in various tumor models. NN3201 can be used in small cell lung cancer (SCLC) and gastrointestinal stromal tumor (GIST) and acute myeloid leukemia (AML) research [1][2].
Precemtabart tocentecan (Precem-TcT; M 9140) is an anti-CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5) antibody-drug conjugate (ADC). Precemtabart tocentecan consists of a tumor-specific anti-CEACAM5 monoclonalantibody Precemtabart (HY-P990940), a highly hydrophilic and stable cleavable β-glucuronide linker, and a topoisomerase 1 inhibitor payload Exatecan (HY-13631), and the drug-linker conjugate for ADC is Mal-Gly-PAB-Exatecan-D-glucuronic acid (HY-153179). Precemtabart tocentecan inhibits the growth of CEACAM5-positive cancer cells. Precemtabart tocentecan exhibits significant antitumor activity in CEACAM5-expressing xenograft models. Precemtabart tocentecan can be used for the study of CEACAM5-expressing advanced solid tumors, especially mCRC .
Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonalantibody containing a modified Fc structure. Talacotuzumab has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models .
Lpathomab (LT3015; LT-3000) is a human IgG1 monoclonalantibody (mAb) targeting LPA. Lpathomab reduces the release of IL-8 and IL-6 cytokines in SKOV3 cells and blocks LPA-triggered tumor cell migration. Lpathomab reduces neovascularization in Matrigel plug and CNV models. Lpathomab inhibits brain injury in the CCI mouse model. Lpathomab can be used in the study of brain injury, ovarian cancer, diabetic neuropathy, and spinal cord injury. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
APG808 (PR001) is an anti-human IL-4Rαmonoclonalantibody. APG808 binds to IL-4Rα, prevents IL-13Rα1/IL-4Rα heterodimer formation, and disrupts IL-13 and IL-4 mediated signaling. APG808 ablates Fc and complement effector functions. APG808 can be used for the research of chronic obstructive pulmonary disease, asthma, atopic dermatitis .
IBI352g4a is a humanized IgG1 monoclonalantibody targeting PVRIG (Kd = 0.53 nM) and acts as a PVRIG/PVRL2 inhibitor. The anti-tumor effect of IBI352g4a depends on the binding of its Fc region to FcγR. IBI352g4a binds to the extracellular domains of human and cynomolgus monkey PVRIG, and blocks the PVRIG-PVRL2 interaction. IBI352g4a induces NK cell activation, promotes their degranulation and tumor killing. IBI352g4a can be used in the research of gastric cancer .
YH004 is an anti-CD137 agonistic monoclonalantibody, with immunostimulating and antineoplastic activities. YH004 activates CD137 expressed on a variety of leukocyte subsets including activated T lymphocytes and natural killer cells. YH004 enhances CD137-mediated signaling and induces cytotoxic T-lymphocyte (CTL) proliferation, cytokine production and promotes anti-tumor response mediated by CTL. YH004 induces NK-mediated tumor cell killing and suppresses the immunosuppressive activity of regulatory T cells. YH004 can be studied in anticancer research .
SAR-443809 is a selective alternative complement system inhibitor and monoclonalantibody targeting complement factor Bb. SAR-443809 blocks the cleavage of C3 and factor B by selectively binding to the activated form of factor Bb, with a KD of 7.3 nM for human factor Bb. SAR-443809 inhibits the amplification loop of the alternative complement pathway and C3 activation, reduces C3b deposition, and blocks the activation of pathways associated with intravascular and extravascular hemolysis. SAR-443809 can be used for the research of hematological and renal disorders mediated by abnormal alternative complement pathway .
Ligelizumab (QGE 031) is a humanized high-affinity anti-immunoglobulin IgEmonoclonalantibody. Ligelizumab selectively inhibits the binding of IgE to the high-affinity receptor FcεRI, while the inhibitory effect on the low-affinity receptor CD23 is weak. Ligelizumab can inhibit the activation of effector cells such as mast cells and Basophil, while reducing the production of IgE by B cells, and restoring the IFN-α production and regulatory T cell (Treg) induction function of plasmacytoid dendritic cells (pDC). Ligelizumab can be used in the study of allergic diseases (such as chronic spontaneous urticaria, allergic asthma) .
MSB-0254 is a human monoclonalantibody (mAb) targeting VEGFR2/KDR/CD309. MSB-0254 inhibits the invasion, migration, and vascular mimetic (VM) formation of U251 and primary glioma cells. MSB-0254 inhibits the growth of U251 and GL261 cell transplanted tumors. MSB-0254 reduces the expression of CD34, VEGFR2, Ki67, MMP2, MMP9, and CD34/PAS. MSB-0254 can be used in advanced solid tumors research .
IO-108 is a humanized IgG4 monoclonalantibody and a competitive inhibitor of LILRB2, with a KD value of 1.97 nM. IO-108 competitively blocks the binding of LILRB2 to its ligands including HLA-G, MHC-I, ANGPTL2 and SEMA4A, reprograms tumor-associated myeloid cells, drives the conversion of suppressive myeloid cells into a pro-inflammatory phenotype, and restores the cytotoxic activity of T cells and NK cells. IO-108 inhibits tumor growth in LILRB2 transgenic mouse models. IO-108 can be used for the research of solid tumors .
Intetumumab (CNTO 95) is a human monoclonalantibody targeting αv integrin, with a Kd value of 1-24 nM. Through high-affinity binding to αv integrin, Intetumumab inhibits its interaction with extracellular matrix proteins (such as vitronectin and fibronectin), thereby blocking the downstream focal adhesion kinase signaling pathway. This further inhibits the adhesion, migration and invasion of tumor cells as well as the proliferation of vascular endothelial cells, promotes cell apoptosis, and exerts anti-tumor and anti-angiogenic effects. Intetumumab can be used in research related to head and neck cancer, non-small cell lung cancer and uterine serous papillary carcinoma .
huAA98 is a humanized monoclonalantibody and also a CD146 inhibitor. huAA98 binds to human CD146, regulates its activity and inhibits cancer-related angiogenesis, as well as tube formation, motility, proliferation and migration of endothelial cells. huAA98 inhibits angiogenesis in the chick chorioallantoic membrane assay and reduces microvessel density in human tumor xenograft models. huAA98 shows immunoreactivity only to neovascular vessels within tumors and inhibits the growth of tumor xenograft models. huAA98 can be used in studies related to cancer-related angiogenesis, liver cancer, leiomyosarcoma and pancreatic cancer .
EOS006215 (EOS-215) is a humanized monoclonalantibody targeting TREM-2. EOS006215 competes with TREM2 ligands, prevents TREM2 multimerization, and blocks downstream signaling. EOS006215 inhibits efferocytosis, reprograms transcriptomic profiles of monocyte-derived macrophages, alters metabolism and immune response genes, and increases pro-inflammatory marker secretion. EOS006215 reduces metastasis burden, delays tumor growth, and reprograms the tumor microenvironment to overcome anti-PD-1 resistance. EOS006215 can be used for the research of triple negative breast cancer and colorectal cancer .
HZD37-5 is a humanized monoclonalantibody specifically recognizing N78 loci of IL-17A. HZD37-5 binds to human and rhesus monkeys, blocks IL-17 induced signal transduction and the release of IL-6, IL-8, CXCL-1 and GM-GSF.HZD37-5 significantly inhibited human IL-17A induced-keratinocyte chemoattractant secretion. HZD37-5 can be used for the research of autoimmune diseases including psoriasis and psoriatic arthritis .
Simtuzumab (AB 0024; GS 6624) is a monoclonalantibody directed against Lysyl oxidase like-2 (LOXL2). Simtuzumab non-competitively blocks collagen cross-linking, reduces LOXL2 protein expression and attenuates extracellular matrix changes. Simtuzumab reduces myocardial fibrosis and prevents cardiac dysfunction. Simtuzumab lowers Myh7 and Nppa gene expression, reduces contraction heterogeneity, and cuts COL1A1 deposition. Simtuzumab can be used for the research of LMNA mutation-induced dilated cardiomyopathy, idiopathic pulmonary fibrosis, and primary sclerosing cholangitis .
DS002 is a human monoclonalantibody targeting NGF/bNGF, with an IC50 of 6.60 nM against human NGF, 1.98 nM against rat NGF, and 8.46 nM against mouse NGF. DS002 blocks NGF-TrkA binding, interrupts pain signal transduction, inhibits TrkA-mediated downstream signaling pathways, and alters aromatic amino acid metabolic pathways. DS002 inhibits cancer cell proliferation. DS002 exerts a preventive effect on Paclitaxel-, Cisplatin- and Vincristine-induced peripheral neuropathy in rats. DS002 can be used in studies related to chronic pain and chemotherapy-induced peripheral neuropathy .
M6903 is a humanized monoclonal IgG2 antibody targeting T cell immunoglobulin and mucin domain-3 (TIM-3) (KD for human TIM-3 is 2.3 nM). M6903 binds to TIM-3, blocking the binding of TIM-3 to phosphatidylserine (PtdSer), carcinoembryonic antigen cell adhesion-related molecule 1 (CEACAM1), and galectin 9 (Gal-9), thus relieving TIM-3-mediated T cell inhibition and exerting the activities of activating antigen-specific T cells and enhancing anti-tumor immunity. M6903 is promising for research of cancers .
IMM20324 is a human monoclonalantibody (mAb) targeting IL38. IMM20324 inhibits the interaction of IL-38 with human IL1RAPL1-Fc and human IL-36R-Fc with IC50 values of 1.267 nM and 1.4667 nM, respectively. IMM20324 has antitumor activity in the B16.F10 syngeneic mouse model. IMM20324 can be used in antitumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
huDMB5F3 (DMB5F3; chDMB5F3) is a human monoclonalantibody against human CD227/MUC1, with a Ka value of 5.89 pM for its human target. huDMB5F3 enters MUC1-positive cancer cells via a temperature-dependent internalization process. huDMB5F3 induces cytotoxicity in MUC1-positive cancer cells. huDMB5F3 can be used in the research of various cancers including breast cancer, pancreatic cancer and gastric cancer .
RKER-216 is a human monoclonal IgG antibody inhibitor targeting ALK2 with a KD of 58.7 pM. RKER-216 reduces hepcidin transcription in Hep3B.RKER-216 competes with BMP ligands for binding to the extracellular domain of ALK2, thereby inhibiting BMP-SMAD signal. RKER-216 mobilizes tissue iron effectively in inflammatory conditions. RKER-216 improves microcytic anemia in a dose-dependent manner by inhibiting SMAD signaling to reduce hepcidin and promote iron absorption and utilization in vivo. RKER-216 can be used for research on anemia of inflammation .
p-SCN-Macropa is a bifunctional macrocyclic chelator featuring macrocyclic polyamine skeletons and thiocyanate (-SCN) reactive moieties. p-SCN-Macropa can conjugate with monoclonalantibodies including Nimotuzumab (HY-P9968), Rituximab (HY-P9913) and Trastuzumab (HY-P9907)-PEG6-DM1 for 225Ac radiolabeling to construct radioimmunoconjugates. p-SCN-Macropa is applicable for the research of colorectal cancer, HER2-positive breast cancer, TROP-2-positive cancers, and PSMA-positive cancers .
Ramantamig (JNJ-79635322) is a humanized monoclonalantibody targeting human CD3ε, GPRC5D, and TNFRSF17 (BCMA). Ramantamig binds to BCMA and GPRC5D on multiple myeloma cells, binds to CD3ε on T cells, forms immunological synapses, and enables T-cell-mediated cytotoxicity. Ramantamig activates T cells concomitantly with inducing myeloma cell cytotoxicity, with no nonspecific T-cell activation in the absence of target myeloma cells. Ramantamig carries mutations to reduce interaction with Fc receptors and disrupt protein A binding of monomeric and homodimerized chains. Ramantamig can be used for the research of multiple myeloma .
1D09C3 is a fully human anti-HLA-DR monoclonalantibody. 1D09C3 induces apoptosis and cell death involving a cascade of events, including ROS generation, JNK activation, mitochondrial membrane depolarization, and AIF release from mitochondria. 1D09C3 shows potent anti-tumor activity and increases overall survival and median survival in JVM-2 cells and GRANTA-519 cells xenograft mice models. 1D09C3 can be used for the researches of cancer, such as chronic lymphocytic leukemia (CLL) .
ADEL-Y01 is a humanized and parental murine blood-brain barrier-penetrating monoclonalantibody against tau-acK280. ADEL-Y01 specifically recognizes tau-acK280 and its surrounding residues, mediates the neutralization and phagocytosis of acetylated tau aggregates, and interferes with the activity of pathological tau protein. ADEL-Y01 prevents the progression of tauopathies, increases neuronal survival rate, reduces tau-related pathological changes, and improves memory impairment. ADEL-Y01 can be used in research related to Alzheimer's disease and tauopathies .
IPH5201 is a selective CD39 inhibitor and a humanized IgG1 monoclonalantibody. IPH5201 selectively binds to and inhibits the enzymatic activity of both membrane-bound and soluble CD39, blocking ATP hydrolysis. IPH5201 enhances the phenotypic maturation and activation of dendritic cells and macrophages. IPH5201 potentiates the anti-tumor effect of Oxaliplatin (HY-17371). IPH5201 shows preliminary evidence of disease stabilization in advanced solid tumor models when used as a single agent or in combination with Durvalumab (HY-P9919). IPH5201 can be used for the research of advanced solid tumors .
GC1118 (GC-1118A) is a fully human anti-EGFRmonoclonalantibody with binding affinity of 0.16 nM (KD) to EGFR. GC1118 displays potent inhibitory effects on high- and low-affinity EGFR ligand-induced signaling. GC1118 shows potent anti proliferative activity in KRAS wild-type and KRAS mutant cells. GC1118 can reach the tumor by crossing both BBB (blood-brain barrier) and BTB (brain-tumor barrier) and shows superior anti-tumor effects in various mice xenograft models. GC1118 can be used for the researches of cancer, such as colorectal cancer .
HuGAL-FR21 is a humanized antiFGFR2IIIb IgG1 monoclonalantibody. HuGAL-FR21 can block the binding of FGF2, FGF7, and FGF10 to FGFR2IIIb and inhibit FGF-induced phosphorylation of FGFR2IIIb. HuGAL-FR21 can downregulate the expression of FGFR2 in SNU-16 cells. HuGAL-FR21 shows the significant anti-tumor activity in athymic nude mice bearing gastric cancer xenograft models. HuGAL-FR21 can be used for research on cancer such as gastric cancer .
Anti-Mouse CXCR4 Antibody is a monoclonalantibody that specifically recognizes murine CXCR4 (C-X-C chemokine receptor 4), also known as fusin or CD184. CXCR4 is a seven-transmembrane G protein–coupled receptor whose principal endogenous ligand is CXCL12 (stromal cell–derived factor-1α, SDF-1α) and is widely expressed in hematopoietic cells, endothelial cells, neurons, as well as embryonic and adult stem cells. The CXCR4–CXCL12 signaling axis activates multiple downstream pathways, including ERK1/2, Ras, p38 MAPK, PLC/MAPK, and SAPK/JNK, thereby regulating cell survival, proliferation, migration, and stemness maintenance. Aberrant overexpression of CXCR4 is closely associated with poor prognosis and metastasis in various cancers, with CXCR4-positive tumor cells preferentially home to CXCL12-rich tissues such as the liver, bone marrow, lung, and lymph nodes. Accordingly, CXCR4 and its CXCL12-related antagonists emerge as attractive targets for experimental anticancer therapy. Anti-Mouse CXCR4 Antibody is generated using a cell-based immunization and screening strategy and exhibits high affinity for both endogenous and exogenous murine CXCR4. Anti-Mouse CXCR4 Antibody can be used for thestudy of chronic lymphocytic leukemia and multiple myeloma .
MOR102 is a fully human IgG4 monoclonalantibody and an ICAM-1 inhibitor, lacking cross-reactivity with ICAM-2 and ICAM-3.MOR102 binds to the LFA-1 binding site within ICAM-1 domain 1, blocks ICAM-1/LFA-1 interaction, binds human keratinocytes with increased binding to interferon-γ-stimulated keratinocytes. MOR102 inhibits lymphocyte adhesion, reduces lymphocyte proliferation, prevents local T-cell activation, reduces inflammatory infiltrate, restores orthokeratotic differentiation, and reduces epidermal thickness. MOR102 can be used for the research of psoriasis .
Riliprubart (SAR 445088) is an anti-C1s humanized IgG4 monoclonalantibody that inhibits activated C1s in the proximal portion of the classical complement system. Riliprubart selectively inhibits activated C1s and prevents the enzymatic action of C1 on its substrates C4 and C2, thus inhibiting the formation of the classical pathway C3 convertase, C4b2a. Riliprubart can be used to study complement-mediated diseases such as systemic lupus erythematosus. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
Daclizumab (Ro 24-7375) is a humanized, monoclonalantibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab inhibits effector T cell activation, regulatory T cell (Treg) expansion and survival, and activation-induced T-cell apoptosis. Daclizumab increases IL-2 bioavailability to bind to the intermediate-affinity IL-2R (IL-2R-IA), driving the expansion of anti-inflammatory CD56bright natural killer (NK) cells. Daclizumab can be used for multiple sclerosis and cancer research .
Ianalumab (VAY-736) (FUT8-KO) is an anti-BAFF-Rmonoclonalantibody expressed in CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose depletion enhances its B cell clearance capacity. Ianalumab (FUT8-KO) competitively blocks the binding of BAFF to BAFF-R, inhibits the BAFF-mediated alternative NF-κB pro-survival signaling pathway, and abrogates the apoptotic (apoptosis) protective effect of BAFF on cancer cells. Ianalumab (FUT8-KO) can be used in research related to primary Sjögren's syndrome and chronic lymphocytic leukemia .
XOMA-213 (LFA-102; X213) is a human monoclonalantibody (mAb) targeting the prolactin receptor (PRLR), with a Kd value of 2 nM against the human target. XOMA-213 blocks PRL-induced cell proliferation and inhibits the activation of multiple PRLR ligands, including PRL and human growth hormone (hGH). XOMA-213 suppresses PRL-induced phosphorylation of Stat5, Akt and ERK1/2 in cells. XOMA-213 induces tumor regression, delays disease progression, and inhibits PRLR signaling as well as tumor growth. XOMA-213 can be used in research related to breast cancer .
AMY109 is an anti-human interleukin-8 (IL-8)monoclonalantibody, with a Ka of 36.8 pM for human IL-8, and a Ka of 380 pM for cynomolgus monkey IL-8. AMY109 binds to human and cynomolgus monkey IL-8 in a pH-dependent manner, inhibits IL-8-mediated activation of CXCR1 and CXCR2, and blocks the downstream biological activities of IL-8. AMY109 inhibits neutrophil recruitment to endometriotic lesions and suppresses monocyte chemoattractant protein-1 production by neutrophils. AMY109 is applicable to research related to endometriosis .
IBC-Ab002 is a humanized anti-PD-L1monoclonalantibody with a modified Fc backbone that shortens its circulating half-life. IBC-Ab002 inhibits PD-L1, triggers immune responses by blocking the PD-1/PD-L1 pathway, promotes the recruitment of myeloid-derived immune cells to the brain, enhances the clearance of toxic substances in the brain, improves neuronal function and reduces inflammation. IBC-Ab002 reduces the risk of accelerated onset of autoimmune diabetes in susceptible mice. IBC-Ab002 can be used in research related to Alzheimer's disease .
Omburtamab is a humanized monoclonalantibody targeting B7-H3 (CD276). Omburtamab selectively binds to B7-H3 highly expressed on the surface of tumor cells and activates anti-tumor immune responses mediated by T cells and natural killer (NK) cells. Omburtamab can promote the specific infiltration of CAR-T cells into tumors, enhance the killing function of NK cells through the CD16 signaling pathway, and regulate tumor cell glucose metabolism (such as inhibiting the Warburg effect). Omburtamab has the potential to inhibit solid tumors such as non-small cell lung cancer (NSCLC) .
COM503 is a high-affinity anti-IL18BP human monoclonalantibody with a Kd value of 0.291 pM. COM503 binds to IL18BP, blocks the IL18BP:IL18 interaction, displaces IL18 from preformed complexes, and enhances the activation and function of T cells and NK cells. COM503 induces anti-tumor effects by relieving the activity inhibition of endogenous IL18 in the tumor microenvironment. COM503 can be used for cancer research. The recommended isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
Rademikibart (CBP-201) is a human monoclonalantibody targeting IL-4Rα and IL-4Rα inhibitor with a KD of 20.7 pM when binding to human IL-4Rα epitopes . Rademikibart does not bind to IL-4Rα from other species. Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation and thymus activation regulated chemokine (TRAC) production. Rademikibart can be used for the research of atopic dermatitis and asthma .
DPAP is a p-ERK1/2 inhibitor with an IC50 of 7.85 μM against p-ERK1/2. DPAP inhibits the expression of p-MEK1/2 and disrupts the Ras-ERK signaling pathway. DPAP inhibits the expression of COX-2 in nerve cells. DPAP damages DNA and mitochondria, induces Apoptosis via the mitochondrial pathway, and upregulates PD-L1. DPAP inhibits melanoma metastasis and angiogenesis, and inactivates spinal microglia and astrocytes. DPAP exhibits anti-melanoma activity and can be combined with anti-PD-1monoclonalantibodies to modify anti-tumor effects. DPAP is applicable for the research of melanoma .
Posdinemab (JNJ-63733657) is a humanized IgG1/κ monoclonalantibody that selectively targets phosphorylated tau (pT217). Posdinemab specifically binds to the pT217+tau epitope rich in the proline domain, blocks tau protein aggregation and seed propagation, and promotes the clearance of extracellular tau species. Posdinemab reduces the levels of free and total p217+tau in cerebrospinal fluid, thereby inhibiting the pathological propagation of tau protein and the formation of neurofibrillary tangles. Posdinemab can be used for the study of progressive supranuclear palsy syndrome and Alzheimer's disease (AD), especially for prodromal or mild AD disease .
N-Phthaloylglycine (Phthaloyl glycine) is a Type II fragmentary hapten (FX-type) with antimicrobial activity.N-Phthaloylglycine acts against Candida albicans, Escherichia coli, and Staphylococcus epidermidis.N-Phthaloylglycine can be used for the research of fungal and bacterial infection .
AMD 3329 octahydrobromide is a potent and selective anti-HIV-1 and HIV-2 compound with activity to inhibit viral replication. AMD 3329 blocks viral invasion by binding to the chemokine receptor CXCR4. AMD 3329 exhibits EC50 values as low as 0.8 and 1.6 nM when inhibiting HIV-1 and HIV-2 replication, showing better antiviral efficacy than AMD3100. AMD 3329 significantly inhibits the binding of specific CXCR4 monoclonalantibodies and the Ca(2+) flux induced by SDF-1alpha. AMD 3329 is also able to effectively interfere with virus-induced syncytium formation, with an EC50 value of 12 nM .
PF-03475952 is a fully human IgG2 monoclonalantibody targeting CD44. PF-03475952 binds an epitope in CD44’s constant exons, blocks CD44-hyaluronic acid interaction, reduces cell surface CD44, and does not cross-react with rodent CD44 or LYVE-1. PF-03475952 induces cancer cell apoptosis, inhibits LPS (HY-D1056)-induced leukocyte cytokine release and cancer metastasis, and reduces CD44 expression on circulating CD3+ lymphocytes in cynomolgus monkeys. PF-03475952 can be used for the research of rheumatoid arthritis and hepatocellular carcinoma .
ZL-1201 is a recombinant humanized monoclonalanti-CD47 IgG4 antibody. ZL-1201 disrupt the CD47-SIRPα interaction. ZL-1201 modulates the tumor microenvironment. ZL-1201 promotes tumor-associated macrophage phagocytic activity. ZL-1201 substantially enhances phagocytosis by M2 macrophages, but not by M1 macrophages. ZL-1201 in combination with both mAb and chemotherapy achieves the maximal antitumor effects in a variety of solid tumor models. ZL-1201 can be used in the study of lymphoma, breast cancer, ovarian cancer, head and neck squamous cell carcinoma, and gastric cancer .
Stapokibart (CM310) is a humanized monoclonalantibody targeting IL-4Rα (KD values of 0.25 nM, 1.50 nM, and 2.75 nM for human, cynomolgus monkey, and rat IL-4Rα, respectively). Stapokibart effectively blocks the interaction of cytokines IL-4 and IL-13 with their co-receptor subunit IL-4Rα. Stapokibart reduces IL-4 and IL-13 mRNA, inhibits CD23 upregulation, and inhibits IL-4 and IL-13-induced STAT6 activation. Stapokibart improves inflammation (airway inflammation, rhinitis, dermatitis) .
GENA-104A16 is a humanized monoclonalantibody targeting CNTN4, with multiple functions including immunostimulation, cytotoxicity and immunoregulation. By binding to CNTN4, GENA-104A16 blocks its interaction with APP, thereby restoring T cell function, inducing tumor cell death and regulating tumor-infiltrating immune cell populations. GENA-104A16 also exerts topoisomerase I inhibitory activity via the payload Exatecan (HY-13631). GENA-104A16 can be used in research related to colon cancer liver metastasis and other CNTN4-expressing solid tumors .
CTB006 is a monoclonalantibody targeting a humanized chimeric recombinant anti-DR5. CTB006 specifically binds to and activates DR5, thereby inducing tumor cell apoptosis, inhibiting tumor growth and reducing tumor drug resistance. 177Lu-radiolabeled CTB006 can deliver targeted radiotherapy to tumor cells; while 89Zr- or 177Lu-labeled CTB006 can serve as a PET/CT imaging agent for detecting DR5 expression levels in preclinical tumor models and screening cancers with DR5 overexpression. CTB006 can be applied to research related to gastrointestinal cancer, colorectal cancer and other solid tumors .
IC 100 is a humanized IgG4κ monoclonalantibody targeting apoptosis-associated speck-like protein (ASC) with blood-brain barrier permeability. IC 100 specifically inhibits ASC after being endocytosed via its Fc segment, blocks ASC polymerization and inflammasome activation, suppresses IL-1β release, forms complexes with ASC and TRIM21, and evades TRIM21-mediated proteasomal degradation. IC 100 alleviates symptoms associated with autoimmune encephalomyelitis, reduces immune cell infiltration and microglial activation in the mouse EAE model. IC 100 is suitable for research on neuroinflammatory and inflammasome-related diseases such as multiple sclerosis. Isotype comparison: HY-P99003 .
OSE-279 is a high-affinity humanized monoclonal bivalent antibody targeting PD-1, the recommended isotype control is HY-P99003. OSE-279 blocks PD-1 ligand binding, inhibits PDL1-induced SHP1 phosphorylation, restores T cell activation, and promotes reactivation of primary T cell effector functions. OSE-279 binds hFcRn receptor, predicts long half-life, induces CD4 and CD8 T cell proliferation, and promotes interleukin 2 and interferon gamma secretion. OSE-279 can be used for the research of advanced malignancies, colon cancer, hepatocarcinoma, mesothelioma .
Emfizatamab (GNC-038) is a monoclonalantibody against CD19/CD3E/TNFRSF9/PD-L1. Emfizatamab exhibits antitumor activity, being capable of activating CD3 and 4-1BB signals on T cells, as well as targeting the high expression of CD19 or PD-L1 on tumor cells. Emfizatamab functions as a CD19-specific T cell engager by mediating direct antitumor activity. Emfizatamab can also overcome the inhibition of T cells by PD-L1. Emfizatamab can be used in the research of tumors such as R/R non-Hodgkin lymphoma or acute lymphoblastic leukemia .
Sintilimab (Anti-PD-1) (IBI308 (Anti-PD-1)) is a safe and effectivel humanized IgG4monoclonalantibody that binds to PD-1 with a KD value of 74 pM. Sintilimab (Anti-PD-1) blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab (Anti-PD-1) combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab (Anti-PD-1) can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .
Tepoditamab (MCLA-117) is a full-length human IgG1 bispecific monoclonalantibody that binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Among others, CLEC12A is a myeloid differentiation antigen. Tepoditamab kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells. Tepoditamab induces upto 30-fold T-cell expansion. Tepoditamab results in moderate to strong cytokine (IFNγ, IL-6, IL-8, IL-10, and TNFα) and IFNγ release in human whole blood and PBMC, respectively. Tepoditamab can be used in acute myeloid leukaemia (AML) research .
Vixticibart (REGN-5381) is a fully human IgG4 monoclonalantibody and NPR1 agonist that targets NPR1. Vixticibart stabilizes the receptor in an activated conformation by binding to the N-terminal domain of NPR1, and enhances the activity of endogenous ligands ANP and BNP without blocking ligand binding when these ligands are present. Vixticibart exerts vasodilatory and hypotensive effects by inducing cGMP production, preferentially dilating venous vessels to reduce systolic and venous pressure, but does not induce diuresis and may trigger a compensatory increase in heart rate. Vixticibart produces a synergistic hypotensive effect when combined with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and is currently mainly used in research related to heart failure and hypertension .
Alirocumab (anti-PCSK9) is an anti-PCSK9 human monoclonalantibody. Alirocumab (anti-PCSK9) inhibits PCSK9. Alirocumab (anti-PCSK9) reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab (anti-PCSK9) increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab (anti-PCSK9) improves atherosclerosis and inflammation .
Imneskibart (AU-007) is a human monoclonalantibody that binds to the CD25-binding epitope of interleukin-2 (IL-2), blocking the binding of IL-2 to the trimeric IL-2 receptor while retaining the ability to bind to the dimeric IL-2 receptor. Imneskibart expands effector T cell and NK cell populations, reduces regulatory T cells, increases the effector T cell/regulatory T cell ratio, and alleviates vascular leakage. Imneskibart can be used in research related to melanoma and non-small cell lung cancer. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .
RC98 is a monoclonalantibody targeting programmed cell death ligand 1 (PD-L1) and acts as a selective PD-L1 inhibitor. RC98 binds specifically to human and cynomolgus monkey PD-L1. RC98 blocks the interaction between PD-L1 and its receptor PD-1 to reverse T-cell inactivation mediated by PD-1/PD-L1 signaling. RC98 enhances the cytotoxic T-lymphocyte-mediated anti-tumor immune response against PD-L1-expressing tumor cells. RC98 can be used for the research of tumor immunity and solid tumors .
DS-3939a (DS-3939) is an anti-TA-MUC1(tumor-associated mucin-1) antibody-drug conjugate (ADC). DS-3939a consists of a humanized anti-TA-MUC1 IgG1 monoclonalantibody Gatipotuzumab ( HY-P99634), a stable and cleavable tetrapeptide-based linker (Gly-Gly-Phe-Gly), and a DNA topoisomerase I inhibitor payload (DXd) (HY-13631D), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). DS-3939a inhibits the growth of TA-MUC1-positive cancer cells (CFPAC-1, NCI-H2110) by inducing DNA damage and apoptosis. DS-3939a exhibits significant antitumor activity in a variety of TA-MUC1-expressing advanced solid tumors. DS-3939a can be used for the study of TA-MUC1-expressing advanced cancers .
mAb-AsnAsn-E104 is a conjugate of an ADC drug toxin molecule and a linker, which contains a degradable PEG linker and the toxin molecule E104 (HY-156174) .
Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonalantibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC50s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis) .
JST‑TfR09 (PPMX‑T003) is a human monoclonalantibody (mAb) targeting transferrin receptor 1 (TfR1/CD71). JST‑TfR09 blocks the binding of transferrin to TfR1, inhibits TfR1 internalization, and suppresses cellular iron uptake. JST‑TfR09 triggers ferritin degradation via activating the autolysosomal system, promotes ROS production and lipid peroxidation, and ultimately induces ferroptosis. JST‑TfR09 exhibits cytotoxicity toward human erythroblasts differentiated from hematopoietic stem cells. JST-TfR09 can be used in leukemia research. Recommended isotype control: Human IgG1 lambda, Isotype Control (HY-P99992) .
Hydrotecan-NH-L-Ala-L-Val-L-Gln(CO-C5-succinimide)-D-glucitol (Example 9) is a conjugate of the ADC toxic molecule and the linker, where the toxic molecule part is Hydrotecan (HY-164378), and the linker part is Mc-Glu(D-Glucamine)-val-ala (HY-178309) .
JMW-3B3 is a humanized IgG1λ monoclonalantibody targeting CTLA-4. JMW-3B3 selectively binds the unique C-terminal sequence of sCTLA-4 to block its immunoregulatory and immunosuppressive activity without cross-reacting with full-length CTLA-4 receptor. JMW-3B3 enhances cytokine profiles in PBMC cultures responding to lupus autoantigen-derived peptides. JMW-3B3 enhances IFN-γ production in anti-CD3 stimulated PBMC from melanoma patients at low anti-CD3 doses. JMW-3B3 can be used for the research of systemic lupus erythematosus and malignant melanoma.
Volrustomig (MEDI-5752) is a human IgG1 κ monoclonalantibody targeting CTLA4/PD1. The isotype control for Volrustomig is Human IgG1 kappa, Isotype Control (HY-P99001). Volrustomig anchors to the surface of T cells by binding PD-1, induces PD-1 internalization and degradation, and preferentially inhibits CTLA-4 on activated PD-1 + T cells. Volrustomig binds to tumor-infiltrating lymphocytes and a subset of PD-1 + B cells, enhances T cell function and IFNγ secretion. Volrustomig reduces the activation of non-tumor-infiltrating lymphocytes and exhibits manageable toxicity. Volrustomig can be used in research on various cancers, such as non-small cell lung cancer, gastric cancer, hepatobiliary cancer, and cervical cancer .
NGM-438 is a humanized monoclonalantibody antagonist of LAIR1, with a Ka of 0.26 nM for human LAIR1 and 4.28 nM for cynomolgus monkey LAIR1. NGM-438 blocks the binding of LAIR1 to its Collagen ligand and antagonizes the Collagen-induced LAIR1 signaling pathway. NGM-438 reverses FcγR signaling inhibition in myeloid cells, induces dendritic cells to secrete TNFα, promotes T cell proliferation, and triggers myeloid inflammation and allogeneic T cell responses. NGM-438 sensitizes refractory mouse lung cancer to PD-1 blockade, increases the content of intratumoral CD8 + T cells and the expression of inflammatory genes. NGM-438 is applicable to research related to solid tumors, refractory solid tumors and non-small cell lung cancer .
MEDI-579 is a fully human monoclonalantibody against PAI-1, with a KD value of 6 pM for human PAI-1 and 105 pM for rat PAI-1. MEDI-579 restores renal plasmin activity and inhibits PAI-1-mediated intracellular signal transduction. MEDI-579 reduces albuminuria, glomerulosclerosis severity, TGF-β1 expression level, and phosphorylated Smad2 level induced in diabetic mice. MEDI-579 decreases the levels of active PAI-1 in plasma and kidneys, and increases plasma plasmin level in a mouse model of lupus nephritis. MEDI-579 can be used in research related to diabetic nephropathy and lupus nephritis. The recommended isotype control is human IgG1 kappa (HY-P99001) .
IMC-EB10 (LY3012218) is an anti-FLT3monoclonalantibody. IMC-EB10 binds to FLT3 with high affinity (Kd = 158 pM) and blocks the binding of FLT3 ligand to FLT3 (IC50 ≈ 10 nM), thereby inhibiting MAPK, STAT5, and PI3K/Akt signaling in leukemia cells. IMC-EB10 can enhance the anti-leukemic effect of Methotrexate (HY-14519) and inhibit leukemias expressing wild-type or ITD-mutated FLT3 receptors. IMC-EB10 prolongs the survival of acute lymphoblastic leukemia (ALL) cells and primary leukemia samples and reduces engraftment in non-obese diabetic/severe combined immunodeficiency patients. IMC-EB10 is indicated for leukemia research .
GSK1995057 is a human monoclonalantibody (mAb) targeting TNFRSF1A. GSK1995057 selectively binds to TNFR1, blocks the binding of TNF-α and LT-α, and does not interfere with TNFR2 signaling. GSK1995057 inhibits the activation of NF-κB, JNK and MAPK pathways, alleviates apoptosis (apoptosis) and inflammatory responses (inhibiting IL-1β, IL-6, IL-10, TNF-α), and prevents viability loss of human nucleus pulposus cells. GSK1995057 inhibits the expression of cytokines and neutrophil adhesion molecules in human pulmonary microvascular endothelial cell monolayers, and reduces inflammatory responses and lung injury symptoms in non-human primates. GSK1995057 forms complexes with HAVH autoantibodies, thereby activating TNFR1 and triggering the release of cytokines and IL-8 in human cells. GSK1995057 can be used in research related to intervertebral disc degeneration and acute lung injury .
Tetracycline/BSA is a tetracycline-carrier protein conjugate of Tetracycline (HY-A0107) and bovine serum albumin (BSA). Tetracycline/BSA can be used as an immobilized capture antigen for the detection of tetracycline residues in milk .
Natalizumab (AN100226; BG00002) is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d). It blocks the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 + T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thus exerting anti-inflammatory and immunomodulatory activity. Natalizumab is used in the study of relapsing-remitting multiple sclerosis (RRMS) and also has applications in the study of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab can also prevent lymphocytes from entering the central nervous system, thereby preventing acute demyelinating relapses .
P2X7R antagonist-1 is an orally active P2X7 receptor antagonist with an IC50 of 3.57 μM. P2X7R antagonist-1 inhibits the proliferation, invasion and metastasis abilities of cancer cells. P2X7R antagonist-1 downregulates the expression of FAK and MMP-9. P2X7R antagonist-1 suppresses tumor growth and metastasis in a mouse breast cancer model. P2X7R antagonist-1 promotes the activation of CD4 and CD8 T cells. P2X7R antagonist-1 can be used in breast cancer-related research .
8-Bromo-2'-deoxyguanosine- 13C, 15N2 is the 13C- and 15N-labeled 8-Bromo-2'-deoxyguanosine (HY-W011168). 8-Bromo-2'-deoxyguanosine is an inflammation-related DNA halogenated adduct and an early biomarker of inflammation-induced oxidative tissue damage. The formation of 8-Bromo-2'-deoxyguanosine precedes that of oxidative and nitrative products, and it can be generated via the MPO-H2O2-Cl --Br - system. 8-Bromo-2'-deoxyguanosine serves as the immunogen for preparing the monoclonalantibody mAb8B3, which can be used to detect early DNA modifications in preclinical models; its urinary level also increases significantly in inflammatory disease models. 8-Bromo-2'-deoxyguanosine can also be produced in the dermis of UV-B irradiated mice, and the extract of Coprinus comatus significantly reduces its level. 8-Bromo-2'-deoxyguanosine finds applications in studies related to inflammatory diseases, diabetes, hepatocellular carcinoma, and UV-B induced skin inflammation .
Lipopolysaccharides, from E. coli (Escherichia coli) O26:B6 are lipopolysaccharide endotoxins and TLR-4 activators derived from E. coli, classified as S-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from E. coli O26:B6 exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A, and can be recognized by the core-specific monoclonalantibody MAb J8-4C10. Lipopolysaccharides, from E. coli O26:B6 can promote an increase in pro-inflammatory cytokines in plasma, thereby triggering hypothalamic-pituitary-adrenal (HPA) activation and leading to adrenal oxidative damage. The pathogenic effects of Lipopolysaccharides, from E. coli O26:B6 can be used to construct various models, such as cellular inflammation models, sepsis, acute lung injury models, adrenal dysfunction models, and bladder infection models, etc .
It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.
ANX-M1 is a blood-brain barrier-permeable anti-C1q antibody. ANX-M1 can slow down the progression of retinal degeneration following photo-oxidative damage. ANX-M1 has been incorporated into nanocarriers to evaluate its brain delivery efficacy in a mouse model of Alzheimer's disease. ANX-M1 is applicable for research on age-related macular degeneration and Alzheimer's disease [1] .
Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecular targets that are involved in the growth, progression, and spread of cancer.
There are several different types of targeted therapy. The most common types are small-molecule drugs and monoclonalantibodies. Small-molecule drugs are small enough to enter cells easily, so they are used for targets that are inside cells, while monoclonalantibodies are usually used for targets that are located outside the cells. Because of high specificity, low side effect and potent anticancer activity, targeted therapy has become the mainstream of new anti-tumor drugs. Various targeted therapies have been approved by FDA and used in the treatment of diseases.
MCE carefully collects a unique of 108 targeted therapy drugs used in cancer treatment. MCE Targeted therapy drug library is a useful tool for the research of targeted therapy.
Antibody-Drug Conjugates (ADCs), a new class of treatment for cancer, are composed with a monoclonalantibody, a linker and a cytotoxic agent also referred to as a payload. To date, several ADCs have received market approval and more than 60 ADCs are currently in clinical trials. ADCs are one of the fastest growing classes of oncology drugs worldwide.
The payload or cytotoxic agent is the most important unit in the ADC. ADC has the capability to kill cancer cell depending on the potency of the payload. MCE provides 115 highly potent cytotoxins that contain auristatin derivatives, maytansinoids, calicheamicin, duocarmycin, pyrrolobenzodiazepines (PBDs), etc.
Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonalantibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines.
MCE Small Molecule Immuno-Oncology Compound Library offers 783 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.
Enfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .
Ifinatamab deruxtecan (DS-7300a) is a B7-H3-targeting Antibody-drug conjugate (ADC), which is composed of a humanized anti-B7-H3 monoclonalantibody, an enzymatically cleavable peptide-based linker, and Exatecan derivative (DXd) (HY-13631D). Ifinatamab deruxtecan is a DNA Topoisomerase I inhibitor. Ifinatamab deruxtecan induces Apoptosis. DS-7300a exerts potent antitumor activities against B7-H3-expressing tumors. against rhabdomyosarcoma, endometrial adenocarcinoma and lung adenocarcinoma. Ifinatamab deruxtecan does not exert direct immunomodulatory effects
Telisotuzumab vedotin (ABBV-399) (Teliso-V) is an anti-c-Metantibody-drug conjugate. Telisotuzumab vedotin consists of an anti-c-Met monoclonalantibody Telisotuzumab (ABT-700) (HY-P99391) and Monomethyl Auristatin E (HY-15162). Telisotuzumab vedotin exerts antitumor activity with acceptable toxicity in vivo. Telisotuzumab vedotin can be used for non-small cell lung cancer (NSCLC) research .
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonalantibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL) .
ADC Control Human IgG1-vcMMAE (solution) is a humanized monoclonalantibody that is an isotype control of ADC human IgG1-vcMMAE and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is vcMMAE (HY-15575) .
ADC Control Human IgG1-Deruxtecan (DAR 8) is a humanized monoclonalantibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
Cetuximab MMAE is an antibody-drug conjugate (ADC) consisting of the EGFR-targeting humanized monoclonalantibody Cetuximab (HY-P9905) conjugated to VcMMAE (HY-15575). Cetuximab MMAE exhibits antitumor activity .
Becotatug vedotin (MRG003) is an Antibody-Drug Conjugate (ADC) that consists of an anti-EGFR humanized IgG1 monoclonalantibody Becotatug (HY-P990049) and MMAE (HY-15162). These two parts are connected through a valine-citrulline (valine-citrulline) linker, where the linker and MMAE constitute the ADC's Drug-Linker conjugate VcMMAE (HY-15575) .
ADC Control Human IgG1-Deruxtecan (DAR 4) is a humanized monoclonalantibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
Precemtabart tocentecan (Precem-TcT; M 9140) is an anti-CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5) antibody-drug conjugate (ADC). Precemtabart tocentecan consists of a tumor-specific anti-CEACAM5 monoclonalantibody Precemtabart (HY-P990940), a highly hydrophilic and stable cleavable β-glucuronide linker, and a topoisomerase 1 inhibitor payload Exatecan (HY-13631), and the drug-linker conjugate for ADC is Mal-Gly-PAB-Exatecan-D-glucuronic acid (HY-153179). Precemtabart tocentecan inhibits the growth of CEACAM5-positive cancer cells. Precemtabart tocentecan exhibits significant antitumor activity in CEACAM5-expressing xenograft models. Precemtabart tocentecan can be used for the study of CEACAM5-expressing advanced solid tumors, especially mCRC .
DS-3939a (DS-3939) is an anti-TA-MUC1(tumor-associated mucin-1) antibody-drug conjugate (ADC). DS-3939a consists of a humanized anti-TA-MUC1 IgG1 monoclonalantibody Gatipotuzumab ( HY-P99634), a stable and cleavable tetrapeptide-based linker (Gly-Gly-Phe-Gly), and a DNA topoisomerase I inhibitor payload (DXd) (HY-13631D), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). DS-3939a inhibits the growth of TA-MUC1-positive cancer cells (CFPAC-1, NCI-H2110) by inducing DNA damage and apoptosis. DS-3939a exhibits significant antitumor activity in a variety of TA-MUC1-expressing advanced solid tumors. DS-3939a can be used for the study of TA-MUC1-expressing advanced cancers .
Sulfonylurea Receptor HRP-Streptavidin is a biotin-binding signal amplifier designed to bind tightly with biotinylated anti-TSH monoclonalantibodies, thereby constituting a key component of the signal amplification system in immunoassays. HRP-Streptavidin is formed by the covalent coupling of Horseradish Peroxidase (HRP) with Streptavidin; it combines the highly efficient catalytic activity of the enzyme with the high affinity of Streptavidin for biotin, making it a potent and sensitive tool for signal amplification. HRP-Streptavidin is suitable for use in Western Blotting, ELISA, and other detection techniques .
AZD0516 is a first-in-class antibody-drug conjugate (ADC) targeting six-transmembrane epithelial antigen of the prostate-2 (STEAP2). The anti-STEAP2 monoclonalantibody (mAb) is conjugated via interchain cysteines to a maleimide-reactive, β-glucuronidase-cleavable linker (HY-173635) bearing the topoisomerase 1 inhibitor, Exatecan (HY-13631). AZD0516 can be used for the study of prostate cancer .
Polatuzumab vedotin solution is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonalantibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin solution has the potential for the research of Large B-cell lymphomas (LBCL) .
M3554 is an anti-GD2 antibody-drug conjugate (ADC) based on the humanized anti-GD2 antibody. M3554 consists of the humanized monoclonalantibody hu14.18 (K322A) (HY-P991040) linked to a topoisomerase 1 inhibitor Exatecan (HY-13631) via a cleavable β-glucuronide linker. M3554 can be used for the study of neuroblastoma, osteosarcoma or glioma .
ADC Control Human IgG1-vcMMAF is a humanized monoclonalantibody that is an isotype control of ADC human IgG1-vcMMAF and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is MC-Val-Cit-PAB-MMAF (vcMMAF; HY-112786) .
Depatuxizumab MMAE is an antibody-drug conjugate (ADC) comprising an antiEGFRmonoclonalantibody (Depatuxizumab) (HY-P99849) and the cytotoxic agent Monomethyl auristatin E (MMAE) (HY-15162). Depatuxizumab MMAE can be used for the study of EGFR-expressing advanced solid tumors.
REGN5093-M114 is a bispecific antibody-drug conjugate (ADC) that targets two epitopes of the MET receptor tyrosine kinase inhibits the proliferation of NSCLC cells, exhibits antitumor efficacy in mouse models. REGN5093-M114 is composed of the human monoclonalanti-MET antibody Davutamig (HY-P990073) and the tubulin-inhibiting linker-payload (HY-148528) .
PE-Cy5 is a tandem fluorescent dye commonly used in flow cytometry, immunofluorescence, and cell biology research. It is formed by the covalent linkage of two fluorescent molecules, namely phycoerythrin and CY5. PE-Cy5 binds to human FcγRI (CD64), and this binding can be blocked by human pooled serum, anti-CD64 monoclonalantibodies targeting the ligand-binding region, or aggregated IgG. PE-Cy5 supports three-color flow cytometry analysis, and whole blood staining can partially reduce its non-specific binding (Ex/Em = 450-500 nm/665 nm) .
PE-CF594 is a labeled monoclonalantibody conjugate that specifically binds to HLA-DR on the surface of monocytes and B cells, while acting as a signal attenuator. Through steric hindrance and a possible fluorescence resonance energy transfer mechanism, PE-CF594 specifically reduces the fluorescence intensity of PE-CD124 staining, but does not interfere with the staining of other PE-labeled antibodies such as CD40, CD4 or CD14. PE-CF594 can also be used to detect the emission signal of mt-Keima after excitation with a 561-nm laser, thereby effectively evaluating mitophagy activity .
Lipopolysaccharides, from E. coli (Escherichia coli) O26:B6 are lipopolysaccharide endotoxins and TLR-4 activators derived from E. coli, classified as S-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from E. coli O26:B6 exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A, and can be recognized by the core-specific monoclonalantibody MAb J8-4C10. Lipopolysaccharides, from E. coli O26:B6 can promote an increase in pro-inflammatory cytokines in plasma, thereby triggering hypothalamic-pituitary-adrenal (HPA) activation and leading to adrenal oxidative damage. The pathogenic effects of Lipopolysaccharides, from E. coli O26:B6 can be used to construct various models, such as cellular inflammation models, sepsis, acute lung injury models, adrenal dysfunction models, and bladder infection models, etc .
It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.
Deferoxamine-DBCO is a bifunctional chelating agent. Deferoxamine-DBCO efficiently chelates with radioactive metals (such as 89Zr) through the DFO structure to achieve radiolabeling. Deferoxamine-DBCO undergoes a metal-free Huisgen cycloaddition reaction with azide-containing biomolecules (such as siRNA, monoclonalantibodies) under bioorthogonal conditions through the DBCO structure to achieve targeted coupling. Deferoxamine-DBCO has efficient metal chelating ability and specific bioorthogonal reaction activity. Deferoxamine-DBCO can be used for targeted radioactive imaging studies of tumors .
Goat Serum Albumin is a plasma protein derived from goats. Goat Serum Albumin is a versatile protein commonly used in various life sciences research applications, including immunoassays and the production and purification of monoclonalantibodies .
Bovine Serum Albumin, Acetylated (Ac-BSA) is a polypeptide of known structure with strong antigenicity. Bovine Serum Albumin, Acetylated produced a significant immune response, validating the accuracy and reliability of the experimental method. Bovine Serum Albumin, Acetylated can be used as a positive control substance in ELISA or WB experiments, and can be used in experiments with acetylated lysine monoclonal or polyclonal antibodies. Bovine Serum Albumin, Acetylated also improves encapsulation efficiency at low concentrations of PLGA, a polymer for biopharmaceutical delivery with biocompatibility, degradability, and controlled release properties .
Tetracycline/BSA is a tetracycline-carrier protein conjugate of Tetracycline (HY-A0107) and bovine serum albumin (BSA). Tetracycline/BSA can be used as an immobilized capture antigen for the detection of tetracycline residues in milk .
Vomitoxin-BSA (DON-BSA) is an artificial antigen containing Deoxynivalenol (Vomitoxin) (HY-N6684) and BSA. Deoxynivalenol is one of the most important mycotoxins related to food chains. Vomitoxin-BSA can be used to generate anti-Deoxynivalenol monoclonalantibodies .
V5 Epitope Tag Peptide TFA is a tag peptide derived from a small epitope present on the P and V proteins of the paramyxovirus of simian virus 5. V5 Epitope Tag Peptide TFA can be used for protein separation and purification, and competitive elution with target proteins .
DSTYSLSSTLTLSK TFA is a generic human peptide and can be used for infliximab quantitative detection . Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α.
N-Boc-trans-4-fluoro-L-proline is a non-natural amino acid substitute used to construct monoclonalantibodies that specifically target the seed conformation of tau protein .
[Lys3]-Bombesin is a biological active peptide. (PET (Positron Emission Tomography) imaging of [Lys3]-bombesin is able to detect gastrin-releasing peptide receptor (GRPR) positive prostate cancer. An immunoconjugate of [Lys3]-bombesin and corresponding monoclonalantibody can specifically induce (CD64)-dependent monocyte and neutrophil-mediated lysis of small cell carcinoma.)
WT1 126-134 peptide is a Wilms' tumor oncogene protein (WT1) peptide (RMFPNAPYL). WT1 126-134 peptide is presented by HLA-A0201 and induces cytotoxic CD8 T cells capable of killing WT1+ positive tumor cells. WT1 126-134 can form stable complexes with the H-2Db (mouse) or HLA-A0201 (human) molecules. WT1 126-134 peptide/HLA-A0201 complex has an extremely high affinity (Kd = 0.2 nM) with the humanized monoclonalantibody (IgG1). WT1 126-134 peptide can be used as a vaccine for T cells or as a target for antibodies .
LEESGGGLVQPGGSMK, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α .
Polyphemusin II-Derived Peptide (T140), a CXCR4 inhibitor, shows high inhibitory activity against HIV-1 entry and the inhibitory effect on the binding of an anti-CXCR4 monoclonalantibody (12G5) to CXCR4 .
CotH3 peptide is a functional peptide unique to Mucorales that binds to the host GRP78 receptor and allows them to invade endothelial cells. CotH3 peptide–targeted monoclonalantibodies protect immunosuppressed mice from mucormycosis caused by R. delemar and other Mucorales. CotH3 peptide also synergizes with antifungal drugs to protect mice with diabetic ketoacidosis (DKA) from R. delemar infection .
Humanized anti-tac (HAT) binding peptide is a peptide that can specifically bind to the Fc region of HAT. HAT is a humanized monoclonalantibody against the low affinity p55 subunit of the interleukin IL-2 receptor. Humanized anti-tac (HAT) binding peptide can be used to develop affinity chromatography media to purify specific monoclonalantibodies .
ELDKWA is the highly conserved amino acids on the ecto-domain of gp41. ELDKWA acts as the epitope of a neutralizing monoclonalantibody 2F5 (mAb 2F5) directed against human immunodeficiency virus type 1 .
LEESGGGLVQPGGSMK acetate, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK acetate can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α .
DSTYSLSSTLTLSK is a generic human peptide and can be used for infliximab quantitative detection . Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α.
LEESGGGLVQPGGSMK TFA, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK TFA can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α .
WT1 126-134 peptide acetate is a Wilms' tumor oncogene protein (WT1) peptide (RMFPNAPYL). WT1 126-134 peptide acetate is presented by HLA-A0201 and induces cytotoxic CD8 T cells capable of killing WT1+ positive tumor cells. WT1 126-134 can form stable complexes with the H-2Db (mouse) or HLA-A0201 (human) molecules. WT1 126-134 peptide acetate/HLA-A0201 complex has an extremely high affinity (Kd = 0.2 nM) with the humanized monoclonalantibody (IgG1). WT1 126-134 peptide acetate can be used as a vaccine for T cells or as a target for antibodies .
MCE Protein A Agarose, a 4% highly cross-linked agarose reagent coupled with recombinant Protein A, effectively purifies mammalian monoclonal and polyclonal antibodies, such as human IgG, IgE, IgM.
MCE Protein L Agarose, a 4% highly cross-linked agarose reagent coupled with recombinant Protein L, effectively purifies mammalian monoclonal and polyclonal antibodies which have kappa light chain.
MCE Protein G Agarose, a 4% highly cross-linked agarose reagent coupled with recombinant Protein G, effectively purifies mammalian monoclonal and polyclonal antibodies, such as human IgG3 and rat IgG2a.
Durvalumab (MEDI 4736) is an human anti-PD-L1monoclonalantibody . Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively .
Zanidatamab (ZW25) is a humanised, bispecific monoclonalantibody targeting 2 distinct HER2 epitopes (ECD2 and ECD4). Zanidatamab has anti-tumour activity .
Avelumab (Anti-Human PD-L1) a fully human IgG1 anti-PD-L1monoclonalantibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab can be used for the study of chordoma .
Camoteskimab is a fully human monoclonalantibody with high affinity targeting IL-18. Camoteskimab is applicable to the research of autoinflammatory diseases .
Pivekimab is a human IgG1 monoclonalantibody that targets interleukin-3 (IL-3) and CD123. Pivekimab is used to synthesize pivekimab sunirine, a CD123-directed antibody-active molecule conjugate (ADC). Pivekimab is used in the study of blastic plasmacytoid dendritic cell neoplasm (BPDCN) .
Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonalantibody targets fibroblast activation protein (FAP). Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC) .
Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonalantibody that binds CD56 (NCAM1). Lorvotuzumab can be used to synthesize an ADC compound, Lorvotuzumab mertansine .
Durvalumab (anti-PD-L1)(MEDI 4736) is a human anti-PD-L1 protein monoclonalantibody. Durvalumab (anti-PD-L1) completely blocks PD-L1 binding to PD-1 and CD80, IC 50 are 0.1 and 0.04 nM respectively, has anti-tumor activity .
Disitamab (RC48-0) is a humanized monoclonalantibody targeting HER2. Disitamab can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (HY-P9985) .
Vadastuximab (Anti-Human CD33 Recombinant Antibody) is a humanized monoclonalantibody targeting CD33. Vadastuximab can be used to synthesize an ADC compound, Vadastuximab talirine .
Adecatumumab (Anti-Human EPCAM Recombinant Antibody; MT201) is a full human monoclonalantibody of the IgG1 isotype, targeting human EpCAM. Adecatumumab is expressed in almost all adenocarcinomas, and its activity is not dependent of K-Ras status .
Olaratumab (IMC-3G3; LY3012207) is an anti-platelet-derived growth factor receptor alpha (PDGFRα) human monoclonal IgG1 antibody with antitumor activity .
Bermekimab (MABp1) is a human monoclonalantibody targeting interleukin-1α(IL-1α) . Bermekimab can prevent tumor-related inflammation. Bermekimab can be used in the research of atopic dermatitis .
Indusatumab (5F9 Monoclonalantibody) is a monoclonalantibody against human GUCY2C (Guanylate cyclase 2C). Indusatumab fails to bind to granulocytes or erythrocytes. Indusatumab can be used to synthesize ADCs, such as Indusatumab vedotin (HY-P99662). Indusatumab can be used in cancer research .
Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonalantibody and ADC antibody. Tisotumab targets tissue factor (TF). Tisotumab can be used to synthesize antibody-drug conjugates (ADCs) targeting tissue factor (TF), Tisotumab vedotin (HY-152963). Tisotumab can be used for the research of solid tumors .
Azintuxizumab is an anti-SLAMF7 human IgG4κ monoclonalantibody. Azintuxizumab can be used in the synthesis of antibody-drug conjugate (ADC), Azintuxizumab vedotin .
Sirtratumab (AGS15C; Ha15-10ac12; Ha15-10ac12.1) is a SLITRK6-specific humanized IgG2 monoclonalantibody, and serves as the parental antibody of the ADC ASG-15ME (HY-P99595). Sirtratumab is applicable for cancer research .
Tixagevimab (AZD8895) is a human monoclonalantibody that targets the SARS-CoV-2 receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor .
Naratuximab (Anti-TSPAN26/CD37 Reference Antibody (naratuximab)) is a humanized monoclonalantibody that binds CD37 (TSPAN26). Naratuximab can be used to synthesize an ADC compound, Naratuximab emtansine .
Matuzumab (EMD 72000) is a humanized anti-EGFRmonoclonalantibody that blocks EGFR activation and downstream signaling, inhibits tumor growth. Deglycosylation and the possible elimination of ADCC activity can reduce the in vivo anti-tumor activity of Mattuzumab .
NN-8828 (NNC-114-0005) is a humanized monoclonalantibody inhibitor targeting interleukin-21 (IL-21). NN-8828 is promising for research of immune system diseases .
Imgatuzumab (RG 7160) is a humanized monoclonalantibody against the EGFR. Imgatuzumab acts as an immunomodulator. Imgatuzumab can be used in research of cancer .
IRAB-B is a human monoclonalantibody targeting INSR. IRAB-B is an insulin receptor (IR) antagonist and can be used in the study of insulin resistance and diabetes .
Ublituximab (LFB-R603; TG-1101; TGTX-1101) is a next-generation, type 1 chimeric monoclonalantibody targeting a unique epitope on the CD20 antigen. Ublituximab has anticancer effects .
Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonalantibody targeting CTLA-4 (CTLA-4). Zalifrelimab antagonizes the inhibitory checkpoints of immune cell activation regulated by CTLA-4 signaling .
Letaplimab (IBI-188) is a human IgG4 anti-CD47monoclonalantibody. CD47 is overexpressed on cancer cells, it is a ligand for SIRPα. Letaplimab enhances tumor cell phagocytosis .
Belantamab (FUT8-KO) is an anti-BCMA (TNFRSF17) monoclonalantibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Belantamab (FUT8-KO) can be used to synthesize antibody-active molecule conjugate (ADC), Belantamab mafodotin .
Oregovomab (Alt-2 monoclonalantibody) is a murine mAb targeting CA125. Oregovomab induces cytotoxic immune response against CA125 expressing tumor cells .
Disitamab (RC48-0) (powder) is a humanized monoclonalantibody targeting HER2. Disitamab (powder) can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (HY-P9985) .
Perakizumab (RG4934) is a humanized IgG1κ monoclonalantibody against IL-17A (Interleukin Related). Perakizumab can be uesd for the research of autoimmune diseases, such as psoriatic arthritis .
Levilimab (BCD-089) is a fully humanized anti-interleukin-6 receptor (IL-6R) monoclonalantibody. Levilimab is an inflammation-alleviating antibody. Levilimab can be used for the research of rheumatoid .
Nurulimab (BCD-145) is an anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA-4) human monoclonalantibody. Nurulimab can be can be used in research of melanoma .
BI-1206 is a recombinant and antagonistic human monoclonalantibody targeting FcγRIIB (CD32B). BI-1206 can block CD20 internalization induced by Rituximab (HY-P9913) itself or combined with others including Ibrutinib (HY-10997), Venetoclax (HY-15531), and CHOP. BI-1206 can enhance or recover the activity of Rituximab or other anti-CD20 monoclonalantibodies. BI-1206 has cytolytic activity against malignant B cells. BI-1206 can be studied for cancer research such as mantle cell lymphoma (MCL) .
Lerdelimumab (CAT-152) is an IgG4 human anti-TGF-β2 recombinant monoclonalantibody. Lerdelimumab can be used as an anti-scarring agent for glaucoma research .
Renvistobart is an immunoglobulin G1-κ, anti-[Homo sapiens TIGIT (T cell immunoreceptor with Ig domain and ITIM, VSIG9, VSTM3)] Homo sapiensmonoclonalantibody .
Lemalesomab (IMMU-MN3) is a mouse IgG1 Anti-NCA-90monoclonalantibody and a Fab'fragment. Lemalesomab can be used for the research of inflammation, infectious lesions and infection imaging .
Ranevetmab (NV-01) is a caninised anti-NGFmonoclonalantibody (mAb). Ranevetmab can alleviate pain, and is used for the research of degenerative joint disease (DJD) pain .
Emzotamig is a monoclonalantibody inhibitor targeting tumor necrosis factor (TNF). Emzotamig is promising for research of autoimmune diseases associated with TNF overexpression, such as rheumatoid arthritis and ankylosing spondylitis .
Ticalicibart is a humanized IgG4κ monoclonalantibody inhibitor targeting PCSK9. Ticalicibart has anti-hyperlipidaemic activity. Ticalicibart can be used for cardiovascular disease like hypercholesterolaemia research .
Befovacimab (BAY 1093884) is a fully human monoclonal IgG2 antibody able to bind to tissue factor pathway inhibitor (TFPI). Befovacimab can be used for haemophilia A/B research .
Tisotumab (Anti-Human F3 Recombinant Antibody) (powder) is a human IgG1 monoclonalantibody and ADC antibody. Tisotumab (powder) targets tissue factor (TF). Tisotumab (powder) can be used to synthesize antibody-drug conjugates (ADCs) targeting tissue factor (TF), Tisotumab vedotin (HY-152963). Tisotumab (powder) can be used for the research of solid tumors .
Rozibafusp alfa (AMG-570) is a humanized IgG2-κ monoclonalantibody targets ICOSL and BAFF. Rozibafusp alfa can be used for the research of systemic lupus erythematosus and other autoimmune diseases .
Tomuzotuximab (Anti-Human EGFR Recombinant Antibody) is a fully human glycoengineered IgG1 monoclonalantibody against EGFR. Tomuzotuximab has anticancer effects .
Ledostomig is an immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonalantibody targeting human netrin-5 (NTS5) and programmed death-1 (PD-1). Ledostomig is promising for research of various cancers .
Ongericimab (JS002) is a humanized anti-PCSK9monoclonalantibody. Ongericimab has lipid-lowering efficacy. Ongericimab can be used in research of hypercholesteremia and hyperlipidemia .
Tamgiblimab (IBI939) is a fully human monoclonalantibody targeting T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT). Tamgiblimab has anticancer effects .
HLX26 is a humanised anti-LAG-3monoclonalantibody. HLX26 has antitumor activity especially advanced solid tumours. HLX26 can be used for lymphoma research .
Minokitug is a humanized monoclonalantibody targeting the CCR2 protein. Minokitug can be used for the research of refractory/relapsed ulcerative colitis .
Elfetabart (DB-1311 Antibody; BNT324 Antibody) is a humanized monoclonalantibody targeting CD276 with antitumor activity. The antibody isotype of Elfetabart is human IgG1κ, and the recommended isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
Olevaprubart is a humanized IgG1-κ monoclonalantibody targeting TNFSF4, which can be used for the research of autoimmune diseases such as atopic dermatitis and alopecia areata .
Anti-Big-ET-1 Antibody is a humanized monoclonalantibody targeting Big-ET-1. Recommended Isotype Control: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
Daxdilimab (FUT8-KO) is an anti-ILT7monoclonalantibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody.
Ombetoxabart is a humanized IgG1-κ monoclonalantibody targeting TcdB (Clostridioides difficile toxin B), which exerts its function by neutralizing the toxicity of TcdB. Ombetoxabart can be used for the study of Clostridioides difficile infection .
Vonaprument is an intravitreally injected C1qantibody fragment, which is a human monoclonalantibody. Vonaprument is applicable to research related to age-related macular degeneration .
Solaprubart is a humanized IgG1-κ monoclonalantibody targeting TNFSF4/OX40L. Solaprubart regulates immune homeostasis by blocking the OX40L-OX40 signaling pathway and can be used for the research of autoimmune diseases such as atopic dermatitis .
Vedastotug is a human monoclonalantibody targeting TNFRSF4/OX40/CD134, with its corresponding isotype control being Human IgG1 kappa, Isotype Control (HY-P99001) .
INA01 is an unlabeled human monoclonalantibody targeting CD71/TFRC, which can be used in ELISA, FACS and functional assays. INA01 is promising for leukemia-related research .
ONCR-201 (PG-101) is a fully human monoclonalantibody targeting epithelial membrane protein 2 (EMP2). ONCR-201 is applicable to research related to breast cancer, ovarian cancer, and endometrial cancer .
Anti-IL-6 Antibody (Chugai SK2) is a murine monoclonalantibody, targeting IL-6. Anti-IL-6 Antibody (Chugai SK2) can be used for inflammatory diseases and cancers research, such as rheumatoid arthritis (RA), crohn's disease (CD) and pancreatic, lung and colon cancer .
Pemtumomab Antibody (R-1549) is an anti-MUC1monoclonalantibody. Pemtumomab Antibody is applicable to research related to breast cancer and other cancers. For isotype control, refer to Mouse IgG1 kappa, Isotype Control (HY-P99977).
Ulviprubart (FUT8-KO) is a humanized anti-KLRG1monoclonalantibody lacking fucosyltransferase 8 (FUT8). Ulviprubart (FUT8-KO) can be used for the research of diseases such as inclusion body myositis (IBM) .
Olokizumab (CDP 6038) is a humanized monoclonalantibody that targets interleukin-6 (IL-6). Olokizumab inhibits IL-6-induced STAT-3 phosphorylation. Olokizumab is used in the study of arthritis .
Elgemtumab(LJM716) is a fully human IgG monoclonalantibody. Elgemtumab can specifically bind to HER3, block ligand-dependent and independent HER3 signal transduction and cell proliferation, and has good anti-tumor potential .
Human IgG2 kappa, Isotype Control is a human monoclonalantibody serving as an isotype control for human IgG2κ antibodies such as Cepeprubart (HY-P990732) and Ersodetug (HY-P990712). Human IgG2 kappa, Isotype Control can be used in T cell research .
Prasinezumab (PRX 002) is a humanized IgG1 monoclonalantibody directed against aggregated α-synuclein. Prasinezumab has the potential for Parkinson's disease research .
Beludavimab (BMS 4182137; VIR 7832) is a monoclonalantibody targeting the spike glycoprotein of SARS-CoV-2. Beludavimab binds to recombinant spike protein receptor-binding domain (S-RBD) with an EC50 value of 14.9 ng/mL and a Kd of 0.21 nM .
Siplizumab (MEDI-507) is a humanized IgG1 monoclonalantibody against CD2. Siplizumab depletes T cells, decreases T cell activation, inhibites T cell proliferation and enriches naïve and bona fide regulatory T cells .
Polatuzumab is a monoclonalantibody that targets CD79b on the surface of B cells. Polatuzumab can be used to synthesize the ADC Polatuzumab Vedotin (HY-132253), which has anti-tumor activity .
Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonalantibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) .
Sipavibart (AZD3152) is a human IgG1 λ2 monoclonalantibody against SARS-CoV-2. Sipavibart is applicable to research related to COVID-19. The isotype control product for Sipavibart is Human IgG1 lambda2, Isotype Control (HY-P990096) .
Anti-Nucleocapsid Antibody (N-P10) is a highly specific SARS-CoV-2 Nucleocapsid (N) protein-targeted recombinant monoclonalantibody. Anti-Nucleocapsid Antibody (N-P10) can be used for research on SARS-CoV-2 infection .
Anti-Nucleocapsid Antibody (N-P11) is a highly specific SARS-CoV-2 Nucleocapsid (N) protein-targeted recombinant monoclonalantibody. Anti-Nucleocapsid Antibody (N-P11) can be used for research on SARS-CoV-2 infection .
Uliledlimab is a potent against CD73 humanizedized monoclonalantibody. Uliledlimab inhibits the conversion of extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab can be used in research of cancer .
Bertilimumab (CAT 213; iCo-008) is a human monoclonalantibody targeting eotaxin-1 (CCL11). Bertilimumab has the potential for allergic disorders research .
Garadacimab (CSL312) is a first-in-class, fully human IgG4 monoclonalantibody targeting activated factor XII (FXIIa). Garadacimab has the potential for hereditary angioedema research .
ALMB-0168 is a Cx43 hemichannel agonist monoclonalantibody. ALMB-0168 activates Cx43 hemichannels to inhibit the growth and migration of osteosarcoma. ALMB-0168 is applicable to relevant research on osteosarcoma .
Afivastobart (AB598) is a human ENTPD1 (CD39)-targeting monoclonalantibody with antineoplastic activity.Afivastobart binds as a monoclonalantibody to modulate Homo sapiensENTPD1 activity.Afivastobart constitutes a glycoform alfa immunoglobulin G1-kappa monoclonalantibody .
Elotuzumab (HuLuc 63) is an IgG1 monoclonalantibody targeting the SLAMF7 receptor. Elotuzumab exerts antitumor activity by activating natural killer cells and inducing antibody-dependent cell-mediated cytotoxicity. Elotuzumab can be combined with Lenalidomide (HY-A0003), Dexamethasone (HY-14648), etc., for the research of tumors such as multiple myeloma .
OSE-703 is a humanized monoclonalantibody inhibitor targeting interleukin-7 receptor α subunit (IL-7Rα). OSE-703 is promising for research of tumors and respiratory diseases .
Cenvacibart is a monoclonalantibody with anticoagulant activity, targeting human coagulation factor XI (F11). Cenvacibart blocks the role of coagulation factor XI in the coagulation cascade, reducing thrombus formation. Cenvacibart is promising for research of thrombotic diseases .
Pamvatamig (FUT8-KO) is an anti-EGFR/METmonoclonalantibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody.
Apitegromab (SRK-015) is an anti-promyostatin monoclonalantibody. Apitegromab can be used for the research of neuromuscular disease including spinal muscular atrophy .
Alsevalimab is a humanized, afucosylated IgG1 monoclonalantibody against B7-H4. Alsevalimab blocks the binding of the B7-H4 protein to the receptors on the surface of T cells, reversing the immunosuppressive state in the tumor microenvironment, thereby activating the killing effect of T cells on cancer cells. Alsevalimab can be used in combination with Pembrolizumab (HY-P9902), and shows good safety profiles .
Rovelizumab is a humanized monoclonal leukointegrin antibody. Rovelizumab is a monoclonalantibody directed against the CD11/CD18 cell adhesion proteins. Rovelizumab can be used for research of multiple sclerosis (MS), hemorrhagic shock, myocardial infarction (MI) and stroke .
Glarivibart is a humanized IgG1κ monoclonalantibody inhibitor targeting Respiratory syncytial virus (RSV) fusion F protein (RSV-F). Glarivibart has significant antiviral activity. Glarivibart can be used for RSV infections research .
Sotevtamab (16B5) is a humanized IgG2 anti-clusterinmonoclonalantibody (mAb). Sotevtamab is an inhibitor of the epithelial to mesenchymal transition. Sotevtamab can be used for cancer research .
Donanemab (LY3002813) is a humanized IgG1 monoclonalantibody directed at an N-terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research .
Emicizumab is a bispecific monoclonalantibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research .
Vemzatatug is a humanized IgG1κ monoclonalantibody inhibitor targeting GPRC5D. Vemzatatug has an antitumor activity. Vemzatatug can be used for cancers like multiple myeloma (MM) research .
BLX-301 is a humanized monoclonalantibody targeting CD20. BLX-301 exhibits anti-tumor activity and can be used in the research of diseases such as non-Hodgkin lymphoma and rheumatoid arthritis .
Clenoliximab (IDEC-151) is a macaque-human chimeric monoclonalantibody (immunoglobulin G4) specific for the CD4 molecule on the surface of T lymphocytes. Clenoliximab can be used for the research of rheumatoid arthritis .
Gantenerumab is a fully humanized anti-Aβ IgG1 monoclonalantibody. Gantenerumab can specifically bind to Aβ fibrils and plaques and can be used in Alzheimer's disease research .
Bepranemab is a humanized IgG4 monoclonalantibody that binds to the central region of tau protein. Bepranemab inhibits the seeding, aggregation of pathological tau protein and the spread of tau pathology to distal brain regions. Bepranemab is applicable to research related to Alzheimer's disease .
MINT1526A (RG-7594) is a humanized IgG1 monoclonalantibody inhibitor targeting α5β1 integrin. MINT1526A has significant anti-angiogenic activity. MINT1526A can be used for cancers research .
Galcanezumab (LY 2951742) is a humanized IgG4 monoclonalantibody against the CGRP ligand. Galcanezumab can be used for migraine or cluster headaches research .
Quilizumab (Anti-Human IGHE Recombinant Antibody) is a humanized IgG1κ monoclonalantibody targeting immunoglobulin epsilon (also konwn as: IGHE, IgE). Quilizumab targets the M1-prime fragment of membrane-expressed IGHE/IgE, leading to IGHE/IgE switching and memory B cell depletion. Quilizumab has potential in asthma research .
Setrusumab (BPS 804) is a fully human monoclonalantibody targets sclerostin. Setrusumab efftively improves bone strength. Setrusumab can be used for the resesrch of Osteogenesis Imperfecta (OI) and cancer .
Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonalantibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation .
SFN68 is a humanized IgG1 neutralizing monoclonalantibody targeting HGF. SFN68 significantly inhibits HGF/c-Met interaction, c-Met activation, and, cell scattering and proliferation mediated by HGF. SFN68 can be used for cancers research .
Tucotuzumab (Anti-EPCAM Recombinant Antibody) is an antigen-specific IgG1 monoclonalantibody that targets human epithelial cell adhesion molecule (EpCAM). Tucotuzumab links two IL-2 molecules and is an immunosuppressant and anti-tumor active molecule .
Inetetamab is a monoclonalantibody binding to domain IV of HER2 receptor. Inetetamab alone or together with tyrosine kinase inhibitors has antitumor activities .
Pozelimab (REGN3918) is a fully human IgG4 anti-C5monoclonalantibody. Pozelimab binds to C5 and C5 variants with high affinity and blocks complement-mediated hemolysis. Pozelimab can be used for the research of complement-mediated diseases .
Rovalpituzumab is a humanized monoclonalantibody against delta-like protein 3 (DLL3). Rovalpituzumab can be used in the synthesis of antibody-drug conjugate (ADC), Rovalpituzumab Tesirine. Rovalpituzumab has activity against small cell lung cancer (SCLC) .
Emaretamig is a humanized IgG1κ monoclonalantibody inhibitor targeting CLDN18 and CD3E. Abdakibart can be used for cancers like gastric and pancreatic cancer research .
Lesabelimab (LDP) is an immunoglobulin G1-kappa anti-CD274monoclonalantibody. CD274 is an immune checkpoint ligand, represses antitumour immunity through the interaction with PDCD1 receptor .
Glembatumumab is a fully human IgG2 monoclonalantibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. Glembatumumab can be coupled to the microtubule inhibitor monomethyl auristatin E to form glembatumumab vedotin. Glembatumumab vedotin is an antibody-agent coupling (ADC) with antitumor activity .
Garetosmab (REGN 2477) is a fully human IgG4 monoclonalantibody that specifically inhibits activin A. Garetosmab can be used for fibrodysplasia ossificans progressiva (FOP) research .
Abdakibart is a humanized IgG4 monoclonalantibody inhibitor targeting IL-1β. Abdakibart can be used for inflammatory disease like type 2 diabetes research .
Tibulizumab (LY 3090106) is a tetravalent bispecific monoclonalantibody targeting B-cell activating factor (BAFF) and IL-17A with Kd values of 60 pM and 14 pM, respectively. Tibulizumab can be used for autoimmune disease research .
Blinatumomab (Anatumomab) is a bispecific monoclonalantibody with two binding sites, one for CD3E on T cells and one for CD19 on B cells. Blinatumomab can be used in research for acute lymphoblastic leukemia .
Vulinacimab (HLX-06) is a human monoclonalantibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2). Vulinacimab specifically binds to and inhibits VEGFR-2, which may inhibit tumor angiogenesis and tumor cell proliferation. Vulinacimab can be used for the research of solid tumors and non-small cell lung cancer .
Ponezumab (PF-04360365; RN 1219) is a humanized anti-amyloid-β (Amyloid-β) IgG2 monoclonalantibody. Ponezumab reduces Aβ levels in the central nervous system and improves the performance of mice in various learning and memory models. Ponezumab is applicable to the research of Alzheimer's disease .
Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research .
Pinatuzumab is a humanized monoclonalantibody targeting cell-surface antigen CD22. Pinatuzumab can be used to synthesize antibody-drug conjugate (ADC) such as Pinatuzumab vedotin (HY-141602). Pinatuzumab can be studied in research on cancer such as non-Hodgkin lymphoma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
IT1208 is a humanized anti-CD4monoclonal IgG1 antibody. IT1208 depletes CD4 + T cells with a manageable safety profile in vivo. IT1208 can be used for colon cancer research .
Tigatuzumab (CS-1008) is a humanized IgG1 monoclonalantibody targets death receptor 5 (DR5). Tigatuzumab induces cell apoptosis of cancer cells and inhibits tumor growth in vivo. Tigatuzumab can be used for the research of cancer .
Girentuximab (G250) is a chimeric monoclonalantibody that binds carbonic anhydrase IX (CAIX), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC) .
Ensituximab (NEO-102; NPC-1C) is a chimeric monoclonal IgG1 antibody targeting a variant of MUC5AC. Ensituximab shows specificity to colorectal and pancreatic cancer .
Lenzilumab (KB 003) is a human monoclonalantibody targeting CSF2/GM-CSF for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies .
Barzolvolimab is a humanized anti-KIT IgG1 monoclonalantibody. Barzolvolimab specificity and potently inhibits KIT activation by SCF. Barzolvolimab can reduce skin mast cells and disease activity in chronic inducible urticaria .
Onvatilimab (JNJ-61610588) is a human IgG1κ anti-VISTA (V-domain Ig Suppressor of T-cell Activation) monoclonalantibody. Onvatilimab can be used in colorectal cancer research .
Isatuximab is a monoclonalantibody targeting the transmembrane receptor and ectoenzyme CD38, a protein highly expressed on hematological malignant cells, including those in multiple myeloma (MM). Isatuximab has antitumor activity via multiple biological mechanisms, including antibody-dependent cellular-mediated cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and direct induction of apoptosis without crosslinking. Isatuximab also directly inhibits CD38 ectoenzyme activity, which is implicated in many cellular functions .
Emapalumab (NI-0501) is a human monoclonal IgG1 antibody that noncompetitively inhibits IFN-γ. Emapalumab binds with high affinity (Kd= 1.4 pM) to both free IFN-γ as well as IFN-γ bound to its receptor. Emapalumab can be used in research of hemophagocytic lymphohistiocytosis (HLH) .
REGN-1400 is a humanized monoclonalantibody inhibitor targeting ErbB3. REGN-1400 reduces tumor cell proliferation by inhibiting ErbB3 and blocking related signaling pathways. REGN-1400 is promising for research of solid tumors such as non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and squamous cell carcinoma of the head and neck (SCCHN) .
VRC01LS is a humanized monoclonalantibody inhibitor targeting the CD4-binding site of HIV-1 envelope glycoprotein (Env). VRC01LS blocks the binding of HIV-1 to host cell CD4 receptor, inhibiting viral entry. VRC01LS is promising for research of HIV-1 infection .
Ganitumab (AMG 479) is a recombinant human monoclonalantibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (KD=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer .
Nemolizumab (CIM331) is a humanized monoclonalantibody that targets the human interleukin-31 receptor a, preventing interleukin-31 (IL-31) from binding to its receptor and the subsequent signaling. Nemolizumab can help reduce itching and sleep disturbances, and it is being studied for atopic dermatitis (AD) .
Apolizumab (Hu1D10) is a humanized monoclonalanti-Human leukocyte antigen-DR beta-chain antibody. Apolizumab can mediate apoptosis of chronic lymphocytic leukemia (CLL) cells in vitro .
MLN2201 is a humanized monoclonalantibody inhibitor, targeting Integrin β2. MLN2201 inhibits the reperfusion injury after stroke and can be used for inflammatory diseases like ischemic stroke research .
Abelacimab (MAA868) is a fully human IgG1 monoclonalantibody that binds with high affinity to the catalytic structural domain of FXI and locks it in the zymogen conformation, thereby preventing its activation by FXIIa or thrombin. Abelacimab can be used in thromboembolic disease studies .
CDX-3379 is a humanized monoclonalantibody inhibitor targeting ErbB3. CDX-3379 binds to ErbB3, blocking the dimerization of ErbB3 with other receptors, thereby inhibiting the phosphorylation of ErbB3. CDX-3379 can inhibit the growth and proliferation of tumor cells. CDX-3379 is promising for research of tumors expressing ErbB3 and NRG1, such as HNSCC .
Geptanolimab (CBT-501) is a humanized IgG4k monoclonalantibody against programmed death-1 (PD-1). Siplizumab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. Siplizumab can be used in research of cancer .
Varlilumab (CDX-1127) is an agonist anti-CD27monoclonalantibody. Varlilumab can promote T cell expansion and activate the immune response. Varlilumab has anti-tumor activity and can be used in the research of hematological malignancies and solid tumors .
Vanucizumab is a first-in-class, bispecific IgG1-like monoclonalantibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects .
Aducanumab (BIIB037) is a human monoclonalantibody that selectively targets aggregated amyloid-beta (Aβ). Aducanumab shows blood-brain-barrier penetration, and can be used for Alzheimer's disease (AD) research .
NC762 is a humanized IgG1κ monoclonalantibody that targets human B7-H4 (B7 homolog 4). NC762 has enhanced binding to CD16a (FcγRIIIa) after being Fc engineered with three point mutations (S239D/A330L/I332E; DLE) and demonstrate increased antibody-dependent cellular cytotoxicity (ADCC) activity. NC762 inhibits tumor growth in vivo through binding to tumor-expressing B7-H4. NC762 can be studies in research on cancer such as advanced or metastatic solid tumors .
Tremelimumab (Ticilimumab) is a fully human monoclonalantibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research .
Tusamitamab is an IgG1 monoclonalantibody that targets CEACAM5. Tusamitamab can be used to synthesize ADC Tusamitamab ravtansine (SAR408701) (HY-P99542) .
Nesvacumab is a fully human immunoglobulin G1 (IgG1) monoclonalantibody that specifically binds and inactivates the Tie2 receptor ligand Angiopoietin-2 (Ang2) with high affinity, but shows no binding to Ang1. Nesvacumab can be used in vascular researches .
Frovocimab (LY 3015014) is a humanized IgG4 monoclonalantibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9 .
Bapineuzumab is an anti-β-amyloid protein (APP)monoclonalantibody. Bapineuzumab is a humanized IgG1 that recognizes the N terminus of Aβ cleared plaques from the brains. Bapineuzumab can be used for the research of Alzheimer’s disease (AD) .
Lacutamab (IPH4102) is a humanizedized monoclonalantibody (mAb) directed against the immune receptor molecule KIR3DL2, produced by recombinant technology in CHO cells. Lacutamab can be used in research of cutaneous T-cell lymphoma .
Onvontatug (BAT8006 Antibody) is a humanized monoclonalantibody targeting folate receptor α (FRα). Onvontatug can be used to construct antibody-drug conjugates (ADCs), such as BAT8006. It is applicable to research related to platinum-resistant ovarian cancer .
Rocatinlimab (AMG 451) (KHK4083) is a fully human immunoglobulin G1 (IgG1) anti-OX40 monoclonalantibody. Rocatinlimab can be used for the research of atopic dermatitis (AD) .
Tralokinumab (CAT354) is a humanized IgG4 monoclonalantibody that specifically binds to and neutralizes IL-13. Tralokinumab can be used in the research of diseases such as asthma, atopic dermatitis, and pulmonary fibrosis .
Enlimomab (BI-RR 0001), a murine IgG2a monoclonalantibody to the human ICAM-1, inhibits leukocyte adhesion to the vascular endothelium, thereby decreasing leukocyte extravasation and inflammatory tissue injury. Enlimomab has anti-inflammatory effects, and can be used for stroke research .
GBR-401 is a humanized anti-CD19monoclonalantibody with high affinity for FcγRIIIa. GBR-401 exerts a potent in vitro and in vivo cytotoxic activity against various B-cell malignancies. GBR-401 induces cell death by antibody dependent cellular cytotoxicity (ADCC) and direct killing effect. GBR-401 demonstrates potent activity of depleting malignant B cells and prolongs mice survival in multiple xenograft severe combined immunodeficiency (SCID) mice models .
PF-07329640 is a humanized monoclonalantibody inhibitor targeting TNFRSF3. PF-07329640 can be used for advanced/metastatic solid tumors like non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) research .
Rosnilimab (Mouse IgG2a) is a mouse-derived IgG2a, Rosnilimab. Rosnilimab is a PD-1 agonistic monoclonalantibody. Rosnilimab (Mouse IgG2a) can be used in research related to ulcerative colitis .
Aprutumab (BAY 1179470) is a fully human fibroblast growth factor receptor 2 (FGFR2)-specific monoclonalantibody. Aprutumab induces FGFR2 endocytosis and degradation in cancer cells expressing FGFR2. Aprutumab serves as the targeted monoclonalantibody component of the antibody-drug conjugate BAY 1187982 (HY-141600) and mediates the endocytosis of the antibody-drug conjugate into FGFR2-positive cells. Aprutumab can be used for the research of FGFR2-positive solid tumors, including studies on gastric cancer and triple-negative breast cancer .
Oleclumab (MEDI9447) is a human IgG1λ monoclonalantibody targeting CD73 and inhibits the exonuclease activity of the extracellular enzyme CD73. Oleclumab can adjust the composition of bone marrow and lymphoid infiltrating leukocyte populations in the tumor microenvironment and has anti-tumor activity .
Emicizumab (Anti-F9 & Factor IX) is a bispecific monoclonalantibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab (Anti-F9 & Factor IX) can be used for hemophilia A research .
Afasevikumab (RG 7624; RO 5553110; NI-1401) is a fully human monoclonal IgG1κ antibody neutralizing both IL-17A and IL-17F. Afasevikumab has anti-inflammatory activities .
Tefibazumab is a humanized IgG1κ monoclonalantibody that binds to the surface-expressed adhesion protein clumping factor A. Tefibazumab can be used for the research of serious Staphylococcus aureus infections .
Erenumab (AMG-334) is a fully human monoclonalantibody. Erenumab inhibits the calcitonin gene-related peptide (CGRP) receptor. Erenumab prevents the increase in dermal blood flow in cynomolgus monkeys. Erenumab can be used in the research of episodic migraine .
Ibalizumab (TMB-355) is a humanized anti-CD4 IgG4 monoclonalantibody. Ibalizumab prevents HIV cell entry by binding to CD4 receptor. Ibalizumab can be used for the research of infection, such as HIV-1 infection .
Botensilimab (AGEN 1181), a human anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonalantibody, is an innate and adaptive immune activator. Botensilimab can be used for the research of cancer .
Xeligekimab (GR 1501) is an anti-human interleukin 17A (IL-17A) humanized monoclonalantibody. Xeligekimab inhibits the pro-inflammatory cascade. Xeligekimab can be used for the research of inflammatory disease, such as radiographic axial spondyloarthritis .
CAP-100 is a monoclonalantibody that targets CCR7. CAP-100 neutralizes the ligand-binding site and signaling of CCR7. CAP-100 strongly inhibits CCR7-induced migration, extravasation, homing, and survival in chronic lymphocytic leukemia (CLL) samples. CAP-100 triggers potent tumor cell killing, mediated by host immune mechanism. CAP-100 shows a favorable toxicity profile on relevant hematopoietic subsets. CAP-100 is involved in research on anti-tumor and disease such as CLL .
Camidanlumab (HuMax-TAC) is a humanized IgG1 monoclonalantibody against CD25. Camidanlumab can be used to synthesize the ADC molecule Camidanlumab tesirine (HY-141599). Camidanlumab can be used in the research of tumors such as lymphoma and leukemia. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
XmAb-2513 is a humanized monoclonalantibody inhibitor targeting CD30. XmAb-2513 has significant anti-proliferative activity and superior antibody-dependent cell-mediated cytotoxicity (ADCC) as well as antibody-dependent cell-mediated phagocytosis (ADCP). XmAb-2513 can be used for hematologic malignancies like Hodgkin Lymphoma (HL) and Anaplastic Large Cell Lymphoma (ALCL) research .
IBI356 is a humanized monoclonalantibody inhibitor targeting OX40L/CD134L/CD252. IBI356 can be used to study chronic inflammatory skin diseases, such as atopic dermatitis .
Sibeprenlimab (VIS649) is a humanized IgG2monoclonalantibody which inhibits a proliferation-inducing ligand (APRIL). Sibeprenlimab suppresses pathogenic immunoglobulins (IgA and IgM), while preserving antibody responses to mRNA-based vaccines against SARS-COV-2. Sibeprenlimab reduces urinary protein-to-creatinine ratio (UPCR) and glomerular filtration rate (GFR). Sibeprenlimab is promising for the research of IgA nephropathy (IgAN) .
Fasinumab (Anti-Human NGF) is a human IgG4 monoclonalantibody to nerve growth factor (NGF). Fasinumab can be used in acute sciatica and knee osteoarthritis (OA) studies .
Paridiprubart (NI-0101) is a humanised anti-TLR4monoclonalantibody. Paridiprubar inhibits the production of pro-inflammatory cytokines by monocytes from rheumatoid arthritis specimen induced by rheumatoid arthritis synovial fluid (RASF). Paridiprubart can be used for the study of rheumatoid arthritis .
Ozanezumab (GSK1223249) is a humanized, Fc-inactivated monoclonalantibody that targets the nervous system protein Nogo-A. Ozanezumab promotes neurite outgrowth and axonal regeneration by neutralizing Nogo-A signaling. Ozanezumab is used for research on neurodegenerative diseases such as amyotrophic lateral sclerosis and multiple sclerosis [1] .
Girancitug is a humanized IgG1κ monoclonalantibody inhibitor targeting VEGFR2/KDR/CD309. Girancitug effectively inhibits angiogenesis. Girancitug can be used for anti-angiogenic therapy in cancers like colorectal and ovarian cancer research .
Galiximab (IDEC-114) is a primatized monoclonal IgG1 antibody targeting CD80. Galiximab variable regions are primatized, and the constant regions are humanized. Galiximab induces antibody-dependent cellular cytotoxicity by blocking CD80-CD28 binding. Galiximab has antitumor activity and can induce apoptosis in tumor cells. Galiximab can be used in the research of relapsed Hodgkin lymphoma and solid tumors .
Betifisolimab (MSB-2311) is a humanized monoclonalantibody directed against the immunosuppressive ligand PD-L1. Betifisolimab has the potential for advanced solid tumors and hematological malignancies research .
S095024 is a humanized IgG1 monoclonalantibody inhibitor targeting CD73. S095024 can be used to study acute respiratory distress syndrome (ARDS), non-small cell lung cancer (NSCLC) and advanced solid tumor malignancies .
Povovetug is a humanized IgG1κ chimeric monoclonalantibody inhibitor targeting NGF/bNGF. Povovetug has a significant analgesic activity. Povovetug can be used for central neuroinflammation like chronic radicular pain research .
Naxitamab (Hu3F8) is a humanized monoclonalantibody targeting the disialoganglioside GD2. Naxitamab can be used in research of neuroblastoma, osteosarcoma and other GD2-positive cancers .
Sotigalimab, a CD40 agonistic monoclonalantibody. Sotigalimab binds CD40 with high affinity and activates antigen-presenting cells, thereby stimulating cancer-specific T cell responses. Sotigalimab is mainly used in the study of metastatic pancreatic cancer and metastatic melanoma .
Lanadelumab (SHP643) is a human IgG1 monoclonalantibody against plasma kallikrein (pKal) with an Ki value of 0.12 nM. Lanadelumab inhibits both free and HMWK (high molecular weight kininogen)-bound pKal. Lanadelumab has the potential for the research of hereditary angioedema .
Ixekizumab (LY2439821) is a humanized IgG4 monoclonalantibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab directly blocks IL-17A binding to IL-17RA (IL-17A receptor) but does not bind to other IL-17 family members. Ixekizumab is used for the research of moderate-to-severe plaque psoriasis .
Varlilumab (CDX-1127) (anti-CD27) is an agonist anti-CD27monoclonalantibody. Varlilumab (anti-CD27) can promote T cell expansion and activate the immune response. Varlilumab (anti-CD27) has anti-tumor activity and can be used in the research of hematological malignancies and solid tumors .
HGS004 is a humanized IgG4 monoclonalantibody inhibitor targeting CCR5. HGS004 has potent antivival activity against a diverse panel of CCR5-tropic HIV-1 and durg (such as Maraviroc (HY-13004))-resistant strains. HGS004 can be used for HIV-1 infections research .
JMT203 is a monoclonalantibody against GFRAL and a body weight gain inducer. JMT203 induces early-onset, sustained and progressive body weight gain in cancer cachexia. JMT203 can be used for research related to cancer cachexia .
Samalizumab (ALXN 6000) is a humanized monoclonalantibody that specifically binds to CD200 and blocks its ligation to the CD200 receptor (CD200R). Samalizumab can be used for multiple myeloma and B-cell chronic lymphocytic leukemia research .
GSK-1070806 (Aletekitug) is a humanized IgG1/κ monoclonalantibody targeting IL-18. GSK-1070806 neutralizes IL-18 activity.GSK-1070806 can be used for the research of inflammation. The isotype control for GSK-1070806 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
Sirukumab (CNTO-136) is a humanized monoclonalanti-IL6 (Interleukin Related) IgG1κ antibody. Sirukumab binds to IL6, preventing IL6-mediated signal transduction and activation of transcriptional activators, thereby blocking the downstream biological effects of IL6. Sirukumab can be used in the study of active lupus nephritis and rheumatoid arthritis .
TQB2916 is a humanized IgG2 monoclonalantibody agonist targeting CD40. TQB2916 has a significant antitumor activity with CD40 occupancy and immune activation. TQB2916 can be used for advanced solid tumors and lymphomas research .
MDX1201 is a humanized monoclonalantibody targeting PSMA1/7. MDX1201 conjugated with a fluorescent dye AlexaTM488 can be used as a probe for near-infrared fluorescence imaging (NIRF) imaging of prostate cancer .
ANB004 is a humanized monoclonalantibody inhibitor, targeting IL-17. ANB004 can be used for autoimmune and inflammatory diseases like multiple sclerosis and rheumatoid arthritis (RA) research .
Mirzotamab is an IgG1κmonoclonalantibody targeting to CD276/B7-H3 with anti-tumor activity. Mirzotamab conjugates with Clezutoclax (HY-137774), a BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC) .
Anti-ITGB1 Antibody (AIIB2) is a monoclonalantibody targeting integrin-β1 (integrin-β1). Anti-ITGB1 Antibody blocks the binding of the ITGB1 subunit to type I collagen ligands, and abrogates the adhesion of cancer cells to type I collagen-coated surfaces. Anti-ITGB1 Antibody inhibits the proliferation and induces apoptosis of human osteosarcoma cells by activating caspase-3 and regulating apoptosis-related proteins. Anti-ITGB1 Antibody is applicable to research related to osteosarcoma and medulloblastoma .
PSB102 is a humanized Fc-enhanced IgG1 monoclonalantibody directed against the human B-cell-specific cell surface antigen and tumor-associated antigen CD20 .
CS5001 Antibody is an IgG1 human monoclonalantibody targeting ROR1. CS5001 Antibody can be used for the synthesis of the ADC CS5001. It is applicable to research related to advanced solid tumors and lymphomas. The recommended isotype control is human IgG1 kappa (HY-P99001) .
BMS-986156 is a fully humanized IgG1 agonist monoclonalantibody agonist corticosteroid-induced tumor necrosis factor receptor-related protein (GITR). BMS-986156 binds to GITR and promotes activation of T effector cells and inactivates T regulatory cells. BMS-986156 is indicated for use in advanced solid tumor studies .
PF-04840082 is a humanized IgG2 monoclonalantibody inhibitor targeting Dkk-1. PF-04840082 binds the physiological antagonist (Dkk-1) of the Wnt/LRP5 signal pathway and increases bone mass and bone mass density by activating osteoblasts. PF-04840082 can be used for osteoporosis research .
Farletuzumab (MORAb-003) is a potent folate receptor-alpha (FRα) inhibitor. Farletuzumab is a humanized monoclonalantibody with high affinity for FRα. Farletuzumab possesses growth-inhibitory functions on cells overexpressing FRα. Farletuzumab can be used in research of cancer .
Lampalizumab (RG 7417) is a humanised monoclonalantibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research .
Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonalantibody targeted against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in mice. Eculizumab can be used in hemolysis studies .
Iladatuzumab (MCDS0593A) is a humanized IgG1 anti-human CD79Bmonoclonalantibody. Iladatuzumab can be used to synthesize antibody-drug conjugates (ADC) Iladatuzumab vedotin (DCDS0780A; HY-P99657), which has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research .
Panitumumab (ABX-EGF) is a fully human IgG2 anti-EGFRmonoclonalantibody with anti-tumor activity. Panitumumab inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab can be used in the research of cancers, such as colon cancer .
FFP-104 is a humanized IgG4 monoclonalantibody inhibitor targeting TNFRSF5/CD40. VX70 can be used for chronic autoimmune liver diseases research, such as primary biliary cholangitis (PBC) .
CTM01 is a murine IgG1 (or humanized IgG4) monoclonalantibody inhibitor targeting MUC1. CTM01 has a broad spectrum anticancer activity against solid tumors of epithelial origin, such as breast, lung and ovarian cancer .
Veltuzumab (IMMU-106) is a humanized anti-CD20 monoclonalantibody. Veltuzumab has low EC50 value of 0.08-0.09 μg/mL in the Daudi cell line. Veltuzumab can be used for the research of cancer including non-Hodgkin lymphoma (NHL) .
Calpurbatug is an immunoglobulin G1 antibody. Calpurbatug has activity with anti-bacterial DNA-binding protein DNABII family and anti-human monoclonal TRL1068 γ1-chain .
Foralumab (NI-0401) is a potent, orally active human monoclonalantibody targeting the CD3. Foralumab modulates immune responses by human cells in NSG mice that were reconstituted with human hematopoietic stem cells .
Zalutumumab is a high affinity, completely human IgG1 monoclonalantibody targeting EGFR. Zalutumumab binds to domain III of the EGF receptor and acts by blocking the binding of EGF and by sterically interfering with the active conformation of the receptor. Zalutumumab binds with IgG and its Fab fragment with EC50s of 7 and 19 nM, respectively. Zalutumumab can be used for the research of cancer .
Panitumumab (ABX-EGF) (powder) is a fully human IgG2 anti-EGFRmonoclonalantibody with anti-tumor activity. Panitumumab (powder) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (powder) can be used in the research of cancers, such as colon cancer .
Enokizumab (MEDI-528) is a monoclonalantibody targeting to interleukin (IL)-9. IL-9 regulates the development of airway inflammation, mucus production, airway hyperresponsiveness, and airway fibrosis largely by increasing mast cell numbers and activity in the airways .
SCH708980 is a humanized monoclonalantibody inhibitor targeting IL-10. SCH708980 has anti-immunosuppressive activity. SCH708980 can be used for visceral leishmaniasis, sepsis-associated kidney injury (SAKI) and osteoporosis research .
KB002 is a humanized monoclonalantibody inhibitor targeting GM-CSF. KB002 has significant immune activity and can be used for asthma, rheumatoid arthritis and chronic Idiopathic thrombocytopenia purpura (ITP) research .
Serplulimab (HLX 10) is a humanized anti-PD-1monoclonalantibody. Serplulimab can inhibit tumor growth, regulate the tumor microenvironment, and has anti-tumor activity. Serplulimab can be used in the research of cancer such as lung cancer and colon cancer .
XKH001 is a recombinant humanized IgG1 monoclonalantibody targeting IL-25. XKH001 has low immunogenicity. XKH001 can be used for the research of type 2 inflammatory diseases .
Relatlimab (BMS-986016) is a human monoclonalantibodyanti-LAG-3antibody generated by immunization of transgenic mice bearing human immunoglobulin miniloci with recombinant LAG-3 protein. Relatlimab blocks LAG-3/MHC II interaction with an IC50 value of 0.67 nM and LAG-3/FGL1 interaction with an IC50 value of 0.019 nM. Relatlimab can be used in research of cancer .
Vantictumab (OMP-18R5) is a fully human IgG2 monoclonalantibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab can be studied against cancers through direct actions on tumor cells, including CSCs, and effects on the stroma, such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma .
Fresolimumab (GC1008) is a human monoclonalantibody against TGF-β that neutralizes all mammalian active subtypes of TGF-β. The binding affinity of Fresolimumab to TGF-β2 is 1.8 nM. Fresolimumab improves Bleomycin (HY-108345)-induced acute lung injury. Fresolimumab radiolabeled with 89Zr can be used for PET analysis of TGF-β expression, antibody uptake and organ distribution. Fresolimumab can be used in the study of cancer, osteogenesis imperfecta, fibrosis and kidney disease .
S-095029 is a humanized IgG1 monoclonalantibody inhibitor targeting NKG2A. S-095029 significantly attenuates Fc-effector functions, inhibits the interaction with its ligand HLA-E, and increases the antibody-dependent cellular cytotoxicity mediated by other Fc-competent mAbs. S-095029 has a potent antitumor activity with enhancement of killing activity and cytokine secretion (IFNγ, TNF-α and CXCL9) of NK and γδ T-cells in co-culture with cancer cells .
Abrilumab is a fully human monoclonalantibody directed against α4β7. Abrilumab selectively binds the α4β7 integrin heterodimer. Abrilumab can be used for the research of inflammatory bowel disease (IBD) .
Zalutumumab (powder) is a high affinity, completely human IgG1 monoclonalantibody targeting EGFR. Zalutumumab (powder) binds to domain III of the EGF receptor and acts by blocking the binding of EGF and by sterically interfering with the active conformation of the receptor. Zalutumumab (powder) binds with IgG and its Fab fragment with EC50s of 7 and 19 nM, respectively. Zalutumumab (powder) can be used for the research of cancer .
Canakinumab (ACZ885) is a recombinant human anti-IL-1βmonoclonalantibody. Canakinumab shows IC50 values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin .
Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonalantibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules. Ieramilimab restores T-cell and NK-cell-mediated antileukemic immunity by reducing exhaustion and augmenting cytokine output and cytotoxicity. Ieramilimab increases the infiltration of cytotoxic T lymphocytes and reduces baseline densities of regulatory T cells (Tregs) and ADAM10-expressing tumor cells. Ieramilimab can be used for the study of various malignancies including melanoma, RCC, and advanced solid tumors .
HuL001 is a specific monoclonalantibody targeting ENO1. HuL001 remodels the tumor microenvironment by inhibiting cancer-associated fibroblasts, thereby suppressing the progression of multiple myeloma. HuL001 can be used for research on cancers such as colorectal cancer, pancreatic ductal adenocarcinoma, and myeloma .
Panitumumab (anti-EGFR) is a fully human IgG2 anti-EGFRmonoclonalantibody with anti-tumor activity. Panitumumab (anti-EGFR) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (anti-EGFR) can be used in the research of cancers, such as colon cancer .
BI-1607 is a humanized monoclonalantibody targeting CD32b/FcγRIIB. BI-1607 has an antagonistic function capable of blocking the inhibitory function of FcγRIIB on immune effector cells. BI-1607 has a significant cytolytic activity against malignant B cells and antitumor activity against HER2-positive solid tumors including advanced gastric cancer (GC) with combination with Trastuzumab (HY-P9907) .
REGN7999 is a monoclonalantibody that inhibits TMPRSS6. REGN7999 inhibits TMPRSS6 activity, preventing Hemojuvelin (HJV) lysis, thereby enhancing BMP6-HJV signaling and increasing serum hepcidin. REGN7999 ameliorates iron overload and impaired erythropoiesis in a β-thalassemia mouse model by inhibiting TMPRSS6 activity. REGN7999 is indicated for research in β-thalassemia .
Tinurilimab (Bay 1834942) is an anti-CEACAM6 (carcinoembryonic antigen-related cell adhesion molecule 6) humanized IgG2 monoclonalantibody. CEACAM6 is an immune checkpoint regulator suppressing the activity of effector T-cells against tumors. Tinurilimab shows an increased tumor cell killing effect in the tumor-cell/T-cell co-culture system .
Pucotenlimab (HX008) is a humanized immunoglobulin G4 (IgG4) anti programmed cell death protein 1 (anti-PD-1)monoclonalantibody. Pucotenlimab can be used for the research of tumor .
HY-0102 is a humanized IgG anti-NKG2Amonoclonalantibody and immune checkpoint inhibitor targeting the NKG2A/HLA-E axis. HY-0102 is applicable for the research of advanced solid tumors .
Sunakiment is a humanized IgG1λ monoclonalantibody inhibitor targeting Thymic stromal lymphopoietin (TSLP). Sunakiment can be used for inflammatory and immune system disorders like ulcerative colitis, rheumatoid arthritis and allergy and cancers research .
ABT-147 is a humanized IgG1 monoclonalantibody inhibitor targeting IL-12. ABT-147 can be used to study autoimmune diseases like rheumatoid arthritis (RA), inflammatory diseases like inflammatory bowel disease (IBD) and other diseases like Asthma .
Inclacumab (Anti-Human selectin P Recombinant Antibody) is a human monoclonal IgG4 antibody selectively targets P-selectin with a Kd value of 9.9 nM. Inclacumab inhibits P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide bind with P-selectin with an IC50 value of 1.9 μg/mL and strongly inhibits cell adhesion .
Olsutamig is a bivalent humanized IgG4κ monoclonalantibody inhibitor targeting FOLH1/PSMA and CD3E. Olsutamig simultaneously binds to PSMA on the tumor cell surface and CD3E on the T cell surface, markedly activating T cells and thereby specifically killing prostate cancer cells .
PUR001 is a monoclonalantibody targeting NTPDase 1 (CD39). PUR001 blocks the hydrolysis of extracellular ATP and ADP into AMP by inhibiting CD39, reduces the production of immunosuppressive adenosine, and increases extracellular ATP concentration to activate anti-tumor immune responses. PUR001 can be used in studies related to solid tumors .
Mavrilimumab (CAM 3001) is a monoclonalantibody that binds to the α subunit of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor and blocks intracellular signalling downstream of GM-CSF. GM-CSF might be a mediator of the hyperactive inflammatory response associated with respiratory failure and death .
Vopratelimab (JTX-2011) is a humanized immunoglobulin G1-kappa agonist monoclonalantibody that pecifically binds to the Inducible CO-Stimulator of T cells (ICOS). Vopratelimab retains species cross-reactivity with affinities of 0.93 nM to hICOS, 0.46 nM to cynomolgus ICOS, 3.7 nM to rat ICOS, and 0.64 nM to mICOS. Vopratelimab has antitumor immune response .
Narsoplimab (OMS 721) is a high-affinity fully human immunoglobulin gamma 4 (IgG4) monoclonalantibody that binds MASP-2 and blocks lectin pathway activation. Narsoplimab can be used in research of hematopoietic stem-cell transplantation and SARS-CoV-2 .
Beruzatatug (BNT326/YL202 Antibody) is an IgG1 monoclonalantibody against HER3. Beruzatatug can be used for the synthesis of ADCs, such as BNT326/YL202 .
Raxibacumab (ABthrax) is a human IgG1 monoclonalantibody against Bacillus anthracis protective antigen (PA). Raxibacumab blocks the toxin’s deleterious effects by preventing binding of the protective antigen component of the anthrax toxin to its receptors in host cells, thereby blocking the toxin’s deleterious effects. Raxibacumab can be used for anti-anthrax research .
AFM15 is a humanized monoclonalantibody inhibitor targeting CD3E. AFM15 can be used to study metabolic and immune system diseases, such as type 1 diabetes and inflammatory bowel disease (IBD) .
Elsilimomab (B-E8) is a IgG1 monoclonalantibody against interleukin-6 (IL-6), with a KD of 22 pM and an IC50 of 1.4 nM. Elsilimomab can be used for the research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA) .
Abagovomab (Anti-Human CA-125 Recombinant Antibody) is a mouse monoclonalanti-idiotypic antibody that targets the tumor-associated antigen CA-125. Produced by mouse hybridoma cells, Abagovomab mimics the human TAA, CA-125. Abagovomab also induces humoral and cellular immune responses against ovarian cancer (OC) .
Surzebiclimab (BGB-A425) is a humanized IgG1-variant monoclonalantibody against T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). Surzebiclimab binds to the extracellular domain of human Tim-3 with high affinity (KD=0.36 nM) and specificity. Surzebiclimab can be used in research of cancer .
Toralizumab (IDEC-131) is a humanized monoclonalantibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab is an immunosuppressive agent. Toralizumab can lead to increased thrombosis. Toralizumab can be studied in research for diseases such as multiple sclerosis, systemic lupus erythematosus (SLE), and Crohn’s disease .
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonalantibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .
Retifanlimab is an anti-programmed cell death protein 1 (anti-PD-1) monoclonalantibody (mAb). Retifanlimab can be used for the research of gastroesophageal adenocarcinoma (GEA) .
Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6monoclonalantibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19 .
Refanezumab (GSK249320) is a brain-penetrant IgG1-type humanized monoclonalantibody directed against myelin-associated glycoprotein (MAG). Refanezumab binds to MAG and blocks MAG-mediated inhibition of axonal regeneration. Refanezumab has the potential for the enhancement of recovery of function poststroke .
CC-90002 is a humanized anti-CD47 monoclonalantibody (mAb). CC-90002 has a high affinity for binding to CD47 with a subnanomolar Kd value. CC-90002 can be used for the research of hematologic malignancies and solid tumors .
Lirentelimab (AK002) is a humanized IgG1 monoclonalantibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab induces cell apoptosis of IL-5-activated eosinophils and inhibits IgE-mediated mast cell activation. Lirentelimab can be used for the research of eosinophilic gastritis and duodenitis .
ZM-008 is an anti-LLT1monoclonalantibody. ZM-008 blocks the interaction between LLT1 and CD161 on the surface of NK cells and T cells. ZM-008 restores anti-tumor immune activity, shifts the tumor microenvironment to an immune-responsive state, and recovers NK cell-mediated cytotoxicity against tumor cells, thereby reversing immunosuppression in immune-resistant "cold" tumors. ZM-008 is applicable to the research of immune-resistant solid tumors .
SAIT-301 is a Met-targeting monoclonalantibody. SAIT-301 inhibits Met activation, induces downregulated expression of phosphorylated Met(p-Met) and phosphorylated ERK(p-ERK), and reduces EGR-1 expression. SAIT-301 inhibits the migration and invasion of nasopharyngeal carcinoma cells. SAIT-301 is applicable to relevant research on nasopharyngeal carcinoma. For the isotype control of SAIT-301, refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
Belimumab (LymphoStat B) is a humanized IgG1λmonoclonalantibody against B-lymphocyte stimulator (BLyS) protein. Belimumab antagonizes BLyS activity in autoimmune diseases and B-lymphocyte malignancies. Belimumab can be used for systemic lupus erythematosus (SLE) research . The component ratio of this product is Active ingredient: Excipients = 1:1.0-1:1.2.
MEDI-5884 is a humanized IgG4Pκ neutralizing monoclonalantibody targeting Endothelial lipase (EL). MEDI-5884 inhibits EL and increases quantity (particularly phosphatidylinositols and cholesteryl esters) and function of high-density lipoproteins (HDL). MEDI-5884 can be used for cardiovascular disease like coronary artery disease (CAD) research .
FTL004 is an anti-CD38monoclonalantibody. FTL004 exhibits enhanced Proapoptotic activity and displays stronger ADCC against CD38 + malignant cells. FTL004 can be used for the research of multiple myeloma and non-Hodgkin lymphoma[1].
Ofatumumab is a fully human anti-CD20monoclonalantibody that induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in CD20-expressing B lymphocytes. Ofatumumab has strong lytic activity against CD20-positive B lymphocytes and eliminates CD20-positive tumor cells through ADCC and CDC. Ofatumumab is particularly effective against drug-resistant cells with low CD20 expression and can be applied to the research of chronic lymphocytic leukemia (CLL) .
RSM-01 is a monoclonalantibody targeting site Ø of the pre-fusion F glycoprotein (Fusion glycoprotein F0) of respiratory syncytial virus (RSV). RSM-01 can be used in studies related to RSV infection .
Prezalumab (AMG 557) is a humanized IgG2 monoclonalantibody targeting ICOSL. Prezalumab inhibits T cell activation and related immune responses by binding to ICOSL and blocking the interaction between ICOS and ICOSL. Prezalumab can be used in the research of autoimmune diseases and inflammatory diseases such as systemic lupus erythematosus. Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002) .
ALX-0651 is a biparatopic humanized monoclonalantibody inhibitor targeting CXCR4. ALX-0651 inhibits hematopoietic stem cell trafficking, tumor progression and metastasis. ALX-0651 can be used for non-Hodgkin’s lymphoma and multiple myeloma research .
CTX-471 is a fully human monoclonalantibody of CD137. CTX-471 has bind affinity for recombinant human, cynomolgus macaque CD137 and mouse CD137 with Kd values of 50 nM, 61 nM and 748 nM, respectively. CTX-471 can be used for the research of immunomodulation and cancer .
TQC2938 is a humanized IgG2 monoclonalantibody inhibitor targeting Stimulation-2 (ST2). TQC2938 inhibits the ST2/IL-33 signaling pathway, reduces the level of downstream Th2 cytokines (such as IL-4, IL-5, and IL-13) and eosinophils as well as other inflammatory cells. TQC2938 can be used for inflammatory diseases like asthma research .
AB011 is a recombinant humanized anti-CLDN18.2 IgG1 monoclonalantibody. AB011 exhibits synergistic effects with cytotoxic compounds in preclinical studies. AB011 can be used for research on advanced gastric/gastroesophageal junction adenocarcinoma and advanced pancreatic cancer .
Sudubrilimab (HS636) is an Ig G1-kappa monoclonalantibody against PDL1. Sudubrilimab is fused at the C terminus of the heavy chain to a TGF-β1 receptor Ⅱ ectodomain (TGFBR2-ECD), and which can sequester the PD-1/PD-L1 pathway and TGF-β bioactivity in the immunosuppressive tumor microenvironment .
Efalizumab is a targeted T cell modulator, and is a humanized monoclonalantibody of CD11a, the α subunit of LFA-1. Efalizumab inhibits T cell activation, cutaneous T cell trafficking, and T cell adhesion to keratinocytes, can be used for plaque psoriasis research .
Mepolizumab (SB 240563) is a humanized monoclonalantibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .
Satralizumab is a humanized monoclonalantibody that targets IL-6R. Satralizumab prevents dTAA formation and progression in rattus norvegicus. Satralizumab can be used for neuromyelitis optica spectrum disorder (NMOSD) and descending thoracic aorta aneurysm (dTAA) research .
Human IgG1 (K214R) kappa, Isotype Control is a human IgG1 kappa monoclonalantibody mutant with a lysine-to-arginine substitution at position 214. Human IgG1 (K214R) kappa, Isotype Control is mainly used as an isotype control in experiments such as immunoprecipitation. Human IgG1 (K214R) kappa, Isotype Control binds to proteins non-specifically, thereby helping researchers verify the interactions of specific antibodies and ensure the accuracy of experimental results .
Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research .
UB-221 is a humanized IgG1 monoclonalantibody inhibitor targeting IgE. UB-221 significantly decreases IgE synthesis by stabilization of membrane-bound CD23 on B lymphocytes and inhibits FcԑRI-mediated basophil activation and degranulation. UB-221 reduces IgE level in cynomolgus macaques and human IgE (ε, κ)-transgenic (hIGHE-knockin) mice. UB-221 can be used for asthma and chronic spontaneous urticaria (CSU) research .
Mepolizumab (anti-IL5) is a humanized monoclonalantibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .
SAR-446523 is a humanized IgG1 monoclonalantibody inhibitor targeting GPRC5D. SAR-446523 significantly induces antibody-dependent cell-mediated cytotoxicity (ADCC). SAR-446523 has potent antitumor activity with improvement of mouse survival in NK humanized NOG huIL15 transgenic mice model bearing MM cells. SAR-446523 can be used for multiple myeloma (MM) research .
Aducanumab (Mouse IGG2a) is a monoclonalantibody that selectively targets aggregated amyloid-beta (Aβ). The variable region of Aducanumab (Mouse IGG2a) is consistent with that of Aducanumab (HY-P9967), while the constant region is of Mouse IGG2a sequence. Aducanumab (Mouse IGG2a) has strong selectivity for Aβ fibrils with EC50s of >1 μM and 0.2 nM for monomeric Aβ1-40 and fibrillar Aβ1-42, respectively. Aducanumab (Mouse IGG2a) can be used for Alzheimer's disease (AD) research .
AGS-009 is a humanized monoclonal neutralising antibody targeting IFN-α. AGS-009 significantly reduces activated lymphocytes, such as CD4 + and CD8 + T cells as well as B cells in SIV infection rhesus macaque models. AGS-009 can be used for autoimmune diseases like systemic lupus erythematosus (SLE) and HIV infections research .
Modakafusp alfa (TAK-573) is a humanized, anti-CD38IgG4monoclonalantibody fused to 2 attenuated IFNα2b molecules, which delivers interferon-alpha to CD38-expressing cells. Modakafusp alfa has direct anti-proliferative activity on multiple myeloma (MM) cancer cells in vitro and induces robust and durable antitumor responses in MM xenograft tumor models. Modakafusp alfa in combination with anti-PD-1 antibodies induces immunomodulation and antitumor responses with good tolerance in mice .
AK006 is a humanized IgG1 monoclonalantibody agonist targeting Sialic acid-binding immunoglobulin-like lectin6 (Siglec-6). AK006 potently inhibits IgE-mediated human mast cell activation. AK006 can be used for inflammatory diseases like chronic urticaria (CU) and asthma research .
ART5803 is a humanized IgG1 monoclonalantibody inhibitor targeting NMDAR. ART5803 binds to the N-terminal domain (NTD) of the NMDAR GluN1 subunit (GluN1-NTD) with a high affinity. ART5803 blocks NMDAR internalization induced by pathogenic autoantibodies and restores cell-surface NMDAR expression and functions. ART5803 reverses behavioral abnormalities and NMDAR expression in marmoset disease models. ABT-147 can be used to study anti-NMDAR encephalitis .
Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonalantibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with Ki values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD) .
TRX585 is a humanised anti-immunoglobulin-like transcript 5 (ILT5) monoclonalantibody. TRX585 has a potent immunoregulatory activity. TRX585 significantly activates human T cells and upregulates NKG2D and Fas ligand, followed by enhancing antitumor activity with potent cytotoxicity. TRX585 can be used for viral infections and malignancies research .
ABX-MA1 is a humanized IgG2 monoclonalantibody inhibitor targeting MCAM/MUC18. ABX-MA1 significantly decreases homotypic aggregation and heterotypic adhesion to HUVECs, and the formation of experimental lung metastasis. ABX-MA1 potently inhibits tumor growth, angiogenesis, and MMP-2 expression in A375SM/WM2664 xenograft mice model, promising for melanoma research .
CQY684 (PCA062 antibody) is a monoclonalantibody targeting CDH3/P-cadherin, which locks P-cadherin in an X-dimer conformation and enhances the stability of this adhesion structure. CQY684 induces P-cadherin phosphorylation and promotes its dissociation from the cytoplasmic region of P-cadherin. As an endocytosis inducer and lysosome-targeting agent, CQY684 facilitates the internalization of the P-cadherin-CQY684 complex and improves the turnover efficiency of P-cadherin. CQY684 serves as a platform for the delivery of intracellular anticancer compounds, which is achieved through the targeted lysosomal transport of the antibody-P-cadherin complex. CQY684 is applicable to the research of breast cancer, esophageal cancer, and head and neck cancer .
VX5 (VX5/5261) is a humanized IgG1κ monoclonalantibody inhibitor targeting BCA-1/CXCL13. VX5 significantly inhibits human CXCL13-mediated internalization of CXCR5, blocks both human and mouse CXCL13-dependent B-cells chemotaxis and migration. VX5 can be used to study autoimmune diseases like multiple sclerosis and arthritis, and cancers like gastric lymphomas and colon cancer .
RO-7303509 (MTBT1466A; RG-6315) is a human monoclonalantibody and TGFβ3 neutralizer. RO-7303509 targets the profibrotic mediator TGFβ3 to alleviate fibrosis. RO-7303509 can be administered via subcutaneous or intravenous routes and is used in research on systemic sclerosis . Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
Vopratelimab (Mouse IgG2a) is a agonist monoclonalantibody that selectively targets Inducible CO-Stimulator of T cells (ICOS). The variable region of Vopratelimab (Mouse IgG2a) is consistent with that of Vopratelimab (HY-P99382), while the constant region is of Mouse IgG2a sequence. Vopratelimab (Mouse IgG2a) has antitumor immune response and enhances combinatorial efficacy with anti-PD-1 (HY-P9902A) therapy .
Spartalizumab is a humanized PD-1 IgG4 monoclonalantibody, with a Kd of 0.83 nM for human PD-1 and a Kd of 0.93 nM for cynomolgus monkey PD-1. Spartalizumab binds to PD-1 and blocks its interaction with the ligands PD-L1 and PD-L2. Spartalizumab induces increased IFNγ release. Spartalizumab can be used in the research of anaplastic thyroid carcinoma (ATC) and neuroendocrine neoplasms (NENs) .
MORAb-028 is a humanized IgG1 monoclonalantibody inhibitor targeting GD2. MORAb-028 has a potent antitumor activity and kills GD2-expressing target cells via complement-mediated cytotoxicity (CDC). MORAb-028 significantly inhibits tumor growth in EL-4-luc xenograft mice model. MORAb-028 can be used for melanoma cancer research .
Nidanilimab (CAN04) is a fully humanized monoclonalanti-IL1RAPantibody with a Kd value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) .
Briquilimab (JSP-191 or AMG-191) is a humanized IgG1 monoclonalantibody that binds human CD117 (c-Kit). Briquilimab blocks the interaction between CD117 receptor and stem cell factor on various CD117 expressing tissues. Briquilimab can lead to inhibition of SCF/c-Kit signaling and MC apoptosis. Briquilimab is a non-toxic approach to target and deplete HSC, enabling blood and immune reconstitution with minimal toxicity with the other agents being used for transient immune suppression to prevent immunologic rejection. Briquilimab can be used in various disease research such as severe combined immunodeficiency (SCID), myelodyplastic syndromes (MDS), acute myeloid leukemia (AML), chronic spontaneous urticarial (CSU), chronic inducible urticarial (CIndU) and asthema .
JS006 is a humanized IgG4κ monoclonalantibody inhibitor targeting TIGIT/CD155. JS006 can be used to study advanced and/or metastatic cancers with resistance to PD-1/PD-L1 inhibitor such as non-small cell lung cancer (NSCLC), advanced lymphoma and advanced/metastatic triple negative breast cancer (TNBC) .
Astegolimab (MSTT 1041A; RG 6149) is a human IgG2 monoclonalantibody. Astegolimab blocks IL-33 signaling by targeting the IL-33 receptor ST2. Astegolimab reduces p53 expression, mitigates IL33-upregulated SASP factors such as IL1α, IL6 and MCP1. Astegolimab mitigates IL33-increased p-p65/p65 ratio. Astegolimab blocks CM-induced neutrophil extracellular trap (NET) formation. Astegolimab is used in chronic obstructive pulmonary disease (COPD) and myocardial research .
MEDI4212 is a humanized IgG1λ monoclonalantibody inhibitor targeting IgE. MEDI4212 potently inhibits human IgE-mediated functional responses through its receptor FcεRI, such as calcium signaling, β-hexosaminidase release and phagocytosis. MEDI4212 prevents the binding of IgE to CD23 with an IC50 of 8 nM. MEDI4212 can be used severe asthma research .
Eptinezumab (ALD-403) is a human monoclonalantibody targeting the α and β subtypes of human calcitonin gene-related peptide (CGRP). Eptinezumab binds to the CGRP ligand and blocks its binding to endogenous CGRP receptors, thereby inhibiting receptor activation. Eptinezumab can be used in research related to migraine .
Ruplizumab (BG 9588) is a humanized anti-CD40L IgG1κ monoclonalantibody. By binding to CD40L, Ruplizumab blocks its interaction with the CD40 receptor, inhibits T-B cell costimulatory signals, and mediates the depletion of activated T cells via the Fc segment. Ruplizumab has immunosuppressive effects. Ruplizumab can be used in the study of systemic lupus erythematosus, organ transplant rejection, and autoimmune diseases. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
SHR-1702 is a monoclonalantibody targeting TIM-3, which specifically binds to and blocks the TIM-3 signaling pathway. SHR-1702 restores the function of immune cells and inhibits the proliferation process of malignant cells. SHR-1702 is mainly used in relevant research on acute myeloid leukemia and myelodysplastic syndromes .
Anafiltamig is a trivalent monoclonalantibody inhibitor targeting CD79B, CD3E and MS4A1. Anafiltamig consists of a humanized IgG1κ anti-CD79B arm and a bispecific scFv-based arm targeting CD3E and MS4A1. Anafiltamig simultaneously bridges T and B cells, activating T cells and specifically killing B cell tumors. Anafiltamig can be used for B cell malignancies such as non-Hodgkin lymphoma research .
Elfritatug (UCB4594) is a humanized monoclonalantibody targeting human leukocyte antigen-G (HLA-G). By binding to HLA-G on the surface of tumor cells, Elfritatug blocks its immunosuppressive effect, thereby enhancing the body's immune response against tumors .
Theralizumab (TGN1412) is a humanized lgG4 superagonistic anti-CD28monoclonalantibody that directly stimulates T cells. Theralizumab can cause cytokine release syndrome (CRS). Theralizumab can be used for the research of rheumatoid arthritis .
Sarilumab is a monoclonalantibody targeting IL6 that binds to IL6R and blocks the binding of IL6, thereby inhibiting the activation of the downstream STAT3 phosphorylation signaling pathway. In tumor cells with active IL6/STAT3 signaling pathways, Sarilumab induces Apoptosis and inhibits cell growth. Sarilumab is applicable to research related to prostate cancer, lung cancer and rheumatoid arthritis .
MM-151 is a humanized IgG1 monoclonalantibody targeting EGFR. MM-151 binds multiple regions of the EGFR extracellular domain (ECD) and reduces its mutations in circulating cell-free tumor DNA with EGFR resistance. MM-151 significantly inhibits EGFR signaling and cell growth. MM-151 can be used for drug-resistant cancers research, such as colorectal, non-small cell lung and triple negative breast cancer .
LY-2624587 is a humanized IgG4 monoclonalantibody antagonist targeting CXCR4. LY-2624587 blocks SDF-1/CXCR4 interaction and SDF-1-induced GTP binding. LY-2624587 significantly inhibits cell migration and induces apoptosis in human lymphoma and leukemia cells. LY-2624587 also inhibits CXCR4 and SDF-1 mediated cell signaling including activation of MAPK and AKT. LY-2624587 can be used for human hematological malignancies like acute myeloid leukemia (AML) research .
SHR-1906 is a selective fully humanized monoclonal IgG1 inhibitory antibody targeting CTGF. SHR-1906 specifically binds to CTGF, thereby blocking the interaction between CTGF and TGF-B1 with an inhibition rate of 55%. SHR-1906increases the survival rate in a pulmonary fibrosis model by reducing TGF-β1 levels and inhibiting fibrotic lesions in lung tissue in Bleomycin (HY-108345)-induced pulmonary fibrosis.SHR-1906 can be used for pulmonary fibrosis (IPF) research. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonalantibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab (HY-P9913). Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL) .
AB-004 is a humanized monoclonalantibody and ADC targeting uPARAP. AB-004 can be conjugated with the topoisomerase-1 inhibitor P1021 via a protease-cleavable tetrapeptide linker to form the ADC ADCE-D01. AB-004 binds to tumor cells expressing uPARAP, triggering the endocytosis of the ADC. AB-004 is applicable for cancer research .
Tislelizumab is a monoclonalantibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small cell lung cancer and hepatocellular carcinoma .
HB-0017 is a humanized IgG1κ monoclonalantibody inhibitor, targeting IL-17A. HB-0017 inhibits the IL-6 secretion induced by IL-17A with an IC50 of 2.09 nM. HB-0017 significantly decreases ear thickness in Imiquimod (HY-B0180)-induced psoriasis-like mice model and alleviates inflammations in IL-17A-induced arthritis and air pouch mice model. The isotype control for the HB-0017 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
Frexalimab (SAR441344) is a second-generation monoclonalantibody targeting the CD40 ligand (CD40L) with a good safety profile. Frexalimab inhibits the binding between CD40 and CD40L to modulate immune response. Frexalimab is likely to help prevent the process of β-cell destruction. Frexalimab is proming for multiple sclerosis, lupus erythematosus, Sj gren’s syndrome and type I diabetes research .
KD6001 is a humanized IgG1κ monoclonalantibody, targeting CTLA4. KD6001 significantly disrupts CTLA-4 interactions with CD80 (IC50: 16 ng/mL) and CD86. KD6001 enhances IL-2 and IFNγ expression in PHA-activated human lymphocytes and exhibits potent antitumor effects. KD6001 effectively inhibits tumor growth in MC38, B16, and Hepa1-6 tumor mice model. KD6001 can be used for cancers research, such as advanced melanoma, hepatocellular carcinoma and liver cancer .
IBI-325 is a humanized monoclonalantibody inhibitor targeting CD73. IBI-325 completely inhibits CD73 enzymatic activity without hook effect. IBI-325 reverses Adenosine monophosphate (HY-A0181)-mediated immune suppression and significantly inhibits T cell proliferation and cytokines (IL-2, IFN-γ and TNF-α) release. IBI-325 has potent antitumor activities in hPBMC-reconstituted mice model and hCD73 knock-in mice model. IBI-325 can be used for cancer immunotherapy research .
Muromonab (Muromonab-CD3; OKT3) is a mouse monoclonalantibody targeting the CD3 antigen. Muromonab specifically binds to the CD3 antigen on the surface of human and higher primate T cells. Muromonab blocks the function of T cell receptors to recognize foreign antigens and inhibits T cell-mediated immune responses, including cell-mediated lymphocyte lysis and T cell proliferation responses. Muromonab can be used to study acute kidney, liver, heart and combined kidney-pancreas transplant rejection, and can also be used to study graft-versus-host disease in bone marrow transplant patients .
OM-RCA-01 is an anti-FGFR1monoclonalantibody with a Kd of 1.59 nM for human FGFR1. OM-RCA-01 inhibits the phosphorylation of FGFR1, blocks FGF-mediated signaling pathways, and suppresses the proliferation of downstream tumor cells. OM-RCA-01 delays tumor growth in lung cancer and renal cancer xenograft models expressing FGFR1. When combined with Nivolumab, OM-RCA-01 enhances the release of IFN-γ and IL-2. OM-RCA-01 is applicable for the research of lung cancer and renal cell carcinoma .
Navivumab (CT-P23) is a monoclonalantibody targeting the hemagglutinin (HA) of influenza A virus. Navivumab binds to the HA2 stem fusion domain and the low-variability HA2 region of influenza viruses. Navivumab neutralizes influenza A viruses of subtypes H1, H2, H5, and H9. Navivumab is applicable to research related to influenza and influenza A .
ING-1 (heMab) is a high-affinity humanized monoclonalantibody against epithelial cell adhesion molecule (Ep-CAM). ING-1 is a transmembrane glycoprotein mediating Ca 2+. ING-1 binds to Ep-CAM on tumor cells and exhibits potent in vitro activity, targeting and inhibiting tumor growth and metastasis in mouse cancer models. ING-1 is useful in the research of breast, colorectal, and lung cancers, among other cancers .
Sintilimab (IBI308) is a safe and effectivel humanized IgG4monoclonalantibody that binds to PD-1 with a KD value of 74 pM. Sintilimab blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .
IOR-T3 is a monoclonalantibody targeting CD3, with biological activities related to T cell activation regulation . IOR-T3 uses its variable region to competitively engage surface CD3 on lymphocytes and trigger robust T cell proliferation and activation. IOR-T3 and its derivatives can be used in studies related to acute transplant rejection .
Zaltenibart (OMS906) is an IgG4 humanized monoclonalantibody and MASP-3 inhibitor. By inhibiting MASP-3, Zaltenibart achieves upstream inhibition of the alternative complement pathway. MASP-3 is an upstream activator of Factor D (Factor D), a key enzyme in the alternative complement pathway. Zaltenibart prevents both intravascular hemolysis and extravascular hemolysis. Zaltenibart is applicable to research related to paroxysmal nocturnal hemoglobinuria .
Efanesoctocog alfa is a B domain-deleted single-chain Factor VIII (FVIII) connected to D'D3 domain of von Willebrand Factor (vWF). Efanesoctocog alfa has an extended half-life. Efanesoctocog alfa can be used for the study of inherited hemophilia A .
Anti-CEACAM5 Antibody (A5B7) is a humanized antibody expressed in CHO cells, targeting CEACAM5/CEA/CD66e. Anti-CEACAM5 Antibody (A5B7) consists of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-CEACAM5 Antibody (A5B7) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Vasigrobart is a CHO-expressed human antibody that targets PDGFB. Vasigrobart has huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Vasigrobart can refer to Human IgG4 kappa, Isotype Control (HY-P99003) .
Lunaxafusp is an anti-ERBB2 scFv-heavy-κ monoclonalantibody composed of a single chain variable fragment, an antibody heavy chain, and a kappa antibody light chain .
Natalizumab (Anti-CD49d) (AN100226; BG00002) Solution is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d), blocking the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab solution inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 + T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thereby exerting anti-inflammatory and immunomodulatory activity. Natalizumab (Anti-CD49d) solution is used in the study of relapsing-remitting multiple sclerosis (RRMS) and is also applied in the research of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab (Anti-CD49d) can also prevent lymphocytes from entering the central nervous system, thus preventing acute demyelinating relapses .
Verekitug (ASP-7266; TRAB-1; UPB-101) is a human monoclonalantibody targeting the thymic stromal lymphopoietin receptor (TSLPR), with a mean half-life of approximately 20 days. At doses of Verekitug ≥100 mg, complete and sustained TSLPR-specific occupancy is achieved, and the antibody does not bind to IL-7Rα. By inhibiting TSLP-driven inflammatory responses, Verekitug blocks TSLP-induced cell proliferation and TARC expression, while reducing fractional exhaled NO levels, blood eosinophil counts, and levels of IL-5 and IgE. Verekitug significantly improves scores for nasal polyps, nasal congestion and olfactory dysfunction, with favorable safety and good tolerability; potential adverse reactions include headache, upper respiratory tract infection, sinusitis and nasopharyngitis. Verekitug is used in relevant studies on asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease .
Anti-CD160 Antibody (MAT 303) is a human monoclonalantibody targeting CD160. Anti-CD160 Antibody (MAT 303) can be used in research related to cancer and autoimmune diseases.
AMT-151 Antibody is a monoclonalantibody inhibitor targeting folate receptor α. AMT-151 Antibody can be used to synthesize the antibody-drug conjugate (ADC) AMT-151. AMT-151 Antibody can be used to research related to cancer .
MRG004A Antibody (HuSC1-39) is a monoclonalantibody inhibitor targeting tissue factor (TF). MRG004A Antibody can be used to synthesize the antibody-drug conjugate (ADC) MRG004A. MRG004A Antibody can be used to research related to cancer .
Cilgavimab (AZD-1061; COV2-2130) is a human SARS-CoV-2-neutralizing monoclonalantibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of SARS-CoV-2 infection .
VIS954 is an anti-APRIL monoclonalantibody. VIS954 can be studied in research for anti-neutrophil cytoplasmic antibody-associated vasculitis (ANCA Vasculitis) and IgA nephrophathy .
Anti-PSMA Antibody (ARX517 antibody) is a humanized IgG1 monoclonalantibody that targets PSMA. Anti-PSMA Antibody is the antibody part of the ADC molecule ARX517. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
CSC012 Antibody is a monoclonalantibody inhibitor targeting IL-1RAP. CSC012 Antibody can be used to synthesize the antibody-drug conjugate (ADC) CSC012. ADV-101 Antibody can be used to research related to acute myeloid leukemia .
SOT102 Antibody is an IgG1 monoclonalantibody targeting CLDN18.2, and the antibody of ADC SOT102. SOT102 Antibody binds selectively to CLDN18.2, and promotes internalization. SOT102 Antibody can be used for the research of cancer [2].
Modotuximab (DS 1024) is an IgG1κ-type chimeric antibody targeting human EGFR protein. Modotuximab binds non-overlapping epitopes on domain III of EGFR, a domain that is intact in EGFRvIII. Modotuximab has antitumor activity in vivo .
Anti-PILRA Antibody is a monoclonalantibody that targets PILRA. Anti-PILRA Antibody can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-PILRA Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-PCI Antibody is a monoclonalantibody that targets PCI. Anti-PCI Antibody can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-PCI Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
ZV0201 Antibody (ZV02) is a monoclonalantibody inhibitor targeting Her2. ZV0201 Antibody can be used to synthesize the antibody-drug conjugate (ADC) ZV0201. ZV0201 Antibody can be used to research related to HER2-positive tumors .
IKS012 (IKS01) Antibody is a monoclonalantibody inhibitor targeting folate receptor α (FRA). IKS012 Antibody can be used to synthesize the antibody-drug conjugate (ADC) IKS012. IKS012 Antibody can be used to research related to platinum-resistant ovarian cancer .
ADV-101 Antibody is a monoclonalantibody inhibitor targeting IL-1RAP. ADV-101 Antibody can be used to synthesize the antibody-drug conjugate (ADC) ADV-101. ADV-101 Antibody can be used to research related to cancer .
Anti-Claudin 6 Antibody (IM-302) is a human monoclonalantibody targeting Claudin-6/CLDN6. Anti-Claudin 6 Antibody (IM-302) can be used in cancer research.
Anti-HER3 Antibody (Ab562) is an anti-HER3monoclonalantibody. Anti-HER3 Antibody (Ab562) can be used to synthesize the antibody-drug conjugate (ADC) AMT-562 (HY-171747) .
Anti-Galanin Antibody is a monoclonalantibody that targets galanin. It can be used in ELISA, FACS, and functional assays. For isotype controls of anti-Galanin Antibody, please refer to Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-NGAL Antibody is a monoclonalantibody targeting NGAL. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-NGAL Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-PTHrP Antibody is a monoclonalantibody that targets PTHrP. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-PTHrP Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CA6 Antibody (huDS6) is a Mucin 1-associated sialoglycotope (CA6) targeting humanized monoclonalantibody. Anti-CA6 Antibody (huDS6) can be used for synthesis of ADCs .
Anti-PRNP Antibody is a monoclonalantibody that targets PRNP. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-PRNP Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-OSCAR Antibody is a monoclonalantibody that targets OSCAR. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-OSCAR Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-LCAT Antibody is a monoclonalantibody targeting LCAT. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-LCAT Antibody, please refer to Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-Neublastin Antibody is a monoclonalantibody targeting neublastin. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Neublastin Antibody, please refer to Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-Apelin Antibody is a monoclonalantibody that targets apelin. It can be used in ELISA, FACS, and functional assays. For isotype controls of anti-Apelin Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Heparanase Antibody is a monoclonalantibody that targets heparanase. It can be used in ELISA, FACS, and functional assays. For isotype controls of anti-heparanase antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Tenascin C Antibody (Neuradiab antibody) is a human monoclonalantibody (mAb) targeting Tenascin C. Anti-Tenascin C Antibody can be used in Glioblastoma research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
MAS82590 (Arumakimig) is a bispecific IL-1β and IL-18monoclonalantibody that reduces inflammasome-mediated inflammation. MAS825 combines the anti-IL-1β and anti-IL-18 monoclonalantibodies (mAbs) inhibition domains in a single bispecific high-affinity cytokine capture molecule .
AVID100 (MAB100) Antibody is a monoclonalantibody inhibitor targeting EGFR, which can be used to synthesize a novel antibody-drug conjugate (ADC) molecule AVID100. AVID100 Antibody is applicable to relevant research on breast cancer, head and neck cancer, and lung cancer .
Anti-FOLH1/PSMA Antibody (J591) (MEDI3726 antibody) is a human monoclonalantibody (mAb) targeting FOLH1/PSMA. Anti-FOLH1/PSMA Antibody (J591) can be used in Prostate cancer research .
Opucolimab (HLX20) is an engineered anti-PD-L1 humanised IgG1 antibody. Opucolimab, when conjugated with camptothecin toxoid, yields the PD-L1-targeting ADC, HLX43 (HY-177439). HLX43 can be used for non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), esophageal squamous cell carcinoma (ESCC), melanoma (MEL), ovarian cancer (Ovc) research .
Anti-c-Met/HGFR Antibody is a humanized IgG1 monoclonalantibody that targets c-Met. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
Inebilizumab is an anti-CD19monoclonalantibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research .
ATG-022 Antibody is a humanized monoclonalantibody targeting Claudin 18.2 (CLDN 18.2). ATG-022 Antibody binds with VcMMAE (HY-15575) to form an Antibody-Drug Conjugate (ADC). ATG-022 Antibody can be used for the research of advanced/metastatic solid tumors and gastric cancer .
Anti-BCAM Antibody is a monoclonalantibody that targets BCAM. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-BCAM Antibody, please refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
Anti-Endothelial Lipase Antibody is a monoclonalantibody targeting endothelial lipase. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Endothelial Lipase Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Fibronectin III Antibody is a monoclonalantibody targeting Fibronectin III. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Fibronectin III Antibody, please refer to Mouse IgG2a kappa, Isotype Control (HY-P99978).
Anti-PRAME Antibody is a monoclonalantibody that targets the melanoma antigen preferentially/PRAME. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-PRAME Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TrkC Antibody is a monoclonalantibody targeting TrkC/NTRK3. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-TrkC Antibody, please refer to Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-Artemin Antibody is a monoclonalantibody that targets artemin. It can be used in ELISA, FACS, and functional assays. For isotype controls of anti-artemin antibody, please refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
Anti-Mouse CD20 Antibody (AISB12) is an anti-mouse CD20 IgG2a monoclonalantibody. Anti-Mouse CD20 Antibody (AISB12) can deplete B cells. Anti-Mouse CD20 Antibody (AISB12) can be used for research on immunology .
Ocrelizumab (Ocrevus) is a humanized anti-CD20monoclonalantibody. Ocrelizumab can induce B cell depletion and inhibit multiple sclerosis lesions in mice through antibody dependent cytotoxicity (ADCC) .
PF-06478924 (PF-06664178 antibody; RN926) is a human monoclonalantibody (mAb) targeting TROP2. PF-06478924 can be used in the study of advanced and metastatic solid tumors .
Anti-CXCR3 Antibody (5H7) is a mouse monoclonalantibody produced using CXCR3 as the antigen. The recommended isotype control is human IgG1 kappa (HY-P99001).
Anti-CD79 Antibody is a monoclonalantibody that targets CD79. Anti-CD79 Antibody can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CD79 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-NGLY1 Antibody is a monoclonalantibody that targets NGLY1. Anti-NGLY1 Antibody can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-NGLY1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Mouse FAP Antibody (73.3) is an anti-mouse FAP IgG1 monoclonalantibody. Anti-Mouse FAP Antibody (73.3) can be used to accurately detect the expression and localization of FAP protein in mice. Anti-Mouse FAP Antibody (73.3) can be used for research on cancer .
Anti-MCT1 Antibody is a monoclonalantibody that targets MCT1. Anti-MCT1 Antibody can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-MCT1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD180 Antibody is a monoclonalantibody that targets CD180. Anti-CD180 Antibody can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CD180 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-MP1 Antibody is a monoclonalantibody that targets MP1. Anti-MP1 Antibody can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-MP1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-NKp46 Antibody is a monoclonalantibody targeting NKp46. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-NKp46 Antibody, please refer to Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-KLK7 Antibody is a monoclonalantibody targeting KLK7. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-KLK7 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CDH19 Antibody is a monoclonalantibody that targets CDH19. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CDH19 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-ADAM17 Antibody is a monoclonalantibody targeting ADAM17. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-ADAM17 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-RNF43 Antibody is a monoclonalantibody targeting RNF43. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-RNF43 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Notch4 Antibody is a monoclonalantibody targeting Notch4. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Notch4 Antibody, please refer to Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-ADMAST4 Antibody is a monoclonalantibody targeting ADMAST4. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-ADMAST4 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-RSPO2 Antibody is a monoclonalantibody that targets RSPO2. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-RSPO2 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD99 Antibody is a monoclonalantibody that targets CD99. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CD99 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-AGR2 Antibody is a monoclonalantibody that targets AGR2. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-AGR2 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TIMP-1 Antibody is a monoclonalantibody that targets TIMP1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-TIMP-1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD84 Antibody is a monoclonalantibody that targets CD84. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CD84 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-KLRB1 Antibody is a monoclonalantibody targeting KLRB1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-KLRB1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CCL21 Antibody is a monoclonalantibody targeting CCL21. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CCL21 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-APCDD1 Antibody is a monoclonalantibody that targets APCDD1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-APCDD1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-LAIR1 Antibody is a monoclonalantibody that targets LAIR1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-LAIR1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Human IgG1 lambda2, Isotype Control is a human monoclonalantibody that is the isotype control of human IgG1λ antibody. Isotype control antibodies can help remove non-specific signals from experimental results and assess the accuracy and reliability of the experiment .
Anti-STAT3 Antibody is a monoclonalantibody that targets STAT3. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-STAT3 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Robo4 Antibody is a monoclonalantibody targeting Robo4. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Robo4 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CCR9 Antibody is a monoclonalantibody targeting CCR9. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CCR9 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TSPAN33 Antibody is a monoclonalantibody targeting TSPAN33. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-TSPAN33 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-FZD5 Antibody is a monoclonalantibody targeting FZD5. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-FZD5 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-EMR2 Antibody is a monoclonalantibody targeting ADGRE2. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-EMR2 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-ApoL1 Antibody is a monoclonalantibody that targets ApoL1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-ApoL1 Antibody, please refer to Rabbit IgG1 kappa, Isotype Control (HY-P99980).
Anti-MSR1 Antibody is a monoclonalantibody that targets MSR1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-MSR1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CXCL13 Antibody is a monoclonalantibody targeting CXCL13. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CXCL13 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-LRP5 Antibody is a monoclonalantibody that targets LRP5. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-LRP5 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-PAD4 Antibody is a monoclonalantibody that targets PAD4. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-PAD4 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Notch2 Antibody is a monoclonalantibody targeting Notch2. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Notch2 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Feladilimab (Anti-ICOS/CD278 Reference Antibody (feladilimab); GSK3359609) is humanized IgG4 anti-ICOS/CD278 agonist monoclonalantibody. Feladilimab can be used for the research of cancer .
Anti-GPRC5D Antibody (LM-305 antibody) is a humanized IgG1 monoclonalantibody that targets GPRC5D. Anti-GPRC5D Antibody is the antibody part of the ADC molecule LM-305. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Protein S Antibody is a monoclonalantibody targeting Protein S. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Protein S Antibody, please refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
Anti-Plexin A1 Antibody is a monoclonalantibody targeting Plexin A1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Plexin A1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Lipocalin-2 Antibody is a monoclonalantibody targeting Lipocalin-2. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Lipocalin-2 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-IL-32 Antibody is a monoclonalantibody that targets IL-32. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-32 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-IL-19 Antibody is a monoclonalantibody that targets IL-19. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-19 Antibody, please refer to Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-IL-26 Antibody is a monoclonalantibody that targets IL-26. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-26 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CHRDL-1 Antibody is a monoclonalantibody that targets CHRDL-1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CHRDL-1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-IL-24 Antibody is a monoclonalantibody that targets IL-24. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-24 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-MMP-16 Antibody is a monoclonalantibody targeting MMP-16. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-MMP-16 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
EU101 (NOV1801) is a humanized agonistic monoclonalantibody targeting the costimulatory receptor CD137, with potential immunostimulatory and antineoplastic activities .
Detumomab is a mouse monoclonalantibody targeting human B-cell lymphoma. Detumomab can be used in the research of cancers such as non-Hodgkin's lymphoma (NHL).
Anti-DR3 Antibody is a monoclonalantibody that targets DR3. Anti-DR3 Antibody can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-DR3 Antibody, please refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
Anti-DKK2 Antibody is a monoclonalantibody that targets DKK2. Anti-DKK2 Antibody can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-DKK2 Antibody, please refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
Praluzatamab is a monoclonalantibody targeting the activated leukocyte cell adhesion molecule (ALCAM/CD116). Praluzatamab can be used to synthesize Praluzatamab ravtansine (antibody-drug conjugates). Praluzatamab can be used for research of cancers .
Ocaratuzumab (AME 133v) is an Fc-engineered humanized IgG1 anti-CD20monoclonalantibody, with a Kd of ~100 pM. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC) .
AGEN1307 is a human monoclonalantibody (mAb) targeting TIGIT. AGEN1307 has an active FcγR binding region and enhances antibody-dependent cellular cytotoxicity (ADCC). AGEN1307 can be used in cancer research .
Anti-Canine CD28 Antibody (1C6) is a mouse-derived monoclonalantibody that targets canine CD28, which isotype control is Mouse IgG1 kappa, Isotype Control (HY-P99977).
Gatipotuzumab (PankoMab) is a humanized monoclonalantibody which recognizes the tumor-specific epitope of mucin-1 (TA-MUC1). Gatipotuzumab reveals a potent tumor-specific antibody-dependent cell cytotoxicity (ADCC) .
Izeltabart (MGA021) is a humanized IgG1 monoclonalantibody targeting ADAM9, which can be used as an ADC Antibody to synthesize the ADC molecule IMGC936 (Izeltabart Tapatansine). Izeltabart can be used in the study of cancer .
Anti-CD326/EPCAM Antibody (3622W94) is a humanized antibody expressed in CHO cells, targeting EpCAM/TROP1/CD326. Anti-CD326/EPCAM Antibody (3622W94) can be used for epithelial cancers research, such as pancreatic, prostate and breast cancer.
Anti-Kremen2 Antibody is a monoclonalantibody that targets Kremen2. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Kremen2 Antibody, please refer to Human IgG1 (N297A) kappa, Isotype Control (HY-P99994).
Anti-CD300A Antibody is a monoclonalantibody targeting CD300A. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CD300A Antibody, please refer to Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-CD326 Antibody (17-1A) is a human monoclonalantibody targeting CD326. Anti-CD326 Antibody (17-1A) can be used in cancer research. The recommended isotype control is Mouse IgG1 kappa (HY-P99977).
SHR-A1403 Antibody is an anti-c-Metmonoclonalantibody. SHR-A1403 Antibody down-regulates phosphorylated c-Met, Akt, ERK, weakens intracellular signal cascades, and mediates antibody-c-Met complex endocytosis. SHR-A1403 Antibody can be used for the research of c-met-overexpressing cancers and pancreatic ductal adenocarcinoma .
Anti-5T4 scFv-Fc Antibody (ASN004 Antibody) is a human IgG1 monoclonalantibody targeting TPBG. Anti-5T4 scFv-Fc Antibody (ASN004 Antibody) can be used in cancer research. The recommended isotype control is human IgG1 kappa (HY-P99001).
MDX-1411 is a fully human monoclonalantibody targeting CD70. MDX-1411 is capable of inducing antibody-dependent cellular cytotoxicity (ADCC). MDX-1411 can be used in the research of B-cell malignancies .
Anti-Dectin-1 Antibody (2M24) is a humanized IgG1 monoclonalantibody that targets Dectin-1. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
Tositumomab (Anti-Human CD20 Recombinant Antibody) is a mouse-derived IgG2a monoclonalantibody, targeting to human CD20. Tositumomab can deplete B cells. Tositumomab can be used for the research of cancer, such as lymphoma .
Onartuzumab (MetMAb) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonalantibody against the MET receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity .
Cusatuzumab (FUT8-KO) is an anti-CD70monoclonalantibody that prepared by knocking out the fucosyltransferase 8 gene (FUT8) to remove fucose and thereby enhance the ADCC activity of the antibody .
Marstacimab (PF-06741086) is an anti-tissue factor pathway inhibitor (TFPI) monoclonalantibody. Marstacimab can be used for the research of hemophilia .
Tavolixizumab (MEDI 0562; Tavolimab) is a human monoclonalantibody to TNFRSF4 (TNF receptor superfamily member 4) for use in cancer immunology research .
Fontolizumab (HuZAF) is a humanized monoclonalanti-IFN-gammaantibody. Fontolizumab is an immunosuppressive agent. Fontolizumab can be used in research of Crohn’s disease .
Birtamimab (NEOD001) is an investigational monoclonalantibody that specifically and selectively target and clear the amyloid. Birtamimab can be used for the research of light chain amyloidosis .
Anti-CCL28 Antibody is a monoclonalantibody targeting CCL28. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CCL28 Antibody, please refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
Maridebart (AMG133 antibody) is a human immunoglobulin G1-kappa, anti-GIPR (gastric inhibitory polypeptide receptor)monoclonalantibody. Maridebart is the antibody portion of Maridebart cafraglutide (HY-164535) and can be used for the synthesis of antibody-drug conjugates (ADC). Maridebart can be used for the reserrch of obesity and type 2 diabetes .
Lexucitug (DCSZ-11) is a humanized monoclonalantibody targeting CD93. The antibody isotype of Lexucitug is human IgG1κ; the recommended isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
Vorsetuzumab mafodotin (SGN-75) is an Auristatin-based anti-CD70antibody-drug conjugate (ADC). Vorsetuzumab mafodotin consists of a humanized monoclonalantibody, Vorsetuzumab and an ADC cytotoxin MMAF. Vorsetuzumab mafodotin has antineoplastic activity .
Bivatuzumab (Anti-CD44 Recombinant Antibody; BIWA 4) is a humanized monoclonalantibody directed against CD44v6. CD44v6 could acts as a sarcoma target for CAR-redirected CIK cells .
Anti-MST1R Antibody (MOR07692) is a humanized IgG1 monoclonalantibody that targets MST1R. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
Lanerkitug (BAY3375968) is a fully human monoclonal IgG1 anti-human CCR8 antibody. Lanerkitug selectively depletes human CCR8 + Tregs via antibody dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP). Lanerkitug can be used in the research of solid tumors .
Anti-IL-34 Antibody is a monoclonalantibody that targets IL-34. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-34 Antibody, please refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
DB-1310 Antibody is a monoclonalantibody inhibitor targeting HER3. DB-1310 Antibody can be used to synthesize the antibody-drug conjugate (ADC) DB-1310. DB-1310 Antibody is applicable to research related to HER3-positive solid tumors, non-small cell lung cancer, breast cancer, colon cancer and prostate cancer .
Labetuzumab is a humanised anti-carcinoembryonic antigen (CEA) monoclonalantibody that inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy .
Atoltivimab (REGN3470), or maftivimab/odesivimab (Inmazeb) is the first Food and agent Administration (FDA)-approved monoclonalantibody to target Zaire ebolavirus (EBOVs) infection .
Boserolimab (MK-5890) is a humanized agonist monoclonalantibody that binds to CD27 to provide a costimulatory signal that enhances T-cell–mediated responses .
CM369 is a humanized monoclonalantibody against CCR8 that possesses potential immunomodulatory and anti-tumor activities. CM369 can be used in cancer research.
Placulumab (ART621) is an anti-TNF α monoclonalantibody. Placulumab has anti-inflammatory activity and has potential applications in inflammatory diseases such as arthritis .
Sovipostobart is an immunoglobulin G1-kappa, anti-CTLA-4 human monoclonalantibody with cleavable prodomain. Sovipostobart is an immunostimulant and antineoplastic .
Anti-UNC5B Antibody (YW88) is a monoclonalantibody against UNC5B. Anti-UNC5B Antibody (YW88) can inhibit the binding of Netrin-1 to Unc5B. Anti-UNC5B Antibody (YW88) can be used in research on angiogenesis .
Anti-Mouse TSLP Antibody (28F12) is an anti-mouse TSLP IgG2a monoclonalantibody. Anti-Mouse TSLP Antibody (28F12) weakens skin inflammation and allergic reactions by reducing Treg cells and lymph node cells. Anti-Mouse TSLP Antibody (28F12) can be used for research on allergic conditions .
Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonalantibody. Denintuzumab binds to CD19 on the surface of B cells. Denintuzumab can be used as the antibody moiety (ADC antibody) of antibody-drug conjugates to synthesize ADC, Denintuzumab Mafodotin (SGN-CD19A). Denintuzumab Mafodotin can be used in the research of acute lymphoblastic leukemia .
Anti-Human/Rat/Fish AChR Antibody (Mab35) is an anti-human/rat/fish AChR IgG1 monoclonalantibody. Anti-Human/Rat/Fish AChR Antibody (Mab35) can attack the AChR of neuromuscular junctions. Anti-Human/Rat/Fish AChR Antibody (Mab35) can be used for the construction of myasthenia gravis models .
Anti-LGR7 Antibody is a monoclonalantibody targeting LGR7/RXFP1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-LGR7 Antibody, please refer to Mouse IgG2a kappa, Isotype Control (HY-P99978).
Anti-UPK-1B Antibody is a monoclonalantibody targeting UPK1B. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-UPK-1B Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD300C Antibody is a monoclonalantibody targeting CD300C. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CD300C Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
CLT030 Antibody is a human monoclonalantibody targeting CLL1/CLEC12A/CD371, with a Kd value of 7.32 nM against human targets. CLT030 Antibody can be used to synthesize the ADC CLT030. It is applicable to research related to acute myeloid leukemia .
Anti-LGALS3BP Antibody is a monoclonalantibody targeting LGALS3BP. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-LGALS3BP Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TEM8 Antibody is a monoclonalantibody targeting TEM8/ANTXR1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-TEM8 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Mouse CD25 Antibody (7D4) is a mouse IgG2 monoclonalantibody targeting CD25. Anti-Mouse CD25 Antibody (7D4) enables the isolation of naive CD4 + T cells by depleting CD25-expressing cells .
Anti-NKG2C Antibody is a monoclonalantibody targeting NKG2C. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-NKG2C Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-SEMA3A Antibody is a monoclonalantibody targeting SEMA3A. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-SEMA3A Antibody, please refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
Anti-NGF2 Antibody is a monoclonalantibody targeting NGF2/NT-3. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-NGF2 Antibody, please refer to Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-Beta Klotho Antibody is a monoclonalantibody targeting *Beta Klotho*. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Beta Klotho Antibody, please refer to Human IgG1 (L234A/L235A) kappa, Isotype Control (HY-P991207).
Cantuzumab is a monoclonalantibody that can binds the CanAg antigen. Cantuzumab is typically linked to one of several cytotoxic agents, yielding antibody-drug conjugates (ADC), such as Cantuzumab mertansine (HY-P99492) and Cantuzumab ravtansine (HY-P99493) .
Anti-LAMP1/CD107a Antibody (SAR-428926 antibody) is an anti-LAMP1 humanized monoclonalantibody. Anti-LAMP1/CD107a Antibody can be used for the antibody part of SAR-428926. AntibodyAnti-LAMP1/CD107a Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
Racotumomab (Anti-Human NGcGM3 Recombinant Antibody) is an anti-idiotype monoclonalantibody (MAb). Racotumomab reacts to Neu-glycolyl (NeuGc)-containing gangliosides, sulfatides, and other antigens expressed in tumors. Racotumomab is an active anticancer agent for lung cancer .
Seniprutug (BCD-180) is a humanized monoclonalantibody targeting the TRBV9 fragment. Seniprutug induces antibody-dependent cell-mediated cytotoxicity to eliminate TRBV9 + T cells. Seniprutug is applicable to research related to active radiographic axial spondyloarthritis .
MEDI-7836 is a humanized monoclonalantibody inhibitor that targets the interleukin-13 receptor. MEDI-7836 is promising for research of inflammation-related diseases .
NI-301 is a human monoclonalantibody (mAb) targeting Transthyretin/TTR. NI-301 can be used in Cardiomyopathies and Familial amyloid neuropathy research .
Romosozumab is a humanized monoclonalanti-sclerostin antibody, it promotes bone formation and inhibits bone resorption by inhibiting sclerostin. Romosozumab can be used for the research of osteoporosis .
Anti-Mouse CD200 Antibody (OX-90) is an anti-mouse CD200 IgG2a monoclonalantibody. Anti-Mouse CD200 Antibody (OX-90) can reduce immune cell infiltration and T cell function by blocking CD200. Anti-Mouse CD200 Antibody (OX-90) can be used for research on immunology .
Anti-CLDN9 Antibody is a monoclonalantibody targeting CLDN9. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CLDN9 Antibody, please refer to Human IgG1 (L234A/L235A) kappa, Isotype Control (HY-P991207).
Anti-ALK7 Antibody is a monoclonalantibody that targets ALK7. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-ALK7 Antibody, please refer to Human IgG1 (L234A/L235A) kappa, Isotype Control (HY-P991207).
Anti-PD-L2 Antibody is a monoclonalantibody targeting PD-L2/CD273. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-PD-L2 Antibody, please refer to Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-IL-27RA Antibody is a monoclonalantibody that targets IL-27RA. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-27RA Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-LRP6 Antibody is a monoclonalantibody that targets LRP6. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-LRP6 Antibody, please refer to Human IgG1 (L234A/L235A) kappa, Isotype Control (HY-P991207).
Anti-IL-17F Antibody is a monoclonalantibody that targets IL-17F. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-17F Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-L1-CAM Antibody is a monoclonalantibody that targets L1-CAM. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-L1-CAM Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Varsetatug (CX-2051 antibody) is a humanized IgG1κ monoclonalantibody inhibitor targeting EpCAM/TROP1/CD326. Varsetatug serves as the antibody component of the ADC compound CX-2051. It can be used in research on cancers including breast cancer, prostate cancer and ovarian cancer .
Sigvotatug (SGN-B6A antibody) is a human IgG1 κ monoclonalantibody against ITGB6.
Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
Sigvotatug can be used as an ADC antibody to synthesize ADC Sigvotatug vedotin (HY-164957) .
Anti-IL-23R Antibody is a monoclonalantibody that targets IL-23R. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-23R Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-ROBO2 Antibody is a monoclonalantibody targeting ROBO2. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-ROBO2 Antibody, please refer to Human IgG1 (L234A/L235A) kappa, Isotype Control (HY-P991207).
Anti-B7-H7 Antibody is a monoclonalantibody targeting HHLA2. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-B7-H7 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-IL-17RB Antibody is a monoclonalantibody targeting IL-17RB. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-17RB Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD226 Antibody is a monoclonalantibody targeting CD226. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CD226 Antibody, please refer to Human IgG1 (L234A/L235A) kappa, Isotype Control (HY-P991207).
Anti-EGFR Antibody (D2C7) is a monoclonalantibody against EGFR. The recombinant immunotoxin D2C7-(scdsFv)-PE38KDEL constructed based on Anti-EGFR Antibody (D2C7) has antineoplastic activity in glioblastoma models .
IMC-D11 (LY-3076226 antibody) is an IgG1 monoclonalantibody against FGFR3. IMC-D11 can be used for the antibody part of LY3076226. IMC-D11 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
Furtisetabart is a humanized monoclonalantibody targeting CD147 with anti-tumor activity. Furtisetabart is of the human IgG4κ antibody subtype, and the recommended isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
Anti-CD172a Antibody (3F9) is a humanized IgG1 monoclonalantibody targeting SIRPα/CD172a. The recommended isotype control is Mouse IgG1 kappa, Isotype Control (HY-P99977).
Ladarutatug is a humanized monoclonalantibody targeting Tyrosine-protein kinase receptor UFO. The Ladarutatug antibody isotype is human IgG4κ; the recommended isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
Lifonebart is a humanized monoclonalantibody targeting TREM2 (triggering receptor expressed on myeloid cells 2). The antibody isotype of Lifonebart is human IgG1κ, and the recommended isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
Oloctinebart is a humanized immunoglobulin G4-kappa, anti-LGALS3monoclonalantibody. Oloctinebart is used for reduction of amyloid beta oligomers formation .
Telazorlimab (GBR-830) is a humanized monoclonalantibody against OX40 costimulatory receptor on activated T cells. Telazorlimab can be used for the research of autoimmune diseases .
Gimsilumab (MORAb-022) is a human anti-GM-CSFmonoclonalantibody. Gimsilumab has the potential for the research of COVID-19 and rheumatoid arthritis (RA) .
BAT5906 is a human monoclonalantibody (mAb) targeting VEGFA. BAT5906 can be used in Wet age-related macular degeneration and Diabetic macular oedema research .
Mitumomab is an anti-idiotypic mouse IgG2b monoclonalantibody that mimics the ganglioside GD3. Mitumomab can be used for the research of small-cell lung carcinoma .
Gerilimzumab (GB224) is a humanized monoclonalantibody inhibitor targeting interleukin-6 (IL-6). Gerilimzumab is promising for research of autoimmune diseases such as rheumatoid arthritis .
Tirnovetmab (KIND-016) is a fully caninized, high-affinity monoclonalantibody that targets IL-31. Tirnovetmab can be used in research related to atopic dermatitis in dogs.
Galegenimab (FHTR 2163) is a humanized monoclonalantibody Fab fragment targeting the HtrA1 trimer. Galegenimab is used in research on age-related macular degeneration (AMD) .
TBL-100 is a human monoclonalantibody (mAb) targeting Tau. TBL-100 can be used in Alzheimer's disease (AD) and Progressive supranuclear palsy research .
Amesotatug is a humanized monoclonalantibody and ANXA1 binder. Amesotatug binds to Homo sapiensANXA1 and exhibits antineoplastic activity. Amesotatug can be used for the research of cancer .
Minretumomab (CC-49) is a murine monoclonalantibody against TAG-72 (tumor-associated glycoprotein 72). Minretumomab is used in cancer and immunity research .
LYN00101 is a human monoclonalantibody (mAb) targeting VEGFA. LYN00101 can be used in Cervical cancer, Colorectal cancer, Gastric cancer and Ovarian cancer research .
CNTO4088 is a monoclonalantibody inhibitor targeting interleukin-23 (IL-23). CNTO4088 is promising for research of autoimmune diseases such as psoriasis and rheumatoid arthritis .
Anti-IL-13 Antibody (C836) is a neutralizing monoclonalantibody targeting human IL-13. The Fab fragment of Anti-IL-13 Antibody (C836) is a heterodimer composed of heavy chains and light chains, each folded into variable and constant domains. Anti-IL-13 Antibody (C836) can be used for chronic inflammatory diseases, such as asthma .
Turmetabart (Anti-SEZ6 Antibody (SC17)) is a humanized anti-SEZ6 IgG1 monoclonalantibody. Anti-SEZ6 Antibody (SC17) can be used to synthesize antibody-drug conjugates (ADC) product, ABBV-011. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Anti-Mouse CD8 beta Antibody (53-5.8) is an anti-mouse CD8 beta IgG2a monoclonalantibody. Anti-Mouse CD8 beta Antibody (53-5.8) can deplete CD8 + T cells and enhance cytotoxicity. Anti-Mouse CD8 beta Antibody (53-5.8) can be used for research on immunology .
Anti-Mouse TCRβ Antibody (HB218) is an anti-mouse TCRβ IgG2b monoclonalantibody. Anti-Mouse TCRβ Antibody (HB218) can deplete TCRβ + T cells. Anti-Mouse TCRβ Antibody (HB218) can be used for research on inflammation conditions and cancer such as spontaneous dermatitis and squamous cell carcinoma (SCC) .
Anti-Mouse/Rat/Human v-H-Ras Antibody (Y13-238) is an anti-mouse/rat/human v-H-Ras IgG2a monoclonalantibody. Anti-Mouse/Rat/Human v-H-Ras Antibody (Y13-238) can be used as a control antibody. Anti-Mouse/Rat/Human v-H-Ras Antibody (Y13-238) is often used for immunofluorescence and immunoprecipitation .
Anti-IL6 Antibody (MH166) is a murine anti-hIL-6monoclonalantibody. Anti-IL6 Antibody (MH166) can completely neutralize the activity of hIL-6 in vitro, but when used in combination with hIL-6 in vivo, Anti-IL6 Antibody (MH166) can enhance the activity and prolong the half-life of hIL-6, and increase the production of antigen-specific antibodies .
Anti-TSHR Antibody (K1-70) is an anti-TSHRmonoclonalantibody. Anti-TSHR Antibody (K1-70) incorporates a single-chain variable fragment into a chimeric antigen receptor to redirect T cells to TSHR-expressing cells. Anti-TSHR Antibody (K1-70) shows antitumor activity with no apparent toxicity. Anti-TSHR Antibody (K1-70) can be used for the research of differentiated thyroid cancer (DTC) .
Anti-CD28 Antibody (9.3) is an anti-human CD28 IgG2a monoclonalantibody. Anti-CD28 Antibody (9.3) can activate T cells. Anti-CD28 Antibody (9.3) can be used for research on immunology. The recommend isotype control of Anti-CD28 Antibody (9.3): Mouse IgG2a kappa, Isotype Control (HY-P99978) .
Anti-CD103 Antibody (hCD103.01A) is a monoclonalantibody targeting human CD103 and can be used in cancer immunotherapy and immunological research. Recommend Isotype Controls: human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Claudin 1 Antibody is a monoclonalantibody targeting CLDN1/CLD1/SEMP1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Claudin 1 Antibody, please refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
Anti-IL-18Rα Antibody is a monoclonalantibody targeting IL-18Ra. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-18Rα Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD133/PROM1 Antibody (CMab-43) is a human IgG2a monoclonalantibody (mAb) targeting PROM1/CD133. Anti-CD133/PROM1 Antibody (CMab-43) can be used in colon cancer research .
Anti-CD32b/FCGR2B Antibody (2B6) is a human monoclonalantibody targeting CD32B. Anti-CD32b/FCGR2B Antibody (2B6) can be used for research on B-cell lymphoma .
Anti-LILRB3 Antibody is a monoclonalantibody targeting LILRB3/ILT5/CD85a. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-LILRB3 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-LILRB1 Antibody is a monoclonalantibody targeting LILRB1/CD85j/ILT2. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-LILRB1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-P2XR4 Antibody is a monoclonalantibody targeting P2XR4. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-P2XR4 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Siglec-10/CD24 Antibody is a monoclonalantibody targeting Siglec-10. It can be used in ELISA, FACS, and functional assays. Isotype controls for Anti-Siglec-10/CD24 Antibody can be found in Human IgG1 kappa, Isotype Control (HY-P99001).
Sonepcizumab (LT 1009) is a fully human anti-S1Pmonoclonalantibody. Sonepcizumab has the potential for the research of metastatic renal cell carcinoma (mRCC) .
Crotedumab (REGN1193) is a fully human IgG4 monoclonalantibody that binds and inhibits glucagon receptor (GCGR), with a KD of 0.1 nM. Crotedumab can be used for the research of diabetes .
Carotuximab (TRC105) is a IgG1 monoclonalantibody that blocks endoglin (CD105) and its downstream Smad signaling pathway. Carotuximab has immunomodulatory and antineoplastic actions .
Remigromig (EYE-103; MK-3000) is a humanized bispecific monoclonalantibody targeting LRP5 and FZD4, suitable for use in research related to macular degeneration .
Suptavumab (REGN2222) is a human monoclonalantibody. Suptavumab can bind and block a conserved epitope on RSV A and B subtypes. Suptavumab can be used for the research of RSV infection .
MK-4166 is a humanized IgG1 agonist monoclonalantibody targeting GITR. MK-4166 enhances the proliferation of both naïve and tumor-infiltrating T lymphocytes .
NGM-707 is a humanized monoclonalantibody that blocks ILT2 and ILT4 receptors. NGM-707 has the potential for the study of advanced and metastatic solid tumors .
Lirilumab (IPH2102) is an anti-KIRmonoclonalantibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research .
Drozitumab (PRO 95780) is a human agonistic monoclonalantibody which binds the death receptor DR5. Drozitumab has potent antitumor activity against rhabdomyosarcoma .
Libivirumab (17.1.41) is a human anti-HBV monoclonalantibody. Libivirumab shows neutralization activity with IC50s of 35, 130 ng/mL for HBsAg, HBeAg, respectively .
Basiliximab (CHI 621) is a recombinant chimeric murine/human IgG1 monoclonalanti-interleukin-2 receptor antibody. Basiliximab can be used for the research of renal transplantation .
Crenezumab (MABT 5102A; RG 7412) is a fully humanized anti-Aβ monoclonalantibody that binds multiple forms of Aβ, such as soluble, oligomeric and fibrillar, for use in Alzheimer's disease research .
Anti-IL11RA Antibody (Hu16E12) is a humanized anti-IL-11αmonoclonalantibody, and its isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
Anti-TM4SF1 Antibody (AGX-A07) is a humanized IgG1 monoclonalantibody that targets TM4SF1. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
Xentuzumab (Anti-Human IGF1 and IGF2 Recombinant Antibody; BI836845) is a recombinant a human monoclonalantibody that targets IGF ligands IGF1 and IGF2. Xentuzumab inhibits both of IGF1 and IGF2 growth-promoting signalling and suppresses AKT activation .
Anti-Human/Mouse EGFR Antibody (7A7) ia an anti-mouse EGFRmonoclonalantibody proposed to be the mouse equivalent of cetuximab. Anti-Human/Mouse EGFR Antibody (7A7) fails to induce tumor regression in the HPV38 tumor model where EGFR is not expressed in mice. Anti-Human/Mouse EGFR Antibody (7A7) can be used in EGFR-expressing HPV38 tumor-related studies .
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen. Gemtuzumab affects cell necrosis by specifically targeting CD33 expressed on the surface of leukaemic cell blasts in acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonalantibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
Anti-Mouse VEGFR-2 Antibody (DC101-Mouse IgG2a) is an anti-mouse VEGFR-2 IgG2a monoclonalantibody. Anti-Mouse VEGFR-2 Antibody (DC101-Mouse IgG2a) is a chimeric antibody of the original DC101 antibody (HY-P990106). Anti-Mouse VEGFR-2 Antibody (DC101-Mouse IgG2a) can react with mouse VEGFR-2 .
Anti-IL-18RAP Antibody is a monoclonalantibody targeting IL-18RAP/IL-18RB. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-18RAP Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-IGFBP2 Antibody (M14) is an human anti-IGFBP2 monoclonal inhibitory antibody, which binds IGFBP2 with high affinity and blocks its binding with IGF1. Anti-IGFBP2 Antibody (M14) inhibits human endothelial cell recruitment, thus blocks the tumor progression of human metastatic cancer .
Anti-NRP2 Antibody is a monoclonalantibody targeting NRP2/VEGF165R2. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-NRP2 Antibody, please refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
Sutantatug (SYS6002 Antibody) is a monoclonalantibody targeting Nectin-4, and serves as the antibody moiety of the ADC CRB-701. Sutantatug is applicable to the research of Nectin-4-positive solid tumors, urothelial carcinoma and cervical cancer. The corresponding isotype control for Sutantatug is Human IgG1 kappa, Isotype Control (HY-P99001) .
Zanolimumab (Anti-Human CD4 Recombinant Antibody) is a fully human monoclonalantibody targets CD4. Zanolimumab effectively inhibits T-cell receptor (TCR) signal transduction. Zanolimumab can be used for the research of heumatoid arthritis, psoriasis, melanoma, cutaneous and peripheral T-cell lymphoma .
Tenatumomab (ST2146) is a murine monoclonalantibody against tenascin-C. And tenascin-C, the large extracellular glycoprotein, is overexpressed in cancer. Tenatumomab has been used for Pretargeted Antibody Guided Radioimmunoresearch (PAGRIT), and delivering radionuclides to tumors via PAGRIT and direct 131Iodine labeling approach .
Motavizumab (MEDI-524) is an anti-human RSV (respiratory syncytial virus) monoclonalantibody. Motavizumab can be used in respiratory syncytial virus infection in high-risk infants research .
Timolumab (BTT1023 ), a recombinant fully human monoclonalantibody that specifically binds VAP-1. Timolumab (BTT1023 ) could be used in the study of chronic inflammatory diseases .
Panobacumab (KBPA101) is a fully human IgM/κ monoclonalantibody generated by immortalizing human B lymphocytes against the LPS O polysaccharide of serotype O11 of P. aeruginosa .
Cetuximab (C225) is a human IgG1 monoclonalantibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity .
Ginisortamab (Mouse IgG1) is the anti-Gremlin-1 monoclonalantibody with mouse IgG1. Ginisortamab (Mouse IgG1) can be used in research of gastrointestinal (GI) tumors .
Ulenistamab (PBP1510) is a first-in-class hunamised IgG1 monoclonalantibody targeting pancreatic adenocarcinoma upregulated factor (PAUF). Ulenistamab can be used for pancreatic cancer (PC) research .
XOMA 129 is a human monoclonalantibody targeting INSR. XOMA 129 is an insulin receptor (IR) antagonist that inhibits the drop in blood glucose. XOMA 129 can be used in the study of hypoglycemia .
Bersanlimab (BI-505) is a fully human monoclonalantibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab has anticancer effects .
Tarcocimab (OG1953) is a humanized anti-VEGFAmonoclonalantibody (IgG1 type). Tarcocimab is available for research in retinal vein occlusion (RVO) and wet age-related macular degeneration (AMD).
Frunevetmab (NV-02) is a felinized anti-nerve growth factor (NGF) monoclonalantibody with a Kd of 20 pM. Frunevetmab can effectively decrease osteoarthritis (OA) pain in cats .
Coprelotamab (GB-221) is an IgG-κ monoclonalantibody targeting EGFR2. The commonly used expression system for Coprelotamab is CHO DG44 (Chinese Hamster Ovary) cells .
hPV19 is a humanized inhibitory monoclonalantibody targeting vascular endothelial growth factor (VEGF) with a unique binding site. hPV19 can be used for the research of advanced solid tumors .
ASN-500 is a human monoclonalantibody (mAb) targeting F/Fusion glycoprotein F0. ASN-500 can be used in respiratory syncytial virus infection research .
Zansecimab (LY-3127804) is a monoclonalantibody against angiopoietin 2 (Ang‑2). Zansecimab can be used in research on angiogenesis, immunomodulation and anti-tumor activity .
UBX2050 is a human monoclonalantibody (mAb) targeting TIE2. UBX2050 can be used in Age-related macular degeneration, Diabetic macular oedema and Diabetic retinopathy research .
IN-002 is a human monoclonalantibody (mAb) targeting F, Fusion glycoprotein F0. IN-002 can be used in respiratory syncytial virus (RSV) infections research.
Anti-Mouse CD28 Antibody (PV-1) is an anti-mouse CD28 IgG monoclonalantibody. Anti-Mouse CD28 Antibody (PV-1) can activate T cells. Anti-Mouse CD28 Antibody (PV-1) can be used for researches on cancer and immunology such as leukemia. The recommend isotype control of Anti-Mouse CD28 Antibody (PV-1): Armenian hamster IgG, Isotype Control (HY-P990305) .
Anti-Mouse VISTA Antibody (13F3) is an anti-mouse VISTA IgG monoclonalantibody. Anti-Mouse VISTA Antibody (13F3) can reverse the immunosuppressive effect of VISTA by blocking its binding to ligands such as VSIG3. Anti-Mouse VISTA Antibody (13F3) exacerbates pulmonary fibrosis (PF) by promoting Th17 cell differentiation. Anti-Mouse VISTA Antibody (13F3) can be used for research on cancer such as breast cancer and PF .
HTI-1511 Antibody (Halozyme patent anti-EGFR) is a monoclonalantibody inhibitor targeting EGFR. HTI-1511 Antibody can be used to synthesize a novel anti-EGFR-ADC, HTI-1511. HTI-1511 Antibody can be used in the research of head and neck squamous cell carcinoma, non-small cell lung cancer, pancreatic cancer, colorectal cancer, renal cell carcinoma, and epidermoid carcinoma .
Amivantamab (FUT8-KO) is an anti-EGFR-METmonoclonalantibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Amivantamab (FUT8-KO) inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells .
Anti-LY6G6D Antibody (1G4) is a humanized IgG1 monoclonalantibody that targets LY6G6D. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD68 Antibody (KP1) is a anti-CD68 monoclonalantibody (mAb). CD68 is present in various cell types, including monocytes/macrophages and fibroblasts. Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977) .
BI-836826 is a IgG1 chimerized and Fc-engineered anti-CD37monoclonalantibody. BI 836826 displays both antibody-dependent cell-mediated cytotoxicity (ADCC) and direct pro-apoptotic activities. BI-836826 can be used for the study of chronic lymphocytic leukemia .
Bimagrumab (Anti-ACVR2B Reference Antibody) is a human monoclonalantibody that blocks activin type II receptor (ActRII), with KDs of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab can be used for the research of pathological muscle loss and weakness .
Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate comprising the humanized monoclonalantibody zilovertamab and and the anti-microtubule cytotoxin monomethyl vedotin. Zilovertamab vedotin binding to tumor cell ROR1 results in rapid internalization, trafficking to lysosomes, antibody–agent conjugate cleavage, and monomethyl vedotin release. Zilovertamab vedotin induces apoptosis. Zilovertamab vedotin can be used in research of cancer .
ZL-1218 (FUT8-KO) is an anti-CCR8monoclonalantibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody. ZL-1218 (FUT8-KO) can be used for the research of solid tumour .
S-531011 (FUT8-KO) is an anti-CCR8monoclonalantibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody. S-531011 (FUT8-KO) can be used for the research of cancer immunity .
Namilumab (AMG203) is a human IgG1 monoclonalantibody that binds with high affinity to the GM-CSF ligand, potently neutralizing GM-CSF. Namilumab can be used for the research of rheumatoid arthritis .
Raludotatug is a humanized anti-CDH6 IgG1 monoclonalantibody. Raludotatug has antitumor activity and can be used to synthesize the ADC molecule Raludotatug deruxtecan (HY-164734) .
BIIB023 is a human monoclonalantibody (mAb) targeting TNFRSF12A/TWEAKR/CD266. BIIB023 can be used in lupus nephritis and rheumatoid arthritis research .
EVO-46120 is a human monoclonalantibody (mAb) targeting F, Fusion glycoprotein F0. EVO-46120 can be used in respiratory syncytial virus (RSV) and metapneumovirus infections research.
Sirexatamab (DKN-01) is a humanized IgG4 monoclonalantibody that can bind to and neutralize circulating DKK1. Sirexatamab exhibits antitumor activity in tumor models expressing DKK1 .
Landogrozumab (LY2495655) is an humanized anti-myostatinmonoclonalantibody. Landogrozumab effectively improves muscle volume, hand grip strength and function. Landogrozumab can be used for the research of muscle wasting disease .
Prolgolimab (BCD-100) is a human IgG1 anti-PD-1monoclonalantibody containing the Fc-silencing 'LALA' mutation. Prolgolimab can be used for the research of advanced melanoma .
Imalumab (BAX69) is a recombinant, human IgG1 monoclonalantibody that targets macrophage inhibitory factor (MIF). Imalumab can be used for the research of ovarian carcinoma, recurrent malignant ascites and cancer .
Nofazinlimab (CS1003) is a humanised IgG4 anti-PD-1monoclonalantibody. Nofazinlimab shows antitumor activity and can be used for the research of unresectable or metastatic hepatocellular carcinoma .
FM-303 is a monoclonalantibody inhibitor targeting interleukin-23 (IL-23). FM-303 is promising for research of immune system diseases and diseases of digestive system .
Ligufalimab (AK 117) is a humanized IgG4 anti-CD47 monoclonalantibody. Ligufalimab does not induce RBC hemagglutination, and induces phagocytosis. Ligufalimab shows anti-tumor activity .
Amrecibart is an anti-coagulation factor 11 human IgG4 κ monoclonalantibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
Garetatug is a humanized monoclonalantibody targeting human CLDN18 (claudin-18). Garetatug specifically binds to CLDN18, interfering with relevant cell signaling pathways and exerting antitumor activity .
Ersodetug is an anti-INSR (insulin receptor) human IgG2 κ monoclonalantibody . Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002).
Vibostolimab is an anti-TIGIT (T cell immunoglobulin and ITIM domain) monoclonalantibody. Vibostolimab shows antitumor activity, and can be used in non-small cell lung cancer (NSCLC) and melanoma research .
Brodalumab (AMG 827) is a human anti-interleukin-17-receptor IgG2 monoclonalantibody that can be used for the research of moderate-to-severe plaque psoriasis and rheumatoid arthritis .
Dazukibart (PF-06823859) is a potent, selective humanized IgG1 neutralizing monoclonalantibody that targets interferon β (IFNβ). Dazukibart can be used in the study of moderate to severe dermatomyositis .
EVO-46135 is a human monoclonalantibody (mAb) targeting F/Fusion glycoprotein F0. EVO-46135 can be used in Respiratory syncytial virus infections and Metapneumovirus infections research.
AT008 is an anti-GPCRmonoclonalantibody that blocks the binding of chemokine ligands to its cell surface receptor CCR4. AT008 can be studied in research for certain haematological and solid cancers.
Anti-EphA2 Antibody (1C1) (MEDI-547 antibody) is an anti-EphA2monoclonalantibody. Anti-EphA2 Antibody (1C1) can induce degradation of EphA2 protein. Anti-EphA2 Antibody (1C1) conjugated with McMMAF (HY-15578) can form an antibody-conjugated drugs, which has potent antitumor activity. Anti-EphA2 Antibody (1C1) can be used for the research of cancer, such as prostate cancer and glioma .
Anti-Rat IgG2b Antibody (RG7/11.1) is an anti-rat IgG2bmonoclonalantibody. Anti-Rat IgG2b Antibody (RG7/11.1) can be used for research on neurological and infection conditions such as temporal lobe epilepsy (TLE). Anti-Rat IgG2b Antibody (RG7/11.1) is often used for the same type control .
Anti-Mouse NKG2AB6 Antibody (16A11) is an anti-mouse NKG2AB6 IgG2b monoclonalantibody. Anti-Mouse NKG2AB6 Antibody (16A11) reduces depletion of antigen-specific CD8 T cells. Anti-Mouse NKG2AB6 Antibody (16A11) can be used for research on cancer such as lung cancer and colon cancer .
Anti-Mouse Kappa Immunoglobulin Light Chain Antibody (HB-58) is an anti-mouse Kappa Immunoglobulin Light Chain IgG1 monoclonalantibody. Anti-Mouse Kappa Immunoglobulin Light Chain Antibody (HB-58) can reduce the phosphorylation levels of Src and Syk in B cells and the antigen presentation ability of B cells. Anti-Mouse Kappa Immunoglobulin Light Chain Antibody (HB-58) can be used for research on immunology .
Anti-Rat FcRn heavy chain heterodimers Antibody (2G3) is an anti-rat FcRn heavy chain heterodimers IgG1 monoclonalantibody. Anti-Rat FcRn heavy chain heterodimers Antibody (2G3) effectively inhibits the binding of FcRn to IgG. Anti-Rat FcRn heavy chain heterodimers Antibody (2G3) is used in studies of the MHC class I heavy chain FcRn heterodimers and their interaction with IgG .
Anti-Mouse myeloperoxidase/MPO Antibody (6G4) is an anti-mouse myeloperoxidase/MPO IgG2c monoclonalantibody. Anti-Mouse myeloperoxidase/MPO Antibody (6G4) can activate the cGAS/STING pathway. Anti-Mouse myeloperoxidase/MPO Antibody (6G4) induces acute and chronic kidney injury in mice. Anti-Mouse myeloperoxidase/MPO Antibody (6G4) is often used in the construction of inflammation conditions models such as anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) .
Anti-TROP2 Antibody (RN927C antibody) is a human monoclonalantibody targeting Trop-2. Anti-TROP2 Antibody exerts in vitro inhibitory effects on a variety of tumor cell lines. Anti-TROP2 Antibody exhibits anti-tumor activity in mouse pancreatic PDX, ovarian PDX, lung PDX and triple-negative breast cancer (TNB) PDX models. Anti-TROP2 Antibody can be used for research on pancreatic cancer, ovarian cancer, lung cancer and triple-negative breast cancer .
Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonalantibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases .
Clazakizumab is a monoclonalantibody with high affinity and specificity for the IL-6 (interleukin-6) cytokine. Clazakizumab may be helpful in inhibiting the cytokine response to SARS-CoV-2 in COVID-19. Clazakizumab can be used for the research of psoriatic arthritis (PsA) and renal antibody-mediated rejection .
ACT017 is a Fab fragment of humanized anti-GPVImonoclonalantibody. ACT017 inhibits collagen-induced platelet aggregation. ACT017 has the potential for the research of acute ischemic stroke .
Zemocimig is an anti-coagulation factor F9 human IgG4 κ monoclonalantibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
Rinumafusp alfa is a human monoclonalantibody targeting ERBB3/HER3. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001).
Ansuvimab (Ansuvimab-zyk) is a recombinant human monoclonal IgG1 antibody that exhibits antiviral activity against Zaire ebolavirus. Ansuvimab binds to the glycoprotein on Zaire ebolavirus to block its entry into host cells .
Izalontamab (SI-B001) is a bispecific anti-EGFR/HER3monoclonalantibody with high selectivity for EGFR/HER3 heterodimer. Izalontamab can be used for the research of cancer .
Iscalimab (CFZ-533) is a non-depleting IGg1 monoclonalantibody targeting CD40 (KD: 0.3 nM). Iscalimab can be used for research of Graves' hyperthyroidism and autoimmune diseases .
Domagrozumab is an anti-myostatin humanized monoclonalantibody with a KD value of 2.6 pM for human myostatin. Domagrozumab induces muscle anabolic activity. Domagrozumab can be used in research of duchenne muscular dystrophy (DMD) .
Adintrevimab (ADG 20) is a human IgG1 monoclonalSARS-CoV (SARS-CoV) antibody. Adintrevimab inhibits SARS-CoV-2 variants and other SARS-like coronaviruses with pandemic potential .
Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonalantibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research .
BAT-6004 is a monoclonalantibody that targets CD47 and is a CD47 inhibitor. BAT-6004 can be used in research on acute myeloid leukemia and diffuse large B-cell lymphoma .
Narnatumab (IMC-RON8) is a neutralizing human monoclonalantibody that blocks RON binding to its ligand, macrophage-stimulating protein (MSP), with a Kd of 32 pM. Narnatumab can be used for the research of cancer .
Idarucizumab is a humanized monoclonalantibody fragment. Idarucizumab is first reversal agent for a direct oral anticoagulant (DOAC). Idarucizumab can specifically neutralize the effects of the oral direct thrombin inhibitor in order to restore hemostasis .
Pidilizumab (CT-011) is a humanized IgG1k anti-PD-1monoclonalantibody. Pidilizumab acts as a DLL1 antagonist. Pidilizumab has the potential for hematologic malignancies research .
Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonalantibody (IgG4P), is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases .
BMS-986090 is a humanized monoclonalantibody antagonist targeting CD40. BMS-986090 is promising for research of autoimmune diseases such as systemic lupus erythematosus (SLE) and focal segmental glomerulosclerosis (FSGS) .
Bentracimab (PB 2452) is a neutralizing monoclonalantibody that binds Ticagrelor (HY-1006) and its major active circulating metabolite with high affinity. Bentracimab can rapidly reverse the antiplatelet effect of Ticagrelor .
Depatuxizumab is a brain-penetrant and humanized tumor-specific antiEGFRmonoclonalantibody. Depatuxizumab inhibits the growth of xenograft models of mutant EGFRvIII and wild-type EGFR. Depatuxizumab can be used for research on cancer .
Cetuximab (PBS) is a human IgG1 monoclonalantibody that can inhibit EGFR. The SPR method measured the Kd value of Cetuximab for EGFR to be 0.201 nM; Cetuximab has a highly effective anti-tumor effect .
DX-2240 is a human monoclonalantibody (mAb) targeting TIE1. DX-2240 inhibits tumor growth and sensitizes tumor vasculature to anti-angiogenic agents (VEGF pathway inhibitors) .
Tezepelumab (anti-TSLP) is human monoclonalantibody (IgG2λ) that binds specifically to TSLP, blocking it from interacting with its heterodimeric receptor. Tezepelumab can be used for the research of severe, uncontrolled asthma .
Ulviprubart (ABC-008) is a monoclonalantibody targeting the KLRG1 receptor that selectively depletes highly differentiated cytotoxic T cells. Ulviprubart can be used in the study of inclusion body myositis (IBM) .
Anti-LGR5/GPR49 Antibody (18G7H6A3) is a human monoclonalantibody (mAb) targeting LGR5/GPR49. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD371/CLEC12A Antibody (H6e7) is a human monoclonalantibody (mAb) targeting CD371/CLEC12A. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Dacetuzumab (SGN-40) is a humanized IgG1, anti-CD40monoclonalantibody with anti-lymphoma activity. Dacetuzumab kills tumor cells via immune effector functions (antibody-dependent cellular cytotoxicity and phagocytosis [ADCC/ADCP]). Dacetuzumab ((SGN-40) can be used for multiple myeloma research .
Mogamulizumab (KW-0761) is a recombinant anti-CCR4monoclonalantibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL) .
Mezagitamab (TAK-079) is a IgG1λ anti-CD38monoclonalantibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP) .
Mirvetuximab (M9346A) is an anti-FOLR1 (folate receptor 1) monoclonalantibody. Mirvetuximab is the antibody moiety of folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research .
Benralizumab (MEDI-563) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonalantibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma .
MB-66 (MAPP-66) is a fully human IgG1 antibody that targets HSV and HIV. MB-66 is a monoclonalantibody film for vaginal application. The isotype control for MB-66 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
Codrituzumab (GC33) is a humanized monoclonalantibody targeting human GPC3 (glypican-3), with high affinity (Kd of 0.673 nM). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth .
Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a phosphatidylserine (PS)-targeting monoclonalantibody, suppresses tumor growth by targeting tumor vasculature and reactivating antitumor immunity. Bavituximab plus Paclitaxel (HY-B0015) and Carboplatin (HY-17393), have enhanced inhibition on non-small-cell lung cancer .
Anti-TREM2 Antibody (AL2p-58) is a humanized IgG1 monoclonalantibody targeting TREM2. Anti-TREM2 Antibody (AL2p-58) can be used for the research of neuroinflammation. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Anti-IL-21R Antibody is a monoclonalantibody targeting IL-21R. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-21R Antibody, please refer to Human IgG1 (L234A/L235A) kappa, Isotype Control (HY-P991207).
Bemarituzumab (FUT8-KO) is an anti-FGFR2bmonoclonalantibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Bemarituzumab (FUT8-KO) lacks a core fucose in the polysaccharide portion of the Fc domain of the antibody, and results in a high affinity to human FcγRIIIa .
Puxitatug (INT-016; AZD8205 Antibody) is a monoclonalantibody targeting VTCN1/B7-H4. Puxitatug can be used to synthesize antibody-drug conjugates (ADCs), such as Puxitatug samrotecan (HY-171689), which can be applied to various solid tumors. Puxitatug can also be used for researching adjuvant therapies for gastric cancer .
Anti-Human/Mouse GRP78 Antibody (N88) is an anti-human/mouse GRP78 IgG1 monoclonalantibody. Anti-Human/Mouse GRP78 Antibody (N88) can activate the Akt signaling pathway. Anti-Human/Mouse GRP78 Antibody (N88) can inhibit the expression of inflammatory factors and plasminogen activator inhibitors induced by TLR agonists. Anti-Human/Mouse GRP78 Antibody (N88) can be used for research on inflammation conditions. Anti-Human/Mouse GRP78 Antibody (N88) can be used for immunoprecipitation .
Tacatuzumab is an anti-AFP (alpha-fetoprotein protein) human IgG1 κ monoclonalantibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
Sevirumab (MSL-109) is a human IgG1 neutralizing monoclonalantibody against cytomegalovirus (CMV). Sevirumab recognizes CMV gH complexes and inhibits CMV replication with an EC50 of 0.3 μg/mL .
Ontuxizumab (MORAb-004) is a humanized IgG1/κ anti-endosialin (TEM-1 or CD248) monoclonalantibody with antitumor effects. Ontuxizumab can be used for the research of cancer .
Ontamalimab (SHP647) is a fully-human IgG2 monoclonalantibody targeting mucosal addressin cell adhesion molecule-1 (MAdCAM-1). Ontamalimab can be used for the research of Crohn's disease .
Suvonstobart is a monoclonalantibody targeting human CD24 (signal transducer CD24). Suvonstobart specifically binds to CD24, activating relevant immune cell signaling pathways and exerting immunostimulatory and antitumor activities .
ASP5094 is a humanized monoclonalantibody against integrin alpha-9. ASP5094 has good safety and tolerability. ASP5094 can be used in the research of diseases such as rheumatoid arthritis .
Anivovetmab (KIND-030) is an anti-VP2 protein (canine parvovirus major capsid protein) monoclonalantibody (IgG2 isotype). Anivovetmab has the potential for studying canine parvovirus infection .
Ciltistotug is a monoclonalantibody targeting human CD40 (TNFRSF5). Ciltistotug activates immune cells after binding to CD40, exerting immunostimulatory and antitumor activities. Ciltistotug is promising for research of cancer immunotherapy .
Futermestotug is a humanized immunoglobulin G1-κ monoclonalantibody targeting human cytotoxic T-lymphocyte associated protein 4 (CTLA4). Futermestotug is promising for research of various malignant tumors .
Vatelizumab (GBR500) is a monoclonalantibody that targets the α2 subunit (CD49b) of very late antigen 2 (VLA-2). Vatelizumab can be used for research on multiple sclerosis .
MAI1738 is a human monoclonalantibody targeting PODXL. MAI1738 can be used for cancer-related research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
Rosmantuzumab (OMP-131R10) is an anti-R-spondin 3 (RSPO3) humanized monoclonalantibody. Rosmantuzumab can be used for the research of advanced telapsed and refractory solid tumors .
Stromab (DS9231) is a human IgG1 monoclonalantibody (mAb) targeting Serpin F2. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
CNTO-6785 is a humanized monoclonalantibody inhibitor targeting interleukin-17A (IL-17A). CNTO-6785 is promising for research of chronic obstructive pulmonary disease (COPD) .
Siltuximab is an anti-IL-6 (interleukin-6) monoclonalantibody, and shows antitumor activity. Siltuximab can be used in Multicentric Castleman's Disease (MCD) and COVID-19 research .
SCH-900117 is a humanized monoclonalantibody inhibitor targeting interleukin-17A (IL-17A). SCH-900117 is promising for research of autoimmune diseases such as psoriasis and rheumatoid arthritis .
Oturkibart is a humanized immunoglobulin G4-κ monoclonalantibody targeting the human interleukin 4 receptor (IL4R). Oturkibart is promising for research of inflammatory diseases, such as asthma and atopic dermatitis .
Demcizumab (OMP 21M18) is an anti-DLL4monoclonalantibody. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models .
Rafivirumab (CR57) is an anti-rabies virus monoclonalantibody for the prophylaxis of rabies. Rafivirumab has neutralizing potency against a broad spectrum of RABV variants. Rafivirumab can be used for research of cocktails .
Anti-CD27 Antibody (M2177) is a human monoclonalantibody (mAb) targeting TNFRSF7/CD27. Anti-CD27 Antibody (M2177) inhibits the binding of sCD70 to human CD27 ECD-Fc. Anti-CD27 Antibody (M2177) can be used in the study of anti-tumor immunity. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Anti-CD27 Antibody (M2191) is a human monoclonalantibody (mAb) targeting TNFRSF7/CD27. Anti-CD27 Antibody (M2191) inhibits the binding of sCD70 to human CD27 ECD-Fc. Anti-CD27 Antibody (M2191) can be used in the study of anti-tumor immunity. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Anti-Mouse/Human Integrin β7 Antibody (FIB504) is an anti-mouse/human Integrin β7 IgG2a monoclonalantibody. Anti-Mouse/Human Integrin β7 Antibody (FIB504) can reduce the residence of type 2 innate lymphoid cells (ILC2s). Anti-Mouse/Human Integrin β7 Antibody (FIB504) can be used for researches on inflammation conditions and cancer such as lupus nephritis and glioma .
Enzelkitug (RO-7502175; RG-6411) (FUT8-KO) is an anti-CCR8monoclonalantibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody. Enzelkitug (FUT8-KO) can be used for the research of various solid tumors and hematological malignancies .
Anti-Mouse T15 VH and T15 VL regions of IgM Antibody (HB33) is an anti-mouse T15 VH and T15 VL regions of IgM IgG1 monoclonalantibody. Anti-Mouse T15 VH and T15 VL regions of IgM Antibody (HB33) is used in studies of the MHC class I heavy chain FcRn heterodimers and their interaction with IgG .
Inebilizumab (FUT8-KO) is an anti-CD19monoclonalantibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody.Inebilizumab (FUT8-KO) exhibits enhanced ADCC against B cells and can be used for research on multiple sclerosis and neuromyelitis optica .
SCT200 is a fully humanized IgG1 anti-EGFRmonoclonalantibody with a Kd of 0.08 nM. SCT200 can kill tumor cells by complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) through the Fc. SCT200 can be used for the study of refractory RAS and BRAF wild-type metastatic colorectal cancer .
Nimotuzumab is a humanized IgG1 monoclonalantibody targeting EGFR with a KD of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab, a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) .
MIL62 is an anti-CD20monoclonalantibody. MIL62 shows enhanced affinity for the FcγRⅢa receptors and direct B-cell killing effects. MIL62 has antibody-dependent cell-mediated cytotoxicity (ADCC) activity. MIL62 can be used for the study of non-Hodgkin lymphoma (NHL) .
TG20 is an anti-CD20monoclonalantibody that binds to a specific discontinuous epitope on CD20 with a Kd of 10–20 nM. TG20 exhibits enhanced antibody-dependent cellular cytotoxicity (ADCC). TG20 also enhances complement-dependent cytotoxicity (CDC) activity. TG20 can be used in research on B-cell lymphomas .
Mirvetuximab (M9346A) (powder) is an anti-FOLR1 (folate receptor 1) monoclonalantibody. Mirvetuximab (powder) is the antibody moiety of folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research .
Anti-Mouse GITR (D265A) Antibody (DTA-1) is an anti-mouse GITR IgG1 monoclonalantibody. Anti-Mouse GITR (D265A) Antibody (DTA-1) is a chimeric antibody of the original DTA-1 antibody (HY-P990124). Anti-Mouse GITR (D265A) Antibody (DTA-1) contains the D265A mutation region. Anti-Mouse GITR (D265A) Antibody (DTA-1) can be used for research on cancer and allergic conditions. The recommed isotype control of Anti-Mouse GITR (D265A) Antibody (DTA-1) is Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-Mouse CD28 (LALA-PG) Antibody (D665) is an anti-mouse CD28 IgG2a monoclonalantibody. Anti-Mouse CD28 (LALA-PG) Antibody (D665) is a chimeric antibody of the original D665 antibody (HY-P990793). Anti-Mouse CD28 (LALA-PG) Antibody (D665) contains the LALA-PG mutation region. Anti-Mouse CD28 Antibody (D665) induces the activation of T cells. Anti-Mouse CD28 Antibody (D665) can be used for research on neurological conditions, inflammation, immunology and cancer, such as Parkinson disease (PD), arthritis and graft-versus-host disease (GVHD).
Anti-Mouse GITR (LALA-PG) Antibody (DTA-1) is an anti-mouse GITR IgG2a monoclonalantibody. Anti-Mouse GITR (LALA-PG) Antibody (DTA-1) is a chimeric antibody of the original DTA-1 antibody (HY-P990124). Anti-Mouse GITR (LALA-PG) Antibody (DTA-1) contains the LALA-PG mutation region. Anti-Mouse GITR (LALA-PG) Antibody (DTA-1) can be used for research on cancer and allergic conditions. The recommed isotype control of Anti-Mouse GITR (LALA-PG) Antibody (DTA-1) is Mouse IgG2a kappa, Isotype Control (HY-P99978).
Anti-Mouse NK1.1 Antibody (PK136) is an anti-mouse NK1.1 IgG2a monoclonalantibody. Anti-Mouse NK1.1 Antibody (PK136) can deplete natural killer (NK) cells. Anti-Mouse NK1.1 Antibody (PK136) inhibits the JAK-STAT and NF-κB signaling pathways. Anti-Mouse NK1.1 Antibody (PK136) can be used for research on inflammation conditions such as non-alcoholic steatohepatitis (NASH) .
Anti-Rat CD8α Antibody (OX-8) is an anti-rat CD8α IgG1 monoclonalantibody. Anti-Rat CD8α Antibody (OX-8) can deplete CD8 + T cells. Anti-Rat CD8α Antibody (OX-8) can enhance airway remodeling. Anti-Rat CD8α Antibody (OX-8) can be used for researches on allergic conditions and infections such as RHV-rn1 virus infection and asthma .
Anti-Mouse FGL-1 Antibody (177R4) is an anti-mouse FGL-1 IgG2a monoclonalantibody. Anti-Mouse FGL-1 Antibody (177R4) can increase CD8 + T cell infiltration. Anti-Mouse FGL-1 Antibody (177R4) enhances the anti-tumor immune effect by blocking FGL1. Anti-Mouse FGL-1 Antibody (177R4) can be used for research on cancer such as lung cancer and breast cancer .
Anti-Flu A (H7N9) HA/Hemagglutinin Antibody (m826) is a humanized monoclonalantibody targeting H7N9. Anti-Flu A (H7N9) HA/Hemagglutinin Antibody (m826) induces antibody-dependent cellular cytotoxicity (ADCC) against cells expressing H7N9 HA. Anti-Flu A (H7N9) HA/Hemagglutinin Antibody (m826) is applicable to studies related to H7N9 avian influenza virus infection .
Armanezumab is a monoclonalantibody that targets and inhibits tau protein, and it specifically binds to the exposed N-terminal domain of pathological tau protein. Armanezumab can be used in relevant studies on Alzheimer's disease, frontotemporal dementia, and Pick's disease .
ALT-100 (Human IgG1) is a humanized IgG1 monoclonalantibody that targets NAMPT. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Diridavumab is a monoclonalanti-HA stalk antibody. Diridavumab stabilizes the prefusion HA structure and prevents pH-dependent fusion of cellular and viral membranes in endosomes. Diridavumab can be used in research of H2 influenza virus .
Arcitumomab is a murine anti-carcinoembryonic antigen (CEA) monoclonalantibody Fab’ fragment. Arcitumomab can be labeled with technetium-99m and can be used for single-photon emission computed tomography (SPECT) imaging .
Secukinumab (Anti-Human IL-17A) is a fully human anti-interleukin-17Amonoclonalantibody. Anti-Human IL-17A can be used for research in psoriasis pathogenesis .
Sontuzumab (AS1402) is a humanizedised IgG1κ MUC1 specific monoclonalantibody. Sontuzumab binds the extracellular MUC1 peptide sequence PDTR with a Kd of ~1 nM. Sontuzumab can be used for the research of breast cancer .
Ompekimig is a humanized immunoglobulin monoclonalantibody targeting human interleukin 4 (IL-4) and interleukin 13 (IL-13). Ompekimig is promising for research of immune-mediated inflammatory diseases, such as asthma and atopic dermatitis .
Gremubamab (MEDI3902) is a humanized IgG1 kappa anti-PcrV/Pslmonoclonalantibody. Gremubamab binds to the PA PcrV protein and Psl exopolysaccharide. Gremubamab has the potential for the research of pseudomonas aeruginosa infections .
Imgatuzumab (FUT8-KO) is a humanized monoclonalantibody against EGFR expressed in CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Imgatuzumab is an immunomodulator. Imgatuzumab may be used in cancer research.
Tozorakimab (MEDI-3506) is a human immunoglobulin G1 monoclonalantibody targeting interleukin-33. Tozorakimab reduces inflammation and epithelial dysfunction. Tozorakimab can be used to research chronic obstructive pulmonary disease .
Edrecolomab (Panorex) is a murine monoclonalantibody to the cell-surface glycoprotein 17-1A, expressed on epithelial tissues and on various carcinomas. Edrecolomab shows anti-tumor activity and can be used in colorectal carcinoma research .
Cetuximab sarotalocan (RM-1929) is an IRdye700DX (near-infrared photosensitizing dye) conjugate of Cetuximab (anti-EGFRmonoclonalantibody). Cetuximab sarotalocan can be used for head and neck cancers research .
Zolimomab is an anti-human monoclonalantibody targeting-CD5. Zolimomab binds to the CD5 antigen found on mature T-cells. Zolimomab can be used for the research of graft-versus-host disease (GVHD) .
PD-360324 is a human monoclonalantibody (mAb) targeting CSF1/M-CSF. PD-360324 can be used in cutaneous lupus erythematosus, pulmonary sarcoidosis and rheumatoid arthritis research .
Tovetumab (MEDI-575) is an anti-PDGFRα monoclonalantibody that selectively blocks the PDGFRα signal transduction. Tovetumab can be used in the research of glioblastoma and non-small cell lung cancer (NSCLC) .
XmAb-7195 (AIMab-7195) is a human monoclonalantibody (mAb) targeting IGHE. XmAb-7195 can be used in Food hypersensitivity, Allergic asthma, Allergic rhinitis, Atopic dermatitis and Conjunctivitis research .
BIIB036 is a human IgG1 monoclonalantibody (mAb) targeting TNFRSF12A/Fn14. BIIB036 inhibits the growth of patient-derived primary colorectal tumors in SCID mice .
Ormutivimab (rhRIG) is a recombinant human monoclonalantibody, targeting rabies virus. Ormutivimab neutralizes a variety of rabies virus strains. Ormutivimab exhibits potent potency against rabies post-exposure prophylaxis (PEP) model .
Anselamimab (CAEL-101) is a chimeric monoclonalantibody for systemic light chain (AL) amyloidosis. Anselamimab can promote phagocytic destruction and subsequent clearance of amyloid deposits. Anselamimab can be used in the research of amyloidosis .
Rulonilimab is a human IgG1 monoclonalantibody against PD-1 that targets, binds and inhibits PD-1 and its downstream signalling pathways with potential immune checkpoint inhibition and anti-tumour activity .
Iparomlimab is an anti-human PD-1/CD279/PDCD1 IgG4κ antibody. Iparomlimab also targets to human monoclonal PSB103 γ4-chain, disulfided with human monoclonal PSB103 κ-chain to form a dimer. Iparomlimab can be used for Oncology research .
MT204 is a humanized IgG1 antibody inhibitor targeting IL-2 of human and rhesus monkey origin. MT204 prevents soluble IL-2 from binding to intermediate-affinity IL-2 receptors and blocks CD25-bound IL-2 on high-affinity IL-2 receptors. MT204 has potently anti-proliferative activity with NKL cells and primary NK cells. MT204 has good tolerability and potent immunosuppressive activity in allogeneic skin graft model of rhesus monkey, promising for immunosuppressive and anti-proliferative therapy .
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonalantibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL) .
Anti-CD19 Antibody (4G7) is an anti-human CD19 IgG1 monoclonalantibody. Anti-CD19 Antibody (4G7) reduces the killing effect of CAR T cells on Raji cells. Anti-CD19 Antibody (4G7) can be used for research on immunology. Anti-CD19 Antibody (4G7) is often used in flow cytometry. The recommend isotype control of Anti-CD19 Antibody (4G7): Mouse IgG1 kappa, Isotype Control (HY-P99977) .
Evinacumab (REGN1500) is a human anti-ANGPTL3 (angiopoietin-like protein 3) monoclonalantibody (IgG4 class antibody). Evinacumab reduces plasma lipids in dyslipidemic mice by blocking ANGPTL3. Evinacumab can be used in studies of homozygous familial hypercholesterolaemia (HoFH), refractory hypercholesterolaemia (both familial and non-familial) and severe hypertriglyceridaemia .
Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonalantibody and an Interleukin-17A (IL-17A) inhibitor. Vunakizumab binds to IL-17A to inhibit downstream cytokines and block inflammatory signaling. Vunakizumab can be used for the research of chronic plaque psoriasis and ankylosing spondylitis .
GB-223 is a human monoclonalantibody (mAb) targeting TNFSF11/RANKL/CD254. GB-223 can be used in Giant cell tumour of bone and Postmenopausal osteoporosis research .
Izenivetmab (ZTS-00075623) is an anti-NGFB IgG2κ monoclonalantibody. Izenivetmab shows anti-inflammatory and analgesic effects by targeting anti-nerve growth factor (NGF). Izenivetmab can be used for the research of osteoarthritis .
Enzelkitug is a humanized immunoglobulin G1-κ monoclonalantibody targeting the human C-C motif chemokine receptor 8 (CCR8). Enzelkitug is promising for research of various solid tumors and hematological malignancies .
Ravulizumab (ALXN1210) is a humanized monoclonalantibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis .
Odesivimab is a human monoclonalantibody, targeting Ebola virus glycoprotein with a KD value of 7.74 nM for recombinant histidine-tagged Makona strain Ebola virus glycoprotein ectodomain protein. Odesivimab can be used in research of Ebola virus infection .
Brazikumab (AMG 139) is a human IgG2 monoclonalantibody, selectively binds the p19 subunit of IL-23, with a KD of 0.138 nM for human IL-23. Brazikumab can be used for the research of Crohn's disease .
Ipilimumab is a fully human monoclonalantibody IgG1κ that blocks the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells. Ipilimumab can be used in unresectable or metastatic melanoma (MM) studies .
MEDI-1912 is a human monoclonalantibody (mAb) targeting NGF/bNGF. MEDI-1912 inhibits signaling through TrkA and p75 receptors. MEDI-1912 can be used in chronic pain research .
Tadocizumab (C4G1; YM-337) is a humanized monoclonalantibody tageting integrin αIIbβ3. Tadocizumab has antiplatelet and antithrombotic effects, and can be used for cardiovascular disease research .
Otilimab (GSK 3196165) is an anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) human monoclonalantibody. Otilimab neutralises the biological function of GM-CSF by blocking the interaction of GM-CSF with its cell surface receptor .
Ficlatuzumab is a monoclonalantibody (McAb) targeting human hepatocyte growth factor (HGF). Ficlatuzumab blocks the activation of the HGF/c-Met signaling pathway, and inhibits c-Met receptor-mediated cancer cell proliferation, migration, and invasion .
Ixotatug is a monoclonalantibody targeting human CLDN6 (claudin-6). Ixotatug specifically binds to CLDN6, interfering with relevant signaling pathways in tumor cells and exerting antitumor activity. Ixotatug is promising for research of cancers .
SIM-0235 is humanized immunoglobulin G1 (IgG1) monoclonalantibody that targets and inhibits TNFR2, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) [1].
PMN310 is a monoclonalantibody targeting amyloid-β oligomers (AβO). PMN310 prevents AβO-induced memory loss and reduces synaptic loss and inflammation in vivo. PMN310 is potentially useful in Alzheimer's disease research .
Anti-Rat β-2-Microglobulin Antibody (4C9) is an anti-rat β-2-Microglobulin IgG1 monoclonalantibody. Anti-Rat β-2-Microglobulin Antibody (4C9) reduces pJNK nuclear translocation and restore SMAD nuclear localization. Anti-Rat β-2-Microglobulin Antibody (4C9) is often used in immunoprecipitation experiments .
Anti-Mouse IL-23 p19 Antibody (G23-8) is a rat-derived anti-mouse IL-23 p19 IgG1 monoclonalantibody. Anti-Mouse IL-23 p19 Antibody (G23-8) alleviates inflammation by restoring CLDN8 expression. Anti-Mouse IL-23 p19 Antibody (G23-8) can be used for research on inflammation conditions such as colitis and asthma .
Anti-DAG1/Dystroglycan Antibody (DAG-6F4) is a human monoclonalantibody against DAG1/Dystroglycan. Anti-DAG1/Dystroglycan Antibody (DAG-6F4) can bind specifically to the α and β subunits of the dystroglycan protein complex. Anti-DAG1/Dystroglycan Antibody (DAG-6F4) is applicable to research related to muscular dystrophy .
Lanerkitug (FUT8-KO) (BAY3375968 (FUT8-KO)) is an anti-CCR8 monoclonalantibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Lanerkitug (HY-P991942) selectively depletes human CCR8+Tregs via antibody dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP). Lanerkitug can be used in the research of solid tumors .
Anti-Mouse Pan-endothelial Cell Antigen/MECA-32 Antibody (MECA-32) is an anti-mouse Pan-endothelial Cell Antigen/MECA-32 IgG2a monoclonalantibody. Anti-Mouse Pan-endothelial Cell Antigen/MECA-32 Antibody (MECA-32) can label endothelial cells. Anti-Mouse Pan-endothelial Cell Antigen/MECA-32 Antibody (MECA-32) is often used for immunohistochemistry, delivery of siRNA and immunofluorescence .
Anti-Mouse TNFR2 Antibody (TR75-54.7) is an anti-mouse TNFR2 IgG monoclonalantibody. Anti-Mouse TNFR2 Antibody (TR75-54.7) can reduce white blood cell count (WBC) and decrease the expression of some pro-inflammatory cytokines such as CCL2 and CXCL5. Anti-Mouse TNFR2 Antibody (TR75-54.7) can be used for researches on inflammation conditions and cancer such as breast cancer .
Anti-Mouse LAG-3 (D265A) Antibody (C9B7W) is an anti-mouse LAG-3 IgG1 monoclonalantibody. Anti-Mouse LAG-3 (D265A) Antibody (C9B7W) is a chimeric antibody of the original C9B7W antibody (HY-P99141). Anti-Mouse LAG-3 (D265A) Antibody (C9B7W) contains the D265A mutation region. Anti-Mouse LAG-3 (D265A) Antibody (C9B7W) can be used for research on cancer .
Anti-CD11a Antibody (AL-57) is a monoclonalantibody targeting human CD11a. Anti-CD11a Antibody (AL-57) binds to HA cells in a dose-dependent manner but did not bind to LA cells. Anti-CD11a Antibody (AL-57) preferentially binds to the active conformation of LFA-1 and blocks LFA-1-mediated adhesion and lymphocyte proliferation. Anti-CD11a Antibody (AL-57) can be used for the research of inflammatory and autoimmune diseases .
Anti-Human/Rat HER2 (neu) Antibody (7.16.4) is an anti-human and anti-rat HER2 IgG2a monoclonalantibody. Anti-Human/Rat HER2 (neu) Antibody (7.16.4) reduces tumor cell proliferation by inhibiting the HER2 signaling pathway. Anti-Human/Rat HER2 (neu) Antibody (7.16.4) can activate CD8 + T cells. Anti-Human/Rat HER2 (neu) Antibody (7.16.4) can be used for research on cancer such as breast cancer .
Anti-Mouse Notch4 Antibody (HMN4-14) is an anti-mouse Notch4 IgG monoclonalantibody. Anti-Mouse Notch4 Antibody (HMN4-14) reduces inflammation by restoring the expression of bispecific proteins. Anti-Mouse Notch4 Antibody (HMN4-14) can inhibit Th2/Th17 cell differentiation and improve Treg cell function. Anti-Mouse Notch4 Antibody (HMN4-14) can be used for research on inflammation conditions such as viral pneumonia and airway inflammation .
Anti-Mouse VEGFR-2 Antibody (DC101) is a rat anti-mouse VEGFR2monoclonalantibody. Anti-Mouse VEGFR-2 Antibody (DC101) inhibits tumor angiogenesis by blocking the binding of VEGF and VEGFR2. Anti-Mouse VEGFR-2 Antibody (DC101) promotes immune cell infiltration and induces tumor cell apoptosis. Anti-Mouse VEGFR-2 Antibody (DC101) can be used for researches on various types of cancer such as melanoma, lung cancer and breast cancer .
Anti-Mouse CD8α Antibody (YTS 105.18) is a non-depleting rat IgG2a monoclonalantibody. Anti-Mouse CD8α Antibody (YTS 105.18) binds to CD8α (epitope c) on mouse CD8 + T cells; when used in combination with a non-depleting anti-CD4 antibody, it does not deplete CD8 + T cells but instead promotes the induction of peripheral tolerance in this cell subset. Anti-Mouse CD8α Antibody (YTS 105.18) can be used in studies of graft rejection .
Anti-CD2 Antibody (CB.219) is an anti-human CD2 IgG2b monoclonalantibody. Anti-CD2 Antibody (CB.219) can reduce the infiltration of T cells, macrophages, and the number of Tregs in the colon. Anti-CD2 Antibody (CB.219) can be used for research on infection and inflammation such as toxoplasma infection and colitis. The recommend isotype control of Anti-CD2 Antibody (CB.219): Mouse IgG2b kappa, Isotype Control (HY-P99982) .
Anti-CD85a/LILRB3 Antibody (7C5) is a human monoclonalantibody targeting LILRB3/ILT5/CD85a. Anti-CD85a/LILRB3 Antibody (7C5) can be used for research on inflammatory and immune diseases. The recommended isotype control is human IgG1 kappa, isotype control (HY-P99001).
Anti-Human/Mouse/Bovine LAG-3 Antibody (ADI-31853) is a monoclonalantibody that specifically binds to human, mouse and bovine LAG-3. Anti-Human/Mouse/Bovine LAG-3 Antibody (ADI-31853) can be used in the research of colon cancer, colorectal cancer and rectal cancer. The recommended isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
XmAb5485 is an Fc-engineered humanized anti-CD40 monoclonalantibody with high affinity to Fc-γ receptors. XmAb5485 induces potent antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) against tumor cells. XmAb5485 inhibits proliferation and induces apoptosis of tumor cells. XmAb5485 shows highly cytotoxic against lymphoma, leukemia and multiple myeloma cell lines as well as primary cancer cells .
Erlizumab (rhuMAb) is a monoclonalantibody against the Integrin b2/ITGB2/CD18 subunit of the Mac-1 receptor. Erlizumab can reduce reperfusion injury in myocardial infarction .
Laventatug is a humanized monoclonalantibody targeting human SLC39A6. Laventatug specifically binds to SLC39A6, interfering with the intracellular zinc ion transport process and thus exerting antitumor activity. Laventatug is promising for research of cancers .
Exerenibart is an immunoglobulin G4-κ monoclonalantibody targeting human transmembrane serine protease 6 (TMPRSS6). Exerenibart is promising for research of diseases associated with iron metabolism disorders, such as iron overload or iron deficiency .
Palivizumab (MEDI 493) is a humanized monoclonalantibody against respiratory syncytial virus (RSV). Palivizumab can bind to RSV F protein with a Kd value of 1.4 nM. Palivizumab can prevent respiratory syncytial virus infection in cotton mice .
Ascrinvacumab (PF-03446962) is a human IgG2 monoclonalantibody targets ALK-1. Ascrinvacumab shows binding efficiency with human ALK1 with a Kd value of 7 nM. Ascrinvacumab can be used for the research of hepatocellular carcinoma (HCC) .
Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3monoclonalantibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes .
Amlitelimab () is an anti-OX40 Ligand (OX40L) monoclonalantibody (mAb). Amlitelimab inhibits OX40-OX40L interaction, and can be used in the research of atopic dermatitis .
GB-0895 is a human monoclonalantibody (mAb) targeting TSLP. GB-0895 can be used in Asthma research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Gimvekibart is a humanized IgG4κ monoclonalantibody inhibitor targeting IL-4Ra/CD124. Gimvekibart can be used for inflammatory diseases like idiopathic pulmonary fibrosis (IPF) research .
Abituzumab (DI17E6) is a humanised anti-integrin αV monoclonalantibody (IgG2 type). Abituzumab effectively reduces the phosphorylation of FAK, Akt and ERK. Abituzumab can be used in cancer research, particularly in prostate cancer .
BMS-986184 is a fully human monoclonalantibody targeting interferon gamma-induced protein 10 (IP-10)/CXCL10. BMS-986184 can be used for the research of lupus nephritis .
Capromab is an anti-human PSMA-targeting monoclonalantibody. Capromab binds specifically to the intracellular domain of PSMA, does not undergo internalization after binding, and targets necrotic cells with disrupted membranes. Capromab can be used for the research of prostate cancer .
Inolimomab is an anti-interleukin-2 receptor (IL-2R) α chain monoclonalantibody. Inolimomab improves the survival rate in the early research of treating acute graft-versus-host disease (aGVHD) .
SM-17 is a humanized monoclonalantibody inhibitor targeting interleukin 25 (IL-25) and interleukin-17 receptor B (IL17RB). SM-17 is promising for research of immune system diseases .
FF-21101 is a human IgG1 monoclonalantibody (mAb) targeting CDH3/P-cadherin. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Isecarosmab (M-6495) is an anti-ADAMTSmonoclonalantibody (mAb) with a KD value of 3.65 pM. Isecarosmab has chondroprotective and anti-inflammatory activities. Isecarosmab can bind albumin to extend plasma half-life .
huCC49 is a human monoclonalantibody targeting TAG-72. huCC49 can be used in cancer-related research. The recommended isotype control is human IgG1 kappa, with the isotype control (HY-P99001) .
ANB032 is a human IgG4 kappa BTLA agonist monoclonalantibody. ANB032 inhibits activated T cell proliferation and reduces secretion of inflammatory cytokines.ANB032 can be used for the research of atopic dermatitis[1].
Zampilimab (UCB-7858) is a monoclonalantibody against transglutaminase 2 (TG2). Zampilimab inhibits TG2 crosslinking transamidation activity with an IC50 of 0.25 nM and a Kd of <50 pM. Zampilimab improves renal fibrosis .
SGM-101 Antibody is a chimeric monoclonalantibody targeting carcinoembryonic antigen (CEA). SGM-101 Antibody can serve as a tumor-specific fluorescent imaging probe after being covalently conjugated with the near-infrared fluorescent dye BM104 . SGM-101 Antibody accumulates in CEA-positive tumor tissues via antigen-antibody specific binding, and emits near-infrared fluorescence to enable imaging of tumor lesions. SGM-101 Antibody can be used in research related to gastric cancer, colorectal cancer, pancreatic cancer, non-small cell lung cancer, breast cancer, peritoneal carcinomatosis, and liver metastases .
MB-314 is a human IgG1 monoclonalantibody (mAb) targeting Lewis Y. MB-314 induces enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. MB-314 increases the release of IFN-γ, TNF-α, MCP-1, and IL-6. MB-314 can be used in cancer research .
Nimotuzumab (powder) is a humanized IgG1 monoclonalantibody targeting EGFR with a KD value of 0.21 nM. Nimotuzumab (powder) is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab (powder), a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) .
Lucatumumab (HCD122) is a fully human anti-CD40 antagonist monoclonalantibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research .
ADC Control Human IgG1-vcMMAE (solution) is a humanized monoclonalantibody that is an isotype control of ADC human IgG1-vcMMAE and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is vcMMAE (HY-15575) .
MIL93 is a humanized defucosylated IgG1 monoclonalantibody targeting Claudin18.2 (CLDN18.2) with enhanced antibody-dependent cellular cytotoxicity (ADCC) activity. MIL93 can be used for research on advanced solid tumors and gastric cancer. The recommended isotype control is human IgG1 kappa (HY-P99001) .
Flanvotumab (IMC-20D7S) is a human monoclonalantibody targeting to tyrosinase-related protein (TYRP1), specifically expressed in melanocytes and melanoma cells. Flanvotumab acts function via natural killing-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Flanvotumab has potent anti-tumor activity and good tolerance .
H2Mab-139 (H2Mab-141;H2Mab-19) is an anti-HER2monoclonalantibody. H2Mab-139 specifically binds to HER2 on various cancer cells. H2Mab-139 can detect HER2 overexpression in colorectal cancer via flow cytometry and immunohistochemical analysis. H2Mab-139 exhibits anti-tumor activity in mouse oral cancer and breast cancer xenografts. H2Mab-139 is applicable to research related to multiple cancers including colon cancer, oral cancer, and breast cancer .
Anti-Mouse OX40/CD134 (LALA-PG) Antibody (OX86) is an anti-mouse OX40/CD134 (LALA-PG) IgG2a monoclonalantibody. Anti-Mouse OX40/CD134 (LALA-PG) Antibody (OX86) is a chimeric antibody of the original OX86 antibody (HY-P990115). Anti-Mouse OX40/CD134 (LALA-PG) Antibody (OX86) can significantly enhance the generation of antigen-specific effector T cells. Anti-Mouse OX40/CD134 (LALA-PG) Antibody (OX86) can be used for research on cancer .
Zigakibart (BION-1301) is an IgG4-kappa, humanized monoclonalantibody against TNFSF13 (tumor necrosis factor (TNF) superfamily member 13, APRIL, CD256). Zigakibart exhibits anti-inflammatory activity .
Revdofilimab (ABBV-368) is a human IgG1 agonist monoclonalantibody against OX40. Among them, OX40 is a member of the TNF receptor superfamily expressed on activated and memory T cell subsets and T regulatory cells .
Bavunalimab (Anti-Human CTLA4xLAG3) is a bispecific human anti-CTLA-4/LAG-3monoclonalantibody. Bavunalimab activates T cells in NSG mice. Bavunalimab can be used for the research of cancer .
Danburstotug (IMC-001) is an IgG1-lambda anti-CD274 (PDL1, B7 homologue 1, B7H1) human monoclonalantibody. Danburstotug also is immunostimulant and antineoplastic .
Sifalimumab (MEDI-545) is an anti-IFNαmonoclonalantibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. Sifalimumab can be used in systemic lupus erythematosus (SLE) research .
Margetuximab (MGAH22) is a chimeric anti-HER2monoclonalantibody optimized Fc domain, with an EC50 value of 39.33 ng/mL. Margetuximab can be used for researching metastatic HER2-positive breast cancer .
Sulesomab (IMMU-MN3) is a murine monoclonalantibody fragment of the IgG1 class that binds to Normal Cross-Reactive Antigen-90 present on leukocytes. Sulesomab is cleared into infection nonspecifically through increased capillary membrane permeability .
Vecantoxatug is a humanized monoclonalantibody targeting Clostridium tetani toxin (TeNT, neurotoxin). Vecantoxatug specifically binds to Clostridium tetani toxin, preventing the toxin from binding to cell receptors and thus exerting antitoxin activity. Vecantoxatug is promising for research of tetanus .
Anrukinzumab (IMA-638) is a humanized anti-IL-13 monoclonalantibody. Anrukinzumab effectively reduces lung inflammation in a cynomolgus monkey model. Anrukinzumab can be used in studies of ulcerative colitis (UC) as well as asthma .
Vedolizumab (anti-α4β7-integrin) is a humanized IgG1 monoclonalantibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease .
CNTO-5825 is a humanized monoclonalantibody inhibitor targeting interleukin-13 (IL-13). CNTO-5825 is promising for research of Th2-type inflammatory related diseases such as asthma and atopic dermatitis .
Gumokimab (AK 111) is a monoclonalantibody targeting IL-17A, which can be used in the study of psoriasis, ankylosing spondylitis. Gumokimab competitively blocks the binding of human IL-17A to IL-17R.
SEA-TGT is a human monoclonalantibody (mAb) targeting TIGIT. SEA-TGT enhances binding to the activating FcγRIIIA while reducing binding to the inhibitory FcγRIIb. SEA-TGT can be used in advanced solid tumors and Lymphoma research .
Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of Spike protein and ACE2. Anti-Spike-RBD mAb is a potential therapeutic approach for SARS-CoV-2 treatment .
Anti-VSIR/VISTA Antibody (SG7) is a human monoclonalantibody (mAb) targeting VISTA/B7-H5. Anti-VSIR/VISTA Antibody (SG7) inhibits VISTA function and prevents PSGL-1 and VSIG3 from binding to VISTA. Anti-VSIR/VISTA Antibody (SG7) has anti-tumor activity in the mouse B16F10 melanoma model. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Anti-RSV F Antibody (R4.C6) is a monoclonalantibody against RSV F, with a Kd of 0.34 nM for the post-fusion RSV F trimer. Anti-RSV F Antibody (R4.C6) recognizes a unique neutralizing epitope spanning epitopes II and IV on both pre-fusion and post-fusion RSV F. Anti-RSV F Antibody (R4.C6) can be used in studies related to respiratory syncytial virus infection .
Anti-Mouse E-selectin/CD62E Antibody (9A9) is an anti-mouse E-selectin/CD62E IgG2b monoclonalantibody. Anti-Mouse E-selectin/CD62E Antibody (9A9) has an inhibitory effect on cancer cell colonization. Anti-Mouse E-selectin/CD62E Antibody (9A9) can be used for researches on inflammation conditions and cancer such as acute microvascular inflammation and breast cancer .
Anti-Mouse MAdCAM-1 Antibody (MECA-367) is an anti-mouse MAdCAM-1 IgG2a monoclonalantibody. Anti-Mouse MAdCAM-1 Antibody (MECA-367) significantly inhibits the migration of pig peripheral blood lymphocytes (PBL) by blocking the function of MAdCAM-1. Anti-Mouse MAdCAM-1 Antibody (MECA-367) selectively inhibits B cell migration to exacerbate inflammation. Anti-Mouse MAdCAM-1 Antibody (MECA-367) can be used for researches on inflammation, metabolic conditions and xenotransplantation such as colitis and diabetes .
Anti-Mouse Jagged 2 Antibody (HMJ2-1) is an anti-mouse Jagged 2 IgG monoclonalantibody. Anti-Mouse Jagged 2 Antibody (HMJ2-1) regulates Treg/Th17 balance through IL-9. Anti-Mouse Jagged 2 Antibody (HMJ2-1) increases Jagged2-Notch signaling through activation of RBP-Jk. Anti-Mouse Jagged 2 Antibody (HMJ2-1) can be used for researches on inflammation conditions and xenotransplantation such as experimental autoimmune encephalomyelitis (EAE) .
Anti-HCMV gB Antibody (SM5-1) is an efficient neutralizing human monoclonalantibody that targets the human cytomegalovirus (HCMV) glycoprotein B (gB). Anti-HCMV gB Antibody (SM5-1) neutralizes HCMV by blocking the conformational changes of gB and interfering with its binding to the gH/gL complex. Anti-HCMV gB Antibody (SM5-1) can broadly neutralize different virus strains and inhibit the infection of various cell types (such as fibroblasts, epithelial cells, and dendritic cells). Anti-HCMV gB Antibody (SM5-1) can be used in HCMV vaccine research .
Anti-Mouse F4/80 Antibody (CI:A3-1) is an anti-mouse F4/80 IgG2b monoclonalantibody. Anti-Mouse F4/80 Antibody (CI:A3-1) can clear macrophages. Anti-Mouse F4/80 Antibody (CI:A3-1) can be used for research on inflammation conditions such as endometriosis. Anti-Mouse F4/80 Antibody (CI:A3-1) often used for flow cytometry analysis and immunohistochemical analysis .
Anti-Mouse CTLA-4 Antibody (9D9) is an anti-mouse CTLA-4 IgG2b monoclonalantibody. Anti-Mouse CTLA-4 Antibody (9D9) can bind to CTLA-4 and block its binding to B7. Anti-Mouse CTLA-4 Antibody (9D9) enhances T cell function by increasing the ratio of CD8 + T cells to regulatory T cells (Tregs). Anti-Mouse CTLA-4 Antibody (9D9) can be used for research on cancer such as colon cancer and melanoma .
Anti-Mouse IL-4 Antibody (11B11) is an anti-mouse IL-4 IgG1 monoclonalantibody. Anti-Mouse IL-4 Antibody (11B11) can inhibit Th2 cell differentiation by blocking the IL-4 signaling pathway. Anti-Mouse IL-4 Antibody (11B11) can significantly reduce fibrosis combined with anti-IL13 mAb. Anti-Mouse IL-4 Antibody (11B11) can be used for researches on cancer and inflammation conditions such as colorectal cancer and prostatitis .
Anti-Mouse/Human IL-7 Antibody (M25) is an anti-mouse IL-7 IgG2b monoclonalantibody. Anti-Mouse/Human IL-7 Antibody (M25) alleviates inflammation by blocking IL-7 signaling and inhibiting innate lymphoid cells (ILC2s) activation. Anti-Mouse/Human IL-7 Antibody (M25) can reduce the number of B cell precursors. Anti-Mouse/Human IL-7 Antibody (M25) can be used for researches on inflammation conditions such as airway inflammation .
Anti-Mouse Vβ4 TCR Antibody (KT4) is an anti-mouse Vβ4 TCR IgG2b monoclonalantibody. Anti-Mouse Vβ4 TCR Antibody (KT4) can reduce the proportion of Vβ4 + T cells without affecting their function. Anti-Mouse Vβ4 TCR Antibody (KT4) can be used for research on immunology and infection conditions such as virus infection. Anti-Mouse Vβ4 TCR Antibody (KT4) is often used in flow cytometry .
Anti-IL-12 p70 Antibody (20C2) is an anti-human IL-12 p70 IgG1 monoclonalantibody. Anti-IL-12 p70 Antibody (20C2) can inhibit the production of IFN-γ. Anti-IL-12 p70 Antibody (20C2) can be used for research on inflammation conditions. The recommend isotype control of Anti-IL-12 p70 Antibody (20C2): Rat IgG1 kappa, Isotype Control (HY-P99979) .
Anti-Mouse CD38 Antibody (NIMR5) is an anti-mouse CD38 IgG2a monoclonalantibody. Anti-Mouse CD38 Antibody (NIMR5) can activate the ERK signaling pathway and promote cell apoptosis. Anti-Mouse CD38 Antibody (NIMR5) can restore T cell function. Anti-Mouse CD38 Antibody (NIMR5) upregulates the expression of CD1d protein and enhances spleen cell proliferation, dendritic cell (DC) and natural killer T cell (NKT) expansion. Anti-Mouse CD38 Antibody (NIMR5) can be used for researches on cancer and immunology such as melanoma and colon cancer .
Anti-CD1a Antibody (OKT-6) is an anti-human CD1a IgG1 monoclonalantibody. Anti-CD1a Antibody (OKT-6) blocks T cell activation by blocking CD1a function. Anti-CD1a Antibody (OKT-6) can reduce the production of IFN-γ. Anti-CD1a Antibody (OKT-6) can be used for researches on cancer and inflammation such as leukemia. The recommend isotype control of Anti-CD1a Antibody (OKT-6): Mouse IgG1 kappa, Isotype Control (HY-P99977) .
Anti-Mouse CD8α Antibody (2.43) is an anti-mouse CD8α IgG2b monoclonalantibody. Anti-Mouse CD8α Antibody (2.43) can significantly deplete CD8 + T cells. Anti-Mouse CD8α Antibody (2.43) can prolong the survival time of liver cell transplantation. Anti-Mouse CD8α Antibody (2.43) can be used for research on immunology. The recommend isotype control of Anti-Mouse CD8α Antibody (2.43): Rat IgG2b kappa, Isotype Control (HY-P990682) .
Zumilokibart (APG-777) is an anti-IL-13 IgG1κ type humanized antibody. The recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).Zumilokibart can be used for the research of atopic dermatitis (AD) .
Etalanetug (Mouse IgG2a) (7G6 Antibody) is a mouse monoclonalantibody targeting the HVPGG motif in the microtubule-binding domain of tau protein. Etalanetug (Mouse IgG2a) reduces the levels of insoluble tau protein in multiple brain regions and inhibits the seeding and spread of pathological tau protein. Etalanetug (Mouse IgG2a) is applicable to research related to Alzheimer's disease .
Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonalantibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 (HY-12454), via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.8 .
Vobramitamab is a humanized B7-H3monoclonalantibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. MGC018 displays potent antitumor activity in preclinical tumor models of breast, ovarian, and lung cancer, as well as melanoma .
BMS-986021 (BMS-986148 antibody) is a human monoclonalantibody expressed in CHO, targeting Mesothelin. BMS-986021 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.46 kDa. For the isotype control of BMS-986021, refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Delpacibart is a humanized IgG1κ monoclonalantibody targeting the transferrin receptor TFRC. Delpacibart can be conjugated with the phosphorodiamidate morpholino oligonucleotide (PMO) Zotadirsen (HY-177972), which targets exon 44 of the dystrophin gene, to synthesize the antibody-oligonucleotide conjugate (AOC) Delpacibart zotadirsen (HY-177564). Delpacibart is suitable for use in Duchenne muscular dystrophy (DMD44) research .
Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) is a humanised monoclonalantibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab blocks the inflammation-driven osteogenic differentiation .
Osemitamab (FUT8-KO) is an anti-claudin-18.2monoclonalantibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study .
Empasiprubar (ARGX-117) is a humanized inhibitory monoclonalantibody targeting complement C2. Empasiprubar binds to the Sushi-2 domain of C2, preventing the formation of C3 pre convertase and inhibiting the activation of classical and lectin pathways upstream of C3 activation. Empasiprubar can prevent complement mediated autoimmune hemolytic anemia and antibody mediated organ transplant rejection. Empasiprubar can prevent neuroglial lymphoconjunctival injury in GM1 antibody mediated mouse models .
Atigotatug (FUT8-KO) is an anti-fuc-GM1monoclonalantibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out, and fucose deficiency enhances the ADCC effect of the antibody. Atigotatug (HY-P990902) is a Fucosyl ganglioside GM1 (fuc-GM1)-targeting IgG1κ type humanized antibody. Atigotatug can induce immune-mediated tumor cell death, such as small cell lung cancer .
W0180 is a human IgG1 monoclonalantibody (mAb) targeting VISTA/B7-H5. W0180 has the potential to activate T cells. W0180 can be used in solid tumors research .
Dalidnetug is a humanized monoclonalantibody targeting human amyloid-beta precursor protein (APP). Dalidnetug specifically binds to APP to reduce the production of amyloid-beta (Aβ), thus exerting the activity of clearing amyloid-beta. Dalidnetug is promising for research of Alzheimer's disease .
Zamerovimab (CTB011) is an anti-rabies humanized IgG1κ monoclonalantibody that binds to the non-overlapping epitopes on the rabies virus (RABV) glycoprotein. Zamerovimab targets residues at and near antigenic site III. Zamerovimab can be used in rabies studies .
GSK-315234 is a human IgG1 monoclonalantibody (mAb) targeting OSM . GSK-315234 can be used in the study of atherosclerosis Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Figitumumab (CP-751871) is a potent and fully human monoclonalanti–insulin-like growth factor 1 receptor (IGF1R) antibody. Figitumumab prevents IGF1 from binding to IGF1R with an IC50 of 1.8 nM .
Regdanvimab (CT-P59) is a human monoclonalantibody that targets the receptor-binding domain of SARS-CoV-2 spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19 .
Mapatumumab (HGS-ETR1) is a fully human IgG1 agonistic monoclonalantibody that targets tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1). Mapatumumab can be used for the research of cancer .
Cosibelimab (CK-301) is a high-affinity, fully human PD-L1-blocking monoclonalantibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab exhibits antitumor efficacy .
Kiatomab is a monoclonalantibody targeting the mouse cancer stem cell-specific antigen KIAA1114. Kiatomab has anti-tumor activity. The corresponding isotype control is Mouse IgG2b kappa, Isotype Control (HY-P99982) .
Cenzestotug is a monoclonalantibody targeting human tumor necrosis factor receptor superfamily member 4 (TNFRSF4). Cenzestotug activates relevant immune cells by binding to TNFRSF4, exerting immunostimulatory and antitumor activities. Cenzestotug is promising for research of cancer immunotherapy .
Certolizumab pegol (Certolizumab) is a recombinant, polyethylene glycosylated, antigen-binding fragment of a humanized monoclonalantibody that selectively targets and neutralizes tumour necrosis factor-α (TNF-α). Certolizumab pegol can be used for rheumatoid arthritis and Crohn disease research .
RTX-003 is a monoclonalantibody targeting CD25. RTX-003 induces the death of regulatory T cells (Tregs) by targeting the IL-2 receptor α chain (CD25), and can enhance anti-tumor immune responses.
Daxdilimab is an anti-ILT7monoclonalantibody, ILT7 is a cell surface molecule specific to the pDC type of dendritic cells. Daxdilimab can be used in acute lung injury (ALI) in patients with COVID-19 infection research .
BI-1808 is a human IgG1 monoclonalantibody that targets TNFR2by blocking interaction of TNFR2 with ligand TNF-α, confers FcγR-dependent depletion of Treg and mediates expansion of intratumoral CD8 + T cells .
Abciximab (C7E3), a chimeric mouse/human monoclonalantibody fragment, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors .
hCBE-11 is a human monoclonalantibody (mAb) targeting TNFRSF3. hCBE-11 can be used in solid tumors research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Rapaprutug is a monoclonalantibody targeting human KARS1 (lysyl-tRNA synthetase 1). Rapaprutug blocks the relevant inflammatory signaling pathways in which KARS1 is involved, reducing the production and release of inflammatory factors. Rapaprutug is promising for research of inflammatory diseases .
SAR442257 is a humanized IgG4-S228P, kappa monoclonalantibody targeting CD38 and CD28 on multiple myeloma cells and co-stimulates CD3 and CD28 on T cells .
Anti-SARS-CoV-2 Spike mAb (CR3022) is a a CHO cell derived human monoclonal IgG1 antibody. It binds to both S1 domain of SARS-CoV/SARS-CoV-2 Spike protein .
CNTO-860 is a humanized anti-tissue factormonoclonalantibody. CNTO-860 can improve tumor control when combined with Paclitaxel (HY-B0015) in colon cancer model and significantly increase tumor-free survival .
JAB-BX102 is a human monoclonalantibody (mAb) targeting NT5E/CD73. JAB-BX102 can be used in the study of cancers such as breast cancer, pancreatic cancer, and prostate cancer .
Anti-Mouse IL-2 Antibody (JES6-1A12) is an anti-mouse IL-2 IgG1 monoclonalantibody. Anti-Mouse IL-2 Antibody (JES6-1A12) can inhibit Treg amplification and enhance Th1 response. Anti-Mouse IL-2 Antibody (JES6-1A12) can form a complex with IL-2 for experimentation. Anti-Mouse IL-2 Antibody (JES6-1A12) can be used for research on infection conditions such as malaria .
Anti-Mouse Vβ8 TCR Antibody (F23.1) is an anti-mouse Vβ8 TCR IgG2a monoclonalantibody. Anti-Mouse Vβ8 TCR Antibody (F23.1) can clear Vβ8 + T cells to alleviate immune conditions. Anti-Mouse Vβ8 TCR Antibody (F23.1) can be used for research on autoimmune conditions. Anti-Mouse Vβ8 TCR Antibody (F23.1) is often used in flow cytometry .
Anti-Mouse L-Selectin/CD62L Antibody (Mel-14) is an anti-mouse L-Selectin/CD62L IgG2a monoclonalantibody. Anti-Mouse L-Selectin/CD62L Antibody (Mel-14) can significantly inhibit the migration of T cells and B cells. Anti-Mouse L-Selectin/CD62L Antibody (Mel-14) can block initial lymphocyte homing. Anti-Mouse L-Selectin/CD62L Antibody (Mel-14) can be used for researches on inflammation, metabolic and infection conditions such as diabetes and parasitic infections .
Anti-Mouse IL-1a Antibody (ALF-161) is an anti-mouse IL-1a IgG1 monoclonalantibody. Anti-Mouse IL-1a Antibody (ALF-161) can inhibit CD8 + T cell response by blocking IL-1a signaling. Anti-Mouse IL-1a Antibody (ALF-161) can reversibly transform myeloid cell expansion and improve T cell function. Anti-Mouse IL-1a Antibody (ALF-161) can be used for researches on immune response and cancer such as breast cancer .
Anti-Mouse IFN gamma Antibody (R4-6A2) is an anti-mouse IFN gamma IgG1 monoclonalantibody. Anti-Mouse IFN gamma Antibody (R4-6A2) can increase the total serum IgG level. Anti-Mouse IFN gamma Antibody (R4-6A2) can be used for researches on immunology and infection conditions such as nymphs infection. The recommend isotype control of Anti-Mouse IFN gamma Antibody (R4-6A2): Rat IgG1 kappa, Isotype Control (HY-P99979) .
Anti-Rat Kappa Immunoglobulin Light Chain Antibody (MAR 18.5) is an anti-rat Kappa Immunoglobulin Light Chain IgG2a monoclonalantibody. Anti-Rat Kappa Immunoglobulin Light Chain Antibody (MAR 18.5) can enhance B cell depletion. Anti-Rat Kappa Immunoglobulin Light Chain Antibody (MAR 18.5) can enhance T cell exhaustion after the injection of CD4 mAb (HY-P990792) and CD8 mAb (HY-P99129). Anti-Rat Kappa Immunoglobulin Light Chain Antibody (MAR 18.5) can be used for research on immunology .
Anti-Mouse DKK3 Antibody (DKK3-4.22) is an anti-mouse DKK3 IgG1 monoclonalantibody. Anti-Mouse DKK3 Antibody (DKK3-4.22) can improve kidney function and increases T cell infiltration. Anti-Mouse DKK3 Antibody (DKK3-4.22) can reduce skin inflammation by blocking the immunosuppressive function of DKK3. Anti-Mouse DKK3 Antibody (DKK3-4.22) can be used for researches on inflammation conditions such as unilateral ureteral obstruction (UUO) and experimental autoimmune encephalomyelitis (EAE) .
RTX-002 is a human monoclonalantibody (mAb) targeting PDCD1/PD-1/CD279. RTX-002 can be used to study autoimmune diseases such as systemic lupus erythematosus and multiple sclerosis .
BTH1704 is a human monoclonalantibody (mAb) targeting MUC1. BTH1704 enables PGG-primed leukocytes to kill iC3b-opsonized tumor cells. BTH1704 can be used in pancreatic and breast cancer research .
Olinvacimab (TTAC-0001) is a fully human anti-VEGFR2monoclonalantibody. Olinvacimab inhibits VEGF binds to KDR with a Kd value of 0.23 nM. Olinvacimab has antiangiogenic activity. Olinvacimab can be used for the research of recurrent glioblastoma and breast cancer .
VPI-2690B is a human monoclonalantibody (mAb) targeting Integrin aVb3. VPI-2690B inhibits TGF-β signaling. VPI-2690B can be used in Diabetic nephropathies research .
HuMax-IL15 is a human IgG1 monoclonalantibody against IL-15. HuMax-IL15 is applicable to the research of rheumatoid arthritis. The recommended isotype control is human IgG1 kappa (HY-P99001) .
Secukinumab (AIN457) is a high affinity, human monoclonalantibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis .
Bemarituzumab is a humanized IgG1 monoclonalantibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has antitumor activity against gastric and breast cancer .
MK-4830 is a fully humanized monoclonalantibody of the immunoglobulin G4 subclass that specifically binds to ILT4 and blocks its interaction with HLA-G and other ligands. MK-4830 inhibits tumor growth in humanized mouse cancer models .
Vilamakitug (XB-2001) is an anti-IL-1α human IgG4 κ monoclonalantibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
Litifilimab (BIIB059) is a humanized anti-BDCA2 IgG1 monoclonalantibody administered subcutaneously. Litifilimab can inhibit the production of type I interferons, cytokines and chemokines. Litifilimab can be used in the research of diseases such as systemic lupus erythematosus .
ASKG-712 (AM712) is a recombinant anti-VEGF humanized monoclonalantibody and Ang-2 antagonist peptide fusion protein. ASKG-712 can be used in Wet age-related macular degeneration and Diabetic macular oedema research .
APNmAb005 is a human monoclonalantibody (mAb) targeting MAPT/Tau/PHF-tau. APNmAb005 blocks tau seeding in vitro and rescues neuronal loss in rTG4510 mice. APNmAb005 can be used in Alzheimer’s disease (AD) research .
Tuvonralimab (PSB-205) is a humanized IgG1 monoclonalantibody against CTLA-4. Tuvonralimab can be used in the research of tumors. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Omodenbamab is an anti-SpA (Staphylococcal protein A) human monoclonalantibody with a KD value of 0.0467 nM. Omodenbamab circumvents a key S. aureus evasion mechanism by targeting the cell wall moiety Protein A (SpA). Omodenbamab can be used in research of S. aureus bloodstream infection .
Elranatamab (PF-06863135) is an anti-CD3E/TNFRSF17 human IgG2κ monoclonalantibody . Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002).
ATL301 is a human monoclonalantibody that targets human ganglioside GD2 (ganglioside GD2). GD2 is a highly expressed glycolipid antigen on the surface of neuroepithelial tumor cells, and is commonly found in neuroblastoma, melanoma, osteosarcoma, small cell lung cancer, etc.
Potravitug is a humanized immunoglobulin G1-κ monoclonalantibody targeting the major capsid protein VP1 of BK polyomavirus (BKV). Potravitug is promising for research of BKV-infection-related diseases, such as BKV-induced nephropathy after organ transplantation .
Letolizumab (BMS-986004) is a monoclonalantibody targeting CD40L, which is produced to express mutant IgG1 lacking effector function, including Fc binding and complement fixation. Letolizumab reduces rejection, thromboembolism and prolongs the survival time .
Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonalantibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research .
Domvanalimab (AB154) is an anti-TIGIT humanized monoclonalantibody. Domvanalimab binds human TIGIT9 and blocks the TIGIT-CD155 interaction. Domvanalimab can be used for studies of non-small cell lung cancer and esophageal cancer .
AMG-529 is a humanized monoclonalantibody against ASGR1 that binds to ASGR1, blocks ligand binding, and causes a dose-dependent increase in ALP (a biomarker of ASGR1 inhibition). AMG-529 can be used for the research of cardiovascular diseases .
Ciduvectamig is an anti-CD3E/TMEFF2 human IgG4 κ monoclonalantibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
Fanolesomab is an anti-human CD15-targeting monoclonalantibody. Fanolesomab binds to the CD15 epitope on white blood cells to enable imaging of white blood cell distribution, migration, and infection sites. Fanolesomab can be used for the research of infection .
Concizumab is an anti-TFPI monoclonalantibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. Concizumab can be used in the study of haemophilia .
Lomtegovimab (BI 767551) is a human anti-SARS-COV-2 spike glycoprotein monoclonalantibody. Lomtegovimab binds and neutralizes SARS-CoV-2. Lomtegovimab shows antiviral efficacy. Lomtegovimab has the potential for the research of COVID-19 .
Bocunebart is a humanized monoclonalantibody targeting human adenylate cyclase-activating polypeptide (ADCYAP1). Bocunebart exerts anti-inflammatory activity by specifically binding to ADCYAP1 and inhibiting related inflammatory signaling pathways. Bocunebart is promising for research of inflammation-related diseases .
Anti-Mouse CD8α Antibody (YTS169.4) is an IgG2 monoclonalantibody targeting mouse CD8α. Anti-Mouse CD8α Antibody (YTS169.4) rapidly depletes or downregulates CD8 + T cells in the spleens of Biozzi AB/H mice. Anti-Mouse CD8α Antibody (YTS169.4) is applicable to research related to hepatitis B virus infection . Recommended isotype control: Rat IgG2b kappa, Isotype Control (HY-P990682).
Anti-Mouse 4-1BB/CD137 Antibody (3H3) is an anti-mouse 4-1BB/CD137 IgG2a monoclonalantibody. Anti-Mouse 4-1BB/CD137 Antibody (3H3) can effectively activate memory T cells and inhibit tumors by increasing Bcl-xL and granzyme B levels. Anti-Mouse 4-1BB/CD137 Antibody (3H3) can be used for research on cancer such as lymphoma and colon cancer .
Anti-Human/Monkey CD16a Antibody (3G8) is a monoclonalantibody targeting CD16a. Anti-Human/Monkey CD16a Antibody (3G8) blocks FcγRIII/CD16a, upregulates the metabolic activity of CD16+ cells, downregulates CD87, a poor prognostic marker, and inhibits the engraftment and growth of leukemia cells in acute myeloid leukemia, and rapidly increases platelet counts in immune thrombocytopenia. Anti-Human/Monkey CD16a Antibody (3G8) is applicable to research related to tumor immunology .
Anti-Mouse LAG-3 Antibody (C9B7W) is an anti-mouse LAG-3 IgG1 monoclonalantibody. Anti-Mouse LAG-3 Antibody (C9B7W) can enhance CD4 + T cell function and exert anti-tumor effects without blocking the interaction between LAG-3 and MHCII. Anti-Mouse LAG-3 Antibody (C9B7W) can be used for research on cancer such as head and neck squamous cell carcinoma (HNSCC) .
Anti-Mouse CD4 Antibody (GK1.5) is an anti-mouse CD4 IgG2b monoclonalantibody. Anti-Mouse CD4 Antibody (GK1.5) can significantly deplete CD4 + T cells. Anti-Mouse CD4 Antibody (GK1.5) can extend the survival rate of xenograft models. Anti-Mouse CD4 Antibody (GK1.5) can be used for research on immunology. The recommend isotype control of Anti-Mouse CD4 Antibody (GK1.5): Rat IgG2b kappa, Isotype Control (HY-P990682) .
Anti-Mouse Ter-119 Antibody (TER-119) is an anti-mouse Ter-119 IgG2b monoclonalantibody. Anti-Mouse Ter-119 Antibody (TER-119) can increase platelet count. Anti-Mouse Ter-119 Antibody (TER-119) can remove red blood cells and their precursor cells to isolate and enrich natural killer (NK) cells. Anti-Mouse Ter-119 Antibody (TER-119) can be used for research on immune thrombocytopenia. Anti-Mouse Ter-119 Antibody (TER-119) can be used to construct a model of immune thrombocytopenic purpura combined with CD41 mAb .
ADC Control Human IgG1-Deruxtecan (DAR 4) is a humanized monoclonalantibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
Dargistotug (M-6223) is a fully human IgG1 monoclonalantibody targeting TIGIT (T cell immune receptor with Ig domain and ITIM). TIGIT is an inhibitory immune checkpoint that promotes NK cell depletion and reduces the secretion of cytokines by binding to CD155 and other antibodies. It can also directly or indirectly inhibit effector T cells and upregulate Tregs cells, thereby exerting immunosuppression. Function .
hu14.18 (K322A) is a humanized anti-disialoganglioside GD2 monoclonalantibody that contains fully human amino acid sequences for immunoglobulin G1 heavy and kappa light chains. hu14.18 (K322A) has antibody-dependent cellular cytotoxicity (ADCC). hu14.18 (K322A) can be used for the study of high-risk neuroblastoma .
VIS832 is an anti-CD138monoclonalantibody. VIS832 induces antibody-dependent cellular cytotoxicity. VIS832 inhibits the growth of disseminated multiple myeloma tumors in vivo. VIS832 exerts anti-tumor effects on multiple myeloma in combination with Lenalidomide (HY-A0003) or Bortezomib (HY-10227). VIS832 can be used in research related to multiple myeloma .
ADC Control Human IgG1-vcMMAF is a humanized monoclonalantibody that is an isotype control of ADC human IgG1-vcMMAF and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is MC-Val-Cit-PAB-MMAF (vcMMAF; HY-112786) .
Osemitamab is an IgG1 antibody targeting to human claudin-18.2. Osemitamab consists of human-Mus musculus monoclonal TST001 γ1-chain, disulfide with human-Mus musculus monoclonal TST001 κ-chain, dimer (ACI). Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study .
Anti-Mouse GITR Antibody (DTA-1) is a rat derived IgG2b monoclonal agonist antibody targeting mouse GITR. Anti-Mouse GITR Antibody (DTA-1) can activate T cells and B cells to enhance immune response. Anti-Mouse GITR Antibody (DTA-1) selectively enhances Th2 cell effector function through GITR signaling. Anti-Mouse GITR Antibody (DTA-1) may exacerbate allergic reactions. Anti-Mouse GITR Antibody (DTA-1) can be used for researches on cancer and allergic conditions such as colon cancer and allergic asthma. The recommed isotype control of Anti-Mouse GITR Antibody (DTA-1) is Rat IgG2b kappa, Isotype Control (HY-P990682) .
Firsekibart is an immunoglobulin G4-λ2 monoclonalantibody targeting human interleukin 1β (IL-1β). Firsekibart is promising for research of inflammation-related diseases, such as rheumatoid arthritis and inflammatory bowel disease .
Priliximab (CEN 000029) is an anti-CD4 humanized monoclonalantibody. Priliximab binds to CD4 on the surface of T cells, resulting in a significant and sustained reduction in circulating CD4 + T cells. Priliximab can be used in research of rheumatoid arthritis (RA) .
Zolbetuximab (IMAB362) is a monoclonalantibody targeting Claudin-18.2. Zolbetuximab mediates specific killing of Claudin-18.2-positive cells through immune effector mechanisms. Zolbetuximab can be used for the research of gastrointestinal adenocarcinomas and pancreatic tumors .
Utomilumab (PF 05082566) is a fully human IgG2 agonist monoclonalantibody that selectively binds to 4-1BB/CD137. Utomilumab can be used in the research of tumors such as follicular and other CD20 + non-Hodgkin lymphomas .
Dectrekumab (QAX576) is a human monoclonalantibody that targets IL-13. Dectrekumab significantly improves intraepithelial esophageal eosinophil counts and dysregulated esophageal disease-related transcripts with Eosinophilic esophagitis (EoE) in a sustained manner and can be used for inflammation and immunology related research .
Pexelizumab (h5G1. 1-SC) is a humanized scFv monoclonalantibody directed against the C5 complement component. Pexelizumab inhibits apoptosis and leukocyte infiltration. Pexelizumab can be used for the research of cerebral IR injury and myocardial infarction .
Valanafusp alfa (AGT-181) is a chimeric monoclonalantibody that fuses human α-L-iduronidase (IDUA) and targets the human insulin receptor (HIR). Valanafusp alfa has brain penetrating properties, making it useful for research on mucopolysaccharidosis type I (MPS I) .
Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) receptor β subunitmonoclonalantibody. Vixarelimab inhibits IL-31 and OSM signalling. Vixarelimab can be used in studies of inflammatory skin diseases such as atopic dermatitis and itchy nodular rash .
AGEN-1571 is a human IgG1 monoclonalantibody (mAb) targeting ILT2. AGEN-1571 promotes adaptive and innate immune responses. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001)
HBM1020 is a fully human monoclonalantibody targeting B7H7. HBM1020 binds to B7H7 and enhances the anti-tumor response of T cells. HBM1020 can be used in research related to advanced solid tumors .
MEDI-8490 is a fully human monoclonalantibody targeting APP/Aβ. MEDI-8490 can be used in research related to neurodegenerative diseases. Recommended isotype control: Human IgG1 lambda1, Isotype Control (HY-P99992).
NMC-001 is a human IgG1 monoclonalantibody (mAb) targeting MDM2. NMC-001 can be used in pancreatic cancer research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Brontictuzumab (OMP 52M51) is a monoclonalantibody (MAb) that inhibits Notch1 signal. Brontictuzumab selectively binds the negative regulatory region of the Notch1. Brontictuzumab inhibits tumor cell proliferation. Brontictuzumab can be used in the research of leukemia and lymphoma .
Trevogrumab (REGN-1033) is a monoclonalantibody targeting GDF8 (growth differentiation factor 8, also known as myostatin). Trevogrumab is used in research on muscle wasting conditions, including disuse atrophy, chronic diseases, and changes in food and nutrient intake .
ES004 is a human monoclonalantibody (mAb) targeting SIRPα/CD172a. ES004 enhances macrophage phagocytosis and induces potent T cell responses to promote tumor killing. ES004 can be used in Solid tumours research .
SHR-2010 is a fully humanized monoclonalantibody targeting MASP-2. SHR-2010 selectively inhibits lectin pathway activation without affecting classical or alternative complement pathways. SHR-2010 can be used for the research of IgA nephropathy .
Cobolimab (TSR-022) is an anti-TIM-3monoclonalantibody. Cobolimab mediates the internalization of TIM3 with an IC50 value of 0.4464 nM. Cobolimab has potential application in solid tumors and non-small cell lung cancer (NSCLC) .
Semorinemab (RG 6100) is an anti-Tau humanized IgG4 monoclonalantibody, targets the N-terminal portion of the Tau protein (amino acid residues 6-23). Semorinemab binds with human Tau with a Kd value of 3.8 nM. Semorinemab can be used for the research of Alzheimer's Disease .
Tesidolumab (LFG316) is a fully-human IgG1/λ anti-C5 monoclonalantibody of 143 kDa (without glycosylation). Tesidolumab (LFG316) blocks cleavage of C5 and prevents subsequent formation of the membrane attack complex .
CJM-112 is a humanized monoclonalantibody inhibitor targeting interleukin-17A (IL-17A). CJM-112 is promising for research of inflammatory diseases, such as hidradenitis suppurativa associated with abnormal IL-17A-related pathways .
Inlecitug is a chimeric monoclonalantibody targeting human KDR (kinase insert domain receptor). Inlecitug specifically binds to KDR, blocking the binding of vascular endothelial growth factor (VEGF) to KDR and inhibiting angiogenesis, thus exerting antitumor activity. Inlecitug is promising for research of cancers .
FZ-A038 is a delta-like ligand 3 (DLL3) targeted, humanized monoclonalantibody. FZ-A038 can be used for synthesis of DLL3 targeting ADC FZ-AD005 (HY-164729) .
Anti-Mouse NKG2A/C/E Antibody (20D5) is an anti-mouse NKG2A/C/E IgG2a monoclonalantibody. Anti-Mouse NKG2A/C/E Antibody (20D5) can activate natural killer (NK) and CD8 + T cells. Anti-Mouse NKG2A/C/E Antibody (20D5) can exacerbate liver pathological damage by enhancing the activation of iNKT cells. Anti-Mouse NKG2A/C/E Antibody (20D5) can be used for researches on cancer and immunology such as lymphoma .
Anti-Mouse IL-9 Antibody (9C1) is an anti-mouse IL-9 IgG2a monoclonalantibody. Anti-Mouse IL-9 Antibody (9C1) can reduce the activation of NF-κB signaling pathway and decrease the infiltration of inflammatory cells. Anti-Mouse IL-9 Antibody (9C1) effectively reduces Th9 cell-mediated allergic reactions and anti-tumor effects. Anti-Mouse IL-9 Antibody (9C1) can be used for researches on inflammation, infection conditions and cancer such as parasitic infections, allergic reactions, breast cancer and osteosarcoma .
Anti-Monkey/Human MDR-1/CD243 Antibody (UIC2) is an anti-monkey/human MDR-1/CD243 IgG2a monoclonalantibody. Anti-Monkey/Human MDR-1/CD243 Antibody (UIC2) can efficiently inhibit P-glycoprotein. Anti-Monkey/Human MDR-1/CD243 Antibody (UIC2) enhances the inhibitory effect on multidrug resistance (MDR) by suppressing drug efflux. Anti-Monkey/Human MDR-1/CD243 Antibody (UIC2) can be used for research on cancer .
Anti-Mouse RANKL/CD254 Antibody (IK22/5) is an anti-mouse RANKL/CD254 IgG2a monoclonalantibody. Anti-Mouse RANKL/CD254 Antibody (IK22/5) inhibits osteoclast formation and activity by specifically blocking the binding of RANKL and RANK. Anti-Mouse RANKL/CD254 Antibody (IK22/5) can inhibit the expression of MuRF1/Trogin-1 and activation of NF-κB. Anti-Mouse RANKL/CD254 Antibody (IK22/5) can be used for research on cancer such as melanoma or colon cancer and osteoporosis .
Anti-Mouse ICOSL/CD275 Antibody (HK5.3) is an anti-mouse ICOSL/CD275 IgG2a monoclonalantibody. Anti-Mouse ICOSL/CD275 Antibody (HK5.3) can inhibit the adhesion between T cells and endothelial cells. Anti-Mouse ICOSL/CD275 Antibody (HK5.3) can reduce the expansion of tissue resident (TR) Treg cells. Anti-Mouse ICOSL/CD275 Antibody (HK5.3) can be used for researches on inflammation and infection conditions such as influenza virus infection and arthritis .
Anti-Mouse/Rat/Bovine VLDL-R Antibody (IgG-6A6) is an anti-mouse/rat/bovine VLDL-R IgG1 monoclonalantibody. Anti-Mouse/Rat/Bovine VLDL-R Antibody (IgG-6A6) can specifically recognize VLDLR type-I and type-II expressed in CHO cells. Anti-Mouse/Rat/Bovine VLDL-R Antibody (IgG-6A6) can be used to detect the expression of VLDLR in different cells and tissues. Anti-Mouse/Rat/Bovine VLDL-R Antibody (IgG-6A6) often used in western blot experiments .
Iluzanebart is a human monoclonal IgG1 antibody and is the agonist antibody for human TREM2 (hTREM2). Iluzanebart improves the survival and function of microglia by activating the TREM2 signaling pathway to compensate for the loss of CSF1R function. Iluzanebart can be used for research of adult-onset leukoencephalopathy associated with CSF1R (colony stimulating factor 1 receptor) (CSF1R-ALSP) .
Dinutuximab (APN-311) is a chimeric human-mouse anti-GD2monoclonalantibody. Dinutuximab can bind to GD2 on the cell surface, triggering antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, and promoting tumor regression. Dinutuximab can inhibit the growth, invasion, and migration and induce apoptosis of tumor cells. Dinutuximab can be used in the research of tumors such as neuroblastoma and breast cancer .
Avelumab (anti-PD-L1) a fully human IgG1 anti-PD-L1monoclonalantibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab (anti-PD-L1) enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab (anti-PD-L1) can be used for the study of chordoma .
MSH-TP15e is a humanized monoclonalantibody inhibitor targeting intercellular adhesion molecule-1 (ICAM-1). MSH-TP15e recruits natural killer cells and significantly triggers antibody-dependent cell-mediated cytotoxicity (ADCC) to inhibit tumor cell growth. MSH-TP15e is promising for research of multiple myeloma (MM) .
MDX-1401 is a fully human IgG1 (κ isotype) monoclonalantibody against CD30, with a Kd value of 0.83 nmol/L. MDX-1401 induces antibody-dependent cellular cytotoxicity in CD30-expressing cells and inhibits tumor growth in CD30+ lymphoma xenograft models. MDX-1401 can be used in research related to malignant lymphoma and Hodgkin lymphoma .
Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonalantibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research .
Sigvotatug (Biotinylated) is a biotinylated derivative of Sigvotatug (HY-P990764). Sigvotatug (Biotinylated) is a humanized IgG1 κ monoclonalantibody inhibitor against ITGB6. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
TB-402, a human IgG4 anticoagulant monoclonalantibody, is a partial Factor VIII inhibitor. TB-402 has a prolonged antithrombotic effect. TB-402 can be used for the prevention of venous thromboembolism (VTE) after total knee replacement (TKR) .
Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38monoclonalantibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .
IMM-20059 is humanized IgG1 monoclonalantibody targeting EPN1. IMM-20059 in combination with Atezolizumab (HY-P9904) significantly enhances tumor regression in the B16.F10 syngeneic melanoma model .
QX-004N (HS-20137) is a monoclonalantibody inhibitor targeting the p19 subunit of interleukin-23 (IL-23). QX-004N is promising for research of immune system diseases and diseases of digestive system .
QX006N is a humanized monoclonalantibody inhibitor targeting human interferon α/β receptor 1 (IFNAR1). QX006N is promising for research of systemic lupus erythematosus (SLE) and other IFNAR1-related autoimmune diseases .
Radanstobart (HFB-200603) is a humanized monoclonalantibody targeting CD272 with antitumor activity. Radanstobart is of the human IgG4κ isotype, and the recommended isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
Sym029 is a human IgG monoclonalantibody (mAb) targeting TNFRSF5/CD40. Sym029 can be used in cancer research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Andecaliximab is a recombinant chimeric IgG4 monoclonalantibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF) .
Etuptamig is a chimeric monoclonalantibody of immunoglobulin λ-chain-γ1, λ-chain-γ3 targeting human natural killer cell cytotoxicity receptor 1 (NCR1). Etuptamig is promising for research of various cancers .
MORAb-066 is a human monoclonalantibody (mAb) targeting CD142/F3/TF. MORAb-066 can be used in Breast cancer, Colorectal cancer, Non-small cell lung cancer and Pancreatic cancer research .
Tregalizumab is a humanized anti-human CD4 monoclonalantibody (IgG1 type) that selectively activates the suppressive properties of regulatory T cells (Tregs) in vitro. Tregalizumab can be used in the research of autoimmune diseases (resulting from insufficient Treg activity) and allergies .
Elegrobart is an immunoglobulin G1-κ monoclonalantibody targeting the human insulin-like growth factor 1 receptor (IGF1R). Elegrobart is promising for research of diseases associated with abnormal IGF1R signaling, especially thyroid eye disease .
Avdoralimab (IPH 5401) is a fully human IgGκ monoclonalantibody that targets the complement C5a receptor 1 (C5aR1) that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research .
Anti-Mouse/Rat/Monkey/Human ICOS/CD278 Antibody (C398.4A) is an anti-mouse/rat/monkey/human ICOS/CD278 IgG monoclonalantibody. Anti-Mouse/Rat/Monkey/Human ICOS/CD278 Antibody (C398.4A) has limited effectiveness in improving T cell function and immune activation. Anti-Mouse/Rat/Monkey/Human ICOS/CD278 Antibody (C398.4A) can be used for researches on cancer and infection conditions such as gliomas and hepatitis B virus infection .
Anti-Mouse Thy1/CD90 Antibody (M5/49.4.1) is an anti-mouse Thy1/CD90 IgG2a monoclonalantibody. Anti-Mouse Thy1/CD90 Antibody (M5/49.4.1) can clear T cells from the spleen and bone marrow. Anti-Mouse Thy1/CD90 Antibody (M5/49.4.1) can be used for researches on immunology and inflammation conditions such as colitis .
Anti-Mouse/Human CD44 Antibody (IM7) is an anti-huamn and mouse CD44 IgG2b monoclonalantibody that recognizes a conserved epitope outside the HA-binding domain of the CD44 molecule. Anti-Mouse/Human CD44 Antibody (IM7) exerts a potent anti-inflammatory effect by inducing the shedding of cell surface CD44, significantly improving symptoms in mice with rheumatoid arthritis without affecting relevant immune responses. Anti-Mouse/Human CD44 Antibody (IM7) can be used for researches on inflammation conditions and cancer such as arthritis and osteosarcoma .
Anti-Mouse DR5/CD262 Antibody (MD5-1) is an anti-mouse DR5/CD262 IgG monoclonalantibody. Anti-Mouse DR5/CD262 Antibody (MD5-1) can eliminate myeloid derived suppressor cells (MDSCs) and enhance T cell anti-tumor immunity. Anti-Mouse DR5/CD262 Antibody (MD5-1) can be used for research on cancer such as gastric and colon cancer .
Anti-Mouse CD40 Antibody (FGK4.5/FGK45) is an agonistic rat-derived IgG2a monoclonalantibody targeting mouse CD40. Anti-Mouse CD40 Antibody (FGK4.5/FGK45) enhances T cells responses, dendritic cells maturation and NK cells activation. Anti-Mouse CD40 Antibody (FGK4.5/FGK45) can be used for the researches of cancer, infection, inflammation and immunology, such as CT26 tumor, vesicular stomatitis virus (VSV) infection and transplantation .
Garivulimab (BGB-A333) is a humanized IgG1-variant monoclonalantibody that specifically targets and binds to PD-L1. Garivulimab selectively blocks the interaction of PD-L1 and PD-1. Garivulimab has antitumor activity .
Lacnotuzumab (MCS110) is a neutralizing humanized IgG1/κ monoclonalantibody targeting CSF-1 that prevents CSF-1 from activating the CSF-1R. Lacnotuzumab can be used for the research of pigmented villonodular synovitis .
MEDI-6469 is a human monoclonalantibody (mAb) targeting TNFRSF4/OX40/CD134. MEDI-6469 targets the OX40 receptor on activated T cells to enhance the immune response against cancer cells. .
ADI-65534 is a human IgG1 monoclonalantibody (mAb) targeting Envelopment polyprotein, M polyprotein. ADI-65534 can be used in Hantavirus infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Tulisokibart (PRA023) is a humanized IgG1-κ monoclonalantibody. Tulisokibart targets to TNFSF15/TL1A. Tulisokibart can be used to study a variety of inflammatory/fibrotic diseases, such as Crohn's Disease (CD) and ulcerative colitis .
ADI-15878 is a human IgG monoclonalantibody (mAb) targeting Envelope glycoprotein, GP2. ADI-15878 can be used in Ebola virus infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Naxitamab (Hu3F8) (Mouse IgG1) is a mouse-derived IgG1 monoclonalantibody targeting the diazoglycoside GD2 (hu3F8). Naxitamab can be used in the research of neuroblastoma, osteosarcoma, and other GD2-positive cancers .
Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonalantibody, acts as an immunomodulator and binds to EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition .
ENx-108A is a human IgG4 monoclonalantibody (mAb) targeting IL-11. BI-765423 can be used in fibrotic diseases research. Recommended isotype control: Human IgG4 kappa, Isotype Control (HY-P99003) .
Burfiralimab (hzVSF-v13) is a monoclonal IgG4 antibody against vimentin expressed on the surface of virus-infected cells, with broad-spectrum antiviral activity and anti-inflammatory effects against virus-induced inflammation. Burfiralimab can be used in severe COVID-19 studies .
Tabalumab (LY2127399) is a human anti-BAFF (B-cell activating factor) monoclonalantibody (IgG4 type) with neutralising activity against membrane bound and soluble BAFF. Tabalumab can be used in studies of autoimmune diseases such as rheumatoid arthritis, renal failure and systemic lupus erythematosus .
Trastuzumab (anti-HER2) is a humanized IgG1 monoclonalantibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab (anti-HER2) has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.
Solanezumab (LY-2062430) is a humanized monoclonal IgG1 antibody directed against the mid-domain of the amyloid-β (Aβ) peptide. Solanezumab binds to the mid-domain of monomeric amyloid-beta to slow brain amyloid accumulation. Solanezumab can be used for the research of Alzheimer’s disease .
ADI-65533 is a human IgG1 monoclonalantibody (mAb) targeting Envelopment polyprotein, M polyprotein. ADI-65533 can be used in Hantavirus infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Imsidolimab (ANB 019) is a high-affinity, humanized monoclonalantibody of anti-IL-36R. Imsidolimab antagonizes IL-36 cytokine signal transduction. Imsidolimab has potential application in generalized pustular psoriasis (GPP) and other inflammatory skin diseases .
Obertamig is an engineered, humanized, anti-CD3E/HLA-G monoclonalantibody with humanized CH2-CH3 modifications and consists of half immunoglobulin IgG1 λ2 and a single-chain variable fragment (scFv) .
Tilrekimig (PF-07275315) is a monoclonalantibody targeting human interleukin-4 (IL-4), interleukin-13 (IL-13) and thymic stromal lymphopoietin (TSLP). Tilrekimig can be used in the research of allergic and inflammatory diseases, such as asthma and atopic dermatitis .
AB054 is a humanized monoclonalantibody targeting factor XII (FXII). AB054 inhibits FXII activation and FXIIa activity through specific binding to the catalytic domain of FXII, and exerts antithrombotic effects in a concentration-dependent manner. AB054 can be used in studies related to thrombosis .
Teneliximab (BMS-224819) is a chimeric monoclonalantibody, blocks the CD40-CD40L interaction. Teneliximab (BMS-224819) has partial agonist activity resulting in some signaling through CD40 and peripheral B cell depletion .
Crizanlizumab is an anti-P-selectinmonoclonalantibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs) and can be used for research of sickle cell disease .
KHK-2866 is a recombinant humanized monoclonalantibody targeting heparin-binding epidermal growth factor-like growth factor (HB-EGF). The predicted molecular weight (MW) of KHK-2866 is 147.68 kDa. KHK-2866 can be used for tumor research .
IDB-002 is a human monoclonalantibody (mAb) targeting F/Fusion glycoprotein F0. IDB-002 can be used in respiratory syncytial virus infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
REGN4659 is a fully human anti-CTLA-4monoclonalantibody and IgG1 antibody. REGN4659 binds to the extracellular domain of human and monkey CTLA-4 with high affinity and specificity. REGN4659 blocks CTLA-4 interaction with CD80 and CD86 ligands. REGN4659 significantly suppresses MC38.Ova tumor growth in CTLA-4 knock-in mice .
huXBR1-402 (NBE-002 Antibody) is a high-affinity (Kd=5.8 nM) humanized chimeric rabbit/human monoclonalantibody that targets ROR1. huXBR1-402 specifically binds to the Ig/Fz domain epitope of human ROR1, directly inhibits the proliferation of ROR1-positive tumor cells and induces apoptosis of leukemia cells (apoptosis) .
Anti-CD220/Insulin Receptor Antibody (IR 83-22) is an anti-human CD220/Insulin Receptor IgG1 monoclonalantibody. Anti-CD220/Insulin Receptor Antibody (IR 83-22) can block Akt overactivation caused by Trip13 deficiency. Anti-CD220/Insulin Receptor Antibody (IR 83-22) can be used for research on cancer such as hepatocellular carcinoma (HCC). Anti-CD220/Insulin Receptor Antibody (IR 83-22) often used in western blotting. The recommend isotype control of Anti-CD220/Insulin Receptor Antibody (IR 83-22): Mouse IgG1 kappa, Isotype Control (HY-P99977) .
Anti-CD8α Antibody (OKT-8) is an anti-human CD8α IgG2a monoclonalantibody. Anti-CD8α Antibody (OKT-8) can reduce the secretion of IFNγ. Anti-CD8α Antibody (OKT-8) can deplete CD8 + T cells. Anti-CD8α Antibody (OKT-8) can be used for researches on inflammation conditions and cancer such as B non-Hodgkin lymphomas (B-NHLs). The recommend isotype control of Anti-CD8α Antibody (OKT-8): Mouse IgG2a kappa, Isotype Control (HY-P99978) .
Anti-Nicastrin Antibody (A5226A) is a monoclonalantibody against Nicastrin and an inhibitor of γ-secretase. Anti-Nicastrin Antibody (A5226A) recognizes the fully glycosylated mature presenilin enhancer in the active γ-secretase complex and inhibits its activity via competition for substrate binding. Anti-Nicastrin Antibody (A5226A) abrogates the growth of cancer cells dependent on γ-secretase activity. Anti-Nicastrin Antibody (A5226A) serves as an imaging tool to visualize the endocytic trafficking of active γ-secretase, and also acts as a detection reagent to evaluate the endocytic efficiency of γ-secretase. Anti-Nicastrin Antibody (A5226A) can be used in studies related to non-small cell lung cancer, T-cell acute lymphoblastic leukemia and Alzheimer's disease .
Anti-Rat TCR alpha/beta Antibody (R73) is an anti-mouse TCR alpha/beta IgG1 monoclonalantibody. Anti-Rat TCR alpha/beta Antibody (R73) suppresses immune response by depleting α/β + T cells. Anti-Rat TCR alpha/beta Antibody (R73) can inhibit the expression of pro-inflammatory cytokines. Anti-Rat TCR alpha/beta Antibody (R73) can extend graft survival time by reducing infiltration of T cells and neutrophils. Anti-Rat TCR alpha/beta Antibody (R73) can be used for researches on inflammation, metabolic conditions and xenotransplantation such as arthritis, acute inflammatory peripheral neuropathy and diabetes .
Anti-Rat FcRn heavy chain heterodimers Antibody (1G3) is an anti-rat FcRn heavy chain heterodimers IgG1 monoclonalantibody. Anti-Rat FcRn heavy chain heterodimers Antibody (1G3) can effectively bind to FcRn and competitively inhibit the binding of IgG to FcRn. Anti-Rat FcRn heavy chain heterodimers Antibody (1G3) can reduce the total serum IgG level. Anti-Rat FcRn heavy chain heterodimers Antibody (1G3) can be used for researches on autoimmune conditions such as experimental autoimmune myasthenia gravis (EAMG). The recommend isotype control of Anti-Rat FcRn heavy chain heterodimers Antibody (1G3): Mouse IgG1 kappa, Isotype Control (HY-P99977) .
Anti-Mouse IL-6 Antibody (MP5-20F3) is an anti-mouse IL-6 IgG1 monoclonalantibody. Anti-Mouse IL-6 Antibody (MP5-20F3) reshapes the tumor microenvironment by blocking IL-6. Anti-Mouse IL-6 Antibody (MP5-20F3) can inhibit the STAT3 pathway and enhance T cell infiltration. Anti-Mouse IL-6 Antibody (MP5-20F3) can be used for researches on inflammation and infection conditions such as malignant pleural effusion (MPE) .
Anti-Mouse IL-4 Antibody (BVD6-24G2) is an anti-mouse IL-4 IgG1 monoclonalantibody. Anti-Mouse IL-4 Antibody (BVD6-24G2) can inhibit IL-4 signaling and promote Treg differentiation. Anti-Mouse IL-4 Antibody (BVD6-24G2) can be used for research on immunology. The recommend isotype control of Anti-Mouse IL-4 Antibody (BVD6-24G2): Rat IgG1 kappa, Isotype Control (HY-P99979) .
Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1) is an anti-mouse E-Cadherin/CD324 IgG1 monoclonalantibody. Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1) can downregulate the HER signaling axis and PI3K/Akt/mTOR signaling pathway. Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1) can inhibit the proliferation of tumor cells and induce their apoptosis. Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1) can be used for researches on cancer and inflammation conditions such as breast cancer, chronic compression injury (CCI) and asthma .
Anti-Mouse CD40L/CD154 Antibody (MR-1) is an anti-mouse CD40L/CD154 IgG monoclonalantibody. Anti-Mouse CD40L/CD154 Antibody (MR-1) reduces the expression of IFN signaling pathway and lowers the level of IFN-β. Anti-Mouse CD40L/CD154 Antibody (MR-1) can prolong the survival time of transplants. Anti-Mouse CD40L/CD154 Antibody (MR-1) can be used for researches on cancer, inflammation conditions and xenotransplantation such as pancreatic cancer and autoimmune cholangitis .
Anti-Mouse IL-3 Antibody (MP2-8F8) is an anti-mouse IL-3 IgG1 monoclonalantibody. Anti-Mouse IL-3 Antibody (MP2-8F8) relieves joint inflammation by reducing synovial leukocyte infiltration and cytokine levels. Anti-Mouse IL-3 Antibody (MP2-8F8) can reduce the accumulation of basophils. Anti-Mouse IL-3 Antibody (MP2-8F8) can be used for researches on inflammation or infection conditions such as arthritis and parasitic infections .
Anti-Mouse IL-10 Antibody (JES5-2A5) is an anti-mouse IL-10 IgG1 monoclonalantibody. Anti-Mouse IL-10 Antibody (JES5-2A5) restores the anti-tumor activity of IL-6 by blocking the IL-10/SOCS3 axis. Anti-Mouse IL-10 Antibody (JES5-2A5) can reverse microcirculation and cognitive deficits. Anti-Mouse IL-10 Antibody (JES5-2A5) can be used for researches on cancer and metabolic disease such as osteosarcoma and type 1 diabetes mellitus (T1DM) .
Anti-Mouse OX40/CD134 Antibody (OX-86) is an anti-mouse OX40/CD134 IgG1 monoclonalantibody. Anti-Mouse OX40/CD134 Antibody (OX-86) can enhance the anti-tumor function of CD8 + T cells. Anti-Mouse OX40/CD134 Antibody (OX-86) can reverse immune suppression, enhance antigen presentation and T cell activation. Anti-Mouse OX40/CD134 Antibody (OX-86) can be used for research on cancer such as papilloma and leukemia .
Lumretuzumab (Anti-Human ERBB3 Recombinant Antibody) is a humanized anti-HER3 (ERBB3) monoclonalantibody. Lumretuzumab effectively inhibits the activity of key oncogenic signaling pathways such as PI3K/AKT and MAPK. Lumretuzumab has been optimized through glycosyl engineering to enhance antibody-dependent cell-mediated cytotoxicity (ADCC). Lumretuzumab can be used to study HER3-positive, HER2-low-expressing solid tumors, especially breast cancer .
Anti-Mouse/Human Mac-2/Galectin-3 Antibody (TIB-166) is a rat-derived anti-mouse/human Mac-2/Galectin-3 IgG2a monoclonalantibody. Anti-Mouse/Human Mac-2/Galectin-3 Antibody (TIB-166) significantly inhibits IL-6 expression (inhibition rates 34.7% and 55.3%). Anti-Mouse/Human Mac-2/Galectin-3 Antibody (TIB-166) is often used for immunoprecipitation, western blot, immunofluorescence, and flow cytometry .
VRDN-002 is a human monoclonalantibody (mAb) targeting IGF1R/CD221. VRDN-002 reduces inflammation and proptosis in thyroid eye disease (TED). VPI-2690B can be used in Graves ophthalmopathy research .
NG004 is a fully human monoclonalantibody targeting Nogo-A. NG004 reduces retinal Nogo-A levels, blocks the binding of the Nogo-A-receptor complex, and neutralizes the Nogo-A protein. NG004 can be used in studies related to diabetic retinopathy, stroke and acute spinal cord injury .
GSK2831781 is a human IgG1 monoclonalantibody (mAb) targeting CD223/LAG3. GSK2831781 can be used in the study of ulcerative colitis Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
KHK2823 is a humanized monoclonalanti-human CD123/IL3RA antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001). KHK2823 can be used in research related to leukemia .
Iratumumab (MDX-060) a human anti-CD30 IgG1κ monoclonalantibody. Iratumumab inhibits the growth of CD30-expressing tumor cells. Iratumumab can be used for research of Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) .
ALLO-647 is a human monoclonalantibody targeting CD52. ALLO-647 transiently and selectively depletes host lymphocytes to promote the proliferation of allogeneic CAR T-cell following infusion. ALLO-647 can be used for the research of B-cell lymphoma and follicular lymphoma .
Gilvetmab is a potent caninized anti-PD-1monoclonalantibody. Gilvetmab blocks the interaction between PD-1 and its ligand PD-L1/L2. Gilvetmab can be used in malignant melanoma and mast cell tumor research .
AMB8LK is a human monoclonalantibody targeting H-ferritin, with specificity for tumor-associated heterologous ferritin. AMB8LK specifically recognizes and binds to H-ferritin overexpressed on the surface of tumor cells. AMB8LK can be used in research related to cancer and immune diseases .
Abazistobart is an immunostimulant and antineoplastic agent targeting the programmed cell death protein 1 (PDCD1). Abazistobart is a chimeric and humanized monoclonalantibody that specifically binds to PDCD1 to block the relevant signaling pathway, thereby activating the immune system and exerting antineoplastic activity. Abazistobart is promising for research of cancers .
COM902 is a human IgG4 monoclonalantibody (mAb) targeting TIGIT. COM902 enhances anti-tumor immune responses. COM902 can be used in Multiple myeloma, Solid tumours and Colorectal cancer research. Recommended isotype control: IgG4-lambda .
Mazorelvimab (CTB012) is an anti-rabies humanized IgG1κ monoclonalantibody that binds to the non-overlapping epitopes on the rabies virus (RABV) glycoprotein. Mazorelvimab binds to highly discontinuous conserved residues that are not in or near antigenic site III. Mezagitamab has potential application in the prevention of rabies .
Cliramitug (NI-006; ALXN2220) is a monoclonalantibody that targets human transthyretin (TTR). Cliramitug binds to TTR and inhibits its amyloidogenic process, exerting amyloid formation-inhibiting activity. Cliramitug can be used in the research of transthyretin amyloidosis-related diseases, such as certain neurological and cardiovascular diseases .
Tuvirumab (OST 577; SDZ-OST 577) is a human IgG1 subclass monoclonalantibody directed against HBV surface antigen (HBsAg). Tuvirumab binds specifically and with high affinity (K=3.6 nM) to HBsAg. Tuvirumab has the potential for chronic hepatitis B research .
Istiratumab (M-6495) is bispecific monoclonalantibody targeting IGF-1R and ErbB3. Istiratumab induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway Istiratumab can be used for research of cancers .
PF-06293620 (RN909) is a monoclonalantibody antagonist of the glucagon receptor.PF-06293620 produces dose-dependent, durable lowering of fasting plasma glucose and reduces HbA1c levels. PF-06293620 can be used for the research of type 2 diabetes mellitus .
MEDI-0680 (AMP-514) is a human IgG4 monoclonalantibody (mAb) targeting PDCD1/PD-1/CD279. MEDI-0680 can be used in Diffuse Large B-Cell Lymphoma (DLBCL) research .
Prafnosbart (DS-6016A) is an IgG1-kappa, anti-ACVR1 (activin A receptor type 1, ACVRLK2, ALK2, ACVR1A, SKR1) humanized monoclonalantibody. Prafnosbart can be used for bone metabolism disorders research .
Alemtuzumab (Campath-IH) is a humanized monoclonalantibody against CD52. Alemtuzumab does not cross-react with murine CD52. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. Alemtuzumab is capable of complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC), as well as induction of apoptosis. Alemtuzumab has the potential for B-cell chronic lymphocytic leukaemia research .
OMTX005 (OMTX705 antibody) is a humanized anti-FAP IgG1 monoclonalantibody that specifically binds to human (EC50: 0.33 nM)/mouse (EC50: 0.14 nM) FAP proteins and FAP-positive cells. OMTX005 exhibits no cytotoxicity when used alone and fails to induce an increase in caspase 3/7 activity in relevant cells. OMTX005 can be used to synthesize the ADC molecule OMTX705 for tumor research .
Duligotuzumab (MEHD-7945A; RG 7597) is a humanized IgG-κ monoclonalantibody targeting EGFR. Duligotuzumab blocks the binding of ligands to these two receptors, inhibits downstream HER/ErbB, AKT and MAPK signaling pathways, induces antibody-dependent cellular cytotoxicity, reduces the proliferation and migration abilities of cancer cells, promotes apoptosis, exerts radiosensitizing effects, and reverses EGFR resistance in cancer cells. Duligotuzumab can be used in tumor-related research .
Lintuzumab (HUM-195) is an anti-CD33 humanized monoclonalantibody. Lintuzumab reduces the production of TNFα-induced pro-inflammatory cytokines and chemokines by AML cells. Lintuzumab promotes tumor cell killing through antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) activities against MDR and MDR+ AML cell lines and primary AML patient samples. Lintuzumab enhances survival and reduces tumor burden in mice .
Denikitug (GS-1811; JTX-1811) is a humanized monoclonalantibody against CCR8 receptor with a KD of 16.8 pM. Denikitug specifically binds to human CCR8, inhibits CCL1-induced downstreamCCR8signaling. Denikitug selectively depletes cells expressing CCR8 via antibody-dependent cellular cytotoxicity (ADCC). Denikitug promotes anti-tumor immunity and can be used for the research of cancer and immunology .
Lokivetmab (Anti-Canine IL31 Recombinant Antibody) is an anti-canine IL-31monoclonalantibody. Lokivetmab inhibits IL-31-mediated activation of pruritogenic signals in peripheral sensory neurons and reduces TH2-weighted inflammation. Lokivetmab demonstrates long-term efficacy in controlling pruritus and improving skin lesions in dogs with canine atopic dermatitis (CAD). Lokivetmab can be used for the research of atopic dermatitis (AD) in dogs .
PNT001 is a human IgG1 monoclonalantibody (mAb) targeting cis-pT231 Tau. PNT001 can be used in Neurodegenerative disorders and Traumatic brain injuries research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Daratumumab (PBS) (Anti-Human CD38) is the first-in-class human-specific anti-CD38monoclonalantibody (IgG1). Daratumumab (PBS) has anti-multiple myeloma (MM) effect. Daratumumab (PBS) impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .
HFB-100204 is a human monoclonalantibody (mAb) targeting CXCR5. HFB-100204 reduces CXCR5+ immune cells, including B cells and Tfh cells, in the blood and spleen of hCXCR5 knockout mice. HFB-100204 can be used in autoimmune diseases research .
Nirsevimab (MEDI8897) is a recombinant monoclonalantibody against human respiratory syncytial virus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC50 values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections .
Nezutatug (HMBD-001) is a humanized IgG1 monoclonalantibody inhibitor targeting HER3. Nezutatug inhibits the dimerization of HER3 and inhibits the growth, proliferation and other activities of tumor cells. Nezutatug is promising for research of cancers, such as pancreatic cancer and non-small cell lung cancer .
Bedinvetmab (ZTS-00508841) is a canine monoclonalantibody (mAb) targeting nerve growth factor (NGF). Bedinvetmab inhibits NGF interaction with tropomyosin receptor kinase A (trkA) and p75 neurotrophin receptor (p75NTR) receptors. Bedinvetmab can be used for the research of osteoarthritis pain in dogs .
Adebrelimab (SHR-1316) is a humanized IgG4 monoclonalPD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC) .
DNL-919 (TAK-920) is a human IgG1 monoclonalantibody (mAb) targeting TREM-2. DNL-919 can be used in Alzheimer's disease research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
RFB4 is an anti-CD22monoclonalantibody. RFB4 can be fused with Pseudomonas aeruginosa exotoxin (PE38) via disulfide bonds to construct recombinant immunotoxins, such as RFB4 (dsFv)-PE38. RFB4 is applicable to the research of cancers including lymphoma .
Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5monoclonalantibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer .
LAE-102 is the selective anti-ActRIIA (activin receptor type IIA or ACVR2) monoclonalantibody. LAE-102 increases muscle mass and reduces fat mass. LAE102 can increase serum activin A levels in vivo. LAE-102 is promising for research of obesity .
Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonalantibody. Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research .
ASP-1948 is a human monoclonalantibody (mAb) targeting NRP1/VEGF165R/CD34. ASP-1948 reverses the suppressive effects of regulatory T cells. ASP-1948 can be used in solid tumors research .
Bleselumab (ASKP 1240) is a human anti-CD40monoclonalantibody (mAb). Bleselumab binds to human CD40 with high affinity (Kd: 0.24 nM). Bleselumab inhibits immune responses by blocking the interaction of CD40 with its ligand CD40L. Bleselumab prevents organ transplant rejection .
Briakinumab (ABT-874) is a fully human anti-IL-12/23p40monoclonalantibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis .
GSK2862277 is a human monoclonalantibody (mAb) targeting TNFRSF1A. GSK2862277 increases neutrophil extracellular trap formation and alveolar macrophage phagocytosis. GSK2862277 can be used in Acute lung injury and Acute Respiratory Distress Syndrome (ARDS) research. Recommended isotype control: VHH-hFc .
Keliximab (SB-210396) is a chimeric human/macaque IgG1 anti-CD4monoclonalantibody with a Ki value of 1.0 nM for soluble CD4. Keliximab blocks T cell proliferation and inhibits IL-2 production. Keliximab can be used for cancer research .
BC011 is a human monoclonalantibody (mAb) targeting TNFRSF1B. BC011 promotes CD8+T cell proliferation and depletes Treg cells, thereby increasing the proportion of effector T cells in the tumor microenvironment. BC011 can be used in tumor Immunity research.
BMS-986179 is a human monoclonalantibody (mAb) targeting NT5E/CD73. BMS-986179 inhibits CD73 enzymatic activity in tumor vasculature and tumor cells. BMS-986179 can be used in advanced solid tumors research .
Ragifilimab (INCAGN-1876) is an agonist monoclonalantibody targeting the glucocorticoid-induced TNFR-related protein (GITR). Ragifilimab binds to and activates GITR on T cells, which stimulates the immune system to enhance its anti-tumor activity. Ragifilimab can be used for advanced or metastatic solid tumors research .
REGN9533 is a human-derived monoclonalantibody against FXII/FXIIa with high affinity for FXII, FXIIa and β-FXIIa. REGN9533 selectively inhibits the intrinsic coagulation pathway and FXIIa-driven plasma kallikrein activity. REGN9533 is applicable to FXIIa-related diseases such as thrombosis and hereditary angioedema .
PF-07868489 is a recombinant monoclonalantibody targeting GDF2/BMP-9. PF-07868489 can be used for the research of pulmonary arterial hypertension (PAH). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Ecleralimab (CSJ-117; NVP-CSJ117) is a Fab-IgG1-λ2 antibody targeting the thymic stromal lymphopoietin (TSLP). Ecleralimab significantly attenuates allergen-induced airway responses and inflammation. Ecleralimab can be used for the study of inhaled asthma .
Lixarkitug (AZD9829 antibody; INT-020) is a humanized IgG1κ antibody targeting IL-3Ra/CD123. Lixarkitug can be conjugated with Samrotecan to form the intact ADC molecule lixarkitug samrotecan (AZD9829), which is used in studies of acute myeloid leukemia (AML) . The isotype control corresponding to Lixarkitug is Human IgG1 kappa, Isotype Control (HY-P99001).
Isatuximab (anti-CD38) is a monoclonalantibody that targets the transmembrane receptor and extracellular enzyme CD38, a protein highly expressed in hematological malignancies, including multiple myeloma. Isatuximab (anti-CD38) exhibits anti-tumor activity through multiple biological mechanisms, including antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cell phagocytosis, and non-crosslinking direct induction of apoptosis. Isatuximab (anti-CD38) also directly inhibits the extracellular enzyme activity of CD38, which is related to many cellular functions .
REGN6569 is a fully human IgG1 monoclonalantibody targeting glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR) with high specificity for GITR. REGN6569 exerts stronger in vitro antibody-dependent cell-mediated cytotoxicity (ADCC) against regulatory T cells expressing GITR. REGN6569 selectively depletes regulatory T cells via antibody-dependent cell-mediated cytotoxicity and increases the proportion of proliferative natural killer (NK) cells in peripheral blood. REGN6569 is applicable for advanced solid malignancies. Isotype control: HY-P99001 .
IASO-782 (RD126) is a fully human monoclonalantibody targeting human CD19. The Fc segment of IASO-782 is mutated to enhance antibody-dependent cell-mediated cytotoxicity (ADCC) while maintaining the integrity of other Fc segment functions, such as ADCP. IASO-782 effectively eliminates CD19+ B cells, plasmablasts, and some plasma cells, thereby reducing or completely eliminating autoreactive antibodies produced by these cells. IASO-782 can be used for the study of immune thrombocytopenic purpura (ITP), warm autoimmune hemolytic anemia (wAIHA) and systemic lupus erythematosus (SLE).
Anti-Mouse Ly6G/Ly6C Antibody (NIMP-R14) is an anti-mouse Ly6G/Ly6C IgG2b monoclonalantibody. Anti-Mouse Ly6G/Ly6C Antibody (NIMP-R14) can deplete granulocytes and monocytes. Anti-Mouse Ly6G/Ly6C Antibody (NIMP-R14) can be used for researches on infection conditions and cancer such as pancreatic cancer and Orientia tsutsugamushi infection .
ZV05 (ZV0501 Antibody) is an anti-5T4monoclonalantibody with an EC50 of 4.3 ng/mL against h5T4. ZV05 does not induce apoptosis or interfere with cell cycle progression. ZV05 accumulates specifically in 5T4-positive tumor xenografts. ZV05 can serve as the antibody component of antibody-active molecule conjugates (ADCs) to bind the 5T4 glycoprotein, thereby enabling targeted delivery of toxins. ZV05 is used in studies of 5T4-positive cancers, including triple-negative breast cancer .
Anti-Mouse TL1A/TNFSF15 Antibody (5G4.6) is an anti-mouse TL1A/TNFSF15 IgG monoclonalantibody. Anti-Mouse TL1A/TNFSF15 Antibody (5G4.6) can reduce TL1A levels and block TL1A-DR3 interactions. Anti-Mouse TL1A/TNFSF15 Antibody (5G4.6) can be used for research on inflammation conditions such as colitis and collagen-induced arthritis (CIA) .
Anti-CD24 Antibody (SWA11) is a human IgG1 monoclonalantibody targeting CD24, with high affinity and specificity for CD24-expressing tumor cells. Anti-CD24 Antibody (SWA11) triggers endocytosis, alters STAT3-dependent gene expression, regulates Src phosphorylation, and blocks CD24-mediated signaling pathways. Anti-CD24 Antibody (SWA11) is applicable to cancer-related research such as lung cancer and ovarian cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Lasrekibart is a humanized monoclonalantibody targeting human interleukin 5 (IL-5). Lasrekibart specifically binds to IL-5, blocking the interaction between IL-5 and its receptor, thus exerting immunosuppressive and anti-inflammatory activities. Lasrekibart is promising for research of allergic and inflammatory diseases, such as asthma .
DCBY02 is a monoclonalantibody targeting CD93 expressed in CHO cells. DCBY02 has a heavy chain of the mlgG type and a light chain of the mkappa type, with a predicted molecular weight (MW) of 150 kDa. The isotype control for DCBY02 can be referenced as Mouse IgG1 kappa, Isotype Control.
Velaprumig is a monoclonalantibody targeting human CD99, CCL25, and anti-human Aβ (Aβ-47F). Velaprumig regulates immune cell migration and reduces β-amyloid-related pathological processes, exerting immunomodulatory and potential anti - Alzheimer's disease activities .
Lusvertikimab (OSE-127) is a humanized IL7Rmonoclonalantibody. Lusvertikimab is not internalized by target cells and prevents IL7R heterodimerization and subsequent downstream signaling. Lusvertikimab has anti-leukemic efficacy and has the potential for B cell precursor acute lymphoblastic leukemia (BCP-ALL) research .
Crusekitug is a humanized monoclonalantibody targeting human interleukin 17A (IL-17A). Crusekitug specifically binds to IL-17A, blocking its signal transduction, thus exerting immunosuppressive and anti-inflammatory activities. Crusekitug is promising for research of autoimmune and inflammatory diseases, such as psoriasis and rheumatoid arthritis .
ST2485 is a monoclonalantitenascinantibody. ST2485 shows additivity in tenascin C binding in vitro as well as in a xenograft model. ST2485 binds human tenascin at an epitope partially shared with BC2. ST2485 cross-reacts with murine tenascin. ST2485 can be studied in antitumor research .
Sym023 is a human monoclonalantibody (mAb) targeting TIM-3/HAVCR2/CD366. Sym023 enhances immunostimulatory and anti-tumor activities. Sym023 can be used in Non-small cell lung cancer, Solid tumors and Lymphoma research .
Gosuranemab (BMS-986168; IPN007; BIIB092) is a humanised IgG4 anti-taumonoclonalantibody. Gosuranemab neutralizes the extracellular tau protein, inhibiting the spread and aggregation of pathological tau protein. Gosuranemab can be used for the research of progressive supranuclear palsy and early Alzheimer’s disease .
Crizanlizumab (anti-P-selectin) is an anti-P-selectin monoclonalantibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs) and can be used for research of sickle cell disease .
Itepekimab (REGN-3500) is an IgG4 monoclonalantibody against IL-33. Itepekimab reduced airway inflammation and related tissue damage in preliminary clinical studies. Itepekimab has potential effects in asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis (AD) .
Sutimlimab is a humanized monoclonal IgG4 antibody. Sutimlimab inhibits complement protein component 1, s subcomponent (C1s). Sutimlimab blocks C3 and C4 activation. Sutimlimab can be used for the research of cold agglutinin disease and complement-mediated hemolytic uremic syndrome .
Latozinemab (AL001) is a recombinant human anti-Sortilinmonoclonalantibody. Latozinemab effectively binds Sortilin with a high affinity and blocks the interaction between progranulin protein (PGRN) and Sortilin receptor. Latozinemab has the potential for progranulin gene (GRN) mutations causative of Frontotemporal dementia (FTD) (FTD-GRN) research .
Anti-Mouse CD47/IAP Antibody (MIAP301) is an anti-mouse CD47/IAP IgG2a monoclonalantibody. Anti-Mouse CD47/IAP Antibody (MIAP301) can effectively block CD47 signaling and enhance macrophage phagocytic function. Anti-Mouse CD47/IAP Antibody (MIAP301) can increase the infiltration of immune cells. Anti-Mouse CD47/IAP Antibody (MIAP301) restores the phagocytic function of myeloid cells and alleviate B cell inhibition. Anti-Mouse CD47/IAP Antibody (MIAP301) may interfere with wound healing. Anti-Mouse CD47/IAP Antibody (MIAP301) can be used for researches on cancer, inflammation and infection conditions such as melanoma, intestinal mucosal repair and sepsis .
Anti-Mouse osteopontin/SPP1 Antibody (100D3) is an anti-mouse osteopontin/SPP1 IgG2c monoclonalantibody. Anti-Mouse osteopontin/SPP1 Antibody (100D3) can reverse the inhibition of osteopontin (OPN) on T cells and enhance cytotoxic T lymphocyte (CTL) killing ability. Anti-Mouse osteopontin/SPP1 Antibody (100D3) can improve dentin density. Anti-Mouse osteopontin/SPP1 Antibody (100D3) can be used for researches on cancer and dental related conditions such as colon cancer. The recommend isotype control of Anti-Mouse osteopontin/SPP1 Antibody (100D3): Mouse IgG2c kappa, Isotype Control (HY-P99981) .
Anti-Mouse Galectin-9 Antibody (RG9-1) is an anti-mouse Galectin-9 IgG2b monoclonalantibody. Anti-Mouse Galectin-9 Antibody (RG9-1) promotes inflammatory response by enhancing the secretion of IFN-γ, TNF-α, and IL-6. Anti-Mouse Galectin-9 Antibody (RG9-1) can increase CD8 T cell and Treg frequency. Anti-Mouse Galectin-9 Antibody (RG9-1) reduces graft survival time by increasing CD4 + and CD8 + T cell infiltration. Anti-Mouse Galectin-9 Antibody (RG9-1) can be used for researches on inflammation conditions, cancer and xenotransplantation such as ischemia-reperfusion, colon cancer, breast cancer and leukemia .
Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) is an anti-mouse/rat/human CD47/IAP IgG1 monoclonalantibody. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can effectively block CD47 signaling and enhance macrophage phagocytic function. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can increase the infiltration of immune cells. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) may interfere with wound healing. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can be used for researches on cancer and inflammation conditions such as breast cancer and intestinal mucosal repair .
Anti-Mouse ICOS Antibody (7E.17G9) is a mouse ICOS agonist IgG2b monoclonalantibody. Anti-Mouse ICOS Antibody (7E.17G9) can upregulate ICOS expression and enhance T cell function. Anti-Mouse ICOS Antibody (7E.17G9) can significantly inhibit the immune regulatory function of dendritic cells (DCs). Anti-Mouse ICOS Antibody (7E.17G9) can eliminate transplant tolerance. Anti-Mouse ICOS Antibody (7E.17G9) can be used for researches on inflammation conditions, cancer and xenotransplantation such as nephritis and pancreatic cancer .
Anti-Mouse/Human CD11b Antibody (M1/70) is an anti-mouse CD11b IgG2b monoclonalantibody. Anti-Mouse/Human CD11b Antibody (M1/70) can significantly inhibit the adhesion between dendritic cells (DCs) and platelets. Anti-Mouse/Human CD11b Antibody (M1/70) can kill ovarian cancer cells and inhibit their migration. Anti-Mouse/Human CD11b Antibody (M1/70) can alleviate renal fibrosis and inflammation. Anti-Mouse/Human CD11b Antibody (M1/70) can be used for researches on inflammation conditions and cancer such as ischemia-reperfusion injury (IRI), thrombotic inflammatory conditions and ovarian cancer .
Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) is an anti-mouse CXCL9/MIG IgG monoclonalantibody. Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) can reduce tumor infiltration of CD8 + cytotoxic T cells (CTLs). Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) can prolong the survival of transplanted hearts. Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) can be used for researches on immunology and cancer such as prostate cancer .
Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) is an anti-mouse CXCR3/CD183 IgG monoclonalantibody. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) weakens the immune response by reducing the infiltration of CD4 + and CD8 + T cells. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) significantly prolongs the survival time of heart or islet transplants in mice. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) can be used for researches on immunology and cancer such as pancreatic cancer .
Anti-Mouse Thy1.1/CD90.1 Antibody (19E12) is an anti-mouse Thy1.1/CD90.1 IgG2a monoclonalantibody. Anti-Mouse Thy1.1/CD90.1 Antibody (19E12) can deplete CD90.1 + cells. Anti-Mouse Thy1.1/CD90.1 Antibody (19E12) can clear Tregs. Anti-Mouse Thy1.1/CD90.1 Antibody (19E12) can be used for researches on inflammation conditions and immune response such as airway inflammation and experimental autoimmune encephalomyelitis (EAE) .
Anti-Mouse CD80/B7-1 Antibody (RM80) is an anti-mouse CD80/B7-1 IgG2a monoclonalantibody. Anti-Mouse CD80/B7-1 Antibody (RM80) can inhibit the number of tissue-resident memory (TRM) cells. Anti-Mouse CD80/B7-1 Antibody (RM80) can prolong the survival time of transplants combined with CD86 mAb. Anti-Mouse CD80/B7-1 Antibody (RM80) can be used for researches on inflammation conditions and immunology such as viral myocarditis and corneal transplant .
Anti-Mouse IL-1b Antibody (B122) is an anti-mouse IL-1b IgG monoclonalantibody. Anti-Mouse IL-1b Antibody (B122) enhances ferroptosis and increases levels of reactive oxygen species (ROS) combined with Sulfasalazine (SAS) (HY-14655). Anti-Mouse IL-1b Antibody (B122) can reduce monocyte infiltration and alleviate T cell exhaustion by blocking IL-1β signaling. Anti-Mouse IL-1b Antibody (B122) can be used for researches on cancer and cardiovascular conditions such as oral squamous cell carcinoma (OSCC), glioblastoma (GBM) and heart failure .
Clesrovimab (MK1654) is a humanized IgG1 monoclonalantibody targeting the respiratory syncytial virus (RSV) protein F. Clesrovimab binds to pre-fusion and post-fusion forms of RSV-A fusion protein with high affinity, with corresponding KD values of 71 pM and 480 pM, respectively. Clesrovimab is applicable for the research of RSV infection .
MEDI7814 is a humanized monoclonalantibody inhibitor targeting C5a and C5adesArg. MEDI7814 binds to recombinant human C5a and serum purified human C5a with affinities of 14 pM and 8 pM, respectively. MEDI7814 is acute inflammatory diseases such as sepsis and renal ischemia-reperfusion injury .
PAS-003 is a humanized monoclonalantibody targerting α5β1 integrin. PAS-003 modulates immune cell migration, immune cell adhesion, improves behavior, and improves survival in ALS mouse models. PAS-003 can be used for the research of amyotrophic lateral sclerosis .
Vofatamab (B-701) is an anti-FGFR3monoclonalantibody (mAb). Vofatamab blocks activation of both the wildtype and genetically activated receptor. Vofatamab can be used in the research of metastatic urothelial carcinoma (mUC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Ranibizumab (RG-6321) (anti-VEGF) is a humanized anti-VEGF monoclonalantibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165) . Ranibizumab (anti-VEGF) slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research .
Anti-SARS-80R mAb (SARS-80R) is a human monoclonal IgG1 antibody produced in CHO cells. Anti-SARS-80R mAb can specifically bind to Spike (S1) protein to prevent SARS virus infection of susceptible cells .
TQB2618 is a human IgG4 monoclonalantibody (mAb) targeting TIM-3/HAVCR2/CD366. TQB2618 activates immune cell function and induces significant anti-tumor activity when used in combination with anti-PD-1 agents .
Gedivumab (MHAA4549A; RG7745) is a human monoclonalantibody that targets influenza A virus (IAV) with high specificity and binds to the highly conserved stem region of the IAV haemagglutinin protein, thereby preventing haemagglutinin maturation and blocking haemagglutinin-mediated membrane fusion in the intranucleosome. Gedivumab can be used in IAV infection disease studies .
HAIL-12 (16G2) is anan anti-human Interleukin-12 (IL-12p70)monoclonalantibody. HAIL-12 inhibits IL-12-mediated proliferation of T cells from human peripheral blood mononuclear cells .
VIR-8190 is a human IgG1 monoclonalantibody (mAb) targeting F, Fusion glycoprotein F0. VIR-8190 can be used in respiratory syncytial virus (RSV) and metapneumovirus infections research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-MERS-3A1 mAb (MERS-3A1) is a human monoclonal IgG1 antibody with the high binding affinity produced in CHO cells.
Anti-MERS-3A1 mAb bocks the binding of MERS-CoV spike protein to DPP4 receptor .
IMP-761 is a human IgG4 monoclonalantibody (mAb) targeting CD223/LAG3. IMP-761 binds to D1 of human LAG32. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
SAR-439459 is a human monoclonalantibody (mAb) targeting TGFB1/TGFβ-1. SAR-439459 blocks TGFβ-mediated pSMAD signaling, and suppression of T cells and NK cells. SAR-439459 has anti-tumor activity .
CC-90006 is a human monoclonalantibody (mAb) targeting PDCD1/PD-1/CD279. CC-90006 can be used in psoriasis research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Conatumumab (AMG 655) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) (Kd: 1 nM for the long form of DR5, 0.8 nM for the short form of DR5). Conatumumab induces apoptosis via caspase activation. Conatumumab can be used in the research of cancers.
.
Orilanolimab (SYNT001) is a humanized, de-immunized and FcRn-blocking monoclonalantibody. Orilanolimab blocks the interaction between FcRn and the Fc portion of IgG molecules. Orilanolimab impedes IgG IC activation of the FcRn-mediated adaptive immune function. And Orilanolimab disrupts the associated pathways related to IgG homeostasis and innate and adaptive immunity .
Enibarcimab is a humanized, non-neutralizing monoclonalantibody targeting adrenomedullin (ADM). Enibarcimab binds to the N-terminus of ADM, retains ADM in the circulation, and mobilizes interstitial ADM to increase the level of active bio-ADM, ultimately stabilizing blood vessels. Enibarcimab can be used in research related to septic shock and acute heart failure .
BVX20 is a human monoclonalantibody that binds to CD20. BVX20 can kill B-cells through recruiting the immune system. BVX20 can be studied in research for relapsed or chemotherapy-resistant follicular B-cell NHL and CD20-positive diffuse large B-cell NHL .
VY7523 is a monoclonalantibody and a selective inhibitor of pathological Tau. VY7523 reduces the propagation of pathogenic Tau in transgenic mouse models. VY7523 can be used in the research of Alzheimer's disease. The isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
Livmoniplimab (ABBV-151) is a monoclonalantibody against GARP/TGF-β1 that can inhibit the release of active TGF-β1. Livmoniplimab has anti-tumor activity in colon cancer mice. Livmoniplimab can be used for the study of locally advanced or metastatic solid tumors .
CBT004 (KB312) is a human IgG1κ type monoclonalantibody against CD83. CD83 is a type I transmembrane glycoprotein and is a highly expressed marker on the surface of mature DCs. It can also be induced to be expressed on activated B cells, some activated T cells, and activated monocytes.
Sacituzumab is a humanized IgG1monoclonalantibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .
BAT1006 is a monoclonalantibody targeting HER2 extracellular domain II with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) for the study of HER2-positive locally advanced/metastatic solid tumors. BAT1006 has an approximately 5-fold enhanced ADCC effect compared to pertuzumab (HY-P9912) and exhibits potent anti-tumor activity in the HER2-positive Calu-3 xenograft mouse model .
DS-1103a is a humanized IgG4 monoclonalantibody targeting SIRPa/CD172a. DS-1103a inhibits the interaction between SIRPα and CD47. DS-1103a enhances antibody-dependent cellular phagocytosis of cancer cells. DS-1103a can be used for the research of solid tumors. The recommended isotype control is: Human IgG4 (S228P) kappa, (HY-P99003) .
ADU-1805 is a humanized monoclonal IgG2 antibody, a selective, pan-allelic anti-SIRPα antibody, with a Kd value of 11.0 × 10 -9 M for hSIRPαV1. ADU-1805 binds to all known hSIRPα alleles. ADU-1805 blocks the SIRPα-CD47 interaction, promotes phagocytosis of cells, and enhances trogocytosis of cells. ADU-1805 can be used in research related to Burkitt lymphoma .
hu3S193 is a human IgG monoclonalantibody (mAb) targeting Lewis Y. hu3S193 has excellent immune effector function (complement-dependent cytotoxicity) (IC50: 1.0 μg/ml) and antibody-dependent cellular cytotoxicity (IC50: 5.0 μg/ml). hu3S193 can be used in small cell lung cancer (SCLC) research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
BI-836858 is a fully human anti-CD33monoclonalantibody. BI-836858 reduces CD33+ cells via antibody-dependent cellular cytotoxicity (ADCC), blocks downstream signaling of S100A9/CD33, decreases the secretion of immunosuppressive cytokines and reactive oxygen species-induced genomic instability, and restores bone marrow hematopoietic function. BI-836858 is applicable to the research of myelodysplastic syndrome (MDS) and AML .
Anti-Mouse MHC Class I (H-2Kd, H-2Dd) Antibody (34-1-2S) is an anti-mouse MHC Class I (H-2Kd, H-2Dd) IgG2a monoclonalantibody. Anti-Mouse MHC Class I (H-2Kd, H-2Dd) Antibody (34-1-2S) can block the interaction between Ly49 and MHC-I. Anti-Mouse MHC Class I (H-2Kd, H-2Dd) Antibody (34-1-2S) can be used for the construction of acute lung injury models .
Anti-Mouse TCR Vγ1.1/Cr4 Antibody (2.11) is an anti-mouse TCR Vγ1.1/Cr4 IgG monoclonalantibody. Anti-Mouse TCR Vγ1.1/Cr4 Antibody (2.11) can deplete Vγ1 γδ T cells. Anti-Mouse TCR Vγ1.1/Cr4 Antibody (2.11) can be used for research on cancer and inflammation conditions such as mastitis and colon cancer .
Anti-Mouse Ly-6G/Ly-6C Antibody (RB6-8C5) is an anti-mouse Ly-6G/Ly-6C IgG2b monoclonalantibody. Anti-Mouse Ly-6G/Ly-6C Antibody (RB6-8C5) can deplete neutrophils and monocytes. Anti-Mouse Ly-6G/Ly-6C Antibody (RB6-8C5) can be used for research on immunology .
Anti-CD200R1/OX2R Antibody (I-4P) is a human monoclonalantibody (mAb) targeting CD200R1/OX2R. Anti-CD200R1/OX2R Antibody (I-4P) can be used in solid tumors research. Recommended isotype control: Human IgG4 kappa, Isotype Control (HY-P99003) .
Anti-CD11a Antibody (MHM24) is a monoclonalantibody targeting murine CD11a. Anti-CD11a Antibody (MHM24) binds to high-affinity (open) and low-affinity (closed) conformations of the αL subunit of LFA-1, and functionally blocks LFA-1-mediated interactions. Anti-CD11a Antibody (MHM24) blocks ICAM-1 binding to LFA-1-expressing cells. Anti-CD11a Antibody (MHM24) inhibits adhesion of high-affinity LFA-1-expressing cells to keratinocytes. Anti-CD11a Antibody (MHM24) inhibits PHA-induced lymphocyte proliferation. Anti-CD11a Antibody (MHM24) can be used for the research of inflammatory and autoimmune diseases. Recommend Isotype Controls: mouse IgG1 kappa, Isotype Control (HY-P99977) .
BOT1711 is a human IgG1κ monoclonalantibody targeting PDGFRB/CD140b. PDGFRB/CD140b belongs to type I receptor tyrosine kinases (RTKs), and is mainly expressed in vascular smooth muscle cells, pericytes, fibroblasts, certain mesenchymal stem cells, and tumor stromal cells.
Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research . The component ratio of this product is Active ingredient : Excipients = 9 : 47.
Omalizumab is a recombinant, humanized, monoclonalantibody against human immunoglobulin E (IgE) with a KD of 0.393 nM. Omalizumab binds to the human FcγRIIb receptors with a KD of 6.37 uM. Omalizumab has the potential for persistent allergic asthma research . The component ratio of this product is Active ingredient : Excipients = 1:1.3-1:1.5.
Arevirumab (Arevirumab-3) is a pan-lineage neutralizing human monoclonalantibody cocktail (8.9F, 12.1F, 37.D). Arevirumab protects cynomolgus monkeys from severe Lassa fever caused by lineage II and III LASV isolates. Arevirumab is applicable to research related to Lassa fever .
GSK-3174998 is a humanized IgG1 OX40/TNFRSF4 agonistic monoclonalantibody. GSK-3174998 has the potential for the study of advanced solid tumors. The isotype control for GSK-3174998 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
Pacibekitug (PF-04236921; TOUR-006) is a fully humanized IgG2 monoclonalantibody targeting IL-6. Pacibekitug binds to and neutralizes IL-6 signaling, thereby inhibiting the pathophysiological role of this pro-inflammatory cytokine in autoimmune diseases (such as rheumatoid arthritis, Crohn's disease, and systemic lupus erythematosus) [1][2].
Nipocalimab (M281) is a fully humanized, recombinant, and non-glycosylated IgG1 monoclonalantibody. Nipocalimab can bind to the IgG-binding site of FcRn with high affinity and inhibit the transplacental transfer of IgG. Nipocalimab can be used in the research of fetal and neonatal hemolytic disease, myasthenia gravis, and various IgG-mediated autoimmune diseases .
Anti-MSLN/Mesothelin (h7D9.v3) is a human monoclonalantibody (mAb) targeting MSLN. Anti-MSLN/Mesothelin (h7D9.v3) can be used in ovarian cancer, mesothelioma, and pancreatic cancer research .
Remternetug (LY3372993) is a monoclonalantibody that targets pyroglutamylated amyloid β fibrils (N3pG-Aβ). Remternetug specifically binds to N3pG-Aβ, thereby clearing amyloid plaques in the brain and reducing amyloid burden. Remternetug can be used in research related to Alzheimer's disease .
ADI-42898 is a human IgG1 monoclonalantibody (mAb) targeting Envelopment polyprotein, M polyprotein. ADI-42898 binds to the Gn/Gc complex and blocks the cell entry of seven HCPS- and HFRS-associated hantaviruses. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
MK-1248 is a human IgG4 monoclonalantibody (mAb) targeting TNFSF18. MK-1248 enhances the proliferative response of tumor-infiltrating lymphocytes to anti-CD3 stimulation and promotes the production of anti-tumor-associated regulatory cytokines. MK-1248 can be used in solid tumors research .
Lu AF87908 is an IgG1 monoclonalantibody targeting the p-Ser396/404 epitope of tau protein, which mainly binds to the pSer396 region. Lu AF87908 can be used in the research of Alzheimer's disease. The recommended isotype control is human IgG1 kappa (HY-P99001) .
Rosnilimab (ANB030) is a PD-1 agonist IgG1 monoclonalantibody. Rosnilimab can inhibit T cell proliferation, the secretion of inflammatory cytokines, and reduce CD4 and CD8 T cells with high PD-1 expression. Rosnilimab can be used in the research of inflammatory diseases such as colitis and rheumatoid arthritis .
Bamlanivimab (Anti-Human SARS-CoV-2) is the first COVID-19 monoclonalantibody (mAb) to be granted Emergency Use Authorization (EUA) in November 2020 by the U.S. Food and agent Administration (FDA). However, Bamlanivimab is withdrawn in April 2021 following the rise of SARS-CoV-2 virus variants resistant to Bamlanivimab .
Seribantumab (MM 121) is a fully human IgG2 monoclonalantibody that targets HER3. Seribantumab blocks the activation of epidermal growth factor receptor (ErbB) family members and its downstream signal. Seribantumab inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models .
AMG 317 is a humanized monoclonalanti-CD124/IL4R/IL-4Rα antibody. Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002). AMG 317 can be used in research related to asthma .
FB-825 is a human monoclonalantibody (mAb) targeting IGHE. FB-825 targets the CεmX domain of membrane IgE (mIgE), resulting in the downregulation of mIgE-positive B cells and the production of IgE. FB-825 can be used in Allergic asthma, Atopic dermatitis, Job syndrome and Allergic rhinitis research .
Carlumab (CNTO 888) is a human anti-CCL2 (chemokine ligand 2) monoclonalantibody. Carlumab binds and neutralises profibrotic activities of human CCL2. Carlumab inhibits tumor growth by reducing macrophage infiltration and decreasing tumor microvascular density. Carlumab can be used for the research of cancer, suah as prostate cancer .
ARGX-119 is a first-in-class humanized agonist monoclonalantibody specific for muscle-specific kinase (MuSK). ARGX-119 can be used for the study of neuromuscular diseases. The isotype control for ARGX-119 can refer to Human IgG1 lambda1, Isotype Control (HY-P99992) .
MEN1112 (OBT357NF) is a selective humanized monoclonalantibody targeting the Bst1/CD157 antigen (EC50=1 nM). MEN1112 exerts potent antitumor activity against acute myeloid leukemia (AML) cells. MEN1112 is promising for research of hematological malignancies such as AML .
SPX-101 (SX001) is a humanized monoclonalantibody targeting CLDN18.2. CLDN18.2 is only transiently expressed in the differentiated epithelial cells of the gastric mucosa and is hardly found in healthy tissues, thus having an extremely wide therapeutic window. SPX-101 can be used for the study of solid tumors.
Tecnemab K1 is an anti-Melanomamonoclonalantibody. Tecnemab K1 accumulates in metastatic lesions of malignant melanoma and some benign lesions. When radiolabeled, Tecnemab K1 can serve as a radiotracer for malignant melanoma research. The isotype control is Mouse IgG1 kappa, Isotype Control (HY-P99977) .
Dostarlimab (TSR-042) is a humanized anti-PD-1monoclonalantibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC50s of 1.8 and 1.5 nM, respectively .
Socazolimab (ZKAB001) is an anti-PD-L1monoclonalantibody. Socazolimab has lasting safety and efficacy in the treatment of recurrent or metastatic cervical cancer. Socazolimab also has potential applications in small cell lung cancer, esophageal squamous cell carcinoma (ESCC), advanced urothelial carcinoma and osteosarcoma .
RG-7258 is a human monoclonalantibody (mAb) targeting CRLF2. RG-7258 blocks dendritic cell activation and mast cell cytokine release. RG-7258 reduces Th2 inflammation in a non-human primate model of allergic lung inflammation. RG-7258 can be used in asthma research .
FPA154 is a human monoclonalantibody against TNFRSF18/GITR/CD357. FPA154 activates NF-κB via the GITR pathway. FPA154 can be used in solid tumor research. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
CSL-360 is a chimeric unconjugated IgG1 monoclonalantibody targeting CD123. CSL-360 efficiently prevents the binding of IL-3 to CD123, abolishing IL-3 induced cell proliferation. CSL-360 can be used for acute myeloid leukemia (AML) research .
Gosuranemab (BMS-986168; IPN007; BIIB092) (powder) is a humanised IgG4 anti-taumonoclonalantibody. Gosuranemab (powder) neutralizes the extracellular tau protein, inhibiting the spread and aggregation of pathological tau protein. Gosuranemab (powder) can be used for the research of progressive supranuclear palsy and early Alzheimer’s disease .
HLX-22 is a humanized monoclonalantibody targeting HER2. HLX-22 induces apoptosis in HER2-overexpressing breast and gastric cancer cells combined with Trastuzumab (HY-P9907). HLX-22 has potent antitumor activity against advanced solid tumors .
Tifcemalimab (JS004; Icatolimab) is a humanized IgG4 monoclonalantibody against BTLA (B and T lymphocyte attenuator). By binding to BTLA, tifcemalimab blocks the interaction of HVEM-BTLA, thereby inhibiting the BTLA-mediated inhibitory signaling pathway. Tifcemalimab can be used in research related to squamous cell non-small cell lung cancer .
Cantuzumab ravtansine (IMGN242; huC242-DM4), an ADC, is a humanized monoclonalantibody, huC242, covalently linked via a disulfide bond to DM4 (HY-12454). Cantuzumab ravtansine has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts .
Dafsolimab (SPV-T3a) is a Mouse IgG2b monoclonalantibody(anti-CD3). Dafsolimab can induce cell death through modulation and activation of the CD3/T cell receptor complex. Dafsolimab can be used for the research of graft-versus-host disease (GVHD) .
Obiltoxaximab (ETI 204) is the second and potent anti-protective antigen (PA) monoclonalantibody with immunogenicity. Obiltoxaximab plays a central role in anthrax toxin assembly and target cell intoxication, promoting survival, and inhibiting bacterial spread to the periphery in animal models. Obiltoxaximab can be used in the research of inhalational anthrax, bacteremia and toxemia .
Anti-Mouse CD3ε Antibody (145-2C11) is an orally active anti-mouse CD3ε IgG1 monoclonalantibody. Anti-Mouse CD3ε Antibody (145-2C11) can inhibit the proliferation of effector T cells and improve the function of regulatory T cells (Tregs). Anti-Mouse CD3ε Antibody (145-2C11) relieves inflammatory response by inhibiting the production of pro-inflammatory cytokines and increasing the secretion of anti-inflammatory factors. Anti-Mouse CD3ε Antibody (145-2C11) can be used for researches on metabolic and immune system conditions such as diabetes and lupus. The recommend isotype control of Anti-Mouse CD3ε Antibody (145-2C11): Armenian hamster IgG, Isotype Control (HY-P990305) .
Anti-Mouse IL-2 Antibody (S4B6-1) is an anti-mouse IL-2 IgG2a monoclonalantibody. Anti-Mouse IL-2 Antibody (S4B6-1) can reduce CD4 + T cells and increase Tregs. Anti-Mouse IL-2 Antibody (S4B6-1) can induce Th17 cell differentiation. Anti-Mouse IL-2 Antibody (S4B6-1) can be used for research on cancer such as melanoma. The recommend isotype control of Anti-Mouse IL-2 Antibody (S4B6-1): Rat IgG2a kappa, Isotype Control (HY-P990679) .
Anti-Mouse TCR gamma/delta Antibody (UC7-13D5) is an anti-mouse TCR gamma/delta IgG monoclonalantibody. Anti-Mouse TCR gamma/delta Antibody (UC7-13D5) can enter the blood-brain barrier. Anti-Mouse TCR gamma/delta Antibody (UC7-13D5) effectively depletes γδ T cells and reduces macrophage and neutrophil infiltration. Anti-Mouse TCR gamma/delta Antibody (UC7-13D5) can reduce the immune response of transplants. Anti-Mouse TCR gamma/delta Antibody (UC7-13D5) can be used for researches on inflammation conditions, virus infection and cancer such as arthritis, JHM virus and breast cancer .
Anti-CD62L Antibody (DREG-200) is a human monoclonalantibody targeting CD62L/L-selectin. Anti-CD62L Antibody (DREG-200) binds to residues 45, 46 and 47 of L-selectin, and blocks L-selectin-mediated interactions, neutrophil rolling, adhesion, aggregation, secondary anchoring, as well as leukocyte rolling on ligands. Anti-CD62L Antibody (DREG-200) reduces myocardial necrosis, coronary endothelial dysfunction, and neutrophil migration driven by neutrophil microparticles. Anti-CD62L Antibody (DREG-200) exerts cardioprotective effects in feline models. Anti-CD62L Antibody (DREG-200) can be used in studies related to myocardial ischemia-reperfusion injury. The recommended isotype control is Mouse IgG1 kappa (HY-P99977) .
Anti-ZnT8 Antibody (mAb43) is a monoclonalantibody targeting the zinc transporter ZnT8, with islet-specific biodistribution characteristics. Anti-ZnT8 Antibody (mAb43) binds to extracellular ZnT8 on the surface of pancreatic β-cells and masks its insulin-co-localizing sites to block autoimmune recognition. Anti-ZnT8 Antibody (mAb43) also promotes an increase in the proportion of regulatory T cells and inhibits B cell antigen presentation, thereby effectively blocking the T cell-mediated cascade of β-cell destruction. Anti-ZnT8 Antibody (mAb43) eliminates insulitis, preserves β-cell mass and induces seroconversion of autoantibodies, without directly altering the insulin secretion function or content of β-cells. Anti-ZnT8 Antibody (mAb43) can be used for research related to type 1 diabetes .
Anti-Mouse TIM-3 Antibody (B8.2C12) is an anti-mouse TIM-3 IgG1 monoclonalantibody. Anti-Mouse TIM-3 Antibody (B8.2C12) can block the binding of Tim-3 with Phosphatidylserine (PtdSer) and CEACAM1 without interfering with the binding to Galectin-9. Anti-Mouse TIM-3 Antibody (B8.2C12) can inhibit tumor growth and activate tumor infiltrating CD8 + T cells. Anti-Mouse TIM-3 Antibody (B8.2C12) can be used for studying cancer such as breast cancer and colon cancer and constructing experimental autoimmune encephalomyelitis (EAE) models .
Anti-CD25/IL-2Rα Antibody (7G7B6) is an anti-human CD25/IL-2Rα IgG2a monoclonalantibody. Anti-CD25/IL-2Rα Antibody (7G7B6) can inhibit the growth of tumors. Anti-CD25/IL-2Rα Antibody (7G7B6) can be used for research on leukemia. The recommend isotype control of Anti-CD25/IL-2Rα Antibody (7G7B6): Mouse IgG2a kappa, Isotype Control (HY-P99978) .
Anti-Mouse CD16/CD32 Antibody (2.4G2) is an anti-mouse CD16/CD32 IgG2b monoclonalantibody. Anti-Mouse CD16/CD32 Antibody (2.4G2) can block Fcγ receptor-mediated immune responses. Anti-Mouse CD16/CD32 Antibody (2.4G2) can block the combination of CD16 and FcγRs to reduce the production of foam cells. Anti-Mouse CD16/CD32 Antibody (2.4G2) can be used for researches on atherosclerosis and autoimmune hematological disorders .
AT-1413 is a human monoclonalantibody (mAb) targeting CD43. AT-1413 induces antibody-dependent cell-mediated cytotoxicity (ADCC) in melanoma cell lines and acute myeloid leukemia (AML) cells. AT-1413 has antitumor activity in AML mouse models. AT-1413 can be used in Acute myeloid leukaemia, Breast cancer, Malignant melanoma and Myelodysplastic syndromes research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Sacituzumab (powder) is a humanized IgG1monoclonalantibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab (powder) demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab (powder) can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .
Benralizumab (anti-IL5RA ) (MEDI-563 (anti-IL5RA ); BIW-8405 (anti-IL5RA)) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonalantibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma study .
MEDI-3622 is a human monoclonalantibody against ADAM17. MEDI-3622 blocks the ADAM17-mediated shedding of CD16A and CD62L on NK cells, and binds with high specificity to a surface loop unique to the metalloprotease catalytic domain of ADAM17. MEDI-3622 enhances IFNγ production by NK cells when they bind to antibody-coated tumor cells. MEDI-3622 can be used in the research of ovarian cancer, Burkitt lymphoma, head and neck cancer, and colorectal cancer .
AGS-1C4D4 is a fully human IgG1κ monoclonalantibody targeting PSCA, with a Ka value of 0.2 nM. AGS-1C4D4 mediates antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against PSCA-expressing cells. AGS-1C4D4 can be used for the research of pancreatic cancer .
Lifastuzumab is a humanized anti-NaPi2b IgG1monoclonalantibody. Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) (HY-15162) through ADC Linker to form an antibody-drug conjugate (ADC) Lifastuzumab vedotin (HY-P99705) with anticancer activity. Lifastuzumab vedotin can be studied in research for non-small cell lung cancer and ovarian cancer. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001) .
IT1208 (FUT8-KO) is a humanized anti-CD4monoclonal IgG1 antibody that has knocked out the fucosyltransferase 8 gene (FUT8). It exhibits enhanced antibody-mediated cytotoxicity (ADCC) effect. IT1208 (FUT8-KO) can effectively eliminate CD4+ T cells in vivo and shows controllable safety. IT1208 (FUT8-KO) can be used in related research on colon cancer .
Aprutumab ixadotin (BAY 1187982) is the first antibody-drug conjugate (ADC) to target FGFR2 and the first to use Auristatin-based payload. Aprutumab ixadotin contains a fully human anti-FGFR2 monoclonalantibody (Aprutumab) (HY-P99007) conjugated by lysine side chains to a non-cleavable linker and via this an innovative Auristatin W derivative. Aprutumab ixadotin can be used for the study of advanced solid tumors, such as FGFR2-positive gastric cancer and triple-negative breast cancer .
ZL-1211 is an anti-CLDN18.2monoclonalantibody. ZL-1211 exhibits enhanced binding affinity to CD16A. ZL-1211 induces ADCC-mediated cell lysis and triggers the production of IFNγ, TNFα and IL6. ZL-1211 promotes antibody-dependent cellular cytotoxicity. ZL-1211 exerts anti-tumor activity in a mouse xenograft model of gastric cancer. ZL-1211 can be used for the research of gastric cancer .
IPH4301 is a monoclonalantibody targeting MICA/B, with dual activities of cytotoxicity and immunoregulation . IPH4301 blocks the interaction between MICA/B and NKG2D, inhibits their hydrolysis into soluble sMICA/B, and mediates antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis against tumor cells expressing MICA/MICB. IPH4301 restores the expression and function of NKG2D on primary NK cells and T cells, reverses the immunosuppression induced by M2 macrophages, and enhances NK cell-mediated tumor cell apoptosis. IPH4301 can be used in research related to cancer and triple-negative breast cancer .
Ladiratuzumab (hLIV22) is a humanized monoclonalantibody against zinc transporter LIV-1/ZIP6. Ladiratuzumab is conjugated to MMAE (HY-15162) via a cleavable dipeptide linker to synthesize an antibody-drug conjugate (ADC) Ladiratuzumab vedotin (HY-P99683). Ladiratuzumab vedotin selectively targets LIV-1 protein overexpressed on the surface of tumor cells, enters cells through antibody-mediated receptor endocytosis, releases MMAE to inhibit microtubule polymerization, and kills adjacent tumor cells with a bystander effect. Ladiratuzumab can be used in the study of solid tumors such as metastatic triple-negative breast cancer (mTNBC) .
AX-202 is a humanized IgG4 monoclonalantibody targeting S100A4. AX-202 neutralizes the activity of S100A4. AX-202 effectively reverses established fibrosis and reduces inflammation and fibrosis-related biomarkers in a mouse model of skin fibrosis. AX-202 is applicable for the research of fibrotic and inflammatory diseases .
AB-3A4 is a human IgG1 monoclonalantibody (mAb) targeting KAAG1. AB-3A4 can be used in the study of ovarian cancer, triple-negative breast cancer, and prostate cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Ziltivekimab (COR-001) is a fully human monoclonalantibody and also an IL-6 inhibitor. Ziltivekimab significantly reduces inflammatory biomarkers and Lipoprotein (a) in chronic kidney disease patients with systemic inflammation. Ziltivekimab does not increase pro-atherosclerotic lipid levels. Ziltivekimab is used in studies related to atherosclerotic thrombotic diseases and chronic kidney disease .
Tildrakizumab (SCH 900222) is a humanized anti-IL-23 (p19 subunit) monoclonalantibody. IL-23 is a critical cytokine to maintain the Th17 cell phenotype. Tildrakizumab has high-affinity for single-chain IL-23 (Kd: 136 pM). Tildrakizumab is effective against moderate to severe plaque psoriasis .
Opamtistomig is a humanized immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonalantibody targeting human programmed death ligand 1 (PD-L1), CD274 and tumor necrosis factor receptor superfamily member 9 (TNFRSF9). Opamtistomig is promising for research of various solid tumors and hematological malignancies .
VERT-002 is a MET degrader and monoclonalantibody. VERT-002 induces nearly complete and profound degradation of the MET protein by enhancing the intrinsic shedding of the MET extracellular domain (ECD). VERT-002 demonstrates significant anti-tumor activity. VERT-002 can be used in non-small cell lung cancer research. .
Losatuxizumab is an anti-EGFRmonoclonalantibody. Losatuxizumab binds to EGFR with EC50s of 0.96 nM for EGFR wild-type, 0.09 nM for EGFR C271A,C283A, 0.12 nM for EGFRvIII, 0.66 nM for EGFR1-501. Losatuxizumab can be used for research of EGFR-expressing cancers .
Rosopatamab (HuJ591) is a humanized antiPSMA IgG1 monoclonalantibody that can be used in cancer research, especially prostate cancer. Rosopatamab can be linked to the low-energy beta-emitting radioisotope lutetium-177 ( 177Lu) through the bifunctional chelator DOTA-NHS ester to obtain a radioimmunoconjugate that targets malignant prostate cells with high efficiency .
Fepixnebart (LY3016859) is a humanized monoclonal hIgG4 antibody, which binds and neutralizes only TGFα and epiregulin with high affinity. Fepixnebart can be used for the study of diabetic nephropathy and broad-spectrum chronic pain, including diabetic peripheral neuropathic pain (DPNP), signs and symptoms of osteoarthritis (OA), and chronic low back pain (CLBP) .
AMG-119 is a humanized IgG1 monoclonalantibody that targets delta-like ligand 3 (DLL3). AMG-119 can be used for the study of relapsed/refractory (R/R) small cell lung cancer (SCLC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Exbivirumab is a monoclonalantibody directed against highly conserved HBsAg epitopes. Exbivirumab enhances the antiviral activity of hepatitis B immunoglobulin (HBIG). Exbivirumab combined with Libivirumab (HY-P99703) decreases circulating HBsAg and hepatitis B virus (HBV) DNA levels in a chronically infected chimpanzee. Exbivirumab can be used for HBV re-infection in liver transplant .
TXB4 is a brain-permeable human monoclonalantibody (mAb) targeting CD71. TXB4 prevents 6-OHDA-induced death of TH-positive neurons in the SNc in a 6-OHDA mouse model of Parkinson's disease (PD). TXB4 can be used in neurodegenerative diseases, acute brain and spinal cord injury, and depression research .
MDX-1414 is a human IgG1 monoclonalantibody (mAb) targeting GPC3. MDX-1414 has antitumor activity in the HepG2 xenograft model. MDX-1414 can be used in liver cancer research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Tafolecimab (IBI-306) is a human lgG2 monoclonalantibody that specifically binds PCSK-9 and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in LDL-C levels. Tafolecimab may be used in studies of hypercholesterolaemia .
TTX-080 is a humanized monoclonal antagonistic antibody targeting human leukocyte antigen G (HLA-G). TTX-080 exerts anti-tumor activity by relieving HLA-G-mediated immune suppression. TTX-080 is promising for research of solid tumors such as metastatic colorectal cancer (mCRC) and head and neck squamous cell carcinoma (mHNSCC) .
Anti-MERS-D12 mAb (MERS-D12; MERS Antibody-D12) is a human monoclonal IgG1. Anti-MERS-D12 mAb binds directly to the DPP4 interacting region of the MERS-CoV Spike receptor binding domain (RBD) and effect neutralization by directly blocking receptor binding .
Petosemtamab (MCLA 158) is an anti- EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonalantibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC) .
AT002 (CBAS-173, EJ212/007-Cl2-5) is a recombinant human IgG1 monoclonalantibody. AT002 targets the cell surface protein activated leukocyte adhesion molecule (ALCAM)/CD166. AT002 can be used in the research of cancer, autoimmune diseases and inflammatory diseases.
Loncastuximab (RB4v1.2) is an anti-CD19monoclonalantibody. Loncastuximab has antitumor activity and can be used in the research of Non-Hodgkin Lymphoma (NHL) and Diffuse Large B-cell Lymphoma (DLBCL). Loncastuximab is capable of synthesizing the ADC molecule Loncastuximab tesirine (HY-P99349) .
Ramucirumab (anti-VEGFR) is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab (anti-VEGFR) is a recombinant human immunoglobulin G1 monoclonalantibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab (anti-VEGFR) is also an angiogenesis inhibitor .
IBI37G5 is a human monoclonalantibody (mAb) targeting TNFRSF18/GITR/CD357. IBI37G5 has anti-tumor activity in MC38 and B16F10 mouse tumor models. IBI37G5 can be used in the study of cancer immunity .
Toripalimab is a selective, recombinant, humanized monoclonalantibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma .
ELB041 (AFS98) is a rat monoclonalanti-murine c-fmsantibody (IgG2a). AFS98 inhibits M-CSF–dependent colony formation and cell growth by blocking the binding of M-CSF to its receptor. AFS98 prevents development of fatty streaks in ApoE-deficient mice. ELB041 can be used for the research of atherosclerosis .
Tilavonemab (ABBV-8E12) is a humanized anti-taumonoclonalantibody that binds to amino acids 25-30 near the N-terminus of the tau protein. Tilavonemab can block the ability of human and mouse neurons to uptake tau aggregates. Tilavonemab can be used for research on Alzheimer’s disease and other tauopathies .
Anti-Mouse OX40L/CD134L Antibody (RM134L) is an anti-mouse OX40L/CD134L IgG2b monoclonalantibody. Anti-Mouse OX40L/CD134L Antibody (RM134L) reduces immune response by inhibiting the OX40/OX40L signaling pathway. Anti-Mouse OX40L/CD134L Antibody (RM134L) can inhibit plasma cell differentiation and antibody secretion. Anti-Mouse OX40L/CD134L Antibody (RM134L) can prolong the survival time of cell transplantation by inhibiting CD4 + T cells. Anti-Mouse OX40L/CD134L Antibody (RM134L) can be used for researches on inflammation and cancer such as graft versus host disease (GVHD), allergic reaction, lupus nephritis and hepatocellular carcinoma (HCC) .
Anti-Mouse Delta-like protein 1/DLL1 Antibody (HMD1-5) is an anti-mouse Delta-like protein 1/DLL1 IgG monoclonalantibody. Anti-Mouse Delta-like protein 1/DLL1 Antibody (HMD1-5) can reverse the inhibition of Treg cells. Anti-Mouse Delta-like protein 1/DLL1 Antibody (HMD1-5) can inhibit the upregulation of GLT-1 expression induced by endothelial cells. Anti-Mouse Delta-like protein 1/DLL1 Antibody (HMD1-5) reduces autoimmune response by reducing B cell activation. Anti-Mouse Delta-like protein 1/DLL1 Antibody (HMD1-5) can be used for research on inflammation conditions such as lupus nephritis .
DS-5573a is a human monoclonalantibody targeting B7-H3, with a Kd of 1.8 nM for the 4Ig isoform and 11 nM for the 2Ig isoform. DS-5573a induces antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis against B7-H3-expressing cancer cells. DS-5573a exerts dose-dependent anti-tumor activity via effector cells. DS-5573a can be used in the research of cancers including breast adenocarcinoma, non-small cell lung cancer, renal cell adenocarcinoma, gastric cancer and prostate cancer .
Pepinemab (VX 15/2503) is a human monoclonalantibody against SEMA4D, a signalling protein 4D (SEMA4D), also known as CD100, which is a regulator of neuronal development and plays a role in a variety of cellular processes. Pepinemab can be used in the study of various neurodegenerative diseases such as Alzheimer's disease by blocking the activity of SEMA4D .
Ginisortamab (UCB6114) is a fully human IgG4P antiGremlin-1monoclonalantibody, with mean IC50 values of 8.2 nM and 9 nM against human and mouse gremlin-1, respectivly. Ginisortamab inhibits gremlin-1 antagonism of BMP signaling pathways. Ginisortamab has the potential for the research of gastrointestinal (GI) tumors .
Duvakitug (TEV-48574) is a humanized IgG1-λ2 monoclonalantibody targeting to TNFSF15/TL1A. Duvakitug' main expression system is CHOK1SV cells endogenously expressing glutamine synthetase (GS). Duvakitug can be used in the study of Crohn's Disease (CD) .
RO-5429083 (RG-7356) is a humanized monoclonalantibody targeting CD44. RO-5429083 binds to the extracellular domain of CD44 and inhibits constitutive EGFR phosphorylation. RO-5429083 suppresses tumor growth in xenograft models and can be used in research related to head and neck squamous cell carcinoma and acute myeloid leukemia .
Lixudebart (ALE.F02) is a humanized immunoglobulin G1-kappa, anti-CLDN1monoclonalantibody. Lixudebart disrupts CLDN1 interactions with CD44 and MMP14, reduces renal macrophage infiltration, epithelial activation, and urinary albumin-to-creatinine ratio, and attenuates glomerulosclerosis. Lixudebart can be used for the research of focal segmental glomerulosclerosis .
JNJ-55920839 (CNTO-6358) is a fully human immunoglobulin G1κ monoclonalantibody and a selective Interferonα/ω neutralizer, with a Kd value of 0.9-10.7 pM against hIFNα and a Kd of 1.44 pM against IFNω. JNJ-55920839 can be used in research related to systemic lupus erythematosus .
GSK3178022 is a human IgG1 monoclonalantibody (mAb) targeting LRP6. GSK3178022 inhibits the expression of WNT target genes SP5 and AXIN2. GSK3178022 has antitumor activity in the RSPO fusion model of colorectal cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
ZEB85 is a human monoclonalantibody (mAb) targeting TrkB. ZEB85 activates TrkB and its downstream cascades, including the ERK, PLCγ, AKT, MAPK signaling pathways and cFOS expression, and enhances neuronal activity. ZEB85 prevents β-amyloid toxicity in cultured hippocampal neurons. ZEB85 is applicable to the research of Alzheimer's disease (AD) .
Tesnatilimab (JNJ-64304500) is a human IgG4 monoclonalantibody targeting NKG2D, with a KD value of 9.2 pM . Tesnatilimab blocks the binding of ligands to the NKG2D receptor, thereby inhibiting downstream proinflammatory cytokine, cytotoxic mediator signaling pathways and proinflammatory immune responses. Tesnatilimab is applicable to research related to Crohn's disease .
PRN100 is a fully humanized monoclonalantibody against cellular prion protein (PrPᶜ), belonging to the IgG4κ isotype. By binding to and stabilizing cellular prion protein, PRN100 is designed to prevent cellular prion protein from being recruited and converted into pathogenic, self-propagating prion (PrPˢᶜ) aggregates. PRN100 can be used for the study of Creutzfeldt-Jakob disease.
Infliximab (Anti-TNF-α) (Avakine (Anti-TNF-α)) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab (Anti-TNF-α) prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab (Anti-TNF-α) has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research .
Anti-HLA-A2 (Hu8F4) is a human monoclonalantibody (mAb) targeting HLA-A2. Anti-HLA-A2 (Hu8F4) can be used in Acute myeloid leukaemia research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Vonlerolizumab (Pogalizumab; MOXR 0916) is a humanized IgG1 monoclonalantibody targeting OX40 (CD134). Pogalizumab partially blocks the interaction between OX40 and its natural ligand OX40L upon binding, thereby activating the NF-κB signaling pathway. Pogalizumab enhances T cell activation and proliferation and has shown antitumor activity in mouse models .
Varisacumab (R 84; GNR-011) is a fully humanized IgG1 monoclonalantibody targeting VEGF. Varisacumab specifically blocks the interaction between VEGF and VEGFR2, but does not interfere with the interaction between VEGF and VEGFR1. Varisacumab achieves effective anti-tumor and anti-angiogenic effects and can be used in the research of non-small cell lung cancer and pancreatic cancer.
ABI793 is a human IgG1 anti-human CD154 (CD40 ligand) monoclonalantibody. ABI793 inhibits immune response by blocking the CD154-CD40 (IC50 = 75 nM) signaling pathway. ABI793 effectively prevents kidney transplant rejection. ABI793 can be used for research on immunological rejection .
Grisnilimab (WT1) is an IgG2a monoclonalantibody targeting CD7. Grisnilimab only binds to lymphoid tissues and T lymphocytes, with no off-target binding to normal tissues. Grisnilimab can be used to synthesize the immunotoxin WT1-SMPT-dgRTA, which exerts cytotoxic effects on T-lymphoblastic leukemia cells. Grisnilimab is applicable to relevant research on leukemia .
QX008N is a humanized IgG1 monoclonalantibody and also a TSLP inhibitor with a KD value of 0.0175 nM. QX008N blocks TSLP-induced signaling pathways by inhibiting the interaction of TSLP-TSLPR-IL-7Rα. QX008N reduces eosinophil and IgE levels, improves pulmonary function, blocks TSLP-induced inflammation, and enhances the inhibitory effect on inflammatory mediators when administered in combination with anti-IL-4R antibodies. QX008N is applicable to relevant research on asthma .
SAR442085 is an Fc-engineered anti-CD38monoclonalantibody with a Kd of 0.2 nM for human CD38. SAR442085 inhibits CD38, induces apoptosis, and triggers antibody-dependent cellular cytotoxicity and phagocytosis in CD38-expressing tumor cells. SAR442085 binds allelic variants of FcγRIIa and FcγRIIIa, enhances NK cell activation, degranulation and cytokine secretion, and exerts anti-tumor activity in human Fc receptor transgenic mice. SAR442085 can be used in the research of multiple myeloma .
MGTA-117 is a humanized monoclonalantibody targeting CD117. MGTA-117 can be used for synthesis of antibody-drug conjugate (ADC), utilizing an amanitin payload. MGTA-117 has potent anti-tumor activity and increases survival in three acute myeloid leukemia (AML) xenograft hNSG mice models (Kasumi-1, AML PDX 1 and AML PDX 2). MGTA-117 enables hematopoietic stem cell transplantation (HSCT) preprocessing in AML, myelodysplasia with excess blasts (MDS-EB) and gene therapy .
Petosemtamab (FUT8-KO) is an anti-EGFR and anti-LGR5monoclonalantibody expressed in CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucosyl loss enhances the ADCC effect of the antibody. Petosemtamab (FUT8-KO) leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab (FUT8-KO) can be used for research on solid tumors such as head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (CRC) .
AO-176 is a humanized anti-CD47 IgG2 monoclonalantibody. AO-176 induces tumor phagocytosis through blocking the CD47-SIRPα interaction. AO-176 preferentially binds to tumor versus normal cells and directly kills tumor by a cell autonomous mechanism not ADCC (antibody-dependent cell-mediated cytotoxicity). AO-176 demonstrates dose-dependent antitumor activity in tumor xenograft models. AO-176 can be used for the researches of cancer, such as lymphoma .
Anti-Canine PD-L1/B7-H1 Antibody (JC071) is an anti-canine PD-L1/B7-H1 IgG1 monoclonalantibody. Anti-Canine PD-L1/B7-H1 Antibody (JC071) can specifically bind to CHO-PDL1 cells and K562-cCD20-cPD-L1 cells. Anti-Canine PD-L1/B7-H1 Antibody (JC071) can enhance the level of IFN-γ. Anti-Canine PD-L1/B7-H1 Antibody (JC071) is often used in western blot experiments .
Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) is an anti-mouse CD106/VCAM-1 IgG1 monoclonalantibody. Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) reduces inflammatory response and oxidative stress by lowering p-STAT3 and reactive oxygen species (ROS) levels. Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) can alleviate cardiac inflammation and fibrosis by reducing the expression of collagen I and collagen III. Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) can be used for research on cardiovascular conditions such as hypertensive heart condition and subretinal fibrosis .
Anti-CD160 Antibody (MAT 302) (CL1-R2) is a human monoclonalantibody targeting CD160. Anti-CD160 Antibody (MAT 302) blocks the CD160-HVEM protein interaction, inhibits FGF2-mediated renal tubular vascular growth, and induces endothelial cell apoptosis. Anti-CD160 Antibody (MAT 302) targets CD160 on neovascularization to exert anti-angiogenic and vascular normalization effects, trigger the production of IFN-γ, TNF and IL-6 by NK cells, and enhance glucose metabolism of NK cells through the AKT/mTOR/s6k signaling pathway. Anti-CD160 Antibody (MAT 302) reduces vascular density, normalizes remaining tumor blood vessels, and inhibits tumor growth in melanoma-bearing mice. Anti-CD160 Antibody (MAT 302) can be used in research related to neovascularization, proliferative diabetic retinopathy, and melanoma .
Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) is an anti-mouse/rat/human CCL2/MCP-1 IgG monoclonalantibody. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can reverse the immunosuppressive microenvironment by blocking the CCL2 signaling pathway. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can reduce the secretion of IFN-γ and the infiltration of macrophages. CCL2/MCP-1 Antibody (2H5) can reduce the amount of HIV virus by increasing the proportion of T cells. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can be used for researches on inflammation conditions, virus infection and cancer such as inflammatory bowel disease (IBD), hepatocellular carcinoma (HCC) and HIV .
Cabotamig is a humanized bispecific T-cell engager antibody targeting CDH17/CD3. Cabotamig is generated from anti-CDH17 monoclonal ARB102 by linking a CD3-binding scFv in the format of IgG4-scFv. Cabotamig can be used for the research of cancer, such as gastric cancer and colon cancers .
Upifitamab is a humanized monoclonalantibody targeting NaPi2b. Upifitamab can be used to synthesize ADC such as Upfitamab rilsodotin. Upfitamab rilsodotin can be used in research for solid tumors including high-grade serious epithelial ovarian, fallopian tube and primary peritoneal cancer (OC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
BI-1910 is a human monoclonalantibody (mAb) targeting TNFRSF1B. BI-1910 enhances T cell activation and induces CD8 T cell-dependent anti-tumor effects. BI-1910 can be used in solid tumors research. Recommended isotype control: Human IgG2 lambda, Isotype Control (HY-P991206) .
ASP8374 is a human IgG4 monoclonalantibody (mAb) targeting TIGIT. ASP8374 increases IL-2 production in Jurkat cells and IFN-γ and TNF-α production in human PBMCs. ASP8374 can be used in advanced solid tumors research. Recommended isotype control: Human IgG4 kappa, Isotype Control (HY-P99003) .
Guselkumab is a recombinant human IgG1 monoclonalantibody against the IL-23p19 subunit. Guselkumab binds to human and cynomolgus monkey IL-23 with Kd values of 3.3 and 1.9 pmol/L, respectively. Guselkumab inhibits production of cytokines lying downstream of the IL-23 signaling pathway and can be used for psoriatic arthritis research .
REGN3051 is a human IgG1 monoclonalantibody (mAb) targeting MERS CoV. REGN3051 reduces viral titers in the lungs of mice expressing human DPP4. REGN3051 decreases lung disease severity and viral replication in marmosets inoculated with MERS-CoV. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
CRB0017 is a recombinant monoclonalantibody targeting ADAMTS5, with high affinity for the spacer domain of ADAMTS5 and strong antigen specificity. CRB0017 binds to the spacer domain of ADAMTS5 and reduces the proteolytic activity of this enzyme. CRB0017 delays articular cartilage degradation, alleviates the pathological severity of osteoarthritis, and decreases the osteoarthritis histopathological score. CRB0017 is applicable to the research of osteoarthritis .
Tucotuzumab celmoleukin (EMD 273066) is an immunocytokine. Tucotuzumab celmoleukin consists of the following components: an IgG1 monoclonalantibody targeting human EpCAM antigen, and two molecules of IL2. Tucotuzumab celmoleukin binds to EpCAM. Tucotuzumab celmoleukin exerts anti-tumor effects on colon adenocarcinoma in synergy with radiofrequency ablation. Tucotuzumab celmoleukin can be used in research related to colon adenocarcinoma and colon cancer .
Eldelumab (BMS-936557) is a human anti-CXCL10 (IP-10) monoclonalantibody (IgG1 type). Eldelumab selectively binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab can be used in studies of autoimmune and auto-inflammatory diseases such as rheumatoid arthritis, ulcerative colitis and crohn's disease .
HBM1007 is a fully human monoclonalantibody targeting CD73. HBM1007 is an extracellular enzyme expressed on the surface of stromal cells and tumor cells, capable of converting extracellular adenosine monophosphate (AMP) into adenosine, and recognizing CD73 via a unique antigenic epitope. HBM1007 inhibits both CD73-dependent and CD73-independent enzyme activities.
Trastuzumab is a humanized IgG1 monoclonalantibody that selectively binds to HER2 with high affinity. Trastuzumab can be used for the research of HER2-positive metastatic breast cancer and gastric cancer . (Note: The product specifications below only indicate the effective content of Trastuzumab. The component ratio of this product is Trastuzumab : excipients = 1:0.6-1:0.9.)
Telisotuzumab (ABT-700) is a bivalent humanized IgG1 anti-c-Metmonoclonalantibody. Telisotuzumab binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab induces apoptosis. Telisotuzumab can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .
Vobarilizumab (ALX-0061) is a humanized bispecific anti-IL-6R and anti-human serum albumin (ALB) monoclonalantibody (mAb) (Kd: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis .
Adezkibart is a human monoclonalantibody immunosuppressant targeting the human FMS-like tyrosine kinase 3 ligand (FLT3LG). Adezkibart is found in the Chinese hamster ovary cell line CHO-K1, which binds to FLT3LG to block the relevant signaling pathway, inhibits the immune response, and exerts immunosuppressive activity. Adezkibart is promising for research of immune-related diseases .
ATR-107 (PF-05230900) is a humanized monoclonalantibody inhibitor that targets the interleukin-21 receptor (IL-21R). The Ka value of ATR-107 is 2-4 nM in cynomolgus monkeys, 16 nM in mice, and 71 nM in rats. ATR-107 can be used in research related to systemic lupus erythematosus and air pouch inflammation .
AR-201 is a human IgG1 monoclonalantibody (mAb) targeting F, Fusion glycoprotein F0. AR-201 has anti-respiratory syncytial virus (RSV) activity. AR-201 can be used in lower respiratory tract illness (LRTI) research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
Reslizumab (Sch 55700) is humanized monoclonalantibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab has high binding affinity for human IL-5, with KD values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively .
Mik-Beta-1 is a human IgG1-kappa anti-IL2RB monoclonalantibody. The isotype control of Mik-Beta-1 can be referenced to Human IgG1 kappa, Isotype Control (HY-P99001). Mik-Beta-1 can be used in research related to the prevention of allograft rejection .
SM201 is a monoclonalantibody that targets FcγRIIB. SM201 specifically binds to FcγRIIB, enhances ITIM phosphorylation of FcγRIIB in an immune complex-dependent manner, and acts synergistically with immune complexes to amplify inhibitory signals. SM201 does not induce apoptosis, activate NK cells, or deplete B cells. SM201 can be used for the research of autoimmune diseases .
Quisovalimab (AVTX-002) is a human-derived monoclonalantibody against LIGHT (TNFSF14). Quisovalimab binds to LIGHT, blocks the signal transduction activity of LIGHT, reduces circulating LIGHT levels and attenuates pro-inflammatory effects. Quisovalimab can be used in research related to Crohn's disease, COVID-19-associated pneumonia and acute respiratory distress syndrome comorbidity .
Asedebart is a CHO-expressed human antibody that targets Adrenocorticotropic hormone (ACTH). Asedebart blocks the binding of ACTH to its receptor through antagonism. Asedebart has huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Asedebart can refer to Human IgG1 kappa, Isotype Control (HY-P99001). Asedebart can be used for inflammatory diseases such as psoriasis and ulcerative colitis research .
Nebaprubart (JJP-1212) is a humanized IgG4κ antibody against FCAR/CD89, and its corresponding isotype control is Human IgG4 kappa, Isotype Control (HY-P99003) .
AMG-329 (MEDI1116) is a human immunoglobulin G1λ monoclonalantibody targeting FLT3L. AMG-329 selectively binds to FLT3L, blocks FLT3L-FLT3 interaction, neutralizes soluble and cell-bound human FLT3L activity. AMG-329 reduces circulating relative proportions of plasmacytoid dendritic cells, conventional dendritic cells, and classical monocytes. AMG-329 does not induce antibody dependent cellular cytotoxicity. AMG-329 can be used for the research of sjögren’s disease .
Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonalantibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo .
Anti-Mouse CD276/B7-H3 Antibody (MJ18) is a rat-derived anti-mouse CD276/B7-H3 IgG1 monoclonalantibody. Anti-Mouse CD276/B7-H3 Antibody (MJ18) can inhibit CD276/B7-H3 and induce tumor cell apoptosis. Anti-Mouse CD276/B7-H3 Antibody (MJ18) enhances anti-tumor immune response by reducing immunosuppressive cells and promoting T cell activation. Anti-Mouse CD276/B7-H3 Antibody (MJ18) can be used for research on cancer such as breast cancer and prostate cancer .
Bezlotoxumab (BLA761046; MBL-CDB1; MDX-1388) is a fully humanized IgG1/kappa monoclonalantibody directed against Clostridium difficile toxin B. Bezlotoxumab mediates the early reconstitution of gut microbiota to reduce the risk of recurrent Clostridium difficile infection (CDI). Bezlotoxumab can be used for the study of recurrent Clostridium difficile infection prevention .
SBT-100 (His Tag) is a human monoclonalantibody (mAb) targeting STAT3. SBT-100 (His Tag) inhibits IL-6-mediated P-STAT3 nuclear translocation in HEp-2 and PANC-1 cells. SBT-100 (His Tag) has tumor growth inhibitory effects on MDA-MB-231 .
BMS-981164 is a human anti-IL31 IgG1-κ monoclonalantibody. BMS-981164 effectively inhibits the IL-31 signaling pathway. The isotype control of BMS-981164 can be referenced to Human IgG1 kappa, Isotype Control (HY-P99001). BMS-981164 is applicable to research related to atopic dermatitis .
PE0116 is a fully human CD137 agonistic monoclonalantibody generated from immunized harbor H2L2 human transgenic mice. PE0116 is a ligand block. PE0116 activates NF-κB signaling which significantly promotes T-cell proliferation and increases cytokine secretion in vitro. PE0116 exhibits robust antitumor activity in MC38 tumor model .
Emactuzumab(RG 7155) is a specific monoclonalantibody that inhibits colonystimulating factor 1 receptor (CSF1R) activation. Emactuzumab has high affinity for CSF-1R with Ki value of 0.2 nM to blocks CSF-1R dimerization. Emactuzumab can be used for the research of several diseases, such as diffuse-type tenosynovial giant cell tumour (dt-GCT) .
KD014 (DX-2400) is a human monoclonalantibody that selectively targets MMP‑14. KD014 inhibits collagen degradation and regulates the polarization of macrophages toward an anti-inflammatory/anti-tumor phenotype. KD014 alleviates joint damage in rheumatoid arthritis and suppresses tumor growth and invasion. KD014 can be used in studies related to breast cancer and rheumatoid arthritis .
Risankizumab (BI 655066) is a humanised IgG monoclonalantibody, targeting IL-23 p19 subunit (Kd <10 pM) and inhibiting IL-17 production induced by human IL-23 in mouse splenocytes (IC50 = 2 pM). Risankizumab can be used to research immunological and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis and erythrodermic psoriasis .
Amlitelimab (FUT8-KO) is Amlitelimab (HY-P99434) expressed in cells with the fucosyltransferase 8 gene (FUT8) knocked out. Amlitelimab (KY1005) is a monoclonalantibody (mAb) against OX40 ligand (OX40L). Amlitelimab inhibits the OX40-OX40L interaction and can be used for research on atopic dermatitis .
LBL-019 is a humanized IgG1 monoclonalantibody targeting TNFR2. LBL-019 costimulates TNFR2 and activates the NF-κB signaling pathway in an Fc crosslinking-dependent manner. LBL-019 can be used for the research of advanced malignant tumors, including hepatocellular carcinoma and melanoma. The recommended isotype control is human IgG1 kappa (HY-P99001) .
Cabiralizumab (FPA 008) is an anti-CSF1Rmonoclonalantibody (MAb). Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis (RA). Cabiralizumab can combine with Nivolumab (HY-P9903) for lung cancer research .
Omoprubart is an anti-C5 complement recombinant humanized monoclonalantibody. Omolubat can prevent C5 from cleaving into C5a and C5b, thereby inhibiting the formation and activation of the C5b-dependent membrane attack complex (MAC) on the surface of susceptible cells, leading to cell lysis (destruction). Omoprubart can be used for the study of paroxysmal nocturnal hemoglobinuria (PNH).
Milatuzumab (hLL1; MEDI-115) is a humanized anti-CD74monoclonalantibody. CD74, a integral membrane protein, is associated with the promotion of B-cell growth and survival. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death .
Vilobelimab (CaCP-29, IFX-1) is a monoclonalanti-C5aantibody to the allergen C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. Vilobelimab acts as a C5a inhibitor, inhibiting neutrophil activation, chemotaxis, and reducing inflammatory signalling, and may be used in studies related to sepsis, COVID-19, etc .
MS17-38 is a monoclonalantibody targeting PODXL-v2. MS17-38 binds to a specific conformational epitope of PODXL-v2 on gastric cancer cells, modulates target function, inhibits gastric cancer cell growth and migration, and blocks tumor growth and lung metastasis. MS17-38 can be used for the research of gastric cancer .
Lecankitug is a humanized monoclonalantibody targeting human interleukin 17A (IL-17A) and interleukin 17F (IL-17F). Lecankitug specifically binds to IL-17A and IL-17F, blocking their signal transduction, thus exerting immunosuppressive and anti-inflammatory activities. Lecankitug is promising for research of autoimmune and inflammatory diseases, such as psoriasis and rheumatoid arthritis .
Cantuzumab mertansine (SB-408075; huC242-DM1), an ADC, is an immunoconjugate of the potent maytansine derivative (DM1 (HY-19792)) and the humanized monoclonalantibody (huC242) directed to CanAg. Cantuzumab mertansine has cytotoxic toward colon cancer cells and has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts .
PF-04382923 is a humanized IgG2Δa monoclonalantibody. PF-04382923 binds with high affinity to the free C-terminal regions of the amyloid-β peptides Aβ1-40 and Aβ1-42. PF-04382923 is indicated for the study of geographic atrophy (GA) associated with dry age-related macular degeneration (ARMD) .
Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) is an anti-mouse/human VLA-4/CD49d IgG2b monoclonalantibody. Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) can reduce VLA-4 positive cells. Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) can inhibit the migration of Tc1 cells to tumors. Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) inhibits the retention of leukemia cells in the spleen and bone marrow by blocking VLA-4. Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) can be used for research on inflammation conditions and cancer such as experimental autoimmune encephalomyelitis (EAE), melanoma and leukemia .
Anti-Mouse CD11a/LFA-1α Antibody (M17/4) is an anti-mouse CD11a/LFA-1α IgG2a monoclonalantibody. Anti-Mouse CD11a/LFA-1α Antibody (M17/4) can reduce the recruitment of effector memory CD8 T cells. Anti-Mouse CD11a/LFA-1α Antibody (M17/4) promotes the formation of xenograft tumors by reducing immune rejection reactions. Anti-Mouse CD11a/LFA-1α Antibody (M17/4) can be used for researches on cancer, infection conditions and immunology such as glioblastoma, parasitic and bacterial infections. The recommend isotype control of Anti-Mouse CD11a/LFA-1α Antibody (M17/4): Rat IgG2a kappa, Isotype Control (HY-P990679) .
DNP002 is a humanized IgG1 monoclonalantibody targeting tumor-associated CEACAM6. DNP002 binds to CEACAM1, CEACAM5 and CEACAM6, and exhibits antibody-dependent cellular cytotoxicity against tumor cells overexpressing these targets. DNP002 binds to CEACAM6 on the surface of tumor-associated neutrophils (including MDSCs) to reverse the immunosuppressive effect in the tumor microenvironment. DNP002 shows anti-tumor activity in advanced solid tumors. DNP002 can be used for the research of advanced solid tumors. The recommended isotype control is human IgG1 kappa (HY-P99001) .
Lonigutamab (hz208F2-4) is a humanized anti-IGF-1Rmonoclonalantibody, serveing as a targeting vector for antibody-drug conjugates (ADCs). Lonigutamab causes G2-M phase cell cycle arrest and increases apoptosis in IGF-1R-overexpressing tumor cells. Lonigutamab demonstrates potent antitumor efficacy in IGF-1R-overexpressing xenograft models. Lonigutamab can be used for the study of Solid tumors with overexpression of IGF-1R and thyroid eye
diseases .
GT103 is a human-derived monoclonalantibody targeting complement factor H (CFH). GT103 binds to a conformationally distinct epitope of CFH on tumor cells. GT103 activates the classical complement pathway, induces complement-dependent cytotoxicity, and triggers antibody-dependent cellular phagocytosis (ADCP) of tumor cells. GT103 increases calreticulin translocation to tumor cell plasma membranes. GT103 mediates B-cell activation via Syk kinase phosphorylation. GT103 inhibits tumor growth and metastasis in animal models. GT103 can be used for the research of non-small cell lung cancer .
Tobevibart (VIR-3434) is a human IgG1 lambda monoclonalantibody against hepatitis B virus (HBV) surface antigen (HBsAg). Tobevibart shows potent neutralization against HBsAg from all HBV genotypes in vitro and inhibits viral entry of HBV and hepatitis delta virus (HDV). Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096) .
BMS-986010 is a monoclonalantibody inhibitor targeting the p19 subunit of interleukin-23 (IL-23). BMS-986010 reduces IL-23-induced STAT3 phosphorylation and inhibits Th17 cell differentiation and the release of proinflammatory cytokines (such as IL-17 and TNF-α). BMS-986010 is promising for research of autoimmune diseases such as psoriasis and Crohn's disease .
Tabituximab barzuxetan (exclude Y90) (OTSA101-DTPA; OTSA101-DTPA-90Y; OTSA101-SS01) is a immunoconjugate composed of a humanized monoclonalantibody targeting FZD-10 (OTSA-101). Tabituximab barzuxetan exhibits anti-tumor activity. Tabituximab barzuxetan can be used for the research of synovial sarcoma .
Ogalvibart (C-135-LS) is a human anti-SARS-CoV-2 monoclonalantibody (IgG1 type). Ogalvibart binds to the spike (S) glycoprotein receptor-binding domain (RBD) of SARS-CoV-2. Ogalvibart in combination with C144LS (1:1 ratio) shows good preventive activity and can effectively block the development of COVID19 in a rhesus monkey disease model .
Cixutumumab (IMC-A12) is a human anti-IGF-1Rmonoclonalantibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer .
Afimkibart (PF-06480605; RVT-3101) is a fully human monoclonalantibody that selectively inhibits trimeric tumor necrosis factor-like ligand 1A (TL1A). Afimkibart neutralizes active trimeric TL1A, blocks TL1A-induced signaling pathways. Afimkibart inhibits NF-κB activation and IFN-γ production. Afimkibart can be used for the research of inflammatory bowel disease .
CAN10 is is a humanized monoclonalantibody inhibitor targeting interleukin 1RAP (IL1RAP). CAN10 blocks IL-1, IL-33, and IL-36 signalling by targeting IL1RAP, preventing downstream proinflammatory and profibrotic responses. CAN10 reduces dermal and pulmonary fibrosis. CAN10 can be used for the research of immune system diseases, such as systemic sclerosis .
Batoclimab (RVT-1401) is a fully humanized IgG1 monoclonalantibody targeting FcRn. Batoclimab has high affinity for the IgG-binding site on FcRn. By competitively binding to the IgG binding site on FcRn, Batoclimab blocks FcRn-mediated recycling of IgG, resulting in enhanced degradation and subsequent reductions in IgG levels. Batoclimab can be used in the research of autoimmune diseases such as myasthenia gravis and thyroid eye disease .
Denosumab is a human monoclonalantibody that targets the protein RANKL. Denosumab binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) and prevents its binding to the RANK receptor (KD of 0.003 nM for human RANKL). Denosumab promotes proliferation and spermatogenesis. Denosumab prevents bone resorption through inhibition of the NF-κB pathway. Denosumab can be used in bone-related studies .
SHR-1802 is a humanized anti-LAG-3monoclonalantibody.SHR-1802 specifically binds to LAG-3 and inhibits its binding to major histocompatibility complex class II (MHC-II), fibrinogen-like protein 1 (FGL1), galectin-3, and liver sinusoidal endothelial cell lectin.SHR-1802 can be used for the research of advanced solid tumors .
Telisotuzumab (ABT-700) (powder) is a bivalent humanized IgG1 anti-c-Metmonoclonalantibody. Telisotuzumab (powder) binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab (powder) induces apoptosis. Telisotuzumab (powder) can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .
Polzastobart (JTX-8064) is a humanized IgG4 monoclonal antagonist antibody that selectively binds LILRB2 and prevents it from binding its ligands, classical and non-classical MHC I molecules. Polzastobart enhances pro-inflammatory cytokine production in macrophages by blocking the ability of LILRB2 to bind HLA-A/B and/or HLA-G, a marker of immunotolerance on cancer cells. Polzastobart is a macrophage immune checkpoint inhibitor .
Rat IgG2a kappa, Isotype Control is a monoclonalantibody derived from rats, representing the immunoglobulin G2a (IgG2a) subclass with a kappa light chain. Rat IgG2a kappa, Isotype Control exhibits high efficiency in inducing K cell mediated cytotoxicity. Rat IgG2a kappa, Isotype Control is utilized in research investigating the roles of different immunoglobulin subclasses in tumor immunology. Rat IgG2a kappa, an isotype control, can be used as an isotype control for Anti-Mouse PD-1 Antibody (RMP1-14) (HY-P99144), Anti-Mouse CD11a/LFA-1α Antibody (M17/4) (HY-P990801), and Anti-Mouse IL-2 Antibody (S4B6-1) (HY-P990796) .
Suciraslimab (SM03) is an anti-human CD22monoclonalantibody. Suciraslimab inhibits NLRP3 and ASC signaling. Suciraslimab suppresses cytokine (IL-1β, IL-12, IL-23) secretion and α4 integrin expression. Suciraslimab improves working memory and neuroinflammation . Suciraslimab isotype control product: Human IgG1 kappa, Isotype Control (HY-P99001).
OX118 is a fully human, ADCC-enhanced monoclonalantibody targeting OX40L, the recommended isotype control is HY-P99001. OX118 blocks OX40L, suppresses effector T-cell proliferation, expands regulatory T-cell populations, and reduces bystander activation across natural killer cells, B cells, and CD14+ monocytes. OX118 can be used for the research of graft-versus-host disease .
Budigalimab (ABBV 181; PR 1648817) is a humanized, recombinant IgG1 monoclonalantibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab has an Fc mutation that reduces the inhibition of Fc receptor interactions and effector factors. Budigalimab can block the binding of PD-1 and PD-L1, which has anti-tumor activity. Budigalimab can be used in the study of solid tumors .
Mirikizumab (LY3074828) is a humanized IgG4 monoclonalantibody that targets the p19 subunit of interleukin 23 (IL-23). Mirikizumab binds to human and monkey IL-23 with high affinity, with Kd values of 21 pM and 55 pM, respectively. By inhibiting the binding of IL-23 to IL-23R, Mirikizumab modulates the immune response and holds potential for research in ulcerative colitis and Crohn's disease .
Suvratoxumab (MEDI4893) is a long-acting, high-affinity human anti-α-toxin monoclonalantibody (IgG1κ type). Suvratoxumab potently neutralizes α-toxin, a key S. aureus virulence factor. Suvratoxumab improves survival and reduces lung injury in an immunocompromised mice model of pneumonia. Suvratoxumab also enhances the antibacterial activity of Vancomycin (HY-B0671) or Linezolid (HY-10394) .
GR-1405 is a human monoclonalantibody (mAb) targeting B7-H1/PD-L1/CD274. GR-1405 enhances cytotoxic T lymphocyte (CTL)-mediated antitumor immune responses against PD-L1-expressing tumor cells. GR-1405 can be used in Lymphoma and Solid tumours research .
STX-100 (BG00011) is a humanized monoclonalantibody targeting αVβ6 integrin. STX-100 specifically binds αVβ6 integrin, blocks latent TGF-β activation via latency-associated peptide (LAP) interaction prevention, and reduces profibrotic responses. STX-100 can be used for the research of idiopathic pulmonary fibrosis, and cancer .
Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonalantibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease .
ALD1613 is a potent neutralizing monoclonalantibody against adrenocorticotropic hormone (ACTH). ALD1613 neutralizes ACTH-induced signaling and inhibits ACTH-induced cyclic AMP accumulation in a mouse adrenal cell line (Y1) via all five melanocortin receptors. ALD1613 significantly reduces plasma corticosterone levels in wild-type rats. ALD1613 can be used in the study of diseases associated with elevated ACTH levels .
Sym-021 is a human monoclonalantibody (mAb) targeting PDCD1/PD-1/CD279. Sym-021 blocks the binding of PD-L1 and PD-L2 ligands, inducing the secretion of interferon IFN-γ and IL-2 and the proliferation of T cells. Sym-021 has anti-tumor activity in PDX mouse models .
INCA033989 is a fully human IgG1 monoclonalantibody targeting mutCALR (KD = 1.75 nM for mutCALR del52; KD = 6.78 nM for mutCALR ins5). INCA033989 antagonizes mutCALR-driven signaling and proliferation. INCA033989 selectively inhibits pSTAT3/pSTAT5. INCA033989 prevents thrombocytosis and reduces the expansion of mutCALR-positive cells. INCA033989 is useful for research on myeloproliferative neoplasms .
Serrumab is a human monoclonalantibody that counteracts the biochemical and immunological effects of Tityus serrulatus venom. Serrumab inhibits the TsV-induced increase in the production of IL-6, TNFα and IL-10. Serrumab also prevents TsV-induced elevations in plasma urea, creatinine, aspartate transaminase and glucose levels, as well as the TsV-induced increase in neutrophil recruitment. Serrumab can be used in research related to envenoming by the Brazilian yellow scorpion .
BI-765423 is a selective monoclonalantibody inhibitor targeting IL-11. BI-765423 blocks IL-11-mediated signaling, inhibits fibroblast activation, and can extend the healthy lifespan of mammals, counteract cellular senescence in human cells, and alleviate inflammatory aging-related pathological processes. BI-765423 is primarily used in research on fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) .
NI-1201 is a monoclonalantibody that targets, in the human IL-6R sequence, the epitope recognized by 25F10 for mice. NI-1201 inhibits both IL-6 cis- and trans-signaling. NI-1201 targets site IIb of hIL-6R. NI-1201 inhibits gp130 binding to IL-6R .
IBI-397 is a human monoclonalantibody (mAb) targeting SIRPα/CD172a . IBI-397 promotes human monocyte-derived dendritic cell-mediated T cell proliferation and increases the expression of CD86 and HLA-DR. IBI-397 has antitumor activity in the mouse MDA-MB-231 tumor model. IBI-397 can be used in Myeloma research .
VHB937 is a potent and selective TREM2 agonist, a human monoclonalantibody, with sub-nanomolar affinity. VHB937 enhances TREM2 surface expression and downstream signaling, such as Syk phosphorylation and calcium mobilization. VHB937 exhibits robust neuroprotective effects in vivo, significantly reducing pathology and pro-inflammatory markers across a broad range of animal models of neuroinflammation and neurodegeneration. VHB937 can be used for neurodegenerative diseases research .
MEDI-8852 is a human IgG1 monoclonalantibody against influenza A virus hemagglutinin (HA). MEDI-8852 binds to the conserved HA stalk epitope and neutralizes viral infectivity. MEDI-8852 reduces viral titers in mouse lung tissues. MEDI-8852 is applicable to research related to pandemic influenza . Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
SAR228810 is a humanized IgG4 monoclonalantibody inhibitor targeting amyloid β (Aβ) with a KD? of ?0.43 ?nM for protofibrillar Aβ over monomeric Aβ. SAR228810 significantly inhibits the brain amyloid plaque formation and oligomer-induced synaptic dysfunction and neurite loss. SAR228810 has significant protection against Aβ-mediated neuritotoxicity. MINT1526A can be used for Alzheimer’s disease imaging and immunotherapy research .
hIMB1636 is a humanized monoclonalantibody targeting Trop2. By binding to the conformational Trop2 epitope, hIMB1636 regulates related signaling pathways, triggers lysosomal endocytosis, and further induces apoptosis, cell cycle arrest, and antibody-dependent cellular cytotoxicity. hIMB1636 effectively inhibits tumor cell proliferation, migration and in vivo tumor growth, and also exerts bystander killing effect and mediates long-term retention. hIMB1636 can be conjugated with NOTA/DOTA for radiolabeling to enable immuno-PET imaging, or prepared as hIMB1636-LDP-AE to significantly inhibit the growth of breast cancer and lung cancer xenografts .
Belantamab (GSK2857916) is a humanized IgG1 anti-BCMA/TNFRSF17 monoclonalantibody. Belantamab is linked to MMAF (HY-15579) through a non-cleavable ADC linker to synthesize the antibody-active molecule conjugate (ADC) Belantamab mafodotin (HY-P3239). After binding to BCMA on the surface of tumor cells, Belantamab mafodotin enters the cell through receptor-mediated endocytosis. After entering the cell, Belantamab mafodotin releases MMAF, blocks cell division by inhibiting tubulin polymerization, arrests the cell cycle and induces cell apoptosis. Belantamab can be used for the study of multiple myeloma, especially relapsed/refractory multiple myeloma .
TPP-9476 (BAY-943 antibody) is an anti-human IL3RA (CD123)monoclonalantibody with human IL3RAKd of 11 nM and cynomolgus monkey IL3RAKd of 16 nM. TPP-9476 binds specifically to human and cynomolgus monkey IL3RA, undergoes target-dependent internalization into lysosomes of IL3RA-positive cells.TPP-9476 exerts antiproliferative effects in IL3RA-expressing acute myeloid leukemia and classical Hodgkin lymphoma cells, reduces tumor burden, improves survival, and induces complete tumor remission in relevant xenograft mouse models .
BIIB022 is a human IgG4 monoclonalantibody (mAb) targeting IGF1R/CD221. BIIB022 blocks IGF-1 and IGF-2-induced phosphorylation of IGF-1R and downstream substrates. BIIB022 can be used in lung, pancreatic, and colon cancer research. Recommended isotype control: Human IgG4 kappa, Isotype Control (HY-P99003) .
MG-1131 is a human monoclonalantibody (mAb) targeting TIGIT. MG-1131 activates NF-κB signaling in T cells and enhances NK-mediated tumor killing activity in a PVR-dependent manner. MG-1131 blocks TIGIT to increase IFN-γ secretion. MG-1131 can be used in anti-tumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
LASN01 is a human IgG1 monoclonalantibody (mAb) targeting IL-11RA. LASN01 inhibits IGF-1 and IL-11-induced hyaluronic acid (HA) release and TGFβ-stimulated procollagen in orbital fibroblasts. LASN01 can be used in thyroid eye disease (TED) research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Metuzumab (Licartin) is a human-mouse chimeric IgG1 monoclonalantibody targeting CD147. Metuzumab induces Apoptosis, reduces levels of Cyclin D1, full-length Caspase-3, and Bcl-2, and increases Bax expression. Metuzumab enhances the sensitivity of non-small cell lung cancer (NSCLC) cells to Gemcitabine (HY-17026). Metuzumab is applicable for research on hepatocellular carcinoma and non-small cell lung cancer [1][2].
DS-8895(DS-8895A) is an anti-EphA2monoclonalantibody with specific binding to EphA2 receptors and EphA2-expressing cells. DS-8895, when conjugated with 89Zr, 111In, or 125I, supports molecular imaging of EphA2 expression in xenograft models. DS-8895 allows noninvasive measurement of EphA2 expresssion in tumors in vivo. .
RO5323441 (TB-403) is a human IgG1 monoclonalantibody (mAb) targeting PlGF. RO5323441 inhibits the binding of human PlGF-1 or PlGF-2 to VEGFR-1 (IC50 values are 0.1 and 0.2 nM, respectively). RO5323441 blocks PlGF-induced VEGFR-1 phosphorylation in Flt-1-transfected HEK293 cells. RO5323441 has antitumor activity .
Vamikibart (RG6179) is a monoclonalantibody targeting IL-6 that can be used to inhibit uveal macular edema (UME) and reduce retinal leakage. Vamikibart can reduce anterior chamber (AC) cell density, indicating a reduction in intraocular inflammation. Vamikibart can also be used to assess the leakage dynamics of ultra-wide-angle fluorescein angiography (UWFA) in the UME model to quantify changes in retinal leakage reflecting the effect of UME inhibition .
Anti-ERBB3/HER3 (SGP1) is a human monoclonalantibody (mAb) targeting ERBB3/HER3. Anti-ERBB3/HER3 (SGP1) inhibits Neuregulin stimulated growth of cultured breast cancer cells. Anti-ERBB3/HER3 (SGP1) can be used in breast cancer research .
IPH5301 is a human IgG1 monoclonalantibody (mAb) targeting NT5E/CD73. IPH5301 has a functionally silent Fc domain, specifically inhibits soluble and membrane CD73 enzyme activity, and restores the proliferation of immune T cells. IPH5301 can be used in anti-tumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
VRC-01 is a broadly neutralizing IgG1monoclonalantibody that targets HIV-1 envelope glycoprotein gp120 Protein. VRC-01 blocks HIV-1 viral entry by mimicking CD4 receptor interaction with HIV-1 gp120 and neutralizes broad HIV-1 clades. VRC-01 can be used for the research of HIV-1 infection .
Dusigitumab is a fully human IgG2λ monoclonalantibody that targets IGF-1 and IGF-2 with picomolar binding affinity. Dusigitumab blocks IGF-1 and IGF-2-induced phosphorylation of IGF-1R as well as activation of IR-A, thereby inhibiting the activation of downstream signaling pathways. Dusigitumab is applicable to research related to advanced solid tumors and hormone receptor-positive metastatic breast cancer .
HGS101 is a fully human CCR5 monoclonalantibody with high affinity to CCR5. HGS101 binds to the 2nd extracellular loop (ECL-2) and acts as a signal antagonist. HGS101 restores Maraviroc (HY-13004) inhibition of Maraviroc-resistant HIV-1 infection of PBMCs. HGS101 shows anti-HIV activity by inhibiting CCR5 signaling in simian immunodeficiency virus-uninfected RMs models .
Ordesekimab (AMG 714; PRV-015) is a fully human IgG1κ anti-IL-15 (Interleukin Related) monoclonalantibody. The binding of Ordesekimab to IL-15 inhibits the interaction of IL-15 with the IL-2Rβ and common γ chain of the IL-15 receptor complex, but not with the IL-15Rα chain. Ordesekimab has the potential for study of nonresponsive celiac disease (NRCD) .
AL002 is a humanized monoclonal IgG1 antibody and a blood-brain barrier-permeable TREM2 modulator. AL002 binds to TREM2 on the surface of microglia, promotes TREM2 clustering and the formation of the TREM2-DAP12 complex, activates the TREM2 signaling pathway and PI3K cascade, and induces TREM2 internalization and degradation. AL002 is applicable to research related to Alzheimer's disease .
TAB-004 is a murine IgG1 monoclonalantibody that specifically binds to the tumor-associated hypoglycosylated mucin 1 (tMUC1), with high selectivity for human tMUC1. TAB-004 can be conjugated with Indocyanine green (ICG) (HY-D0711) for in vivo targeted imaging. TAB-004 can be used for the research of early detection, tumor progression monitoring and cancer stem cell targeting in breast cancer and pancreatic cancer.
VIR-7229 is a human IgG1 monoclonalantibody (mAb) targeting Receptor-Binding Domain, RBD, Spike glycoprotein. VIR-7229 exerts antiviral activity by competing with ACE2 for binding and inducing S1 protein shedding. VIR-7229 can be used in SARS-CoV-2 infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
PTX-35 is a human IgG monoclonalantibody (mAb) targeting TNFRSF25. PTX-35 reduces the suppressive activity of regulatory T cells and enhances CD4+ T cell effector responses in a mouse melanoma model. PTX-35 can be used in Islet cell transplant rejection and Solid tumours research. Recommended isotype control: Human IgG1 lambda2, Isotype Control (HY-P990096) .
HeFi-1 is a mouse anti-CD30 IgG1 monoclonalantibody. HeFi-1 recognizes the ligand-binding site on CD30. HeFi-1 can inhibit the growth of tumor cells with high expression of CD30. HeFi-1 can induce eosinophil apoptosis. HeFi-1 can be used for researches on cancer or inflammation conditions such as anaplastic large-cell lymphoma (ALCL) and asthma .
Fezakinumab (ILV 094) is an anti-IL-22monoclonalantibody. Fezakinumab inhibits IL-22 signal transduction, and regulates the JAK1/STAT3 pathway as well as apoptotic proteins. Fezakinumab alleviates airway remodeling, alveolar enlargement and inflammatory cell infiltration in lung tissues. Fezakinumab reduces the levels of neutrophils, lymphocytes, eosinophils and macrophages in lung tissues. Fezakinumab can be used in the research of chronic obstructive pulmonary disease and skin diseases .
STT-5058 (ARGX-116; NN5058) is a human monoclonalantibody targeting ApoC3 and belongs to the class of ApoC3 inhibitors. STT-5058 exhibits pH-dependent circulation properties and binds to a unique epitope on ApoC3. STT-5058 reduces triglyceride levels and accelerates the clearance of atherogenic remnant lipoproteins containing ApoC3. STT-5058 can be used in research related to hypertriglyceridemia, dyslipidemia and cardiovascular diseases .
S-531011 is a human IgG1 monoclonalantibody (mAb) targeting CCR8. S-531011 reduces tumor-infiltrating CCR8+ Tregs and has anti-tumor activity in CT26.WT and EMT6 tumor-bearing mouse tumor models. S-531011 can be used in the study of cancer immunity. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Teprotumumab is an IGF-1 receptor (IGF-1R) blocking human monoclonalantibody. Teprotumumab binds to the ligand binding extracellular α-subunit domain of IGF-1R. Teprotumumab inhibits TSH and IGF-1 action in fibrocytes. Teprotumumab attenuates TSH-dependent IL-6 and IL-8 expression and Akt phosphorylation. Teprotumumab can be used for thyroid-associated ophthalmopathy research .
Opicinumab (BIIB033) is a human IgG1 monoclonalantibody targeting LINGO-1. Opicinumab binds LINGO-1 to block its negative regulatory signaling, suppress axonal degeneration, enhance axonal regeneration, promote remyelination, and exert neuroprotective effects.Opicinumab maintains axonal protective effects during co-administration with methylprednisolone. Opicinumab can be used for the research of multiple sclerosis, acute optic neuritis, and optic neuritis. .
Golimumab (CNTO-148) is a potent human IgG1 TNFα antagonist monoclonalantibody. Golimumab has anti-inflammation activitity and inhibits IL-6 and IL-1β production. Golimumab acts via targeting and neutralizing TNF to prevent inflammation and destruction of cartilage and bone. Golimumab has the anticancer activity and induces cell apoptosis. Golimumab can be used for rheumatoid arthritis, Crohn's disease and cancer research .
LR004 is an EGFRmonoclonalantibody, with a Kd of 2.80×10 -9 M against human EGFR. LR004 shows extremely weak inhibitory effect on the viability of EGFR-positive tumor cells in vitro, but inhibits the growth of EGFR-positive tumor xenografts as a single agent. LR004 is applicable to research related to advanced colorectal cancer, solid tumors, esophageal squamous cell carcinoma, epidermoid carcinoma, colon cancer and breast cancer .
SHR-1707 is a humanized anti-Aβ IgG1 monoclonalantibody. SHR-1707 binds Aβ fibrils and monomers, blocking plaque formation and promoting the microglial phagocytosis of Aβ. SHR-1707 reduces brain Aβ deposition in 5xFAD transgenic mice. SHR-1707 can be used for Alzheimer’s disease research. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
REGN-7257 is a humanized monoclonalantibody targeting IL2RG. REGN-7257 blocks the signal transduction induced by common gamma chain (γc) cytokines via the IL2RG chain of the γc cytokine receptor complex. REGN-7257 is applicable for research on immune-mediated diseases and T cell-mediated diseases . Its corresponding isotype control is Human IgG4 kappa, Isotype Control (HY-P99003).
Denosumab (anti-TNFSF11) is a human monoclonalantibody that targets the protein RANKL. Denosumab binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) and prevents its binding to the RANK receptor (KD of 0.003 nM for human RANKL). Denosumab promotes proliferation and spermatogenesis. Denosumab prevents bone resorption through inhibition of the NF-κB pathway. Denosumab can be used in bone-related studies .
Tepilukimig is a bivalent humanized IgG1κ monoclonalantibody inhibitor targeting TSLP-IL7Rα and TSLP-CRLF2. Tepilukimig inhibits the binding of TSLP to its receptors (IL7Rα and CRLF2) on the cell surface, thereby completely interrupting the inflammatory signaling pathway driven by TSLP. Tepilukimig can be used for allergic and inflammatory diseases like atopic dermatitis and asthma research .
Casirivimab (REGN10933) is a human monoclonalantibody that targets the SARS-CoV-2 virus, which causes COVID-19. Casirivimab is ineffective against COVID-19 variants. Casirivimab can be used in combination with Imdevimab (HY-P99342), which alters the lung response of K18-hACE2 mice to the SARS-CoV-2 δ variant, effectively reducing viral load and improving symptoms .
AR20.5 is a human monoclonalantibody (mAb) targeting MUC1. AR20.5 increases the number of activated CD8 T cells, CD3+CD4−CD8−(DN) T cells, and mature dendritic cells in pancreatic tumor-bearing mice. AR20.5 can be used in anti-pancreatic cancer immunity research .
ADG-106 is a fully human agonistic monoclonal IgG4 antibody against CD137 (4-1BB). ADG-106 has the mechanism to activate CD137 via strong FcγRIIB-mediated crosslinking while antagonizing CD137 ligands. The isotype control for ADG-106 can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
DS-1501 is a human monoclonalantibody (mAb) targeting Siglec-15/CD33L3. DS-1501 inhibits osteoclastogenesis. DS-1501 suppresses the decrease of lumbar spine bone mineral density (BMD) in ovariectomized (OVX) rats. DS-1501 can be used in Osteoporosis research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Vensobafusp alfa (KP-104) is a fusion protein composed of an IgG4 monoclonalantibody directed against terminal complement protein C5 fused to the complement factor H 1-5 domain (FH1-5). Vensobafusp alfa shows anti-inflammatory and immunomodulatory activities. The isotype control for Vensobafusp alfa can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) . .
NIAID RSVF2-5 is a human monoclonalantibody fragment. NIAID RSVF2-5 binds to conserved, distinct conformational epitopes on RSV fusion glycoprotein, and shows activity against RSVsubgroup A and B strains. NIAID RSVF2-5 reduces pulmonary and lung viral titers in RSV-infected rodents. NIAID RSVF2-5 can be used for the research of respiratory syncytial virus infection .
Imdevimab (REGN10987) is a human monoclonalantibody that targets SARS-CoV-2 virus. Imdevimab can be used in combination with Casirivimab (HY-P99341) to reduce viral load and transiently increases anti-receptor-binding domain IgG titers. Imdevimab maintains most of its neutralization activity against viruses with B.1.1.7, B.1.351 and mink cluster 5 spike proteins .
Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) is an anti-mouse Delta-like protein 4/DLL4 IgG monoclonalantibody. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can reduce angiogenesis and density by blocking the DLL4-Notch signaling pathway. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) reduces inflammatory response by decreasing NF-κB activity and pro-inflammatory factors (IL-1β, iNOS, IL-6) levels. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can inhibit Th17 cell differentiation and IL-17A production. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can reduce macrophage infiltration and alleviate insulin resistance. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can be used for researches on inflammation, metabolic conditions and cancer such as atherosclerosis, pancreatic cancer and asthma .
Necitumumab (11F8; IMC-11F8; LY3012211) is a human IgG monoclonalantibody directed against EGFR. Necitumumab binds to the EGF binding site of EGFR, blocks ligand binding, neutralizes ligand-induced EGFR phosphorylation and downstream signaling, induces EGFR internalization and degradation, and mediates antibody-dependent cellular cytotoxicity (ADCC) in EGFR-expressing cells. Necitumumab enhances antitumour activity in combination with Gemcitabine (HY-17026) and Cisplatin (HY-17394) in murine non-small-cell lung cancer xenograft models. Necitumumab can be used in research on cancers such as non-small cell lung cancer and colorectal cancer .
Neihulizumab (ALTB-168) is an immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), leading to downregulation of activated T-cells. Neihulizumab can be uesd for steroid-refractory acute graft-versus-host-disease (SR-aGVHD), psoriasis, psoriatic arthritis and ulcerative colitis research .
JS007 is a humanized IgG1 monoclonalantibody and also a CTLA-4 binder, with a Kd of 0.21 nM for CTLA-4. JS007 blocks the interaction between CTLA-4 and B7-1. JS007 activates T cells, promotes increased IL-2 secretion, and inhibits tumor growth in CTLA-4 knock-in mouse syngeneic tumor models. JS007 is applicable to research related to cancer and advanced solid tumors.
TQB-2858 is a bifunctional fusion protein composed of a monoclonalantibody against PD-L1 fused with the extracellular domain of TGF-β receptor. TQB-2858 has a high affinity for PD-L1, TGF-β1, and TGF-β3 and exhibited high PD-L1 target occupancy. TQB-2858 can be used for the study of osteosarcoma and alveolar soft part sarcoma (ASPS) .
Aquaporumab (AQmabAM) is an engineered human monoclonal IgG antibody. Aquaporumab is a selective inhibitor of aquaporin 4 (AQP4), binding tightly to AQP4 and competitively displacing AQP4-IgG from serum [1][2]. Aquaporumab significantly reduces neuromyelitis optica lesions in spinal cord slice cultures and in mice receiving intracerebral injection of AQP4-IgG and complement [1][2]. Aquaporumab can be used for research on neuromyelitis optica spectrum disorders [1][2]."}
Cofetuzumab (PF-06523435) is a humanized IgG1-κ monoclonalantibody targeting PTK7. The expression system of Cofetuzumab is typically CHO (Chinese hamster ovary) cells. Cofetuzumab downregulates PTK7 expression, modulates its downstream signaling pathways, and inhibits tumor sphere formation of ovarian cancer cells. Cofetuzumab can be used to synthesize the ADC molecule Cofetuzumab pelidotin (HY-P99829). Cofetuzumab is applicable to the research of tumors such as ovarian cancer .
JM1-24-3 is an anti-MUC18 mouse monoclonalantibody with a Kd value of 1.60e-9 M. JM1-24-3 reduces the phosphorylation levels of p-AKT (Ser473) and p-mTOR (Ser2448) in a time-dependent manner. JM1-24-3 exhibits anticancer activity against melanoma. JM1-24-3 can be used in studies related to metastatic melanoma .
WM-A1-3389 is an anti-human IGSF1monoclonal antibody and tumor growth inhibitor. WM-A1-3389 specifically binds to the C-terminus of IGSF1, increases secretion of Granzyme B, IFN?γ, and TNF?α, and inhibits growth of colon cancer or biliary tract cancer in xenogeneic or allogeneic mouse implantation models. WM-A1-3389 can be used for the research of colon cancer, biliary tract cancer, and head and neck cancer .
Temtokibart (ARGX-112) is a monoclonalantibody and also an IL-22RA1 inhibitor. Temtokibart inhibits the signal transduction of IL-22, IL-20 and IL-24. Temtokibart reduces the expression levels of inflammatory proteins, chemokines, immune cell migration and markers of activated immune pathways. Temtokibart improves the expression of genes related to immunity and epidermal barrier function. Temtokibart is applicable to research on moderate-to-severe atopic dermatitis .
Dalotuzumab (MK-0646) is a recombinant humanized monoclonalantibody (IgG1 type) targeting IGF-1R. Dalotuzumab acts by inhibiting IGF-1- and IGF-2-mediated tumor cell proliferation, IGF-1R autophosphorylation, and Akt phosphorylation. Dalotuzumab also induces apoptosis and cycle arrest. Dalotuzumab in combination with other anticancer agents such as statins can enhance the antitumor activity of Dalotuzumab in vitro and in vivo .
Netakimab (BCD-085) is a humanized IgG1κ monoclonalanti-IL-17antibody that binds to and blocks IL-17 and IL-17A activity, including reduction of downstream IL-6 production. Netakimab can be used for the research of moderate-to-severe plaque psoriasis, ankylosing spondylitis, and COVID-19 with cytokine release syndrome . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
Annexuzlimab is a humanised IgG1 monoclonalantibody which specifically binds to ANXA1 disrupting its interaction with formyl peptide receptors 1 and 2 (FPR1/2). Annexuzlimab arrests cell cycle progression with cancer cells accumulating in the G1 phase. Annexuzlimab targets secreted ANXA1, preventing FPR1/2 activation and reducing cancer progression. Annexuzlimab can be used for the research of triple negative breast cancer, pancreatic cancer and osteosarcoma .
Lecanemab (Mouse IGG2a) (Mab158) is a monoclonalantibody that targets soluble β-amyloid and has the potential to reduce cognitive decline. The variable region of Lecanemab (Mouse IGG2a) is consistent with that of Lecanemab, while the constant region is of Mouse IGG2a sequence. Lecanemab (Mouse IGG2a) almost abolishes Aβ accumulation in astrocytes and rescues neurons from Aβ-induced cell death. Lecanemab (Mouse IGG2a) holds promise for research in the field of Alzheimer's disease .
Plozalizumab (MLN-1202) is a humanized anti-CCR2 IgG1 monoclonalantibody. Plozalizumab blocks the recruitment of myeloid cells to the tumor microenvironment by inhibiting the CCL2/CCR2 axis. In addition, Plozalizumab also ameliorates synovial inflammation in rheumatoid arthritis. Plozalizumab can be used in the research of malignant melanoma and bone metastasis-related cancers. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
DLX-105 is a human monoclonalantibody (mAb) targeting TNFSF2/TNFa. DLX-105 reduces skin epidermal thickness and the expression of K16 and Ki67. DLX-105 down-regulates the mRNA levels of IL-17, TNF-α, IL-23p19, IL-12p40, and IFN-γ. DLX-105 can be used in psoriasis research .
VTX-0811 is a human IgG4 monoclonalantibody (mAb) targeting PSGL1/CD162. VTX-0811 up-regulates TNF-α/NF-κB and chemokine-mediated signaling and down-regulates oxidative phosphorylation, fatty acid metabolism, and Myc signaling pathways. VTX-0811 increases the proportion of CD8+ T cells among infiltrating T cells. VTX-0811 has antitumor activity in a humanized mouse PDX model of melanoma .
Favezelimab (MK-4280) is a humanized monoclonalantibody targeting LAG-3. Favezelimab blocks the interaction between LAG-3 and its ligand, MHC class II molecules. Favezelimab is applicable to research on relapsed/refractory classical Hodgkin lymphoma, relapsed/refractory diffuse large B-cell lymphoma, and relapsed/refractory indolent B-cell lymphoma . For the isotype control of Favezelimab, refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
Zaptuzumab (AD5-10) is a DR5-specific humanized monoclonalantibody that selectively binds to DR5 with high affinity. Zaptuzumab specifically induces cancer cell death by both caspase-apoptosis and autophagic cell death (ACD). Zaptuzumab activates both ADCC and CDC. Zaptuzumab induces ROS generation and GSH level reduction. Zaptuzumab shows a significant suppression of the tumor growth and good safety in various xenografts mice tumor models .
REGN2878 (PRLR ADC antibody) is a monoclonalantibody targeting the prolactin receptor (PRLR) and can block prolactin‑mediated activation of PRLR. REGN2878 exhibits an equilibrium dissociation constant (KD) of 1.05 nM and an IC50 of 0.344 nM for human PRLR. REGN2878 can be rapidly internalized and degraded in lysosomes by PRLR‑positive tumor cells, showing antigen‑specific binding and targeted enrichment properties. REGN2878 derivatives can be used as an immunoPET agent for antigen‑specific imaging of PRLR‑related tumors, and can also serve as a component of ADCs to exert anti‑tumor activity in breast cancer xenograft models. REGN2878 can be used in the research of breast cancer and prostate cancer. Isotype Comparison HY-P99001 .
Ifinatamab deruxtecan (DS-7300a) is a B7-H3-targeting Antibody-drug conjugate (ADC), which is composed of a humanized anti-B7-H3 monoclonalantibody, an enzymatically cleavable peptide-based linker, and Exatecan derivative (DXd) (HY-13631D). Ifinatamab deruxtecan is a DNA Topoisomerase I inhibitor. Ifinatamab deruxtecan induces Apoptosis. DS-7300a exerts potent antitumor activities against B7-H3-expressing tumors. against rhabdomyosarcoma, endometrial adenocarcinoma and lung adenocarcinoma. Ifinatamab deruxtecan does not exert direct immunomodulatory effects
Unasnemab (MT-3921) is a humanised IgG1 monoclonalantibody that binds to repulsive guidance molecule A (RGMa). Unasnemab improves locomotor function and promotes neuroregeneration. Unasnemab exerts ameliorative effects on hippocampal neurogenesis impairment and cognitive decline in db/db mice, Streptozotocin (STZ) (HY-13753)-induced type 1 diabetic and bilateral common carotid artery stenosis (BCAS)-induced mice. Unasnemab can be used for the research of spinal cord injury, diabetes-induced neurological impairments .
MAb604.107 is a human monoclonalantibody (mAb) targeting NOTCH1. MAb604.107 inhibits the proliferation and CD34/CD44 expression of primary T-ALL cells. MAb604.107 has anti-tumor activity in four tumor xenograft mouse models: MDA-MB-231, HCC-1806, BT-474, and HCT-116. MAb604.107 can be used in T acute lymphoblastic leukemia research .
MEDI0639 (21H3RK) is a human monoclonalantibody (mAb) targeting DLL4. MEDI0639 inhibits Notch1 binding to Dll4. MEDI0639 reverses Notch1-mediated growth inhibition of human umbilical vein endothelial cells in vitro. MEDI0639 promotes human angiogenesis and reduces the number of vessels covered by smooth muscle actin-positive mural cells. MEDI0639 can be used in Small cell lung cancer and solid tumors research .
Ripertamab (SCT400) is a recombinant human-mouse chimeric anti-CD20 IgG1κ monoclonalantibody. As an immunomodulator, ripertamab reduces the levels of pathogenic autoantibodies, alleviates immune complex deposition, and blocks the antigen-presenting function of cells. Ripertamab depletes CD20-positive cells. Ripertamab can induce infusion-related reactions, pulmonary toxicity, neutropenia and thrombocytopenia. Ripertamab is applicable to research related to non-Hodgkin's lymphoma, primary membranous nephropathy and idiopathic membranous nephropathy .
ONC-841 is a blood-brain barrier-permeable, humanized monoclonalantibody targeting SIGLEC10. As an immune checkpoint inhibitor, ONC-841 restores the functions of immune effector cells such as T cells and enhances anti-tumor immune responses by blocking inhibitory signals mediated by SIGLEC10. ONC-841 restores the phagocytic and migratory activities of microglia, and promotes the phagocytosis of Amyloid-β and Tau protein aggregates by microglia. ONC-841 is applicable to research related to solid tumors and Alzheimer's disease .
Masavibart (ZRC3308-A7) is an anti-SARS-CoV-2 monoclonalantibody (IgG1 type). Masavibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2 spike protein. Masavibart can be used in combination with ZRC3308-B10 (HY-145643) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease .
Rendomab B4 (Rendomab-B49) is a monoclonalantibody targeting ETB. Rendomab B4 preferentially binds to ETB in the active conformational state and exhibits selectivity for ETB on melanoma cells. Rendomab B4 inhibits the G protein-dependent phospholipase C (PLC) pathway, blocks ET-3-induced Gαi/o-mediated inhibition of adenylate cyclase, and does not affect the activation of the ERK1/2 pathway. Rendomab B4 is applicable to melanoma-related research .
AG01 is a monoclonalantibody against progranulin (GP88). AG01 inhibits triple-negative breast cancer (TNBC) cell proliferation and migration, reduces the expression of phosphorylated protein kinases p-Src, p-AKT, and p-ERK, and reduces the expression of oncogenic proteins such as Axl, c-MET, HIF-1α, and VEGF. AG01 inhibits tumor growth and Ki67 expression in a TNBC xenograft mouse model. AG01 can be used in the research of TNBC and other cancers .
Brelovitug (BJT-778) is a humanized IgG1 neutralizing monoclonalantibody targeting hepatitis B surface antigen (HBsAg). Brelovitug binds with high affinity to HBsAg purified from HBV serotypes ad and ay, with Kd values of 0.22 nM and 0.39 nM, respectively. Brelovitug binds with high affinity to HBsAg of HBV genotypes A, B, C and D, with IC50 values of 0.07, 0.02, 0.02 and 0.07 nM, respectively. Brelovitug can be used in research related to chronic hepatitis B and chronic hepatitis D .
RLYB331 (KY1066) is a is a monoclonalantibody targeting Matriptase-2 (TMPRSS6) . RLYB331 binds to the serine protease active site of matriptase-2, blocking protease activity to increase hepcidin expression. RLYB331 reduces iron overload, inhibits α-aggregates, reduces ROS, inhibits apoptosis, and enhances erythroid differentiation. RLYB331 ameliorates ineffective erythropoiesis in β-thalassemic mouse models. RLYB331 can be used for the research of β-thalassemia .
GIGA-564 is a fully human anti-CTLA4 IgG1 monoclonalantibody with a Kd of 9.8 nM. GIGA-564 binds to a unique epitope of CTLA-4, mediates FcR-dependent signaling pathways, depletes CTLA-4-highly-expressing regulatory T cells within tumors, and inhibits the proliferation of peripheral regulatory T cells. GIGA-564 exhibits anti-tumor activity in mouse models. GIGA-564 can be used for tumor research .
Gocdacimab (MEDI6570) is a fully human IgG1 monoclonalantibody inhibitor targeting the lectin-like oxidized low-density lipoprotein receptor LOX-1. By binding to LOX-1 and blocking its function, gocdacimab effectively reduces the level of free soluble LOX-1, thereby inhibiting key pathological processes such as lipid accumulation, foam cell formation, and vascular wall inflammation. Gocdacimab can interfere with atherosclerosis-related mechanisms, and it is used for research on atherosclerosis, and type 2 diabetes mellitus .
BND-35 is a human monoclonalantibody (mAb) targeting LILRB4/ILT3/CD85k. BND-35 blocks the interaction of ILT3 with APOE and fibronectin, enhances the pro-inflammatory activity of various myeloid cells, and reverses ILT3-mediated immunosuppression of T cells by various suppressive myeloid cells. BND-35 has anti-tumor activity in the hILT3 transgenic mouse tumor model .
Aldastotug (PYX-106; BSI-060T) is a human monoclonalantibody (mAb) targeting Siglec-15/CD33L3. Aldastotug reverses Siglec-15-mediated immunosuppression and enhances T-cell proliferation. Aldastotug induces significantly increased levels of IFNγ and TNFα in T cells. Aldastotug can be used in cancer immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Quavonlimab (MK-1308) is a humanized IgG1 monoclonalantibody targeting CTLA-4. As a competitive inhibitor of CTLA-4, Quavonlimab blocks the binding of CTLA-4 to its ligands CD80 and CD86. Quavonlimab increases interferon production, expands and activates T cells, reduces tumor regulatory T cells, inhibits tumor growth, and induces the proliferation of Ki67-positive CD4 and CD8 cells. Quavonlimab can be used in studies related to solid tumors .
Nepuvibart (ZRC3308-B10) is an anti-SARS-CoV-2 monoclonalantibody (IgG1 type). Nepuvibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2 spike protein. Nepuvibart can be used in combination with ZRC3308-A7 (HY-145642) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease .
Evolocumab (AMG 145) is a human monoclonalantibody that inhibits PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9 protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H2O2-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation .
Sphingomab (LT1002) is a mouse-derived IgG1 κ monoclonalantibody and also an inhibitor targeting S1P, with high affinity for S1P and a Kd value of 0.03 ± 0.002 nM. Sphingomab blocks S1P-mediated IL-8 release in ovarian cancer cells. Sphingomab exhibits anti-angiogenic activity in a mouse model of choroidal neovascularization. Sphingomab reduces peripheral blood lymphocyte counts. Sphingomab can be used in the research of ovarian cancer and age-related macular degeneration .
Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonalantibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent. Recommend Isotope Control: Human IgG1 lambda1, Isotype Control (HY-P99992) .
APX002 is an anti-IL-1β humanized monoclonalantibody that binds to IL-1β with an affinity of 1.99×10 ?10M. APX002 blocks IL-1β receptor binding, inhibits IL-1β-induced downstream cell signaling and biological effects.APX002 can be used for the research of rheumatoid arthritis, diabetes, gout, cryopyrin-associated periodic syndrome, chronic obstructive pulmonary disorder, atherosclerosis, vasculitis .
Firivumab (CT-P22; CT120) is a human IgG1 monoclonalinfluenza A virus hemagglutinin (Anti-IAV HA)antibody. Firivumab is capable of neutralizing H1N1, H5N1, H6N1, H6N2, H8N4, H8N8, H9N2 and H12N7. Firivumab shows protection against H1N1 virus in mice .
TQH-2722 is a humanized IgG4 anti-IL-4Rα monoclonalantibody. TQH-2722 targets the IL-4Rα receptor in humans, effectively disrupting the interaction between IL-4Rα and the downstream cytokines IL-4 and IL-13, thereby inhibiting inflammatory response. TQH-2722 can be used for the study of atopic dermatitis (AD) and chronic rhinosinusitis with nasal polyps (CRSwNP) .
VIR-2482 is a monoclonalantibody targeting influenza A hemagglutinin (HA). VIR-2482 is generated by introducing LS mutations (M428L/N434S) into the Fc region of MEDI8852 (HY-P991446). VIR-2482 binds to the conserved HA stem epitope across all 18 influenza A HA subtypes, neutralizes a broad spectrum of H1N1 and H3N2 strains, binds to FcγRIIIa, FcγRIIa and C1q, and induces antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. VIR-2482 reduces morbidity and mortality caused by seasonal influenza A strains and provides prophylactic protection in mice. VIR-2482 can be used in research related to influenza A disease .
Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1monoclonalantibody with an EC50 of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC50 values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma .
Erfonrilimab (KN-046) is a monoclonalantibody targeting PD-L1/CTLA-4. Erfonrilimab blocks the PD-L1 and CTLA-4 pathways, thereby regulating T cell function. Erfonrilimab enhances the secretion of IL-2 in superantigen-stimulated peripheral blood mononuclear cells. Erfonrilimab inhibits tumor growth in xenograft and double gene knock-in mouse models. Erfonrilimab can be used in research related to a variety of advanced solid tumors, including non-small cell lung cancer and nasopharyngeal carcinoma.
EU-103 is a humanized monoclonalantibody targeting V-Set And Immunoglobulin Domain Containing 4 (VSIG4) with a KD value ranging from 10 −7 and 10 −9. EU-103 blocks the interaction between VSIG4 and CD8+ T cells, promotes the conversion of M2 macrophages into M1 macrophages, induces the proliferation of CD8+ T cells and the secretion of pro-inflammatory cytokines, thereby inhibiting tumor growth. EU-103 is promising for research of cancers, such as bladder cancer, breast cancer, and colon cancer .
ABB071 is a humanized anti-CD180monoclonalantibody. ABB071 can down-regulate the highly expressed TLR7 and IRF5 genes in systemic lupus erythematosus and induce the expression of PNPT1 and DNASE1L3 genes. ABB071 can inhibit the expression of genes related to the type I interferon pathway as well as interferon-stimulated genes (ISGs). ABB071 has anti-inflammatory activity and can reduce the levels of inflammatory cytokines. ABB071 can be used for research on systemic lupus erythematosus and psoriasis .
CE-355621 is a humanized anti-c-Met IgG1 monoclonalantibody. CE-355621 can effectively bind with human c-Met (KD = 200 pM, IC50 = 466 pM) in A549 cells and cyno c-Met (KD = 610 pM) in cynomolgus kidney cells. CE-355621 inhibits the c-Met signaling pathway by blocking HGF binding. CE-355621 significantly inhibits the growth of tumors dependent on the c-Met/HGF pathway. CE-355621 can be used for research on cancer such as glioblastoma and gastric cancer .
Fremanezumab (TEV-48125) is a humanized lgG2 monoclonalantibody that selectively and potently binds to calcitonin gene related peptide (CGRp) (IC50 values = 7.943 nM). Fremanezumab binds to mouse CGRP with an IC50 value of 19.6 nM. Fremanezumab counteracts anti-inflammatory effects of CGRP in vitro, including CGRP-mediated inhibition of LPS (HY-D1056)-induced microglial activation. Fremanezumab selectively inhibits the activation of Aδ meningeal nociceptors by cortical spreading depression (CSD) in rats. Fremanezumab can be used for the study of inflammation and chronic migraine .
Alirocumab is an anti-PCSK9 human monoclonalantibody. Alirocumab inhibits PCSK9. Alirocumab reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab improves atherosclerosis and inflammation .
OI-3 is a monoclonalantibody targeting CD146 (MCAM). OI-3 specifically binds to CD146 on the surface of human mesothelioma cells and undergoes endocytosis; both chimeric (chOI-3) and murine (mOI-3) variants possess this activity. When conjugated with 212Pb to form 212Pb-TCMC-OI-3, OI-3 acts as a cytotoxic agent that delivers α-emitting radionuclides to induce targeted cytotoxicity. OI-3 can be used in research related to malignant peritoneal mesothelioma .
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonalantibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC50 of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al .
YS110 is a humanized anti-CD26 (DPP4) IgG1 monoclonalantibody. YS110 induces CD26 nuclear translocation through the caveolin pathway. YS110 inhibits the proliferation of tumor cell by delaying G2/M cell cycle transition. YS110 inhibits the infection of Middle East respiratory syndrome coronavirus (MERS CoV) by blocking the binding of MERS CoV S1 to CD26. YS110 can be used for researches on cancer or infection such as Malignant Mesothelioma and MERS .
Atibuclimab (IC14), is a chimeric monoclonalantibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab attenuates Lipopolysaccharides (HY-D1056) (LPS)-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist. Atibuclimab can be used for the research of amyotrophic lateral sclerosis, sepsis, community-acquired pneumonia, or acute lung injury .
Quetmolimab (E6011) is a humanized anti-Fractalkine (CX3CL1) monoclonalantibody. Quetmolimab binds to membrane-bound and soluble Fractalkine, neutralizes Fractalkine-induced migration of CX3CR1-expressing cells, mediates target-bound complex elimination from serum. Quetmolimab suppresses free soluble Fractalkine levels in cynomolgus monkeys, with target engagement linked to increased serum total Fractalkine concentration. Quetmolimab can be used for the research of Crohn’s disease, rheumatoid arthritis, and primary biliary cholangitis .
ATG-031 is a humanized anti-CD24monoclonalantibody with high affinity and specificity. ATG-031 interacts with Siglec-10 expressed by tumor-associated macrophages. ATG-031 effectively stimulates macrophage-mediated phagocytosis and induces cancer cell destruction by blocking the anti-phagocytic surface proteins. ATG-031 can be used in the study of haematological malignancies as well as solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
GSK2618960 is a human monoclonalantibody (mAb) targeting IL-7Ra/CD127. GSK2618960 inhibits IL-7-induced STAT5 phosphorylation. GSK2618960 enhances CD4 T cell proliferation response and increases CD83, CD86, and CD209 expression in PBMCs. GSK2618960 can be used for the research of autoimmune and allergic inflammatory diseases. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonalantibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC50 around 97 pM. Elezanumab promotes neuroregeneration and neuroprotection in neuronal injury and demyelination models binds N-terminal RGMa, blocks BMP signaling and lacks RGMc cross-reactivity. elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism .
SHR-1703 is a long-acting humanized anti-IL-5 IgG1 monoclonalantibody. SHR-1703 can selectively recognize and bind to IL-5, blocking the binding of IL-5 to the α chain of the receptor on the surface of eosinophils, thereby inhibiting the proliferation, activation, and migration of eosinophils, and ultimately reducing eosinophil-mediated inflammation and damage. SHR-1703 can be used in the research of eosinophil-related diseases, such as eosinophilic asthma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
FAZ-053 is a human monoclonalantibody (mAb) targeting B7-H1/PD-L1/CD274. FAZ-053 inhibits the interaction of PD-L1 with PD-1 and B7-1 on monocytes, dendritic cells, and B cells. FAZ-053 enhances interleukin 2 production. FAZ-053 can be used in advanced alveolar soft tissue sarcoma (ASPS), chordoma, and triple-negative breast cancer research .
FB102 is an anti-human CD122 (IL-2Rβ)monoclonalantibody with selective activity. FB102 blocks the proliferation and activation of pathogenic NK cells and specific T cell subsets induced by IL-2 and IL-15, without affecting the proliferation of regulatory T cells. FB102 inhibits IL-2/IL-15-induced activation of CD4+ and CD8+ T cells in in vitro disease models. FB102 is applicable to research related to celiac disease .
Mipletamig (APVO-436) is a bispecific CD123 x CD3monoclonalantibody. Mipletamig simultaneously binds to both CD3-expressing T cells and CD123-expressing cancer cells, thereby crosslinking CD123-expressing tumor cells and cytotoxic T lymphocytes (CTLs). This results in the activation and proliferation of T-cells and causes CTL-mediated cell lysis of CD123-expressing tumor cells. Mipletamig can be used for the study of acute myeloid leukemia (AML) .
MOR-106 (MOR12743) is a humanized anti-IL-17C IgG1 monoclonalantibody. MOR-106 inhibits the NF-κB signaling pathway by specifically binding to IL-17C (IC50 = 59 pM for human IL-17C, IC50 = 55 pM for mouse IL-17C). MOR-106 can effectively inhibit skin inflammation and reduce related inflammatory factors in animal models of psoriasis and atopic dermatitis .
Cusatuzumab (ARGX-110) is a selective competitive blocker targeting CD70 (with an equilibrium dissociation constant of 17 pM for binding to human CD70). Cusatuzumab also possesses enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. It is a humanized IgG1 monoclonalantibody, artificially synthesized through humanization and genetic engineering modifications (CH2 region mutation to enhance effector function). Cusatuzumab has a dual mechanism of action: firstly, it competitively blocks the interaction between CD70 and CD27, inhibiting the CD27-NF-κB signaling pathway, reducing regulatory T cell (Treg) activation and tumor cell proliferation; secondly, by enhancing binding to FcγRIIIa, it mediates ADCC and antibody-dependent cellular phagocytosis (ADCP), directly lysing CD70-positive tumor cells. Cusatuzumab can efficiently eliminate leukemia stem cells (LSCs), induce tumor cell differentiation and apoptosis, restore immune surveillance, and target CD70-positive tumors. Cusatuzumab is used in the study of acute myeloid leukemia (AML) .
Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonalantibody containing a modified Fc structure. Talacotuzumab has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models .
Lpathomab (LT3015; LT-3000) is a human IgG1 monoclonalantibody (mAb) targeting LPA. Lpathomab reduces the release of IL-8 and IL-6 cytokines in SKOV3 cells and blocks LPA-triggered tumor cell migration. Lpathomab reduces neovascularization in Matrigel plug and CNV models. Lpathomab inhibits brain injury in the CCI mouse model. Lpathomab can be used in the study of brain injury, ovarian cancer, diabetic neuropathy, and spinal cord injury. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
APG808 (PR001) is an anti-human IL-4Rαmonoclonalantibody. APG808 binds to IL-4Rα, prevents IL-13Rα1/IL-4Rα heterodimer formation, and disrupts IL-13 and IL-4 mediated signaling. APG808 ablates Fc and complement effector functions. APG808 can be used for the research of chronic obstructive pulmonary disease, asthma, atopic dermatitis .
IBI352g4a is a humanized IgG1 monoclonalantibody targeting PVRIG (Kd = 0.53 nM) and acts as a PVRIG/PVRL2 inhibitor. The anti-tumor effect of IBI352g4a depends on the binding of its Fc region to FcγR. IBI352g4a binds to the extracellular domains of human and cynomolgus monkey PVRIG, and blocks the PVRIG-PVRL2 interaction. IBI352g4a induces NK cell activation, promotes their degranulation and tumor killing. IBI352g4a can be used in the research of gastric cancer .
YH004 is an anti-CD137 agonistic monoclonalantibody, with immunostimulating and antineoplastic activities. YH004 activates CD137 expressed on a variety of leukocyte subsets including activated T lymphocytes and natural killer cells. YH004 enhances CD137-mediated signaling and induces cytotoxic T-lymphocyte (CTL) proliferation, cytokine production and promotes anti-tumor response mediated by CTL. YH004 induces NK-mediated tumor cell killing and suppresses the immunosuppressive activity of regulatory T cells. YH004 can be studied in anticancer research .
SAR-443809 is a selective alternative complement system inhibitor and monoclonalantibody targeting complement factor Bb. SAR-443809 blocks the cleavage of C3 and factor B by selectively binding to the activated form of factor Bb, with a KD of 7.3 nM for human factor Bb. SAR-443809 inhibits the amplification loop of the alternative complement pathway and C3 activation, reduces C3b deposition, and blocks the activation of pathways associated with intravascular and extravascular hemolysis. SAR-443809 can be used for the research of hematological and renal disorders mediated by abnormal alternative complement pathway .
Ligelizumab (QGE 031) is a humanized high-affinity anti-immunoglobulin IgEmonoclonalantibody. Ligelizumab selectively inhibits the binding of IgE to the high-affinity receptor FcεRI, while the inhibitory effect on the low-affinity receptor CD23 is weak. Ligelizumab can inhibit the activation of effector cells such as mast cells and Basophil, while reducing the production of IgE by B cells, and restoring the IFN-α production and regulatory T cell (Treg) induction function of plasmacytoid dendritic cells (pDC). Ligelizumab can be used in the study of allergic diseases (such as chronic spontaneous urticaria, allergic asthma) .
MSB-0254 is a human monoclonalantibody (mAb) targeting VEGFR2/KDR/CD309. MSB-0254 inhibits the invasion, migration, and vascular mimetic (VM) formation of U251 and primary glioma cells. MSB-0254 inhibits the growth of U251 and GL261 cell transplanted tumors. MSB-0254 reduces the expression of CD34, VEGFR2, Ki67, MMP2, MMP9, and CD34/PAS. MSB-0254 can be used in advanced solid tumors research .
IO-108 is a humanized IgG4 monoclonalantibody and a competitive inhibitor of LILRB2, with a KD value of 1.97 nM. IO-108 competitively blocks the binding of LILRB2 to its ligands including HLA-G, MHC-I, ANGPTL2 and SEMA4A, reprograms tumor-associated myeloid cells, drives the conversion of suppressive myeloid cells into a pro-inflammatory phenotype, and restores the cytotoxic activity of T cells and NK cells. IO-108 inhibits tumor growth in LILRB2 transgenic mouse models. IO-108 can be used for the research of solid tumors .
Intetumumab (CNTO 95) is a human monoclonalantibody targeting αv integrin, with a Kd value of 1-24 nM. Through high-affinity binding to αv integrin, Intetumumab inhibits its interaction with extracellular matrix proteins (such as vitronectin and fibronectin), thereby blocking the downstream focal adhesion kinase signaling pathway. This further inhibits the adhesion, migration and invasion of tumor cells as well as the proliferation of vascular endothelial cells, promotes cell apoptosis, and exerts anti-tumor and anti-angiogenic effects. Intetumumab can be used in research related to head and neck cancer, non-small cell lung cancer and uterine serous papillary carcinoma .
huAA98 is a humanized monoclonalantibody and also a CD146 inhibitor. huAA98 binds to human CD146, regulates its activity and inhibits cancer-related angiogenesis, as well as tube formation, motility, proliferation and migration of endothelial cells. huAA98 inhibits angiogenesis in the chick chorioallantoic membrane assay and reduces microvessel density in human tumor xenograft models. huAA98 shows immunoreactivity only to neovascular vessels within tumors and inhibits the growth of tumor xenograft models. huAA98 can be used in studies related to cancer-related angiogenesis, liver cancer, leiomyosarcoma and pancreatic cancer .
EOS006215 (EOS-215) is a humanized monoclonalantibody targeting TREM-2. EOS006215 competes with TREM2 ligands, prevents TREM2 multimerization, and blocks downstream signaling. EOS006215 inhibits efferocytosis, reprograms transcriptomic profiles of monocyte-derived macrophages, alters metabolism and immune response genes, and increases pro-inflammatory marker secretion. EOS006215 reduces metastasis burden, delays tumor growth, and reprograms the tumor microenvironment to overcome anti-PD-1 resistance. EOS006215 can be used for the research of triple negative breast cancer and colorectal cancer .
HZD37-5 is a humanized monoclonalantibody specifically recognizing N78 loci of IL-17A. HZD37-5 binds to human and rhesus monkeys, blocks IL-17 induced signal transduction and the release of IL-6, IL-8, CXCL-1 and GM-GSF.HZD37-5 significantly inhibited human IL-17A induced-keratinocyte chemoattractant secretion. HZD37-5 can be used for the research of autoimmune diseases including psoriasis and psoriatic arthritis .
Simtuzumab (AB 0024; GS 6624) is a monoclonalantibody directed against Lysyl oxidase like-2 (LOXL2). Simtuzumab non-competitively blocks collagen cross-linking, reduces LOXL2 protein expression and attenuates extracellular matrix changes. Simtuzumab reduces myocardial fibrosis and prevents cardiac dysfunction. Simtuzumab lowers Myh7 and Nppa gene expression, reduces contraction heterogeneity, and cuts COL1A1 deposition. Simtuzumab can be used for the research of LMNA mutation-induced dilated cardiomyopathy, idiopathic pulmonary fibrosis, and primary sclerosing cholangitis .
DS002 is a human monoclonalantibody targeting NGF/bNGF, with an IC50 of 6.60 nM against human NGF, 1.98 nM against rat NGF, and 8.46 nM against mouse NGF. DS002 blocks NGF-TrkA binding, interrupts pain signal transduction, inhibits TrkA-mediated downstream signaling pathways, and alters aromatic amino acid metabolic pathways. DS002 inhibits cancer cell proliferation. DS002 exerts a preventive effect on Paclitaxel-, Cisplatin- and Vincristine-induced peripheral neuropathy in rats. DS002 can be used in studies related to chronic pain and chemotherapy-induced peripheral neuropathy .
M6903 is a humanized monoclonal IgG2 antibody targeting T cell immunoglobulin and mucin domain-3 (TIM-3) (KD for human TIM-3 is 2.3 nM). M6903 binds to TIM-3, blocking the binding of TIM-3 to phosphatidylserine (PtdSer), carcinoembryonic antigen cell adhesion-related molecule 1 (CEACAM1), and galectin 9 (Gal-9), thus relieving TIM-3-mediated T cell inhibition and exerting the activities of activating antigen-specific T cells and enhancing anti-tumor immunity. M6903 is promising for research of cancers .
IMM20324 is a human monoclonalantibody (mAb) targeting IL38. IMM20324 inhibits the interaction of IL-38 with human IL1RAPL1-Fc and human IL-36R-Fc with IC50 values of 1.267 nM and 1.4667 nM, respectively. IMM20324 has antitumor activity in the B16.F10 syngeneic mouse model. IMM20324 can be used in antitumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
huDMB5F3 (DMB5F3; chDMB5F3) is a human monoclonalantibody against human CD227/MUC1, with a Ka value of 5.89 pM for its human target. huDMB5F3 enters MUC1-positive cancer cells via a temperature-dependent internalization process. huDMB5F3 induces cytotoxicity in MUC1-positive cancer cells. huDMB5F3 can be used in the research of various cancers including breast cancer, pancreatic cancer and gastric cancer .
RKER-216 is a human monoclonal IgG antibody inhibitor targeting ALK2 with a KD of 58.7 pM. RKER-216 reduces hepcidin transcription in Hep3B.RKER-216 competes with BMP ligands for binding to the extracellular domain of ALK2, thereby inhibiting BMP-SMAD signal. RKER-216 mobilizes tissue iron effectively in inflammatory conditions. RKER-216 improves microcytic anemia in a dose-dependent manner by inhibiting SMAD signaling to reduce hepcidin and promote iron absorption and utilization in vivo. RKER-216 can be used for research on anemia of inflammation .
Ramantamig (JNJ-79635322) is a humanized monoclonalantibody targeting human CD3ε, GPRC5D, and TNFRSF17 (BCMA). Ramantamig binds to BCMA and GPRC5D on multiple myeloma cells, binds to CD3ε on T cells, forms immunological synapses, and enables T-cell-mediated cytotoxicity. Ramantamig activates T cells concomitantly with inducing myeloma cell cytotoxicity, with no nonspecific T-cell activation in the absence of target myeloma cells. Ramantamig carries mutations to reduce interaction with Fc receptors and disrupt protein A binding of monomeric and homodimerized chains. Ramantamig can be used for the research of multiple myeloma .
1D09C3 is a fully human anti-HLA-DR monoclonalantibody. 1D09C3 induces apoptosis and cell death involving a cascade of events, including ROS generation, JNK activation, mitochondrial membrane depolarization, and AIF release from mitochondria. 1D09C3 shows potent anti-tumor activity and increases overall survival and median survival in JVM-2 cells and GRANTA-519 cells xenograft mice models. 1D09C3 can be used for the researches of cancer, such as chronic lymphocytic leukemia (CLL) .
ADEL-Y01 is a humanized and parental murine blood-brain barrier-penetrating monoclonalantibody against tau-acK280. ADEL-Y01 specifically recognizes tau-acK280 and its surrounding residues, mediates the neutralization and phagocytosis of acetylated tau aggregates, and interferes with the activity of pathological tau protein. ADEL-Y01 prevents the progression of tauopathies, increases neuronal survival rate, reduces tau-related pathological changes, and improves memory impairment. ADEL-Y01 can be used in research related to Alzheimer's disease and tauopathies .
IPH5201 is a selective CD39 inhibitor and a humanized IgG1 monoclonalantibody. IPH5201 selectively binds to and inhibits the enzymatic activity of both membrane-bound and soluble CD39, blocking ATP hydrolysis. IPH5201 enhances the phenotypic maturation and activation of dendritic cells and macrophages. IPH5201 potentiates the anti-tumor effect of Oxaliplatin (HY-17371). IPH5201 shows preliminary evidence of disease stabilization in advanced solid tumor models when used as a single agent or in combination with Durvalumab (HY-P9919). IPH5201 can be used for the research of advanced solid tumors .
GC1118 (GC-1118A) is a fully human anti-EGFRmonoclonalantibody with binding affinity of 0.16 nM (KD) to EGFR. GC1118 displays potent inhibitory effects on high- and low-affinity EGFR ligand-induced signaling. GC1118 shows potent anti proliferative activity in KRAS wild-type and KRAS mutant cells. GC1118 can reach the tumor by crossing both BBB (blood-brain barrier) and BTB (brain-tumor barrier) and shows superior anti-tumor effects in various mice xenograft models. GC1118 can be used for the researches of cancer, such as colorectal cancer .
HuGAL-FR21 is a humanized antiFGFR2IIIb IgG1 monoclonalantibody. HuGAL-FR21 can block the binding of FGF2, FGF7, and FGF10 to FGFR2IIIb and inhibit FGF-induced phosphorylation of FGFR2IIIb. HuGAL-FR21 can downregulate the expression of FGFR2 in SNU-16 cells. HuGAL-FR21 shows the significant anti-tumor activity in athymic nude mice bearing gastric cancer xenograft models. HuGAL-FR21 can be used for research on cancer such as gastric cancer .
Anti-Mouse CXCR4 Antibody is a monoclonalantibody that specifically recognizes murine CXCR4 (C-X-C chemokine receptor 4), also known as fusin or CD184. CXCR4 is a seven-transmembrane G protein–coupled receptor whose principal endogenous ligand is CXCL12 (stromal cell–derived factor-1α, SDF-1α) and is widely expressed in hematopoietic cells, endothelial cells, neurons, as well as embryonic and adult stem cells. The CXCR4–CXCL12 signaling axis activates multiple downstream pathways, including ERK1/2, Ras, p38 MAPK, PLC/MAPK, and SAPK/JNK, thereby regulating cell survival, proliferation, migration, and stemness maintenance. Aberrant overexpression of CXCR4 is closely associated with poor prognosis and metastasis in various cancers, with CXCR4-positive tumor cells preferentially home to CXCL12-rich tissues such as the liver, bone marrow, lung, and lymph nodes. Accordingly, CXCR4 and its CXCL12-related antagonists emerge as attractive targets for experimental anticancer therapy. Anti-Mouse CXCR4 Antibody is generated using a cell-based immunization and screening strategy and exhibits high affinity for both endogenous and exogenous murine CXCR4. Anti-Mouse CXCR4 Antibody can be used for thestudy of chronic lymphocytic leukemia and multiple myeloma .
MOR102 is a fully human IgG4 monoclonalantibody and an ICAM-1 inhibitor, lacking cross-reactivity with ICAM-2 and ICAM-3.MOR102 binds to the LFA-1 binding site within ICAM-1 domain 1, blocks ICAM-1/LFA-1 interaction, binds human keratinocytes with increased binding to interferon-γ-stimulated keratinocytes. MOR102 inhibits lymphocyte adhesion, reduces lymphocyte proliferation, prevents local T-cell activation, reduces inflammatory infiltrate, restores orthokeratotic differentiation, and reduces epidermal thickness. MOR102 can be used for the research of psoriasis .
Riliprubart (SAR 445088) is an anti-C1s humanized IgG4 monoclonalantibody that inhibits activated C1s in the proximal portion of the classical complement system. Riliprubart selectively inhibits activated C1s and prevents the enzymatic action of C1 on its substrates C4 and C2, thus inhibiting the formation of the classical pathway C3 convertase, C4b2a. Riliprubart can be used to study complement-mediated diseases such as systemic lupus erythematosus. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
Daclizumab (Ro 24-7375) is a humanized, monoclonalantibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab inhibits effector T cell activation, regulatory T cell (Treg) expansion and survival, and activation-induced T-cell apoptosis. Daclizumab increases IL-2 bioavailability to bind to the intermediate-affinity IL-2R (IL-2R-IA), driving the expansion of anti-inflammatory CD56bright natural killer (NK) cells. Daclizumab can be used for multiple sclerosis and cancer research .
Ianalumab (VAY-736) (FUT8-KO) is an anti-BAFF-Rmonoclonalantibody expressed in CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose depletion enhances its B cell clearance capacity. Ianalumab (FUT8-KO) competitively blocks the binding of BAFF to BAFF-R, inhibits the BAFF-mediated alternative NF-κB pro-survival signaling pathway, and abrogates the apoptotic (apoptosis) protective effect of BAFF on cancer cells. Ianalumab (FUT8-KO) can be used in research related to primary Sjögren's syndrome and chronic lymphocytic leukemia .
XOMA-213 (LFA-102; X213) is a human monoclonalantibody (mAb) targeting the prolactin receptor (PRLR), with a Kd value of 2 nM against the human target. XOMA-213 blocks PRL-induced cell proliferation and inhibits the activation of multiple PRLR ligands, including PRL and human growth hormone (hGH). XOMA-213 suppresses PRL-induced phosphorylation of Stat5, Akt and ERK1/2 in cells. XOMA-213 induces tumor regression, delays disease progression, and inhibits PRLR signaling as well as tumor growth. XOMA-213 can be used in research related to breast cancer .
AMY109 is an anti-human interleukin-8 (IL-8)monoclonalantibody, with a Ka of 36.8 pM for human IL-8, and a Ka of 380 pM for cynomolgus monkey IL-8. AMY109 binds to human and cynomolgus monkey IL-8 in a pH-dependent manner, inhibits IL-8-mediated activation of CXCR1 and CXCR2, and blocks the downstream biological activities of IL-8. AMY109 inhibits neutrophil recruitment to endometriotic lesions and suppresses monocyte chemoattractant protein-1 production by neutrophils. AMY109 is applicable to research related to endometriosis .
IBC-Ab002 is a humanized anti-PD-L1monoclonalantibody with a modified Fc backbone that shortens its circulating half-life. IBC-Ab002 inhibits PD-L1, triggers immune responses by blocking the PD-1/PD-L1 pathway, promotes the recruitment of myeloid-derived immune cells to the brain, enhances the clearance of toxic substances in the brain, improves neuronal function and reduces inflammation. IBC-Ab002 reduces the risk of accelerated onset of autoimmune diabetes in susceptible mice. IBC-Ab002 can be used in research related to Alzheimer's disease .
Omburtamab is a humanized monoclonalantibody targeting B7-H3 (CD276). Omburtamab selectively binds to B7-H3 highly expressed on the surface of tumor cells and activates anti-tumor immune responses mediated by T cells and natural killer (NK) cells. Omburtamab can promote the specific infiltration of CAR-T cells into tumors, enhance the killing function of NK cells through the CD16 signaling pathway, and regulate tumor cell glucose metabolism (such as inhibiting the Warburg effect). Omburtamab has the potential to inhibit solid tumors such as non-small cell lung cancer (NSCLC) .
COM503 is a high-affinity anti-IL18BP human monoclonalantibody with a Kd value of 0.291 pM. COM503 binds to IL18BP, blocks the IL18BP:IL18 interaction, displaces IL18 from preformed complexes, and enhances the activation and function of T cells and NK cells. COM503 induces anti-tumor effects by relieving the activity inhibition of endogenous IL18 in the tumor microenvironment. COM503 can be used for cancer research. The recommended isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
Rademikibart (CBP-201) is a human monoclonalantibody targeting IL-4Rα and IL-4Rα inhibitor with a KD of 20.7 pM when binding to human IL-4Rα epitopes . Rademikibart does not bind to IL-4Rα from other species. Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation and thymus activation regulated chemokine (TRAC) production. Rademikibart can be used for the research of atopic dermatitis and asthma .
Posdinemab (JNJ-63733657) is a humanized IgG1/κ monoclonalantibody that selectively targets phosphorylated tau (pT217). Posdinemab specifically binds to the pT217+tau epitope rich in the proline domain, blocks tau protein aggregation and seed propagation, and promotes the clearance of extracellular tau species. Posdinemab reduces the levels of free and total p217+tau in cerebrospinal fluid, thereby inhibiting the pathological propagation of tau protein and the formation of neurofibrillary tangles. Posdinemab can be used for the study of progressive supranuclear palsy syndrome and Alzheimer's disease (AD), especially for prodromal or mild AD disease .
PF-03475952 is a fully human IgG2 monoclonalantibody targeting CD44. PF-03475952 binds an epitope in CD44’s constant exons, blocks CD44-hyaluronic acid interaction, reduces cell surface CD44, and does not cross-react with rodent CD44 or LYVE-1. PF-03475952 induces cancer cell apoptosis, inhibits LPS (HY-D1056)-induced leukocyte cytokine release and cancer metastasis, and reduces CD44 expression on circulating CD3+ lymphocytes in cynomolgus monkeys. PF-03475952 can be used for the research of rheumatoid arthritis and hepatocellular carcinoma .
ZL-1201 is a recombinant humanized monoclonalanti-CD47 IgG4 antibody. ZL-1201 disrupt the CD47-SIRPα interaction. ZL-1201 modulates the tumor microenvironment. ZL-1201 promotes tumor-associated macrophage phagocytic activity. ZL-1201 substantially enhances phagocytosis by M2 macrophages, but not by M1 macrophages. ZL-1201 in combination with both mAb and chemotherapy achieves the maximal antitumor effects in a variety of solid tumor models. ZL-1201 can be used in the study of lymphoma, breast cancer, ovarian cancer, head and neck squamous cell carcinoma, and gastric cancer .
Stapokibart (CM310) is a humanized monoclonalantibody targeting IL-4Rα (KD values of 0.25 nM, 1.50 nM, and 2.75 nM for human, cynomolgus monkey, and rat IL-4Rα, respectively). Stapokibart effectively blocks the interaction of cytokines IL-4 and IL-13 with their co-receptor subunit IL-4Rα. Stapokibart reduces IL-4 and IL-13 mRNA, inhibits CD23 upregulation, and inhibits IL-4 and IL-13-induced STAT6 activation. Stapokibart improves inflammation (airway inflammation, rhinitis, dermatitis) .
GENA-104A16 is a humanized monoclonalantibody targeting CNTN4, with multiple functions including immunostimulation, cytotoxicity and immunoregulation. By binding to CNTN4, GENA-104A16 blocks its interaction with APP, thereby restoring T cell function, inducing tumor cell death and regulating tumor-infiltrating immune cell populations. GENA-104A16 also exerts topoisomerase I inhibitory activity via the payload Exatecan (HY-13631). GENA-104A16 can be used in research related to colon cancer liver metastasis and other CNTN4-expressing solid tumors .
CTB006 is a monoclonalantibody targeting a humanized chimeric recombinant anti-DR5. CTB006 specifically binds to and activates DR5, thereby inducing tumor cell apoptosis, inhibiting tumor growth and reducing tumor drug resistance. 177Lu-radiolabeled CTB006 can deliver targeted radiotherapy to tumor cells; while 89Zr- or 177Lu-labeled CTB006 can serve as a PET/CT imaging agent for detecting DR5 expression levels in preclinical tumor models and screening cancers with DR5 overexpression. CTB006 can be applied to research related to gastrointestinal cancer, colorectal cancer and other solid tumors .
IC 100 is a humanized IgG4κ monoclonalantibody targeting apoptosis-associated speck-like protein (ASC) with blood-brain barrier permeability. IC 100 specifically inhibits ASC after being endocytosed via its Fc segment, blocks ASC polymerization and inflammasome activation, suppresses IL-1β release, forms complexes with ASC and TRIM21, and evades TRIM21-mediated proteasomal degradation. IC 100 alleviates symptoms associated with autoimmune encephalomyelitis, reduces immune cell infiltration and microglial activation in the mouse EAE model. IC 100 is suitable for research on neuroinflammatory and inflammasome-related diseases such as multiple sclerosis. Isotype comparison: HY-P99003 .
OSE-279 is a high-affinity humanized monoclonal bivalent antibody targeting PD-1, the recommended isotype control is HY-P99003. OSE-279 blocks PD-1 ligand binding, inhibits PDL1-induced SHP1 phosphorylation, restores T cell activation, and promotes reactivation of primary T cell effector functions. OSE-279 binds hFcRn receptor, predicts long half-life, induces CD4 and CD8 T cell proliferation, and promotes interleukin 2 and interferon gamma secretion. OSE-279 can be used for the research of advanced malignancies, colon cancer, hepatocarcinoma, mesothelioma .
Emfizatamab (GNC-038) is a monoclonalantibody against CD19/CD3E/TNFRSF9/PD-L1. Emfizatamab exhibits antitumor activity, being capable of activating CD3 and 4-1BB signals on T cells, as well as targeting the high expression of CD19 or PD-L1 on tumor cells. Emfizatamab functions as a CD19-specific T cell engager by mediating direct antitumor activity. Emfizatamab can also overcome the inhibition of T cells by PD-L1. Emfizatamab can be used in the research of tumors such as R/R non-Hodgkin lymphoma or acute lymphoblastic leukemia .
Sintilimab (Anti-PD-1) (IBI308 (Anti-PD-1)) is a safe and effectivel humanized IgG4monoclonalantibody that binds to PD-1 with a KD value of 74 pM. Sintilimab (Anti-PD-1) blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab (Anti-PD-1) combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab (Anti-PD-1) can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .
Tepoditamab (MCLA-117) is a full-length human IgG1 bispecific monoclonalantibody that binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Among others, CLEC12A is a myeloid differentiation antigen. Tepoditamab kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells. Tepoditamab induces upto 30-fold T-cell expansion. Tepoditamab results in moderate to strong cytokine (IFNγ, IL-6, IL-8, IL-10, and TNFα) and IFNγ release in human whole blood and PBMC, respectively. Tepoditamab can be used in acute myeloid leukaemia (AML) research .
Vixticibart (REGN-5381) is a fully human IgG4 monoclonalantibody and NPR1 agonist that targets NPR1. Vixticibart stabilizes the receptor in an activated conformation by binding to the N-terminal domain of NPR1, and enhances the activity of endogenous ligands ANP and BNP without blocking ligand binding when these ligands are present. Vixticibart exerts vasodilatory and hypotensive effects by inducing cGMP production, preferentially dilating venous vessels to reduce systolic and venous pressure, but does not induce diuresis and may trigger a compensatory increase in heart rate. Vixticibart produces a synergistic hypotensive effect when combined with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and is currently mainly used in research related to heart failure and hypertension .
Alirocumab (anti-PCSK9) is an anti-PCSK9 human monoclonalantibody. Alirocumab (anti-PCSK9) inhibits PCSK9. Alirocumab (anti-PCSK9) reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab (anti-PCSK9) increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab (anti-PCSK9) improves atherosclerosis and inflammation .
Imneskibart (AU-007) is a human monoclonalantibody that binds to the CD25-binding epitope of interleukin-2 (IL-2), blocking the binding of IL-2 to the trimeric IL-2 receptor while retaining the ability to bind to the dimeric IL-2 receptor. Imneskibart expands effector T cell and NK cell populations, reduces regulatory T cells, increases the effector T cell/regulatory T cell ratio, and alleviates vascular leakage. Imneskibart can be used in research related to melanoma and non-small cell lung cancer. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .
RC98 is a monoclonalantibody targeting programmed cell death ligand 1 (PD-L1) and acts as a selective PD-L1 inhibitor. RC98 binds specifically to human and cynomolgus monkey PD-L1. RC98 blocks the interaction between PD-L1 and its receptor PD-1 to reverse T-cell inactivation mediated by PD-1/PD-L1 signaling. RC98 enhances the cytotoxic T-lymphocyte-mediated anti-tumor immune response against PD-L1-expressing tumor cells. RC98 can be used for the research of tumor immunity and solid tumors .
Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonalantibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC50s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis) .
JST‑TfR09 (PPMX‑T003) is a human monoclonalantibody (mAb) targeting transferrin receptor 1 (TfR1/CD71). JST‑TfR09 blocks the binding of transferrin to TfR1, inhibits TfR1 internalization, and suppresses cellular iron uptake. JST‑TfR09 triggers ferritin degradation via activating the autolysosomal system, promotes ROS production and lipid peroxidation, and ultimately induces ferroptosis. JST‑TfR09 exhibits cytotoxicity toward human erythroblasts differentiated from hematopoietic stem cells. JST-TfR09 can be used in leukemia research. Recommended isotype control: Human IgG1 lambda, Isotype Control (HY-P99992) .
JMW-3B3 is a humanized IgG1λ monoclonalantibody targeting CTLA-4. JMW-3B3 selectively binds the unique C-terminal sequence of sCTLA-4 to block its immunoregulatory and immunosuppressive activity without cross-reacting with full-length CTLA-4 receptor. JMW-3B3 enhances cytokine profiles in PBMC cultures responding to lupus autoantigen-derived peptides. JMW-3B3 enhances IFN-γ production in anti-CD3 stimulated PBMC from melanoma patients at low anti-CD3 doses. JMW-3B3 can be used for the research of systemic lupus erythematosus and malignant melanoma.
Volrustomig (MEDI-5752) is a human IgG1 κ monoclonalantibody targeting CTLA4/PD1. The isotype control for Volrustomig is Human IgG1 kappa, Isotype Control (HY-P99001). Volrustomig anchors to the surface of T cells by binding PD-1, induces PD-1 internalization and degradation, and preferentially inhibits CTLA-4 on activated PD-1 + T cells. Volrustomig binds to tumor-infiltrating lymphocytes and a subset of PD-1 + B cells, enhances T cell function and IFNγ secretion. Volrustomig reduces the activation of non-tumor-infiltrating lymphocytes and exhibits manageable toxicity. Volrustomig can be used in research on various cancers, such as non-small cell lung cancer, gastric cancer, hepatobiliary cancer, and cervical cancer .
NGM-438 is a humanized monoclonalantibody antagonist of LAIR1, with a Ka of 0.26 nM for human LAIR1 and 4.28 nM for cynomolgus monkey LAIR1. NGM-438 blocks the binding of LAIR1 to its Collagen ligand and antagonizes the Collagen-induced LAIR1 signaling pathway. NGM-438 reverses FcγR signaling inhibition in myeloid cells, induces dendritic cells to secrete TNFα, promotes T cell proliferation, and triggers myeloid inflammation and allogeneic T cell responses. NGM-438 sensitizes refractory mouse lung cancer to PD-1 blockade, increases the content of intratumoral CD8 + T cells and the expression of inflammatory genes. NGM-438 is applicable to research related to solid tumors, refractory solid tumors and non-small cell lung cancer .
MEDI-579 is a fully human monoclonalantibody against PAI-1, with a KD value of 6 pM for human PAI-1 and 105 pM for rat PAI-1. MEDI-579 restores renal plasmin activity and inhibits PAI-1-mediated intracellular signal transduction. MEDI-579 reduces albuminuria, glomerulosclerosis severity, TGF-β1 expression level, and phosphorylated Smad2 level induced in diabetic mice. MEDI-579 decreases the levels of active PAI-1 in plasma and kidneys, and increases plasma plasmin level in a mouse model of lupus nephritis. MEDI-579 can be used in research related to diabetic nephropathy and lupus nephritis. The recommended isotype control is human IgG1 kappa (HY-P99001) .
IMC-EB10 (LY3012218) is an anti-FLT3monoclonalantibody. IMC-EB10 binds to FLT3 with high affinity (Kd = 158 pM) and blocks the binding of FLT3 ligand to FLT3 (IC50 ≈ 10 nM), thereby inhibiting MAPK, STAT5, and PI3K/Akt signaling in leukemia cells. IMC-EB10 can enhance the anti-leukemic effect of Methotrexate (HY-14519) and inhibit leukemias expressing wild-type or ITD-mutated FLT3 receptors. IMC-EB10 prolongs the survival of acute lymphoblastic leukemia (ALL) cells and primary leukemia samples and reduces engraftment in non-obese diabetic/severe combined immunodeficiency patients. IMC-EB10 is indicated for leukemia research .
GSK1995057 is a human monoclonalantibody (mAb) targeting TNFRSF1A. GSK1995057 selectively binds to TNFR1, blocks the binding of TNF-α and LT-α, and does not interfere with TNFR2 signaling. GSK1995057 inhibits the activation of NF-κB, JNK and MAPK pathways, alleviates apoptosis (apoptosis) and inflammatory responses (inhibiting IL-1β, IL-6, IL-10, TNF-α), and prevents viability loss of human nucleus pulposus cells. GSK1995057 inhibits the expression of cytokines and neutrophil adhesion molecules in human pulmonary microvascular endothelial cell monolayers, and reduces inflammatory responses and lung injury symptoms in non-human primates. GSK1995057 forms complexes with HAVH autoantibodies, thereby activating TNFR1 and triggering the release of cytokines and IL-8 in human cells. GSK1995057 can be used in research related to intervertebral disc degeneration and acute lung injury .
Natalizumab (AN100226; BG00002) is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d). It blocks the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 + T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thus exerting anti-inflammatory and immunomodulatory activity. Natalizumab is used in the study of relapsing-remitting multiple sclerosis (RRMS) and also has applications in the study of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab can also prevent lymphocytes from entering the central nervous system, thereby preventing acute demyelinating relapses .
ANX-M1 is a blood-brain barrier-permeable anti-C1q antibody. ANX-M1 can slow down the progression of retinal degeneration following photo-oxidative damage. ANX-M1 has been incorporated into nanocarriers to evaluate its brain delivery efficacy in a mouse model of Alzheimer's disease. ANX-M1 is applicable for research on age-related macular degeneration and Alzheimer's disease [1] .
γ-Amanitin an ADC cytotoxin and isolated from the mushroom. γ-Amanitin inhibits RNA polymerase II and disrupts synthesis of mRNA. γ-Amanitin shows similar effects to α-Amanitin and β-Amanitin. γ-Amanitin competitively binds to monoclonalantibody (mAb), with an IC50 of 163.1 ng/mL. γ-Amanitin is toxic to a variety of cells .
Ki67/MKI67 is localized on mitotic chromosomes and maintains its dispersion during nuclear envelope disassembly. It covers a large portion of the chromosome surface and prevents chromatin from collapsing into clumps. Ki67/MKI67 Protein, Human (His) is the recombinant mouse-derived Ki-67(MKI67) protein, expressed by E. coli , with N-6*His labeled tag.
8-Bromo-2'-deoxyguanosine- 13C, 15N2 is the 13C- and 15N-labeled 8-Bromo-2'-deoxyguanosine (HY-W011168). 8-Bromo-2'-deoxyguanosine is an inflammation-related DNA halogenated adduct and an early biomarker of inflammation-induced oxidative tissue damage. The formation of 8-Bromo-2'-deoxyguanosine precedes that of oxidative and nitrative products, and it can be generated via the MPO-H2O2-Cl --Br - system. 8-Bromo-2'-deoxyguanosine serves as the immunogen for preparing the monoclonalantibody mAb8B3, which can be used to detect early DNA modifications in preclinical models; its urinary level also increases significantly in inflammatory disease models. 8-Bromo-2'-deoxyguanosine can also be produced in the dermis of UV-B irradiated mice, and the extract of Coprinus comatus significantly reduces its level. 8-Bromo-2'-deoxyguanosine finds applications in studies related to inflammatory diseases, diabetes, hepatocellular carcinoma, and UV-B induced skin inflammation .
Mertansine-d3 (DM1-d3) is the deuterium labeled Mertansine (HY-19792). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonalantibody with a linker to create an antibody-drug conjugate (ADC) .
Mertansine- 13C,d3 (DM1- 13C,d3) is the 13C- and deuterium labeled Mertansine (HY-19792). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonalantibody with a linker to create an antibody-drug conjugate (ADC) .
Deferoxamine-DBCO is a bifunctional chelating agent. Deferoxamine-DBCO efficiently chelates with radioactive metals (such as 89Zr) through the DFO structure to achieve radiolabeling. Deferoxamine-DBCO undergoes a metal-free Huisgen cycloaddition reaction with azide-containing biomolecules (such as siRNA, monoclonalantibodies) under bioorthogonal conditions through the DBCO structure to achieve targeted coupling. Deferoxamine-DBCO has efficient metal chelating ability and specific bioorthogonal reaction activity. Deferoxamine-DBCO can be used for targeted radioactive imaging studies of tumors .
8-Bromo-2'-deoxyguanosine is an inflammation-related DNA halogenated adduct and an early biomarker of inflammation-induced oxidative tissue damage. The formation of 8-Bromo-2'-deoxyguanosine precedes that of oxidative and nitrative products, and it can be generated via the MPO-H2O2-Cl --Br - system. 8-Bromo-2'-deoxyguanosine serves as the immunogen for preparing the monoclonalantibody mAb8B3, which can be used to detect early DNA modifications in preclinical models; its urinary level also increases significantly in inflammatory disease models. 8-Bromo-2'-deoxyguanosine can also be produced in the dermis of UV-B irradiated mice, and the extract of Coprinus comatus significantly reduces its level. 8-Bromo-2'-deoxyguanosine finds applications in studies related to inflammatory diseases, diabetes, hepatocellular carcinoma, and UV-B induced skin inflammation .
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
MedchemExpress Validation 03
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
MedchemExpress Validation 04
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website.
Privacy and Cookie Policy
![[Lys3]-Bombesin](http://file.medchemexpress.com/product_pic/hy-p5413.gif)
